"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,A,US 1985822 A,002-464-430-654-636,1934-12-25,1934,US 69925033 A,1933-11-22,US 69925033 A;;US 67389233 A,1933-06-01,Sliver balling machine,,GORDON FRASER;;JOHN FRASER,GORDON FRASER;;JOHN FRASER,,https://lens.org/002-464-430-654-636,Granted Patent,no,0,1,1,1,0,D01G15/62;;D01G15/62,D01G15/62,,0,0,,,,EXPIRED
2,US,A1,US 2017/0349370 A1,019-320-147-492-082,2017-12-07,2017,US 201715598215 A,2017-05-17,US 201715598215 A;;US 201662343944 P,2016-06-01,TEA BAG CONFIGURED TO BE SUSPENDED IN A WATER BOTTLE,"A tea bag is configured to be inserted within a water bottle. The tea bag includes a long, thin tea containment bag configured to be inserted within the water bottle and be removed from the water bottle after steeping without compressing with an opening of the water bottle tea leaves within the tea containment bag as the bag is removed from the bottle. The tea bag additionally includes a tea bag line useful to suspend the tea containment bag within the water bottle.",FRASER JOHN;;FRASER TOM,FRASER JOHN;;FRASER TOM,,https://lens.org/019-320-147-492-082,Patent Application,yes,0,2,2,2,0,B65D85/8085;;B65D85/8085;;B65D1/0246;;B65D23/12;;B65D41/04;;B65D51/24;;B65D85/808;;B65D85/808;;B65D85/812;;B65D85/812,B65D85/808;;B65D1/02;;B65D23/12;;B65D41/04;;B65D51/24,,0,0,,,,DISCONTINUED
3,GB,A,GB 190412580 A,184-923-069-674-715,1905-03-30,1905,GB 190412580D A,1904-06-03,GB 190412580T A,1904-06-03,Improvements in Wheels or Rollers more particularly adapted for use in Spinning Frames and the like.,"12,580. Fraser, J., Fraser, P., and Fraser, N. June 3. Rollers.-Relates to the constructon of wheels and rollers having peripheral parts of leather or like material, which are particularly adapted for use as drawing-rollers in spinning-frames. Dished discs A, B are placed face to face, with a distancepiece E between, and are held against the shoulder D on the shaft by the not G. At their outer edges, the discs are formed to carry between them a ring H built up of leather or suitable material, and held in place by bolts J which either pass through the leather &c. and discs or through the discs alone as shown in Fig. 1. The discs may be strengthened by having V-shaped radial ribs stamped in them. If a cast-iron spindle is used, renewable ends of steel &c., consisting of shouldered studs L, fitting into holes formed in the spindle and held by pins, may be provided.",FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,,https://lens.org/184-923-069-674-715,Patent Application,no,0,1,1,1,0,,,,0,0,,,,DISCONTINUED
4,WO,A1,WO 2018/213544 A1,134-199-734-465-211,2018-11-22,2018,US 2018/0033136 W,2018-05-17,US 201715598215 A;;US 201662343944 P,2016-06-01,TEA BAG CONFIGURED TO BE SUSPENDED IN A WATER BOTTLE,"A tea bag (10) is configured to be inserted within a water bottle (100). The tea bag includes a long, thin tea containment bag (20) configured to be inserted within the water bottle and be removed from the water bottle after steeping without compressing with an opening (110) of the water bottle tea leaves within the tea containment bag as the bag is removed from the bottle. The tea bag additionally includes a tea bag line (50) useful to suspend the tea containment bag within the water bottle.",FRASER JOHN;;FRASER TOM,FRASER JOHN;;FRASER TOM,,https://lens.org/134-199-734-465-211,Patent Application,yes,8,4,2,2,0,B65D85/808;;B65D85/812;;B65D85/8085;;B65D85/8085;;B65D41/04;;B65D1/0246;;B65D23/12;;B65D51/24;;B65D85/812;;B65D85/808,B65D85/808;;B65D85/812,,0,0,,,,PENDING
5,CA,A,CA 28397 A,066-171-874-263-874,1888-01-20,1888,CA 28397D A,,CA 28397T A,,HOT WATER BOILER,,FRASER THOMAS;;FRASER JOHN,FRASER THOMAS;;FRASER JOHN,,https://lens.org/066-171-874-263-874,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
6,US,A,US 2004045 A,129-674-726-235-116,1935-06-04,1935,US 70347433 A,1933-12-21,GB 2004045X A,1932-12-28,Sliver roll forming machine,,GORDON FRASER;;JOHN FRASER,GORDON FRASER;;JOHN FRASER,,https://lens.org/129-674-726-235-116,Granted Patent,no,0,4,1,1,0,D01G27/00;;D01G27/00,D01G27/00,,0,0,,,,EXPIRED
7,US,A,US 1998128 A,014-527-967-499-155,1935-04-16,1935,US 75424034 A,1934-11-22,GB 1998128X A,1933-05-27,Bobbin drag device for spinning and like textile frames,,GORDON FRASER;;NORMAN FRASER;;JOHN FRASER,GORDON FRASER;;NORMAN FRASER;;JOHN FRASER,,https://lens.org/014-527-967-499-155,Granted Patent,no,0,0,1,1,0,D01H7/06;;D01H7/06,D01H7/06,,0,0,,,,EXPIRED
8,US,A,US 1565725 A,019-614-022-419-483,1925-12-15,1925,US 4195425 A,1925-07-07,US 4195425 A,1925-07-07,Spindle and rove stopping assembly for spinning frames and like textile machinery,,GORDON FRASER;;NORMAN FRASER;;JOHN FRASER,GORDON FRASER;;NORMAN FRASER;;JOHN FRASER,,https://lens.org/019-614-022-419-483,Granted Patent,no,0,2,1,1,0,D01H13/1608;;D01H13/182;;D01H13/182;;D01H13/1608,D01H13/16;;D01H13/18,,0,0,,,,EXPIRED
9,GB,A,GB 190017794 A,179-109-727-812-714,1901-08-10,1901,GB 190017794D A,1900-10-08,GB 190017794T A,1900-10-08,"Improvements in and connected with Evaporative ""Surface Condensing Apparatus.","17,794. Fraser, J., Fraser, P., and Fraser, N. Oct. 8. Condensers; airpumps.-Relates to evaporative surface condensing - apparatus, and a doubleacting air - pump adapted for use therewith. Figs. 1 and 2 show vertical sections at rightangles to each other. The steam to be condensed first circulates through the upper half of the horizontal tubes A<1>, then passes into the header covering the tube-plate A<2>, and returns through the lower tubes A'. Beneath the tubes is a tank D supplied with cooling-water by a ball cock E. A centrifugal pump G forces the water up through a stand-pipe delivering into a strainer, whereby scale or other matter is arrested. From the strainer the water passes into perforated troughs H, and thence flows over the tubes A<1>, meeting an upward air current produced by the blower J. The water of condensation flows by a sloping branch A<3> directly into the middle of the pump barrel M, without passing any intervening inlet or suction valves. Spring-closed outlet valves N, P are arranged at each end of the barrel, somewhat resembling covers. The pump bucket L<2> is of the plain piston type, and traverses the entire length of the barrel, so that there are no clearance spaces and the barrel is emptied completely at each stroke.",FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,,https://lens.org/179-109-727-812-714,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
10,GB,A,GB 190307643 A,111-286-210-755-235,1904-01-28,1904,GB 190307643D A,1903-04-02,GB 190307643T A,1903-04-02,"Improvements in the Presser Rollers of Drawing and Roving Frames or similar Machines for Preparing Flax, Hemp, Jute and other Fibres for Spinning","7643. Fraser, J., Fraser, P., and Fraser, N. April 2. Rollers and roller heads.-Relates to the presser rollers of drawing and roving frames &c., for preparing flax, hemp, jute, &c. for spinning. The leather covering A, built up of sections A', fits on the tapered periphery B<1> of the flanged disc B<2>. Pointed pins C<1> on the flange B<3> and cover C, which is screwed up by a bolt C<2>, are forced into the leather, which is thus secured tightly. In a modification, applicable to broader rollers, transverse grooves or preferably dovetail recesses D', Fig. 3, are formed in the inside surface of each section of the ring A and also in the periphery B', which is made without taper. Type metal or other cement is run into these grooves &c. and the cover screwed on as before. In other modifications, a groove is also left between the leather and the periphery B<1>, and this is also filled with cement &c. Leather rings can be fixed to separate iron cylinders by the methods described and the combinations used as replacements. Or separate cylinder parts G, Fig. 7, formed of type metal may be used and are preferably cast between the leather covering A and a taper mandril, having the same taper as the boss B'.",FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,,https://lens.org/111-286-210-755-235,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
11,FR,A,FR 576467 A,098-452-911-218-178,1924-08-21,1924,FR 576467D A,1924-01-30,GB 576467X A,1923-03-06,Mécanisme perfectionné pour la commande des broches de filature et des broches analogues,,,FRASER GORDON;;FRASER NORMAN;;FRASER JOHN,,https://lens.org/098-452-911-218-178,Granted Patent,no,0,0,1,1,0,D01H1/24,D01H1/24,,0,0,,,,EXPIRED
12,US,A,US 1912072 A,120-765-597-723-856,1933-05-30,1933,US 64829832 A,1932-12-21,GB 1912072X A,1932-01-14,Roving frame,,GORDON FRASER;;NORMAN FRASER;;JOHN FRASER,GORDON FRASER;;NORMAN FRASER;;JOHN FRASER,,https://lens.org/120-765-597-723-856,Granted Patent,no,0,4,1,1,0,D01H1/00;;D01H2700/01;;D01H1/00;;D01H2700/01,D01H1/00,,0,0,,,,EXPIRED
13,GB,A,GB 191128334 A,125-387-699-474-623,1912-07-11,1912,GB 191128334D A,1911-12-16,GB 191128334T A,1911-12-16,Improvements in Winding Machinery for Yarn or Thread.,"28,334. Fraser, J., Fraser, N., and Fraser, G. Dec. 16. Creel arrangements.-A drag-lever A for the delivery bobbins of winding-machines is stiffened by being made of channelled section, the end C being flat and bent around washers D on the ends of a spindle E adjustably fixed in a bracket G fixed to the machine frame. A spring K is coiled around the spindle between it and the lever, one end being fastened to the lever and the other being bent into a slot L in the spindle. By turning the spindle, the pressure of the lever against the yarn on the bobbin may be adjusted.",FRASER JOHN;;FRASER NORMAN;;FRASER GORDON,FRASER JOHN;;FRASER NORMAN;;FRASER GORDON,,https://lens.org/125-387-699-474-623,Patent Application,no,0,0,1,1,0,B65H59/04;;B65H2701/31,B65H59/04,,0,0,,,,DISCONTINUED
14,GB,A,GB 190503001 A,055-449-382-260-794,1905-06-15,1905,GB 190503001D A,1905-02-14,GB 190503001T A,1905-02-14,Improvements in Footstep Bearings for Cop Winding and like Spindles,"3001. Frazer, J., Frazer, P., and Frazer, N. Feb. 14. Step bearings for cop-winding, spinning-machine and like spindles. The spindle B is constructed with a chamber B<1> to receive the end of the spindle on to which are screwed the usual collars B<3>, B<4> carrying between them the loose collar B<5>. After lowering the collars into the chamber, the collar B<5> is partially turned so as to engage the projections B<6>, B' formed on it with undercut recesses B<8>, B<9> formed in the chamber B', a cover B<13> with projecting lugs B"", B<15> being then applied to secure it. The chamber is filled with lubricant, which can be drawn off by removing a screw plug B<12>.",FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,,https://lens.org/055-449-382-260-794,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
15,US,A,US 1960146 A,053-579-504-330-758,1934-05-22,1934,US 67389233 A,1933-06-01,GB 1960146X A,1932-06-21,Sliver balling machine,,GORDON FRASER;;NORMAN FRASER;;JOHN FRASER,GORDON FRASER;;NORMAN FRASER;;JOHN FRASER,,https://lens.org/053-579-504-330-758,Granted Patent,no,0,1,1,1,0,D01G27/00;;D01G27/00,D01G27/00,,0,0,,,,EXPIRED
16,FR,E,FR 35801 E,080-258-897-067-760,1930-03-28,1930,FR 35801D A,1928-08-06,FR 35801T A,1928-08-06,Procédé et appareil pour la fabrication de tresses ou lacets,,,FRASER GORDON;;FRASER NORMAN;;FRASER JOHN,,https://lens.org/080-258-897-067-760,Amended Patent,no,0,0,1,1,0,D04D7/00,D04D7/00,,0,0,,,,DISCONTINUED
17,US,A,US 1791076 A,100-895-519-403-128,1931-02-03,1931,US 39410729 A,1929-09-20,GB 1791076X A,1929-02-28,Sliver-balling machine,,GORDON FRASER;;NORMAN FRASER;;JOHN FRASER,GORDON FRASER;;NORMAN FRASER;;JOHN FRASER,,https://lens.org/100-895-519-403-128,Granted Patent,no,0,3,1,1,0,D01G27/00;;D01G27/00,D01G27/00,,0,0,,,,EXPIRED
18,US,A,US 1559413 A,032-072-566-399-123,1925-10-27,1925,US 69074424 A,1924-02-05,US 69074424 A,1924-02-05,Driving mechanism for spinning and like spindles,,GORDON FRASER;;NORMAN FRASER;;JOHN FRASER,GORDON FRASER;;NORMAN FRASER;;JOHN FRASER,,https://lens.org/032-072-566-399-123,Granted Patent,no,0,1,1,1,0,D01H1/243;;D01H1/243,D01H1/243,,0,0,,,,EXPIRED
19,GB,A,GB 190003467 A,065-940-201-204-164,1900-12-22,1900,GB 190003467D A,1900-02-22,GB 190003467T A,1900-02-22,Improvements in Winding Machinery for Yarn or Thread.,"3467. Fraser, J., Fraser, P., and Fraser, N. Feb.22. Winding-machines.-The drag on the delivery bobbin is diminished automatically as the diameter of the bobbin decreases. The drag lever C, one end of which engages with the bobbin A, is depressed by a weighted roller E on the end of a pivoted lever F, so that, as the bobbin A is unwound, the levers F, C move from the dotted to the full line position and the drag on the bobbin A is diminished. Removable weights may be strung on the lever F.",FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,,https://lens.org/065-940-201-204-164,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
20,FR,E,FR 38654 E,123-316-460-948-38X,1931-06-26,1931,FR 38654D A,1930-06-14,FR 38654T A,1930-06-14,Perfectionnements aux machines à bobiner la mèche,,,FRASER GORDON;;FRASER NORMAN;;FRASER JOHN,,https://lens.org/123-316-460-948-38X,Amended Patent,no,0,0,1,1,0,B65H67/04;;B65H2701/31,B65H67/04,,0,0,,,,DISCONTINUED
21,FR,A,FR 645503 A,003-211-738-406-963,1928-10-26,1928,FR 645503D A,1927-12-09,FR 645503T A,1927-12-09,Procédé et appareil pour la fabrication de tresses ou lacets,,,FRASER GORDON;;FRASER NORMAN;;FRASER JOHN,,https://lens.org/003-211-738-406-963,Granted Patent,no,0,0,1,1,0,D07B7/14,D07B7/14,,0,0,,,,EXPIRED
22,GB,A,GB 190121308 A,045-228-181-898-255,1902-08-28,1902,GB 190121308D A,1901-10-24,GB 190121308T A,1901-10-24,Improvements in Clutches,"21,308. Fraser, J., Fraser, P., and Fraser, N. Oct. 24. Clutches; ratchet gear- ing.-The screw K by which the friction band A is expanded in the shell S is rotated by ratchet and pawl, so that any desired pressure may be imparted to it by successive movement of the operating-sleeve P<2>. The ratchet - wheel is fixed to the screw at the side of a loose lever P, which is linked to the sleeve and carries two pawls. The tails of the pawls are pressed apart by a spring ; between their toothed ends is a fixed segmental plate which, when the lever is moved, throws the idle pawl out of gear. Move- ments of the sleeve out- wards from its central position cause the engage- ment of one pawl and rotation of the screw in one direction; movements inwards from the central position bring the other pawl into action to rotate the screw in the opposite direction. Reverse movement of the screw on the return stroke of a pawl is prevented by a washer K<3>, on the stem of the screw, which is pressed against the supporting-key K<2> by a spring.",FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,,https://lens.org/045-228-181-898-255,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
23,GB,A,GB 190017795 A,069-196-428-037-64X,1901-08-10,1901,GB 190017795D A,1900-10-08,GB 190017795T A,1900-10-08,Improvements in Twisting Machinery.,"17,795. Fraser, J., Fraser, P., and Fraser, N. Oct. 8. Spindle apparatus.-Relates to improvements on the invention described in Specification No. 239, A.D. 1895. The driving-cylinder for each band A is replaced by a number of conical drums or pulleys B. The band passes from the guidepulleys over one of the pulleys B, round one of a set of pulleys D to the corresponding pulley D of the opposite set, and thence to the second of the drums B, round which it makes a complete turn and again pursues a course similar to that described above.",FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,,https://lens.org/069-196-428-037-64X,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
24,GB,A,GB 190728474 A,064-072-103-842-812,1908-01-30,1908,GB 190728474D A,1907-12-27,GB 190728474T A,1907-12-27,"Improvements in connection with Drawing, Roving, and like Frames.","28,474. Fraser, J., Fraser, P., and Fraser, N. Dec. 27. Rollers and roller heads. - In order that the pressure on the top rollers of drawing, roving, or like frames may be released and the rollers removed, the half-bearing J, Fig. 1, which presses on the spindle H of the top roller, is formed in one with, or secured to a hand - lever K, which is forked at the base, the hooked end of the weighting-strap E being pivoted at L in the fork ; or the end of the strap may be forked, the hand-lever being placed in the fork. The pin L is situated on that side of the centre of the spindle H opposite the weighting-strap, and to release the pressure, the hand-lever is pulled in the direction of the arrow, the half-bearing turning around the spindle. This allows the strap E to drop until the tail-end of the lever C rests on a support M provided for it on the back-rail N of the frame, whereupon the rollers and strap may be removed and replaced as desired.",FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,,https://lens.org/064-072-103-842-812,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
25,GB,A,GB 191005984 A,102-391-963-028-532,1910-08-25,1910,GB 191005984D A,1910-03-10,GB 191005984T A,1910-03-10,An Improved Card Cylinder for Carding Engines.,"5984. Fraser, J., Fraser, P., and Fraser, N. March 10. Carding-engines.-Card-cylinders such as are used in carding jute are cast in halves A, B, which are secured together by bolts L and are provided with end spiders C, D having naves E, F. The spiders may, as shown, be formed integral with the halves A, B, or the spiders may be bolted to end flanges on the halves. The halves are formed with end flanges H, J, the flanges H being recessed to receive a shoulder M on the flange J. In some cases, a spider may be secured between the flanges H, J.",FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,,https://lens.org/102-391-963-028-532,Patent Application,no,0,3,1,1,0,D01G15/16,D01G15/16,,0,0,,,,DISCONTINUED
26,GB,A,GB 190300020 A,065-750-722-698-975,1903-11-12,1903,GB 190300020D A,1903-01-01,GB 190300020T A,1903-01-01,"Improvements in Spinning, Twisting and like Frames","20. Fraser, J., Fraser, P., and Fraser, N. Jan. 1. Spindle apparatus.-Relates to spinning and twisting frames, in which each spindle is driven by a separate band, the object being to keep the bands taut. The spindle D is driven by a band G from a cylinder H, and the band is kept taut by a weighted cord K<1> or spring L attached to an arm K<2> fixed to the vertical rod C to which the brackets C<2>, C<3> are fixed. These brackets have cup shaped sockets E for the convex parts D', D' of the spindle bearings D<3> in which the spindles D revolve. These bearings are preferably of the type described in Specification No. 2905, A.D. 1899. The parts D<1>, D<2> bear against the projections E<1>, E<2>, E<3>, and are kept from revolving by pins J, which, however, allow the spindle bearings and spindles to be readily removed through the open front of the sockets. The rod C turns freely in the fixed brackets A<1>, A<2> of the frame, and is adjusted by a set-screw C<1>. Instead of the weight or spring L, a spring may be coiled round the rod C. Means may be provided to relieve the weights K to stop the spindles.",FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,,https://lens.org/065-750-722-698-975,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
27,US,A,US 2022113 A,082-821-575-082-784,1935-11-26,1935,US 56676231 A,1931-10-03,GB 2022113X A,1930-10-04,Sliver conveying apparatus,,GORDON FRASER;;NORMAN FRASER;;JOHN FRASER,GORDON FRASER;;NORMAN FRASER;;JOHN FRASER,,https://lens.org/082-821-575-082-784,Granted Patent,no,0,0,1,1,0,D01G15/46;;D01G15/46,D01G15/46,,0,0,,,,EXPIRED
28,US,A,US 634407 A,098-607-790-222-667,1899-10-03,1899,US 1897/0662593 A,1897-12-20,US 1897/0662593 A,1897-12-20,TWISTING MACHINERY.,,FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,,https://lens.org/098-607-790-222-667,Granted Patent,no,0,0,1,1,0,D01H13/1658;;D01H13/1658,,,0,0,,,,EXPIRED
29,FR,A,FR 684216 A,159-534-807-185-37X,1930-06-23,1930,FR 684216D A,1929-10-30,GB 684216X A,1929-02-28,Perfectionnements aux machines à bobiner la mèche,,,FRASER GORDON;;FRASER NORMAN;;FRASER JOHN,,https://lens.org/159-534-807-185-37X,Granted Patent,no,0,0,1,1,0,D01G15/62,D01G15/62,,0,0,,,,EXPIRED
30,FR,A,FR 747906 A,075-717-970-670-187,1933-06-26,1933,FR 747906D A,1932-12-21,GB 747906X A,1932-01-14,"Perfectionnements aux métiers à bobiner, métiers à retordre et analogues",,,FRASER GORDON;;FRASER NORMAN;;FRASER JOHN,,https://lens.org/075-717-970-670-187,Granted Patent,no,0,0,1,1,0,D01H9/046,D01H9/04,,0,0,,,,EXPIRED
31,FR,A,FR 756615 A,082-114-867-999-778,1933-12-13,1933,FR 756615D A,1933-06-07,GB 756615X A,1932-06-21,Machines à bobiner la mèche perfectionnée,,,FRASER GORDON;;FRASER NORMAN;;FRASER JOHN,,https://lens.org/082-114-867-999-778,Granted Patent,no,0,1,1,1,0,D01G27/00,D01G27/00,,0,0,,,,EXPIRED
32,GB,A,GB 190409155 A,124-986-593-630-649,1905-02-16,1905,GB 190409155D A,1904-04-21,GB 190409155T A,1904-04-21,Improvements in Winding Machinery for Yarn or Thread.,"9155. Fraser, J., Fraser, P., and Fraser, N. April 21. Winding-machines.-A uniform tension is maintained on the yarn as it is drawn off the bobbin A by a brake lever F, which turns about a pin E in a bracket C fixed to the carrier rail D, and has a tail G provided with holes N through any one of which a rod J pivoted to the bracket C may project. A spring H is compressed between the tail G and an adjustable collar L on the rod J. The lever F is bent so that the yarn, which is drawn off in a downward direction, passes clear of it. The greatest pressure of the lever is exerted when the bobbin is full, and gradually decreases as the diameter of the bobbin decreases.",FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,,https://lens.org/124-986-593-630-649,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
33,GB,A,GB 189501979 A,028-966-927-665-668,1895-10-12,1895,GB 189501979D A,1895-01-29,GB 189501979T A,1895-01-29,Improvements in Twisting Machinery.,,FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,,https://lens.org/028-966-927-665-668,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
34,US,A,US 1891406 A,055-785-959-195-599,1932-12-20,1932,US 54217031 A,1931-06-04,GB 1891406X A,1930-06-04,Apparatus for receiving balls or rolls of sliver discharged from a sliver balling machine,,GORDON FRASER;;NORMAN FRASER;;JOHN FRASER,GORDON FRASER;;NORMAN FRASER;;JOHN FRASER,,https://lens.org/055-785-959-195-599,Granted Patent,no,0,0,1,1,0,D01G27/00;;D01G27/00,D01G27/00,,0,0,,,,EXPIRED
35,US,A,US 717380 A,085-517-200-515-603,1902-12-30,1902,US 1902/0122562 A,1902-09-08,US 1902/0122562 A,1902-09-08,HACKLING-MACHINE.,,FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,,https://lens.org/085-517-200-515-603,Granted Patent,no,0,3,1,1,0,D01B5/00;;D01G19/08,,,0,0,,,,EXPIRED
36,GB,A,GB 191021267 A,102-762-246-199-005,1911-01-12,1911,GB 191021267D A,1910-09-13,GB 191021267T A,1910-09-13,An Improved Wrought-iron or Steel Pulley Spoke and Manner of Manufacturing same.,"21,267. Fraser, N., Fraser, H., and Fraser, J. Sept. 13. Pulleys. - A pulley spoke A is formed by stamping a flat strip to channel s e c t i o n, splitting the outer end, and splaying apart, flattening and piercing the ends B, C for securing to the rim D. The inner end F is flared slightly, and the hub G cast about it.",FRASER NORMAN;;FRASER HENRY;;FRASER JOHN,FRASER NORMAN;;FRASER HENRY;;FRASER JOHN,,https://lens.org/102-762-246-199-005,Patent Application,no,0,0,1,1,0,F16H55/44,F16H55/44,,0,0,,,,DISCONTINUED
37,GB,A,GB 189500239 A,051-829-429-790-661,1895-10-12,1895,GB 189500239D A,1895-01-04,GB 189500239T A,1895-01-04,Improvements in Twisting Machinery.,,FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,,https://lens.org/051-829-429-790-661,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
38,US,A,US 1795427 A,061-377-298-294-542,1931-03-10,1931,US 45940630 A,1930-06-05,GB 1855029 A,1929-06-17,Sliver-balling machine,,GORDON FRASER;;NORMAN FRASER;;JOHN FRASER,GORDON FRASER;;NORMAN FRASER;;JOHN FRASER,,https://lens.org/061-377-298-294-542,Granted Patent,no,0,0,2,2,0,D01G27/00;;D01G27/02;;D01G27/00;;D01G27/02,D01G27/00;;D01G27/02,,0,0,,,,EXPIRED
39,GB,A,GB 190500664 A,070-593-123-871-646,1905-08-10,1905,GB 190500664D A,1905-01-13,GB 190500664T A,1905-01-13,Improvements in Presser Rollers of Drawing and like Frames.,"664. Fraser, J., Fraser, P., and Fraser, N. Jan. 13. Rollers for drawing and like frames are made up of two wooden disks A, B built up of thin layers glued with the grain lying in alternate directions to prevent warping. The periphery of the roller is recessed to hold a leather disk built up of two or more disks D, Fig. 1, preferably in segments, the grain surfaces abutting, or of strips F, Fig. 2, placed diagonally, the ends being scarfed to fit the recess. In the latter case, the grain surfaces are arranged so that hard and soft parts extend alternately across the ring. If the roller is broad, the strips may be in one or more pieces. The whole is held together by screws E or by bolts. Wooden pegs may be inserted to keep the leather in position.",FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,,https://lens.org/070-593-123-871-646,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
40,GB,A,GB 190122370 A,079-966-293-245-652,1903-01-01,1903,GB 190122370D A,1901-11-06,GB 190122370T A,1901-11-06,"Improvements in Drawing and Roving Frames, or similar Machines, for Preparing Flax, Jute, and other Fibres for Spinning.","22,370. Fraser, J., Fraser, P., and Fraser, N. Nov. 6. Gill boxes or frames for flax, jute, &c. The gill bars E are carried round the lower curved part of a race A' by means of rings G, which have internal teeth G<1> for engaging with the bars and external teeth whereby the ring is driven by a pinion H. The gill bars are provided at the ends with cranks, the crank-pins K<1> engaging with a cam-groove L' in the frame, whereby the bars are caused to turn in the manner desired as they travel round the race. Or the ends of the bars may be twisted and caused to engage with a cam-groove in the frame. The pinion H is mounted on a sleeve which is driven from the shaft J through a pin which breaks in the usual way when the parts of the machine jam &c. In drawing-frames having only two or three sets or heads of bars, instead of fitting such frames each with a breakable driving- pin, the pin may be fixed in the end of the driving- shaft common to all the sets of bars ; and in roving-frames, instead of using a sleeve, short shafts with a pinion at each end may be employed, the driving-pins being in the wheels which drive these shafts.",FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,,https://lens.org/079-966-293-245-652,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
41,GB,A,GB 190516342 A,186-541-750-735-08X,1905-10-19,1905,GB 190516342D A,1905-08-11,GB 190516342T A,1905-08-11,Improvements in Belt-pulleys.,"16,342. Fraser, J., Fraser, P., and Fraser, N. Aug. 11. Pulleys are made with radial arms of malleable iron &c. having their inner ends attached to the pulley hub and their outer ends bent round at right-angles in a swan-neck curve and secured to the pulley rim, as shown in Figs. 1 and 4. Specification No. 9842, A.D. 1890, is referred to.",FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,,https://lens.org/186-541-750-735-08X,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
42,FR,A,FR 766124 A,013-769-745-665-264,1934-06-21,1934,FR 766124D A,1933-12-26,GB 766124X A,1932-12-28,Machines à bobiner la mèche perfectionnées,,,FRASER GORDON;;FRASER NORMAN;;FRASER JOHN,,https://lens.org/013-769-745-665-264,Granted Patent,no,0,0,1,1,0,B65H54/02;;B65H2701/31,B65H54/02,,0,0,,,,EXPIRED
43,GB,A,GB 191409604 A,029-679-428-450-659,1914-12-10,1914,GB 191409604D A,1914-04-18,GB 191409604T A,1914-04-18,Improvements in Bearing Bushes.,"9604. Fraser, J., Fraser, P., and Fraser, N. April 18. Bushes.-In a bearing for the spindles of carding-machine rollers &c., projections and recesses G, H, preferably V- shaped, are formed on the engaging faces of the two halves E, F of the bush, to render these parts self-alining. The projections and recesses may stop short of the ends of the bush, or may be interrupted, so as tn position the halves longitudinally. Each face A may have both projections and recesses.",FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,,https://lens.org/029-679-428-450-659,Patent Application,no,0,1,1,1,0,F16C33/06,F16C33/06,,0,0,,,,DISCONTINUED
44,GB,A,GB 190324544 A,092-562-899-384-331,1904-09-01,1904,GB 190324544D A,1903-11-12,GB 190324544T A,1903-11-12,Improvements in and connected with Roving and like Frames.,"24,544. Fraser, J., Fraser, P., and Fraser, N. Nov. 12. Spindle apparatus.-The hinged ""eyeboard"" A, employed for steadying the upper ends of the spindles used in roving and like frames, is provided with a device C for absorbing shock when thrown down into its acting position and for assisting its reversal to the upturned position required in doffing the frames. It is jointed behind the hinges F to rods C which have play in guiding- eyes E and are subject to helical springs H between the eyes and collars J.",FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,,https://lens.org/092-562-899-384-331,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
45,GB,A,GB 190815620 A,037-066-899-920-088,1909-06-17,1909,GB 190815620D A,1908-07-23,GB 190815620T A,1908-07-23,Improvements in Evaporative Condensers.,"15,620. Fraser, J., Fraser, P., and Fraser, N. July 23. Condensers.-Relates to evaporative condensers of the type described in Specification No. 17,794, A.D. 1900, and consists in providing side by side two horizontal sections of tubes A, B, through which the steam passes in succession, each section having a supply of cooling water and air which is wholly or partly independent of that to 'the other section. The sections A, B are separated by a partition Q, the steam passing from the section A to the section B by way of a suitable header. Each section has separate water tanks F, G, pumps H, J, spraying-nozzles supplied with water by pipes K, L, and separate air-blowers mounted on the shaft X. The section A is of greater surface area than the section B.",FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,,https://lens.org/037-066-899-920-088,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
46,GB,A,GB 189902905 A,145-891-742-343-345,1899-12-23,1899,GB 189902905D A,1899-02-09,GB 189902905T A,1899-02-09,Improvements in and connected with Spindles for Spinning and Twisting.,"2905. Fraser, J., Fraser, P., and Fraser, N. Feb. 9. Spindle apparatus.- The spindle is carried in lower and upper bearing-tubes B, C, which are clamped by screws E<2>, E<3> or clips in sockets D, E carried by a bracket K secured to the rail, the parts of the tubes which are clamped by the sockets being provided with convex belts B<1>, C<2> to facilitate the adjustment of the tubes with regard to one another. The lower tube is also adjustable vertically. In the upper part of each tube is a recess for receiving lubricant. which in the case of the lower tube is covered by the wharl H', the lubricant passing along a groove G<1> to the bottom of the tube, where a ball G is placed on which the squared end of the spindle rests. The lower end of the upper tube rests in a recess H<2> in the upper end of the wharl containing lubricant. The bracket K may be provided with sockets for one or more spindles. Ordinary footstep bearings may be used in combination with upper bearings of the kind described. A method of applying the invention to existing machines is also described.",FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,,https://lens.org/145-891-742-343-345,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
47,FR,A,FR 327473 A,033-034-422-212-699,1903-06-24,1903,FR 327473D A,1902-12-18,FR 327473T A,1902-12-18,"Des perfectionnements apportés au bancs d'étirage et bancs à broches en gros, ou machines similaires, pour la préparation du lin, du jute, et autres fibres, pour la filature",,FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,JOHN FRASER;;PATRICK FRASER;;NORMAN FRASER,,https://lens.org/033-034-422-212-699,Granted Patent,no,0,1,1,1,0,D01H5/10,D01H5/10,"IV, 1",0,0,,,,EXPIRED
48,GB,A,GB 190121678 A,116-143-110-199-159,1902-10-02,1902,GB 190121678D A,1901-10-29,GB 190121678T A,1901-10-29,"Improvements in Roving Frames or similar Machines for Preparing Flax, Jute, and other Fibres for Spinning.","21,678. Fraser, J., Fraser, P., and Fraser, N. Oct. 29. Roving-frames for flax, jute, &c. In frames in which an expanding pulley A, A' is employed for controlling the motion of the bobbins &c., the usual snail cam E for operating the expanding pulley is connected by an adjustable link G, lever H, and link K with a block L', which slides on a fixed rod L and is connected to the usual spindle B<1> of the expanding cone. The shaft E' of the cam E is operated in the usual manner by a weighted cord, and its motion is controlled from the bobbin rail in the usual way. The expanding cone is driven by a band M' from a pulley M, which is carried by a pair of weighted levers N turning on the shaft P of. the drawing- rollers and is driven by gearing therefrom.",FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,FRASER JOHN;;FRASER PATRICK;;FRASER NORMAN,,https://lens.org/116-143-110-199-159,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
49,CA,A,CA 7501 A,006-263-848-822-072,1877-06-01,1877,CA 7501D A,,CA 7501T A,,IMPROVEMENTS ON DRILL AND BROADCAST SOWERS,,FRASER JOHN,FRASER JOHN,,https://lens.org/006-263-848-822-072,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
50,CA,A,CA 351802 A,045-440-671-640-052,1935-07-23,1935,CA 351802D A,,CA 351802T A,,LIQUID DISPENSER,,AVERY HARDOLL LTD,FRASER JOHN,,https://lens.org/045-440-671-640-052,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
51,GB,A,GB 708202 A,069-237-227-546-315,1954-04-28,1954,GB 292052 A,1952-02-04,GB 292052 A,1952-02-04,Improvements in or relating to coupling devices for pipes or conduits,"708,202. Pipe couplings. AVERY-HARDOLL, Ltd. Nov. 24, 1952 [Feb. 4, 1952], No. 2920/52. Addition to 691,568. Class 99 (1). In a disconnectible, valved, spigot-and-socket coupling according to the parent Specification, the groove 29 in the spigot member is of dovetail cross-section, the packing ring 30 being of such a crosssection that it is retained in the groove but stands slightly proud of the spigot surface so as to be compressed by the wall of the socket as coupling is effected. To avoid trapping of pressure fluid in the groove behind the ring passages 31, 32 lead to the exterior of the spigot on both sides of the ring. Specification 679,762 is referred to.",AVERY HARDOLL LTD,FRASER JOHN,,https://lens.org/069-237-227-546-315,Granted Patent,no,0,0,1,1,0,F16L37/32;;F16L37/113,F16L37/113;;F16L37/32,F2G G14A1         G21F;;F2G G21F          G21F,0,0,,,,EXPIRED
52,GB,A,GB 722944 A,125-133-002-126-216,1955-02-02,1955,GB 1994552 A,1952-08-07,GB 1994552 A,1952-08-07,Improvements in or relating to valves for controlling the flow of liquids,"722,944. Fluid-pressure servomotor-control systems. AVERY-HARDOLL, Ltd. July 29, 1953 [Aug. 7, 1952; July 6, 1953], Nos. 19945/52 and 18708/53. Class 135. In a device for controlling the filling of tanks &c. in which an inlet valve is kept open by liquid flowing into the tank and is closed by resilient means and by pressure in a control chamber supplied with liquid from the upstream side of the valve, the escape of liquid from the control chamber being controlled by auxiliary valve means responsive to the level of liquid in the tank, the auxiliary valve means is operated in two stages, and the closing movement of the inlet valve following the first stage also reduces the rate at which liquid enters the control chamber. In an embodiment, an elbow 13 is secured to the bottom of a tank 11 and the flow of liquid into or out of the tank through the elbow is controlled by a valve 21. The valve carries a piston-like extension 22 which slides in a control chamber 24 in a housing 16 secured to the bottom of the tank. Liquid flowing in through the elbow 13 forces open the valve and flows into the tank through apertures 15 in the housing. In opening, the valve rides up a hollow stem 25 to uncover ports 31, 32 therein so that liquid can also flow into the control chamber through the ports 31, 32, the stem, and further ports 30 in the stem. While the tank is filling, the liquid entering the control chamber flows out again into the tank past valves 33A, 33B, venturis 41, and ports 44. In flowing through the venturis, the liquid entrains air from the space above the surface of the liquid in the tank through hoods 47, 48 depending inside the tank, tubes 45, 46, and apertures 43 at the throats of the venturis. The tubes 47, 48 also communicate with spaces 39A, 39B above pistons or diaphragms 38A, 38B secured to the stems of valves 33A, 33B. When the level of liquid in the tank reaches the lower end of hood 48, the flow of air through pipe 46 is cut off and the resulting depression applied to space 39B causes piston 38B to rise and valve 33B to close. The resulting restriction in flow of liquid through the control chamber causes a slight rise of pressure therein, which rise of pressure, with the help of the loading spring 23, partially closes valve 21 until port 32 is covered and liquid can flow into the control chamber only through port 31. As soon as the level of liquid in the tank reaches the lower end of hood 47, valve 33A will be closed in the same way to shut off all flow out of the control chamber. Pressure will now build up in the latter sufficiently to close valve 21 completely. To empty the tank, stem 25 is lifted by means of a handle 54 until a projection 55 on the stem contacts and so lifts the valve. In a modification, the two auxiliary valves 33A, 33B are replaced by a single valve, the stem of which acts, at its upper end, as a valve to change-over control from tube 46 to tube 45 when the level of liquid in the tank reaches hood 48.",AVERY HARDOLL LTD,FRASER JOHN,,https://lens.org/125-133-002-126-216,Granted Patent,no,0,2,1,1,0,F16K21/20,F16K21/20,,0,0,,,,EXPIRED
53,GB,A,GB 189613746 A,134-427-650-093-555,1896-07-25,1896,GB 189613746D A,1896-06-22,GB 189613746T A,1896-06-22,Improvements in and connected with Fuse Lighters.,,FRASER JOHN,FRASER JOHN,,https://lens.org/134-427-650-093-555,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
54,GB,A,GB 742486 A,154-426-198-957-193,1955-12-30,1955,GB 471753 A,1953-02-19,GB 471753 A,1953-02-19,Improvements in or relating to liquid measuring and dispensing apparatus,"742,486. Liquids proportioning and dispensing apparatus. AVERY-HARDOLL, Ltd. March, 31, 1954 [Feb. 19, 1953], No. 4717/53. Class 86. [Also in Groups XVIII and XXVIII] A liquid measuring and dispensing apparatus for dispensing a predetermined quantity of a mixture of two liquids in a predetermined proportion, comprises in combination a primary reciprocating pump calibrated to deliver at each operation a quantity of one liquid equal to the predetermined quantity, a secondary reciprocating pump adjustable to deliver simultaneously a selected smaller quantity of the second liquid, and a receiving chamber separate from said pumps, said receiving chamber being adjustable with the secondary pump to receive from the primary pump during the dispensing operation, a quantity of liquid equal to that delivered by the secondary pump. An apparatus for delivering petrol mixed with one of three different grades of oil includes a petrol pump cylinder 16, Figs. 3 and 4, and three oil pump cylinders 26, 27 and 28 each for a different grade of oil, equally spaced around a chamber 29. A piston 17 in the cylinder 16 is connected by a rod 22 to an air pressure motor cylinder 21 which moves over a fixed piston 23 to impart a single working stroke to the piston 17 in response to rotary displacement of a control knob 59. The knob 59 is attached to a spring-biassed shaft 58 carrying a cam arm 57, Fig. 7, which normally opens an outlet valve 56 in the piston 23, and when the shaft 58 is rotated, opens an inlet valve 55. During the working stroke of the motor the cam 57 is retained in engagement with the inlet valve 55 by the engagement of a cam track, Fig. 6 (not shown), on the air motor cylinder, with a cam follower secured to the shaft 58. At the end of the working stroke the cam and cam follower disengage, permitting the shaft 58 to spring back to the position in which the cam 57 opens the outlet valve 56. The return stroke of the piston 17 is effected by a spring 25. The chamber 29 contains a piston 39 on a piston rod 41 which is coupled to the air motor cylinder 21 by a lever 45 pivoted at 46. Each of the cylinders 26, 27, 28 contains a piston 37 on a piston rod 34 formed with a head 35 notched at 36 and the piston rod 41 is coupled to one of the piston rods 34, selected according to the grade of oil required by means of a quadrant arm 42, Fig. 4, secured to the piston rod 41 which is brought by rotation of the piston rod 41 to engage the notch 36 in the head 35 of the selected piston rod 34. The piston 39 and the selected piston 37 have equal lengths of stroke and they move in unison with the piston 17, but the length of stroke of the pistons 39 and 37 is selected to provide any one of four different petrol oil ratios by adjusting the point of connection between the piston rod 41 and lever 45 to one of four pegs 49, 51, 52, 53 spaced along the lever 45. For this purpose three equally spaced radial arms 43 having notched ends are fixed to the piston rod 41 which can be rotated to a position wherein any selected one of the pegs 49, 51, 52 or 53 is engaged by the notched end of one of the arms 43 whilst the quadrant 42 engages the selected one of the piston rods 34. The space in the cylinder 29 behind the piston 39 is connected through a conduit 54 with the cylinder 16 and during each working stroke of the piston 17 this space takes from the petrol pump a volume of petrol equal to the volume of oil delivered from the selected oil pump cylinder 26, 27 or 28, so that the total volume of mixed liquids dispensed by the petrol pump and the selected oil pump is equal to the volume of petrol pumped from the cylinder 15, this volume being calibrated by adjusting a stop 18 to control the length of stroke of the piston 17. The piston rod 41 is slidable in but non-rotatable with respect to a tubular shaft 63 carrying a setting knob 64 and dial 65 by means of which the rod 41 can be turned to select the grade of oil and the proportion to be dispersed. A slidable rod 67 co-operates at one end with a cam 69 carried by the air motor control shaft and at the other end with a disc 66 having twelve edge notches carried by the tubular shaft 63 whereby the air motor can be set in operation only if the shaft 63 is properly set to one of its twelve operative positions, and the setting of the shaft 63 cannot be altered once the air motor has been set in operation. Reservoirs for the petrol and the three grades of oil contain floats having rods 83, 85, 86 and 87 respectively which normally support pivoted fingers 84, 88, 89 and 91. The underside of each finger is notched to engage a lug 93 carried by the air motor control shaft 58. In the event of the supply of petrol or the supply of any grade of oil selected by the setting of the shaft 63 falling below a predetermined level in the reservoir, the corresponding finger falls to lock the shaft 58 and prevent operation of the air pressure motor. Each working stroke of the apparatus must be initiated by an actuation of the knob 59, and the total quantity of mixture delivered is shown by an indicating drum 72 rotated by means of a ratchet wheel 73 driven by a pawl 74 on the lever 45 and held until released by actuating a plunger 77 of a zeroing device. The petrol delivered from the pump passes through a conduit 96 into a well 97 at one end of an elongated narrow mixing chamber 98 having three oil chambers 99, 101, 102 extending completely across it and each connected to one of the cylinders 26, 27, 28 and opening through a small orifice 103 into a horizontal channel 104 connecting the well 97 to a well 105 from which the mixture is discharged through a hose 13. One side of the mixing chamber is transparent.",AVERY HARDOLL LTD,FRASER JOHN,,https://lens.org/154-426-198-957-193,Granted Patent,no,0,1,1,1,0,B67D7/742,B67D7/74,B8N NHAB          NHAB;;B8N N24B3         NHAB;;B8N N24B4         NHAB;;B8N N24C2B        NHAB;;B8N N24C2D        NHAB;;B8N N24F5A        NHAB;;B8N N24F5B        NHAB;;F1W WCV           WCV;;F1W W100          WCV;;F1W W216          WCV;;F1W W400          WCV;;F1W W420          WCV;;F1W W508          WCV,0,0,,,,EXPIRED
55,GB,A,GB 715899 A,186-206-577-700-482,1954-09-22,1954,GB 2232051 A,1951-09-24,GB 2232051 A,1951-09-24,Improvements in or relating to coupling devices for pipes or conduits,"715,899. Pipe couplings. AVERY-HARDOLL, Ltd. Aug. 20, 1952 [Sept. 24, 1951], No. 22320/51. Class 99 (1). In a coupling in which coupling actuated valves 17, 34 move axially together as one during the connection of the coupling parts 10, 12, the valve 17 being opened by the valve 34, a member 43 actuating the valve 34 has a limited lost motion with respect to said valve. The member 43 opens, during such lost motion, pilot valves 22, 41 in the valves 17, 34 respectively providing communication between the interior of the coupling part 12 and a chamber 16 in which the valve 17 is slidable, so that fluid pressure on the valves 17, 34 is balanced during their actuation. The actuating member 43 includes a conical shell 44, wings 45, and rollers 48 which ride in helical cam slots 49 in a sleeve 51 fixed in the coupling part 12. The pilot valve 41 is secured to the member 43, and is normally seated in the valve 34, which is carried slidably between the shell 44 and a shoulder 55. To effect coupling, rollers 32 in the socket part 12 pass through slots 33 in a flange 11 of the spigot part 10, and the socket is rotated by a handle 78 to engage the rollers behind the flange. A seating ring 37 for valve 34 is rotatably mounted in the socket, and has a lug 67 adapted to engage one of the slots 33, and has lugs 66 engaging the wings 45 of member 43, whereby the latter rotates relatively to the socket and is axially moved by the cam slots 49. Rotation is limited by a stop 81. A locking device (not shown) comprises a manuallyreleasable spring-urged plunger in the socket adapted to engage a recess in the flange 11. The seal effected by a packing ring 75 is broken at the end of the rotary uncoupling movement by engagement of the rollers 32 with members 83 on the spigot 10. Specifications 670,666 and 679,762 are referred to.",AVERY HARDOLL LTD,FRASER JOHN,,https://lens.org/186-206-577-700-482,Granted Patent,no,0,3,1,1,0,F16L37/113;;F16L37/32,F16L37/113;;F16L37/32,F2G G14A1         G4G;;F2G G27           G4G;;F2G G4G           G4G,0,0,,,,EXPIRED
56,CA,A,CA 506945 A,186-225-594-069-710,1954-11-02,1954,CA 506945D A,,CA 506945T A,,APPARATUS FOR DISPENSING LIQUIDS,,AVERY HARDOLL LTD,FRASER JOHN,,https://lens.org/186-225-594-069-710,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
57,US,A,US 1037889 A,194-491-719-072-422,1912-09-10,1912,US 1909/0529114 A,1909-11-20,US 1909/0529114 A,1909-11-20,PRESS FOR MAKING PIPES.,,FRASER JOHN,FRASER JOHN,,https://lens.org/194-491-719-072-422,Granted Patent,no,0,0,1,1,0,B21D39/021;;B21D39/021;;Y10T29/53791;;Y10T29/53791,,,0,0,,,,EXPIRED
58,GB,A,GB 690153 A,026-803-460-500-077,1953-04-15,1953,GB 953851 A,1951-04-24,GB 953851 A,1951-04-24,Improvements in or relating to closure devices for fluid supply connections and the like,"690,153. Closures for pipes. AVERYHARDOLL, Ltd. Dec. 20, 1951 [April 24, 1951], No. 9538/51. Class 99 (ii). A pipe closure which is described as applied to a coupling member of the coupling described in Specification 679,762 comprises a cap applied by rotation, a sealing ring rotatably mounted within the cap which is outwardly spring-urged, and a limit stop so arranged that the cap is moved outwardly a short distance just prior to engagement of the stop. Rollers 19 within the cap 16 engage behind lugs 12 on the coupling member, a stop 20, Fig. 3 engaging one of the lugs just after the centre of each roller has passed beyond the edge of each lug. Mounted on a pin 31 within the cap is a pair of flanged discs 22, 23 pressed apart by a spring 34. The disc 22 engages within the flange 25 of the disc 23, and is sealed thereto by a sealing ring 27. The flange 25 is of curved profile, engages within the socket 11 of the coupling member, and carries a sealing ring 28 which engages the base 13 of the socket. The disc 23 has openings 30 so that pressure fluid leaking past the valve 15 assists the spring to force the rollers against the lugs, and the sealing ring 28 against its seat 13. The flanged discs may be replaced by a bellows construction.",AVERY HARDOLL LTD,FRASER JOHN,,https://lens.org/026-803-460-500-077,Granted Patent,no,0,2,1,1,0,F16L55/1155;;F16L55/1286,F16L55/115;;F16L55/128,F2P PTE           PTE,0,0,,,,EXPIRED
59,US,A,US 3027765 A,021-777-093-727-166,1962-04-03,1962,US 80480759 A,1959-04-07,US 80480759 A,1959-04-07,Liquid meters,,AVERY HARDOLL LTD,JOHN FRASER,,https://lens.org/021-777-093-727-166,Granted Patent,no,3,2,1,1,0,G01F15/02;;G01F15/02,G01F15/02,,0,0,,,,EXPIRED
60,CA,A,CA 565551 A,048-243-366-685-170,1958-11-04,1958,CA 565551D A,,CA 565551T A,,APPARATUS FOR DISPENSING LIQUIDS,,AVERY HARDOLL LTD,FRASER JOHN,,https://lens.org/048-243-366-685-170,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
61,US,A,US 2161920 A,070-562-776-560-405,1939-06-13,1939,US 15212837 A,1937-07-06,GB 2161920X A,1936-07-10,Liquid measuring and dispensing apparatus,,AVERY HARDOLL LTD,JOHN FRASER,,https://lens.org/070-562-776-560-405,Granted Patent,no,0,3,1,1,0,B67D7/28;;B67D7/42;;B67D7/28;;B67D7/42,B67D7/28;;B67D7/42,,0,0,,,,EXPIRED
62,US,A,US 1037888 A,102-416-843-948-439,1912-09-10,1912,US 1909/0526854 A,1909-11-08,US 1909/0526854 A,1909-11-08,MACHINE FOR MAKING PIPES.,,FRASER JOHN,FRASER JOHN,,https://lens.org/102-416-843-948-439,Granted Patent,no,0,0,1,1,0,B21D39/021;;B21D39/021;;Y10T29/53791;;Y10T29/53791,,,0,0,,,,EXPIRED
63,FR,A,FR 608553 A,118-854-409-985-318,1926-07-29,1926,FR 608553D A,1925-12-15,GB 608553X A,1924-12-20,Perfectionnements aux appareils pour mesurer les liquides,,BRITISH PETROLEUM CO,FRASER JOHN,,https://lens.org/118-854-409-985-318,Granted Patent,no,0,0,1,1,0,B67D7/166,B67D7/16,,0,0,,,,EXPIRED
64,ZA,B,ZA 841332 B,130-561-314-350-788,1984-10-31,1984,ZA 841332 A,1984-02-23,ZA 841332 A,1984-02-23,LATCH LOCK,,PRESS MASTER MFG PTY LTD,FRASER JOHN,,https://lens.org/130-561-314-350-788,Granted Patent,no,0,0,1,1,0,,E05B/,,0,0,,,,EXPIRED
65,ZA,B,ZA 828074 B,174-159-839-578-372,1983-09-28,1983,ZA 828074 A,1982-11-04,ZA 828074 A,1982-11-04,METHOD OF MANUFACTURING PEG STAYS,,PRESS MASTER MFG PTY LTD,FRASER JOHN,,https://lens.org/174-159-839-578-372,Granted Patent,no,0,0,1,1,0,,E05C/,,0,0,,,,EXPIRED
66,US,A,US 1109521 A,183-573-131-858-15X,1914-09-01,1914,US 1909/0526855 A,1909-11-08,US 1909/0526855 A,1909-11-08,MACHINE FOR EDGING METAL PLATES.,,FRASER JOHN,FRASER JOHN,,https://lens.org/183-573-131-858-15X,Granted Patent,no,0,4,1,1,0,B21B1/224;;B21B1/224,B21B1/22,,0,0,,,,EXPIRED
67,US,A,US 2161919 A,190-765-143-105-059,1939-06-13,1939,US 15063537 A,1937-06-26,GB 2161919X A,1936-07-10,Improvements relating to registering mechanisms,,AVERY HARDOLL LTD,JOHN FRASER,,https://lens.org/190-765-143-105-059,Granted Patent,no,0,2,1,1,0,B67D7/08;;B67D7/08,B67D7/08,,0,0,,,,EXPIRED
68,GB,A,GB 847284 A,193-163-464-567-917,1960-09-07,1960,GB 3885257 A,1957-12-13,GB 3885257 A,1957-12-13,Improvements in or relating to devices for delivering measured quantities of liquids,"847,284. Dispensing liquids. AVERYHARDOLL Ltd. Dec. 15, 1958 [Dec. 13, 1957], No. 38852/57. Class 116 [Also in Groups XIX and XXVIII] A piston 24 actuated by a hand lever 14 draws liquid from a pipe 32 and discharges it through a valve 45 to a chamber 23 from which the piston draws the liquid into the upper end of the cylinder and subsequently discharges it to an outlet 37. The piston 24 is coupled through a lost motion connection to a piston 31 in a cylinder 22 so that liquid is drawn from a pipe 33 and discharged to an outlet 41, the degree of lost motion being adjustable to vary the ratio of liquids discharged through the outlets 37, 41, the combined volume discharged being constant. The outlets 37, 41 are connected by a hose to a discharge nozzle. Applied to the dispensing of a petrol/oil mixture the pipes 32, 33, are connected to a petrol tank and oil tank respectively. The volume discharged from the lower portion of the cylinder by the piston 24 is greater than that from the upper so that the chamber 23 is supplied with excess liquid. A float 42 opens the discharge valve 45 when a given level is reached. The handle 14 is connected to the piston through a device ensuring full stroke operation. The handle also actuates a pointer (see Group XIX) indicating the volume discharged and also a total stroke counter; when the discharge nozzle is suspended from a hook the pointer is returned to zero and a bolt engages the handle to prevent operation. Specification 818,966 is referred to.",AVERY HARDOLL LTD,FRASER JOHN,,https://lens.org/193-163-464-567-917,Granted Patent,no,0,0,1,1,0,B67D7/70,B67D7/70,F1W WCU           WCU;;F1W W100          WCU;;F1W W202          WCU;;F1W W203          WCU;;F1W W400          WCU;;F1W W420          WCU;;F1W W508          WCU;;G4D DDK           DK;;G4D D421          DK;;G4D D422          DK,0,0,,,,EXPIRED
69,GB,A,GB 735364 A,000-693-913-913-950,1955-08-17,1955,GB 874653 A,1953-03-30,GB 874653 A,1953-03-30,Improvements in or relating to liquid dispensing apparatus,"735,364. Fluid-pressure servomotor-control systems. AVERY-HARDOLL, Ltd. March 29, 1954 [March 30, 1953; July 1, 1953], Nos. 8746/53 and 18266/53. Class 135. A hosecock for a liquid dispensing apparatus comprises a main valve 17 coacting with a seat 18 between an inlet 12 and an outlet nozzle 14, a pilot valve 24 actuated by a hand-lever 15 coacting with a lever 61, and an auxiliary pilot valve 34 operable by suction due to the stoppage of a flow of air when an air opening 41 is submerged by the rising level of liquid in a tank being filled whereby to cause closure of the main valve. Inlet pressure has access through a small opening 56 to a chamber 21 where it acts on the main valve in the closing direction. When the lever 15 is operated to open the pilot valve 24 the pressure in chamber 21 is released through a port 23, moving the valve 34 against its loading spring 38. The pressure liquid so released then escapes to the nozzle 14 through ports 32, and the main valve is opened, to an extent determined by the degree of opening of the pilot valve 24, by inlet pressure acting on an annular area of the valve surrounding a sealing ring 27. Some of the liquid discharged passes through ports 44 to an annular passage formed between a venturi 28 and a pipe 39 thereby inducing a flow of air from the opening 41 to the pipe 39 and thence through a ribbed, annular passage between a member 37 and the pipe 39 to the throat of the venturi. When the opening 41 becomes submerged the venturi causes a suction to be applied behind the valve 34 to cause the latter to move fully to the left to close the ports 32 and cut-off the escape from the chamber 21 thereby causing the main valve to close.",AVERY HARDOLL LTD,FRASER JOHN,,https://lens.org/000-693-913-913-950,Granted Patent,no,0,2,1,1,0,B67D7/48,B67D7/48,,0,0,,,,EXPIRED
70,GB,A,GB 191107498 A,013-907-814-569-747,1912-01-25,1912,GB 191107498D A,1911-03-25,GB 191107498T A,1911-03-25,An Escape or Life-saving Chamber for Submarine Vessels.,"7498. Fraser, J. March 25. Buoys.-An escape chamber for use with submarine boats is mounted in a U-shaped frame D, Figs. 1, 2, and 3, capable of imparting to it both side and vertical movements so that there will be no fouling even when there is considerable list, such movement being obtained by means of gear operated from within the chamber. The shaft F, which carries pinions engaging with the racks M carried in the bottom of the well, serves to right the chamber, and the shaft G, which carries pinions engaging racks on the frame D, serves to raise the chamber from the well. Access to the chamber is obtained through a hatch which communicates with a chamber running the length of the working parts of the submarine boat. The escape buoy is r e l e a s e d by removing the locking-screws K, righted; and raised from the well. The speed of rising is controlled by wire ropes attached to the submarine which pass round drums S fitted with band brakes at each end of the escape chamber. The chamber is provided with hatches which can be opened from within and without, one P in the upper part of the chamber being attached by a screw Q to the bottom of the chamber. The chamber is provided with mast, sail, and rudder, and carries a supply of compressed air or oxygen and also force pumps, rockets, and telephonic communication apparatus.",FRASER JOHN,FRASER JOHN,,https://lens.org/013-907-814-569-747,Patent Application,no,0,1,1,1,0,B63G8/41,B63G8/41,,0,0,,,,DISCONTINUED
71,US,A,US 2227578 A,106-973-707-042-074,1941-01-07,1941,US 26649139 A,1939-04-07,GB 2227578X A,1938-04-25,Hose cock for use with apparatus for dispensing measured quantities of liquid,,AVERY HARDOLL LTD,JOHN FRASER,,https://lens.org/106-973-707-042-074,Granted Patent,no,0,11,1,1,0,B67D7/48;;B67D7/48;;Y10T137/7738;;Y10T137/7738;;Y10T137/7782;;Y10T137/7782;;Y10T137/7789;;Y10T137/7789;;Y10T137/7905;;Y10T137/7905,B67D7/48,,0,0,,,,EXPIRED
72,US,A,US 1495171 A,121-331-815-363-288,1924-05-27,1924,US 63029223 A,1923-04-06,US 63029223 A,1923-04-06,Chassis for vehicles,,JOHN FRASER,JOHN FRASER,,https://lens.org/121-331-815-363-288,Granted Patent,no,0,6,1,1,0,B60G99/006;;B60G99/006,B60G99/00,,0,0,,,,EXPIRED
73,GB,A,GB 734362 A,135-749-831-638-209,1955-07-27,1955,GB 3143252 A,1952-12-11,GB 3143252 A,1952-12-11,Improvements in or relating to bayonet-type couplings,"734,362. Bayonet fastenings. AVERYHARDOLL, Ltd. Dec. I, 1953 [Dec. 11, 1952]. No. 31432/52. Class 44. [Also in Group XXVIII] In order that cross-mating of coupling members of pipe lines for different fluids may be prevented the members of a bayonet-type coupling have, in addition to the normal bayonet projections and slots 16, 18 further cooperating elements 21, 29 which permit relative axial movement of the members to the position for interengaging relative rotation only at pre-determined relative angular positions of said members. In one form the additional elements comprise three equally spaced pins 21 on the socket member 10 which cooperate with aligned slots 29, 30, in flanges 27, 28 on the spigot member 11. A ring 31 having three equally spaced slots 32 is adjustably secured to the flange 28 so that its slots register with three of nine spaced pairs of slots 29, 30 in order that the relative angular position of the effective slots and the bayonet lugs 16 may be varied. Similarly the pins 21 may be selectively secured in three of nine spaced holes 24. Specification 679,762, [Group XXVIII], is referred to.",AVERY HARDOLL LTD,FRASER JOHN,,https://lens.org/135-749-831-638-209,Granted Patent,no,0,0,1,1,0,F16L37/252,F16L37/252,E2A ACSA          ACSA;;F2G G14A1         G4G;;F2G G4G           G4G,0,0,,,,EXPIRED
74,AU,B,AU 1930/026681 B,146-145-123-615-542,1930-11-05,1930,AU 1930/026681 A,1930-10-02,AU 1930/026681 A,1930-10-02,Improvements in or relating to flow meters forthe measurement of liquid,,BRITISH PETROLEUM CO,JOHN FRASER,,https://lens.org/146-145-123-615-542,Granted Patent,no,0,0,1,1,0,,G01F3/18,,0,0,,,,EXPIRED
75,US,A,US 835856 A,178-632-586-234-876,1906-11-13,1906,US 1906/0317779 A,1906-05-19,US 1906/0317779 A,1906-05-19,METALLIC TIE AND RAIL-FASTENER.,,FRASER JOHN,FRASER JOHN,,https://lens.org/178-632-586-234-876,Granted Patent,no,0,0,1,1,0,E01B11/08;;E01B11/08,,,0,0,,,,EXPIRED
76,EP,A1,EP 3104708 A1,011-962-015-300-679,2016-12-21,2016,EP 15747076 A,2015-02-09,US 201461938052 P;;US 201461938040 P;;US 2015/0015028 W,2014-02-10,REGENERATIVE CELL THERAPY FOR CENTRAL NERVOUS SYSTEM (CNS) DISORDERS AND PTSD,,CYTORI THERAPEUTICS INC,FRASER JOHN,,https://lens.org/011-962-015-300-679,Patent Application,yes,0,0,4,4,0,A61K35/28;;A61K35/28;;A61P25/00,A01N63/00;;A61K35/32,,0,0,,,,DISCONTINUED
77,US,A,US 731766 A,024-593-567-694-793,1903-06-23,1903,US 1903/0152929 A,1903-04-16,US 1903/0152929 A,1903-04-16,METALLIC TIE AND RAIL-FASTENER.,,FRASER JOHN,FRASER JOHN,,https://lens.org/024-593-567-694-793,Granted Patent,no,0,0,1,1,0,E01B11/62;;E01B11/62,,,0,0,,,,EXPIRED
78,US,A,US 2729471 A,049-077-731-073-419,1956-01-03,1956,US 30685952 A,1952-08-28,GB 2729471X A,1951-09-24,Valved coupling devices for pipes or conduits,,AVERY HARDOLL LTD,JOHN FRASER,,https://lens.org/049-077-731-073-419,Granted Patent,no,6,16,1,1,0,F16L37/32;;F16L37/32;;F16L37/113;;F16L37/113;;Y10T137/86759;;Y10T137/86759;;Y10T137/86976;;Y10T137/86976;;Y10T137/87273;;Y10T137/87273;;Y10T137/87949;;Y10T137/87949,F16L37/113;;F16L37/32,,0,0,,,,EXPIRED
79,GB,A,GB 679762 A,076-414-749-571-065,1952-09-24,1952,GB 1279650 A,1950-05-22,GB 1279650 A;;GB 1023903X A,1949-08-02,Improvements in or relating to coupling devices for pipes or conduits,"679,762. Stuffing-boxes. AVERY-HARDOLL, Ltd. Feb. 23, 1951 [May 22, 1950], No. 12796/50. Addition to 670,666, [Group XXVIII]. Class 122(v) [Also in Group XXVIII] A shell 97 retained in position on a valve member 58 of a pipe coupling (see Group XXVIII) carries round - section packing rings 99, 105, the ring 105 being confined between a flange of the shell and a washer 101 that engages a shoulder 100 and is acted upon by springs 102 to urge the shell outwardly.",AVERY HARDOLL LTD,FRASER JOHN,,https://lens.org/076-414-749-571-065,Granted Patent,no,0,0,2,5,0,F16L37/32;;F16L37/113,F16L37/113;;F16L37/32,F2G G14A1         G4G;;F2G G4G           G4G,0,0,,,,EXPIRED
80,CA,A1,CA 3074480 A1,165-158-163-301-558,2019-03-07,2019,CA 3074480 A,2018-08-29,US 201762553393 P;;US 2018/0048528 W,2017-09-01,BALLASTED ACTIVATED SLUDGE TREATMENT COMBINED WITH HIGH-RATE LIQUIDS/SOLIDS SEPARATION SYSTEMS,"Described is a method of treating wastewater. The method includes receiving the wastewater at a ballasted activated sludge secondary treatment aeration basin. The method also includes adding a ballast material to the wastewater, treating the wastewater in the ballasted activated sludge secondary treatment aeration basin to produce a ballasted mixed liquor effluent, receiving the ballasted mixed liquor effluent at a high-rate heavy solids removal zone that includes one or more high-rate heavy solids removal units, and removing ballasted heavy solids from the ballasted mixed liquor effluent using the one or more high-rate heavy solids removal units to produce a concentrated ballasted heavy solids effluent and a clarified liquid effluent. Also described is a system for treating wastewater including a ballasted activated sludge secondary treatment aeration basin and a high-rate heavy solids removal zone for treating a ballasted mixed liquor effluent.",CAROLLO ENG INC,FRASER JOHN,,https://lens.org/165-158-163-301-558,Patent Application,no,0,0,8,8,0,C02F3/1226;;C02F3/308;;C02F2305/12;;C02F3/307;;Y02W10/10;;C02F1/004;;C02F3/107;;C02F3/1215;;C02F3/121;;C02F3/1221;;B01D21/0039;;B01D17/02;;C02F3/308;;C02F2305/12;;C02F3/1221;;B01D17/02;;C02F3/107;;C02F3/1226;;B01D21/0039;;C02F3/121;;C02F3/307;;C02F1/004;;C02F3/1215;;Y02W10/10;;C02F3/1215;;C02F3/1226;;C02F3/307;;C02F3/308;;C02F2305/12,C02F3/12;;B01D21/02;;C02F3/30,,0,0,,,,PENDING
81,AT,T1,AT E486668 T1,027-858-427-044-190,2010-11-15,2010,AT 01964960 T,2001-06-08,US 59675900 A;;EP 0106479 W,2000-06-15,KAPAZITIVER MIKROBEARBEITETER ULTRASCHALLWANDLER UND ZUGEHÖRIGES BETRIEBSVERFAHREN,"An ultrasonic transducer is formed by a plurality of cMUT cells, each comprising a charged diaphragm plate capacitively opposing an oppositely charged base plate. The diaphragm plate is distended toward the base plate by a bias charge. The base plate includes a central portion elevated toward the center of the diaphragm plate to cause the charge of the cell to be of maximum density at the moving center of the diaphragm plate. For harmonic operation the drive pulses applied to the cells are predistorted in consideration of the nonlinear operation of the device to reduce contamination of the transmit signal at the harmonic band. The cMUT cells can be fabricated by conventional semiconductor processes and hence integrated with ancillary transducer circuitry such as a bias charge regulator. The cMUT cells can also be fabricated by micro-stereolithography whereby the cells can be formed using a variety of polymers and other materials.",KONINKL PHILIPS ELECTRONICS NV,FRASER JOHN,,https://lens.org/027-858-427-044-190,Granted Patent,no,0,0,12,16,0,B06B1/0292;;B33Y80/00;;B33Y10/00;;B33Y80/00;;B33Y10/00;;B06B1/0292,B81B3/00;;A61B8/00;;B06B1/02;;H04R19/00,,0,0,,,,EXPIRED
82,CA,A,CA 660647 A,083-064-533-800-726,1963-04-02,1963,CA 660647D A,,CA 660647T A,,LIQUID METERS,,AVERY HARDOLL LTD,FRASER JOHN,,https://lens.org/083-064-533-800-726,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
83,US,A,US 948047 A,134-825-822-463-617,1910-02-01,1910,US 1906/0322149 A,1906-06-18,US 1906/0322149 A,1906-06-18,GYRATORY MACHINE.,,FRASER JOHN,FRASER JOHN,,https://lens.org/134-825-822-463-617,Granted Patent,no,0,4,1,1,0,B06B1/167;;B06B1/167;;Y10T74/18552;;Y10T74/18552,,,0,0,,,,EXPIRED
84,US,A,US 2661135 A,141-911-346-448-030,1953-12-01,1953,US 26106951 A,1951-12-11,GB 2661135X A,1950-12-14,Apparatus for dispensing liquids,,AVERY HARDOLL LTD,JOHN FRASER,,https://lens.org/141-911-346-448-030,Granted Patent,no,5,2,1,1,0,F01M11/04;;F01M11/04,F01M11/04,,0,0,,,,EXPIRED
85,IL,A,IL 286809 A,152-133-405-447-46X,2021-10-31,2021,IL 28680921 A,2021-09-29,US 201962827322 P;;US 2020/0025911 W,2019-04-01,Flow through aerobic granular sludge system and method,,CAROLLO ENG INC;;FRASER JOHN,FRASER JOHN,,https://lens.org/152-133-405-447-46X,Patent Application,no,0,0,6,6,0,C02F3/301;;C02F2203/004;;Y02W10/10;;C02F3/301;;C02F2203/004;;C02F1/006;;C02F3/1226;;C02F3/301;;C02F2203/004;;C02F2301/046,,,0,0,,,,PENDING
86,GB,A,GB 783984 A,175-062-265-420-351,1957-10-02,1957,GB 558755 A,1955-02-24,GB 558755 A,1955-02-24,Improvements in or relating to valves for controlling the flow of liquids,"783,984. Fluid-actuated valves. AVERYHARDOLL, Ltd. Nov. 24, 1955 [Feb. 24, 1955], No. 5587/55. Class 135. A valve controlling liquid flow from 21 to 29, comprises a main valve 24 controlled by a pilot valve 36 varying the pressure in a control chamber 27 which tends to close the valve while the pressure upstream of the valve tends to open it, the pilot valve when moved to connect the chamber 27 to the downstream side via passage 37, cutting-off the chamber from the upstream side via passage 34, and means, e.g. the venturi 47, whereby liquid flow through the valve applies suction to the chamber. The pilot valve is initially lifted to open the downstream and close the upstream connection to the control chamber by a crank 42 and shaft 43 connected to a hand lever 52, the latter also setting a flow meter 10 when a hand lever pawl 57 engages a stop 58 on a lever 53 loose on shaft 43 and connected to the meter. The pressure differential across piston 25 opens the main valve, the opening movement being increased by venturi suction applied to the chamber via passage 37. The pilot and main valves may be lowered to stop flow either by the meter acting on the hand lever through the pawl and stop 58 or by movement of the hand lever alone so that the pawl 57 snaps under a stop 59 on lever 53. Specification 737,696 is referred to.",AVERY HARDOLL LTD,FRASER JOHN,,https://lens.org/175-062-265-420-351,Granted Patent,no,0,0,2,2,0,F16K31/363,F16K31/363,F2V VA7           VA7,0,0,,,,EXPIRED
87,US,A,US 2841191 A,176-275-971-740-956,1958-07-01,1958,US 66255557 A,1957-05-21,GB 2841191X A,1953-03-30,Liquid dispensing apparatus,,AVERY HARDOLL LTD,JOHN FRASER,,https://lens.org/176-275-971-740-956,Granted Patent,no,1,12,1,1,0,B67D7/48;;B67D7/48,B67D7/48,,0,0,,,,EXPIRED
88,GB,A,GB 763358 A,006-209-143-155-970,1956-12-12,1956,GB 147954 A,1954-01-18,GB 147954 A,1954-01-18,Improvements in or relating to filling means for tanks and the like,"763,358. Filling tanks. AVERY-HARDOLL, Ltd. Jan. 13,1955 [Jan. 18, 1954], No. 1479/54. Class 21. The invention relates to a tank for use with filling nozzles that automatically stop the supply when the rising liquid level covers one or more orifices in said nozzle. The tank 10 has a vertical and permanently, attached tubular member 15, threaded in a ring 14, to accommodate the supply nozzle 24, 25. Openings 18 in the tube 15 permit the rising liquid level to act on the orifices 29 and 30 in the nozzle that are coupled to the automatic control means. The desired liquid level is set by vertical adjustment of the tube 15. A tube 23 extending to the bottom of the tank is a sliding fit in the end of the tube 15 and carries an inner packing ring 22 for embracing the nozzle 25. The tube 15 has an upper abutment surface 27 and carries a lock nut 17. Specification 698,644 [Group XXIX], is referred to.",AVERY HARDOLL LTD,FRASER JOHN,,https://lens.org/006-209-143-155-970,Granted Patent,no,0,0,1,1,0,F16K21/18;;G05D9/02,F16K21/18;;G05D9/02,B8T TEFE          TEFE;;B8T T802          TEFE;;B8T T90M1         T90Y;;B8T T90Y          T90Y;;U1S S1359,0,0,,,,EXPIRED
89,US,A1,US 2021/0070642 A1,014-629-773-671-575,2021-03-11,2021,US 201816642567 A,2018-08-29,US 201816642567 A;;US 201762553393 P;;US 2018/0048528 W,2017-09-01,Ballasted Activated Sludge Treatment Combined with High-Rate Liquids/Solids Separation Systems,"Described is a method of treating wastewater. The method includes receiving the wastewater at a ballasted activated sludge secondary treatment aeration basin. The method also includes adding a ballast material to the wastewater, treating the wastewater in the ballasted activated sludge secondary treatment aeration basin to produce a ballasted mixed liquor effluent, receiving the ballasted mixed liquor effluent at a high-rate heavy solids removal zone that includes one or more high-rate heavy solids removal units, and removing ballasted heavy solids from the ballasted mixed liquor effluent using the one or more high-rate heavy solids removal units to produce a concentrated ballasted heavy solids effluent and a clarified liquid effluent. Also described is a system for treating wastewater including a ballasted activated sludge secondary treatment aeration basin and a high-rate heavy solids removal zone for treating a ballasted mixed liquor effluent.",CAROLLO ENG INC,FRASER JOHN,CAROLLO ENGINEERS INC (2018-08-31),https://lens.org/014-629-773-671-575,Patent Application,yes,2,0,8,8,0,C02F3/1226;;C02F3/308;;C02F2305/12;;C02F3/307;;Y02W10/10;;C02F1/004;;C02F3/107;;C02F3/1215;;C02F3/121;;C02F3/1221;;B01D21/0039;;B01D17/02;;C02F3/308;;C02F2305/12;;C02F3/1221;;B01D17/02;;C02F3/107;;C02F3/1226;;B01D21/0039;;C02F3/121;;C02F3/307;;C02F1/004;;C02F3/1215;;Y02W10/10;;C02F3/1215;;C02F3/1226;;C02F3/307;;C02F3/308;;C02F2305/12,C02F3/12;;C02F3/30,,1,0,,,Translation of DE_102005040839_A1 (Year: 2007),DISCONTINUED
90,EP,A4,EP 3104708 A4,023-719-000-956-208,2017-08-09,2017,EP 15747076 A,2015-02-09,US 201461938052 P;;US 201461938040 P;;US 2015/0015028 W,2014-02-10,REGENERATIVE CELL THERAPY FOR CENTRAL NERVOUS SYSTEM (CNS) DISORDERS AND PTSD,,CYTORI THERAPEUTICS INC,FRASER JOHN,,https://lens.org/023-719-000-956-208,Search Report,no,2,0,4,4,0,A61K35/28;;A61K35/28;;A61P25/00,A01N63/00;;A61K35/32;;A61P25/00,,4,3,044-139-513-291-484;;023-616-474-190-572;;070-141-688-141-774,24761343;;10.1089/wound.2012.0408;;pmc3900001;;10.1242/dmm.001198;;19132123;;pmc2615170;;pmc3866490;;24381292;;10.1523/jneurosci.2425-13.2014,"JOHN K. FRASER ET AL: ""The Celution System: Automated Processing of Adipose-Derived Regenerative Cells in a Functionally Closed System"", ADVANCES IN WOUND CARE, vol. 3, no. 1, 1 January 2014 (2014-01-01), pages 38 - 45, XP055378023, ISSN: 2162-1918, DOI: 10.1089/wound.2012.0408;;P. A. WALKER ET AL: ""Progenitor cell therapies for traumatic brain injury: barriers and opportunities in translation"", DISEASE MODELS & MECHANISMS, vol. 2, no. 1-2, 1 January 2009 (2009-01-01), pages 23 - 38, XP055070224, ISSN: 1754-8403, DOI: 10.1242/dmm.001198;;N. TAJIRI ET AL: ""Intravenous Transplants of Human Adipose-Derived Stem Cell Protect the Brain from Traumatic Brain Injury-Induced Neurodegeneration and Motor and Cognitive Impairments: Cell Graft Biodistribution and Soluble Factors in Young and Aged Rats"", JOURNAL OF NEUROSCIENCE, vol. 34, no. 1, 31 December 2013 (2013-12-31), US, pages 313 - 326, XP055378054, ISSN: 0270-6474, DOI: 10.1523/JNEUROSCI.2425-13.2014;;See also references of WO 2015120388A1",DISCONTINUED
91,US,A,US 999982 A,066-682-923-128-586,1911-08-08,1911,US 1909/0477665 A,1909-02-13,US 1909/0477665 A,1909-02-13,APPARATUS FOR UNITING PIPE LENGTHS.,,FRASER JOHN,FRASER JOHN,,https://lens.org/066-682-923-128-586,Granted Patent,no,0,5,1,1,0,B23B31/40;;B23B31/40;;B23K37/0531;;B23K37/0531,,,0,0,,,,EXPIRED
92,GB,A,GB 818966 A,085-758-205-707-599,1959-08-26,1959,GB 2288256 A,1956-07-24,GB 2288256 A,1956-07-24,Improvements in or relating to apparatus for dispensing liquids,"818,966. Continuous-discharge mixing- apparatus; mixing liquids in flow. AVERYHARDOLL Ltd. July 18, 1957 [July 24, 1956], No. 22882/56. Class 86 [Also in Groups XVIII, XIX, XXIV and XXVIII] Apparatus for mixing liquids, such as petrol and oil, in measured quantities comprises a main pump 25, Fig. 2, in a tank 10 for the petrol and subsidiary pumps 26, 26a in oil tanks 24, 24a. The main pump 25 is driven by a hand lever 15 through a pawl mechanism (see Group XXIV) which ensures a full delivery stroke of the pump before a suction stroke can be made and vice-versa. The drive to the pump includes a roller 40, Fig. 4, mounted on an arm of a shaft 42, which also carries additional rollers 45 on an arm 44, and by axial movement of the shaft the rollers 45 may selectively engage one of the ends 46, 46a of the piston rods 47, 47a of the pumps 26, 26a. The pumps deliver to a mixing chamber 14 Which may be of the type described in Specification 763,150.",AVERY HARDOLL LTD,FRASER JOHN,,https://lens.org/085-758-205-707-599,Granted Patent,no,0,0,1,1,0,B67D7/742,B67D7/74,B1C CAGA          CAGA;;B1C C126          CAGA;;B1C C687          CAGA;;F1W WCA           WCA;;F1W W100          WCA;;F1W W506          WCA;;F1W W508          WCA;;G4D DDB           DB;;G4D D421          DB;;G4D D422          DB,0,0,,,,EXPIRED
93,DE,B,DE 1062504 B,087-772-454-474-806,1959-07-30,1959,DE S0030375 A,1952-09-23,GB 1062504X A,1951-09-24,"Loesbare Leitungskupplung mit in den Kupplungshaelften angeordneten, selbsttaetigen Absperrventilen",,S A T A M SA APPAREILLAGES MEC,FRASER JOHN,,https://lens.org/087-772-454-474-806,Patent Application,no,6,1,1,1,0,F16L37/113;;F16K1/12;;F16L37/32,F16K1/12;;F16L37/113;;F16L37/32,,0,0,,,,DISCONTINUED
94,GB,A,GB 688162 A,102-945-951-034-830,1953-02-25,1953,GB 3057050 A,1950-12-14,GB 3057050 A,1950-12-14,Improvements in or relating to apparatus for dispensing liquids,"688,162. Dispensing measured quantities of liquids. AVERY-HARDOLL, Ltd. Dec. 11, 1951 [Dec. 14, 1950; Oct. 17, 1951], Nos. 30570/50 and 24268/51. Classes 106 (v) and 116 [Also in Group XXVIII]. A liquid dispensing unit, particularly for the supply of lubricating oil at garages, comprises a conical piston 40 displaceable in a cylinder 34 in one direction by oil entering a manually-operable valve 52 and in the other direction to expel the measured quantity of oil by a spring 59, and means are provided for preventing fraudulent closing of the valve until completion of the filling or emptying operations; the dispensing unit is used in combination with a supply unit having a number of circularlyarranged supply points 15 each connected by a pipe 16 to a supply of oil under pressure and the dispensing unit and the supply points are provided with interlocking means which, when engaged, bring the valve 52 in the dispensing unit to a position where it can operate a valve 91 in the supply point, the opening of the valves preventing release of the interlocking means. The dispensing unit, when not in use, is stowed in a central compartment 12 under a cover 26 which has a lockable latch 28 and is pivoted on a cover plate 17 rotatable to bring an aperture 22 over the desired supply point 15, and to indicate the brand of oil at one of several windows 21. The cylinder 34 of the dispensing unit is transparent and is fitted in an apertured casing 36 which tapers to a delivery nozzle 37 having a conical valve 52; the valve is urged to the closed position by a spring 56 and is opened by a lever 57 pivoted in a handle 39 and acting on the valve rod 49. In use, the dispensing unit is engaged with the supply point by a bayonet-clip formed by a flange 71 on the delivery nozzle and a groove 77 in the supply unit and the rotation of the unit to engage the clip brings wings 55 on the valve 52 into alignment with grooves 96 in a valve seat member 80. The seat member 80 is axially movable but rotationally fixed and is depressed slightly by the nozzle, against the action of a spring 85, to form a fluidtight seal. The lever 57 can then be operated to open both the valve 52 and a spring-loaded valve 91 in the valve seat member 80 and, while the valves are open, relative turning of the two units in order to remove the dispensing unit is prevented by engagement of the wings 55 with the grooves 96 in the seat member and also with grooves 46 in the nozzle 37. As the piston 40 begins to move upwards, balls 65 in apertures in a sleeve 47 fixed to the casing 36 are forced inwards by a chamfered ring 62 on a sleeve 48 fixed to the piston and are held in this position by the narrower internal bore of the sleeve 48 while the cylinder is filling. The balls act on a ring 66 on the valve rod and prevent the valve 52 from being closed. When the cylinder is full, the balls are prevented from moving outward into the recess 61 at the lower end of the sleeve 48 by a spring 67 which engages them radially outwards of their centres and the valve 52 must be momentarily opened fully by means of the lever 57 so that the conical nose of a plunger 68 positively displaces the balls outwardly. In emptying the cylinder, the balls act similarly to prevent the valve 52 being closed until all the contents have been delivered, and the final opening of the valve to its fullest extent to displace the balls into the recess 60 at the upper end of the sleeve 48 allows free escape of the last drops of oil. A flanged plug 98 in each supply point has a small-bore passage through it and a notch 99 in the side and is raised by the flow of oil to operate an external indicator (not shown) by means of a lever 102.",AVERY HARDOLL LTD,FRASER JOHN,,https://lens.org/102-945-951-034-830,Granted Patent,no,0,4,1,1,0,F16N3/08,F16N3/08,B8N NHCB          NHCB;;B8N NKB           KB+50X;;B8N N24A2         NHCB;;B8N N24B4         NHCB;;B8N N24C2A        NHCB;;B8N N24D11        NHCB;;B8N N24E8         NHCB;;B8N N50X          KB+50X;;F1R R15D          R15D,0,0,,,,EXPIRED
95,US,A,US 2184420 A,127-976-825-791-637,1939-12-26,1939,US 21724838 A,1938-07-02,GB 2184420X A,1937-07-15,Transfer mechanism for counting and computing mechanism,,AVERY HARDOLL LTD,JOHN FRASER,,https://lens.org/127-976-825-791-637,Granted Patent,no,0,2,1,1,0,G06M1/163;;Y10T74/19874;;Y10T74/19633;;Y10T74/19874;;Y10T74/19633;;G06M1/163,G06M1/16,,0,0,,,,EXPIRED
96,DE,C,DE 924609 C,125-282-821-005-88X,1955-03-03,1955,DE S0028631 A,1952-05-22,GB 924609X A,1951-05-24,Einrichtung zur Messung und Ausgabe von Fluessigkeiten,,POUR TOUS APP MECANIQUES SA,FRASER JOHN,,https://lens.org/125-282-821-005-88X,Granted Patent,no,0,0,1,1,0,B67D7/08,B67D7/08,,0,0,,,,EXPIRED
97,GB,A,GB 732282 A,129-025-313-707-795,1955-06-22,1955,GB 675153 A,1953-03-11,GB 675153 A,1953-03-11,Improvements in or relating to valves for controlling the flow of liquids,"732,282. Fluid-pressure servomotor-control systems. AVERY-HARDOLL, Ltd. March 9, 1954 [March 11, 1953], No. 6751/53. Class 135. In a valve 29, Fig. 2, e.g. for filling tank vehicles, of the type which is opened by liquid inlet pressure at 14 and closed by liquid pressure in a chamber 36 under the control of means responsive to tank liquid level, escape of liquid from the chamber is controlled by a relay valve 75, 85, closed in two stages as a float 19, Fig. 5, rises; and admission of liquid to the chamber is determined by the position of the valve 29. Inlet pressure raises the valve against a spring 35 and lifts a shoulder 49 off a ring 48 so that liquid flows via groove 47 and port 46 into tube 43 secured to the valve casing 12 by arms 39 and on which the valve slides, and via port 45 into a control chamber 36 behind the piston 27 carrying the valve, into a pipe 17, 18 and into the tank 10 via ports 67. When the float rises to a certain height its rod 68 allows a valve 75 to close on its seat 78 and restrict flow in pipe 17 to a notch 79 so that pressure in the chamber 36 increases and valve 29 moves downwards to restrict inflow to the tank to a narrow passage around seat lip 34 and also to throttle the flow through valve 48, so that inflow to the chamber 36 equals the flow in pipe 17. As the float rises to its final level, its rod 68 breaks contact with valve 75 and closes the ring valve 85 on to its seat orifices 83 so that valve 29 closes on to the rings 32 and 48. The tank is drained by opening valve 29 through a lever 55.",AVERY HARDOLL LTD,FRASER JOHN,,https://lens.org/129-025-313-707-795,Granted Patent,no,0,0,1,1,0,F16K31/34,F16K31/34,,0,0,,,,EXPIRED
98,DE,B,DE 1133198 B,148-167-780-345-263,1962-07-12,1962,DE S0043743 A,1955-04-29,GB 1133198X A,1954-05-04,Entlastetes Ventil,,S A T A M SA APPAREILLAGES MEC,FRASER JOHN,,https://lens.org/148-167-780-345-263,Patent Application,no,5,1,1,1,0,F16K1/12;;F16K39/024,F16K1/12;;F16K39/02,,0,0,,,,DISCONTINUED
99,CA,A,CA 40299 A,054-638-058-051-487,1892-09-10,1892,CA 40299D A,,CA 40299T A,,FERTILIZER DISTRIBUTOR,,FRASER JOHN;;AMERICAN HARROW COMPANY,FRASER JOHN,,https://lens.org/054-638-058-051-487,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
100,US,A,US 1708217 A,095-037-844-828-357,1929-04-09,1929,US 22284527 A,1927-09-29,US 22284527 A;;GB 2968428 A,1927-09-29,Vehicle chassis,,JOHN FRASER,JOHN FRASER,,https://lens.org/095-037-844-828-357,Granted Patent,no,0,7,1,2,0,B60G9/00;;B60G9/00,B60G9/00,,0,0,,,,EXPIRED
101,GB,A,GB 842135 A,094-448-042-885-122,1960-07-20,1960,GB 3885357 A,1957-12-13,GB 3885357 A,1957-12-13,Improvements in or relating to liquid dispensing apparatus,"842,135. Liquid flow indicators. AVERYHARDOLL Ltd. Dec. 11, 1958 [Dec. 13, 1957], No. 38853/57. Class 69 (1). In a sight glass arrangement for liquid dispensing apparatus of the kind in which the liquid is measured by means of a meter and delivered in a continuous stream to a receptacle, the sight glass 25 being arranged in a loop of a small-bore piping 21, 22, the ends of which are connected to a main large-bore conduit leading directly from a meter to a delivery hose respectively upstream and downstream of a flowrestricting device which produces a pressure drop between the two ends of the loop, the flowrestricting device comprises a disc 17 resiliently urged in an upstream direction in the large-bore conduit and co-operating with a downstreamfacing step 14 in this conduit.",AVERY HARDOLL LTD,FRASER JOHN,,https://lens.org/094-448-042-885-122,Granted Patent,no,0,1,1,1,0,G01P13/004,G01P13/00,G1R RK            RK,0,0,,,,EXPIRED
102,EP,A1,EP 3947297 A1,104-878-312-694-248,2022-02-09,2022,EP 20782400 A,2020-03-31,US 201962827322 P;;US 2020/0025911 W,2019-04-01,FLOW THROUGH AEROBIC GRANULAR SLUDGE SYSTEM AND METHOD,,CAROLLO ENG INC,FRASER JOHN,,https://lens.org/104-878-312-694-248,Patent Application,yes,0,0,6,6,0,C02F3/301;;C02F2203/004;;Y02W10/10;;C02F3/301;;C02F2203/004;;C02F1/006;;C02F3/1226;;C02F3/301;;C02F2203/004;;C02F2301/046,C02F3/02;;C02F3/28;;C02F3/30,,0,0,,,,PENDING
103,CA,A,CA 307802 A,129-067-086-767-565,1931-01-20,1931,CA 307802D A,,CA 307802T A,,APPARATUS FOR DELIVERING MEASURED QUANTITIES OF LIQUID,,FRASER JOHN,FRASER JOHN,,https://lens.org/129-067-086-767-565,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
104,DE,C,DE 959774 C,143-210-819-528-307,1957-03-14,1957,DE S0034706 A,1953-08-07,GB 959774X A,1952-08-07,Ventil fuer die Kontrolle der Fuellung von Behaeltern,,POUR TOUS APP MECANIQUES SA,FRASER JOHN,,https://lens.org/143-210-819-528-307,Granted Patent,no,2,1,1,1,0,F16K21/20,F16K21/20,,0,0,,,,EXPIRED
105,CA,A,CA 568168 A,150-223-751-155-503,1958-12-30,1958,CA 568168D A,,CA 568168T A,,VALVES FOR CONTROLLING THE FLOW OF LIQUIDS,,AVERY HARDOLL LTD,FRASER JOHN,,https://lens.org/150-223-751-155-503,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
106,US,A,US 1763427 A,039-551-407-540-102,1930-06-10,1930,US 26068128 A,1928-03-10,GB 1763427X A,1927-03-15,Apparatus for the measurement of liquids,,BRITISH PETROLEUM CO,JOHN FRASER,,https://lens.org/039-551-407-540-102,Granted Patent,no,0,0,1,1,0,B67D7/166;;B67D7/166,B67D7/16,,0,0,,,,EXPIRED
107,WO,A1,WO 2020/205834 A1,080-413-976-043-30X,2020-10-08,2020,US 2020/0025911 W,2020-03-31,US 201962827322 P,2019-04-01,FLOW THROUGH AEROBIC GRANULAR SLUDGE SYSTEM AND METHOD,"A flow through aerobic granular sludge (AGS) system includes a flow through reactor. The flow through reactor includes a first adsorption zone and first and second unaerated and aerated zones and may include a wastewater distribution system and a selector zone. The first adsorption zone includes AGS granules and may include a mixing device. The first and second unaerated zones are under anaerobic, anoxic, or both anaerobic and anoxic conditions and each may include a mixing device. The first and second aerated zones are under aerobic conditions and each may include an aeration device. The flow through reactor is configured such that the wastewater and AGS granules in the first adsorption zone flow continuously from the first adsorption zone through the first unaerated zone, the first aerated zone, the second unaerated zone, the second aerated zone, and optionally to the selector zone and out of the flow through reactor.",CAROLLO ENG INC,FRASER JOHN,,https://lens.org/080-413-976-043-30X,Patent Application,yes,5,6,6,6,0,C02F3/301;;C02F2203/004;;Y02W10/10;;C02F3/301;;C02F2203/004;;C02F1/006;;C02F3/1226;;C02F3/301;;C02F2203/004;;C02F2301/046,C02F3/02;;C02F3/28;;C02F3/30,,1,0,,,See also references of EP 3947297A4,PENDING
108,GB,A,GB 703791 A,074-770-328-858-373,1954-02-10,1954,GB 2232251 A,1951-09-24,GB 2232251 A,1951-09-24,"Improvements in or relating to liquid meters, pumps and motors","703,791. Reciprocating pumps. AVERYHARDOLL, Ltd. July 23, 1952 [Sept. 24, 1951], No. 22322/51. Drawings to Specification. Class 102 (1). [Also in Group XXIX] A pump of the type described in Specification 625,993, [Group XXIX], has its rotary disc distributing valve engaging a metal plate seat thin enough to be formed by piercing and secured to the body by sweating.",AVERY HARDOLL LTD,FRASER JOHN,,https://lens.org/074-770-328-858-373,Granted Patent,no,0,0,1,1,0,G01F3/18,G01F3/18,F1W WEGA          WEGA;;F1W W100          WEGA;;F1W W108          WEGA;;F1W W112          WEGA;;F1W W208          WEGA;;F1W W506          WEGA,0,0,,,,EXPIRED
109,CA,A1,CA 3135606 A1,082-189-923-434-111,2020-10-08,2020,CA 3135606 A,2020-03-31,US 201962827322 P;;US 2020/0025911 W,2019-04-01,FLOW THROUGH AEROBIC GRANULAR SLUDGE SYSTEM AND METHOD,"A flow through aerobic granular sludge (AGS) system includes a flow through reactor. The flow through reactor includes a first adsorption zone and first and second unaerated and aerated zones and may include a wastewater distribution system and a selector zone. The first adsorption zone includes AGS granules and may include a mixing device. The first and second unaerated zones are under anaerobic, anoxic, or both anaerobic and anoxic conditions and each may include a mixing device. The first and second aerated zones are under aerobic conditions and each may include an aeration device. The flow through reactor is configured such that the wastewater and AGS granules in the first adsorption zone flow continuously from the first adsorption zone through the first unaerated zone, the first aerated zone, the second unaerated zone, the second aerated zone, and optionally to the selector zone and out of the flow through reactor.",CAROLLO ENG INC,FRASER JOHN,,https://lens.org/082-189-923-434-111,Patent Application,no,0,1,6,6,0,C02F3/301;;C02F2203/004;;Y02W10/10;;C02F3/301;;C02F2203/004;;C02F1/006;;C02F3/1226;;C02F3/301;;C02F2203/004;;C02F2301/046,C02F3/02;;C02F3/28;;C02F3/30,,0,0,,,,PENDING
110,DE,C,DE 873048 C,104-972-203-443-520,1953-04-09,1953,DE S0026326 A,1951-12-14,GB 873048X A,1950-12-14,"Einrichtung zur Ausgabe und Dosierung von Fluessigkeiten, insbesondere von OEl",,POUR TOUS APP MECANIQUES SA,FRASER JOHN,,https://lens.org/104-972-203-443-520,Granted Patent,no,0,0,1,1,0,B67D7/60,B67D7/60,,0,0,,,,EXPIRED
111,CA,A,CA 286877 A,119-886-761-369-947,1929-01-29,1929,CA 286877D A,,CA 286877T A,,LIQUID MEASURE,,BRITISH PETROLEUM CO,FRASER JOHN,,https://lens.org/119-886-761-369-947,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
112,US,A,US 2697418 A,140-210-027-494-381,1954-12-21,1954,US 12181549 A,1949-10-17,GB 2697418X A,1948-11-08,Liquid meter,,AVERY HARDOLL LTD,JOHN FRASER,,https://lens.org/140-210-027-494-381,Granted Patent,no,14,1,1,1,0,G01F3/065;;G01F3/065,G01F3/06,,0,0,,,,EXPIRED
113,EP,A1,EP 3676228 A1,163-165-258-162-880,2020-07-08,2020,EP 18852021 A,2018-08-29,US 201762553393 P;;US 2018/0048528 W,2017-09-01,BALLASTED ACTIVATED SLUDGE TREATMENT COMBINED WITH HIGH-RATE LIQUIDS/SOLIDS SEPARATION SYSTEMS,,CAROLLO ENG INC,FRASER JOHN,,https://lens.org/163-165-258-162-880,Patent Application,yes,0,0,8,8,0,C02F3/1226;;C02F3/308;;C02F2305/12;;C02F3/307;;Y02W10/10;;C02F1/004;;C02F3/107;;C02F3/1215;;C02F3/121;;C02F3/1221;;B01D21/0039;;B01D17/02;;C02F3/308;;C02F2305/12;;C02F3/1221;;B01D17/02;;C02F3/107;;C02F3/1226;;B01D21/0039;;C02F3/121;;C02F3/307;;C02F1/004;;C02F3/1215;;Y02W10/10;;C02F3/1215;;C02F3/1226;;C02F3/307;;C02F3/308;;C02F2305/12,C02F3/12;;B01D21/02;;C02F3/30,,0,0,,,,PENDING
114,CA,A,CA 187710 A,197-466-786-564-333,1918-12-03,1918,CA 187710D A,1918-05-29,CA 187710T A,1918-05-29,CHURN,,FRASER JOHN,FRASER JOHN,,https://lens.org/197-466-786-564-333,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
115,GB,A,GB 732146 A,022-616-138-053-433,1955-06-22,1955,GB 3143152 A,1952-12-11,GB 3143152 A,1952-12-11,Improvements in or relating to swivelling joints for pipes or conduits,"732,146. Filters. AVERY-HARDOLL, Ltd. Nov. 11, 1953 [Dec. 11, 1952], No. 31431/52. Class 46. [Also in Group XXVIII] A swivelling pipe joint includes a filter which is readily removable by unfastening the bolt 16 which secures the coupling parts 10, 11, the filter comprising a gauze screen having an outer frusto-conical portion 43 mounted on an apertured support 45 fitting within the coupling part 11, and a re-entrant inner frusto-conical portion 44 carried by the bolt 16.",AVERY HARDOLL LTD,FRASER JOHN,,https://lens.org/022-616-138-053-433,Granted Patent,no,0,3,1,1,0,F16L27/0841,F16L27/08,B1D DNA           B1DNA;;B1D DNJA          DNJA;;F2G G6B           G6Z;;F2G G6C1          G6Z;;F2G G6D           G6Z;;F2G G6Z           G6Z,0,0,,,,EXPIRED
116,CA,A,CA 14852 A,025-003-463-410-737,1882-05-29,1882,CA 14852D A,,CA 14852T A,,IMPROVEMENTS ON DRILL AND BROADEAST SOWERS,,FRASER JOHN,FRASER JOHN,,https://lens.org/025-003-463-410-737,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
117,GB,A,GB 737696 A,024-698-227-637-822,1955-09-28,1955,GB 471653 A,1953-02-19,GB 471653 A,1953-02-19,Improvements in or relating to liquid-meter operated means for controlling valves,"737,696. Fluid-actuated valves. AVERYHARDOLL, Ltd. Feb. 15, 1954 [Feb. 19, 1953], No. 4716/53. Class 135. A liquid meter operated 'controlling means for a main valve 69 has a pilot valve 77, Fig. 1, held open by resiliently-loaded retaining means 39, Fig. 3, e.g. acting through a crank 31, link 59 and crank 61, 62, 78, and released for closing by movement of one element 33 of a screw and nut which is restrained against rotation by the retaining means, e.g. by a rod 32 on crank 31 engaging a lug 34 on nut 33, the other screw element 30 being driven by the meter 10, e.g. through bevel gears. 17, 18, clutch 19, cyclometer counter 22, pins 24, starwheel 25 and gears 27, 28, to rotate the screw until co-operating abutments 35, 37 on the elements engage and the crank 31 is turned by the meter to disengage the retaining means. As shown, a half revolution of a pin 24 corresponds to the flow of a unit quantity of liquid. A handle 48 is pushed in to engage and rotate a shaft 29 to screw the nut 33 a certain distance to the left along the screw 30 corresponding to the quantity of liquid to be delivered which is indicated by a counter 46, 47. A pump is started to supply liquid via pipe 14, the meter and valve inlet 64 so that liquid passes an orifice 73, behind a main valve piston 71, and orifice 76 to chamber 75. The crank 31 is moved manually to engage the detent 39 and open valve 77 so that pressure behind the piston is relieved via pipe 74 and the main valve opens. During delivery of the last unit quantity of liquid the engaged abutments 35, 37 through the rod 32 force the part 38 on crank 31 under the detent 39 so that a follower 43 pivoted on the crank rides a cam 44 which allows the pilot valve and the main valve to close gradually until a complete cut-off occurs at a point 45 on the cam when the last unit finishes.",AVERY HARDOLL LTD,FRASER JOHN,,https://lens.org/024-698-227-637-822,Granted Patent,no,0,1,2,2,0,B67D7/301;;F16K21/16;;G01F15/001,B67D7/30;;F16K21/16;;G01F15/00,F2V VS22          VS22,0,0,,,,EXPIRED
118,DE,C,DE 834456 C,045-747-227-638-956,1952-03-20,1952,DE S0020075 A,1950-10-01,GB 834456X A,1946-08-15,Fluessigkeitsverteilervorrichtungen,,POUR TOUS APP S MECANIQUES LA,FRASER JOHN,,https://lens.org/045-747-227-638-956,Granted Patent,no,0,0,1,1,0,B67D7/08,B67D7/08,,0,0,,,,EXPIRED
119,CA,A,CA 55869 A,106-121-651-018-373,1897-05-10,1897,CA 55869D A,1896-07-07,CA 55869T A,1896-07-07,FUSE LIGHTER,,FRASER JOHN,FRASER JOHN,,https://lens.org/106-121-651-018-373,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
120,GB,A,GB 709932 A,133-272-328-423-51X,1954-06-02,1954,GB 1222351 A,1951-05-24,GB 1222351 A,1951-05-24,Improvements in or relating to liquid measuring and dispensing apparatus,"709,932. Dispensing liquids. AVERY-HARDOLL, Ltd. May 12, 1952 [May 24, 1951], No. 12223/51. Class 116 Means for automatically cutting off the supply of liquid and closing the valves after the delivery of a predetermined quantity comprises a lever, operable by the starting control and having projection and a settable disc with a slot: after presetting and operating the starting control, the projection engages the edge of the disc and rocks about the projection, to open the valve and close the switch. Engaging the projection in the slot effects partial closure of the valve when the disc returns to the zero position and further entry into the slot effects complete closure of the valve and switching off of the motor. A shaft 10 is connected to the indicators, a shaft 11 to a totalizer, both shafts rotating once for each unit delivered, and a shaft 12 for zeroizing. On a spindle 14 is a settable disc 13 having a slot 33 with chamfered edge, a frustoconical face and a toothed periphery against which bears a locating roller 17. A gear wheel 21 coaxial with the disc 13 meshes with a gear wheel 22 on a shaft 23 which engages with a pinion 24 on a shaft 26 coaxial with which is a pinion 25 engageable with a pinion 27. The pinion 27 is displaceable by a cam 66 on a lever 38' pivoted to a lever 36 which is guided in the pump casing and supports the lever 38 on a pivot 37. The lever 38 has a projection 39 bearing against the disc 13 and the projection is shaped to allow gradual entry into the slot 33. The lever has a slot engageable by a rod 43 operated by a starting handle 44 and retained by a detent. The lever is displaceable against the spring 71 to prevent jamming. A spindle 48 carries a two-armed lever, one arm 49 having a roller engaging in a slot 51 at the end of lever 38 and the other arm 52 engaging a cam 53 eccentrically and adjustably mounted on the shaft 23 and rotatable once for each unit delivered. Disc 65 retains the lever 36 in position to prevent delivery unless zeroizing has been effected and to prevent zeroizing until the starting handle is off. The lever 38 carries at one end a lever 72 connected by a rod to a valve 41. An arm 75 is pivoted at 76 and engages the rods and an arm 77 engages an abutment on the lever 72 so that upward movement of the lever opens the valve. A spring 79 urges the valve to the closed position. A lever 82 is connected to the rod 72 and to a pivot 81 also carrying a lever 83 connected to a rod 80 and the motor switch. A spring 85 urges the lever 83 to the switch closed position. In operation, turning a knob sets the disc 13 for a predetermined amount. The handle 44 is operated to open the valve and close the motor switch. During the delivery of the last gallon projection 39 engages the slot 33 and partially closes the valve at the completion of delivery, lever 52 slides on the cam 53 and effects further movement of the lever 38 to completely close the valve and close the motor switch the latter being effected at this stage by a lost motion connection. Specifications 426,267, 615,776 and 657,146 are referred to.",AVERY HARDOLL LTD,FRASER JOHN,,https://lens.org/133-272-328-423-51X,Granted Patent,no,0,3,1,1,0,B67D7/08,B67D7/08,B8N NHCC          NHCC;;B8N N24D13        NHCC;;B8N N24F5A        NHCC;;B8N N24F5B        NHCC,0,0,,,,EXPIRED
121,GB,A,GB 769323 A,167-926-508-556-313,1957-03-06,1957,GB 1298054 A,1954-05-04,GB 1298054 A,1954-05-04,Improvements in or relating to valves,"769,323. Slow-closing valves. AVERYHARDOLL, Ltd. April 21, 1955 [May 4, 1954], No. 12980/54. Class 135. Construction.-In a valve comprising a body 29, Fig. 3, having a through passage in which is an annular seat 32, a valve closure member 36 co-operating with the seat to close the passage and movable away from the seat 32 into a chamber 55 having a permanently open restricted communication with the flow passage on the upstream side of the seat 32, a pilot valve 48 to connect the chamber 55 with the flow passage on the downstream side of the seat 32, and manually operated means, such as an arm 27, for opening first the pilot valve and then the valve closure 36, a latch, for example a pawl 84, Fig. 7, is provided to hold the closure member 36 in the open position. The valve in a branch of a pressure fuel main such as is used for refuelling aircraft is disposed below ground level and comprises the hollow bulbous body 29, Fig. 3, having a cup-shaped member 34 intermediate its ends supported on radial webs 35; the upper end of member 34 serves as a guide for the closure member 36 provided with a lower cylindrical part 37, slidable in a non- fluid-tight manner in the member 34, and an upper conical part 38. A resilient packing ring 39 abutting the seat 32 in the valve closed position shown is secured between the member 36 and a cap 41 thereon, which latter has lugs 42 engaging slots 43 in the seat 32 to guide the member 36. The cap 41 is positioned by a cage 44 incorporating a depending valve seat for the frusto-conical head 49 of the pilot valve 48 formed with a stem 47 slidable in the member 36; with the pilot valve 48 open a flow path through the member 36 is afforded by the orifice 52. The pilot valve 48 and the closure member 36 are urged on to their seats by a spring 53, one end of which abuts a sleeve 54 in the chamber 55 comprised by the interior of the member 34; liquid pressure in the chamber 55 assists the closing action of the spring. The lower end of the stem 47 which passes through a partition 58 into a cylinder 59 threaded to the lower end of the member 34, has a piston 61 thereon that is slidable in the cylinder 59, the piston movement being limited by a shoulder 63 and a nut 64 both on the stem 47; internal axial grooves 65 in the piston 61 open into radial ports 66 in its upper surface so that when abutting shoulder 63 liquid can pass the piston by traversing grooves 65 and ports 66 whilst when it engages the nut 64 the grooves 65 are closed thereby. The lower end of the stem 47 is axially bored 67 and via radial holes 68 and 70 interconnects the lower end of the cylinder 59 with the chamber 55 when the valve is closed. According to the Provisional Specification the lower part of the closure element is provided with a guide rod, that passes through the cup-shaped member and a pilot valve stem which is connected by a diametral pin to a flanged collar around the element. A horizontal shaft passes through the valve body and with a fork engages the flange as well as having two arms, one of which is movable to open the valve and the other is arranged to engage a latch. Latching mechanism.-A collar 72 on the stem 47 is engaged by a finger 73 on a spindle 74 having a plate 77, Fig. 7, fixed thereto comprising two graduated portions 78 and 79, the portion 78 co-operating with stops 81 and 82 to limit the rotation of the spindle; the portion 79 is notched 83 for engagement by the spring- loaded pawl, 84 which holds the valve in the open position. A sleeve 86 loose on the spindle 74 carries a bell crank lever 87 and the operating lever 27, Fig. 3, one arm of the lever carrying a pawl 88, Fig. 7, loaded by a spring 91 cooperating with a lug 89 on the portion 78; the lever 27 and lever 87 are spring urged in a clockwise direction, their movement being limited by a stop 94 on the portion 78. With the parts in the positions shown, and upon pulling a tension member 26 thus moving the arm 27 anti-clockwise, the pawl 88 engages the lug 89 and the plate 77 is moved with the arm 27 to open the valve; after traversing a given angle the spring 91 moves through dead-centre and on further movement tends to swing the pawl 88 away from lug 89 but is prevented from doing so by undercutting of the latter. The portion 78 engages the stop 82 and upon releasing the chain attached to the arm 27 the pawl 88 clears the lug 89 and the lever 87 swings back against the stop 94, under the influence of the spring 91 and a further spring loading the arm 27, leaving the plate 77 latched in the valve open position. To close the valve the chain is again pulled to turn the arm 27 and lever 87 in an anti-clockwise direction; the latter engages a projection 95 on the pawl 84 and rocks it clear of the notch 83 so that the plate 77 is free to turn clockwise and the spring 53 closes the valve; movement of the arm 27 is limited by a stop 96. Operation.-Liquid in the body 29, Fig. 3, enters the chamber 55 between the members 34 and 36 and upon rotating the arm 27 to open the valve the finger 73 moves the stem 47 downwardly unseating the pilot valve 48 so relieving the pressure in chamber 55; the valve then abuts the closure member 36 and moves it away from the seat 32. The hole 68 passes through the partition 58 and permits free flow of liquid from the upper end of the cylinder 59 to the chamber 55; at the same time liquid also passes from the lower to the upper part of the cylinder via the grooves 65 and ports 66. Upon rotating the arm 27 to close the valve and after the unlatching operation the spring 53 urges the stem 47 and hence the element 36 upwardly whereupon the grooves 65 are closed and liquid cannot pass through the piston; until the hole 68 is obturated by the partition 58 liquid can flow from the upper part of the cylinder 59 to the chamber 55 but thereafter such flow is prevented and liquid can only escape into the chamber by way of an adjustable orifice 69 controlled by a needle 71 whereby the rate of valve closure can be set as required.",AVERY HARDOLL LTD,FRASER JOHN,,https://lens.org/167-926-508-556-313,Granted Patent,no,0,6,1,1,0,F16K1/126,F16K1/12,F2V VS21          VS21,0,0,,,,EXPIRED
122,GB,A,GB 190320881 A,166-304-779-573-032,1904-08-11,1904,GB 190320881D A,1903-09-29,GB 190320881T A,1903-09-29,Improvements in Automatic Couplings for Railway Carriages Waggons and other Vehicles.,"20,881. Fraser, J. Sept. 29. Couplings, automatic and non - automatic. - A swinging hook d is pivoted to a coupling-head a on each vehicle in such a manner that it tends to swing into coupling position. The outer faces of the hooks are formed so that, when two vehicles are pushed together, the hooks swing outwards and upwards and then fall into engagement. Each hook can be lifted out of engagement with the other by means of a chain g passing round pulleys h, i and attached to a rod enclosed in a tube l. Handles k on the rod project through longitudinal slots in the tube and are engaged with transverse slots when it is desired to hold the coupling-hooks raised. The coupling-heads a have hooks b for the reception of ordinary link couplings, and may be secured to the draw-bars by means of straps n and bolts o.",FRASER JOHN,FRASER JOHN,,https://lens.org/166-304-779-573-032,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
123,GB,A,GB 190828476 A,003-649-399-015-998,1909-09-16,1909,GB 190828476D A,1908-12-31,GB 190828476T A,1908-12-31,Improvements in and relating to Turnip Topping and Tailing Machines.,,FRASER JOHN,FRASER JOHN,,https://lens.org/003-649-399-015-998,Patent Application,no,0,1,1,1,0,,,,0,0,,,,DISCONTINUED
124,CA,A,CA 304374 A,014-269-357-781-445,1930-09-30,1930,CA 304374D A,,CA 304374T A,,FLOW METER FOR MEASURING LIQUIDS,,BRITISH PETROLEUM CO,FRASER JOHN,,https://lens.org/014-269-357-781-445,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
125,WO,A1,WO 2019/046416 A1,069-406-517-578-774,2019-03-07,2019,US 2018/0048528 W,2018-08-29,US 201762553393 P,2017-09-01,BALLASTED ACTIVATED SLUDGE TREATMENT COMBINED WITH HIGH-RATE LIQUIDS/SOLIDS SEPARATION SYSTEMS,"Described is a method of treating wastewater. The method includes receiving the wastewater at a ballasted activated sludge secondary treatment aeration basin. The method also includes adding a ballast material to the wastewater, treating the wastewater in the ballasted activated sludge secondary treatment aeration basin to produce a ballasted mixed liquor effluent, receiving the ballasted mixed liquor effluent at a high-rate heavy solids removal zone that includes one or more high-rate heavy solids removal units, and removing ballasted heavy solids from the ballasted mixed liquor effluent using the one or more high-rate heavy solids removal units to produce a concentrated ballasted heavy solids effluent and a clarified liquid effluent. Also described is a system for treating wastewater including a ballasted activated sludge secondary treatment aeration basin and a high-rate heavy solids removal zone for treating a ballasted mixed liquor effluent.",CAROLLO ENG INC,FRASER JOHN,,https://lens.org/069-406-517-578-774,Patent Application,yes,16,2,8,8,0,C02F3/1226;;C02F3/308;;C02F2305/12;;C02F3/307;;Y02W10/10;;C02F1/004;;C02F3/107;;C02F3/1215;;C02F3/121;;C02F3/1221;;B01D21/0039;;B01D17/02;;C02F3/308;;C02F2305/12;;C02F3/1221;;B01D17/02;;C02F3/107;;C02F3/1226;;B01D21/0039;;C02F3/121;;C02F3/307;;C02F1/004;;C02F3/1215;;Y02W10/10;;C02F3/1215;;C02F3/1226;;C02F3/307;;C02F3/308;;C02F2305/12,C02F3/12;;B01D21/02;;C02F3/30,,1,0,,,See also references of EP 3676228A4,PENDING
126,GB,A,GB 857348 A,086-759-500-530-90X,1960-12-29,1960,GB 989958 A,1958-03-27,GB 989958 A,1958-03-27,Improvements in or relating to rotary metering devices for liquids,"857,348. Integrating-apparatus. AVERY-HARDOLL Ltd. March 26, 1959 [March 27, 1958], No. 9899/58. Class 106 (4). [Also in Group XXVI] Integrating-apparatus for a liquid meter having weight-recording mechanism 31 driven by the rotor of the meter through change-speed gearing incorporates density-responsive means 26 which is adapted to continuously regulate the said gearing in accordance with density variations in order to give a true measure of the weight of liquid passing through the said meter. The density-responsive means comprises a float 48 carrying a slotted arm 51 which is pivotably and slidably connected to a piston 53 provided with a rack 88. Variations in the density of liquid in the float chamber 49 causes corresponding movement of the float which controls the setting of valves, (see Figs. 6 .. 9 not shown), determining the pressure differential across the piston. Reciprocation of the piston and its associated rack 88 causes the driven disc 106 of a continuously-variable speed friction gearing to move radially across the driving disc 105 thereof which is connected by a gear train 93 ... 97, 103, 104 to the gearing 24 disposed between a volume registering mechanism 25 and the rotor of the meter. The disc 106 drives the member 31 through rods, see Fig. 3 (not shown), engaging notches in a disc 109 driving bevel-gears 112 coupled to a differential gear of the epicyclic type 101, 114, 115. In a modification, Fig. 13 (not shown), the float is mounted on a cental tube which is pivotably connected to the piston and carries valve members for controlling the flow through the density responsive means. The tube carries a slidably adjustable weight and the piston carries a rack bar for operating the changespeed gearing disposed between the rotor of the meter and the weight recording apparatus.",AVERY HARDOLL LTD,FRASER JOHN,,https://lens.org/086-759-500-530-90X,Granted Patent,no,0,2,1,1,0,G01F15/02,G01F15/02,,0,0,,,,EXPIRED
127,US,A,US 2665926 A,094-715-693-096-956,1954-01-12,1954,US 21410051 A,1951-03-06,US 21410051 A,1951-03-06,Coupling device for pipes or conduits,,AVERY HARDOLL LTD,JOHN FRASER,,https://lens.org/094-715-693-096-956,Granted Patent,no,7,25,1,1,0,F16L37/113;;F16L37/32;;Y10T137/87941;;Y10T137/87941;;F16L37/113;;F16L37/32,F16L37/113;;F16L37/32,,0,0,,,,EXPIRED
128,IL,B1,IL 272932 B1,103-149-309-286-511,2023-06-01,2023,IL 27293220 A,2020-02-26,US 201762553393 P;;US 2018/0048528 W,2017-09-01,Ballasted activated sludge treatment combined with high rate liquids/solids separation systems,,CAROLLO ENG INC;;FRASER JOHN,FRASER JOHN,,https://lens.org/103-149-309-286-511,Unknown,no,8,0,8,8,0,C02F3/1226;;C02F3/308;;C02F2305/12;;C02F3/307;;Y02W10/10;;C02F1/004;;C02F3/107;;C02F3/1215;;C02F3/121;;C02F3/1221;;B01D21/0039;;B01D17/02;;C02F3/308;;C02F2305/12;;C02F3/1221;;B01D17/02;;C02F3/107;;C02F3/1226;;B01D21/0039;;C02F3/121;;C02F3/307;;C02F1/004;;C02F3/1215;;Y02W10/10;;C02F3/1215;;C02F3/1226;;C02F3/307;;C02F3/308;;C02F2305/12,B01D17/02;;B01D21/00,,1,0,,,"SAKAI ET AL, NPL1, 1 August 1997 (1997-08-01)",PENDING
129,DE,B,DE 1044542 B,113-394-261-437-086,1958-11-20,1958,DE S0038089 A,1954-03-10,GB 1044542X A,1953-03-11,Ventil zum Fuellen von Behaeltern,,S A T A M SA APPAREILLAGES MEC,FRASER JOHN,,https://lens.org/113-394-261-437-086,Patent Application,no,4,0,1,1,0,F16K31/34;;G01F15/105,F16K31/34;;G01F15/10,,0,0,,,,DISCONTINUED
130,US,A,US 2665925 A,119-746-549-988-447,1954-01-12,1954,US 17649850 A,1950-07-28,GB 2665925X A,1949-08-02,Coupling device for pipes or conduits,,AVERY HARDOLL LTD,JOHN FRASER,,https://lens.org/119-746-549-988-447,Granted Patent,no,7,6,1,1,0,F16L37/113;;F16L37/113;;F16L37/32;;F16L37/32;;Y10T137/87941;;Y10T137/87941,F16L37/113;;F16L37/32,,0,0,,,,EXPIRED
131,ZA,B,ZA 83656 B,165-287-192-821-318,1983-11-30,1983,ZA 83656 A,1983-02-01,ZA 83656 A,1983-02-01,WINDOW HANDLE,,SOUTH CANNON HYDRAULICS PTY LT,FRASER JOHN,,https://lens.org/165-287-192-821-318,Granted Patent,no,0,0,1,1,0,,E05B/,,0,0,,,,EXPIRED
132,US,A,US 2775258 A,062-517-024-284-935,1956-12-25,1956,US 41485654 A,1954-03-08,GB 2775258X A,1953-03-11,Valves for controlling the flow of liquids,,AVERY HARDOLL LTD,JOHN FRASER,,https://lens.org/062-517-024-284-935,Granted Patent,no,3,5,1,1,0,F16K21/18;;F16K21/18;;G05D9/04;;G05D9/04;;Y10T137/73;;Y10T137/73;;Y10T137/7371;;Y10T137/7371,F16K21/18;;G05D9/04,,0,0,,,,EXPIRED
133,DE,C,DE 833014 C,090-281-340-336-888,1952-03-03,1952,DE S0020074 A,1950-10-01,GB 2469946 A,1946-08-19,Fluessigkeitsverteilervorrichtung,,POUR TOUS APP MECANIQUES SA,FRASER JOHN,,https://lens.org/090-281-340-336-888,Granted Patent,no,0,0,2,2,0,B67D7/84;;B67D7/56,B67D7/56;;B67D7/84,,0,0,,,,EXPIRED
134,US,A,US 2845048 A,097-304-119-693-708,1958-07-29,1958,US 43857854 A,1954-06-22,GB 2845048X A,1953-07-01,Rotary liquid motors,,AVERY HARDOLL LTD,JOHN FRASER,,https://lens.org/097-304-119-693-708,Granted Patent,no,9,3,1,1,0,F01C1/3441;;G01F3/065;;F01C1/3441;;G01F3/065,F01C1/344;;G01F3/06,,0,0,,,,EXPIRED
135,EP,A4,EP 3676228 A4,118-286-748-629-93X,2021-05-26,2021,EP 18852021 A,2018-08-29,US 201762553393 P;;US 2018/0048528 W,2017-09-01,BALLASTED ACTIVATED SLUDGE TREATMENT COMBINED WITH HIGH-RATE LIQUIDS/SOLIDS SEPARATION SYSTEMS,,CAROLLO ENG INC,FRASER JOHN,,https://lens.org/118-286-748-629-93X,Search Report,no,4,0,8,8,0,C02F3/1226;;C02F3/308;;C02F2305/12;;C02F3/307;;Y02W10/10;;C02F1/004;;C02F3/107;;C02F3/1215;;C02F3/121;;C02F3/1221;;B01D21/0039;;B01D17/02;;C02F3/308;;C02F2305/12;;C02F3/1221;;B01D17/02;;C02F3/107;;C02F3/1226;;B01D21/0039;;C02F3/121;;C02F3/307;;C02F1/004;;C02F3/1215;;Y02W10/10;;C02F3/1215;;C02F3/1226;;C02F3/307;;C02F3/308;;C02F2305/12,C02F3/12;;B01D17/02;;B01D21/00;;B01D21/02;;B01D21/26;;C02F1/00;;C02F3/30,,2,1,127-187-906-734-034,10.1016/s0043-1354(97)00023-7,"SAKAI Y ET AL: ""Simultaneous removal of organic and nitrogen compounds in intermittently aerated activated sludge process using magnetic separation"", WATER RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 31, no. 8, 1 August 1997 (1997-08-01), pages 2113 - 2116, XP004877681, ISSN: 0043-1354, DOI: 10.1016/S0043-1354(97)00023-7;;See also references of WO 2019046416A1",PENDING
136,GB,A,GB 2558172 A,113-113-528-914-66X,2018-07-11,2018,GB 201606224 A,2016-04-12,GB 201606224 A,2016-04-12,A method for cleaning drill pipe,A method of cleaning the internal diameters of drill pipe comprises of a cleaning tool 1 comprising a cleaning element such as radially extending bristles 4; the overall mass of the tool overcomes the buoyancy and friction force of the fluid in the pipe and allows the cleaning tool to fall through the pipe under its own weight; the method further comprises a landing sub 7 (Figure 4) with an internal profile which catches and prevents the tool from travelling further down the pipe. The tool may comprise a handle 2 and a nose 5. The tool can be uncoupled so that different sections can be replaced. The cleaning tool may comprise a tracking device so that it can be located in the pipe.,CHERISH BODMAN;;JOHN FRASER;;JASON FONG;;CORETRAX TECH LIMITED,JOHN FRASER,,https://lens.org/113-113-528-914-66X,Patent Application,no,7,1,3,3,0,E21B37/02;;E21B17/006;;B08B9/049;;B08B9/04;;E21B37/02;;F16L55/26,E21B37/02;;B08B9/04;;E21B31/00;;F16L55/26,,0,0,,,,ACTIVE
137,US,A,US 2126103 A,148-112-396-394-636,1938-08-09,1938,US 74243634 A,1934-09-01,GB 2126103X A,1934-07-28,Liquid measuring and dispensing apparatus,,AVERY HARDOLL LTD,JOHN FRASER,,https://lens.org/148-112-396-394-636,Granted Patent,no,0,2,1,1,0,B67D7/26;;B67D7/26,B67D7/26,,0,0,,,,EXPIRED
138,US,A,US 1763426 A,164-718-556-086-963,1930-06-10,1930,US 7602725 A,1925-12-17,GB 1763426X A,1924-12-20,Apparatus for the measurement of liquids by volume,,BRITISH PETROLEUM CO,JOHN FRASER,,https://lens.org/164-718-556-086-963,Granted Patent,no,0,3,1,1,0,B67D7/166;;B67D7/166,B67D7/16,,0,0,,,,EXPIRED
139,US,A,US 2302201 A,023-619-094-406-005,1942-11-17,1942,US 32823740 A,1940-04-06,GB 2302201X A,1939-05-15,Liquid measuring and dispensing apparatus,,AVERY HARDOLL LTD,JOHN FRASER,,https://lens.org/023-619-094-406-005,Granted Patent,no,0,3,1,1,0,B67D7/22;;B67D7/22,B67D7/22,,0,0,,,,EXPIRED
140,US,A,US 2224540 A,011-474-164-612-26X,1940-12-10,1940,US 31873240 A,1940-02-13,GB 2224540X A,1939-02-07,Liquid measuring and dispensing apparatus,,AVERY HARDOLL LTD,JOHN FRASER,,https://lens.org/011-474-164-612-26X,Granted Patent,no,0,13,1,1,0,B67D7/30;;B67D7/30,B67D7/30,,0,0,,,,EXPIRED
141,EP,A4,EP 3947297 A4,031-870-753-450-027,2022-12-28,2022,EP 20782400 A,2020-03-31,US 201962827322 P;;US 2020/0025911 W,2019-04-01,FLOW THROUGH AEROBIC GRANULAR SLUDGE SYSTEM AND METHOD,,CAROLLO ENG INC,FRASER JOHN,,https://lens.org/031-870-753-450-027,Search Report,no,2,0,6,6,0,C02F3/301;;C02F2203/004;;Y02W10/10;;C02F3/301;;C02F2203/004;;C02F1/006;;C02F3/1226;;C02F3/301;;C02F2203/004;;C02F2301/046,C02F3/02;;C02F3/28;;C02F3/30,,1,0,,,See also references of WO 2020205834A1,PENDING
142,US,A,US 2773707 A,037-378-919-785-083,1956-12-11,1956,US 39736953 A,1953-12-10,GB 2773707X A,1952-12-11,Selective interlocking lug coupling,,AVERY HARDOLL LTD,JOHN FRASER,,https://lens.org/037-378-919-785-083,Granted Patent,no,3,2,1,1,0,F16L37/252;;F16L37/252,F16L37/252,,0,0,,,,EXPIRED
143,US,A,US 2161918 A,067-841-357-252-225,1939-06-13,1939,US 15063437 A,1937-06-26,GB 2161918X A,1936-07-10,Improvements relating to registering mechanisms,,AVERY HARDOLL LTD,JOHN FRASER,,https://lens.org/067-841-357-252-225,Granted Patent,no,0,0,1,1,0,B67D7/08;;B67D7/08,B67D7/08,,0,0,,,,EXPIRED
144,CA,A,CA 531376 A,070-247-630-522-617,1956-10-09,1956,CA 531376D A,,CA 531376T A,,VALVES FOR CONTROLLING THE FLOW OF LIQUIDS,,AVERY HARDOLL LTD,FRASER JOHN,,https://lens.org/070-247-630-522-617,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
145,GB,A,GB 687678 A,102-251-652-981-188,1953-02-18,1953,GB 2939150 A,1950-11-30,GB 2939150 A,1950-11-30,Improvements in pumping apparatus,"687,678. Rotary pumps. AVERY-HARDOLL, Ltd. Sept. 3, 1951 [Nov. 30, 1950], No. 29391/50. Class 110(ii) An apparatus having a power-operated positive pump 10 and a hand-operated pump 20 in series in which the latter, when stationary, allows liquid to be pumped through it, has a relief valve 44 between the outlet of pump 10 and the inlet of pump 20. Manual control means is used to open the valve 44 when the pump 10 is stationary and the pump 20 is to be actuated. As shown, this comprises a pin 51 which is pressed inwards to contact a member 43 and lift the valve 44 from its seating 45; the pin is retained in this position by rotation of a knob 54 so that a projection 56 is held behind an abutment 52. For normal pumping, liquid from pipe 39 passes through a filter 38, inlet chamber 34 and the pumping chamber 14 to a pipe 28, lifts valves 27, 24 and is delivered through a port 30. Pairs of vanes 11 are held apart by rods 13 and the tips bear on a chamber bore comprising two arcs of circles 15, 16 which are connected by curved portions 17.",AVERY HARDOLL LTD,FRASER JOHN,,https://lens.org/102-251-652-981-188,Granted Patent,no,0,0,1,1,0,F04C11/005,F04C11/00,,0,0,,,,EXPIRED
146,CA,A,CA 6074 A,101-963-751-303-509,1876-05-06,1876,CA 6074D A,,CA 6074T A,,MACHINE FOR FITTING THIMBLE SKEINS ON LUMBER WAGON AXLES,,FRASER JOHN,FRASER JOHN,,https://lens.org/101-963-751-303-509,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
147,IL,B2,IL 272932 B2,140-119-068-295-840,2023-10-01,2023,IL 27293220 A,2020-02-26,US 201762553393 P;;US 2018/0048528 W,2017-09-01,Ballasted activated sludge treatment combined with high rate liquids/solids separation systems,,CAROLLO ENG INC;;FRASER JOHN,FRASER JOHN,,https://lens.org/140-119-068-295-840,Unknown,no,0,0,8,8,0,C02F3/1226;;C02F3/308;;C02F2305/12;;C02F3/307;;Y02W10/10;;C02F1/004;;C02F3/107;;C02F3/1215;;C02F3/121;;C02F3/1221;;B01D21/0039;;B01D17/02;;C02F3/308;;C02F2305/12;;C02F3/1221;;B01D17/02;;C02F3/107;;C02F3/1226;;B01D21/0039;;C02F3/121;;C02F3/307;;C02F1/004;;C02F3/1215;;Y02W10/10;;C02F3/1215;;C02F3/1226;;C02F3/307;;C02F3/308;;C02F2305/12,B01D17/02;;B01D21/00,,0,0,,,,PENDING
148,ZA,B,ZA 828072 B,195-055-381-003-811,1983-09-28,1983,ZA 828072 A,1982-11-04,ZA 828072 A,1982-11-04,LATCH,,SOUTH CANNON HYDRAULICS PROPRI,FRASER JOHN,,https://lens.org/195-055-381-003-811,Granted Patent,no,0,0,1,1,0,,E05B/;;E05C/,,0,0,,,,EXPIRED
149,GB,A,GB 708301 A,014-037-763-233-425,1954-05-05,1954,GB 2232151 A,1951-09-24,GB 2232151 A,1951-09-24,Improvements in or relating to devices for supplying liquid under air pressure,"708,301. Forcing liquids by gaseous pressure. AVERY-HARDOLL, Ltd. Aug. 15, 1952 [Sept. 24, 1951], No. 22321/51. Class 102 (2). In apparatus for forcing liquids by air pressure, the container 10 contains a float 43 that slides on a rod 42 fitted with stops 44, 45. A lever 47 is pivoted at 48 and carries a spring- loaded pawl 53 cooperating with a lever 55 connected to a rod 57 so as to provide a snapaction of the valve 65 at the extreme limits of movement of the float 43. The valve 65 controls an atmospheric port 68 and a port 69 supplied with air under pressure. The supply of air under pressure to the container 10 forces the liquid through openings 38 in a disc 36 attached to a guide sleeve 35. The disc is maintained a short distance from the base by feet 39 and its edges are close to the housing 41 to leave an insufficient cross sectional area for the flow of liquid. The liquid thus raises the disc to uncover the ports 29. The disc in its raised position prevents the rod 42 from descending sufficiently to actuate the valve 65 to connect the container 10 to atmosphere.",AVERY HARDOLL LTD,FRASER JOHN,,https://lens.org/014-037-763-233-425,Granted Patent,no,0,4,1,1,0,F16N37/02,F16N37/02,F1R R3A1          R3A1;;F1R R3B10B        R3A1;;F1R R3B11A        R3A1;;F1R R3B12         R3A1,0,0,,,,EXPIRED
150,GB,A,GB 707682 A,030-914-756-236-240,1954-04-21,1954,GB 2952851 A,1951-12-17,GB 2952851 A,1951-12-17,Improvements in or relating to pits for housing valves and the like,"707,682. Valve &c. pits. AVERY-HARDOLL, Ltd. Nov. 12, 1952 (Dec. 17, 1951], No. 29528/51. Class 33 A lining for a valve &c. pit comprises a base member 16 slidably contained within the lining 10 so that if the latter is urged downwardly the base may remain still. A packing ring 18 makes a fluid-tight joint and thin washers 25 retain the base and lining in relative position under normal loads, whilst deforming under high loading to allow the lining to drop.",AVERY HARDOLL LTD,FRASER JOHN,,https://lens.org/030-914-756-236-240,Granted Patent,no,0,3,1,1,0,E03B9/10,E03B9/10,,0,0,,,,EXPIRED
151,GB,A,GB 698644 A,035-044-522-618-524,1953-10-21,1953,GB 1835351 A,1951-08-02,GB 1835351 A,1951-08-02,Improvements in or relating to valves for controlling the flow of liquids,"698,644. Valves. AVERY-HARDOLL, Ltd. July 25, 1952 [Aug. 2, 1951], No. 18353/51. Class 135 A valve for controlling the flow of liquid into a vessel and of the kind in which the flow of liquid through the valve induces a suction of air through a passage, and when the inlet to the passage is closed by the rising level of the liquid in the vessel, the suction acts on a piston, diaphragm, &c. to close the valve is characterized in that the valve is closed in two stages, there being a reduced rate of flow of liquid after the first stage. In the figure, valve 57 is shown in the closed position in which the liquid from the inlet 13 can pass through a hole 58 to the back of the valve to balance the upward thrust of the liquid on the outer surface of the valve. The valve will then be held closed by its loading spring 72 which abuts at its upper end against a disc 69, upward movement of the latter being prevented by a spring ring 71. When a valve 66 closing an aperture in the bottom of valve 57 is raised by means of a handle 65, the liquid inside valve 57 escapes and the inlet pressure opens valve 57 to allow liquid to flow into the vessel 10 past a non-return valve 53. Valve 66 slides on a tube 59 which, at its lower end, is secured in a venturi tube 55, and as this venturi is in the path of the outflowing liquid, air will be drawn down the tube. The latter communicates at its upper end with the chamber underneath a piston 73, this chamber also communicating, according to the position of the piston, through a tube 77 or 78 with a further tube 35 or 36 depending into the vessel 10. Both tubes 35, 36 are open at the bottom, but tube 35 is longer than 36. With valve 57 fully open and piston 73 in its uppermost position, tube 36 will be cut off from, and tube 35 will be in communication with. the chamber under the piston, and as soon as the level of liquid in the vessel 10 reaches tube 35 and prevents air being drawn therethrough, the suction produced by the venturi 55 will act on piston 73 and pull it down to an intermediate position, and, thus, valve 57 will be partially closed and the flow of liquid into vessel 10 will be reduced. In this intermediate position, tube 35 will be cut off from, and tube 36 will be put into communication with, the chamber under the piston. As soon as the opening in tube 36 is closed off by the rising liquid, the suction induced by the venturi will act on the piston and pull it right down to close off both valves 66 and 57. A detent 84 holds the piston in its uppermost and intermediate positions. To allow various measured quantities of liquid to be fed into the vessel 10, a number of pairs of tubes 35, 36 are provided and the pair required for any particular quantity is selected by a rotary disc valve 31. The main valve unit is separable and is provided with a flange which engages at one side under an arcuate groove 22 on a base fitting and which, at the other side, is engaged by a detent 23. In a modification, the pairs of tubes 35, 36 are arranged in a circle in the casing surrounding valve 57 and the particular pair to be used is selected by rotating the casing. The tube up which air is drawn by the venturi is selected by a valve formed in the valve stem which carries piston 73. Valve 66 is actuated by a rotary movement of the operating handle.",AVERY HARDOLL LTD,FRASER JOHN,,https://lens.org/035-044-522-618-524,Granted Patent,no,0,0,1,1,0,F16K21/20;;G05D9/04,F16K21/20;;G05D9/04,F2V VS15          VS15,0,0,,,,EXPIRED
152,DE,C,DE 959590 C,066-559-926-761-818,1957-03-07,1957,DE S0039784 A,1954-06-29,GB 959590X A,1953-07-01,Durchlaufzaehler fuer Fluessigkeiten,,S A T A M SA APPAREILLAGES MEC,FRASER JOHN,,https://lens.org/066-559-926-761-818,Granted Patent,no,0,1,1,1,0,G01F3/065,G01F3/06,,0,0,,,,EXPIRED
153,FR,A,FR 652166 A,092-093-820-432-275,1929-03-05,1929,FR 652166D A,1928-02-17,GB 652166X A,1927-03-15,Perfectionnements aux appareils pour la mesure des liquides,,BRITISH PETROLEUM CO,FRASER JOHN,,https://lens.org/092-093-820-432-275,Granted Patent,no,0,0,1,1,0,B67D7/166,B67D7/16,,0,0,,,,EXPIRED
154,US,A,US 1109522 A,092-351-986-726-731,1914-09-01,1914,US 1909/0527706 A,1909-11-12,US 1909/0527706 A,1909-11-12,MACHINE FOR FORMING SHEET-METAL PIPES.,,FRASER JOHN,FRASER JOHN,,https://lens.org/092-351-986-726-731,Granted Patent,no,0,3,1,1,0,B21D7/06;;B21D7/06,,,0,0,,,,EXPIRED
155,DE,C,DE 952503 C,134-840-264-875-830,1956-11-15,1956,DE 952503D A,1954-02-18,GB 471653 A,1953-02-19,Zapfventilsteuerung fuer Durchflussmesser,,S A T A M SA APPAREILLAGES MEC,FRASER JOHN,,https://lens.org/134-840-264-875-830,Granted Patent,no,0,0,2,2,0,B67D7/301;;F16K21/16;;G01F15/001,B67D7/30;;F16K21/16;;G01F15/00,,0,0,,,,EXPIRED
156,US,A,US 896527 A,173-206-580-683-300,1908-08-18,1908,US 1907/0373338 A,1907-05-13,US 1907/0373338 A,1907-05-13,TYMPAN-SHEET.,,TARBETT AND FRASER;;WILLIAM A TARBETT;;FRASER JOHN,FRASER JOHN,,https://lens.org/173-206-580-683-300,Granted Patent,no,0,1,1,1,0,B41F27/1231;;B41F27/1231,,,0,0,,,,EXPIRED
157,DE,C,DE 858617 C,173-087-081-095-038,1952-12-08,1952,DE S0023196 A,1951-05-19,GB 858617X A,1950-05-22,Kupplungsvorrichtung fuer Leitungen oder Schlaeuche,,S A T A M SA APPAREILLAGES MEC,FRASER JOHN,,https://lens.org/173-087-081-095-038,Granted Patent,no,0,14,1,1,0,F16L37/32;;F16L37/113,F16L37/113;;F16L37/32,,0,0,,,,EXPIRED
158,ZA,B,ZA 828075 B,189-649-638-117-031,1983-08-31,1983,ZA 828075 A,1982-11-04,ZA 828075 A,1982-11-04,SLIDING WINDOW LATCH,,SOUTH CANNON HYDRAULICS PTY LT,FRASER JOHN,,https://lens.org/189-649-638-117-031,Granted Patent,no,0,0,1,1,0,,E05C/,,0,0,,,,EXPIRED
159,WO,A1,WO 2015/120388 A1,066-565-351-379-28X,2015-08-13,2015,US 2015/0015028 W,2015-02-09,US 201461938052 P;;US 201461938040 P,2014-02-10,REGENERATIVE CELL THERAPY FOR CENTRAL NERVOUS SYSTEM (CNS) DISORDERS AND PTSD,"Provided herein are compositions comprising regenerative cells (e.g., from adipose tissue), for therapy for central nervous system (CNS) disorders, including disorders characterized by excitotoxicity, neuroinflammation, neurodegeneration, and compromise of the blood brain barrier.",CYTORI THERAPEUTICS INC,FRASER JOHN,,https://lens.org/066-565-351-379-28X,Patent Application,yes,9,6,4,4,0,A61K35/28;;A61K35/28;;A61P25/00,A01N63/00;;A61K35/32,,1,0,,,See also references of EP 3104708A4,PENDING
160,GB,A,GB 823979 A,067-838-179-056-629,1959-11-18,1959,GB 2973056 A,1956-09-28,GB 2973056 A,1956-09-28,Improvements in or relating to valve devices for controlling the filling of tanks and like receptacles with liquids,"823,979. Fluid-pressure servomotor-control systems. AVERY-HARDOLL Ltd. Aug. 2, 1957 [Sept. 28, 1956], No. 29730/56. Class 135. A valve device for controlling the filling of tanks with liquid comprises a main filling valve opened by the pressure of liquid supplied to the tank and closed by liquid pressure built up in a control chamber, and a pilot valve controlling the escape of liquid from the chamber, the pilot valve comprising a body formed with a liquid passage in which are arranged in series at least two valve seats engaged each by a corresponding spring-urged closure member having a substantially spherical closure surface, and a pin movable in this passage in response to changes of liquid level in the tank to displace said closure members successively from their seats as the liquid level falls and to release the closure members successively for re-engagement with their seats as the liquid level rises. As shown, a main filling valve 12 at the bottom of a tank 10, 11 is closed stepwise during a filling operation by the pressure of liquid in a control chamber 31 which is supplied with the inflowing liquid through a stationary tube 32, outflow from this chamber being controlled by a pilot valve 18. The pilot valve comprises a body 33 having three oblique bores 36, 39, 42 which house three spring-loaded ball-valve closure members 44 obturating corresponding seat openings from the bores, the seat openings being connected together for series flow by a vertical through flow passage 34, and the lowest seat opening having a permanent leak port 49. An actuating pin 48 connected to a float 19 displaces the ball closure members successively from their seats on falling of the float and allows them to re-seat on rising of the float. On rising level in the tank, closure of the lowest ball so restricts outflow from the control chamber that the main valve partially closes to a position where the outflow is balanced by a restricted inflow through tube 32; whilst on a predetermined full level being reached, closure of the second ball causes the main valve to close completely. The third or top ball constitutes a safety closure device which functions similarly to the second ball in the event of failure of the second ball to operate. In alternative embodiments, one of the two upper ball closures may be omitted; or the lowest ball closure associated with the leak port 49 may be omitted in which case the main valve closes completely in a single step. Specification 732,282 is referred to.",AVERY HARDOLL LTD,FRASER JOHN,,https://lens.org/067-838-179-056-629,Granted Patent,no,0,3,1,1,0,B67D7/362;;F16K3/26;;F16K31/34,B67D7/36;;F16K3/26;;F16K31/34,F2V VA11          VA11,0,0,,,,EXPIRED
161,US,A,US 2815149 A,118-646-252-047-422,1957-12-03,1957,US 52134555 A,1955-07-11,GB 2815149X A,1954-07-20,Apparatus for dispensing liquids,,AVERY HARDOLL LTD,JOHN FRASER,,https://lens.org/118-646-252-047-422,Granted Patent,no,8,1,1,1,0,B67D7/742;;B67D7/742,B67D7/74,,0,0,,,,EXPIRED
162,CA,A,CA 526471 A,119-170-410-743-278,1956-06-19,1956,CA 526471D A,,CA 526471T A,,COUPLING DEVICES FOR PIPES OR CONDUITS,,AVERY HARDOLL LTD,FRASER JOHN,,https://lens.org/119-170-410-743-278,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
163,GB,A,GB 189322895 A,130-590-659-891-566,1894-11-03,1894,GB 189322895D A,1893-11-29,GB 189322895T A,1893-11-29,"Improvements in Frames for Show Cards, Pictures, and the like.",,FRASER JOHN,FRASER JOHN,,https://lens.org/130-590-659-891-566,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
164,FR,A,FR 663652 A,165-394-074-228-701,1929-08-23,1929,FR 663652D A,1928-11-08,FR 663652T A,1928-11-08,Châssis de véhicule,,,FRASER JOHN,,https://lens.org/165-394-074-228-701,Granted Patent,no,0,1,1,1,0,B60G99/002,B60G99/00,,0,0,,,,EXPIRED
165,GB,A,GB 763150 A,169-404-582-543-902,1956-12-05,1956,GB 2116054 A,1954-07-20,GB 2116054 A,1954-07-20,Improvements in or relating to apparatus for dispensing liquids,"763,150. Continuous - discharge mixing- machines. AVERY-HARDOLL, Ltd. June 30, 1955 [July 20, 1954], No. 21160/54. Class 86 [Also in Groups XVIII and XXIV] Petrol and oil to be mixed are fed, the petrol from a pipe 51 and the oil from either of two pipes 50, 49, to a passage 120 leading past a baffle 123 to a mixing chamber 121 from which the mixed liquids are drawn by a pipe 122. Ball valves control the admission of oil to the passage 120 and the device is covered with a glass panel so that its action is visible.",AVERY HARDOLL LTD,FRASER JOHN,,https://lens.org/169-404-582-543-902,Granted Patent,no,0,2,1,1,0,B67D7/742;;G05D11/132,B67D7/74;;G05D11/13,B1C CABB          CABB;;B1C C125          CABB;;B1C C2012         CABB;;B1C C632          CABB;;B8N NHAB          NHAB;;B8N N24B4         NHAB;;B8N N24C2A        NHAB;;B8N N24C2D        NHAB;;B8N N24D11        NHAB;;B8N N24E9         NHAB;;B8N N24F5A        NHAB;;F1W WDX           WDX;;F1W W100          WDX;;F1W W508          WDX,0,0,,,,EXPIRED
166,CA,A,CA 563881 A,029-838-359-910-433,1958-09-30,1958,CA 563881D A,,CA 563881T A,,LIQUID-METER OPERATED MEANS FOR CONTROLLING VALVES,,AVERY HARDOLL LTD,FRASER JOHN,,https://lens.org/029-838-359-910-433,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
167,GB,A,GB 681222 A,035-309-346-114-765,1952-10-22,1952,GB 1053650 A,1950-04-28,GB 1053650 A,1950-04-28,Improvements in or relating to liquid meters,"681,222. Counting-apparatus. AVERYHARDOLL, Ltd. Feb. 28, 1951 [April 28, 1950], No. 10536/50. Class 106 (i). The driving means for the registering mechanism of liquid meters comprises a differential gear interposed between the meter spindle and the registering mechanism, one element of the differential gear being driven by the meter at a constant speed ratio, a second element of the differential gear being connected to the registering mechanism, the third element of the differential gear being driven by the meter through a continuously, variable friction gear. The driven member of the friction gear is movable through a zero position in which no drive is transmitted thereto and is driven in opposite directions when moved to opposite sides of said zero position. The meter spindle 11, Fig. 2, drives a ring-gear 19 through gears 12 and 13. The internal teeth of the ring 19 drive a planet-wheel 24 on a carrier 23 which through gears 28, 29, worm and worm-wheel 32, 33, gear 36, Fig. 1, drives a cyclometer type counter 35. The planet gear 24 also meshes with a sun-wheel 26 carried by a shaft 25. The external teeth of the ring gear 19 drive the driving-member 39, Fig. 2, of a continuouslyvariable friction gearing 39, 41, the driven member 41 of which is carried by a shaft 44 which carries a worm 45 which meshes with a wormwheel 27 on the shaft 25. The arrangement is such that if the roller 41 is at the centre of the disc 39 no drive is transmitted to sun-wheel 26 as the roller 41 is stationary. The shaft 44 may be adjusted longitudinally in any direction for calibration purposes to effect rotation of the roller 41 in any direction so that the sunwheel 26 rotates in the same or opposite direction as the ring-gear 19, as desired. In a modification. Fig. 3, the shaft 44 is also controlled by a bellows 55 connected to a container 59 which bellows and container are completely full of liquid. The bellows 55 expands or contracts as the temperature of the liquid rises and falls so providing a compensating effect on the counter 35.",AVERY HARDOLL LTD,FRASER JOHN,,https://lens.org/035-309-346-114-765,Granted Patent,no,0,1,1,1,0,G01F15/02,G01F15/02,G4D DDM           DM;;G4D D421          DM,0,0,,,,EXPIRED
168,US,A,US 1885517 A,032-553-080-821-504,1932-11-01,1932,US 53970631 A,1931-05-25,GB 1885517X A,1930-05-29,Flow meter for the measurement of liquid,,ANGLO PERSIAN OIL COMPANY LTD,JOHN FRASER,,https://lens.org/032-553-080-821-504,Granted Patent,no,0,5,1,1,0,G01F3/18;;G01F3/18,G01F3/18,,0,0,,,,EXPIRED
169,US,A,US 1972014 A,054-494-203-791-626,1934-08-28,1934,US 69568033 A,1933-10-28,US 69568033 A,1933-10-28,Spring assembly for vehicle chassis,,JOHN FRASER,JOHN FRASER,,https://lens.org/054-494-203-791-626,Granted Patent,no,0,3,1,1,0,B60G21/05;;B60G21/05,B60G21/05,,0,0,,,,EXPIRED
170,US,A,US 952565 A,058-826-121-748-265,1910-03-22,1910,US 1908/0460205 A,1908-10-30,US 1908/0460205 A,1908-10-30,GYRATORY MACHINE.,,FRASER JOHN,FRASER JOHN,,https://lens.org/058-826-121-748-265,Granted Patent,no,0,10,1,1,0,B06B1/167;;B06B1/167;;Y10T74/18552;;Y10T74/18552,,,0,0,,,,EXPIRED
171,GB,A,GB 691568 A,086-727-597-550-15X,1953-05-13,1953,GB 592451 A,1951-03-12,GB 592451 A,1951-03-12,Improvements in or relating to coupling devices for pipes or conduits,"691,568. Pipe couplings. AVERY-HARDOLL, Ltd. Dec. 7, 1951 [March 12, 1951], No. 5924/51. Class 99 (i). In a disconnectible coupling in which coupling members 10, 20 have coupling-actuated valves 14, 23, a spigot part 22 is grooved to receive a sealing ring 29 which engages the wall of a socket part 12, when the coupling is made, at a circumferentially continuous zone, the socket wall from its mouth to near the zone being discontinuous, e.g. provided with spaced notches 18. The invention is described as applied to the coupling according to Specification 679,762 in which the notches 18 are for the purpose of engaging lugs 26 to prevent rotation of the valve seating ring 22 relative to the socket during the rotary coupling movement of the members 10, 20.",AVERY HARDOLL LTD,FRASER JOHN,,https://lens.org/086-727-597-550-15X,Granted Patent,no,0,8,1,1,0,F16L37/32,F16L37/32,F2G G14A1         G21F;;F2G G21F          G21F,0,0,,,,EXPIRED
172,US,A,US 2762389 A,097-565-113-259-981,1956-09-11,1956,US 37294553 A,1953-08-07,GB 2762389X A,1952-08-07,Valves for controlling the flow of liquids,,AVERY HARDOLL LTD,JOHN FRASER,,https://lens.org/097-565-113-259-981,Granted Patent,no,7,6,1,1,0,F16K21/20;;F16K21/20;;Y10T137/73;;Y10T137/73;;Y10T137/7371;;Y10T137/7371,F16K21/20,,0,0,,,,EXPIRED
173,DE,C,DE 929165 C,156-341-466-081-061,1955-06-20,1955,DE S0028047 A,1952-04-09,GB 929165X A,1951-04-24,Schliessvorrichtung fuer Leitungsanschluesse,,T A M LA SA POUR TOUS APP S ME,FRASER JOHN,,https://lens.org/156-341-466-081-061,Granted Patent,no,1,1,1,1,0,F16L55/1155,F16L55/115,,0,0,,,,EXPIRED
174,US,A,US 2675939 A,187-561-110-071-646,1954-04-20,1954,US 27007052 A,1952-02-05,GB 2675939X A,1951-04-24,Closure device for fluid supply connections and the like,,AVERY HARDOLL LTD,JOHN FRASER,,https://lens.org/187-561-110-071-646,Granted Patent,no,7,6,1,1,0,B60K15/0406;;B60K15/0406;;F16L55/1155;;F16L55/1155,B60K15/04;;F16L55/115,,0,0,,,,EXPIRED
175,GB,A,GB 831007 A,171-657-671-497-159,1960-03-23,1960,GB 1092157 A,1957-04-03,GB 1092157 A,1957-04-03,Improvements in or relating to automatically closing hosecocks,"831,007. Fluid-pressure servomotor-control systems. AVERY-HARDOLL Ltd. March 24, 1958 [April 3, 1957], No. 10921/57. Class 135. In an automatically closing hosecock for dispensing liquid fuels of the kind in which the flow of fuel through the hosecock 10 induces suction in a tube 16 leading from an orifice 18 adjacent the tip of the hosecock nozzle, the suction drawing air through the tube until the orifice is closed by being immersed in liquid, whereupon the flow of air is stopped, causing the valve to close, a ball 22 is provided in the tube 16 to move freely between a seat 19 and a stop 21 the ball being located on the side of the seat nearer the tip of the nozzle so that it is urged away from the seat by gravity when the nozzle is pointed downwardly. When the nozzle end becomes immersed in liquid the ball 22 is sucked upwardly to seat on the seat 19 thus closing the tube. The valve itself may be of any suitable form such as that described in Specification 735,364.",AVERY HARDOLL LTD,FRASER JOHN,,https://lens.org/171-657-671-497-159,Granted Patent,no,0,0,2,2,0,B67D7/48;;B67D7/42,B67D7/48,,0,0,,,,EXPIRED
176,CA,A,CA 535795 A,192-490-700-701-439,1957-01-15,1957,CA 535795D A,,CA 535795T A,,COUPLING DEVICES FOR PIPES OR CONDUITS,,AVERY HARDOLL LTD,FRASER JOHN,,https://lens.org/192-490-700-701-439,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
177,US,A,US 2760680 A,003-822-320-849-516,1956-08-28,1956,US 41067954 A,1954-02-16,GB 2760680X A,1953-02-19,Liquid-meter operated means for controlling valves,,AVERY HARDOLL LTD,JOHN FRASER,,https://lens.org/003-822-320-849-516,Granted Patent,no,2,1,1,1,0,G01F15/001;;G01F15/001,G01F15/00,,0,0,,,,EXPIRED
178,US,A,US 1879870 A,008-232-959-820-361,1932-09-27,1932,US 35797829 A,1929-04-25,GB 1879870X A,1928-07-14,Pump for delivering measured quantities of liquid,,JOHN FRASER,JOHN FRASER,,https://lens.org/008-232-959-820-361,Granted Patent,no,0,1,1,1,0,B67D7/60;;Y10T137/7851;;Y10T137/7851;;B67D7/60,B67D7/60,,0,0,,,,EXPIRED
179,CH,A,CH 13126 A,042-635-918-000-905,1897-04-30,1897,CH 13126D A,1896-10-12,CH 13126T A,1896-10-12,Allume-fusées,,FRASER JOHN,FRASER JOHN,,https://lens.org/042-635-918-000-905,Granted Patent,no,0,0,1,1,0,F42B3/26,F42B3/26,41,0,0,,,,EXPIRED
180,GB,A,GB 684170 A,044-609-964-622-258,1952-12-10,1952,GB 1030950 A,1950-04-26,GB 1030950 A,1950-04-26,Improvements in or relating to liquid supply systems,"684,170. Dispensing liquids. AVERY-HARDOLL, Ltd. Feb. 26, 1951 [April 26, 1950]. No. 10309/50. Class 116. [Also in Group XXIX] In a liquid supply system in which liquid is pumped from a reservoir through a conduit, a pressure reducing valve is located. in the conduit at a point remote from the delivery end thereof and is controlled in accordance with the pressure at the throat of a venturi located in the conduit on the downstream side of the valve. As shown in Fig. 1, fuel is supplied from a main line 8 through a meter 16, a reducing valve 12 and a venturi 13 to a tank 10. The reducing valve, Fig. 2, comprises two chambers 24, 25, with an opening 27. A cylinder 31 houses a piston 29 with a closure member 28. The piston has an aperture 32 and a bottom closure 34 with apertures 42 communicating with the atmosphere and connecting at 41 with a conduit 21 leading to the venturi 13. A piston 36 slides in the member 34 and has a grooved head 44. The valve is connected to a short conduit 14. The pressure of the liquid flowing through the valve is such that the piston 36 being forced downwardly under the action of a spring 48, lever 49 and pin 51 the head 28 is moved from the opening 27. Opposing this is the pressure in the tube 21 which urges the piston 36 upwardly and when great enough causes the head 44 to engage shoulders 46 allowing the pressure to rise in the piston 29 and so force the piston upwardly so that the member 28 closes the aperture 27 and thus stops flow of liquid. The venturi unit, Fig. 3, comprises a tube 58 in which is a stem 62 having holes 66 and communicating with an enlarged box 67 and an outlet 70 to the conduit 21.",AVERY HARDOLL LTD,FRASER JOHN,,https://lens.org/044-609-964-622-258,Granted Patent,no,0,0,1,1,0,B64F1/28;;B64F1/28;;G05D16/166,B64F1/28;;G05D7/01;;G05D16/10,B8N NJA           JA(PETROL);;B8N NJA           NJA;;B8N N24D1         JA(PETROL);;B8N N24D1         NJA,0,0,,,,EXPIRED
181,DE,C,DE 922686 C,076-752-579-198-668,1955-01-20,1955,DE S0027528 A,1952-03-07,GB 922686X A,1951-03-12,Kupplungsvorrichtung fuer Rohr- und Schlauchleitungen,,POUR TOUS APP MECANIQUES SA,FRASER JOHN,,https://lens.org/076-752-579-198-668,Granted Patent,no,4,3,1,1,0,F16L37/32;;F16L37/113,F16L37/113;;F16L37/32,,0,0,,,,EXPIRED
182,US,A,US 2681073 A,133-233-624-446-482,1954-06-15,1954,US 30187952 A,1952-07-31,GB 2681073X A,1951-08-02,Valve for controlling the flow of liquids,,AVERY HARDOLL LTD,JOHN FRASER,,https://lens.org/133-233-624-446-482,Granted Patent,no,4,7,1,1,0,F16K21/20;;Y10T137/88054;;Y10T137/88062;;Y10T137/7287;;Y10T137/88054;;Y10T137/88062;;Y10T137/7287;;F16K21/20,F16K21/20,,0,0,,,,EXPIRED
183,CA,A,CA 565520 A,138-355-667-063-833,1958-11-04,1958,CA 565520D A,,CA 565520T A,,ROTARY LIQUID METERS,,AVERY HARDOLL LTD,FRASER JOHN,,https://lens.org/138-355-667-063-833,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
184,DE,B,DE 1044431 B,163-029-559-342-74X,1958-11-20,1958,DE S0029618 A,1952-08-01,GB 1044431X A,1951-08-02,Vorrichtung zum selbsttaetigen Absperren eines Fluessigkeitsstromes beim Fuellen eines Behaelters,,POUR TOUS APP MECANIQUES SA,FRASER JOHN,,https://lens.org/163-029-559-342-74X,Patent Application,no,1,0,1,1,0,F16K21/20,F16K21/20,,0,0,,,,DISCONTINUED
185,IL,A,IL 272932 A,171-065-046-259-746,2020-04-30,2020,IL 27293220 A,2020-02-26,US 201762553393 P;;US 2018/0048528 W,2017-09-01,Ballasted activated sludge treatment combined with high rate liquids/solids separation systems,,CAROLLO ENG INC;;FRASER JOHN,FRASER JOHN,,https://lens.org/171-065-046-259-746,Patent Application,no,0,0,8,8,0,C02F3/1226;;C02F3/308;;C02F2305/12;;C02F3/307;;Y02W10/10;;C02F1/004;;C02F3/107;;C02F3/1215;;C02F3/121;;C02F3/1221;;B01D21/0039;;B01D17/02;;C02F3/308;;C02F2305/12;;C02F3/1221;;B01D17/02;;C02F3/107;;C02F3/1226;;B01D21/0039;;C02F3/121;;C02F3/307;;C02F1/004;;C02F3/1215;;Y02W10/10;;C02F3/1215;;C02F3/1226;;C02F3/307;;C02F3/308;;C02F2305/12,,,0,0,,,,PENDING
186,US,A1,US 2022/0194832 A1,188-427-065-286-478,2022-06-23,2022,US 202017599682 A,2020-03-31,US 202017599682 A;;US 201962827322 P;;US 2020/0025911 W,2019-04-01,Flow Through Aerobic Granular Sludge System and Method,"A flow through aerobic granular sludge (AGS) system includes a flow through reactor. The flow through reactor includes a first adsorption zone and first and second unaerated and aerated zones and may include a wastewater distribution system and a selector zone. The first adsorption zone includes AGS granules and may include a mixing device. The first and second unaerated zones are under anaerobic, anoxic, or both anaerobic and anoxic conditions and each may include a mixing device. The first and second aerated zones are under aerobic conditions and each may include an aeration device. The flow through reactor is configured such that the wastewater and AGS granules in the first adsorption zone flow continuously from the first adsorption zone through the first unaerated zone, the first aerated zone, the second unaerated zone, the second aerated zone, and optionally to the selector zone and out of the flow through reactor.",CAROLLO ENG INC,FRASER JOHN,CAROLLO ENGINEERS INC (2020-04-01),https://lens.org/188-427-065-286-478,Patent Application,yes,0,0,6,6,0,C02F3/301;;C02F2203/004;;Y02W10/10;;C02F3/301;;C02F2203/004;;C02F1/006;;C02F3/1226;;C02F3/301;;C02F2203/004;;C02F2301/046,C02F3/30;;C02F1/00;;C02F3/12,,0,0,,,,PENDING
187,CA,A,CA 83377 A,181-233-815-166-871,1903-10-13,1903,CA 83377D A,1903-09-15,CA 83377T A,1903-09-15,METALLIC TIE AND RAIL FASTENER,,FRASER JOHN,FRASER JOHN,,https://lens.org/181-233-815-166-871,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
188,WO,A1,WO 2004/075987 A1,187-731-155-571-600,2004-09-10,2004,IB 2004000505 W,2004-02-23,US 45114803 P,2003-02-28,MOTION-TRACKING IMPROVEMENTS FOR HIFU ULTRASOUND THERAPY,High intensity focused ultrasound (HIFU) for medically treating tumors is automatically administered under robotic control in dosage intervals that alternate with ultrasonic imaging intervals. The HIFU transmitter is re-aimed for each dosage to compensate for motion of the tumor due to heart beats and other events.,KONINKL PHILIPS ELECTRONICS NV;;FRASER JOHN,FRASER JOHN,,https://lens.org/187-731-155-571-600,Patent Application,yes,4,43,3,3,0,A61B5/1127;;A61B8/08;;A61B8/0833;;A61B8/4218;;A61B8/463;;A61B8/467;;A61B8/483;;A61B8/5276;;A61B2017/00694;;A61N7/02;;A61B8/461;;A61B34/30;;A61B2090/065;;A61B2090/378;;A61N7/02;;A61B8/08;;A61B8/467;;A61B8/483;;A61B2017/00694;;A61B5/1127;;A61B8/463;;A61B8/5276;;A61B8/4218;;A61B8/0833;;A61B8/461;;A61B2090/378;;A61B34/30;;A61B2090/065,A61B8/08;;A61B17/00;;A61B19/00;;A61N7/02,,0,0,,,,PENDING
189,GB,A,GB 190904739 A,056-994-413-814-199,1909-07-15,1909,GB 190904739D A,1909-02-26,GB 190904739T A,1909-02-26,Improvements in Flyers for Spinning and like Machines.,"4739. Fraser, J., Fraser, H., and Fraser, G. S. Feb. 26. Spindle apparatus. - In flyers of the type in which sheet-metal tubular legs are secured to a top, the arms C are set so that the yarn, which is wound around the cylindrical part of the top and leaves it tangentially, enters the guide-trough of the legs centrally. Short lengths of stout wire are welded on to the legs and bent to receive the eyes G. The top may be a drop forging, a stamping, or a malleable or steel casting.",FRASER JOHN;;FRASER HENRY;;FRASER GORDON SCOTT,FRASER JOHN;;FRASER HENRY;;FRASER GORDON SCOTT,,https://lens.org/056-994-413-814-199,Patent Application,no,0,1,1,1,0,D01H7/30,D01H7/30,,0,0,,,,DISCONTINUED
190,US,A,US 1351637 A,064-650-940-787-517,1920-08-31,1920,US 25551118 A,1918-09-24,US 25551118 A,1918-09-24,Sewing-machine for plaited-soled shoes,,NORMAN FRASER;;JOHN FRASER;;SCOTT FRASER GORDON,NORMAN FRASER;;JOHN FRASER;;SCOTT FRASER GORDON,,https://lens.org/064-650-940-787-517,Granted Patent,no,0,0,1,1,0,D05B15/04;;D05B15/04,D05B15/04,,0,0,,,,EXPIRED
191,FR,A,FR 488064 A,104-740-377-925-746,1918-08-16,1918,FR 488064D A,1917-12-19,GB 488064X A,1917-11-28,Machine à coudre les semelles tressées aux empeignes de chaussures,,NORMAN FRASER;;JOHN FRASER;;GORDON SCOTT FRASER,FRASER NORMAN;;FRASER JOHN;;FRASER GORDON SCOTT,,https://lens.org/104-740-377-925-746,Granted Patent,no,0,0,1,1,0,D05B23/003;;D05D2303/30,D05B23/00,"XVI, 4",0,0,,,,EXPIRED
192,GB,A,GB 115591 A,111-020-094-607-72X,1918-05-16,1918,GB 1758217 A,1917-11-28,GB 1758217 A,1917-11-28,Improved Sewing-machine for Plaited-soled Shoes.,"115,591. Fraser, N., Fraser, J., and Fraser, G. S. Nov. 28, 1917. Boot-sole sewing - machines; welting and turnshoe.-Relates to a machine for sewing together the soles and uppers of jute and the like plaited-soled shoes. The sole and upper lightly tacked together and turned inside out are held by hand on an inclined table A, Fig. 3, so that the needle passes in a diagonal direction from about the centre of the peripheral edge of the sole to the inside thereof and the thread is locked by a shuttle thread in the usual manner. During stitching, the work is held by a spike B guided by a link B<1> and connected to a cam-and-spring- controlled arm B<2>. Feed by wheels.-The work is fed by a spiked wheel A<1> which engages the edge of the sole and is intermittingly rotated through the shaft A<2> gearing with a shaft A<4> which is driven by the pawl and ratchet A<3>, cam-actuated lever A', and link A'. Lock-stitching by shuttles.-The needle-bar C<5> is reciprocated in a vertical guide C<6> by a camactuated lever C<3> and link C<4>. The shutter E, Fig. 8, is reciprocated in rectilinear guides E' by a link E<2> connecting it with a cam-actuated lever E<3>. Governing needle-thread.-The take-up device comprises two hinged arms D, D<1>, Fig. 4, pressed together by a spring D<2> and carried on an arm D' which is rocked by connexion with a cam-andspring-actuated lever D'. The thread is led to the take-up through a pressure device and a tension device consisting of two disks pressed together by a spring.",FRASER NORMAN;;FRASER JOHN;;FRASER GORDON SCOTT,FRASER NORMAN;;FRASER JOHN;;FRASER GORDON SCOTT,,https://lens.org/111-020-094-607-72X,Granted Patent,no,0,0,1,1,0,D05B15/04,D05B15/04,,0,0,,,,EXPIRED
193,GB,A,GB 191008148 A,154-652-966-527-272,1911-01-19,1911,GB 191008148D A,1910-04-05,GB 191008148T A,1910-04-05,Improvements in Presser Rollers for Drawing and Roving Frames and the like.,"8148. Fraser, J., Fraser, P., and Fraser, G. S. April 5. Rollers.-In a presser roller, for drawing and roving frames of the type built up of annular segmental laminations of leather secured between flanges on a metal cylinder, the leather surface is built up of a series of annular sections A, B, C, each built up of segmental laminations D. The laminations in each layer break joint with those in the next layer, and the laminations of each section are held together by a series of pins A<1>, B<1>, C<1> parallel with the axis and equidistant therefrom. The pins C' in the sections C next the flanges E<1> are of a length equal to the width of the sections, while the pins A<1>, B<1> in the other sections are about half as long again as the width of each section. The series of sections held together by the pins in an annular unit is prevented from rotating by a series of pins G<1>, G<2> passing through the flanges E, E<1> into the unit. The leather annulus and metal cylinder D<1> are tapered as usual, and segments or rings of sheet metal &c., which may be perforated, may be inserted between the leather laminations at intervals.",FRASER JOHN;;FRASER PATRICK;;FRASER GORDON SCOTT,FRASER JOHN;;FRASER PATRICK;;FRASER GORDON SCOTT,,https://lens.org/154-652-966-527-272,Patent Application,no,0,0,1,1,0,D01H5/74;;D01H2700/245,D01H5/74,,0,0,,,,DISCONTINUED
194,GB,A,GB 2393743 A,109-534-960-082-55X,2004-04-07,2004,GB 0223026 A,2002-10-03,GB 0223026 A,2002-10-03,Downhole scraper sub that is pumped down the well annulus,A sub to be pumped down an annulus of a well comprises a cylindrical body with annular seals 2 on its internal surface to seal against the drillstring or tubing 10 and annular seals 4 on its external surface to seal against the casing. The sub is pumped down the annulus by fluid pressure supplied from above and the seals are made of a flexible rubber so that sealing is maintained as they pass over joints in the tubing or casing. A fluid bypass port 3 is provided in the sub body but is blocked by a rupture disc to prevent fluid bypassing the sub under normal pressure conditions. The sub may carry scraper blades 1 or measuring gauges.,FRASER JOHN PAUL;;FRASER JAMES ANTON,FRASER JOHN PAUL;;FRASER JAMES ANTON,"FRASER, JAMES A (2004-01-14)",https://lens.org/109-534-960-082-55X,Patent Application,no,3,0,3,3,0,E21B37/04;;E21B23/10,E21B23/10,E1F FLC           FLC,0,0,,,,EXPIRED
195,AU,A1,AU 2008/341007 A1,012-401-023-150-11X,2009-07-02,2009,AU 2008/341007 A,2008-12-18,AU 2007/906997 A;;AU 2008/001864 W;;AU 2008/341007 A,2007-12-20,Analytical method and apparatus,,CYANTIFIC INSTR PTY LTD,ROSS FRASER JOHN,ORICA AUSTRALIA PTY LTD (2014-03-20),https://lens.org/012-401-023-150-11X,Patent Application,no,0,0,5,5,0,G01N1/4055;;G01N31/16;;G01N2001/4066;;Y10T436/175383;;Y10T436/172307;;Y10T436/25;;Y10T436/173845;;Y10T436/17;;Y10T436/201666;;Y10T436/174614;;Y10T436/255;;Y10T436/25875;;Y10T436/25375;;Y10T436/175383;;Y10T436/172307;;Y10T436/25;;Y10T436/173845;;Y10T436/17;;Y10T436/201666;;Y10T436/174614;;Y10T436/255;;Y10T436/25875;;Y10T436/25375;;G01N31/16;;G01N1/4055;;G01N2001/4066,G01N31/16;;G01N33/18,,0,0,,,,INACTIVE
196,US,A,US 1521441 A,011-572-876-606-262,1924-12-30,1924,US 63395023 A,1923-04-23,US 63395023 A,1923-04-23,Rectifier,,FRASER JOHN W,FRASER JOHN W,,https://lens.org/011-572-876-606-262,Granted Patent,no,0,0,1,1,0,H01G9/06;;H01G9/06,H01G9/06,,0,0,,,,EXPIRED
197,GB,B,GB 2143351 B,024-359-474-901-540,1986-06-25,1986,GB 8318631 A,1983-07-09,GB 8318631 A,1983-07-09,TEMPERATURE-COMPENSATING CIRCUIT FOR CONNECTING A CONSTANT CURRENT SOURCE TO A LOAD,,FERRANTI PLC,STEWART JOHN FRASER,,https://lens.org/024-359-474-901-540,Granted Patent,no,0,0,3,3,0,H03K17/567;;H03K17/615,H03K17/567;;H03K17/615,G4G2B2;;G4G2E3;;G4GS,0,0,,,,EXPIRED
198,US,B1,US 6375617 B1,027-494-677-493-55X,2002-04-23,2002,US 90899601 A,2001-07-18,US 90899601 A;;US 64587200 A,2000-08-24,Ultrasonic diagnostic imaging system with dynamic microbeamforming,"
    An ultrasonic imaging method and apparatus are described for imaging the coronary arteries of the heart. The vascular system is infused with an ultrasonic contrast agent. A volumetric region of the heart wall including a coronary artery is three dimensionally scanned. A projection image of the volumetric region is produced from the scanning, providing a two dimensional contrast image of the coronary artery with the appearance of an angiogram. Preferably the coronary artery signals are segmented from contrast signals emanating from the myocardium and the heart blood pool so that the coronary arteries are clearly highlighted and distinct in the ultrasonic angiogram. 
",ATL ULTRASOUND,FRASER JOHN D,,https://lens.org/027-494-677-493-55X,Granted Patent,yes,16,153,28,46,0,A61B8/06;;A61B8/0883;;A61B8/0891;;A61B8/4472;;A61B8/481;;A61B8/483;;A61B8/543;;G01S7/52074;;G01S7/52095;;G01S15/8963;;G01S15/8979;;G01S15/8993;;G10K11/341;;Y10S128/916;;G01S7/52025;;G01S7/5208;;G01S15/8918;;G01S15/8925;;G01S15/894;;A61B8/483;;G01S7/52025;;G01S7/5208;;G01S7/52095;;G01S15/8963;;G01S15/8979;;G01S15/8993;;G10K11/346;;A61B8/483;;A61B8/481;;G01S15/8963;;A61B8/543;;A61B8/0883;;G01S7/52095;;A61B8/06;;G01S7/52074;;G01S15/8993;;A61B8/0891;;G01S15/8979;;A61B8/4472;;G10K11/341;;Y10S128/916;;G01S15/8925;;G01S15/8918;;G01S7/52025;;G01S15/894;;G01S7/5208,A61B8/06;;G01S7/52;;G01S15/89;;G06T1/00;;G10K11/34,600/443;;600/459;;128/916,0,0,,,,EXPIRED
199,CA,A,CA 371214 A,074-672-600-895-597,1938-01-11,1938,CA 371214D A,,CA 371214T A,,BOLT AND RIVET MAKING MACHINE,,FRASER JOHN GEORGE,FRASER JOHN GEORGE,,https://lens.org/074-672-600-895-597,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
200,EP,A4,EP 1747543 A4,077-719-658-135-093,2009-12-30,2009,EP 05737801 A,2005-05-09,AU 2005/000660 W;;AU 2004/902622 A,2004-05-17,"METHOD, APPARATUS AND SYSTEM FOR PARKING OVERSTAY DETECTION",,VEHICLE MONITORING SYSTEMS PTY,WELCH FRASER JOHN,,https://lens.org/077-719-658-135-093,Search Report,no,3,0,12,15,0,G07B15/02;;G07F17/246;;G08G1/14;;G08G1/14;;G07F17/246;;G07B15/02,G07F17/24;;B60Q1/48;;G08G1/14,,1,0,,,See also references of WO 2005111963A1,ACTIVE
201,US,A,US 1764014 A,155-686-381-359-885,1930-06-17,1930,US 4518625 A,1925-07-22,US 4518625 A,1925-07-22,Latch,,KAWNEER CO,ALEXANDER FRASER JOHN,,https://lens.org/155-686-381-359-885,Granted Patent,no,0,1,1,1,0,E05F11/00;;Y10T292/0994;;Y10T292/0994;;E05F11/00,E05F11/00,,0,0,,,,EXPIRED
202,BR,A,BR 8107806 A,171-600-784-159-431,1982-09-08,1982,BR 8107806 A,1981-11-30,US 22819581 A,1981-01-26,ARTIGO COMPOSTO,,CORNING GLASS WORKS,MACDOWELL JOHN FRASER,,https://lens.org/171-600-784-159-431,Patent Application,no,0,0,10,10,0,C04B14/42;;C04B14/42;;C08J5/08;;C08J5/08;;E04C5/07;;E04C5/07;;Y10T428/249932;;Y10T428/249932;;Y10T428/24994;;Y10T428/24994;;Y10T428/268;;Y10T428/268;;Y10T428/2964;;Y10T428/2964;;Y10T428/298;;Y10T428/298;;Y10T428/315;;Y10T428/315;;Y10T428/31507;;Y10T428/31507;;Y10T428/31525;;Y10T428/31525;;Y10T428/31601;;Y10T428/31601;;Y10T428/31612;;Y10T428/31612;;Y10T428/31627;;Y10T428/31627;;Y10T428/31645;;Y10T428/31645,C03C21/00;;C03C25/00;;C04B14/42;;C08J5/08;;E04C5/07,,0,0,,,,DISCONTINUED
203,AU,A1,AU 2016/201902 A1,160-794-936-829-182,2016-04-21,2016,AU 2016/201902 A,2016-03-24,AU 2009/329831 A;;AU 2016/201902 A;;AU 2008/906642 A,2008-12-24,Method and system for detecting vehicle offences,5 Methods and systems for uniquely identifying a vehicle that has committed a potential violation are disclosed. One method comprises the steps of: obtaining first data for uniquely identifying vehicles that enter a zone of interest (610); obtaining second data relating to a potential violation committed by a particular vehicle in the zone of interest (620); correlating the first and second data to identify a portion of the first data recorded 10 while the particular vehicle was present in the zone of interest (630); extracting a unique identifier of the particular vehicle from the first data (640); and recording the unique identifier and an association between the unique identifier and the second data (650).,VEHICLE MONITORING SYSTEMS PTY LTD,WELCH FRASER JOHN,,https://lens.org/160-794-936-829-182,Patent Application,no,0,0,7,7,0,G08G1/017;;G08G1/017;;G07B15/063;;G07B15/063;;G08G1/0175;;G08G1/0175;;G08G1/04;;G08G1/04;;G08G1/042;;G08G1/042;;G08G1/148;;G08G1/148,G07C1/10;;G08G1/14,,0,0,,,,DISCONTINUED
204,KR,A,KR 20110114606 A,185-637-324-195-711,2011-10-19,2011,KR 20117017688 A,2009-12-09,US 14133008 P,2008-12-30,"ULTRASONIC TEETH CLEANING APPLIANCE HAVING SPATIAL, TEMPORAL AND/OR FREQUENCY VARIATIONS",,KONINKL PHILIPS ELECTRONICS NV,FRASER JOHN DOUGLAS,,https://lens.org/185-637-324-195-711,Patent Application,no,4,1,16,16,0,A61C17/20;;A61C17/20,A46B13/04;;A61C17/022;;A61C17/22,,0,0,,,,ACTIVE
205,US,B1,US 6632178 B1,183-566-516-252-575,2003-10-14,2003,US 70290700 A,2000-10-27,US 70290700 A;;US 59675900 A,2000-06-15,Fabrication of capacitive micromachined ultrasonic transducers by micro-stereolithography,"
    An ultrasonic transducer is formed by a plurality of cMUT cells, each comprising a charged diaphragm plate capacitively opposing an oppositely charged base plate. The cMUT cells can be fabricated by conventional semiconductor processes and hence integrated with ancillary transducer circuitry such as a bias charge regulator. The cMUT cells can also be fabricated by micro-stereolithography whereby the cells can be formed using a variety of polymers and other materials. 
",KONINKL PHILIPS ELECTRONICS NV,FRASER JOHN DOUGLAS,,https://lens.org/183-566-516-252-575,Granted Patent,yes,9,95,12,16,0,B06B1/0292;;B33Y80/00;;B33Y10/00;;B33Y80/00;;B33Y10/00;;B06B1/0292,B81B3/00;;A61B8/00;;B06B1/02;;H04R19/00,600/459;;600/437;;367/181;;367/170,14,8,082-337-270-109-398;;026-259-720-194-306;;006-310-271-609-945;;034-191-699-999-872;;053-311-251-537-664;;145-533-012-965-61X;;002-759-109-262-730;;039-706-930-548-559,10.1109/ultsym.1995.495627;;10.1109/ultsym.1994.401810;;18290242;;10.1109/58.39112;;10.1109/58.677612;;18244219;;10.1109/ultsym.1996.583986;;10.1109/ultsym.1996.584150;;10.1109/84.749409;;10.1109/58.368314,"Jin et al., ""The Microfabrication of Capacitive Ultrasonic Transducers,"" IEEE Journal of Microelectromechanical Systems, vol. 7, No. 3, Sep. 1998, pp. 295-302. </STEXT>;;Jin et al., ""Surface Micromachined Capacitive Ultrasonic Immersion Transducers,"" IEEE 1998, pp. 649-654. </STEXT>;;Jin et al., ""The Microfabrication of Capacitive Ultrasonic Transducers,"" 1997 International COnference on Solid-State Sensor and Actuators, Chicago (IL), Jun. 16-19, 1997, pp. 437-440. </STEXT>;;“Silicon Ultrasound,"" Sensant Corporation, 1999. </STEXT>;;Ladabaum et al., ""Micromachined Ultrasonic Transducers (MUTs),"" pp. 501-504, IEEE Ultrasonics Symposium, 1995. </STEXT>;;Oralkan et al., ""Simulation and Experimental Characterization of a 2-D, 3-MHZ Capacitive Micromachined Ultrasonic Transducer (CMUT) Array Element,"" Edward L. Ginzton Laboratory, Stanford University. </STEXT>;;Haller et al., ""A Surface Micromachined ELectrostatic Ultrasonic Air Transducer,"" pp. 1241-1244, IEEE Ultrasonic Symposium, 1994. </STEXT>;;Suzuki et al., ""A Silicon Electrostatic Ultrasonic Transducer,"" IEEE Trans. on Ultras., Ferro. and Freq. Control, vol. 35, No. 6, Nov. 1989, pp. 620-627. </STEXT>;;Ladabaum et al., ""Surface Micromachined Capacitive Ultrasonic Transducers,"" IEEE Trans. on Ultras., Ferro., and Freq. Control, vol. 45, No. 3, May 1998, pp. 687-690. </STEXT>;;Ladabaum et al., ""Microfabricated Ultrasonic Transducers: Towards Robust Models and Immersion Devices,"" IEEE Ultrasonic Symposium, 1996, pp. 335-338. </STEXT>;;Eccardt et al., ""Surface Micromachined Ultrasonic Transducers in CMOS technology,"" IEEE Ultrasonics Symposium, 1996, pp. 959-962. </STEXT>;;Jin et al., ""Fabrication and Characterization of Surface Micromachined Capacitive Ultrasonic Immersion Transducers,"" IEEE Journal of Microelectromechanical Systems, vol. 8, No. 1, Mar. 1999, pp. 100-114. </STEXT>;;Schindel et al., ""The Design and Characterization of Micromachined Air-Coupled Capacitance Transducers,"" IEEE Trans. on Ultras. Ferro. and Freq. Control, vol. 42, No. 1, Jan. 1995, pp. 42-50. </STEXT>;;Haller et al., ""A Surface Micromachined Electrostatic Ultrasonic Air Transducer,"" IEEE Trans. on Ultras., Ferro. and Freq. Control, vol. 43, No. 1, Jan. 1996, pp. 1-6.</STEXT>",EXPIRED
206,WO,A1,WO 2001/053009 A1,196-554-883-525-997,2001-07-26,2001,EP 0100192 W,2001-01-10,US 48858300 A,2000-01-21,HEX PACKED TWO DIMENSIONAL ULTRASONIC TRANSDUCER ARRAYS,"A two dimensional ultrasonic transducer array (10) suitable for three dimensional phased array scanning is formed of hexagonally close packed transducer elements (20). In a preferred embodiment the transducer elements have a rectilinear shape, allowing the array to be fabricated with conventional dicing saw processes.",KONINKL PHILIPS ELECTRONICS NV,FRASER JOHN D,,https://lens.org/196-554-883-525-997,Patent Application,yes,4,10,6,6,0,B06B1/0622;;B06B1/0622,G01N29/24;;A61B8/00;;B06B1/06;;H04R17/00,,0,0,,,,PENDING
207,AU,A,AU 1977/029868 A,015-704-782-133-756,1979-04-26,1979,AU 1977/029868 A,1977-10-19,NZ 18237976 A,1976-10-20,PIPE SUPPORTS,,FRASER D J;;FRASER S I,FRASER DONALD JOHN;;FRASER SHIRLEY ISMAY,,https://lens.org/015-704-782-133-756,Patent Application,no,0,0,1,2,0,,F16L3/00,,0,0,,,,DISCONTINUED
208,NO,B1,NO 347327 B1,173-509-479-061-687,2023-09-18,2023,NO 20160618 A,2016-04-12,GB 201320104 A;;GB 2014053317 W,2013-11-14,AN IMPROVED SUPPORT DEVICE FOR USE IN A WELLBORE AND A METHOD FOR DEPLOYING A BARRIER IN A WELLBORE,,CORETRAX GLOBAL LTD,MURRAY JOHN KENNETH FRASER;;FRASER JOHN;;FONG JASON,"CORETRAX TECHNOLOGY LIMITED, GB (2018-12-17);;CORETRAX GLOBAL LIMITED, GB (2023-02-13)",https://lens.org/173-509-479-061-687,Granted Patent,no,1,0,9,9,0,E21B23/06;;E21B33/127;;E21B33/134;;E21B17/02;;E21B33/127;;E21B17/02;;E21B23/06;;E21B33/127;;E21B33/134;;E21B17/02;;E21B19/16;;E21B17/02;;E21B23/06;;E21B33/127;;E21B33/134;;E21B2200/06;;E21B34/10,E21B23/06;;E21B33/127;;E21B33/134,,0,0,,,,PENDING
209,WO,A1,WO 2015/071644 A1,089-341-446-761-440,2015-05-21,2015,GB 2014053317 W,2014-11-07,GB 201320104 A,2013-11-14,AN IMPROVED SUPPORT DEVICE FOR USE IN A WELLBORE AND A METHOD FOR DEPLOYING A BARRIER IN A WELLBORE,"A downhole support device for use in a wellbore is provided, where the device (200) is adapted to be run into the wellbore (202) through or on a workstring (204). The device (200) comprises an inflatable element (206) adapted to be selectively connectable to the workstring (204). The inflatable element (206) selectively applies a biasing force to an external structure such, for example, a wall (214) of the wellbore (202) when in an inflated state. The inflatable element (206) has an inlet (208) for receiving and being inflated by a flowing substance. The device (200) also comprises an inflation mechanism (210) and a disconnect mechanism (222) adapted to be selectively disconnectable from the workstring (204). A method of deploying a barrier in a wellbore which makes use of the support device is also provided.",SMJM LTD,MURRAY JOHN KENNETH FRASER;;FRASER JOHN;;FONG JASON,,https://lens.org/089-341-446-761-440,Patent Application,yes,5,1,9,9,0,E21B23/06;;E21B33/127;;E21B33/134;;E21B17/02;;E21B33/127;;E21B17/02;;E21B23/06;;E21B33/127;;E21B33/134;;E21B17/02;;E21B19/16;;E21B17/02;;E21B23/06;;E21B33/127;;E21B33/134;;E21B2200/06;;E21B34/10,E21B23/06;;E21B33/127;;E21B33/134,,0,0,,,,PENDING
210,EP,A1,EP 0726873 A1,007-610-278-724-162,1996-08-21,1996,EP 94927723 A,1994-09-27,GB 9402095 W;;GB 9322770 A,1993-11-04,DOLLY,,GRIP HOUSE LTD,FRASER DENNIS JOHN,,https://lens.org/007-610-278-724-162,Patent Application,yes,0,0,9,9,0,B66F11/048;;B66F11/048;;F16M11/046;;F16M11/046;;F16M11/10;;F16M11/10;;F16M11/18;;F16M11/18;;F16M11/2014;;F16M11/2014;;F16M11/42;;F16M11/42;;F16M2200/08;;F16M2200/08,B66F11/04;;F16M11/42,,1,0,,,See references of WO 9512542A1,EXPIRED
211,GB,A,GB 189816693 A,007-504-588-245-280,1899-06-17,1899,GB 189816693D A,1898-08-02,GB 189816693T A,1898-08-02,Improvement in Swinging Supports for Typewriters and the like.,"16,693. Gregory, J. F. Aug. 2. Brackets.-Relates to a swinging bracket or support for type-writers &c. The type-writer is secured to a disc N provided with arms P and adjustably secured by a bolt and nut 0 to a plate M formed on a bracket F swung upon pins G, H in lugs C, D formed upon a plate A adapted to be secured to the desk. The pin G is screwed and provided with a nut I by which the bracket can be drawn down until a bevelled edge K formed on it engages a similar edge on the plate A and clamps the bracket in position.",GREGORY JOHN FRASER,GREGORY JOHN FRASER,,https://lens.org/007-504-588-245-280,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
212,AU,A1,AU 2021/200165 A1,026-310-106-716-240,2021-03-18,2021,AU 2021/200165 A,2021-01-13,AU 2021/200165 A;;AU 2018/282421 A;;AU 2017/201635 A;;AU 2013/202590 A;;AU 2011/204924 A,2011-07-21,"Method, apparatus and system for parking overstay detection","METHOD, APPARATUS AND SYSTEM FOR PARKING OVERSTAY Methods, apparatuses and systems for identifying overstay of a vehicle (624, 644) in a parking space (610, 620, 630, 640, 650, 660) are disclosed herein. The method comprises the steps of detecting presence of a vehicle in a parking space using a detection apparatus (612, 622, 632, 642, 652, 662), processing and storing data relating to presence of the vehicle in the detection apparatus, determining whether the vehicle has overstayed a defined time duration in the parking space; and wirelessly transmitting data relating to identified instances of overstay of the vehicle in the parking space.",VEHICLE MONITORING SYSTEMS PTY LTD,WELCH FRASER JOHN,,https://lens.org/026-310-106-716-240,Patent Application,no,0,0,8,8,0,,G08G1/14,,0,0,,,,DISCONTINUED
213,GB,A,GB 2227229 A,025-129-180-074-554,1990-07-25,1990,GB 8901071 A,1989-01-18,GB 8901071 A,1989-01-18,Package tray,"A package tray of a style generally known as a ""W-pack"" comprises two hinged base portions (20, 22) integrally thermoformed from a plastics material in the shape of a W. When loaded with biscuits etc. the hinge (24) folds and the tray flattens so that it becomes substantially rectangular. Ribs (26a) are provided on the base portions which abut each other in the flattened condition, and act as stops preventing further undesirable collapsing of the tray beyond the rectangular configuration. <IMAGE>",POLBETH PACKAGING LTD,BURNETT JOHN FRASER,,https://lens.org/025-129-180-074-554,Patent Application,no,0,2,2,2,0,B65D85/36,B65D85/36,B8P PR            PR;;U1S S1094,0,0,,,,DISCONTINUED
214,US,A,US 3500098 A,012-011-108-870-999,1970-03-10,1970,US 3500098D A,1965-10-22,CA 929195 A;;US 50162365 A,1965-04-27,INTENSE NEUTRON GENERATOR,,CA ATOMIC ENERGY LTD,FRASER JOHN S,,https://lens.org/012-011-108-870-999,Granted Patent,no,0,6,5,5,0,H05H6/00;;H05H6/00,H05H6/00,313/61,0,0,,,,EXPIRED
215,US,P1,US 2018/0139882 P1,015-565-737-798-428,2018-05-17,2018,US 201615530002 V,2016-11-16,US 201615530002 V,2016-11-16,Cordyline Plant Named 'Paso Doble',"A new cultivar of Cordyline plant named ‘Paso Doble’ that is characterized by leaves that are linear in shape, upright and dark red in color with dark pink margins.",FRASER PETER JOHN,FRASER PETER JOHN,,https://lens.org/015-565-737-798-428,Patent Application,yes,0,0,2,2,0,A01H6/12;;A01H5/12;;A01H5/12;;A01H6/12,A01H6/12;;A01H5/12,PLT 383,0,0,,,,PENDING
216,WO,A1,WO 2005/111963 A1,079-778-213-220-968,2005-11-24,2005,AU 2005/000660 W,2005-05-09,AU 2004/902622 A,2004-05-17,"METHOD, APPARATUS AND SYSTEM FOR PARKING OVERSTAY DETECTION","Methods, apparatuses and systems for identifying overstay of a vehicle (624, 644) in a parking space (610, 620, 630, 640, 650, 660) are disclosed herein. The method comprises the steps of detecting the presence of the vehicle in a parking space using a detection apparatus (612, 622, 632, 642, 652, 662), processing and storing data relating to the presence of vehicle in the detection apparatus, wirelessly (672, 674) waking-up the detection apparatus, wirelessly retrieving at least a portion of the data from the detection apparatus, and identifying overstay of the vehicle in the parking space based on the retrieved data. Wireless wake-up of a detection apparatus may be irregularly performed by an occasionally present data collection apparatus (680). Apparatuses and systems are also disclosed for performing the foregoing method.",VEHICLE MONITORING SYSTEMS PTY;;WELCH FRASER JOHN,WELCH FRASER JOHN,,https://lens.org/079-778-213-220-968,Patent Application,yes,8,3,12,15,0,G08G1/14;;G08G1/14;;G07B15/02;;G07B15/02;;G07F17/246;;G07F17/246,B60Q1/48;;G08G1/14,,2,0,,,"PATENT ABSTRACTS OF JAPAN vol. 1998, no. 11;;See also references of EP 1747543A4",PENDING
217,GB,A,GB 2281710 A,098-367-577-760-255,1995-03-15,1995,GB 9416593 A,1994-08-17,GB 9317070 A,1993-08-17,Moulding plastics sheet material,"When moulding plastics sheet material (44) using reciprocating moulding members (18, 34), the moulding surface is partially defined by the interior surface of a cutting blade (32) having a cutting edge (40) which is arranged to contact but not cut the sheet material during the forming procedure. When the forming is complete, the cutting edge (40) cuts through the sheet (44) at the desired peripheral edge of the formed product, thus dispensing with a subsequent trimming step. The sheet may be applied to the moulding surface by blowing hot air from the other moulding member (18) which is itself heated for initial heating of the sheet, the sheet being blown against it for that purpose.",POLBETH PACKAGING LTD,BURNETT JOHN FRASER,,https://lens.org/098-367-577-760-255,Patent Application,no,8,0,3,3,0,B29C49/4278;;B29C35/02;;B29C51/10;;B29C51/32,B29C35/02;;B29C51/10;;B29C51/32;;B29C69/00,B5A AT16U         AT16U;;B5A A1R314C1X     AT16U;;B5A A1R419        AT16U;;B5A A1R420        AT16U;;B5A A2A1          AT16U;;B5A A2A4B         AT16U;;B5A A2B1          AT16U;;B5A A2H5          AT16U;;B5A A9G1          AT16U;;B5A A9H1          AT16U;;B5A A9N1          AT16U,0,0,,,,DISCONTINUED
218,DE,T2,DE 69914709 T2,111-716-855-575-810,2004-07-15,2004,DE 69914709 T,1999-12-03,US 20641998 A,1998-12-07,Dämpfer für die Überbrückungskupplung eines Momentwandlers mit einer nachgiebigen Druckscheibe,,FORD GLOBAL TECH LLC,MACDONALD FRASER JOHN,,https://lens.org/111-716-855-575-810,Granted Patent,no,0,0,5,5,0,F16H45/02;;F16H2045/0294,F16H45/02,,0,0,,,,EXPIRED
219,EP,B1,EP 2688686 B1,119-881-986-669-593,2022-08-17,2022,EP 12713338 A,2012-03-13,US 201161466172 P;;IB 2012051173 W,2011-03-22,ULTRASONIC CMUT WITH SUPPRESSED ACOUSTIC COUPLING TO THE SUBSTRATE,,KONINKLIJKE PHILIPS NV,FRASER JOHN DOUGLAS,KONINKLIJKE PHILIPS N.V. (2020-03-18),https://lens.org/119-881-986-669-593,Granted Patent,yes,5,0,12,12,0,G01H11/06;;B06B1/0292;;G10K11/002;;G01H11/06;;B06B1/0292;;G10K11/002;;A61B8/4494,G01H11/06;;B06B1/02;;G10K11/00,,0,0,,,,ACTIVE
220,US,A,US 1385125 A,116-945-210-973-548,1921-07-19,1921,US 37818820 A,1920-05-01,US 37818820 A,1920-05-01,Door-fastener,,GARFIELD L EVANS,GEORGE FRASER JOHN,,https://lens.org/116-945-210-973-548,Granted Patent,no,0,3,1,1,0,E05B3/10;;Y10T292/858;;Y10T292/858;;E05B3/10,E05B3/10,,0,0,,,,EXPIRED
221,EP,A3,EP 1008784 A3,133-668-942-385-892,2001-04-04,2001,EP 99309749 A,1999-12-03,US 20641998 A,1998-12-07,Torque converter bypass clutch damper having compliant pressure disc,"A hydrokinetic torque converter includes an impeller cover (12) and a bypass clutch. The impeller cover (12) has welded to it a clutch plate (70), which carries friction material (80) adjacent a clutch piston (60). The piston (60) supports a pressure disc (79) and carries it axially into engagement with the clutch plate (70). The disc (79) flexes into conformance with the surface of the clutch plate (70) beginning at a radially inner region and progressing radially outward as clutch apply pressure increases.",FORD GLOBAL TECH INC,MACDONALD FRASER JOHN,"FORD GLOBAL TECHNOLOGIES, LLC (2003-11-26)",https://lens.org/133-668-942-385-892,Search Report,yes,5,0,5,5,0,F16H45/02;;F16H2045/0294,F16H45/02,,1,0,,,"PATENT ABSTRACTS OF JAPAN vol. 011, no. 120 (M - 580) 15 April 1987 (1987-04-15)",EXPIRED
222,DE,D1,DE 3666220 D1,136-446-348-653-714,1989-11-16,1989,DE 3666220 T,1986-04-10,US 73720485 A,1985-05-23,B2O3-P2O5-SIO2 GLASS-CERAMICS,,CORNING GLASS WORKS,MACDOWELL JOHN FRASER,,https://lens.org/136-446-348-653-714,Granted Patent,no,0,0,6,6,0,C03C13/006;;C03C13/006;;C03C10/0054;;C03C10/0054,C03C3/064;;C03B32/02;;C03C3/097;;C03C10/00;;C03C10/02;;C03C13/00,,0,0,,,,EXPIRED
223,DE,A1,DE 3925486 A1,158-084-356-938-093,1990-02-08,1990,DE 3925486 A,1989-08-01,US 22677388 A,1988-08-01,ERDALKALIALUMINOBORAT-GLASKERAMIK,,CORNING INC,MACDOWELL JOHN FRASER,,https://lens.org/158-084-356-938-093,Patent Application,no,0,1,3,3,0,C03C10/0054;;C03C10/0054;;C03C10/0009;;C03C10/0009;;H05K1/0306;;H05K1/0306,C03C10/00;;C03C10/02;;H05K1/03,,0,0,,,,DISCONTINUED
224,CA,A,CA 842579 A,159-342-719-400-547,1970-05-26,1970,CA 842579D A,,CA 842579T A,,METHOD OF SULFUR RECOVERY FROM SULFUR-CONTAINING HYDROGEN SULFIDE RICH FORMATIONS,,SHELL OIL CO,FRASER JOHN P,,https://lens.org/159-342-719-400-547,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
225,CH,A,CH 426599 A,172-531-294-230-872,1966-12-15,1966,CH 898663 A,1963-07-18,US 21179462 A,1962-07-23,Procédé de fabrication d'un objet en céramique semicristalline,,CORNING GLASS WORKS,JOHN FRASER MACDOWELL,,https://lens.org/172-531-294-230-872,Granted Patent,no,0,0,9,10,0,C03C3/062;;C03C3/085;;C03C3/062;;C03C3/085,C03C3/062;;C03C3/085,"32B,3/30",0,0,,,,EXPIRED
226,US,A1,US 2016/0251938 A1,092-308-490-495-171,2016-09-01,2016,US 201415033675 A,2014-11-07,GB 201320104 A;;GB 2014053317 W,2013-11-14,IMPROVED SUPPORT DEVICE FOR USE IN A WELLBORE AND A METHOD FOR DEPLOYING A BARRIER IN A WELLBORE,"A downhole support device for use in a wellbore is provided, where the device ( 200 ) is adapted to be run into the wellbore ( 202 ) through or on a workstring ( 204 ). The device ( 200 ) comprises an inflatable element ( 206 ) adapted to be selectively connectable to the workstring ( 204 ). The inflatable element ( 206 ) selectively applies a biasing force to an external structure such, for example, a wall ( 214 ) of the wellbore ( 202 ) when in an inflated state. The inflatable element ( 206 ) has an inlet ( 208 ) for receiving and being inflated by a flowing substance. The device ( 200 ) also comprises an inflation mechanism ( 210 ) and a disconnect mechanism ( 222 ) adapted to be selectively disconnectable from the workstring ( 204 ). A method of deploying a barrier in a wellbore which makes use of the support device is also provided.",SMJM LTD,MURRAY JOHN KENNETH FRASER;;FRASER JOHN;;FONG JASON,CORETRAX GLOBAL LIMITED (2022-04-21);;SMJM LIMITED (2016-03-30);;CORETRAX TECHNOLOGY LIMITED (2018-11-12),https://lens.org/092-308-490-495-171,Patent Application,yes,24,17,9,9,0,E21B23/06;;E21B33/127;;E21B33/134;;E21B17/02;;E21B33/127;;E21B17/02;;E21B23/06;;E21B33/127;;E21B33/134;;E21B17/02;;E21B19/16;;E21B17/02;;E21B23/06;;E21B33/127;;E21B33/134;;E21B2200/06;;E21B34/10,E21B33/127;;E21B34/10,,0,0,,,,ACTIVE
227,US,B2,US 10465476 B2,194-979-778-845-033,2019-11-05,2019,US 201415033675 A,2014-11-07,GB 201320104 A;;GB 2014053317 W,2013-11-14,Support device for use in a wellbore and a method for deploying a barrier in a wellbore,"A downhole support device for use in a wellbore is provided, where the device ( 200 ) is adapted to be run into the wellbore ( 202 ) through or on a workstring ( 204 ). The device ( 200 ) comprises an inflatable element ( 206 ) adapted to be selectively connectable to the workstring ( 204 ). The inflatable element ( 206 ) selectively applies a biasing force to an external structure such, for example, a wall ( 214 ) of the wellbore ( 202 ) when in an inflated state. The inflatable element ( 206 ) has an inlet ( 208 ) for receiving and being inflated by a flowing substance. The device ( 200 ) also comprises an inflation mechanism ( 210 ) and a disconnect mechanism ( 222 ) adapted to be selectively disconnectable from the workstring ( 204 ). A method of deploying a barrier in a wellbore which makes use of the support device is also provided.",SMJM LTD;;CORETRAX TECH LIMITED,MURRAY JOHN KENNETH FRASER;;FRASER JOHN;;FONG JASON,CORETRAX GLOBAL LIMITED (2022-04-21);;SMJM LIMITED (2016-03-30);;CORETRAX TECHNOLOGY LIMITED (2018-11-12),https://lens.org/194-979-778-845-033,Granted Patent,yes,29,2,9,9,0,E21B23/06;;E21B33/127;;E21B33/134;;E21B17/02;;E21B33/127;;E21B17/02;;E21B23/06;;E21B33/127;;E21B33/134;;E21B17/02;;E21B19/16;;E21B17/02;;E21B23/06;;E21B33/127;;E21B33/134;;E21B2200/06;;E21B34/10,E21B34/10;;E21B17/02;;E21B19/16;;E21B23/06;;E21B33/127;;E21B33/134;;E21B34/00,,1,0,,,"PCT Search Report (PCT/GB2014/053317), dated Nov. 3, 2015.",ACTIVE
228,US,B2,US 8769753 B2,014-410-178-621-665,2014-07-08,2014,US 200913141551 A,2009-12-09,US 200913141551 A;;US 14133008 P;;IB 2009055611 W,2008-12-30,"Ultrasonic teeth cleaning appliance having spatial, temporal and/or frequency variations","The appliance includes an appliance body ( 12 ) as well as a system for producing microbubbles ( 20 ) and a system for producing an ultrasound signal beam ( 22 ) in a frequency range which activates at least some of the microbubbles. The appliance includes at least one of the following: (a) an array of ultrasound transducer elements ( 40 ) which produce a plurality of ultrasound signal beams; (b) an amplitude modulation assembly ( 51 ) for modulating the amplitude of the ultrasound signal; and (c) a frequency modulation system ( 61 ) for changing the frequency of the ultrasound signals over a selected range, to impact a range of microbubble sizes.",FRASER JOHN DOUGLAS;;KONINKL PHILIPS NV,FRASER JOHN DOUGLAS,KONINKLIJKE PHILIPS ELECTRONICS N V (2009-12-09),https://lens.org/014-410-178-621-665,Granted Patent,yes,12,3,16,16,0,A61C17/20;;A61C17/20,A61C17/20,15/22.1;;15/167.1;;433/119,0,0,,,,ACTIVE
229,CA,A,CA 790696 A,023-338-345-723-830,1968-07-23,1968,CA 790696D A,,CA 790696T A,,INTENSE NEUTRON GENERATOR,,CA ATOMIC ENERGY LTD,FRASER JOHN S,,https://lens.org/023-338-345-723-830,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
230,WO,A2,WO 2001/097559 A2,039-010-164-579-739,2001-12-20,2001,EP 0106868 W,2001-06-15,US 59675900 A;;US 69823200 A,2000-06-15,CAPACITIVE MICROMACHINED ULTRASONIC TRANSDUCERS.,"An ultrasonic transducer is formed by a plurality of cMUT cells (10), each comprising a charged diaphragm plate (14) capacitively opposing an oppositely charged base plate (12). The diaphragm plate (14) is distended toward the base plate (12) by a bias charge. The base plate (12) includes a central portion (28) elevated toward the center of the diaphragm plate (14) to cause the charge of the cell to be of maximum density at the moving center of the diaphragm plate (14). For harmonic operation the drive pulses applied to the cells (10) are predistorted in consideration of the nonlinear operation of the device to reduce contamination of the transmit signal at the harmonic band. The cMUT cells (10) can be fabricated by conventional semiconductor processes and hence integrated with ancillary transducer circuitry such as a bias charge regulator (30). The cMUT cells (10) can also be fabricated by micro-stereolithography whereby the cells (10) can be formed using a variety of polymers and other materials.",KONINKL PHILIPS ELECTRONICS NV,FRASER JOHN D,,https://lens.org/039-010-164-579-739,Patent Application,yes,0,11,4,16,0,B06B1/0292;;B33Y80/00;;B33Y80/00;;B06B1/0292,A61B8/12;;B81B3/00;;B06B1/02;;H04R1/02;;H04R7/00;;H04R19/00,,0,0,,,,PENDING
231,EP,B1,EP 1022491 B1,028-536-053-218-655,2004-07-28,2004,EP 00300286 A,2000-01-17,US 23798399 A,1999-01-25,Torque converter having resiliently loaded bypass clutch piston,,LAWRENCE TECHNOLOGICAL UNIVERS,MACDONALD FRASER JOHN,LAWRENCE TECHNOLOGICAL UNIVERSITY (2003-08-13),https://lens.org/028-536-053-218-655,Granted Patent,yes,6,0,6,6,0,F16H45/02;;F16H2045/0278;;F16H2045/0289;;F16H45/02;;F16H2045/0278;;F16H2045/0289,F16H45/02,,1,0,,,"FROSLIE, MILEK, SMITH: ""Design Practices- Passenger Car Automatic Transmissions Part I"" 1962 , SAE , NEW YORK XP000905044 * page 81 - page 99 *",EXPIRED
232,EP,A2,EP 1294493 A2,068-921-652-303-132,2003-03-26,2003,EP 01956480 A,2001-06-15,EP 0106868 W;;US 59675900 A;;US 69823200 A,2000-06-15,CAPACITIVE MICROMACHINED ULTRASONIC TRANSDUCERS.,,KONINKL PHILIPS ELECTRONICS NV,FRASER JOHN D,,https://lens.org/068-921-652-303-132,Patent Application,yes,0,0,4,16,0,B06B1/0292;;B33Y80/00;;B33Y80/00;;B06B1/0292,B81B3/00;;A61B8/12;;B06B1/02;;H04R1/02;;H04R7/00;;H04R19/00,,0,0,,,,DISCONTINUED
233,AU,B4,AU 2010/101354 B4,069-921-065-304-970,2011-01-27,2011,AU 2010/101354 A,2010-12-02,AU 2008/200089 A;;AU 2010/101354 A;;AU 2004/902622 A,2004-05-17,"Method, apparatus and system for parking overstay detection",,VEHICLE MONITORING SYSTEMS PTY LTD,WELCH FRASER JOHN,,https://lens.org/069-921-065-304-970,Limited Patent,no,4,0,12,15,0,G08G1/14;;G08G1/14;;G07B15/02;;G07B15/02;;G07F17/246;;G07F17/246,G08G1/14;;B60Q1/48,,0,0,,,,INACTIVE
234,WO,A1,WO 2010/076705 A1,118-242-977-595-636,2010-07-08,2010,IB 2009055611 W,2009-12-09,US 14133008 P,2008-12-30,"ULTRASONIC TEETH CLEANING APPLIANCE HAVING SPATIAL, TEMPORAL AND/OR FREQUENCY VARIATIONS","The appliance includes an appliance body (12) as well as a system for producing microbubbles (20) and a system for producing an ultrasound signal beam (22) in a frequency range which activates at least some of the microbubbles. The appliance includes at least one of the following: (a) an array of ultrasound transducer elements (40) which produce a plurality of ultrasound signal beams; (b) an amplitude modulation assembly (51) for modulating the amplitude of the ultrasound signal; and (c) a frequency modulation system (61) for changing the frequency of the ultrasound signals over a selected range, to impact a range of microbubble sizes.",KONINKL PHILIPS ELECTRONICS NV;;FRASER JOHN DOUGLAS,FRASER JOHN DOUGLAS,,https://lens.org/118-242-977-595-636,Patent Application,yes,8,8,16,16,0,A61C17/20;;A61C17/20,A61C17/20,,0,0,,,,PENDING
235,WO,A1,WO 1995/012542 A1,165-972-442-617-228,1995-05-11,1995,GB 9402095 W,1994-09-27,GB 9322770 A,1993-11-04,DOLLY,"A dolly has a wheeled body (10) with an upwardly-opening recess therein within which is received a rotatable base unit or turret (24) containing the hydraulics for raising and lowering a boom arm (26). The boom arm may be positioned either facing forwardly of the body (10) or laterally of the body. In each case, the boom arm is received within an aperture (30, 32, 34), the apertures being suitably sized to allow the boom arm to be lowered to a position below the horizontal. The base unit (24) may be lifted out of the recess, and may be used with another body of a different size.",GRIP HOUSE LTD;;FRASER DENNIS JOHN,FRASER DENNIS JOHN,,https://lens.org/165-972-442-617-228,Patent Application,yes,4,1,9,9,0,B66F11/048;;B66F11/048;;F16M11/046;;F16M11/046;;F16M11/10;;F16M11/10;;F16M11/18;;F16M11/18;;F16M11/2014;;F16M11/2014;;F16M11/42;;F16M11/42;;F16M2200/08;;F16M2200/08,B66F11/04;;F16M11/42,,0,0,,,,PATENTED
236,CA,A,CA 376868 A,155-433-311-707-308,1938-10-04,1938,CA 376868D A,,CA 376868T A,,TRAILER LIGHT,,KEESHIN MOTOR EXPRESS CO INC,FRASER EDWIN JOHN,,https://lens.org/155-433-311-707-308,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
237,US,A,US 1675172 A,000-897-296-968-220,1928-06-26,1928,US 8358226 A,1926-01-25,US 8358226 A,1926-01-25,Valve,,MILWAUKEE VALVE CO,FRASER JR JOHN,,https://lens.org/000-897-296-968-220,Granted Patent,no,0,0,1,1,0,F16K41/043;;F16K41/16;;F16K41/043;;F16K41/16,F16K41/04;;F16K41/16,,0,0,,,,EXPIRED
238,AU,A1,AU 2004/201820 A1,027-672-346-087-185,2004-11-25,2004,AU 2004/201820 A,2004-05-03,AU 2004/201820 A;;AU 2003/902143 A,2003-05-05,Improvements in and relating to boat covers,,FRASER CHRISTOPHER JOHN,FRASER CHRISTOPHER JOHN,,https://lens.org/027-672-346-087-185,Patent Application,no,0,0,1,2,0,,B63B17/02,,0,0,,,,DISCONTINUED
239,AU,A1,AU 2008/200089 A1,018-716-841-882-413,2008-01-31,2008,AU 2008/200089 A,2008-01-08,AU 2005/243110 A;;AU 2008/200089 A;;AU 2004/902622 A,2004-05-17,"Method, apparatus and system for parking overstay detection",,VEHICLE MONITORING SYSTEMS PTY LTD,WELCH FRASER JOHN,,https://lens.org/018-716-841-882-413,Patent Application,no,0,1,3,15,0,,G08G1/14,,0,0,,,,DISCONTINUED
240,US,A,US 1677692 A,056-953-129-396-953,1928-07-17,1928,US 20448127 A,1927-07-09,US 20448127 A,1927-07-09,Electrical cut-out,,RAINBOW LIGHT INC,FRASER STOKES JOHN,,https://lens.org/056-953-129-396-953,Granted Patent,no,0,8,1,1,0,H01H83/10;;H01H83/10,H01H83/10,,0,0,,,,EXPIRED
241,DE,D1,DE 60012379 D1,048-088-582-925-717,2004-09-02,2004,DE 60012379 T,2000-01-17,US 23798399 A,1999-01-25,Momentwandler mit einer Überbrückungskupplung mit einem federbelasteten Kolben,,LAWRENCE TECHNOLOGICAL UNIVERS,MACDONALD FRASER JOHN,,https://lens.org/048-088-582-925-717,Granted Patent,no,0,0,6,6,0,F16H45/02;;F16H2045/0278;;F16H2045/0289;;F16H45/02;;F16H2045/0278;;F16H2045/0289,F16H45/02,,0,0,,,,EXPIRED
242,EP,A2,EP 1294494 A2,072-455-958-658-744,2003-03-26,2003,EP 01964960 A,2001-06-08,EP 0106479 W;;US 59675900 A,2000-06-15,CAPACITIVE MICROMACHINED ULTRASONIC TRANSDUCER AND OPERATING METHOD THEREOF,"An ultrasonic transducer is formed by a plurality of cMUT cells, each comprising a charged diaphragm plate capacitively opposing an oppositely charged base plate. The diaphragm plate is distended toward the base plate by a bias charge. The base plate includes a central portion elevated toward the center of the diaphragm plate to cause the charge of the cell to be of maximum density at the moving center of the diaphragm plate. For harmonic operation the drive pulses applied to the cells are predistorted in consideration of the nonlinear operation of the device to reduce contamination of the transmit signal at the harmonic band. The cMUT cells can be fabricated by conventional semiconductor processes and hence integrated with ancillary transducer circuitry such as a bias charge regulator. The cMUT cells can also be fabricated by micro-stereolithography whereby the cells can be formed using a variety of polymers and other materials.",KONINKL PHILIPS ELECTRONICS NV,FRASER JOHN D,"KONINKLIJKE PHILIPS ELECTRONICS N.V., NL (2014-11-26);;KONINKLIJKE PHILIPS N.V., NL (2014-03-28)",https://lens.org/072-455-958-658-744,Patent Application,yes,0,0,12,16,0,B06B1/0292;;B33Y80/00;;B33Y10/00;;B33Y80/00;;B33Y10/00;;B06B1/0292,B81B3/00;;A61B8/00;;B06B1/02;;H04R19/00,,0,0,,,,EXPIRED
243,GB,A,GB 2143351 A,097-295-873-330-253,1985-02-06,1985,GB 8318631 A,1983-07-09,GB 8318631 A,1983-07-09,Temperature-compensating circuit for connecting a constant current source to a load,"A circuit for connecting a constant current source CS to a load C, e.g. a sampling capacitor, includes a first switch S1 operable to make and break a connection between the source and the load. A second switch S2 is provided, which is operable to connect a bypass impedance BZ across the output of the current source when the load is disconnected from the load, and to disconnect the bypass impedance when the source is connected to the load. A control circuit SS controls the operation of the two switches. The switches are arranged to have similar temperature-dependent characteristics and to be located so as to be subjected to the same temperature variations. <IMAGE>",FERRANTI PLC,STEWART JOHN FRASER,,https://lens.org/097-295-873-330-253,Patent Application,no,0,0,3,3,0,H03K17/567;;H03K17/615,H03K17/567;;H03K17/615,G4G GS            GS;;G4G G2B2          GS;;G4G G2E3          GS,0,0,,,,EXPIRED
244,US,A,US 6053292 A,119-567-954-279-560,2000-04-25,2000,US 23798399 A,1999-01-25,US 23798399 A,1999-01-25,Torque converter having resiliently loaded bypass clutch piston,"A hydrokinetic torque converter includes an impeller cover and a bypass clutch. A drive ring is located between adjacent surfaces of the cover and a clutch piston, which moves axially on a support surface. The piston is welded at a radially outer position to thin clutch plate, which is supported at another radial location on the cover. As the piston moves into engagement with the ring and cover, the clutch plate permits this movement by bending elastically. When clutch apply pressure is reduced, energy stored in the clutch plate is used to move the piston out of engagement with the drive ring and cover.",FORD GLOBAL TECH INC,MACDONALD FRASER JOHN,REGAN STEVE (2002-12-18);;FORD GLOBAL TECHNOLOGIES INC. A CORP. OF MI (1999-01-11),https://lens.org/119-567-954-279-560,Granted Patent,yes,3,22,6,6,0,F16H45/02;;F16H2045/0278;;F16H2045/0289;;F16H45/02;;F16H2045/0278;;F16H2045/0289,F16H45/02,192/3.28;;192/3.3,0,0,,,,EXPIRED
245,EP,A4,EP 1532177 A4,110-999-840-147-326,2005-08-24,2005,EP 03733654 A,2003-06-04,NZ 0300111 W;;NZ 51937102 A,2002-06-04,IMMUNOMODULATORY CONSTRUCTS AND THEIR USES,"The invention relates to immunomodulators. In particular the invention relates to specific immunomodulators based on the superantigen SMEZ-2 and more particularly based on mutants of the superantigen SMEZ-2, which are adapted to target antigen-presenting-cells for the purpose of enhancing or suppressing a host immune response.",AUCKLAND UNISERVICES LTD,FRASER JOHN DAVID,AUCKLAND UNISERVICES LIMITED (2009-11-13),https://lens.org/110-999-840-147-326,Search Report,no,1,0,14,14,0,A61K39/092;;A61K39/385;;A61K2039/6037;;C07K14/315;;A61P37/02;;C07K14/315;;A61K39/092;;A61K2039/6037;;A61K39/385,C12N15/09;;A61K39/00;;A61K39/09;;A61K39/385;;A61K39/39;;C07K14/315;;C07K19/00;;C12N15/31,,0,0,,,,EXPIRED
246,US,A,US 5762466 A,127-710-004-931-884,1998-06-09,1998,US 64093496 A,1996-08-22,GB 9322770 A;;GB 9402095 W,1993-11-04,Dolly,"A dolly has a wheeled body (10) with an upwardly-opening recess therein within which is received a rotatable base unit or turret (24) containing the hydraulics for raising and lowering a boom arm (26). The boom arm may be positioned either facing forwardly of the body (10) or laterally of the body. In each case, the boom arm is received within an aperture (30,32,34), the apertures being suitably sized to allow the boom arm to be lowered to a position below the horizontal. The base unit (24) may be lifted out of the recess, and may be used with another body of a different size.",GRIP HOUSE LTD,FRASER DENNIS JOHN,GRIP HOUSE LIMITED (1996-06-07),https://lens.org/127-710-004-931-884,Granted Patent,yes,7,15,9,9,0,B66F11/048;;B66F11/048;;F16M11/046;;F16M11/046;;F16M11/10;;F16M11/10;;F16M11/18;;F16M11/18;;F16M11/2014;;F16M11/2014;;F16M11/42;;F16M11/42;;F16M2200/08;;F16M2200/08,B66F11/04;;F16M11/42,414/680;;248/129;;254/124,0,0,,,,EXPIRED
247,US,B1,US 6443901 B1,132-449-259-830-457,2002-09-03,2002,US 59675900 A,2000-06-15,US 59675900 A,2000-06-15,Capacitive micromachined ultrasonic transducers,"
    An ultrasonic transducer is formed by a plurality of cMUT cells, each comprising a charged diaphragm plate capacitively opposing an oppositely charged base plate. The diaphragm plate is distended toward the base plate by a bias charge. The base plate includes a central portion elevated toward the center of the diaphragm plate to cause the charge of the cell to be of maximum density at the moving center of the diaphragm plate. For harmonic operation the drive pulses applied to the cells are predistorted in consideration of the nonlinear operation of the device to reduce contamination of the transmit signal at the harmonic band. The cMUT cells can be fabricated by conventional semiconductor processes and hence integrated with ancillary transducer circuitry such as a bias charge regulator. The cMUT cells can also be fabricated by micro-stereolithography whereby the cells can be formed using a variety of polymers and other materials. 
",KONINKL PHILIPS ELECTRONICS NV,FRASER JOHN DOUGLAS,ATL ULTRASOUND INC (2000-06-14);;KONINKLIJKE PHILIPS ELECTRONICS N.V (2002-06-26),https://lens.org/132-449-259-830-457,Granted Patent,yes,8,180,12,16,0,B06B1/0292;;B33Y80/00;;B33Y10/00;;B33Y80/00;;B33Y10/00;;B06B1/0292,B81B3/00;;A61B8/00;;B06B1/02;;H04R19/00,600/459,14,9,082-337-270-109-398;;026-259-720-194-306;;006-310-271-609-945;;034-191-699-999-872;;053-311-251-537-664;;145-533-012-965-61X;;039-706-930-548-559;;035-648-627-747-629;;077-532-492-057-434,10.1109/ultsym.1995.495627;;10.1109/ultsym.1994.401810;;18290242;;10.1109/58.39112;;10.1109/58.677612;;18244219;;10.1109/ultsym.1996.583986;;10.1109/ultsym.1996.584150;;10.1109/58.368314;;10.1109/58.484456;;10.1109/sensor.1997.613679,"Sensant Corp., ""Silicon Ultrasound tm"" Fact Sheet, Sensant Corporation, 1999.;;Ladabaum, et al., ""Micromachined Ultrasonic Transducers (MUTs),"" pp. 501-504, IEEE Ultrasonics Symposium, 1995.;;Oralkan, et al., ""Simulation and Expermental Characterization of a 2-D, 3mHz Capacitive Micromachined Ultrasonic Transducer (CMUT) Array Element,"" Edward L. Ginzton Laboratory, Stanford University, Stanford, CA 94305-4085.;;Haller et al., ""A Surface Micromachined Electrostatic Ultrasonic Air Transducer,"" pp. 1241-1244, 1994 Ultrasonic Symposium.;;Suzuki et al., ""A Silicon Electrostatic Ultrasonic Transducer,"" IEEE Trans. on Ultrasonics, Ferroelectrics and Frequency Control, vol. 36, No. 6, pp. 620-627, Nov. 1989.;;Ladabaum, et al., ""Surface Micromachined Capacivite Ultrasonic Transducers,"" IEEE Trans. on Ultrasonics, Ferroelectrics and Frequency Control, vol. 45, No. 3, pp. 678-690, May 1998.;;Ladabaum, et al., ""Microfabricated Ultrasonic Transducers: Towards Robust Models and Immersion Devices,"" pp. 335-338, 1996 IEEE Ultrasonics Symposium.;;Eccardt, et al., ""Surface micromachined ultrasound transducers in CMOS technology,"" pp. 959-962 1996 IEEE Ultrasonics Symposium.;;Jin, et al., ""Fabrication and Characterization of Surface Micromachined Capacitive Ultrasonic Immersion Transducers,"" pp. 100-114, IEEE Journal of Micro-Electromechanical Systems, vol. 8, No. 1, Mar. 1999.;;Schindel, et al., ""The Design and Characterization of Micromachined AirCoupled Capacitance Transducers,"" pp. 42-50, IEEE Trans. on Ultrasonics, Ferroelectrics and Frequency Control, vol 42, No. 1, Jan. 1995.;;Haller et al., ""A Surface Micromachined Electrostatic Ultrasonic Air Transducer,"" pp. 1-6, IEEE Trans. on Ultrasonics, Ferroelectrics and Frequency Control, vol. 43, No. 1, Jan. 1996.;;Jin, et al., ""The Microfabrication of Capacitive Ultrasonic Transducers,"" pp. 295-302, IEEE Jurnal of Microelectromechanical Systems, vol. 7, No. 3, Sep. 1998.;;Jin, et al., ""Surface Micromachined Capacitive Ultrasonic Immersion Transducers,"" pp. 649-654, IEEE 1998.;;Jin, et al., ""The Microfabrication of Capacitive Ultrasonic Transducers,"" pp. 437-440, Transducers '97, 1997 International Conference on Solid-State Sensors and Actuators, Chicago, Jun. 16-19, 1997.",EXPIRED
248,WO,A2,WO 2001/097562 A2,149-102-804-219-456,2001-12-20,2001,EP 0106479 W,2001-06-08,US 59675900 A,2000-06-15,CAPACITIVE MICROMACHINES ULTRASONIC TRANSDUCERS,"An ultrasonic transducer is formed by a plurality of cMUT cells (10), each comprising a charged diaphragm plate (14) capacitively opposing an oppositely charged base plate (12). The diaphragm plate (14) is distended toward the base plate (12) by a bias charge. The base plate (12) includes a central portion (28) elevated toward the center of the diaphragm plate (14) to cause the charge of the cell to be of maximum density at the moving center of the diaphragm plate (14). For harmonic operation the drive pulses applied to the cells (10) are predistorted in consideration of the nonlinear operation of the device to reduce contamination of the transmit signal at the harmonic band. The cMUT cells (10) can be fabricated by conventional semiconductor processes and hence integrated with ancillary transducer circuitry such as a bias charge regulator (30). The cMUT cells (10) can also be fabricated by micro-stereolithography whereby the cells (10) can be formed using a variety of polymers and other materials.",KONINKL PHILIPS ELECTRONICS NV,FRASER JOHN D,,https://lens.org/149-102-804-219-456,Patent Application,yes,0,18,12,16,0,B06B1/0292;;B33Y80/00;;B33Y10/00;;B33Y80/00;;B33Y10/00;;B06B1/0292,A61B8/00;;B81B3/00;;B06B1/02;;H04R19/00,,0,0,,,,PENDING
249,US,P2,US PP027515 P2,172-991-957-043-144,2016-12-27,2016,US 201514756351 V,2015-09-01,US 201514756351 V,2015-09-01,Cordyline plant named ‘Zumba’,"A new cultivar of Cordyline plant named ‘Zumba’ that is characterized by leaves that are linear in shape, outwardly arching and pink in color with dark red margins.",FRASER PETER JOHN,FRASER PETER JOHN,,https://lens.org/172-991-957-043-144,Plant Patent,yes,0,0,1,1,0,A01H5/12;;A01H6/12;;A01H5/12;;A01H6/12,A01H6/12;;A01H5/12,PLT 383,0,0,,,,PENDING
250,AU,A4,AU 2010/101354 A4,005-993-134-281-567,2011-01-06,2011,AU 2010/101354 A,2010-12-02,AU 2008/200089 A;;AU 2010/101354 A;;AU 2004/902622 A,2004-05-17,"Method, apparatus and system for parking overstay detection",,VEHICLE MONITORING SYSTEMS PTY LTD,WELCH FRASER JOHN,,https://lens.org/005-993-134-281-567,Limited Patent,no,0,0,12,15,0,G08G1/14;;G08G1/14;;G07B15/02;;G07B15/02;;G07F17/246;;G07F17/246,G08G1/14;;B60Q1/48,,0,0,,,,INACTIVE
251,AU,A,AU 1973/051231 A,027-100-227-223-523,1974-07-18,1974,AU 1973/051231 A,1972-01-24,AU 1973/051231 A,1972-01-24,JIG FOR PRECAST BRICK WALL PANELS,,FRASER D J,FRASER DONALD JOHN,,https://lens.org/027-100-227-223-523,Patent Application,no,0,0,2,2,0,B28B19/0053,B28B19/00,,0,0,,,,EXPIRED
252,US,A,US 1526539 A,021-575-437-998-571,1925-02-17,1925,US 55837022 A,1922-05-04,US 55837022 A,1922-05-04,Bifuncticnal storage battery,,FRASER JOHN W,FRASER JOHN W,,https://lens.org/021-575-437-998-571,Granted Patent,no,0,1,1,1,0,H01M10/18;;H01M10/44;;Y02E60/10;;H01M10/18;;H01M10/44;;Y02E60/10,H01M10/18;;H01M10/44,,0,0,,,,EXPIRED
253,US,A,US 1049839 A,063-326-338-757-98X,1913-01-07,1913,US 1912/0693367 A,1912-04-26,US 1912/0693367 A,1912-04-26,APPLIANCE FOR ELECTROPLATING PLANTS.,,FRASER JOHN A,FRASER JOHN A,,https://lens.org/063-326-338-757-98X,Granted Patent,no,0,4,1,1,0,B66C1/485;;B66C1/485,,,0,0,,,,EXPIRED
254,NZ,A,NZ 552100 A,060-960-833-787-659,2010-03-26,2010,NZ 55210005 A,2005-05-09,AU 2004/902622 A;;AU 2005/000660 W,2004-05-17,"Method, apparatus and system for parking overstay detection","An apparatus for identifying overstay of a vehicle in a parking space comprises a detector adapted to detect presence of a vehicle in the parking space and a processor coupled to the detector. The processor is adapted to process and store data received from the detector and to determine from the data and independently of any parking payment system whether the vehicle has overstayed a defined time duration in the parking space. The apparatus also has a radio receiver coupled to the processor for receiving wakeup signals; a radio transmitter coupled to the processor for transmitting data relating to identified instances of overstay of the vehicle in the parking space; and a battery for providing power to the detector, processor, radio receiver, and radio transmitter. The apparatus is encased in a self-contained, sealed housing.",VEHICLE MONITORING SYSTEMS PTY,WELCH FRASER JOHN,,https://lens.org/060-960-833-787-659,Patent Application,no,0,0,12,15,0,G08G1/14;;G08G1/14;;G07B15/02;;G07B15/02;;G07F17/246;;G07F17/246,B60Q1/48;;G08G1/14,,0,0,,,,DISCONTINUED
255,GB,A,GB 1005338 A,112-561-142-905-843,1965-09-22,1965,GB 1286564 A,1964-03-26,DE C0032661 A;;NL 6404280 A,1964-04-17,Semicrystalline glass-ceramic body and method of making it,"A semicrystalline glass-ceramic body is made by melting a glass-forming composition, simultaneously cooling below the transformation point and shaping, exposing the shape to a temperature of 1000-1600 DEG C., and, after the desired crystallization, cooling to room temperature. The composition is substantially free from TiO2 and consists essentially in per cent by weight of: Al2O3, 35-70; SiO2, 10-64; not more than a total of 40% of at least one modifying oxide in the proportion: P2O5, 1-20; Li2O, 4-10; Na2O, 4-10; K2O, 1-15; Rb2O, 4-25; Cs2O, 4-15; CaO, 4-10; SrO, 4-10; BaO, 4-40; La2O3, 4-20; and a total of 0-40% of at least one refractory oxide in the proportion ZrO2, 0-25; ThO2, 0-30; MgO, 0-20; or BeO, 0-10. The preferred heat treatment schedule is a two-step process: (a) 1000-1200 DEG C. for 1-4 hrs., followed by (b) 1400-1600 DEG C. for 6-12 hrs.; or, alternatively, in a one-step process the body is held at e.g. 1000 DEG C. for e.g. 24 hours or longer. The crystals formed are predominantly of high alumina compounds, e.g. mullite.",CORNING GLASS WORKS,MACDOWELL JOHN FRASER,,https://lens.org/112-561-142-905-843,Granted Patent,no,0,4,4,6,0,C03C10/0027;;C03C10/0009,C03C10/00,C1M MAA           MAA;;C1M M1G           -;;C1M M101          MAA;;C1M M127          MAA;;C1M M134          MAA;;C1M M140          MAA;;C1M M141          MAA;;C1M M142          MAA;;C1M M144          MAA;;C1M M146          MAA;;C1M M149          MAA;;C1M M150          MAA;;C1M M153          MAA;;C1M M155          MAA;;C1M M157          MAA;;C1M M158          MAA;;C1M M159          MAA;;C1M M160          MAA;;C1M M162          MAA;;C1M M178          MAA;;C1M M179          MAA;;C1M M213          MAA;;C1M M214          MAA;;C1M M221          MAA;;C1M M221          M11B;;C1M M226          MAA;;C1M M290          MAA,0,0,,,,EXPIRED
256,US,A,US 1624784 A,182-458-586-236-787,1927-04-12,1927,US 75445124 A,1924-12-06,US 75445124 A,1924-12-06,Safe control and signal for pump-operating mechanism,,HENRY E FARABEE,JAMES FRASER JOHN,,https://lens.org/182-458-586-236-787,Granted Patent,no,0,3,1,1,0,G05G17/00;;Y10T74/2154;;Y10T74/2154;;G05G17/00,G05G17/00,,0,0,,,,EXPIRED
257,US,A,US 1078668 A,004-205-176-790-11X,1913-11-18,1913,US 1909/0511478 A,1909-08-06,US 1909/0511478 A,1909-08-06,FILING-CABINET.,,METAL SECTIONAL FURNITURE COMPANY,FRASER JOHN A,,https://lens.org/004-205-176-790-11X,Granted Patent,no,0,3,1,1,0,A47B2210/0059;;A47B2210/0059;;A47B88/427,,,0,0,,,,EXPIRED
258,US,B2,US 6469422 B2,018-668-526-437-770,2002-10-22,2002,US 6237402 A,2002-01-30,US 6237402 A;;US 48858300 A,2000-01-21,Hex packed two dimensional ultrasonic transducer arrays,"
    A two dimensional ultrasonic transducer array suitable for three dimensional phased array scanning is formed of hexagonally close packed transducer elements. In a preferred embodiment the transducer elements have a rectilinear shape, allowing the array to be fabricated with conventional dicing saw processes. 
",KONINK PHILIPS ULTRASOUND N V,FRASER JOHN DOUGLAS,KONINKLIJKE PHILIPS ELECTRONICS N.V (2002-07-15),https://lens.org/018-668-526-437-770,Granted Patent,yes,25,9,6,6,0,B06B1/0622;;B06B1/0622,G01N29/24;;A61B8/00;;B06B1/06;;H04R17/00,310/334,3,2,029-149-071-016-455;;076-783-249-506-244,10.1109/ultsym.1994.401882;;10.1109/ultsym.1996.584367,"Fatemi, M. et al., ""Efficient Generation of Limited Diffraction Beans by Hexagonal Arrays,"" Biomedical Engineering Dept., Amirkabir Univ., Tehran, Iran, Ultras. Imag., vol. 16, No. 1, Jan., 1994, p. 53.;;Fatemi, M., et al., ""Application of Hexagonal Arrays in Generation and Steering of Limiged Diffraction Beams,"" IEEE, 1994 Ultrasonic Symposium, pp. 1531-1534 1/94.;;Mills et al., ""Combining Multi-Layers and Composites to Increases SNR for Medical Ultrasound Transducers,"" IEEE, 1996 Ultrasonics Symposium, pp. 1509-1512 12/96.",EXPIRED
259,US,A,US 5029011 A,032-810-870-915-120,1991-07-02,1991,US 50928190 A,1990-04-13,US 50928190 A,1990-04-13,Engraving apparatus with oscillatory movement of tool support shaft monitored and controlled to reduce drift and vibration,"An engraving apparatus for engraving the outer surface of a cylinder used in a gravure printing process includes an engraving stylus mounted onto a shaft for engraving the surface of the cylinder. A drive mechanism is employed for producing angular movement of the shaft and the stylus aboout the central axis of the shaft. A position sensor comprising a light beam illuminator and a light beam detector is associated with the shaft to sense the angular movement of the shaft and produce a shaft position signal representative thereof. A reference signal generator is employed for producing a reference drive signal and a video signal generator is used to produce a video drive signal representative of the information to be engraved into the surface of the cylinder. A feedback control is employed which is responsive to high frequency portions of the video signal, the reference drive signal and the shaft position signal, and generates a corrected drive signal including a correction for any variations in the amplitude of the angular oscillatory movement of the shaft. The corrected drive signal and the video signal are then combined and supplied to an engraver driver which produces an engraver drive signal for actuating the drive mechanism. The engraving apparatus may further include an electronic damping mechanism connected to the position sensor and responsive to the shaft position signal for generating a negative feedback signal to the engraver driver to provide damping for the shaft and the engraving tool.",OHIO ELECTRONIC ENGRAVERS INC,FRASER JOHN W,OHIO ELECTRONIC ENGRAVERS INC (1990-04-13);;MDC MAX DAETWYLER AG (2000-05-11);;DAETWYLER GRAPHICS AG (2010-03-10),https://lens.org/032-810-870-915-120,Granted Patent,yes,8,60,1,1,0,B41C1/045;;B41C1/045;;B44B3/061;;B44B3/061;;H04N1/4005;;H04N1/4005;;H04N1/40025;;H04N1/40025;;Y10T409/304312;;Y10T409/304312;;Y10T409/308064;;Y10T409/308064,B41C1/045;;B44B3/06;;H04N1/40,358/299;;409/208,0,0,,,,EXPIRED
260,AU,B,AU 2009/014624 B,051-362-893-192-271,1910-06-07,1910,AU 2009/014624 A,1909-05-26,AU 2009/014624 A,1909-05-26,An improved fire alarm,,JOHN CHARLES FRASER,JOHN CHARLES FRASER,,https://lens.org/051-362-893-192-271,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
261,CA,A1,CA 2748333 A1,084-641-021-644-196,2010-07-01,2010,CA 2748333 A,2009-12-23,AU 2008/906642 A;;AU 2009/001698 W,2008-12-24,METHOD AND SYSTEM FOR DETECTING VEHICLE OFFENCES,Methods and systems for uniquely identifying a vehicle that has committed a potential violation are disclosed. One method comprises the steps of: obtaining first data for uniquely identifying vehicles that enter a zone of interest (610); obtaining second data relating to a potential violation committed by a particular vehicle in the zone of interest (620); correlating the first and second data to identify a portion of the first data recorded while the particular vehicle was present in the zone of interest (630); extracting a unique identifier of the particular vehicle from the first data (640); and recording the unique identifier and an association between the unique identifier and the second data (650).,VEHICLE MONITORING SYSTEMS PTY LTD,WELCH FRASER JOHN,,https://lens.org/084-641-021-644-196,Patent Application,no,0,2,7,7,0,G08G1/017;;G08G1/017;;G07B15/063;;G07B15/063;;G08G1/0175;;G08G1/0175;;G08G1/04;;G08G1/04;;G08G1/042;;G08G1/042;;G08G1/148;;G08G1/148,G07C1/10;;G08G1/14,,0,0,,,,DISCONTINUED
262,EP,A1,EP 2380143 A1,082-329-185-371-551,2011-10-26,2011,EP 09833942 A,2009-12-23,AU 2009/001698 W;;AU 2008/906642 A,2008-12-24,METHOD AND SYSTEM FOR DETECTING VEHICLE OFFENCES,,VEHICLE MONITORING SYSTEMS PTY LTD,WELCH FRASER JOHN,,https://lens.org/082-329-185-371-551,Patent Application,yes,0,0,7,7,0,G08G1/017;;G08G1/017;;G07B15/063;;G07B15/063;;G08G1/0175;;G08G1/0175;;G08G1/04;;G08G1/04;;G08G1/042;;G08G1/042;;G08G1/148;;G08G1/148,G07C1/10;;G08G1/017;;G08G1/14,,0,0,,,,DISCONTINUED
263,AU,A1,AU 2018/282421 A1,150-314-022-493-899,2019-01-17,2019,AU 2018/282421 A,2018-12-20,AU 2018/282421 A;;AU 2017/201635 A;;AU 2013/202590 A;;AU 2011/204924 A,2011-07-21,"Method, apparatus and system for parking overstay detection","METHOD, APPARATUS AND SYSTEM FOR PARKING OVERSTAY Methods, apparatuses and systems for identifying overstay of a vehicle (624, 644) in a parking space (610, 620, 630, 640, 650, 660) are disclosed herein. The method comprises the steps of detecting presence of a vehicle in a parking space using a detection apparatus (612, 622, 632, 642, 652, 662), processing and storing data relating to presence of the vehicle in the detection apparatus, determining whether the vehicle has overstayed a defined time duration in the parking space; and wirelessly transmitting data relating to identified instances of overstay of the vehicle in the parking space.",VEHICLE MONITORING SYSTEMS PTY LTD,WELCH FRASER JOHN,,https://lens.org/150-314-022-493-899,Patent Application,no,0,0,8,8,0,,G08G1/14,,0,0,,,,DISCONTINUED
264,US,B1,US 6328696 B1,161-769-585-760-786,2001-12-11,2001,US 69799500 A,2000-10-27,US 69799500 A;;US 59675900 A,2000-06-15,Bias charge regulator for capacitive micromachined ultrasonic transducers,"An ultrasonic transducer is formed by a plurality of cMUT cells, each comprising a charged diaphragm plate capacitively opposing an oppositely charged base plate. A feedback controlled bias charge regulator controls the bias charge of the capacitive plates. The cMUT cells can be fabricated by conventional semiconductor processes and hence integrated with ancillary transducer circuitry such as the bias charge regulator.",ATL ULTRASOUND INC,FRASER JOHN DOUGLAS,,https://lens.org/161-769-585-760-786,Granted Patent,yes,2,156,12,16,0,B06B1/0292;;B33Y80/00;;B33Y10/00;;B33Y80/00;;B33Y10/00;;B06B1/0292,B81B3/00;;A61B8/00;;B06B1/02;;H04R19/00,600/459;;367/118,14,8,082-337-270-109-398;;026-259-720-194-306;;006-310-271-609-945;;034-191-699-999-872;;053-311-251-537-664;;145-533-012-965-61X;;002-759-109-262-730;;039-706-930-548-559,10.1109/ultsym.1995.495627;;10.1109/ultsym.1994.401810;;18290242;;10.1109/58.39112;;10.1109/58.677612;;18244219;;10.1109/ultsym.1996.583986;;10.1109/ultsym.1996.584150;;10.1109/84.749409;;10.1109/58.368314,"""Silicon Ultrasound,"" Sensant Corporation, 1999.;;Ladabaum et al., ""Micromachined Ultrasonic Transducers (MUTs),"" pp. 501-504, IEEE Ultrasonics Symposium, 1995.;;Oralkan et al., ""Simulation and Experimental Characterization of a 2-D, 3-MHZ Capacitive Micromachined Ultrasonic Transducer (CMUT) Array Element,"" Edward L. Ginzton Laboratory, Stanford University.;;Haller et al., ""A Surface Micromachined Electrostatic Ultrasonic Air Transducer,"" pp. 1241-1244, IEEE Ultrasonic Symposium, 1994.;;Suzuki et al., ""A Silicon Electrostatic Ultrasonic Transducer,"" IEEE Trans. on Ultras., Ferro. and Freq. and Control, vol. 35, No. 6, Nov. 1989, pp. 620-627.;;Ladabaum et al., ""Surface Micromachined Capacitive Ultrasonic Transducers,"" IEEE Trans. on Ultras., Ferro., and Freq. Control, vol. 45, No. 3, May 1998, pp. 687-690.;;Ladabaum et al., ""Microfabricated Ultrasonic Transducers: Towards Robust Models and Immersion Devices,"" IEEE Ultrasonic Symposium, 1996, pp. 335-338.;;Eccardt et al., ""Surface Micromachined Ultrasonic Transducers in CMOS Technology,"" IEEE Ultrasonics Symposium, 1996, pp. 959-962.;;Jin et al., ""Fabrication and Characterization of Surface Micromachined Capacitive Ultrasonic Immersion Transducers,"" IEEE Journal of Microelectromechanical Systems, vol. 8, No. 1, Mar. 1999, pp. 100-114.;;Schindel et al., ""The Design and Characterization of Micromachined Air-Coupled Capacitance Transducers,"" IEEE Trans. on Ultras. Ferro. and Freq. Control, vol. 42, No. 1, Jan. 1995, pp. 42-50.;;Haller et al., ""A Surface Micromachined Electrostatic Ultrasonic Air Transducer,"" IEEE Trans. on Ultras., Ferro. and Freq. Control, vol. 43, No. 1, Jan. 1996, pp. 1-6.;;Jin et al., ""The Microfabrication of Capacitive Ultrasonic Transducers,"" IEEE Journal of Microelectromechanical Systems, vol. 7, No. 3, Sep. 1998, pp. 295-302.;;Jin et al., ""Surface Micromachined Capacitive Ultrasonic Immersion Transducers,"" IEEE 1998, pp. 649-654.;;Jin et al., ""The Microfabrication of Capacitive Ultrasonic Transducers,"" 1997 International COnference on Solid-State Sensor and Actuators, Chicago (IL), Jun. 16-19, 1997, pp. 437-440.",EXPIRED
265,WO,A1,WO 1993/013338 A1,173-538-526-912-599,1993-07-08,1993,EP 9202479 W,1992-10-30,US 81185891 A,1991-12-23,DAMPER AND BYPASS CLUTCH FOR HYDRODYNAMIC TORQUE CONVERTER,"A bypass clutch damper for an automatic transmission torque converter includes a support plate (91) and a turbine rotor (26), both fixed to the transmission input shaft. The support ring defines annular spring pockets (92, 100) about the axis of rotation containing coiled helical springs (102), each spring (102) having one end contacting the support plate (91). The opposite end of each of the damper springs (102) contacts a drive ring of a torque converter clutch. A clutch plate (70) is fixed to an impeller cover (12), and a clutch piston (60), fixed to the cover (14), is hydraulically actuated to move toward the drive ring (74) and the clutch plate (70). Friction surfaces on the drive ring (74) are forced into frictional contact with the clutch plate (70) and piston (60) in accordance with differential pressure across the clutch piston. The drive ring (74), when engaged, compresses the springs and causes functional contact as the springs move in frictional contact with the surfaces of the spring pockets.",FORD MOTOR CO;;FORD WERKE AG;;FORD FRANCE;;FORD MOTOR CO,MACDONALD FRASER JOHN,,https://lens.org/173-538-526-912-599,Patent Application,yes,6,24,2,2,0,F16H45/02;;F16F15/129;;F16H2045/0278;;F16H2045/0289,F16F15/129;;F16H45/02,,0,0,,,,PENDING
266,EP,A2,EP 1532177 A2,181-544-163-121-480,2005-05-25,2005,EP 03733654 A,2003-06-04,NZ 0300111 W;;NZ 51937102 A,2002-06-04,IMMUNOMODULATORY CONSTRUCTS AND THEIR USES,"The invention relates to immunomodulators. In particular the invention relates to specific immunomodulators based on the superantigen SMEZ-2 and more particularly based on mutants of the superantigen SMEZ-2, which are adapted to target antigen-presenting-cells for the purpose of enhancing or suppressing a host immune response.",AUCKLAND UNISERVICES LTD,FRASER JOHN DAVID,AUCKLAND UNISERVICES LIMITED (2009-11-13),https://lens.org/181-544-163-121-480,Patent Application,yes,0,0,14,14,13,A61K39/092;;A61K39/385;;A61K2039/6037;;C07K14/315;;A61P37/02;;C07K14/315;;A61K39/092;;A61K2039/6037;;A61K39/385,C12N15/09;;A61K39/00;;A61K39/09;;A61K39/385;;A61K39/39;;C07K14/315;;C07K19/00;;C12N15/31,,0,0,,,,EXPIRED
267,NO,A1,NO 20160618 A1,164-495-707-416-742,2016-04-12,2016,NO 20160618 A,2016-04-12,GB 201320104 A;;GB 2014053317 W,2013-11-14,AN IMPROVED SUPPORT DEVICE FOR USE IN A WELLBORE AND A METHOD FOR DEPLOYING A BARRIER IN A WELLBORE,,SMJM LTD,MURRAY JOHN KENNETH FRASER;;FRASER JOHN;;FONG JASON,"CORETRAX TECHNOLOGY LIMITED, GB (2018-12-17);;CORETRAX GLOBAL LIMITED, GB (2023-02-13)",https://lens.org/164-495-707-416-742,Patent Application,no,1,0,9,9,0,E21B23/06;;E21B33/127;;E21B33/134;;E21B17/02;;E21B33/127;;E21B17/02;;E21B23/06;;E21B33/127;;E21B33/134;;E21B17/02;;E21B19/16;;E21B17/02;;E21B23/06;;E21B33/127;;E21B33/134;;E21B2200/06;;E21B34/10,E21B23/06;;E21B33/127;;E21B33/134,,0,0,,,,PENDING
268,AU,A1,AU 2020/300519 A1,006-007-984-455-112,2022-02-24,2022,AU 2020/300519 A,2020-06-30,US 201962868983 P;;US 202062956898 P;;US 2020/0040370 W,2019-06-30,Recombinant AAV vectors with altered immunogencity and methods of making the same,"The present invention provides methods of generating a recombinant AAV vector with reduced immunogenicity, comprising: providing eukaryotic cells with a nucleic acid comprising a sequence of interest that is flanked by AAV inverted terminal repeats, wherein the nucleic acid comprises CpG dinucleotide sites, wherein at least a portion of the CpG dinucleotide sites are methylated, wherein the eukaryotic cell expresses one or more other components necessary to achieve recombinant AAV biosynthesis, whereby the recombinant AAV vector is generated by the eukaryotic cell, wherein the generated recombinant AAV vector comprises nucleic acid wherein at least a portion of the CpG dinucleotide sites are methylated.",WRIGHT JOHN,WRIGHT JOHN FRASER,,https://lens.org/006-007-984-455-112,Patent Application,no,0,0,5,5,0,C12N15/86;;C12N2750/14143;;C12N2750/14152;;C12N2750/14151;;C12N2750/14133;;C07K14/47;;C12N9/1007;;C12N9/644;;C12Y304/21022;;C07K14/755;;C07K14/4708;;A61P21/00;;A61P35/00;;C07K14/8125;;A61P11/00;;A61P7/04;;A61K35/76;;C12N9/1007;;C12N15/64;;C12N15/86;;C12N2330/51;;C12N2750/14133;;C12N2750/14143;;C12N2750/14152,A61K35/76;;C12N15/09;;C12N15/63;;C12N15/87;;C12Q1/68,,0,0,,,,PENDING
269,EP,B1,EP 0617774 B1,040-870-461-219-401,1997-06-18,1997,EP 92923237 A,1992-10-30,EP 9202480 W;;US 81209291 A,1991-12-23,SLIPPING BYPASS CLUTCH FOR HYDROKINETIC TORQUE CONVERTER,,FORD WERKE AG;;FORD FRANCE;;FORD MOTOR CO,MACDONALD FRASER JOHN,,https://lens.org/040-870-461-219-401,Granted Patent,yes,4,0,7,7,0,F16H45/02;;F16H45/02;;F16H2045/0278;;F16H2045/0278;;F16H2045/0289;;F16H2045/0289,F16H45/02,,0,0,,,,EXPIRED
270,EP,B1,EP 1532177 B1,078-347-090-673-498,2008-10-22,2008,EP 03733654 A,2003-06-04,NZ 0300111 W;;NZ 51937102 A,2002-06-04,IMMUNOMODULATORY CONSTRUCTS AND THEIR USES,"The invention relates to immunomodulators. In particular the invention relates to specific immunomodulators based on the superantigen SMEZ-2 and more particularly based on mutants of the superantigen SMEZ-2, which are adapted to target antigen-presenting-cells for the purpose of enhancing or suppressing a host immune response.",AUCKLAND UNISERVICES LTD,FRASER JOHN DAVID,AUCKLAND UNISERVICES LIMITED (2009-11-13),https://lens.org/078-347-090-673-498,Granted Patent,yes,2,0,14,14,0,A61K39/092;;A61K39/385;;A61K2039/6037;;C07K14/315;;A61P37/02;;C07K14/315;;A61K39/092;;A61K2039/6037;;A61K39/385,C07K19/00;;C12N15/09;;A61K35/74;;A61K39/00;;A61K39/09;;A61K39/385;;A61K39/39;;C07H19/00;;C07K14/00;;C07K14/315;;C07K16/12;;C12N1/20;;C12N15/31;;C12Q1/68,,4,0,,,"FRASER J.D. ET AL.: 'The bacterial superantigen streptococcal mitogenic exotoxin Z is the major immunoactive agent of streptococcus pyogenes' JOURNAL OF IMMUNOLOGY vol. 169, no. 5, 01 September 2002, pages 2561 - 2569, XP002992534;;PROFT T. ET AL.: 'The streptococcal superantigen SMEZ exhibits wide allelic varition, mosaic structure and significant antigenic variation' JOURNAL OF EXPERIMENTAL MEDICINE vol. 191, no. 10, 15 May 2000, pages 1765 - 1776, XP008045700;;ARCUS V.L. ET AL.: 'Conservation and variation in superantigen structure and activity highlighted by the three dimensional structures of two new superantigens from streptococcus pyogenes' JOURNAL OF MOLECULAR BIOLOGY vol. 299, no. 1, 26 May 2000, pages 157 - 168, XP004470896;;PROFT T. ET AL.: 'Identification and characterisation of novel superantigens from streptococcus pyogenes' JOURNAL OF EXPERIMENTAL MEDICINE vol. 189, no. 1, 04 January 1999, pages 89 - 101, XP001058404",EXPIRED
271,EP,A1,EP 1747543 A1,082-927-788-732-256,2007-01-31,2007,EP 05737801 A,2005-05-09,AU 2005/000660 W;;AU 2004/902622 A,2004-05-17,"METHOD, APPARATUS AND SYSTEM FOR PARKING OVERSTAY DETECTION",,VEHICLE MONITORING SYSTEMS PTY,WELCH FRASER JOHN,,https://lens.org/082-927-788-732-256,Patent Application,yes,0,1,12,15,0,G08G1/14;;G08G1/14;;G07B15/02;;G07B15/02;;G07F17/246;;G07F17/246,G07F17/24;;B60Q1/48;;G08G1/14,,0,0,,,,ACTIVE
272,US,A,US 1827573 A,097-402-315-104-228,1931-10-13,1931,US 29568128 A,1928-07-27,US 29568128 A,1928-07-27,Receptacle closure,,MILWAUKEE VALVE CO,FRASER JR JOHN,,https://lens.org/097-402-315-104-228,Granted Patent,no,0,1,1,1,0,G05D23/12;;G05D23/12,G05D23/12,,0,0,,,,EXPIRED
273,US,A,US 1061463 A,098-430-167-366-537,1913-05-13,1913,US 1909/0511480 A,1909-08-06,US 1909/0511480 A,1909-08-06,FOLLOWER-BLOCK FOR FILING-CABINETS.,,METAL SECTIONAL FURNITURE COMPANY,FRASER JOHN A,,https://lens.org/098-430-167-366-537,Granted Patent,no,0,4,1,1,0,B42F17/02;;B42F17/02,,,0,0,,,,EXPIRED
274,GB,A,GB 189920104 A,111-714-558-929-628,1899-10-21,1899,GB 189920104D A,1899-10-06,GB 189920104T A,1899-10-06,Combined Scissors and Tape Measure.,"20,104. Fraser, J. M. Oct. 6. Combination tools.-A tape measure B is attached either inside one of the shanks, Fig. 1, or outside one of the blades, Fig. 4, of a pair of scissors.",FRASER JOHN MALCOLM,FRASER JOHN MALCOLM,,https://lens.org/111-714-558-929-628,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
275,DE,B,DE 1289923 B,143-506-738-684-650,1969-02-27,1969,DE A0051514 A,1966-02-07,CA 929195 A;;US 50162365 A,1965-04-27,Neutronen-Generator zur Erzeugung hoher Neutronenfluesse,,CA ATOMIC ENERGY LTD,STILES FRASER JOHN,,https://lens.org/143-506-738-684-650,Patent Application,no,1,1,5,5,0,H05H6/00;;H05H6/00,H05H6/00,,0,0,,,,DISCONTINUED
276,US,A1,US 2010/0098666 A1,140-627-321-381-082,2010-04-22,2010,US 58168409 A,2009-10-19,US 58168409 A;;US 2008/0060654 W;;US 91219307 P,2007-04-17,Humanized Viral Vectors and Methods of Use Thereof,"The present invention provides humanized viral vectors and methods of use thereof for delivery of transgenes or therapeutic nucleic acids to human subjects. Humanized viral vectors are modified from known viral vectors such as those based on AAV by coating their surface with a human protein such as human serum albumin and optionally a lipid coating or formulation, so that the foreign or non-human nature of the vector is masked. The coating is performed in a manner that reduces or prevents binding of antibodies to the vector surface, thereby reducing or preventing antibody-mediated clearance of vector, but still allowing the vector to transduce target cells and achieve therapeutic gene transfer. Such humanized vectors therefore evade pre-existing immune surveillance, reduce immune responses, and achieve therapeutic gene transfer in the presence of pre-existing antibodies to the viral vector.",WRIGHT JOHN FRASER,WRIGHT JOHN FRASER,THE CHILDREN'S HOSPITAL OF PHILADELPHIA (2010-02-02),https://lens.org/140-627-321-381-082,Patent Application,yes,7,25,4,4,0,C07K14/765;;C12N15/86;;C12N2750/14143;;C12N2750/14145;;C12N2810/85;;A61K38/4846;;C12N9/644;;C12Y304/21022;;A61P7/00;;C12N15/86;;C12N2750/14143;;C12N2810/85;;C12N2750/14145;;C07K14/765;;A61K48/00;;C12N15/8645;;A61K38/4846;;A61K47/12;;A61K47/42;;C12N7/00;;C12N9/644;;C12Y304/21022,A61K48/00;;A61P7/00;;C12N15/00;;C12N15/86,424/93.2;;435/320.1;;X514 44  R,4,1,040-230-796-647-103,10.1128/jvi.76.24.12900-12907.2002;;12438615;;pmc136730,"Ponnazhagan et al. Journal of Virology 76(24):12900-12907, 2002.;;Lee et al. Chapter 20:Albumin Modification in Scaffolding in Tissue Engineering. Ma and Elisseeff (eds.) CRC PressTaylor and Francis Group: Boca Raton, 2006. See pp. 283, 284, 289, and 290.;;Cross-link Wikipedia Printout (http://en.wikipedia.org/wiki/Cross-link. Pages 1-6, printed 4/23/2015);;Crosslink definition - Google search printout (pp.1-2, printed 4/23/2015)",DISCONTINUED
277,CA,A,CA 57884 A,182-398-139-135-173,1897-10-23,1897,CA 57884D A,1897-06-28,CA 57884T A,1897-06-28,SUPPORT FOR TYPEWRITER AND THE LIKE,,GREGORY JOHN FRASER,GREGORY JOHN FRASER,,https://lens.org/182-398-139-135-173,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
278,DE,A1,DE 1496075 A1,186-048-374-812-491,1970-10-29,1970,DE 1496075 A,1963-07-22,US 21179462 A,1962-07-23,Glas-Kristall-Mischkoerper und Verfahren zu seiner Herstellung,,CORNING GLASS WORKS,FRASER MACDOWELL JOHN,,https://lens.org/186-048-374-812-491,Patent Application,no,0,0,9,10,0,C03C3/062;;C03C3/085;;C03C3/062;;C03C3/085,C03C3/062;;C03C3/085,,0,0,,,,DISCONTINUED
279,EP,A1,EP 0768035 A1,000-426-069-404-387,1997-04-16,1997,EP 96115872 A,1996-10-03,GB 9520684 A,1995-10-10,Inter-tidal algal control,"Shoreline structures such as dock steps, jetties and slipways, which are covered at high tide and exposed by low tide are colonised by inter-tidal-algae which render the surfaces slippery. There is consequently a risk that persons, livestock or vehicles crossing them will skid or slip resulting in accidents and causing personal injury or damage to property. The inter-tidal algae can be controlled by periodic treatment with aqueous hydrogen peroxide solution having a concentration of between 2.5 and 5% w/w without leaving undesirable residuals that could enter the marine food chain and without harming local populations of beneficial invertebrates.",SOLVAY INTEROX LTD,FRASER JOHN ANGUS,,https://lens.org/000-426-069-404-387,Patent Application,yes,1,0,2,2,0,A01N59/00,A01N59/00,,2,0,,,"DATABASE WPI Derwent World Patents Index; AN 92-427722, XP002022624;;DATABASE WPI Derwent World Patents Index; AN 80-09979C, XP002022625",DISCONTINUED
280,AU,B2,AU 2011/204924 B2,011-699-955-973-130,2013-08-29,2013,AU 2011/204924 A,2011-07-21,AU 2008/200089 A;;AU 2011/204924 A,2008-01-08,"Method, apparatus and system for parking overstay detection","METHOD, APPARATUS AND SYSTEM FOR PARKING OVERSTAY Methods, apparatuses and systems for identifying overstay of a vehicle (624, 644) in a parking space (610, 620, 630, 640, 650, 660) are disclosed herein. The method comprises the steps of detecting presence of a vehicle in a parking space using a detection io apparatus (612, 622, 632, 642, 652, 662), processing and storing data relating to presence of the vehicle in the detection apparatus, determining whether the vehicle has overstayed a defined time durationin the parking space; and wirelessly transmitting data relating to identified instances of overstay of the vehicle in the parking space.",VEHICLE MONITORING SYSTEMS PTY LTD,WELCH FRASER JOHN,,https://lens.org/011-699-955-973-130,Granted Patent,no,2,0,8,8,0,,G08G1/14,,0,0,,,,INACTIVE
281,BR,A2,BR PI0918363 A2,032-606-385-195-82X,2016-08-23,2016,BR PI0918363 A,2009-12-09,IB 2009055611 W;;US 14133008 P,2008-12-30,dispositivo para limpeza de dentes,,KONINKL PHILIPS ELECTRONICS NV,FRASER JOHN DOUGLAS,KONINKLIJKE PHILIPS N.V. (NL) (2017-05-23),https://lens.org/032-606-385-195-82X,Patent Application,no,0,0,16,16,0,A61C17/20;;A61C17/20,A61C17/20,,0,0,,,,DISCONTINUED
282,DE,D1,DE 69914709 D1,046-984-997-867-021,2004-03-18,2004,DE 69914709 T,1999-12-03,US 20641998 A,1998-12-07,Dämpfer für die Überbrückungskupplung eines Momentwandlers mit einer nachgiebigen Druckscheibe,,FORD GLOBAL TECH LLC,MACDONALD FRASER JOHN,,https://lens.org/046-984-997-867-021,Granted Patent,no,0,0,5,5,0,F16H45/02;;F16H2045/0294,F16H45/02,,0,0,,,,EXPIRED
283,GB,A,GB 190722691 A,080-678-651-835-919,1908-01-09,1908,GB 190722691D A,1907-10-15,GB 190722691T A,1907-10-15,"Improvements in and relating to Stoppers for Bottles, Jars and similar Vessels.","22,691. Fraser, J. J. Oct. 15. Stoppers, expansible.-The stopper consists of a tubular member 1 fitted with an elastic washer 4, suitably of rubbing tubing, a plug 9 fitted in the member 1, an operating-rod 16, and an expanding member 5, the rod 16 and the member 5 being formed with racks which gear with pinions 14 mounted in the plug 9. The stopper is inserted in the condition shown in Fig. 2, and then, by pressing down the rod 16, the member 5 is drawn upwards, so expanding the washer 4 tightly against the neck. A reverse movement of the red 16 releases the stopper.",FRASER JOHN JEREMIAH,FRASER JOHN JEREMIAH,,https://lens.org/080-678-651-835-919,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
284,US,A,US 4223182 A,104-906-383-220-256,1980-09-16,1980,US 55603144 A,1944-09-27,US 55603144 A,1944-09-27,Transmission of signals with privacy,"In a speech transmission system, a first privacy apparatus for making reversible alterations in speech message waves for rendering unauthorized reception of the message difficult, a second privacy apparatus for making a different kind of reversible alterations in the speech message waves for increasing the difficulty of unauthorized reception of the message, a common coding mechanism for controlling the alterations made in both privacy apparatuses, said coder supplying control potentials to the first of said privacy apparatuses, and means in said first privacy apparatus for translating said control potentials into control potentials of different character for controlling said second privacy apparatus.",BELL TELEPHONE LABOR INC,FRASER JOHN M,,https://lens.org/104-906-383-220-256,Granted Patent,yes,5,6,1,1,0,H04K1/06;;H04K1/06,H04K1/06,179  15 R,0,0,,,,EXPIRED
285,US,A1,US 2002/0130591 A1,098-963-304-143-244,2002-09-19,2002,US 6237402 A,2002-01-30,US 6237402 A;;US 48858300 A,2000-01-21,Hex packed two dimensional ultrasonic transducer arrays,"
   A two dimensional ultrasonic transducer array suitable for three dimensional phased array scanning is formed of hexagonally close packed transducer elements. In a preferred embodiment the transducer elements have a rectilinear shape, allowing the array to be fabricated with conventional dicing saw processes. 
",FRASER JOHN DOUGLAS,FRASER JOHN DOUGLAS,KONINKLIJKE PHILIPS ELECTRONICS N.V (2002-07-15),https://lens.org/098-963-304-143-244,Patent Application,yes,0,27,6,6,0,B06B1/0622;;B06B1/0622,G01N29/24;;A61B8/00;;B06B1/06;;H04R17/00,310/334,0,0,,,,EXPIRED
286,CA,A1,CA 2567464 A1,123-577-217-448-962,2005-11-24,2005,CA 2567464 A,2005-05-09,AU 2004/902622 A;;AU 2005/000660 W,2004-05-17,"METHOD, APPARATUS AND SYSTEM FOR PARKING OVERSTAY DETECTION",,VEHICLE MONITORING SYSTEMS PTY,WELCH FRASER JOHN,,https://lens.org/123-577-217-448-962,Patent Application,no,0,4,12,15,0,G08G1/14;;G08G1/14;;G07B15/02;;G07B15/02;;G07F17/246;;G07F17/246,G08G1/14;;B60Q1/48,,0,0,,,,ACTIVE
287,US,A,US 1689236 A,119-648-307-429-563,1928-10-30,1928,US 7530625 A,1925-12-14,US 7530625 A,1925-12-14,Valve structure,,MILWAUKEE VALVE CO,FRASER JR JOHN,,https://lens.org/119-648-307-429-563,Granted Patent,no,0,29,1,1,0,F16K35/025;;F16K35/025,F16K35/02,,0,0,,,,EXPIRED
288,WO,A2,WO 2012/127360 A2,132-190-589-196-92X,2012-09-27,2012,IB 2012051173 W,2012-03-13,US 201161466172 P,2011-03-22,ULTRASONIC CMUT WITH SUPPRESSED ACOUSTIC COUPLING TO THE SUBSTRATE,An array of cMUT cells are formed on individually isolated massive plates on a substrate. The mass of each plate provides an inertial force in opposition to the force and motion of transmission by the cell which reduces the resultant translation of motion in the plate. The reduction in motion results in less coupling of acoustic energy into the substrate and contamination of the signals of adjacent cMUT cells by lateral waves. The unwanted wave coupling into the substrate can be further damped by compliant or sparse periodic mounting of the massive plates on the substrate.,KONINKL PHILIPS ELECTRONICS NV;;FRASER JOHN DOUGLAS,FRASER JOHN DOUGLAS,,https://lens.org/132-190-589-196-92X,Patent Application,yes,10,5,12,12,0,G01H11/06;;B06B1/0292;;G10K11/002;;G01H11/06;;B06B1/0292;;G10K11/002;;A61B8/4494,,,0,0,,,,PENDING
289,US,A1,US 2017/0128594 A1,133-881-472-778-415,2017-05-11,2017,US 201715411489 A,2017-01-20,US 201715411489 A;;US 58168409 A;;US 2008/0060654 W;;US 91219307 P,2007-04-17,Humanized Viral Vectors and Methods of Use Thereof,"The present invention provides humanized viral vectors and methods of use thereof for delivery of transgenes or therapeutic nucleic acids to human subjects. Humanized viral vectors are modified from known viral vectors such as those based on AAV by coating their surface with a human protein such as human serum albumin and optionally a lipid coating or formulation, so that the foreign or non-human nature of the vector is masked. The coating is performed in a manner that reduces or prevents binding of antibodies to the vector surface, thereby reducing or preventing antibody-mediated clearance of vector, but still allowing the vector to transduce target cells and achieve therapeutic gene transfer. Such humanized vectors therefore evade pre-existing immune surveillance, reduce immune responses, and achieve therapeutic gene transfer in the presence of pre-existing antibodies to the viral vector.",THE CHILDREN'S HOSPITAL OF PHILADELPHIA,WRIGHT JOHN FRASER,THE CHILDREN'S HOSPITAL OF PHILADELPHIA (2010-02-02),https://lens.org/133-881-472-778-415,Patent Application,yes,0,22,4,4,0,C07K14/765;;C12N15/86;;C12N2750/14143;;C12N2750/14145;;C12N2810/85;;A61K38/4846;;C12N9/644;;C12Y304/21022;;A61P7/00;;C12N15/86;;C12N2750/14143;;C12N2810/85;;C12N2750/14145;;C07K14/765;;A61K48/00;;C12N15/8645;;A61K38/4846;;A61K47/12;;A61K47/42;;C12N7/00;;C12N9/644;;C12Y304/21022,A61K48/00;;A61K38/48;;A61K47/12;;A61K47/42;;C12N7/00;;C12N9/64;;C12N15/86,,0,0,,,,ACTIVE
290,AU,A,AU 1977/024103 A,174-415-081-773-085,1978-10-12,1978,AU 1977/024103 A,1976-04-08,AU 1977/024103 A,1976-04-08,JIG FOR MANUFACTURE OF BRICK PANELS,,FRASER D J,FRASER DONALD JOHN,,https://lens.org/174-415-081-773-085,Patent Application,no,0,0,2,2,0,E04C2/041,E04C2/04;;E04G21/16;;E04G21/22,,0,0,,,,EXPIRED
291,AU,A1,AU 2005/243110 A1,169-071-736-004-459,2005-11-24,2005,AU 2005/243110 A,2005-05-09,AU 2004/902622 A;;AU 2005/000660 W;;AU 2005/243110 A,2004-05-17,"Method, apparatus and system for parking overstay detection",,VEHICLE MONITORING SYSTEMS PTY,WELCH FRASER JOHN,,https://lens.org/169-071-736-004-459,Patent Application,no,0,0,3,15,0,,G08G1/14,,0,0,,,,INACTIVE
292,AU,A,AU 1995/039196 A,159-296-618-041-448,1997-06-05,1997,AU 1995/039196 A,1995-12-01,AU 1995/039196 A,1995-12-01,The Fraser lifter,,DONALD JOHN FRASER,FRASER DONALD JOHN,,https://lens.org/159-296-618-041-448,Patent Application,no,0,0,1,1,0,,A61G1/003;;A61G1/013;;A61G7/05,,0,0,,,,PENDING
293,EP,A2,EP 1008784 A2,162-813-957-232-119,2000-06-14,2000,EP 99309749 A,1999-12-03,US 20641998 A,1998-12-07,Torque converter bypass clutch damper having compliant pressure disc,"A hydrokinetic torque converter includes an impeller cover (12) and a bypass clutch. The impeller cover (12) has welded to it a clutch plate (70), which carries friction material (80) adjacent a clutch piston (60). The piston (60) supports a pressure disc (79) and carries it axially into engagement with the clutch plate (70). The disc (79) flexes into conformance with the surface of the clutch plate (70) beginning at a radially inner region and progressing radially outward as clutch apply pressure increases.",FORD GLOBAL TECH INC,MACDONALD FRASER JOHN,"FORD GLOBAL TECHNOLOGIES, LLC (2003-11-26)",https://lens.org/162-813-957-232-119,Patent Application,yes,6,5,5,5,0,F16H45/02;;F16H2045/0294,F16H45/02,,1,0,,,"FROSBIE, MILEK, SMITH: """"bonding technique"""", S.A.E.DESIGN PRACTICES VOL.5, vol. 5, 1962",EXPIRED
294,AU,A1,AU 2013/216683 A1,173-357-865-239-850,2013-10-03,2013,AU 2013/216683 A,2013-08-16,AU 2005/332046 A;;AU 2013/216683 A,2005-05-25,Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions,"Abstract Adipose derived regenerative cells are used to treat patients, including patients with cardiovascular conditions, diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells, e.g. stem and/or progenitor cells, obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, adipose derived regenerative cells are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic cardiovascular benefit.",CYTORI THERAPEUTICS INC,FRASER JOHN K,,https://lens.org/173-357-865-239-850,Patent Application,no,0,0,2,2,0,,A61K35/34;;C12N5/00;;C12N5/0775,,0,0,,,,INACTIVE
295,US,A,US 869700 A,181-005-939-920-085,1907-10-29,1907,US 1907/0372075 A,1907-05-06,US 1907/0372075 A,1907-05-06,BOTTLE-STOPPER.,,FRASER JOHN J,FRASER JOHN J,,https://lens.org/181-005-939-920-085,Granted Patent,no,0,8,1,1,0,B65D39/12;;B65D39/12,,,0,0,,,,EXPIRED
296,EP,B1,EP 0726873 B1,197-904-356-221-055,1997-11-19,1997,EP 94927723 A,1994-09-27,GB 9402095 W;;GB 9322770 A,1993-11-04,DOLLY,,GRIP HOUSE LTD,FRASER DENNIS JOHN,,https://lens.org/197-904-356-221-055,Granted Patent,yes,4,0,9,9,0,B66F11/048;;B66F11/048;;F16M11/046;;F16M11/046;;F16M11/10;;F16M11/10;;F16M11/18;;F16M11/18;;F16M11/2014;;F16M11/2014;;F16M11/42;;F16M11/42;;F16M2200/08;;F16M2200/08,B66F11/04;;F16M11/42,,0,0,,,,EXPIRED
297,WO,A1,WO 2008/128251 A1,012-884-727-194-320,2008-10-23,2008,US 2008/0060654 W,2008-04-17,US 91219307 P,2007-04-17,HUMANIZED VIRAL VECTORS AND METHODS OF USE THEREOF,"The present invention provides humanized viral vectors and methods of use thereof for delivery of transgenes or therapeutic nucleic acids to human subjects. Humanized viral vectors are modified from known viral vectors such as those based on AAV by coating their surface with a human protein such as human serum albumin so that the foreign or non-human nature of the vector is masked. The coating is performed in a manner that reduces or prevents binding of antibodies to the vector surface, thereby reducing or preventing antibody-mediated clearance of vector, but still allowing the vector to transduce target cells and achieve therapeutic gene transfer. Such humanized vectors therefore evade pre-existing immune surveillance, reduce immune responses, and achieve therapeutic gene transfer in the presence of pre-existing antibodies to the viral vector.",PHILADELPHIA CHILDREN HOSPITAL;;WRIGHT JOHN FRASER,WRIGHT JOHN FRASER,,https://lens.org/012-884-727-194-320,Patent Application,yes,4,12,4,4,0,C07K14/765;;C12N15/86;;C12N2750/14143;;C12N2750/14145;;C12N2810/85;;A61K38/4846;;C12N9/644;;C12Y304/21022;;A61P7/00;;C12N15/86;;C12N2750/14143;;C12N2810/85;;C12N2750/14145;;C07K14/765;;A61K48/00;;C12N15/8645;;A61K38/4846;;A61K47/12;;A61K47/42;;C12N7/00;;C12N9/644;;C12Y304/21022,A61K39/12;;C12N1/20,,1,1,003-201-288-739-680,16612598;;10.1007/s00262-006-0158-2,"HEDLEY S.J. ET AL.: ""Targeted and shielded adenovectors for cancer therapy"", CANCER IMMUNOL. IMMUNOTHER., vol. 55, April 2006 (2006-04-01), pages 1412 - 1419, XP019422514",PENDING
298,AU,A1,AU 2009/329831 A1,039-233-116-480-126,2011-07-21,2011,AU 2009/329831 A,2009-12-23,AU 2008/906642 A;;AU 2009/001698 W;;AU 2009/329831 A,2008-12-24,Method and system for detecting vehicle offences,Methods and systems for uniquely identifying a vehicle that has committed a potential violation are disclosed. One method comprises the steps of: obtaining first data for uniquely identifying vehicles that enter a zone of interest (610); obtaining second data relating to a potential violation committed by a particular vehicle in the zone of interest (620); correlating the first and second data to identify a portion of the first data recorded while the particular vehicle was present in the zone of interest (630); extracting a unique identifier of the particular vehicle from the first data (640); and recording the unique identifier and an association between the unique identifier and the second data (650).,VEHICLE MONITORING SYSTEMS PTY LTD,JOHN WELCH FRASER,,https://lens.org/039-233-116-480-126,Patent Application,no,0,0,7,7,0,G08G1/017;;G08G1/017;;G07B15/063;;G07B15/063;;G08G1/0175;;G08G1/0175;;G08G1/04;;G08G1/04;;G08G1/042;;G08G1/042;;G08G1/148;;G08G1/148,G07C1/10;;G08G1/14,,0,0,,,,DISCONTINUED
299,US,A,US 1227604 A,044-981-696-250-232,1917-05-29,1917,US 1914/0813600 A,1914-01-21,US 1914/0813600 A,1914-01-21,METAL-FORMING MACHINE.,,KAWNEER MFG COMPANY,FRASER JOHN A,,https://lens.org/044-981-696-250-232,Granted Patent,no,0,1,1,1,0,B21D5/08;;B21D5/08,,,0,0,,,,EXPIRED
300,US,B2,US 7547769 B2,051-999-025-375-885,2009-06-16,2009,US 51681305 A,2005-07-05,NZ 51937102 A;;NZ 0300111 W,2002-06-04,Immunomodulatory constructs and their uses,"The invention relates to immunomodulators. In particular the invention relates to specific immunomodulators based on the superantigen SMEZ-2 and more particularly based on mutants of the superantigen SMEZ-2, which are adapted to target antigen-presenting-cells for the purpose of enhancing or suppressing a host immune response.",AUCKLAND UNISERVICES LTD,FRASER JOHN DAVID,AUCKLAND UNISERVICES LIMITED (2005-03-14),https://lens.org/051-999-025-375-885,Granted Patent,yes,24,0,14,14,13,A61K39/092;;A61K39/385;;A61K2039/6037;;C07K14/315;;A61P37/02;;C07K14/315;;A61K39/092;;A61K2039/6037;;A61K39/385,C07K14/00;;C12N15/09;;A61K39/00;;A61K39/09;;A61K39/385;;A61K39/39;;C07K14/315;;C07K17/00;;C07K19/00;;C08H1/00;;C12N15/31,530/403;;530/350,14,14,102-264-935-104-831;;129-498-572-506-242;;018-781-067-577-962;;027-823-002-465-547;;031-731-686-337-306;;038-849-700-470-356;;014-056-638-943-210;;029-465-313-002-422;;072-117-375-070-090;;072-117-375-070-090;;014-056-638-943-210;;029-465-313-002-422;;040-811-602-314-323;;065-971-427-681-969,10.1099/0022-1317-83-5-1167;;11961272;;8985754;;10.1089/hyb.1996.15.429;;12720278;;10.1002/jmr.612;;10.1006/jmbi.2000.3725;;10860729;;pmc2193151;;10811869;;10.1084/jem.191.10.1765;;12193726;;10.4049/jimmunol.169.5.2561;;10.1016/s1074-7613(00)80646-9;;9881971;;10689316;;10.1016/s1357-4310(99)01657-3;;pmc2212189;;9500785;;10.1084/jem.187.6.823;;pmc2212189;;9500785;;10.1084/jem.187.6.823;;10.1016/s1074-7613(00)80646-9;;9881971;;10689316;;10.1016/s1357-4310(99)01657-3;;10.4049/jimmunol.165.4.2306;;10925320;;9579542;;10.1046/j.1523-1747.1998.00189.x,"Parks et al., May 2002, J. General Virol. vol. 83: 1167-1172.;;Yan et al., ""Characterization of Monoclonal Antibodies to the 26-kDa Glutathione S-transferase of Schistosoma japonicum"", 1996, Hybridoma, vol. 15:429-33.;;Hong-Gellar et al., ""Therapeutic approaches to superantigen-based disease: a review"", 2003, J. Mol. Rec. , vol. 16:91-101.;;Arcus et al. ""Conservation and variation in superantigen structure and activity highlighted by the three-dimensional structures of two new superantigens from streptococcus pyogenes"". Biology 299:157-168, 2000.;;Proft et al. ""The streptococcal superantigen SMEZ exhibits wide allelic variation, mosaic structure, and significant antigenic variation"". J. Exp. Med. 191(10):1765-1776, May 2000.;;Unnikrishnan et al. ""The bacterial superantigen streptococcal mitogenic exotoxin Z is the major immunoactive agent of streptococcus pyogenes"". The Journal of Immunology 169:2561-2569, 2002.;;Li et al. ""Three-dimensional structure of the complex between a T cell receptor beta chain and the superantigen staphylococcal enterotoxin B"". Immunity 9:807-816, Dec. 1998.;;Fraser et al. ""Superantigens-powerful modifiers of the immune system"". Molecular Medicine 6:125-132, Mar. 2000.;;Leder et al. ""A Mutational analysis of the binding of staphylococcal enterotoxins B and C3 to the T cell receptor beta chain and major histocompatibility complex class II"". J. Exp. Med. 187(6):823-833, Mar. 1998.;;Lukas Leder et al. ""A mutational analysis of the binding of staphylococcal enterotoxins B and C3 to the T cell receptor beta chain and major histocompatibility complex class II"". Journal of Experimental Medicine 187(6):823-833, Mar. 16, 1998.;;Hongmin Li et al. ""Three-dimensional structure of the complex between a T cell receptor beta chain and the superantigen staphylococcal exterotoxin B"". Immunity 9(6):807-816, Dec. 1998.;;John Fraser et al. ""Superantigens: Powerful modifiers of the immune system"". Molecular Medicine Today 6(3):125-132, Mar. 2000.;;McCormick, John K. et al. ""Development of Streptococcal Pyrogenic Exotoxin C Vaccine Toxoids that are Protective in the Rabbit Model of Toxic Shock Syndrome."" The Journal of Immunology (2000), pp. 2306-2312.;;Nestle et al., ""Human Dermal Dendritic Cells Process and Present Soluble Protein Antigens"", The Journal of Investigative Dermatology, vol. 110, No. 5, May 1998, pp. 762-766.",EXPIRED
301,EP,A4,EP 3989994 A4,097-936-923-791-742,2023-08-09,2023,EP 20835340 A,2020-06-30,US 201962868983 P;;US 202062956898 P;;US 2020/0040370 W,2019-06-30,RECOMBINANT AAV VECTORS WITH ALTERED IMMUNOGENCITY AND METHODS OF MAKING THE SAME,,WRIGHT JOHN FRASER,WRIGHT JOHN FRASER,,https://lens.org/097-936-923-791-742,Search Report,no,1,0,5,5,0,C12N15/86;;C12N2750/14143;;C12N2750/14152;;C12N2750/14151;;C12N2750/14133;;C07K14/47;;C12N9/1007;;C12N9/644;;C12Y304/21022;;C07K14/755;;C07K14/4708;;A61P21/00;;A61P35/00;;C07K14/8125;;A61P11/00;;A61P7/04;;A61K35/76;;C12N9/1007;;C12N15/64;;C12N15/86;;C12N2330/51;;C12N2750/14133;;C12N2750/14143;;C12N2750/14152,A61K35/76;;C12N15/09;;C12N15/63;;C12N15/87;;C12Q1/68,,5,4,050-344-389-291-726;;034-505-364-566-249;;080-402-768-566-030;;121-911-746-985-163,30710128;;10.1038/s41573-019-0012-9;;pmc6927556;;10.3390/v11010038;;30634383;;pmc6356613;;10.1111/j.0300-9475.2004.01373.x;;14871290;;10.1016/j.ymthe.2020.01.026;;32035026;;pmc7054817,"DAN WANG ET AL: ""Adeno-associated virus vector as a platform for gene therapy delivery"", NATURE REVIEWS DRUG DISCOVERY, 1 February 2019 (2019-02-01), pages 358 - 378, XP055735836, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6927556/> [retrieved on 20201001], DOI: 10.1038/s41573-019-0012-9;;TÓTH RENÁTA ET AL: ""Methylation Status of the Adeno-Associated Virus Type 2 (AAV2)"", VIRUSES, vol. 11, no. 1, 9 January 2019 (2019-01-09), pages 38, XP093058222, DOI: 10.3390/v11010038;;CORNELIE J ET AL: ""Methylated CpG-containing plasmid activates the immune system"", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, BLACKWELL SCIENCE PUBL., OXFORD, GB, vol. 59, no. 2, 10 February 2004 (2004-02-10), pages 143 - 151, XP002990004, ISSN: 0300-9475, DOI: 10.1111/J.0300-9475.2004.01373.X;;WRIGHT J. FRASER: ""Codon Modification and PAMPs in Clinical AAV Vectors: The Tortoise or the Hare?"", MOLECULAR THERAPY, vol. 28, no. 3, 1 March 2020 (2020-03-01), US, pages 701 - 703, XP093057734, ISSN: 1525-0016, DOI: 10.1016/j.ymthe.2020.01.026;;See also references of WO 2021003195A1",PENDING
302,EP,B1,EP 1747543 B1,100-890-988-371-664,2013-04-24,2013,EP 05737801 A,2005-05-09,AU 2005/000660 W;;AU 2004/902622 A,2004-05-17,"METHOD, APPARATUS AND SYSTEM FOR PARKING OVERSTAY DETECTION",,VEHICLE MONITORING SYSTEMS PTY LTD,WELCH FRASER JOHN,,https://lens.org/100-890-988-371-664,Granted Patent,yes,9,1,12,15,0,G08G1/14;;G08G1/14;;G07B15/02;;G07B15/02;;G07F17/246;;G07F17/246,G07F17/24;;B60Q1/48;;G08G1/14,,1,0,,,"PATENT ABSTRACTS OF JAPAN vol. 1998, no. 11 & JP 10 172 092 A (OMRON CORP) 26 June 1998",ACTIVE
303,WO,A3,WO 2003/101173 A3,112-493-770-664-022,2004-03-04,2004,NZ 0300111 W,2003-06-04,NZ 51937102 A,2002-06-04,IMMUNOMODULATORY CONSTRUCTS AND THEIR USES,"The invention relates to immunomodulators. In particular the invention relates to specific immunomodulators based on the superantigen SMEZ-2 and more particularly based on mutants of the superantigen SMEZ-2, which are adapted to target antigen-presenting-cells for the purpose of enhancing or suppressing a host immune response.",AUCKLAND UNISERVICES LTD;;FRASER JOHN DAVID,FRASER JOHN DAVID,,https://lens.org/112-493-770-664-022,Search Report,yes,1,0,14,14,0,A61K39/092;;A61K39/385;;A61K2039/6037;;C07K14/315;;A61P37/02;;C07K14/315;;A61K39/092;;A61K2039/6037;;A61K39/385,C12N15/09;;A61K39/00;;A61K39/09;;A61K39/385;;A61K39/39;;C07K14/315;;C07K19/00;;C12N15/31,,4,4,038-849-700-470-356;;031-731-686-337-306;;027-823-002-465-547;;013-657-500-788-251,12193726;;10.4049/jimmunol.169.5.2561;;pmc2193151;;10811869;;10.1084/jem.191.10.1765;;10.1006/jmbi.2000.3725;;10860729;;9874566;;pmc1887688;;10.1084/jem.189.1.89,"FRASER J.D. ET AL.: ""The bacterial superantigen streptococcal mitogenic exotoxin Z is the major immunoactive agent of streptococcus pyogenes"", JOURNAL OF IMMUNOLOGY, vol. 169, no. 5, 1 September 2002 (2002-09-01), pages 2561 - 2569, XP002992534;;PROFT T. ET AL.: ""The streptococcal superantigen SMEZ exhibits wide allelic varition, mosaic structure and significant antigenic variation"", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 191, no. 10, 15 May 2000 (2000-05-15), pages 1765 - 1776, XP008045700;;ARCUS V.L. ET AL.: ""Conservation and variation in superantigen structure and activity highlighted by the three dimensional structures of two new superantigens from streptococcus pyogenes"", JOURNAL OF MOLECULAR BIOLOGY, vol. 299, no. 1, 26 May 2000 (2000-05-26), pages 157 - 168, XP004470896;;PROFT T. ET AL.: ""Identification and characterisation of novel superantigens from streptococcus pyogenes"", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 189, no. 1, 4 January 1999 (1999-01-04), pages 89 - 101, XP001058404",PENDING
304,BR,A2,BR 112013023981 A2,119-333-195-690-081,2016-12-13,2016,BR 112013023981 A,2012-03-13,IB 2012051173 W;;US 201161466172 P,2011-03-22,conjunto de células cmut de um transdutor ultrassônico,"resumo conjunto de células cmut de um transdutor ultrassônico um conjunto de células cmut é formado em grandes placas isoladas individualmente sobre um substrato. a massa de cada placa fornece uma força de inércia em oposição à força e movimento da transmissão pela célula, o que reduz a conversão resultante do movimento na placa. a redução do movimento resulta em menos acoplamento de energia acústica ao substrato e contaminação dos sinais de células cmut adjacentes por ondas laterais. o acoplamento não desejado de onda ao substrato pode ser adicionalmente amortecido com montagem periódica compatível ou esparsa das grandes placas sobre o substrato. 1/1",KONINKL PHILIPS NV,FRASER JOHN DOUGLAS,,https://lens.org/119-333-195-690-081,Patent Application,no,0,0,12,12,0,G01H11/06;;B06B1/0292;;G10K11/002;;G01H11/06;;B06B1/0292;;G10K11/002;;A61B8/4494,G10K11/00;;B06B1/02,,0,0,,,,DISCONTINUED
305,EP,B1,EP 2384162 B1,124-663-848-664-554,2017-02-22,2017,EP 09801785 A,2009-12-09,IB 2009055611 W;;US 14133008 P,2008-12-30,"ULTRASONIC TEETH CLEANING APPLIANCE HAVING SPATIAL, TEMPORAL AND/OR FREQUENCY VARIATIONS",,KONINKLIJKE PHILIPS NV,FRASER JOHN DOUGLAS,KONINKLIJKE PHILIPS N.V. (2013-09-25),https://lens.org/124-663-848-664-554,Granted Patent,yes,5,0,16,16,0,A61C17/20;;A61C17/20,A61C17/20,,0,0,,,,ACTIVE
306,EP,B1,EP 0202751 B1,140-011-160-994-025,1989-10-11,1989,EP 86302642 A,1986-04-10,US 73720485 A,1985-05-23,B2O3-P2O5-SIO2 GLASS-CERAMICS,,CORNING GLASS WORKS,"MACDOWELL, JOHN FRASER",,https://lens.org/140-011-160-994-025,Granted Patent,yes,0,0,6,6,0,C03C13/006;;C03C13/006;;C03C10/0054;;C03C10/0054,C03C3/064;;C03B32/02;;C03C3/097;;C03C10/00;;C03C10/02;;C03C13/00,,1,0,,,"Phase Diagrams for Ceramists, Am.Ceramic Soc. 1979, pp.262-263",EXPIRED
307,US,A1,US 2012/0007983 A1,003-028-727-860-92X,2012-01-12,2012,US 200913141642 A,2009-12-23,AU 2008/906642 A;;AU 2009/001698 W,2008-12-24,METHOD AND SYSTEM FOR DETECTING VEHICLE OFFENCES,Methods and systems for uniquely identifying a vehicle that has committed a potential violation are disclosed. One method comprises the steps of: obtaining first data for uniquely identifying vehicles that enter a zone of interest ( 610 ); obtaining second data relating to a potential violation committed by a particular vehicle in the zone of interest ( 620 ); correlating the first and second data to identify a portion of the first data recorded while the particular vehicle was present in the zone of interest ( 630 ); extracting a unique identifier of the particular vehicle from the first data ( 640 ); and recording the unique identifier and an association between the unique identifier and the second data ( 650 ).,WELCH FRASER JOHN,WELCH FRASER JOHN,VEHICLE MONITORING SYSTEMS PTY LTD (2011-08-08),https://lens.org/003-028-727-860-92X,Patent Application,yes,7,76,7,7,0,G08G1/017;;G08G1/017;;G07B15/063;;G07B15/063;;G08G1/0175;;G08G1/0175;;G08G1/04;;G08G1/04;;G08G1/042;;G08G1/042;;G08G1/148;;G08G1/148,G06K9/00;;H04N7/18,348/148;;382/104;;X348E07085,0,0,,,,DISCONTINUED
308,US,A1,US 2011/0256503 A1,011-903-797-420-009,2011-10-20,2011,US 200913141551 A,2009-12-09,US 200913141551 A;;US 14133008 P;;IB 2009055611 W,2008-12-30,"ULTRASONIC TEETH CLEANING APPLIANCE HAVING SPATIAL, TEMPORAL AND/OR FREQUENCY VARIATIONS","The appliance includes an appliance body ( 12 ) as well as a system for producing microbubbles ( 20 ) and a system for producing an ultrasound signal beam ( 22 ) in a frequency range which activates at least some of the microbubbles. The appliance includes at least one of the following: (a) an array of ultrasound transducer elements ( 40 ) which produce a plurality of ultrasound signal beams; (b) an amplitude modulation assembly ( 51 ) for modulating the amplitude of the ultrasound signal; and (c) a frequency modulation system ( 61 ) for changing the frequency of the ultrasound signals over a selected range, to impact a range of microbubble sizes.",KONINKL PHILIPS ELECTRONICS NV,FRASER JOHN DOUGLAS,KONINKLIJKE PHILIPS ELECTRONICS N V (2009-12-09),https://lens.org/011-903-797-420-009,Patent Application,yes,2,39,16,16,0,A61C17/20;;A61C17/20,A61C3/03,433/119,0,0,,,,ACTIVE
309,AU,A1,AU 2003/238740 A1,021-881-144-252-800,2003-12-19,2003,AU 2003/238740 A,2003-06-04,NZ 51937102 A;;NZ 0300111 W,2002-06-04,IMMUNOMODULATORY CONSTRUCTS AND THEIR USES,"The invention relates to immunomodulators. In particular the invention relates to specific immunomodulators based on the superantigen SMEZ-2 and more particularly based on mutants of the superantigen SMEZ-2, which are adapted to target antigen-presenting-cells for the purpose of enhancing or suppressing a host immune response.",AUCKLAND UNISERVICES LTD,FRASER JOHN DAVID,,https://lens.org/021-881-144-252-800,Patent Application,no,0,0,14,14,0,A61K39/092;;A61K39/385;;A61K2039/6037;;C07K14/315;;A61P37/02;;C07K14/315;;A61K39/092;;A61K2039/6037;;A61K39/385,C12N15/09;;A61K39/00;;A61K39/09;;A61K39/385;;A61K39/39;;C07K14/315;;C07K19/00;;C12N15/31,,0,0,,,,EXPIRED
310,CA,A,CA 394439 A,055-183-718-845-53X,1941-02-04,1941,CA 394439D A,,CA 394439T A,,CONDUIT COUPLER CLOSURE,,KEESHIN MOTOR EXPRESS CO,FRASER EDWIN JOHN,,https://lens.org/055-183-718-845-53X,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
311,US,A1,US 2013/0331705 A1,066-073-973-868-159,2013-12-12,2013,US 201214000891 A,2012-03-13,US 201214000891 A;;US 201161466172 P;;IB 2012051173 W,2011-03-22,ULTRASONIC CMUT WITH SUPPRESSED ACOUSTIC COUPLING TO THE SUBSTRATE,An array of cMUT cells are formed on individually isolated massive plates on a substrate. The mass of each plate provides an inertial force in opposition to the force and motion of transmission by the cell which reduces the resultant translation of motion in the plate. The reduction in motion results in less coupling of acoustic energy into the substrate and contamination of the signals of adjacent cMUT cells by lateral waves. The unwanted wave coupling into the substrate can be further damped by compliant or sparse periodic mounting of the massive plates on the substrate.,FRASER JOHN DOUGLAS;;KONINKL PHILIPS ELECTRONICS NV,FRASER JOHN DOUGLAS,KONINKLIJKE PHILIPS ELECTRONICS N.V (2012-03-23),https://lens.org/066-073-973-868-159,Patent Application,yes,13,34,12,12,0,G01H11/06;;B06B1/0292;;G10K11/002;;G01H11/06;;B06B1/0292;;G10K11/002;;A61B8/4494,A61B8/00,600/459,0,0,,,,DISCONTINUED
312,EP,A3,EP 1022491 A3,099-752-666-862-330,2001-04-04,2001,EP 00300286 A,2000-01-17,US 23798399 A,1999-01-25,Torque converter having resiliently loaded bypass clutch piston,"A hydrokinetic torque converter includes an impeller cover (12) and a bypass clutch. A drive ring (74) is located between adjacent surfaces of the cover (12) and a clutch piston (60), which moves axially on a support surface. The piston (60) is welded at a radially outer position to thin clutch plate (70), which is supported at another radial location on the cover (12). As the piston (60) moves into engagement with the ring (74) and cover (12), the clutch plate (70) permits this movement by bending elastically. When clutch apply pressure is reduced, energy stored in the clutch plate (70) is used to move the piston (60) out of engagement with the drive ring (74).",FORD GLOBAL TECH INC,MACDONALD FRASER JOHN,LAWRENCE TECHNOLOGICAL UNIVERSITY (2003-08-13),https://lens.org/099-752-666-862-330,Search Report,yes,6,0,6,6,0,F16H45/02;;F16H2045/0278;;F16H2045/0289;;F16H45/02;;F16H2045/0278;;F16H2045/0289,F16H45/02,,1,0,,,"FROSLIE, MILEK, SMITH: ""Design Practices- Passenger Car Automatic Transmissions Part I"", 1962, SAE, NEW YORK, XP000905044",EXPIRED
313,CA,A1,CA 2175840 A1,114-036-487-924-190,1995-05-11,1995,CA 2175840 A,1994-09-27,GB 9322770 A,1993-11-04,DOLLY,"A dolly has a wheeled body (10) with an upwardly-opening recess therein within which is received a rotatable base unit or turret (24) containing the hydraulics for raising and lowering a boom arm (26). The boom arm may be positioned either facing forwardly of the body (10) or laterally of the body. In each case, the boom arm is received within an aperture (30, 32, 34), the apertures being suitably sized to allow the boom arm to be lowered to a position below the horizontal. The base unit (24) may be lifted out of the recess, and may be used with another body of a different size.",GRIP HOUSE LTD,FRASER DENNIS JOHN,,https://lens.org/114-036-487-924-190,Patent Application,no,0,0,9,9,0,B66F11/048;;B66F11/048;;F16M11/046;;F16M11/046;;F16M11/10;;F16M11/10;;F16M11/18;;F16M11/18;;F16M11/2014;;F16M11/2014;;F16M11/42;;F16M11/42;;F16M2200/08;;F16M2200/08,B66F11/04;;F16M11/42,,0,0,,,,DISCONTINUED
314,US,B2,US 7825826 B2,127-006-782-498-280,2010-11-02,2010,US 57989505 A,2005-05-09,AU 2004/902622 A;;AU 2005/000660 W,2004-05-17,"Method, apparatus and system for parking overstay detection","Methods, apparatuses and systems for identifying overstay of a vehicle ( 624, 644 ) in a parking space ( 610, 620, 630, 640, 650, 660 ) are disclosed herein. The method comprises the steps of detecting presence of a vehicle in a parking space using a detection apparatus ( 612, 622, 632, 642, 652, 662 ), processing and storing data relating to presence of the vehicle in the detection apparatus, wirelessly ( 672, 674 ) waking-up the detection apparatus, wirelessly retrieving at least a portion of the data from the detection apparatus, and identifying overstay of the vehicle in the parking space based on the retrieved data. Wireless wake-up of a detection apparatus may be irregularly performed by an occasionally present data collection apparatus ( 680 ). Apparatuses and systems are disclosed for performing the foregoing method.",VEHICLE MONITORING SYSTEMS PTY,WELCH FRASER JOHN,VEHICLE MONITORING SYSTEMS PTY LTD (2007-03-14),https://lens.org/127-006-782-498-280,Granted Patent,yes,20,70,12,15,0,G08G1/14;;G08G1/14;;G07B15/02;;G07B15/02;;G07F17/246;;G07F17/246,B60Q1/48;;G08G1/14,340/932.2;;340/933,5,0,,,"Examiner's First Report on Australian Patent Application No. 2005243110, 3 pages, Feb. 16, 2007.;;Examiner's Report No. 2 on Australian Patent Application No. 2005243110, 2 pages, Jun. 7, 2007.;;Examination Report, New Zealand Application No. 552100, May 8, 2008, 2 pages.;;Supplementary European Search Report for corresponding European Application No. EP 05 73 7801 dated Nov. 30, 2009.;;EPO Communication for corresponding European Application No. EP 05 73 7801 dated Feb. 16, 2010.",ACTIVE
315,CA,A,CA 232680 A,132-080-329-867-902,1923-07-17,1923,CA 232680D A,,CA 232680T A,,MOTOR VEHICLE TRANSMISSION,,FRASER JOHN DANIEL,FRASER JOHN DANIEL,,https://lens.org/132-080-329-867-902,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
316,EP,A1,EP 0202751 A1,123-961-430-765-066,1986-11-26,1986,EP 86302642 A,1986-04-10,US 73720485 A,1985-05-23,B2O3-P2O5-SiO2 Glass-ceramics.,"This invention is directed to the production of transparent, translucent, or opaque glass-ceramic articles containing BPO 4  as the predominant crystal phase by heat treating precursor glass articles consisting essentially, expressed in terms of weight percent on the oxide basis, of about:  ",CORNING GLASS WORKS,MACDOWELL JOHN FRASER,,https://lens.org/123-961-430-765-066,Patent Application,yes,5,2,6,6,0,C03C13/006;;C03C13/006;;C03C10/0054;;C03C10/0054,C03C3/064;;C03B32/02;;C03C3/097;;C03C10/00;;C03C10/02;;C03C13/00,,0,0,,,,EXPIRED
317,AU,A,AU 1994/077028 A,120-955-311-423-821,1995-05-23,1995,AU 1994/077028 A,1994-09-27,GB 9322770 A;;GB 9402095 W,1993-11-04,Dolly,,GRIP HOUSE LTD,FRASER DENNIS JOHN,,https://lens.org/120-955-311-423-821,Patent Application,no,0,0,9,9,0,B66F11/048;;B66F11/048;;F16M11/046;;F16M11/046;;F16M11/10;;F16M11/10;;F16M11/18;;F16M11/18;;F16M11/2014;;F16M11/2014;;F16M11/42;;F16M11/42;;F16M2200/08;;F16M2200/08,B66F11/04;;F16M11/42,,0,0,,,,PENDING
318,US,P1,US 2017/0105326 P1,140-247-053-770-123,2017-04-13,2017,US 201514756776 V,2015-10-10,US 201514756776 V,2015-10-10,COPROSMA PLANT NAMED 'Golden Star',A new cultivar of Coprosma plant named ‘Golden Star’ that is characterized by a compact habit and variegated yellow leaves with an irregular green center and orange margins.,FRASER PETER JOHN,FRASER PETER JOHN,,https://lens.org/140-247-053-770-123,Patent Application,yes,0,0,2,2,0,,A01H5/00,PLT 373,0,0,,,,PENDING
319,US,A1,US 2023/0144548 A1,134-285-017-129-400,2023-05-11,2023,US 202017624200 A,2020-06-30,US 202017624200 A;;US 202062956898 P;;US 201962868983 P;;US 2020/0040370 W,2019-06-30,RECOMBINANT AAV VECTORS WITH ALTERED IMMUNOGENCITY AND METHODS OF MAKING THE SAME,"The present invention provides methods of generating a recombinant AAV vector with reduced immunogenicity, comprising: providing eukaryotic cells with a nucleic acid comprising a sequence of interest that is flanked by AAV inverted terminal repeats, wherein the nucleic acid comprises CpG dinucleotide sites, wherein at least a portion of the CpG dinucleotide sites are methylated, wherein the eukaryotic cell expresses one or more other components necessary to achieve recombinant AAV biosynthesis, whereby the recombinant AAV vector is generated by the eukaryotic cell, wherein the generated recombinant AAV vector comprises nucleic acid wherein at least a portion of the CpG dinucleotide sites are methylated.",WRIGHT JOHN FRASER,WRIGHT JOHN FRASER,,https://lens.org/134-285-017-129-400,Patent Application,yes,0,0,5,5,4,C12N15/86;;C12N2750/14143;;C12N2750/14152;;C12N2750/14151;;C12N2750/14133;;C07K14/47;;C12N9/1007;;C12N9/644;;C12Y304/21022;;C07K14/755;;C07K14/4708;;A61P21/00;;A61P35/00;;C07K14/8125;;A61P11/00;;A61P7/04;;A61K35/76;;C12N9/1007;;C12N15/64;;C12N15/86;;C12N2330/51;;C12N2750/14133;;C12N2750/14143;;C12N2750/14152,C12N15/86;;A61K35/76;;C12N9/10;;C12N15/64,,0,0,,,,PENDING
320,US,A1,US 2017/0065638 A1,150-162-399-076-34X,2017-03-09,2017,US 201515117665 A,2015-02-09,US 201515117665 A;;US 201461938052 P;;US 201461938040 P;;US 2015/0015028 W,2014-02-10,REGENERATIVE CELL THERAPY FOR CENTRAL NERVOUS SYSTEM (CNS) DISORDERS AND PTSD,"Provided herein are compositions comprising regenerative cells (e.g., from adipose tissue), for therapy for central nervous system (CNS) disorders, including disorders characterized by excitotoxicity, neuroinflammation, neurodegeneration, and compromise of the blood brain barrier.",CYTORI THERAPEUTICS INC,FRASER JOHN K,CYTORI THERAPEUTICS INC (2016-08-18);;LOREM VASCULAR PTE. LTD (2019-04-24),https://lens.org/150-162-399-076-34X,Patent Application,yes,5,20,4,4,0,A61K35/28;;A61K35/28;;A61P25/00,A61K35/28,,4,4,079-537-610-598-238;;025-595-313-749-534;;006-638-481-058-853;;000-355-360-894-70X,11846913;;10.1227/00006123-200111000-00031;;10.1097/00006123-200111000-00031;;10.3171/jns.2006.104.2.272;;16509501;;10.1517/14728210902769601;;pmc2773142;;19249984;;23971414;;pmc3765323;;10.1186/1742-2094-10-106,"Mahmood et al., Treatment of traumatic brain injury in female rats with intravenous administration of bone marrow stromal cells. Neurosurgery, Vol. 49, No. 5 (Nov 2001) pages 1196-1204.;;Mahmood et al., Long-term recovery after bone marrow stromal cell treatment of traumatic brain injury in rats. Journal of Neurosurgery, Vol. 104 (2006) pages 272-277.;;Xiong et al., Emerging treatments for traumatic brain injury. Expert Opinion on Emerging Drugs, Vol. 14, No. 1 (2009) pages 67-84.;;Zhang et al., Anti-inflammatory and immunomodulatory mechanisms of mesenchymal stem cell transplantation in experimental traumatic brain injury. Journal of Neuroinflammation, Vol. 10 (23 Aug 2013) pages 1-12.",DISCONTINUED
321,AT,T1,AT E412014 T1,158-944-167-396-819,2008-11-15,2008,AT 03733654 T,2003-06-04,NZ 51937102 A,2002-06-04,IMMUNMODULATORISCHE KONSTRUKTE UND DEREN VERWENDUNGEN,"The invention relates to immunomodulators. In particular the invention relates to specific immunomodulators based on the superantigen SMEZ-2 and more particularly based on mutants of the superantigen SMEZ-2, which are adapted to target antigen-presenting-cells for the purpose of enhancing or suppressing a host immune response.",AUCKLAND UNISERVICES LTD,FRASER JOHN DAVID,,https://lens.org/158-944-167-396-819,Granted Patent,no,0,0,14,14,0,A61K39/092;;A61K39/385;;A61K2039/6037;;C07K14/315;;A61P37/02;;C07K14/315;;A61K39/092;;A61K2039/6037;;A61K39/385,C12N15/09;;A61K39/00;;A61K39/09;;A61K39/385;;A61K39/39;;C07K14/315;;C07K19/00;;C12N15/31,,0,0,,,,EXPIRED
322,AU,B2,AU 2008/341007 B2,008-225-626-416-39X,2013-12-05,2013,AU 2008/341007 A,2008-12-18,AU 2007/906997 A;;AU 2008/001864 W;;AU 2008/341007 A,2007-12-20,Analytical method and apparatus,"A method for determining the amount of a chemical species in a sample, in particular the amount of weak acid dissociable cyanide or total cyanide in a sample, and an apparatus for performing said method. The method comprises the steps of: i) treating the sample to liberate the chemical species into a gaseous stream; ii) directing the gaseous stream to a scrubber; iii) absorbing the chemical species into a scrubber solution; and iv) determining the amount of chemical species absorbed into the scrubber solution, wherein any remaining chemical species not absorbed into the scrubber solution is directed or recirculated to the scrubber in the gaseous stream and step iii) is repeated to increase absorption of the chemical species prior to performing step iv).",ORICA AUSTRALIA PTY LTD,ROSS FRASER JOHN,ORICA AUSTRALIA PTY LTD (2014-03-20),https://lens.org/008-225-626-416-39X,Granted Patent,no,1,0,5,5,0,G01N1/4055;;G01N31/16;;G01N2001/4066;;Y10T436/175383;;Y10T436/172307;;Y10T436/25;;Y10T436/173845;;Y10T436/17;;Y10T436/201666;;Y10T436/174614;;Y10T436/255;;Y10T436/25875;;Y10T436/25375;;Y10T436/175383;;Y10T436/172307;;Y10T436/25;;Y10T436/173845;;Y10T436/17;;Y10T436/201666;;Y10T436/174614;;Y10T436/255;;Y10T436/25875;;Y10T436/25375;;G01N31/16;;G01N1/4055;;G01N2001/4066,G01N31/16;;G01N33/18,,0,0,,,,INACTIVE
323,US,S,US D0863066 S,021-509-044-700-88X,2019-10-15,2019,US 201829654881 F,2018-06-28,US 201829654881 F,2018-06-28,Knife holder,,FRASER MATTHEW JOHN,FRASER MATTHEW JOHN,,https://lens.org/021-509-044-700-88X,Design Right,no,24,7,1,1,0,,,0903;;D 9721,0,0,,,,ACTIVE
324,AU,C1,AU 2011/204924 C1,032-845-633-203-816,2016-02-11,2016,AU 2011/204924 A,2011-07-21,AU 2008/200089 A;;AU 2011/204924 A,2008-01-08,"Method, apparatus and system for parking overstay detection","METHOD, APPARATUS AND SYSTEM FOR PARKING OVERSTAY Methods, apparatuses and systems for identifying overstay of a vehicle (624, 644) in a parking space (610, 620, 630, 640, 650, 660) are disclosed herein. The method comprises the steps of detecting presence of a vehicle in a parking space using a detection io apparatus (612, 622, 632, 642, 652, 662), processing and storing data relating to presence of the vehicle in the detection apparatus, determining whether the vehicle has overstayed a defined time durationin the parking space; and wirelessly transmitting data relating to identified instances of overstay of the vehicle in the parking space.",VEHICLE MONITORING SYSTEMS PTY LTD,WELCH FRASER JOHN,,https://lens.org/032-845-633-203-816,Amended Patent,no,2,0,8,8,0,,G08G1/14,,0,0,,,,INACTIVE
325,EP,A1,EP 0494357 A1,028-957-953-534-990,1992-07-15,1992,EP 91119227 A,1991-11-12,US 63919691 A,1991-01-09,Glass-ceramic-bonded ceramic composites.,"This invention is particularly directed to the production of glass-ceramics specifically designed for bonding hard refractory particulate ceramics into dense, mechanically strong composite bodies. The inventive glass-ceramics are crystallized in situ from divalent metal borate glasses. The invention is particularly drawn to composite articles where Al₂O₃ particles comprise the hard refractory ceramic and the inventive glasses react therewith to form an exceptionally strong bond therebetween accompanied with the development of divalent metal aluminoborate crystals.",CORNING INC,MACDOWELL JOHN FRASER,,https://lens.org/028-957-953-534-990,Patent Application,yes,5,1,4,4,0,C03C3/14;;C03C14/004;;C03C14/004;;C03C10/0054;;C03C10/0054;;C03C2214/04;;C03C2214/04;;C03C2214/20;;C03C2214/20,C03C3/064;;C03C3/066;;C03C3/14;;C03C3/23;;C03C10/00;;C03C10/02;;C03C14/00,,3,1,015-744-123-598-118,10.1111/j.1151-2916.1990.tb07590.x,"JOURNAL OF THE AMERICAN CERAMIC SOCIETY. vol. 73, no. 8, August 1990, COLUMBUS US pages 2287 - 2292; J.F.MACDOWELL: 'Aluminoborate Glass-Ceramics with Low Thermal Expansivity';;PHYSICS AND CHEMISTRY OF GLASSES. vol. 28, no. 1, February 1987, SHEFFIELD GB pages 1 - 3; M.F.FAHMY ET AL: 'Crystallisation of BaO.4B2O3 Glasses.';;CHEMICAL ABSTRACTS, vol. 102, no. 24, June 1985, Columbus, Ohio, US; abstract no. 208300E, page 281",DISCONTINUED
326,US,A,US 3415573 A,036-094-739-183-893,1968-12-10,1968,US 57396066 A,1966-08-22,US 57396066 A,1966-08-22,Method of sulfur recovery from sulfur-containing hydrogen sulfide rich formations,,SHELL OIL CO,FRASER JOHN P,,https://lens.org/036-094-739-183-893,Granted Patent,no,6,18,1,1,0,E21B43/281;;E21B43/281,E21B43/28,299/4,0,0,,,,EXPIRED
327,GB,A,GB 189604266 A,055-971-423-533-050,1897-01-16,1897,GB 189604266D A,1896-02-25,GB 189604266T A,1896-02-25,"Improvements in Evaporative and other Condensers, Evaporators, and the like.",,FRASER HARRY JOHN,FRASER HARRY JOHN,,https://lens.org/055-971-423-533-050,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
328,WO,A1,WO 2010/071942 A1,076-700-902-083-066,2010-07-01,2010,AU 2009/001698 W,2009-12-23,AU 2008/906642 A,2008-12-24,METHOD AND SYSTEM FOR DETECTING VEHICLE OFFENCES,Methods and systems for uniquely identifying a vehicle that has committed a potential violation are disclosed. One method comprises the steps of: obtaining first data for uniquely identifying vehicles that enter a zone of interest (610); obtaining second data relating to a potential violation committed by a particular vehicle in the zone of interest (620); correlating the first and second data to identify a portion of the first data recorded while the particular vehicle was present in the zone of interest (630); extracting a unique identifier of the particular vehicle from the first data (640); and recording the unique identifier and an association between the unique identifier and the second data (650).,VEHICLE MONITORING SYSTEMS PTY;;WELCH FRASER JOHN,WELCH FRASER JOHN,,https://lens.org/076-700-902-083-066,Patent Application,yes,7,2,7,7,0,G08G1/017;;G08G1/017;;G07B15/063;;G07B15/063;;G08G1/0175;;G08G1/0175;;G08G1/04;;G08G1/04;;G08G1/042;;G08G1/042;;G08G1/148;;G08G1/148,G07C1/10;;G08G1/14,,3,0,,,PATENT ABSTRACTS OF JAPAN;;PATENT ABSTRACTS OF JAPAN;;See also references of EP 2380143A4,PENDING
329,DE,D1,DE 60143391 D1,102-517-707-017-026,2010-12-16,2010,DE 60143391 T,2001-06-08,US 59675900 A;;EP 0106479 W,2000-06-15,KAPAZITIVER MIKROBEARBEITETER ULTRASCHALLWANDLER UND ZUGEHÖRIGES BETRIEBSVERFAHREN,"An ultrasonic transducer is formed by a plurality of cMUT cells, each comprising a charged diaphragm plate capacitively opposing an oppositely charged base plate. The diaphragm plate is distended toward the base plate by a bias charge. The base plate includes a central portion elevated toward the center of the diaphragm plate to cause the charge of the cell to be of maximum density at the moving center of the diaphragm plate. For harmonic operation the drive pulses applied to the cells are predistorted in consideration of the nonlinear operation of the device to reduce contamination of the transmit signal at the harmonic band. The cMUT cells can be fabricated by conventional semiconductor processes and hence integrated with ancillary transducer circuitry such as a bias charge regulator. The cMUT cells can also be fabricated by micro-stereolithography whereby the cells can be formed using a variety of polymers and other materials.",KONINKL PHILIPS ELECTRONICS NV,FRASER JOHN D,,https://lens.org/102-517-707-017-026,Granted Patent,no,0,0,12,16,0,B06B1/0292;;B33Y80/00;;B33Y10/00;;B33Y80/00;;B33Y10/00;;B06B1/0292,B06B1/02;;B81B3/00;;A61B8/00;;H04R19/00,,0,0,,,,EXPIRED
330,AU,A1,AU 2013/202590 A1,119-128-904-791-895,2013-05-02,2013,AU 2013/202590 A,2013-04-05,AU 2011/204924 A;;AU 2013/202590 A,2011-07-21,"Method, apparatus and system for parking overstay detection","METHOD, APPARATUS AND SYSTEM FOR PARKING OVERSTAY Methods, apparatuses and systems for identifying overstay of a vehicle (624, 644) in a parking space (610, 620, 630, 640, 650, 660) are disclosed herein. The method 10 comprises the steps of detecting presence of a vehicle in a parking space using a detection apparatus (612, 622, 632, 642, 652, 662), processing and storing data relating to presence of the vehicle in the detection apparatus, determining whether the vehicle has overstayed a defined time duration in the parking space; and wirelessly transmitting data relating to identified instances of overstay of the vehicle in the parking space. 7292907_1",VEHICLE MONITORING SYSTEMS PTY LTD,WELCH FRASER JOHN,,https://lens.org/119-128-904-791-895,Patent Application,no,0,0,8,8,0,,G08G1/14,,0,0,,,,DISCONTINUED
331,EP,A2,EP 2688686 A2,119-341-783-534-544,2014-01-29,2014,EP 12713338 A,2012-03-13,US 201161466172 P;;IB 2012051173 W,2011-03-22,ULTRASONIC CMUT WITH SUPPRESSED ACOUSTIC COUPLING TO THE SUBSTRATE,,KONINKL PHILIPS NV,FRASER JOHN DOUGLAS,KONINKLIJKE PHILIPS N.V. (2020-03-18),https://lens.org/119-341-783-534-544,Patent Application,yes,0,0,12,12,0,G01H11/06;;B06B1/0292;;G10K11/002;;G01H11/06;;B06B1/0292;;G10K11/002;;A61B8/4494,B06B1/02;;G10K11/00,,0,0,,,,ACTIVE
332,EP,B1,EP 1008784 B1,133-390-728-106-385,2004-02-11,2004,EP 99309749 A,1999-12-03,US 20641998 A,1998-12-07,Torque converter bypass clutch damper having compliant pressure disc,,FORD GLOBAL TECH LLC,MACDONALD FRASER JOHN,"FORD GLOBAL TECHNOLOGIES, LLC (2003-11-26)",https://lens.org/133-390-728-106-385,Granted Patent,yes,5,0,5,5,0,F16H45/02;;F16H2045/0294,F16H45/02,,1,0,,,"PATENT ABSTRACTS OF JAPAN vol. 011, no. 120 (M-580), 15 April 1987 (1987-04-15) & JP 61 262262 A (DAIKIN MFG CO LTD), 20 November 1986 (1986-11-20) & JP 61 262262 A (DAIKIN) 20 November 1986 (1986-11-20)",EXPIRED
333,US,A,US 1400354 A,166-481-767-166-189,1921-12-13,1921,US 36691420 A,1920-03-18,US 36691420 A,1920-03-18,Electric heating-plug,,FRASER JOHN W,FRASER JOHN W,,https://lens.org/166-481-767-166-189,Granted Patent,no,0,2,1,1,0,H05B3/00;;H05B3/00,H05B3/00,,0,0,,,,EXPIRED
334,AU,A1,AU 2023/201771 A1,147-083-645-033-289,2023-04-20,2023,AU 2023/201771 A,2023-03-22,AU 2023/201771 A;;AU 2021/200165 A;;AU 2018/282421 A;;AU 2017/201635 A;;AU 2013/202590 A;;AU 2011/204924 A,2011-07-21,"Method, apparatus and system for parking overstay detection","METHOD, APPARATUS AND SYSTEM FOR PARKING OVERSTAY Methods, apparatuses and systems for identifying overstay of a vehicle (624, 644) in a parking space (610, 620, 630, 640, 650, 660) are disclosed herein. The method comprises the steps of detecting presence of a vehicle in a parking space using a detection apparatus (612, 622, 632, 642, 652, 662), processing and storing data relating to presence of the vehicle in the detection apparatus, determining whether the vehicle has overstayed a defined time duration in the parking space; and wirelessly transmitting data relating to identified instances of overstay of the vehicle in the parking space.",VEHICLE MONITORING SYSTEMS PTY LTD,WELCH FRASER JOHN,,https://lens.org/147-083-645-033-289,Patent Application,no,0,0,8,8,0,,G08G1/14,,0,0,,,,DISCONTINUED
335,US,A1,US 2002/0045823 A1,163-031-621-331-826,2002-04-18,2002,US 90899601 A,2001-07-18,US 90899601 A;;US 64587200 A,2000-08-24,ULTRASONIC DIAGNOSTIC IMAGING SYSTEM WITH DYNAMIC MICROBEAMFORMING,"
   An ultrasonic imaging method and apparatus are described for imaging the coronary arteries of the heart. The vascular system is infused with an ultrasonic contrast agent. A volumetric region of the heart wall including a coronary artery is three dimensionally scanned. A projection image of the volumetric region is produced from the scanning, providing a two dimensional contrast image of the coronary artery with the appearance of an angiogram. Preferably the coronary artery signals are segmented from contrast signals emanating from the myocardium and the heart blood pool so that the coronary arteries are clearly highlighted and distinct in the ultrasonic angiogram. 
",FRASER JOHN D.,FRASER JOHN D,,https://lens.org/163-031-621-331-826,Patent Application,yes,0,12,28,46,0,A61B8/06;;A61B8/0883;;A61B8/0891;;A61B8/4472;;A61B8/481;;A61B8/483;;A61B8/543;;G01S7/52074;;G01S7/52095;;G01S15/8963;;G01S15/8979;;G01S15/8993;;G10K11/341;;Y10S128/916;;G01S7/52025;;G01S7/5208;;G01S15/8918;;G01S15/8925;;G01S15/894;;A61B8/483;;G01S7/52025;;G01S7/5208;;G01S7/52095;;G01S15/8963;;G01S15/8979;;G01S15/8993;;G10K11/346;;A61B8/483;;A61B8/481;;G01S15/8963;;A61B8/543;;A61B8/0883;;G01S7/52095;;A61B8/06;;G01S7/52074;;G01S15/8993;;A61B8/0891;;G01S15/8979;;A61B8/4472;;G10K11/341;;Y10S128/916;;G01S15/8925;;G01S15/8918;;G01S7/52025;;G01S15/894;;G01S7/5208,A61B8/06;;G01S7/52;;G01S15/89;;G06T1/00;;G10K11/34,600/443;;600/459,0,0,,,,EXPIRED
336,US,A1,US 2006/0246067 A1,176-923-959-402-551,2006-11-02,2006,US 51681305 A,2005-07-05,NZ 51937102 A;;NZ 0300111 W,2002-06-04,Immunomodulatory constructs and their uses,"The invention relates to immunomodulators. In particular the invention relates to specific immunomodulators based on the superantigen SMEZ-2 and more particularly based on mutants of the superantigen SMEZ-2, which are adapted to target antigen-presenting-cells for the purpose of enhancing or suppressing a host immune response.",FRASER JOHN D,FRASER JOHN D,AUCKLAND UNISERVICES LIMITED (2005-03-14),https://lens.org/176-923-959-402-551,Patent Application,yes,19,7,14,14,13,A61K39/092;;A61K39/385;;A61K2039/6037;;C07K14/315;;A61P37/02;;C07K14/315;;A61K39/092;;A61K2039/6037;;A61K39/385,A61K39/395;;C12N15/09;;A61K39/00;;A61K39/09;;A61K39/385;;A61K39/39;;C07H21/04;;C07K14/315;;C07K14/74;;C07K19/00;;C12N15/31;;C12P21/06,424/144.1;;424/184.1;;435/69.1;;435/320.1;;435/325;;530/350;;536/23.5,0,0,,,,EXPIRED
337,WO,A3,WO 2012/127360 A3,027-003-020-556-131,2013-04-25,2013,IB 2012051173 W,2012-03-13,US 201161466172 P,2011-03-22,ULTRASONIC CMUT WITH SUPPRESSED ACOUSTIC COUPLING TO THE SUBSTRATE,An array of cMUT cells are formed on individually isolated massive plates on a substrate. The mass of each plate provides an inertial force in opposition to the force and motion of transmission by the cell which reduces the resultant translation of motion in the plate. The reduction in motion results in less coupling of acoustic energy into the substrate and contamination of the signals of adjacent cMUT cells by lateral waves. The unwanted wave coupling into the substrate can be further damped by compliant or sparse periodic mounting of the massive plates on the substrate.,KONINKL PHILIPS ELECTRONICS NV;;FRASER JOHN DOUGLAS,FRASER JOHN DOUGLAS,,https://lens.org/027-003-020-556-131,Search Report,yes,5,0,12,12,0,G01H11/06;;B06B1/0292;;G10K11/002;;G01H11/06;;B06B1/0292;;G10K11/002;;A61B8/4494,B06B1/02;;G10K11/00,,0,0,,,,PENDING
338,FR,A1,FR 2498590 A1,046-956-228-494-592,1982-07-30,1982,FR 8201061 A,1982-01-25,US 22819581 A,1981-01-26,ARTICLES COMPOSITES RENFORCES PAR DES MACROFILAMENTS DE VERRE OU DE VITROCERAMIQUE,"<P>L'INVENTION SE RAPPORTE AUX MATIERES COMPOSITES.</P><P>ELLE CONCERNE UN ARTICLE COMPOSITE COMPRENANT UNE PHASE DE MATRICE ET UNE PHASE RENFORCANTE AYANT UN RAPPORT D'ASPECT ELEVE, CARACTERISE EN CE QUE LA PHASE RENFORCANTE D'UN RAPPORT D'ASPECT ELEVE EST CONSTITUEE D'ELEMENTS ALLONGES PRECONTRAINTS MULTIPLES, EN VERRE OU EN VITROCERAMIQUE, AYANT UNE EPAISSEUR MINIMALE DANS LA GAMME D'ENVIRON 0,025 A 2,54CM, UN RAPPORT DE L'EPAISSEUR MINIMALE A LA LONGUEUR D'AU MOINS ENVIRON 10:1 ET DES COUCHES DE SURFACE CONTRAINTES EN COMPRESSION DONNANT A CHACUN DES ELEMENTS UN MODULE DE RUPTURE PAR FLEXION APRES ABRASION D'AU MOINS 700MPA.</P><P>APPLICATION A LA FABRICATION DE STRUCTURES PORTEUSES MASSIVES TELLES QUE POUTRES, CABLES, COLONNES, ETC.</P>",CORNING GLASS WORKS,MACDOWELL JOHN FRASER,,https://lens.org/046-956-228-494-592,Patent Application,no,4,0,10,10,0,C04B14/42;;C04B14/42;;C08J5/08;;C08J5/08;;E04C5/07;;E04C5/07;;Y10T428/249932;;Y10T428/249932;;Y10T428/24994;;Y10T428/24994;;Y10T428/268;;Y10T428/268;;Y10T428/2964;;Y10T428/2964;;Y10T428/298;;Y10T428/298;;Y10T428/315;;Y10T428/315;;Y10T428/31507;;Y10T428/31507;;Y10T428/31525;;Y10T428/31525;;Y10T428/31601;;Y10T428/31601;;Y10T428/31612;;Y10T428/31612;;Y10T428/31627;;Y10T428/31627;;Y10T428/31645;;Y10T428/31645,C03C21/00;;C03C25/00;;C04B14/42;;C08J5/08;;E04C5/07,,0,0,,,,DISCONTINUED
339,US,B1,US 10390642 B1,048-592-791-583-779,2019-08-27,2019,US 201816021452 A,2018-06-28,US 201816021452 A,2018-06-28,Knife holder and display,"A holder and display device includes three rectangular rigid panels, and a knife receiving structure formed on an inner surface of one of the rigid panels. A flexible sheet is attached to each of the rigid panels such that the flexible sheet hingably connects the rigid panels together, whereby the three panels may hinge with respect to each other via the flexible sheet between a closed configuration and a display configuration.",FRASER MATTHEW JOHN,FRASER MATTHEW JOHN,,https://lens.org/048-592-791-583-779,Granted Patent,yes,14,0,1,1,0,A47G21/14;;A47G21/14;;A47F5/108;;A47F7/00;;B65D61/02;;B65D73/0078,A47G21/14;;A47F5/10;;A47F7/00;;B65D73/00,,0,0,,,,INACTIVE
340,US,A,US 2757816 A,057-552-589-960-059,1956-08-07,1956,US 35402753 A,1953-05-11,US 35402753 A,1953-05-11,Bottle stopper,,ALDEN FRASER JOHN,ALDEN FRASER JOHN,,https://lens.org/057-552-589-960-059,Granted Patent,no,5,8,1,1,0,B65D39/04;;B65D39/04,B65D39/04,,0,0,,,,EXPIRED
341,US,A,US 3517546 A,072-311-479-312-663,1970-06-30,1970,US 3517546D A,1968-05-06,US 72689568 A,1968-05-06,DETECTOR CONFIGURATION FOR THE ULTRASONIC LEAK DETECTOR,,SHELL OIL CO,FRASER JOHN P,,https://lens.org/072-311-479-312-663,Granted Patent,no,6,11,1,1,0,G01M3/246;;G01N29/14;;G01M3/246;;G01N29/14,G01M3/24;;G01N29/14,73/40.5,0,0,,,,EXPIRED
342,CN,A,CN 103501922 A,128-639-183-491-120,2014-01-08,2014,CN 201280014348 A,2012-03-13,IB 2012051173 W;;US 201161466172 P,2011-03-22,Ultrasonic cmut with suppressed acoustic coupling to the substrate,An array of cMUT cells are formed on individually isolated massive plates on a substrate. The mass of each plate provides an inertial force in opposition to the force and motion of transmission by the cell which reduces the resultant translation of motion in the plate. The reduction in motion results in less coupling of acoustic energy into the substrate and contamination of the signals of adjacent cMUT cells by lateral waves. The unwanted wave coupling into the substrate can be further damped by compliant or sparse periodic mounting of the massive plates on the substrate.,KONINKL PHILIPS ELECTRONICS NV,FRASER JOHN DOUGLAS,,https://lens.org/128-639-183-491-120,Patent Application,no,6,3,12,12,0,G01H11/06;;B06B1/0292;;G10K11/002;;G01H11/06;;B06B1/0292;;G10K11/002;;A61B8/4494,B06B1/02;;G10K11/00,,0,0,,,,ACTIVE
343,AU,A1,AU 2017/201635 A1,147-037-862-920-514,2017-03-30,2017,AU 2017/201635 A,2017-03-09,AU 2017/201635 A;;AU 2013/202590 A;;AU 2011/204924 A,2011-07-21,"Method, apparatus and system for parking overstay detection","METHOD, APPARATUS AND SYSTEM FOR PARKING OVERSTAY Methods, apparatuses and systems for identifying overstay of a vehicle (624, 644) in a parking space (610, 620, 630, 640, 650, 660) are disclosed herein. The method comprises the steps of detecting presence of a vehicle in a parking space using a detection apparatus (612, 622, 632, 642, 652, 662), processing and storing data relating to presence of the vehicle in the detection apparatus, determining whether the vehicle has overstayed a defined time duration in the parking space; and wirelessly transmitting data relating to identified instances of overstay of the vehicle in the parking space.",VEHICLE MONITORING SYSTEMS PTY LTD,WELCH FRASER JOHN,,https://lens.org/147-037-862-920-514,Patent Application,no,0,0,8,8,0,,G08G1/14,,0,0,,,,DISCONTINUED
344,US,B2,US 8513022 B2,138-739-360-811-617,2013-08-20,2013,US 80863408 A,2008-12-18,AU 2007/906997 A;;AU 2008/001864 W,2007-12-20,Analytical method and apparatus,"A method for determining the amount of a chemical species in a sample, in particular the amount of weak acid dissociable cyanide or total cyanide in a sample, and an apparatus for performing said method. The method comprises the steps of: i) treating the sample to liberate the chemical species into a gaseous stream; ii) directing the gaseous stream to a scrubber; iii) absorbing the chemical species into a scrubber solution; and iv) determining the amount of chemical species absorbed into the scrubber solution, wherein any remaining chemical species not absorbed into the scrubber solution is directed or recirculated to the scrubber in the gaseous stream and step iii) is repeated to increase absorption of the chemical species prior to performing step iv).",ROSS FRASER JOHN;;CYANTIFIC INSTR PTY LTD,ROSS FRASER JOHN,ORICA AUSTRALIA PTY LTD (2013-04-26);;CYANTIFIC INSTRUMENTS PTY LTD (2008-12-08),https://lens.org/138-739-360-811-617,Granted Patent,yes,27,0,5,5,0,G01N1/4055;;G01N31/16;;G01N2001/4066;;Y10T436/175383;;Y10T436/172307;;Y10T436/25;;Y10T436/173845;;Y10T436/17;;Y10T436/201666;;Y10T436/174614;;Y10T436/255;;Y10T436/25875;;Y10T436/25375;;Y10T436/175383;;Y10T436/172307;;Y10T436/25;;Y10T436/173845;;Y10T436/17;;Y10T436/201666;;Y10T436/174614;;Y10T436/255;;Y10T436/25875;;Y10T436/25375;;G01N31/16;;G01N1/4055;;G01N2001/4066,G01N30/08;;G01N1/40;;G01N21/01;;G01N30/34;;G01N33/00,436/109;;422/68.1;;422/81;;422/82.09;;422/83;;422/88;;422/91;;436/106;;436/111;;436/112;;436/113;;436/129;;436/164;;436/167;;436/174;;436/177;;436/178;;436/181,25,18,029-491-350-815-94X;;000-006-034-826-431;;022-673-109-559-022;;115-436-934-937-196;;092-497-728-571-345;;005-007-942-769-926;;004-945-668-075-01X;;026-521-896-408-292;;082-645-928-088-787;;064-484-708-391-066;;056-310-137-798-494;;004-005-812-534-461;;089-767-067-701-403;;082-492-290-358-623;;178-619-077-344-800;;124-545-625-967-518;;021-866-384-264-119;;093-718-471-028-410,10.1021/ac60095a029;;5084780;;10.1021/ac50011a024;;10.1021/ac00232a040;;10.1021/es960016i;;12542298;;10.1021/es0258273;;15363536;;10.1016/j.jhazmat.2004.06.029;;16506799;;10.1021/jf052061s;;10.1016/j.talanta.2006.06.010;;19071417;;10.1039/an9638800751;;10.1520/jfs10005j;;4781749;;10.1021/bk-1992-0508.ch006;;10.1016/0021-9673(93)80077-l;;10.1016/0003-2670(95)00247-w;;10.1007/s002160051153;;10.1016/j.hydromet.2005.01.002;;15607585;;10.1016/j.forsciint.2004.03.032;;10.1002/cjce.5450610605,"Ludzack F. J. et al, Analytical Chemistry 1954, 26, 1784-1792.;;Goulden, P. D. et al, Analytical Chemistry 1972, 44, 1845-1849.;;Broderius, S. J. et al, Analytical Chemistry 1977, 49, 424-428.;;Broderius, S. J., Analytical Chemistry 1981, 53, 1472-1477.;;Sebroski, J. R. et al, Environmental Science and Technology 1997, 31, 52-57.;;Zheng, A. et al, Environmental Science and Technology 2003, 37, 107-115.;;Gonen, N. et al, Journal of Hazardous Materials 2004, B113, 231-236.;;Chou, P.-Y. et al, Journal of Agricultural and Food Chemistry 2006, 54, 1551-1556.;;Hassan, S. S. M. et al, Talanta 2007, 71, 1088-1095.;;Bark, L. S. et al, Analyst 1963, 88, 751-760.;;Shanahan, R., Journal of Forensic Science 1973, 18, 25-30.;;Fleming, S. W. et al, ""On-Line Analyzer for Chlorocarbons in Wastewater"" in Pollution Prevention in Industrial Processes, Chapter 6, ACS Symposium Series, Breen, J. et al. ed., 1992, vol. 508, pp. 48-61.;;Lesage, S., Journal of Chromatography 1993, 642, 65-74.;;Kolodsick, K. et al, Analytica Chimica Acta 1995, 313, 75-82.;;Aguilar, M. et al, Fresenius Journal of Analytical Chemistry 1999, 363, 121-123.;;Method 9010C ""Total and Amenable Cyanide: Distillation"" Revision 3, Nov. 2004, 10 pages.;;Vapur, H. et al, Hydrometallurgy 2005, 77, 279-286.;;Lv, J. et al, Forensic Science International 2005, 148, 15-19.;;Vapur, H. et al, Minerals Engineering 2007, 20, 729-737.;;Avedesian, M. M. et al, Canadian Journal of Chemical Engineering 1983, 61, 801-806.;;Engineeringnews.co.za (Nov. 3, 2006) ""Mintek-developed instrument measures WAD cyanide on line""; Website [Online] Available Web Site: http://www.engineeringnews.co.za/print-version/mintekdeveloped-instrument-measures-wad-cyanide-on-line-2006-11-03; Last Update: Nov. 18, 2010; Accessed on Nov. 18, 2010.;;OI Analytical, (May 8, 2007) ""CNSolution(TM) Automated Cyanide Analyzer""; Available Web Site: http://www.oico.com/default.aspx?id=product&productID=94; Last update: Nov. 18, 2010; Accessed on: Nov. 18, 2010.;;Process Analytical Systems, (Jan. 20, 2005) ""WAD 1000 On-Line WAD Cyanide Analyser""; Available Web Site: http://www.process-anatytical.co.za/prod05.htm; Last update: Nov. 27, 2008; Accessed on: Nov. 18, 2010.;;CyanideCode.org (May 3, 2006) Cyanide Facts: Sampling and Analysis of Cyanide in Gold Mining Operations; Website [Online] Available Web Site: http://www.cyanidecode.org/cyanide-sampling.php; Last Update: Feb. 2, 2007; Accessed on Aug. 9, 2010.;;ICM Code (Sep. 2006) International Cyanide Management Institute, The International Cyanide Management Code.",INACTIVE
345,CA,C,CA 2086062 C,157-745-673-836-241,2004-03-23,2004,CA 2086062 A,1992-12-22,GB 9224317 A,1992-11-20,BLOW-MOLDED LID FOR RIBBED CUPS,"A blow-molded lid is provided for closing a cup which has a circular to p edge and a rib projecting outwardly from the top edge. The lid includes an outwardly projecting bead which in axial section curves downwardly and inwardly to a radius smaller than the maximum radius of the rib. The bead thus define s an inwardly concave groove adapted to snap over the rib. The lid incorporates a strengthening configuration closely upwardly adjacent to the bead, the strengthening configuration including a step-like formation.",HANSON JOHN FRASER,HANSON JOHN FRASER,,https://lens.org/157-745-673-836-241,Granted Patent,no,0,0,3,3,0,,B65D43/10,,0,0,,,,EXPIRED
346,DE,D1,DE 60324285 D1,153-906-555-466-453,2008-12-04,2008,DE 60324285 T,2003-06-04,NZ 51937102 A;;NZ 0300111 W,2002-06-04,IMMUNMODULATORISCHE KONSTRUKTE UND DEREN VERWENDUNGEN,"The invention relates to immunomodulators. In particular the invention relates to specific immunomodulators based on the superantigen SMEZ-2 and more particularly based on mutants of the superantigen SMEZ-2, which are adapted to target antigen-presenting-cells for the purpose of enhancing or suppressing a host immune response.",AUCKLAND UNISERVICES LTD,FRASER JOHN DAVID,,https://lens.org/153-906-555-466-453,Granted Patent,no,0,0,14,14,0,A61K39/092;;A61K39/385;;A61K2039/6037;;C07K14/315;;A61P37/02;;C07K14/315;;A61K39/092;;A61K2039/6037;;A61K39/385,C07K19/00;;C12N15/09;;A61K35/74;;A61K39/00;;A61K39/09;;A61K39/385;;A61K39/39;;C07H19/00;;C07K14/00;;C07K14/315;;C07K16/12;;C12N1/20;;C12N15/31;;C12Q1/68,,0,0,,,,EXPIRED
347,CA,A,CA 379115 A,172-294-000-336-019,1939-01-24,1939,CA 379115D A,,CA 379115T A,,TRAILER,,KEESHIN MOTOR EXPRESS CO INC,FRASER EDWIN JOHN,,https://lens.org/172-294-000-336-019,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
348,CH,A,CH 452070 A,179-725-903-512-032,1968-05-31,1968,CH 278066 A,1966-02-25,CA 929195 A;;US 50162365 A,1965-04-27,Neutronen-Generator,,CA ATOMIC ENERGY LTD,JOHN S FRASER,,https://lens.org/179-725-903-512-032,Granted Patent,no,0,0,5,5,0,H05H6/00;;H05H6/00,H05H6/00,"21G,21/12",0,0,,,,EXPIRED
349,US,P3,US PP028272 P3,188-640-308-709-053,2017-08-15,2017,US 201514756776 V,2015-10-10,US 201514756776 V,2015-10-10,Coprosma plant named ‘Golden Star’,A new cultivar of Coprosma plant named ‘Golden Star’ that is characterized by a compact habit and variegated yellow leaves with an irregular green center and orange margins.,FRASER PETER JOHN,FRASER PETER JOHN,,https://lens.org/188-640-308-709-053,Plant Patent,yes,0,0,2,2,0,,A01H5/02,PLT 226,1,0,,,"UPOV hit on Coprosma plant named ‘Golden Star’, NZ PBR SHM360, published Oct. 9, 2015.",PENDING
350,EP,A4,EP 2380143 A4,000-650-031-176-266,2012-06-13,2012,EP 09833942 A,2009-12-23,AU 2009/001698 W;;AU 2008/906642 A,2008-12-24,METHOD AND SYSTEM FOR DETECTING VEHICLE OFFENCES,,VEHICLE MONITORING SYSTEMS PTY LTD,WELCH FRASER JOHN,,https://lens.org/000-650-031-176-266,Search Report,no,5,0,7,7,0,G08G1/017;;G08G1/017;;G07B15/063;;G07B15/063;;G08G1/0175;;G08G1/0175;;G08G1/04;;G08G1/04;;G08G1/042;;G08G1/042;;G08G1/148;;G08G1/148,G07C1/10;;G08G1/017;;G08G1/14,,1,0,,,See also references of WO 2010071942A1,DISCONTINUED
351,DE,T2,DE 60012379 T2,009-764-069-341-629,2004-12-09,2004,DE 60012379 T,2000-01-17,US 23798399 A,1999-01-25,Momentwandler mit einer Überbrückungskupplung mit einem federbelasteten Kolben,,LAWRENCE TECHNOLOGICAL UNIVERS,MACDONALD FRASER JOHN,,https://lens.org/009-764-069-341-629,Granted Patent,no,0,2,6,6,0,F16H45/02;;F16H2045/0278;;F16H2045/0289;;F16H45/02;;F16H2045/0278;;F16H2045/0289,F16H45/02,,0,0,,,,EXPIRED
352,US,A,US 2349087 A,021-016-613-611-153,1944-05-16,1944,US 46587842 A,1942-11-17,US 46587842 A,1942-11-17,Work clamp,,HARTLEY FRASER JOHN,HARTLEY FRASER JOHN,,https://lens.org/021-016-613-611-153,Granted Patent,no,0,12,1,1,0,B25B5/106;;Y10T409/309016;;Y10T409/309016;;B25B5/106,B25B5/10,,0,0,,,,EXPIRED
353,US,A,US 1040923 A,018-584-095-899-077,1912-10-08,1912,US 1912/0693368 A,1912-04-26,US 1912/0693368 A,1912-04-26,ELECTROPLATING APPLIANCE.,,FRASER JOHN A,FRASER JOHN A,,https://lens.org/018-584-095-899-077,Granted Patent,no,0,0,1,1,0,C25D17/06;;C25B9/65;;C25D17/06;;C25B9/65,,,0,0,,,,EXPIRED
354,GB,A,GB 190123333 A,084-154-191-203-547,1902-10-16,1902,GB 190123333D A,1901-11-18,GB 190123333T A,1901-11-18,Improvements in Steam Boilers or Generators,"23,333. Fraser, H. J. Nov. 18. Multitubular boilers for motor cars &c. A central firebox or combustion chamber b is connected by horizontal tubes d with a smoke-box at each end, whence return flues f pass to an uptake g<1>, which, in the arrangement shown in Fig. 1, opens directly from the firebox, but may be cut-off therefrom by a sliding damper h in one of the flues f. Figs. 3 and 5 show another arrangement, with curved flue tubes f opening into an uptake which has no direct connection with the firebox. The fire may burn on a conical grate 1, Fig. 1, within the firebox, or on an ordinary grate in a downward extension, part of which is shown in Figs. 3 and 5, and which may be brick-lined or water-jacketed. In the former case, the fire is fed from above through door j, Fig. 1, and in the latter through an opening n, Fig. 5, in the side of the combustion chamber b. The steam is superheated in coils p, Fig. 1, in the smoke-boxes, or in a dome p, Figs. 3 and 5, in the uptake. Steam jets may be delivered at q into the flues f to increase the draught.",FRASER HARRY JOHN,FRASER HARRY JOHN,,https://lens.org/084-154-191-203-547,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
355,WO,A3,WO 2001/097562 A3,115-925-086-340-764,2002-04-18,2002,EP 0106479 W,2001-06-08,US 59675900 A,2000-06-15,CAPACITIVE MICROMACHINED ULTRASONIC TRANSDUCERS,"An ultrasonic transducer is formed by a plurality of cMUT cells (10), each comprising a charged diaphragm plate (14) capacitively opposing an oppositely charged base plate (12). The diaphragm plate (14) is distended toward the base plate (12) by a bias charge. The base plate (12) includes a central portion (28) elevated toward the center of the diaphragm plate (14) to cause the charge of the cell to be of maximum density at the moving center of the diaphragm plate (14). For harmonic operation the drive pulses applied to the cells (10) are predistorted in consideration of the nonlinear operation of the device to reduce contamination of the transmit signal at the harmonic band. The cMUT cells (10) can be fabricated by conventional semiconductor processes and hence integrated with ancillary transducer circuitry such as a bias charge regulator (30). The cMUT cells (10) can also be fabricated by micro-stereolithography whereby the cells (10) can be formed using a variety of polymers and other materials.",KONINKL PHILIPS ELECTRONICS NV,FRASER JOHN D,,https://lens.org/115-925-086-340-764,Search Report,yes,4,0,12,16,0,B06B1/0292;;B33Y80/00;;B33Y10/00;;B33Y80/00;;B33Y10/00;;B06B1/0292,A61B8/00;;B06B1/02;;B81B3/00;;H04R19/00,,0,0,,,,PENDING
356,CA,A1,CA 2748440 A1,123-696-869-439-756,2010-07-08,2010,CA 2748440 A,2009-12-09,US 14133008 P;;IB 2009055611 W,2008-12-30,"ULTRASONIC TEETH CLEANING APPLIANCE HAVING SPATIAL, TEMPORAL AND/OR FREQUENCY VARIATIONS","The appliance includes an appliance body (12) as well as a system for producing microbubbles (20) and a system for producing an ultrasound signal beam (22) in a frequency range which activates at least some of the microbubbles. The appliance includes at least one of the following: (a) an array of ultrasound transducer elements (40) which produce a plurality of ultrasound signal beams; (b) an amplitude modulation assembly (51) for modulating the amplitude of the ultrasound signal; and (c) a frequency modulation system (61) for changing the frequency of the ultrasound signals over a selected range, to impact a range of microbubble sizes.",KONINKL PHILIPS ELECTRONICS NV,FRASER JOHN DOUGLAS,,https://lens.org/123-696-869-439-756,Patent Application,no,0,0,16,16,0,A61C17/20;;A61C17/20,A61C17/20,,0,0,,,,INACTIVE
357,WO,A1,WO 2009/079689 A1,182-725-532-972-58X,2009-07-02,2009,AU 2008/001864 W,2008-12-18,AU 2007/906997 A,2007-12-20,ANALYTICAL METHOD AND APPARATUS,"A method for determining the amount of a chemical species in a sample, in particular the amount of weak acid dissociable cyanide or total cyanide in a sample, and an apparatus for performing said method. The method comprises the steps of: i) treating the sample to liberate the chemical species into a gaseous stream; ii) directing the gaseous stream to a scrubber; iii) absorbing the chemical species into a scrubber solution; and iv) determining the amount of chemical species absorbed into the scrubber solution, wherein any remaining chemical species not absorbed into the scrubber solution is directed or recirculated to the scrubber in the gaseous stream and step iii) is repeated to increase absorption of the chemical species prior to performing step iv).",CYANTIFIC INSTR PTY LTD;;ROSS FRASER JOHN,ROSS FRASER JOHN,,https://lens.org/182-725-532-972-58X,Patent Application,yes,5,1,5,5,0,G01N1/4055;;G01N31/16;;G01N2001/4066;;Y10T436/175383;;Y10T436/172307;;Y10T436/25;;Y10T436/173845;;Y10T436/17;;Y10T436/201666;;Y10T436/174614;;Y10T436/255;;Y10T436/25875;;Y10T436/25375;;Y10T436/175383;;Y10T436/172307;;Y10T436/25;;Y10T436/173845;;Y10T436/17;;Y10T436/201666;;Y10T436/174614;;Y10T436/255;;Y10T436/25875;;Y10T436/25375;;G01N31/16;;G01N1/4055;;G01N2001/4066,G01N33/18;;G01N31/16,,0,0,,,,PENDING
358,US,A,US 1671362 A,193-459-861-547-63X,1928-05-29,1928,US 16790327 A,1927-02-14,US 16790327 A,1927-02-14,Window construction,,KAWNEER CO,FRASER JOHN A,,https://lens.org/193-459-861-547-63X,Granted Patent,no,0,11,1,1,0,E06B3/5009;;E06B3/5009;;E05Y2800/10;;E05Y2800/10;;E05Y2800/744;;E05Y2800/744;;E06B3/50;;E06B3/50,E06B3/50,,0,0,,,,EXPIRED
359,GB,B,GB 2393743 B,018-747-654-798-779,2006-03-08,2006,GB 0223026 A,2002-10-03,GB 0223026 A,2002-10-03,Pumpable sub,,FRASER JOHN PAUL;;FRASER JAMES ANTON,FRASER JOHN PAUL;;FRASER JAMES ANTON,"FRASER, JAMES A (2004-01-14)",https://lens.org/018-747-654-798-779,Granted Patent,no,3,0,3,3,0,E21B37/04;;E21B23/10,E21B37/04;;E21B23/10,E1F FLC           FLC,0,0,,,,EXPIRED
360,US,B1,US 6328697 B1,011-617-211-378-118,2001-12-11,2001,US 69823200 A,2000-10-27,US 69823200 A;;US 59675900 A,2000-06-15,Capacitive micromachined ultrasonic transducers with improved capacitive response,"An ultrasonic transducer is formed by a plurality of cMUT cells, each has a charged diaphragm plate capacitively opposing an oppositely charged base plate. The diaphragm plate is distended toward the base plate by a bias charge. The base plate includes a central portion elevated toward the center of the diaphragm plate to cause the charge of the cell to be of maximum density at the moving center of the diaphragm plate.",ATL ULTRASOUND INC,FRASER JOHN DOUGLAS,,https://lens.org/011-617-211-378-118,Granted Patent,yes,4,111,12,16,0,B06B1/0292;;B33Y80/00;;B33Y10/00;;B33Y80/00;;B33Y10/00;;B06B1/0292,B81B3/00;;A61B8/00;;B06B1/02;;H04R19/00,600/459;;367/118;;310/138,0,0,,,,EXPIRED
361,US,B1,US 6384516 B1,008-627-089-246-699,2002-05-07,2002,US 48858300 A,2000-01-21,US 48858300 A,2000-01-21,Hex packed two dimensional ultrasonic transducer arrays,"
    A two dimensional ultrasonic transducer array suitable for three dimensional phased array scanning is formed of hexagonally close packed transducer elements. In a preferred embodiment the transducer elements have a rectilinear shape, allowing the array to be fabricated with conventional dicing saw processes. 
",ATL ULTRASOUND INC,FRASER JOHN DOUGLAS,ATL ULTRASOUND INC (2000-01-19),https://lens.org/008-627-089-246-699,Granted Patent,yes,23,73,6,6,0,B06B1/0622;;B06B1/0622,G01N29/24;;A61B8/00;;B06B1/06;;H04R17/00,310/334,4,3,029-149-071-016-455;;029-149-071-016-455;;076-783-249-506-244,10.1109/ultsym.1994.401882;;10.1109/ultsym.1994.401882;;10.1109/ultsym.1996.584367,"Fatemi et al., ""Application of Hexagonal Arrays in Generation and Steering of Limited Diffraction Beams,"" pp. 1531-1534, 1994 IEEE Ultrasonic Symposium.;;Fatemi, M. et al., ""Efficient Generation of Limited Diffraction Beams by Hexagonal Arrays,"" Biomedical Engineering Dept., Amirkabir University, Tehran, Iran, Ultrasonic Imaging, vol. 16, No. 1, Jan. 1994, p. 53.;;Fatemi, M., et al., ""Application of Hexagonal Arrays in Generation and Steering of Limited Difraction Beams,"" IEEE, 1994 Ultrasonic Symposium, pp. 1531-1534 Dec. 1994.;;Mills et al., ""Combining Multi-Layers and Composites to Increase SNR for Medical Ultrasound Transducers,"" at pp. 1509-1512, IEEE Ultrasonics Symposium Jan. 1996.",EXPIRED
362,AU,B2,AU 2005/243110 B2,019-609-356-827-923,2007-11-29,2007,AU 2005/243110 A,2005-05-09,AU 2004/902622 A;;AU 2005/000660 W;;AU 2005/243110 A,2004-05-17,"Method, apparatus and system for parking overstay detection",,VEHICLE MONITORING SYSTEMS PTY LTD,WELCH FRASER JOHN,,https://lens.org/019-609-356-827-923,Granted Patent,no,2,0,3,15,0,,G08G1/14,,0,0,,,,INACTIVE
363,CA,A,CA 531664 A,051-467-368-628-605,1956-10-16,1956,CA 531664D A,,CA 531664T A,,BOTTLE STOPPER,,FRASER JOHN A,FRASER JOHN A,,https://lens.org/051-467-368-628-605,Granted Patent,no,0,2,1,1,0,,,,0,0,,,,EXPIRED
364,AU,B2,AU 2003/238740 B2,102-617-267-696-210,2009-04-09,2009,AU 2003/238740 A,2003-06-04,NZ 51937102 A;;NZ 0300111 W,2002-06-04,Immunomodulatory constructs and their uses,"The invention relates to immunomodulators. In particular the invention relates to specific immunomodulators based on the superantigen SMEZ-2 and more particularly based on mutants of the superantigen SMEZ-2, which are adapted to target antigen-presenting-cells for the purpose of enhancing or suppressing a host immune response.",AUCKLAND UNISERVICES LTD,FRASER JOHN DAVID,,https://lens.org/102-617-267-696-210,Granted Patent,no,1,0,14,14,0,A61K39/092;;A61K39/385;;A61K2039/6037;;C07K14/315;;A61P37/02;;C07K14/315;;A61K39/092;;A61K2039/6037;;A61K39/385,C12N15/09;;A61K39/00;;A61K39/09;;A61K39/385;;A61K39/39;;C07K14/315;;C07K19/00;;C12N15/31,,0,0,,,,EXPIRED
365,EP,A1,EP 2384162 A1,089-279-230-242-102,2011-11-09,2011,EP 09801785 A,2009-12-09,IB 2009055611 W;;US 14133008 P,2008-12-30,"ULTRASONIC TEETH CLEANING APPLIANCE HAVING SPATIAL, TEMPORAL AND/OR FREQUENCY VARIATIONS",,KONINKL PHILIPS ELECTRONICS NV,FRASER JOHN DOUGLAS,KONINKLIJKE PHILIPS N.V. (2013-09-25),https://lens.org/089-279-230-242-102,Patent Application,yes,0,0,16,16,0,A61C17/20;;A61C17/20,A61C17/20,,1,0,,,See references of WO 2010076705A1,ACTIVE
366,WO,A1,WO 1993/013339 A1,103-683-898-037-299,1993-07-08,1993,EP 9202480 W,1992-10-30,US 81209291 A,1991-12-23,SLIPPING BYPASS CLUTCH FOR HYDROKINETIC TORQUE CONVERTER,"A hydrokinetic torque converter includes an impeller cover (14) and a bypass clutch located within the impeller cover (14). The impeller cover (14) has welded to it a clutch plate (70), which is connected by a splined connection (68) to a clutch piston (60) rotatably supported on a turbine rotor (26). A drive ring (74) carries friction surfaces (80) adjacent the clutch piston (60) and clutch plate (74). The drive ring (74) extends axially into engagement with a helical spring (102) carried in a damper assembly (100, 102) arranged in series with the damper between the impeller cover (14) and the input shaft of the transmission.",FORD WERKE AG;;FORD FRANCE;;FORD MOTOR CO;;FORD MOTOR CO,MACDONALD FRASER JOHN,,https://lens.org/103-683-898-037-299,Patent Application,yes,4,30,7,7,0,F16H45/02;;F16H45/02;;F16H2045/0278;;F16H2045/0278;;F16H2045/0289;;F16H2045/0289,F16H45/02,,0,0,,,,PATENTED
367,EP,A1,EP 0617774 A1,122-767-586-771-774,1994-10-05,1994,EP 92923237 A,1992-10-30,EP 9202480 W;;US 81209291 A,1991-12-23,SLIPPING BYPASS CLUTCH FOR HYDROKINETIC TORQUE CONVERTER.,"Convertisseur de couple hydrocinétique comprenant un couvercle de pompe à hélice (14) ainsi qu'un accouplement de dérivation à friction situé à l'intérieur dudit couvercle de pompe (14). Un disque d'embrayage (70) est soudé à ce dernier et est relié à l'aide d'une liaison cannelée (68) à un piston d'embrayage (60) monté rotatif sur un rotor de turbine (26). Un anneau d'entraînement (74) comporte des surfaces de frottement (80) adjacentes au piston d'embrayage (60) et un disque d'embrayage (74). L'anneau d'entraînement (74) s'étend axialement de façon à venir en contact avec un ressort hélicoïdal (102) situé dans un ensemble amortisseur (100, 102) agencé en série, l'amortisseur étant placé entre le couvercle de pompe (14) et l'arbre primaire de transmission.",FORD WERKE AG;;FORD FRANCE;;FORD MOTOR CO,MACDONALD FRASER JOHN,,https://lens.org/122-767-586-771-774,Patent Application,yes,0,0,7,7,0,F16H45/02;;F16H45/02;;F16H2045/0278;;F16H2045/0278;;F16H2045/0289;;F16H2045/0289,F16H45/02,,1,0,,,See references of WO 9313339A1,EXPIRED
368,CA,C,CA 2567464 C,150-388-894-958-034,2016-06-28,2016,CA 2567464 A,2005-05-09,AU 2004/902622 A;;AU 2005/000660 W,2004-05-17,"METHOD, APPARATUS AND SYSTEM FOR PARKING OVERSTAY DETECTION","Methods, apparatuses and systems for identifying overstay of a vehicle (624, 644) in a parking space (610, 620, 630, 640, 650, 660) are disclosed herein. The method comprises the steps of detecting the presence of the vehicle in a parking space using a detection apparatus (612, 622, 632, 642, 652, 662), processing and storing data relating to the presence of vehicle in the detection apparatus, wirelessly (672, 674) waking-up the detection apparatus, wirelessly retrieving at least a portion of the data from the detection apparatus, and identifying overstay of the vehicle in the parking space based on the retrieved data. Wireless wake-up of a detection apparatus may be irregularly performed by an occasionally present data collection apparatus (680). Apparatuses and systems are also disclosed for performing the foregoing method.",VEHICLE MONITORING SYSTEMS PTY LTD,WELCH FRASER JOHN,,https://lens.org/150-388-894-958-034,Granted Patent,no,0,0,12,15,0,G07B15/02;;G07F17/246;;G08G1/14;;G08G1/14;;G07F17/246;;G07B15/02,G08G1/14;;B60Q1/48,,0,0,,,,ACTIVE
369,US,P3,US PP029714 P3,149-723-913-205-127,2018-09-25,2018,US 201615530002 V,2016-11-16,US 201615530002 V,2016-11-16,Cordyline plant named ‘Paso Doble’,"A new cultivar of Cordyline plant named ‘Paso Doble’ that is characterized by leaves that are linear in shape, upright and dark red in color with dark pink margins.",FRASER PETER JOHN,FRASER PETER JOHN,,https://lens.org/149-723-913-205-127,Plant Patent,yes,0,0,2,2,0,A01H6/12;;A01H5/12;;A01H5/12;;A01H6/12,A01H6/12;;A01H5/12,PLT 383,0,0,,,,PENDING
370,US,B2,US 10787681 B2,186-680-086-677-482,2020-09-29,2020,US 201715411489 A,2017-01-20,US 201715411489 A;;US 58168409 A;;US 2008/0060654 W;;US 91219307 P,2007-04-17,Humanized viral vectors and methods of use thereof,"The present invention provides humanized viral vectors and methods of use thereof for delivery of transgenes or therapeutic nucleic acids to human subjects. Humanized viral vectors are modified from known viral vectors such as those based on AAV by coating their surface with a human protein such as human serum albumin and optionally a lipid coating or formulation, so that the foreign or non-human nature of the vector is masked. The coating is performed in a manner that reduces or prevents binding of antibodies to the vector surface, thereby reducing or preventing antibody-mediated clearance of vector, but still allowing the vector to transduce target cells and achieve therapeutic gene transfer. Such humanized vectors therefore evade pre-existing immune surveillance, reduce immune responses, and achieve therapeutic gene transfer in the presence of pre-existing antibodies to the viral vector.",CHILDRENS HOSPITAL PHILADELPHIA,WRIGHT JOHN FRASER,THE CHILDREN'S HOSPITAL OF PHILADELPHIA (2010-02-02),https://lens.org/186-680-086-677-482,Granted Patent,yes,7,0,4,4,0,C07K14/765;;C12N15/86;;C12N2750/14143;;C12N2750/14145;;C12N2810/85;;A61K38/4846;;C12N9/644;;C12Y304/21022;;A61P7/00;;C12N15/86;;C12N2750/14143;;C12N2810/85;;C12N2750/14145;;C07K14/765;;A61K48/00;;C12N15/8645;;A61K38/4846;;A61K47/12;;A61K47/42;;C12N7/00;;C12N9/644;;C12Y304/21022,C12N15/85;;A61K38/48;;A61K47/12;;A61K47/42;;A61K48/00;;C07K14/765;;C12N7/00;;C12N9/64;;C12N15/86;;C12N15/864,,8,5,005-294-577-104-33X;;003-201-288-739-680;;055-406-926-990-606;;040-230-796-647-103;;040-230-796-647-103,9813671;;10.1038/sj.gt.3300665;;16612598;;10.1007/s00262-006-0158-2;;10.1073/pnas.94.4.1426;;9037069;;pmc19807;;10.1128/jvi.76.24.12900-12907.2002;;12438615;;pmc136730;;10.1128/jvi.76.24.12900-12907.2002;;12438615;;pmc136730,"Chillon et al., Adenovirus Complexed With Polyethylene Glycol and Cationic Lipid is Shielded From Neutralizing Antibodies in vitro, Gene Ther., 1998, 5:995-1002.;;Cross-link Wikipedia Printout (http://en.wikipedia.org/wiki/Cross-link. pp. 1-6, printed Apr. 23, 2015).;;Crosslink definition—Google search printout (pp. 1-2, printed Apr. 23, 2015).;;Hedley et al., Targeted and Shielded Adenovectors for Cancer Therapy, Cancer Immunol. Immunother., 2006, 55:1412-1419.;;Koeberl et al., Persistent Expression of Human Clotting Factor IX from Mouse Liver After Intravenous Injection of Adeno-Associated Virus Vectors, Proc. Natl. Acad. Sci. USA, 1997, 94(4):1426-31.;;Lee et al., Chapter 20:Albumin Modification in Scaffolding in Tissue Engineering. Ma and Elisseeff (eds.) CRC PressTaylor and Francis Group: Boca Raton, 2006. See pp. 283, 284, 289, and 290.;;Ponnazhagan et al., Conjugate-Based Targeting of Recombinant Adeno-Associated Virus Type 2 Vectors by Using Avidin-Linked Ligands, Journal of Virology, 2002, 76(24):12900-12907.;;Ponnazhagan, Selvarangan, et al. “Conjugate-based targeting of recombinant adeno-associated virus type 2 vectors by using avidin-linked ligands.” Journal of virology 76.24 (2002): 12900-12907.",ACTIVE
371,WO,A3,WO 2001/097559 A3,193-018-729-719-031,2002-04-18,2002,EP 0106868 W,2001-06-15,US 59675900 A;;US 69823200 A,2000-06-15,CAPACITIVE MICROMACHINED ULTRASONIC TRANSDUCERS.,"An ultrasonic transducer is formed by a plurality of cMUT cells (10), each comprising a charged diaphragm plate (14) capacitively opposing an oppositely charged base plate (12). The diaphragm plate (14) is distended toward the base plate (12) by a bias charge. The base plate (12) includes a central portion (28) elevated toward the center of the diaphragm plate (14) to cause the charge of the cell to be of maximum density at the moving center of the diaphragm plate (14). For harmonic operation the drive pulses applied to the cells (10) are predistorted in consideration of the nonlinear operation of the device to reduce contamination of the transmit signal at the harmonic band. The cMUT cells (10) can be fabricated by conventional semiconductor processes and hence integrated with ancillary transducer circuitry such as a bias charge regulator (30). The cMUT cells (10) can also be fabricated by micro-stereolithography whereby the cells (10) can be formed using a variety of polymers and other materials.",KONINKL PHILIPS ELECTRONICS NV,FRASER JOHN D,,https://lens.org/193-018-729-719-031,Search Report,yes,5,0,4,16,0,B06B1/0292;;B33Y80/00;;B33Y80/00;;B06B1/0292,A61B8/12;;B81B3/00;;B06B1/02;;H04R1/02;;H04R7/00;;H04R19/00,,0,0,,,,PENDING
372,US,A,US 1574383 A,023-455-301-056-709,1926-02-23,1926,US 59043822 A,1922-09-25,US 59043822 A,1922-09-25,Motor-vehicle transmission,,DANIEL FRASER JOHN,DANIEL FRASER JOHN,,https://lens.org/023-455-301-056-709,Granted Patent,no,0,7,1,1,0,A01D11/025;;A01D11/025;;B60K17/04;;B60K17/04,A01D11/02;;B60K17/04,,0,0,,,,EXPIRED
373,CA,A,CA 294414 A,023-168-714-802-472,1929-11-05,1929,CA 294414D A,,CA 294414T A,,MOTOR VEHICLE TRANSMISSION,,FRASER JOHN DANIEL,FRASER JOHN DANIEL,,https://lens.org/023-168-714-802-472,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
374,WO,A2,WO 2003/101173 A2,069-643-440-371-968,2003-12-11,2003,NZ 0300111 W,2003-06-04,NZ 51937102 A,2002-06-04,IMMUNOMODULATORY CONSTRUCTS AND THEIR USES,"The invention relates to immunomodulators. In particular the invention relates to specific immunomodulators based on the superantigen SMEZ-2 and more particularly based on mutants of the superantigen SMEZ-2, which are adapted to target antigen-presenting-cells for the purpose of enhancing or suppressing a host immune response.",AUCKLAND UNISERVICES LTD;;FRASER JOHN DAVID,FRASER JOHN DAVID,,https://lens.org/069-643-440-371-968,Patent Application,yes,0,0,14,14,0,A61K39/092;;A61K39/385;;A61K2039/6037;;C07K14/315;;A61P37/02;;C07K14/315;;A61K39/092;;A61K2039/6037;;A61K39/385,C12N15/09;;A61K39/00;;A61K39/09;;A61K39/385;;A61K39/39;;C07K14/315;;C07K19/00;;C12N15/31,,0,0,,,,PENDING
375,US,A,US 1071150 A,068-468-489-357-241,1913-08-26,1913,US 1911/0637571 A,1911-07-08,US 1911/0637571 A,1911-07-08,PRINTER'S FURNITURE.,,FRANK W VAWTER,FRASER JOHN A,,https://lens.org/068-468-489-357-241,Granted Patent,no,0,0,1,1,0,B41B1/04;;B41B1/04,,,0,0,,,,EXPIRED
376,US,A1,US 2011/0039347 A1,056-613-645-713-045,2011-02-17,2011,US 80863408 A,2008-12-18,AU 2007/906997 A;;AU 2008/001864 W,2007-12-20,Analytical Method and Apparatus,"A method for determining the amount of a chemical species in a sample, in particular the amount of weak acid dissociable cyanide or total cyanide in a sample, and an apparatus for performing said method. The method comprises the steps of: i) treating the sample to liberate the chemical species into a gaseous stream; ii) directing the gaseous stream to a scrubber; iii) absorbing the chemical species into a scrubber solution; and iv) determining the amount of chemical species absorbed into the scrubber solution, wherein any remaining chemical species not absorbed into the scrubber solution is directed or recirculated to the scrubber in the gaseous stream and step iii) is repeated to increase absorption of the chemical species prior to performing step iv).",CYANTIFIC INSTR PTY LTD,ROSS FRASER JOHN,ORICA AUSTRALIA PTY LTD (2013-04-26);;CYANTIFIC INSTRUMENTS PTY LTD (2008-12-08),https://lens.org/056-613-645-713-045,Patent Application,yes,26,3,5,5,0,G01N1/4055;;G01N31/16;;G01N2001/4066;;Y10T436/175383;;Y10T436/172307;;Y10T436/25;;Y10T436/173845;;Y10T436/17;;Y10T436/201666;;Y10T436/174614;;Y10T436/255;;Y10T436/25875;;Y10T436/25375;;Y10T436/175383;;Y10T436/172307;;Y10T436/25;;Y10T436/173845;;Y10T436/17;;Y10T436/201666;;Y10T436/174614;;Y10T436/255;;Y10T436/25875;;Y10T436/25375;;G01N31/16;;G01N1/4055;;G01N2001/4066,G01N31/16,436/109;;422/69,20,18,029-491-350-815-94X;;000-006-034-826-431;;022-673-109-559-022;;115-436-934-937-196;;092-497-728-571-345;;005-007-942-769-926;;004-945-668-075-01X;;026-521-896-408-292;;082-645-928-088-787;;064-484-708-391-066;;056-310-137-798-494;;093-718-471-028-410;;004-005-812-534-461;;089-767-067-701-403;;082-492-290-358-623;;178-619-077-344-800;;124-545-625-967-518;;021-866-384-264-119,10.1021/ac60095a029;;5084780;;10.1021/ac50011a024;;10.1021/ac00232a040;;10.1021/es960016i;;12542298;;10.1021/es0258273;;15363536;;10.1016/j.jhazmat.2004.06.029;;16506799;;10.1021/jf052061s;;10.1016/j.talanta.2006.06.010;;19071417;;10.1039/an9638800751;;10.1520/jfs10005j;;4781749;;10.1002/cjce.5450610605;;10.1021/bk-1992-0508.ch006;;10.1016/0021-9673(93)80077-l;;10.1016/0003-2670(95)00247-w;;10.1007/s002160051153;;10.1016/j.hydromet.2005.01.002;;15607585;;10.1016/j.forsciint.2004.03.032,"Ludzack F. J. et al, Analytical Chemistry 1954, 26, 1784-1792.;;Goulden, P. D. et al, Analytical Chemistry 1972, 44, 1845-1849.;;Broderius, S. J. et al, Analytical Chemistry 1977, 49, 424-428.;;Broderius, S. J., Analytical Chemistry 1981, 53, 1472-1477.;;Sebroski, J. R. et al, Environmental Science and Technology 1997, 31, 52-57.;;Zheng, A. et al, Environmental Science and Technology 2003, 37, 107-115.;;Gonen, N. et al, Journal of Hazardous Materials 2004, B113, 231-236.;;Chou, P.-Y. et al, Journal of Agricultural and Food Chemistry 2006, 54, 1551-1556.;;Hassan, S. S. M. et al, Talanta 2007, 71, 1088-1095.;;Bark, L. S. et al, Analyst 1963, 88, 751-760.;;Shanahan, R., Journal of Forensic Science 1973, 18, 25-30.;;Avedesian, M. M. et al, Canadian Journal of Chemical Engineering 1983, 61, 801-806.;;Fleming, S. W. et al, ""On-Line Analyzer for Chlorocarbons in Wastewater"" in Pollution Prevention in Industrial Processes, Chapter 6, ACS Symposium Series, Breen, J. et al. ed., 1992, Volume 508, pages 48-61.;;Lesage, S., Journal of Chromatography 1993, 642, 65-74.;;Kolodsick, K. et al, Analytica Chimica Acta 1995, 313, 75-82.;;Aguilar, M. et al, Fresenius Journal of Analytical Chemistry 1999, 363, 121-123.;;Method 9010C ""Total and Amenable Cyanide: Distillation"" Revision 3, November 2004, 10 pages.;;Vapur, H. et al, Hydrometallurgy 2005, 77, 279-286.;;Lv, J. et al, Forensic Science International 2005, 148, 15-19.;;Vapur, H. et al, Minerals Engineering 2007, 20, 729-737.",INACTIVE
377,EP,A1,EP 1165258 A1,092-066-140-950-235,2002-01-02,2002,EP 01903634 A,2001-01-10,EP 0100192 W;;US 48858300 A,2000-01-21,HEX PACKED TWO DIMENSIONAL ULTRASONIC TRANSDUCER ARRAYS,,KONINKL PHILIPS ELECTRONICS NV,FRASER JOHN D,,https://lens.org/092-066-140-950-235,Patent Application,yes,0,0,6,6,0,B06B1/0622;;B06B1/0622,G01N29/24;;A61B8/00;;B06B1/06;;H04R17/00,,1,0,,,See references of WO 0153009A1,DISCONTINUED
378,CA,A1,CA 2488234 A1,085-924-044-215-593,2003-12-11,2003,CA 2488234 A,2003-06-04,NZ 51937102 A;;NZ 0300111 W,2002-06-04,IMMUNOMODULATORY CONSTRUCTS AND THEIR USES,"The invention relates to immunomodulators. In particular the invention relat es to specific immunomodulators based on the superantigen SMEZ-2 and more particularly based on mutants of the superantigen SMEZ-2, which are adapted to target antigen-presenting-cells for the purpose of enhancing or suppressing a host immune response.",AUCKLAND UNISERVICES LTD,FRASER JOHN DAVID,,https://lens.org/085-924-044-215-593,Patent Application,no,0,0,14,14,13,A61K39/092;;A61K39/385;;A61K2039/6037;;C07K14/315;;A61P37/02;;C07K14/315;;A61K39/092;;A61K2039/6037;;A61K39/385,C12N15/09;;A61K39/00;;A61K39/09;;A61K39/385;;A61K39/39;;C07K14/315;;C07K19/00;;C12N15/31,,0,0,,,,DISCONTINUED
379,AU,A1,AU 2011/204924 A1,121-259-496-335-461,2011-08-11,2011,AU 2011/204924 A,2011-07-21,AU 2008/200089 A;;AU 2011/204924 A,2008-01-08,"Method, apparatus and system for parking overstay detection","METHOD, APPARATUS AND SYSTEM FOR PARKING OVERSTAY Methods, apparatuses and systems for identifying overstay of a vehicle (624, 644) in a parking space (610, 620, 630, 640, 650, 660) are disclosed herein. The method comprises the steps of detecting presence of a vehicle in a parking space using a detection io apparatus (612, 622, 632, 642, 652, 662), processing and storing data relating to presence of the vehicle in the detection apparatus, determining whether the vehicle has overstayed a defined time durationin the parking space; and wirelessly transmitting data relating to identified instances of overstay of the vehicle in the parking space.",VEHICLE MONITORING SYSTEMS PTY LTD,JOHN WELCH FRASER,,https://lens.org/121-259-496-335-461,Patent Application,no,0,0,8,8,0,,G08G1/14,,0,0,,,,INACTIVE
380,US,A,US 5947243 A,189-575-940-989-704,1999-09-07,1999,US 89191197 A,1997-07-14,US 89191197 A,1997-07-14,Torque converter bypass clutch damper having single piece spring retainer,"A hydrokinetic torque converter includes an impeller cover and bypass clutch located within the impeller housing. The impeller cover has welded to it a clutch plate, which carries friction material adjacent the clutch piston. The piston has legs that extend axially into engagement with helical springs carried in a damper assembly arranged in series with the damper between the impeller cover and the input shaft of the transmission. The springs are located in a retainer that accommodates two, three or four springs, as required by the torque requirements of the clutch and damper. The spring constant of the damper can be linear or piecewise linear over the full displacement range of the damper springs.",FORD GLOBAL TECH INC,MACDONALD FRASER JOHN,FORD GLOBAL TECHNOLOGIES (1998-03-16);;FORD MOTOR COMPANY (1997-07-02),https://lens.org/189-575-940-989-704,Granted Patent,yes,13,30,1,1,0,F16H45/02;;F16H45/02;;F16H2045/0294;;F16H2045/0294,F16H45/02,192/3.29;;192/55.61,0,0,,,,EXPIRED
381,US,A1,US 2006/0293598 A1,181-761-104-919-354,2006-12-28,2006,US 55143005 A,2005-08-24,US 55143005 A;;US 45114803 P;;IB 2004000505 W,2003-02-28,Motion-tracking improvements for hifu ultrasound therapy,High intensity focused ultrasound (HIFU) for medically treating tumors is automatically administered under robotic control in dosage intervals that alternate with ultrasonic imaging intervals. The HIFU transmitter is re-aimed for each dosage to compensate for motion of the tumor due to heart beats and other events.,KONINKL PHILIPS ELECTRONICS NV,FRASER JOHN D,,https://lens.org/181-761-104-919-354,Patent Application,yes,5,82,3,3,0,A61B5/1127;;A61B8/08;;A61B8/0833;;A61B8/4218;;A61B8/463;;A61B8/467;;A61B8/483;;A61B8/5276;;A61B2017/00694;;A61N7/02;;A61B8/461;;A61B34/30;;A61B2090/065;;A61B2090/378;;A61N7/02;;A61B8/08;;A61B8/467;;A61B8/483;;A61B2017/00694;;A61B5/1127;;A61B8/463;;A61B8/5276;;A61B8/4218;;A61B8/0833;;A61B8/461;;A61B2090/378;;A61B34/30;;A61B2090/065,A61B8/00;;A61B8/08;;A61B17/00;;A61B19/00;;A61N7/02,600/439,0,0,,,,DISCONTINUED
382,AU,B2,AU 2013/216683 B2,013-891-788-770-987,2016-06-23,2016,AU 2013/216683 A,2013-08-16,AU 2005/332046 A;;AU 2013/216683 A,2005-05-25,Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions,"Abstract Adipose derived regenerative cells are used to treat patients, including patients with cardiovascular conditions, diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells, e.g. stem and/or progenitor cells, obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, adipose derived regenerative cells are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic cardiovascular benefit.",CYTORI THERAPEUTICS INC,FRASER JOHN K,,https://lens.org/013-891-788-770-987,Granted Patent,no,3,5,2,2,0,,A61K35/34;;C12N5/00;;C12N5/0775,,0,0,,,,INACTIVE
383,DE,A1,DE 3151722 A1,021-267-091-705-908,1982-09-09,1982,DE 3151722 A,1981-12-29,US 22819581 A,1981-01-26,VERSTAERKTE GEGENSTAENDE,,CORNING GLASS WORKS,MACDOWELL JOHN FRASER,,https://lens.org/021-267-091-705-908,Patent Application,no,0,0,10,10,0,C04B14/42;;C04B14/42;;C08J5/08;;C08J5/08;;E04C5/07;;E04C5/07;;Y10T428/249932;;Y10T428/249932;;Y10T428/24994;;Y10T428/24994;;Y10T428/268;;Y10T428/268;;Y10T428/2964;;Y10T428/2964;;Y10T428/298;;Y10T428/298;;Y10T428/315;;Y10T428/315;;Y10T428/31507;;Y10T428/31507;;Y10T428/31525;;Y10T428/31525;;Y10T428/31601;;Y10T428/31601;;Y10T428/31612;;Y10T428/31612;;Y10T428/31627;;Y10T428/31627;;Y10T428/31645;;Y10T428/31645,C03C21/00;;C03C25/00;;C04B14/42;;C08J5/08;;E04C5/07,,0,0,,,,DISCONTINUED
384,CA,C,CA 2748440 C,025-369-782-294-653,2017-01-24,2017,CA 2748440 A,2009-12-09,US 14133008 P;;IB 2009055611 W,2008-12-30,"ULTRASONIC TEETH CLEANING APPLIANCE HAVING SPATIAL, TEMPORAL AND/OR FREQUENCY VARIATIONS","The appliance includes an appliance body (12) as well as a system for producing microbubbles (20) and a system for producing an ultrasound signal beam (22) in a frequency range which activates at least some of the microbubbles. The appli-ance includes at least one of the following: (a) an array of ultrasound transducer elements (40) which produce a plurality of ultra-sound signal beams; (b) an amplitude modulation assembly (51) for modulating the amplitude of the ultrasound signal; and (c) a frequency modulation system (61) for changing the frequency of the ultrasound signals over a selected range, to impact a range of microbubble sizes.",KONINL PHILIPS ELECTRONICS NV,FRASER JOHN DOUGLAS,,https://lens.org/025-369-782-294-653,Granted Patent,no,0,0,16,16,0,A61C17/20;;A61C17/20,A61C17/20,,0,0,,,,INACTIVE
385,GB,A,GB 190511576 A,042-343-250-317-798,1905-08-17,1905,GB 190511576D A,1905-06-02,GB 190511576T A,1905-06-02,"Improvements in Handles or Grips for Tennis & other Racquets, Golf Clubs, Cricket Bats, Hand Tools, Boat Tillers, Swords and for any other like purpose.","11,576. Fraser, J. G. June 2. Rackets; golf; bats; baseball ; croquet; polo; gymnastic apparatus; hockey.-Handles for tennis &c. rackets, golf clubs, cricket bats, baseball clubs, croquet mallets, polo sticks, gymnastic apparatus, hockey sticks, &c. are constructed so as to give a firm grip. The invention is shown as applied. to a tennis racket. The ordinary handle is covered by a grip formed of a block b of cork composition, drilled to receive the prepared end c of the handle. The part c is grooved or jagged, and is glued or cemented to the part b. A protecting-ferrule e of vulcanized fibre is fitted to the end of the handle. The block b is suitably shaped, and may be roughened to suit the article to which it is applied.",FRASER JOHN GRANT,FRASER JOHN GRANT,,https://lens.org/042-343-250-317-798,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
386,EP,A1,EP 3989994 A1,061-125-495-842-308,2022-05-04,2022,EP 20835340 A,2020-06-30,US 201962868983 P;;US 202062956898 P;;US 2020/0040370 W,2019-06-30,RECOMBINANT AAV VECTORS WITH ALTERED IMMUNOGENCITY AND METHODS OF MAKING THE SAME,,WRIGHT JOHN FRASER,WRIGHT JOHN FRASER,,https://lens.org/061-125-495-842-308,Patent Application,yes,0,0,5,5,4,C12N15/86;;C12N2750/14143;;C12N2750/14152;;C12N2750/14151;;C12N2750/14133;;C07K14/47;;C12N9/1007;;C12N9/644;;C12Y304/21022;;C07K14/755;;C07K14/4708;;A61P21/00;;A61P35/00;;C07K14/8125;;A61P11/00;;A61P7/04;;A61K35/76;;C12N9/1007;;C12N15/64;;C12N15/86;;C12N2330/51;;C12N2750/14133;;C12N2750/14143;;C12N2750/14152,A61K35/76;;C12N15/09;;C12N15/63;;C12N15/87;;C12Q1/68,,0,0,,,,PENDING
387,EP,A2,EP 1022491 A2,085-845-488-814-305,2000-07-26,2000,EP 00300286 A,2000-01-17,US 23798399 A,1999-01-25,Torque converter having resiliently loaded bypass clutch piston,"A hydrokinetic torque converter includes an impeller cover (12) and a bypass clutch. A drive ring (74) is located between adjacent surfaces of the cover (12) and a clutch piston (60), which moves axially on a support surface. The piston (60) is welded at a radially outer position to thin clutch plate (70), which is supported at another radial location on the cover (12). As the piston (60) moves into engagement with the ring (74) and cover (12), the clutch plate (70) permits this movement by bending elastically. When clutch apply pressure is reduced, energy stored in the clutch plate (70) is used to move the piston (60) out of engagement with the drive ring (74).",FORD GLOBAL TECH INC,MACDONALD FRASER JOHN,LAWRENCE TECHNOLOGICAL UNIVERSITY (2003-08-13),https://lens.org/085-845-488-814-305,Patent Application,yes,3,4,6,6,0,F16H45/02;;F16H2045/0278;;F16H2045/0289;;F16H45/02;;F16H2045/0278;;F16H2045/0289,F16H45/02,,0,0,,,,EXPIRED
388,GB,A,GB 191105021 A,133-793-072-670-94X,1911-12-07,1911,GB 191105021D A,1911-02-28,GB 191105021T A,1911-02-28,Improved Construction of Motor-car or Trolley for use on Railways.,"5021. Fraser, J. D. Feb. 28. Tyres, non-elastic, and rims.-Light wire wheels for a railway inspection trolly are fitted with detachable flanged tyres or rims 13.",FRASER JOHN DONALD,FRASER JOHN DONALD,,https://lens.org/133-793-072-670-94X,Patent Application,no,0,0,1,1,0,B61D15/12,B61D15/12,,0,0,,,,DISCONTINUED
389,DK,T3,DK 1747543 T3,138-439-898-373-669,2013-07-22,2013,DK 05737801 T,2005-05-09,AU 2004/902622 A;;AU 2005/000660 W,2004-05-17,"Fremgangsmåde, apparat og system til registrering af overskredet parkeringstid",,VEHICLE MONITORING SYSTEMS PTY LTD,WELCH FRASER JOHN,,https://lens.org/138-439-898-373-669,Granted Patent,no,0,0,12,15,0,G08G1/14;;G08G1/14;;G07B15/02;;G07B15/02;;G07F17/246;;G07F17/246,G07F17/24;;B60Q1/48;;G08G1/14,,0,0,,,,ACTIVE
390,EP,B1,EP 1294494 B1,167-310-015-144-980,2010-11-03,2010,EP 01964960 A,2001-06-08,EP 0106479 W;;US 59675900 A,2000-06-15,CAPACITIVE MICROMACHINED ULTRASONIC TRANSDUCER AND OPERATING METHOD THEREOF,"An ultrasonic transducer is formed by a plurality of cMUT cells, each comprising a charged diaphragm plate capacitively opposing an oppositely charged base plate. The diaphragm plate is distended toward the base plate by a bias charge. The base plate includes a central portion elevated toward the center of the diaphragm plate to cause the charge of the cell to be of maximum density at the moving center of the diaphragm plate. For harmonic operation the drive pulses applied to the cells are predistorted in consideration of the nonlinear operation of the device to reduce contamination of the transmit signal at the harmonic band. The cMUT cells can be fabricated by conventional semiconductor processes and hence integrated with ancillary transducer circuitry such as a bias charge regulator. The cMUT cells can also be fabricated by micro-stereolithography whereby the cells can be formed using a variety of polymers and other materials.",KONINKL PHILIPS ELECTRONICS NV,FRASER JOHN D,"KONINKLIJKE PHILIPS ELECTRONICS N.V., NL (2014-11-26);;KONINKLIJKE PHILIPS N.V., NL (2014-03-28)",https://lens.org/167-310-015-144-980,Granted Patent,yes,4,0,12,16,0,B06B1/0292;;B33Y80/00;;B33Y10/00;;B33Y80/00;;B33Y10/00;;B06B1/0292,B06B1/02;;B81B3/00;;A61B8/00;;H04R19/00,,0,0,,,,EXPIRED
391,CA,A,CA 338352 A,187-607-642-275-480,1934-01-02,1934,CA 338352D A,,CA 338352T A,,WIRE TREATING METHOD,,LAIDLAW BALE TIE COMPANY,FRASER JOHN GEORGE,,https://lens.org/187-607-642-275-480,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
392,GB,B,GB 2520431 B,039-856-810-875-399,2020-04-01,2020,GB 201419863 A,2014-11-07,GB 201320104 A,2013-11-14,An improved support device for use in a wellbore and a method for deploying a barrier in a wellbore,,CORETRAX TECH LIMITED,JOHN KENNETH FRASER MURRAY;;JOHN PAUL FRASER;;JASON FONG,,https://lens.org/039-856-810-875-399,Granted Patent,no,8,0,9,9,0,E21B23/06;;E21B33/127;;E21B33/134;;E21B17/02;;E21B33/127;;E21B17/02;;E21B23/06;;E21B33/127;;E21B33/134;;E21B17/02;;E21B19/16;;E21B17/02;;E21B23/06;;E21B33/127;;E21B33/134;;E21B2200/06;;E21B34/10,E21B33/127,,0,0,,,,ACTIVE
393,GB,A,GB 2520431 A,034-128-380-171-895,2015-05-20,2015,GB 201419863 A,2014-11-07,GB 201320104 A,2013-11-14,An improved support device for use in a wellbore and a method for deploying a barrier in a wellbore,"A downhole support device 200 adapted to be run into the wellbore 202 through or on a workstring 204. The device 200 comprises an inflatable 206 for filling with cement or other fluid, detachably connected 222 to the workstring 204, and an inflation valve 210. When filled, the inflatable 206 expands so as to plug the borehole. The inflation valve 210 is preferably a slide valve, which is opened by applying sufficient pressure. The inflatable also features a non-return valve 270 to prevent deflation, a relief valve 268 to prevent excess pressure within the inflatable and a safety valve 272 to protect the relief valve from damage. The device also features retractable engaging elements, which connect to the workstring to prevent premature disconnection. The inflatable may have a burst preventing sheath 216 and be filled with a catalyst for speeding up hardening of the packer. Also included is a method for using the packer to form a barrier in a borehole (e.g. oil well).",SMJM LTD,MURRAY JOHN KENNETH FRASER;;FRASER JOHN PAUL;;FONG JASON,,https://lens.org/034-128-380-171-895,Patent Application,no,7,0,9,9,0,E21B23/06;;E21B33/127;;E21B33/134;;E21B17/02;;E21B33/127;;E21B17/02;;E21B23/06;;E21B33/127;;E21B33/134;;E21B17/02;;E21B19/16;;E21B17/02;;E21B23/06;;E21B33/127;;E21B33/134;;E21B2200/06;;E21B34/10,E21B33/127,,0,0,,,,ACTIVE
394,CA,A,CA 39177 A,131-229-007-686-144,1892-06-22,1892,CA 39177D A,,CA 39177T A,,VACUUM PUMP,,WILSON JOHN;;FRASER JOHN W,WILSON JOHN;;FRASER JOHN W,,https://lens.org/131-229-007-686-144,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
395,IE,A1,IE 921459 A1,085-050-275-977-283,1992-11-18,1992,IE 921459 A,1992-07-01,GB 9109763 A;;GB 9114714 A;;GB 9204320 A,1991-05-07,HERPESVIRUS PARTICLES AND VACCINE,"In addition to virions, herpesvirus-infected cells produce non-infectious particles, termed L-particles, which consist of tegument surrounded by envelope but lack the nucleocapsid. L-particles of a herpesvirus can be prepared substantially free of infectious virions, e.g. by allowing an appropriate temperature-sensitive mutant to replicate at its non-permissive temperature, and such L-particles are useful as a component of a vaccine against the herpesvirus. They can also be prepared to contain a foreign protein or peptide, by use of a recombinant herpesvirus.",MEDICAL RES COUNCIL,MCLAUCHLAN JOHN;;RIXON FRASER JOHN,,https://lens.org/085-050-275-977-283,Patent Application,no,0,0,14,20,0,A61K39/245;;C12N15/86;;C12N2710/16634;;C12N2710/16643;;C07C69/734;;C07C69/738;;C07D317/60;;C07D405/08;;C07C45/71;;C07C49/84;;C07D307/79;;C07C62/30;;C07C62/32;;C07C62/34;;A61K2039/5252;;A61K39/12;;A61P13/02;;A61P15/00;;A61P31/12;;A61P31/22;;A61P43/00;;A61P9/00;;A61P9/08;;A61P9/10;;A61P9/12,A61K31/34;;A61K31/343;;A61K31/19;;A61K31/357;;A61K31/36;;A61K31/38;;A61K31/381;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/41;;A61K31/415;;A61K31/44;;A61K31/443;;A61K31/66;;A61K39/245;;A61P9/00;;A61P9/08;;A61P9/10;;A61P9/12;;A61P13/02;;A61P15/00;;A61P31/12;;A61P31/22;;A61P43/00;;C07C13/465;;C07C23/34;;C07C25/22;;C07C33/38;;C07C35/32;;C07C39/23;;C07C43/188;;C07C43/21;;C07C45/71;;C07C49/84;;C07C59/00;;C07C61/20;;C07C61/39;;C07C62/06;;C07C62/14;;C07C62/30;;C07C62/32;;C07C62/34;;C07C67/31;;C07C67/343;;C07C69/734;;C07C69/738;;C07C69/757;;C07C211/42;;C07C211/57;;C07C235/82;;C07C323/00;;C07D209/04;;C07D213/60;;C07D233/56;;C07D249/02;;C07D257/02;;C07D257/04;;C07D275/02;;C07D277/22;;C07D307/79;;C07D317/50;;C07D317/60;;C07D333/10;;C07D405/08;;C07D405/12;;C07D407/08;;C07F9/30;;C07F9/38;;C12N7/00;;C12N15/09;;C12N15/869,,0,0,,,,DISCONTINUED
396,NZ,A,NZ 242641 A,100-151-698-688-736,1993-09-27,1993,NZ 24264192 A,1992-05-07,GB 9109763 A;;GB 9114714 A;;GB 9204320 A,1991-05-07,HERPESVIRUS PARTICLES LACKING A CAPSID AND VIRAL DNA AND VIRAL PREPARATIONS CONTAINING THEM,"In addition to virions, herpesvirus-infected cells produce non-infectious particles, termed L-particles, which consist of tegument surrounded by envelope but lack the nucleocapsid. L-particles of a herpesvirus can be prepared substantially free of infectious virions, e.g. by allowing an appropriate temperature-sensitive mutant to replicate at its non-permissive temperature, and such L-particles are useful as a component of a vaccine against the herpesvirus. They can also be prepared to contain a foreign protein or peptide, by use of a recombinant herpesvirus.",MEDICAL RES COUNCIL,MCLAUGHLAN JOHN;;RIXON FRASER JOHN,,https://lens.org/100-151-698-688-736,Patent Application,no,0,0,14,20,0,A61K39/245;;C12N15/86;;C12N2710/16634;;C12N2710/16643;;C07C69/734;;C07C69/738;;C07D317/60;;C07D405/08;;C07C45/71;;C07C49/84;;C07D307/79;;C07C62/30;;C07C62/32;;C07C62/34;;A61K2039/5252;;A61K39/12;;A61P13/02;;A61P15/00;;A61P31/12;;A61P31/22;;A61P43/00;;A61P9/00;;A61P9/08;;A61P9/10;;A61P9/12,A61K31/34;;A61K31/343;;A61K31/357;;A61K31/36;;A61K31/38;;A61K31/381;;A61K31/19;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/41;;A61K31/415;;A61K31/44;;A61K31/443;;A61K31/66;;A61K39/245;;A61P9/00;;A61P9/08;;A61P9/10;;A61P9/12;;A61P13/02;;A61P15/00;;A61P31/12;;A61P31/22;;A61P43/00;;C07C13/465;;C07C23/34;;C07C25/22;;C07C33/38;;C07C35/32;;C07C39/23;;C07C43/188;;C07C43/21;;C07C45/71;;C07C49/84;;C07C59/00;;C07C61/20;;C07C61/39;;C07C62/06;;C07C62/14;;C07C62/30;;C07C62/32;;C07C62/34;;C07C67/31;;C07C67/343;;C07C69/734;;C07C69/738;;C07C69/757;;C07C211/42;;C07C211/57;;C07C235/82;;C07C323/00;;C07D209/04;;C07D213/60;;C07D233/56;;C07D249/02;;C07D257/02;;C07D257/04;;C07D275/02;;C07D277/22;;C07D307/79;;C07D317/50;;C07D317/60;;C07D333/10;;C07D405/08;;C07D405/12;;C07D407/08;;C07F9/30;;C07F9/38;;C12N7/00;;C12N15/09;;C12N15/869,,0,0,,,,PENDING
397,GB,A,GB 809272 A,162-762-579-651-641,1959-02-18,1959,GB 1773854 A,1954-06-16,GB 1773854 A,1954-06-16,Improvements in or relating to the coating of surfaces with aqueous emulsions of bitumen,"A surface such as that of concrete, masonry or steelwork is coated with an aqueous emulsion containing bitumen and in smaller amount polyvinyl acetate, the coating is dried and there is then applied a decorative composition which, when dry, adheres strongly without bleed of bitumen thereunto, said decorative composition comprising an aqueous emulsion of polyvinyl acetate containing a substantial amount of finely divided solid, e.g. cement, sand or powdered limestone or granite. Optional ingredients specified are plasticizers such as dibutyl phthalate, pigments, wetting agents such as ""Teepol"" (Registered Trade Mark), dispersing and emulsifying agents, stabilizers such as sodium hexametaphosphate and rust-preventive agents such as sodium benzoate. The bitumen may be a naturally occurring hydrocarbon or the residue from petroleum distillation. In the method of the invention priming coats are not necessary, and, if desired, the bituminous coating may exceed 1/8 inch when wet.ALSO:A surface such as that of concrete, masonry or steel work is coated with an aqueous emulsion containing bitumen and in smaller amount polyvinyl acetate, the coating is dried and there is then applied a decorative composition which, when dry, adheres strongly without bleed of bitumen thereunto, said decorative composition comprising an aqueous emulsion of polyvinyl acetate containing a ubstantial amount of finely divided solid, e.g. cement, sand or powdered limestone or granite. Optional ingredients specified are plasticizers such as dibutyl phthalate, pigments, wetting agents such as ""Teepol"" (Registered Trade Mark), dispersing and emulsifying agents, stabilizers such as sodium hexametaphosphate and rust preventive agents such as sodium benzoate. The bitumen may be a naturally occurring hydrocarbon or the residue from petroleum distillation. In the method of the invention priming coats are not necessary, and, if desired, the bituminous coating may exceed 1/8 inch when wet.",GUNAC LTD,TAYLOR JOHN FRASER;;WILLIAMS JOHN,,https://lens.org/162-762-579-651-641,Granted Patent,no,0,1,1,1,0,B05D7/54;;C09D195/005,B05D7/26;;C09D195/00,B2E EAM;;B2E E19Y;;B2E E193;;B2E E197;;B2E E20Y;;B2E E206;;B2E E298;;B2E E327;;B2E E349;;B2E E360;;B2E E420;;B2E E421;;B2E E44Y;;B2E E461;;B2E E473;;B2E E485;;B2E E486;;B2E E487;;B2E E498;;B2E E568;;B2E E59Y;;B2E E592;;B2E E62X;;B2E E62Y;;B2E E622;;B2E E631;;B2E E65Y;;B2E E671;;B2E E683;;B2E E695;;B2E E696;;B2E E697;;B2E E708;;B2E E778;;C3M MXA           MXA;;C3M MXA           MXAW;;C3M MXAW          MXAW;;C3M M136          MX;;C3M M136          MXAW;;C3M M166          MX;;C3M M166          MXAW;;C3M M200          MX;;C3M M200          MXAW,0,0,,,,EXPIRED
398,PT,A,PT 100460 A,116-462-606-184-645,1993-08-31,1993,PT 10046092 A,1992-05-06,GB 9109763 A;;GB 9114714 A;;GB 9204320 A,1991-05-07,PARTIICULAS DERIVADAS DE VIRUS DE HERPES E VACINAS QUE AS CONTEM,"In addition to virions, herpesvirus-infected cells produce non-infectious particles, termed L-particles, which consist of tegument surrounded by envelope but lack the nucleocapsid. L-particles of a herpesvirus can be prepared substantially free of infectious virions, e.g. by allowing an appropriate temperature-sensitive mutant to replicate at its non-permissive temperature, and such L-particles are useful as a component of a vaccine against the herpesvirus. They can also be prepared to contain a foreign protein or peptide, by use of a recombinant herpesvirus.",MEDICAL RES COUNCIL,MCLAUCHLAN JOHN;;RIXON FRASER JOHN,,https://lens.org/116-462-606-184-645,Patent Application,no,0,0,14,20,0,A61K39/245;;C12N15/86;;C12N2710/16634;;C12N2710/16643;;C07C69/734;;C07C69/738;;C07D317/60;;C07D405/08;;C07C45/71;;C07C49/84;;C07D307/79;;C07C62/30;;C07C62/32;;C07C62/34;;A61K2039/5252;;A61K39/12;;A61P13/02;;A61P15/00;;A61P31/12;;A61P31/22;;A61P43/00;;A61P9/00;;A61P9/08;;A61P9/10;;A61P9/12,A61K31/34;;A61K31/343;;A61K31/19;;A61K31/357;;A61K31/36;;A61K31/38;;A61K31/381;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/41;;A61K31/415;;A61K31/44;;A61K31/443;;A61K31/66;;A61K39/245;;A61P9/00;;A61P9/08;;A61P9/10;;A61P9/12;;A61P13/02;;A61P15/00;;A61P31/12;;A61P31/22;;A61P43/00;;C07C13/465;;C07C23/34;;C07C25/22;;C07C33/38;;C07C35/32;;C07C39/23;;C07C43/188;;C07C43/21;;C07C45/71;;C07C49/84;;C07C59/00;;C07C61/20;;C07C61/39;;C07C62/06;;C07C62/14;;C07C62/30;;C07C62/32;;C07C62/34;;C07C67/31;;C07C67/343;;C07C69/734;;C07C69/738;;C07C69/757;;C07C211/42;;C07C211/57;;C07C235/82;;C07C323/00;;C07D209/04;;C07D213/60;;C07D233/56;;C07D249/02;;C07D257/02;;C07D257/04;;C07D275/02;;C07D277/22;;C07D307/79;;C07D317/50;;C07D317/60;;C07D333/10;;C07D405/08;;C07D405/12;;C07D407/08;;C07F9/30;;C07F9/38;;C12N7/00;;C12N15/09;;C12N15/869,,0,0,,,,EXPIRED
399,PT,B,PT 100460 B,073-083-188-524-169,1999-07-30,1999,PT 10046092 A,1992-05-06,GB 9109763 A;;GB 9114714 A;;GB 9204320 A,1991-05-07,PARTIICULAS DERIVADAS DE VIRUS DE HERPES E VACINAS QUE AS CONTEM,"In addition to virions, herpesvirus-infected cells produce non-infectious particles, termed L-particles, which consist of tegument surrounded by envelope but lack the nucleocapsid. L-particles of a herpesvirus can be prepared substantially free of infectious virions, e.g. by allowing an appropriate temperature-sensitive mutant to replicate at its non-permissive temperature, and such L-particles are useful as a component of a vaccine against the herpesvirus. They can also be prepared to contain a foreign protein or peptide, by use of a recombinant herpesvirus.",MEDICAL RES COUNCIL,MCLAUCHLAN JOHN;;RIXON FRASER JOHN,,https://lens.org/073-083-188-524-169,Granted Patent,no,0,0,14,20,0,A61K39/245;;C12N15/86;;C12N2710/16634;;C12N2710/16643;;C07C69/734;;C07C69/738;;C07D317/60;;C07D405/08;;C07C45/71;;C07C49/84;;C07D307/79;;C07C62/30;;C07C62/32;;C07C62/34;;A61K2039/5252;;A61K39/12;;A61P13/02;;A61P15/00;;A61P31/12;;A61P31/22;;A61P43/00;;A61P9/00;;A61P9/08;;A61P9/10;;A61P9/12,A61K31/34;;A61K31/343;;A61K31/19;;A61K31/357;;A61K31/36;;A61K31/38;;A61K31/381;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/41;;A61K31/415;;A61K31/44;;A61K31/443;;A61K31/66;;A61K39/245;;A61P9/00;;A61P9/08;;A61P9/10;;A61P9/12;;A61P13/02;;A61P15/00;;A61P31/12;;A61P31/22;;A61P43/00;;C07C13/465;;C07C23/34;;C07C25/22;;C07C33/38;;C07C35/32;;C07C39/23;;C07C43/188;;C07C43/21;;C07C45/71;;C07C49/84;;C07C59/00;;C07C61/20;;C07C61/39;;C07C62/06;;C07C62/14;;C07C62/30;;C07C62/32;;C07C62/34;;C07C67/31;;C07C67/343;;C07C69/734;;C07C69/738;;C07C69/757;;C07C211/42;;C07C211/57;;C07C235/82;;C07C323/00;;C07D209/04;;C07D213/60;;C07D233/56;;C07D249/02;;C07D257/02;;C07D257/04;;C07D275/02;;C07D277/22;;C07D307/79;;C07D317/50;;C07D317/60;;C07D333/10;;C07D405/08;;C07D405/12;;C07D407/08;;C07F9/30;;C07F9/38;;C12N7/00;;C12N15/09;;C12N15/869,,0,0,,,,EXPIRED
400,DE,A1,DE 2246570 A1,008-594-610-527-566,1973-06-07,1973,DE 2246570 A,1972-09-22,US 20353271 A,1971-12-01,KRAFTBETAETIGTE GELENKVERBINDUNG,,SUNDSTRAND CORP,MACDONALD JOHN GEORGE FRASER,,https://lens.org/008-594-610-527-566,Patent Application,no,0,3,8,8,0,B64C13/00;;F15B15/06;;F15B15/068;;F16H25/04;;F16H25/186;;F16H25/20;;F16H25/2204;;Y10T74/1836;;Y10T74/18312;;Y10T74/18672;;Y10T74/1836;;Y10T74/18312;;Y10T74/18672;;F15B15/068;;F16H25/20;;F16H25/04;;F16H25/186;;F16H25/2204;;F15B15/06;;B64C13/00,F16C11/04;;A47C17/02;;A47C21/04;;B64C13/00;;B64C13/28;;E05D7/00;;F15B15/06;;F15B15/08;;F16H25/04;;F16H25/16;;F16H25/18;;F16H25/20;;F16H25/22;;F24H1/18;;H01H37/02,,0,0,,,,DISCONTINUED
401,KR,A,KR 20160055827 A,023-332-237-858-765,2016-05-18,2016,KR 20167008154 A,2014-09-17,US 201361880086 P;;US 201461977466 P;;US 2014/0056145 W,2013-09-19,METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS,"본 발명의 측면은 의약 분야, 구체적으로 통증 및/또는 섬유증을 조절하는 것에 대한 지방 조직 및 그의 구성요소의 효과에 관한 것이다.",CYTORI THERAPEUTICS INC,FRASER JOHN;;MAGALON GUY,,https://lens.org/023-332-237-858-765,Patent Application,no,0,7,18,18,0,A61K35/35;;A61K35/28;;A61P17/00;;A61P19/02;;A61P25/02;;A61P25/04;;A61P29/00;;A61P37/00;;A61P43/00;;A61K35/35;;A61K35/28;;A61K9/0019,A61K35/28;;G01N33/68,,0,0,,,,DISCONTINUED
402,FI,A,FI 13 A,044-304-477-031-808,1848-02-23,1848,FI 13D A,,FI 13T A,,Såkallade strömsnurror att genom vattnets reaktionskraft sättas i rörelse,,,JOHN JULIN;;ALEX FRASER,,https://lens.org/044-304-477-031-808,Granted Patent,no,0,0,1,1,0,Y02E10/20,F03B3/02,,0,0,,,,EXPIRED
403,GB,A,GB 2281508 A,061-903-057-806-057,1995-03-08,1995,GB 9316560 A,1993-08-10,GB 9316560 A,1993-08-10,Foldable wall type seat or table,"A foldable support for a table or seat is designed to be secured to a vertical surface such as a wall or the front of a bar, and to fold flat against the surface when not in use. To this end, the support comprises an upper support strut 30 for supporting the table or seat, this strut having one end pivotally connected to the surface via a bracket. The other end of the upper support strut is pivotally connected to a pair of telescopically and pivotally interconnected support struts 36, 38, which when telescoped together form a rigid bracing member whose lower end is pivotally connected to the surface or the floor. When the upper support strut is lifted, the telescopically interconnected struts move longitudinally apart to a point where they can pivot with respect to each other, enabling the table or seat to be folded flat against the surface. The telescoping is via a pin and slot connection 52, 54, and the strut is locked via a locking tongue 56. <IMAGE>",MASTERTON JOHN FRASER CRUX,MASTERTON JOHN FRASER CRUX,,https://lens.org/061-903-057-806-057,Patent Application,no,3,4,2,2,0,A47C9/06;;A47B5/04,A47B5/04;;A47C9/06,A4L LBPB          LBPB;;A4L LBP6          LBPB;;A4L LBP8          LBPB;;A4L L114          LBPB;;A4L L119          LBPB,0,0,,,,DISCONTINUED
404,EP,A4,EP 3046417 A4,121-578-831-199-988,2016-09-07,2016,EP 14845486 A,2014-09-17,US 201361880086 P;;US 201461977466 P;;US 2014/0056145 W,2013-09-19,METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS,,CYTORI THERAPEUTICS INC,FRASER JOHN;;MAGALON GUY,,https://lens.org/121-578-831-199-988,Search Report,no,1,0,18,18,0,A61K35/35;;A61K35/28;;A61P17/00;;A61P19/02;;A61P25/02;;A61P25/04;;A61P29/00;;A61P37/00;;A61P43/00;;A61K35/35;;A61K35/28;;A61K9/0019,C12N5/077;;A61K35/28;;A61K35/35;;A61P17/00;;A61P37/00;;A61P43/00;;C12N5/0775,,3,2,021-400-102-617-760;;006-485-162-197-149,22526170;;10.3727/096368912x639017;;24050783;;10.1016/j.revmed.2013.08.007,"POZZI M R ET AL: ""AUTOLOGOUS FAT TRANSFER FOR DIGITAL ULCERS TREATMENT IN SYSTEMIC SCLEROSIS"", ANNALS OF THE RHEUMATIC DISEASES, vol. 72, no. Suppl. 3, June 2013 (2013-06-01), & ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY (EULAR); MADRID, SPAIN; JUNE 12 -15, 2013, pages 649, XP009190959;;SCUDERI N ET AL: ""Human adipose-derived stromal cells for cell-based therapies in the treatment of systemic sclerosis"", CELL TRANSPLANTATION 2013 COGNIZANT COMMUNICATION CORPORATION USA, vol. 22, no. 5, 17 April 2012 (2012-04-17), pages 779 - 795, XP002759956, ISSN: 0963-6897;;DAUMAS A ET AL: ""Interests and potentials of adipose tissue in scleroderma"", REVUE DE MEDECINE INTERNE 2013 ELSEVIER MASSON SAS FRA, vol. 34, no. 12, 17 September 2013 (2013-09-17), pages 763 - 769, XP002759957, ISSN: 0248-8663",ACTIVE
405,DE,A1,DE 1496077 A1,175-863-008-461-208,1969-08-14,1969,DE 1496077 A,1963-08-08,US 21566162 A,1962-08-08,Eine kristalline Oberflaechenschicht aufweisender Glaskoerper und Verfahren zu seiner Herstellung,,CORNING GLASS WORKS,FRASER MAC DOWELL JOHN,,https://lens.org/175-863-008-461-208,Patent Application,no,0,1,5,5,0,C03C10/0045;;Y10T428/315;;Y10T428/315,C03C10/00;;C03C10/08,,0,0,,,,DISCONTINUED
406,DK,C,DK 41831 C,049-079-610-227-409,1930-03-17,1930,DK 41831D A,1928-02-25,GB 41831X A,1927-02-28,Anordning til Skivebelysning til Brug ved Sigteøvelser med Gaværer eller andre Skydevaaben.,,LAMONT JOHN WILLIAM FRASER,LAMONT JOHN WILLIAM FRASER,,https://lens.org/049-079-610-227-409,Granted Patent,no,0,0,1,1,0,,,72F-7.,0,0,,,,EXPIRED
407,EP,B1,EP 1066771 B1,056-937-616-859-601,2005-09-28,2005,EP 00305609 A,2000-07-03,GB 9915947 A;;GB 0005503 A,1999-07-07,Applicator and assembly,,GEKA BRUSH GMBH,FORDHAM JOHN FRASER WOOD,GEKA BRUSH GMBH (2001-08-16),https://lens.org/056-937-616-859-601,Granted Patent,yes,4,4,8,15,0,A45D40/267;;A46B3/18;;A46B9/021;;A46B2200/1053,A45D34/04;;A45D40/26;;A46B3/18;;A46B9/02,,0,0,,,,EXPIRED
408,EP,B1,EP 1915221 B1,077-418-834-022-479,2018-04-18,2018,EP 06780137 A,2006-07-19,IB 2006052475 W;;US 70639805 P,2005-08-08,ULTRASOUND TRANSDUCER ARRAYS,,KONINKLIJKE PHILIPS NV,FRASER JOHN;;DUFORT BENOIT,KONINKLIJKE PHILIPS N.V. (2013-09-25),https://lens.org/077-418-834-022-479,Granted Patent,yes,5,0,10,10,0,B06B1/0207;;B06B1/0207,B06B1/02,,0,0,,,,ACTIVE
409,EP,A1,EP 4222116 A1,109-321-266-866-777,2023-08-09,2023,EP 21876256 A,2021-09-27,US 202063084752 P;;US 2021/0052164 W,2020-09-29,WASTEWATER TREATMENT SYSTEM AND METHOD USING AEROBIC GRANULAR SLUDGE WITH IMMERSED MEMBRANE SEPARATION,,CAROLLO ENG INC,FRASER JOHN;;GILMORE ANDREW,,https://lens.org/109-321-266-866-777,Patent Application,yes,0,0,5,5,0,Y02W10/10;;C02F3/301;;C02F3/085;;C02F3/1273;;C02F3/301;;Y02W10/10;;C02F3/085;;C02F3/1273;;C02F3/1273;;C02F3/301;;C02F2305/12,C02F3/08;;C02F3/12;;C02F3/30,,0,0,,,,PENDING
410,EP,B1,EP 3046417 B1,021-699-385-350-427,2017-07-05,2017,EP 14845486 A,2014-09-17,US 201361880086 P;;US 201461977466 P;;US 2014/0056145 W,2013-09-19,METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF RAYNAUD'S PHENOMENON ASSOCIATED WITH SCLERODERMA,,CYTORI THERAPEUTICS INC,FRASER JOHN;;MAGALON GUY,,https://lens.org/021-699-385-350-427,Granted Patent,yes,3,0,18,18,0,A61K35/35;;A61K35/28;;A61P17/00;;A61P19/02;;A61P25/02;;A61P25/04;;A61P29/00;;A61P37/00;;A61P43/00;;A61K35/35;;A61K35/28;;A61K9/0019,C12N5/077;;A61K35/28;;A61K35/35;;A61P17/00;;A61P37/00;;A61P43/00;;C12N5/0775,,3,0,,,"POZZI M R ET AL: ""AUTOLOGOUS FAT TRANSFER FOR DIGITAL ULCERS TREATMENT IN SYSTEMIC SCLEROSIS"", ANNALS OF THE RHEUMATIC DISEASES, vol. 72, no. Suppl. 3, June 2013 (2013-06) , page 649, XP009190959, & ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY (EULAR); MADRID, SPAIN; JUNE 12 -15, 2013;;SCUDERI N ET AL: ""Human adipose-derived stromal cells for cell-based therapies in the treatment of systemic sclerosis"", CELL TRANSPLANTATION 2013 COGNIZANT COMMUNICATION CORPORATION USA, vol. 22, no. 5, 17 April 2012 (2012-04-17) , pages 779-795, XP002759956, ISSN: 0963-6897;;DAUMAS A ET AL: ""Interests and potentials of adipose tissue in scleroderma"", REVUE DE MEDECINE INTERNE 2013 ELSEVIER MASSON SAS FRA, vol. 34, no. 12, 17 September 2013 (2013-09-17), pages 763-769, XP002759957, ISSN: 0248-8663",ACTIVE
411,MX,A,MX 2016003127 A,049-885-408-612-879,2016-10-28,2016,MX 2016003127 A,2014-09-17,US 201361880086 P;;US 201461977466 P;;US 2014/0056145 W,2013-09-19,METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS.,"Aspects of the present invention relate to the field of medicine, specifically, the effect of adipose tissue and its components on modulating pain and/or fibrosis.",CYTORI THERAPEUTICS INC,JOHN FRASER;;GUY MAGALON,,https://lens.org/049-885-408-612-879,Patent Application,no,0,5,18,18,0,A61K35/35;;A61K35/28;;A61P17/00;;A61P19/02;;A61P25/02;;A61P25/04;;A61P29/00;;A61P37/00;;A61P43/00;;A61K35/35;;A61K35/28;;A61K9/0019,A01N63/00,,0,0,,,,PENDING
412,DE,A1,DE 1496466 A1,120-405-902-761-834,1969-12-04,1969,DE 1496466 A,1965-10-08,US 40301564 A,1964-10-12,Glas-Kristall-Mischkoerper und Verfahren zu seiner Herstellung,,CORNING GLASS WORKS,FRASER MAC DOWELL JOHN,,https://lens.org/120-405-902-761-834,Patent Application,no,0,0,5,6,0,C03C10/0009;;C03C10/0009,C03C10/00,,0,0,,,,DISCONTINUED
413,GB,B,GB 2561480 B,123-373-857-233-316,2021-03-31,2021,GB 201809215 A,2016-12-22,GB 2016054031 W;;GB 201522652 A,2015-12-22,Squeeze packer and method of setting a squeeze packer,,CORETRAX TECH LIMITED,JASON FONG;;JOHN FRASER,,https://lens.org/123-373-857-233-316,Granted Patent,no,2,0,8,8,0,E21B23/06;;E21B29/00;;E21B33/1293;;E21B33/1294;;E21B43/116;;E21B34/142;;E21B23/06;;E21B29/00;;E21B33/1293;;E21B33/1294;;E21B43/116;;E21B34/142;;E21B23/06;;E21B29/00;;E21B33/1293;;E21B33/1294;;E21B43/116;;E21B34/142;;E21B34/142;;E21B33/1285;;E21B33/1293;;E21B33/14;;E21B34/102,E21B23/06;;E21B29/00;;E21B33/129;;E21B34/14;;E21B43/116,,1,0,,,"Coretrax, ""Coretrax - CX-SV Squeeze Packer"", (20160622), page 1, URL: https://www.youtube.com/watch?v=yFK9sb41o0M, (20170206), XP054977133",ACTIVE
414,WO,A1,WO 2015/042182 A1,184-710-786-631-057,2015-03-26,2015,US 2014/0056145 W,2014-09-17,US 201461977466 P;;US 201361880086 P,2013-09-19,METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS,"Aspects of the present invention relate to the field of medicine, specifically, the effect of adipose tissue and its components on modulating pain and/or fibrosis.",CYTORI THERAPEUTICS INC;;FRASER JOHN;;MAGALON GUY,FRASER JOHN;;MAGALON GUY,,https://lens.org/184-710-786-631-057,Patent Application,yes,32,6,18,18,0,A61K35/35;;A61K35/28;;A61P17/00;;A61P19/02;;A61P25/02;;A61P25/04;;A61P29/00;;A61P37/00;;A61P43/00;;A61K35/35;;A61K35/28;;A61K9/0019,A01N63/00,,27,21,021-400-102-617-760;;028-976-226-158-427;;045-787-458-363-087;;007-126-466-697-398;;068-929-730-624-924;;012-526-554-878-117;;084-476-732-626-801;;032-279-003-745-289;;026-563-150-261-584;;019-810-335-711-889;;113-651-591-024-609;;197-698-560-021-363;;009-852-354-311-269;;023-361-891-946-332;;098-468-861-318-395;;118-594-841-874-424;;158-997-957-027-443;;018-667-753-289-435;;157-994-310-553-91X;;041-201-637-014-038;;035-982-850-526-072,22526170;;10.3727/096368912x639017;;11014457;;10.1016/0963-6897(95)00006-j;;7640867;;10.1177/096368979500400306;;10.1016/0304-3835(80)90091-9;;7013975;;10.1016/j.mvr.2004.08.002;;15501245;;12100134;;10.1046/j.1365-2141.2002.03561.x;;12571853;;10.1002/art.10759;;12424614;;10.1038/sj.gt.3301816;;10.1006/mthe.2002.0711;;12409257;;10.1016/s1525-0016(02)90711-2;;9579858;;10.1126/science.2660259;;2660259;;2255890;;10.1038/scientificamerican1190-68;;1608446;;10.1038/357455a0;;10.1161/01.cir.90.4.2070;;7923695;;2299088;;10.1016/s0735-1097(10)80079-8;;8261224;;10.1097/00019501-199305000-00011;;pmc325139;;8180504;;15622378;;10.1016/j.jvs.2004.08.027;;10.1053/ejvs.2001.1532;;11748945;;5423802;;10.1159/000249385;;3896883,"SCUDERI ET AL.: ""Human adipose-derived stromal cells for cell-based therapies in the treatment of systemic sclerosis"", CELL TRANSPLANTATION, vol. 22, no. 5, 2013, pages 779 - 795;;MERSKEY H, BOGDUK N: ""Classification of Chronic Pain, International Association for the Study of Pain (IASP) Task Force on Taxonomy"", 1994, IASP PRESS, pages: 209 - 214;;KOLTZENBURG, M., CLIN. J. OF PAIN, vol. 16, 2000, pages S131 - S 13 8;;""Physicians' Desk Reference, 57th ed."", vol. 329, 2003, pages: 329,1417;;""Physicians' Desk Reference, 57th ed."", 2003, pages: 2563;;""Physicians' Desk Reference, 57th ed."", 2003, pages: 1979,200;;WILLIAMS ET AL.: ""Collagenase lot selection and purification for adipose tissue digestion"", CELL TRANSPLANT, vol. 4, no. 3, 1995, pages 281 - 9;;TWENTYMAN ET AL.: ""Use of bacterial neutral protease for disaggregation of mouse tumours and multicellular tumor spheroids"", CANCER LETT., vol. 9, no. 3, 1980, pages 225 - 8;;NG ET AL.: ""Interstitial flow differentially stimulates blood and lymphatic endothelial cell morphogenesis in vitro"", MICROVASC RES., vol. 68, no. 3, November 2004 (2004-11-01), pages 258 - 64;;WATTS ET AL.: ""Variable product purity and functional capacity after CD34 selection: a direct comparison of the CliniMACS (v2.1) and Isolex 300i (v2.5) clinical scale devices"", BR J HAEMATOL., vol. 118, no. 1, July 2002 (2002-07-01), pages 117 - 23;;""Remington's Pharmaceutical Sciences, 18th ed."", 1990, MACK PUBL. CO, pages: 1435 - 1712;;GELSE ET AL.: ""Articular cartilage repair by gene therapy using growth factor-producing mesenchymal cells"", ARTHRITIS RHEUM., vol. 48, 2003, pages 430 - 41;;HUARD ET AL.: ""Muscle-derived cell-mediated ex vivo gene therapy for urological dysfunction"", GENE THER., vol. 9, 2002, pages 1617 - 26;;KIM ET AL.: ""Ex vivo gene delivery of IL-IRa and soluble TNF receptor confers a distal synergistic therapeutic effect in antigen-induced arthritis"", MOL. THER., vol. 6, 2002, pages 591 - 600;;ANDERSON: ""Human Gene Therapy"", NATURE, vol. 392, no. 6679, 1998, pages 25 - 20;;FRIEDMANN: ""Progress toward human gene therapy"", SCIENCE, vol. 244, no. 4910, 1989, pages 1275 - 1281;;VERMA: ""Gene therapy."", SCIENTIFIC AMERICAN, vol. 263, no. 5, 1990, pages 68 - 84;;MILLER: ""Human gene therapy comes of age"", NATURE, vol. 357, 1992, pages 455 - 460;;LINCOFF ET AL.: ""Local drug delivery for the prevention of restenosis. Fact, fancy, and future"", CIRCULATION, vol. 90, 1994, pages 2070 - 2084;;WOLINSKY ET AL.: ""Use of a perforated balloon catheter to deliver concentrated heparin into the wall of the normal canine artery"", J. AM. COLL. CARDIOL., vol. 15, 1990, pages 475 - 481;;LAMBERT ET AL.: ""Local drug delivery catheters: functional comparison of porous and microporous designs"", CORON. ARTERY DIS., vol. 4, 1993, pages 469 - 475;;MAZUR ET AL.: ""Coronary restenosis and gene therapy"", TEXAS HEART INSTITUTE JOURNAL, vol. 21, 1994, pages 104 - 111;;PAVCNIK ET AL.: ""Second-generation percutaneous bioprosthetic valve: a short-term study in sheep"", EUR. J. ENDOVASC. SURG., vol. 40, 2004, pages 1223 - 1227;;ARTS ET AL.: ""Contaminants from the Transplant Contribute to Intimal Hyperplasia Associated with Microvascular Endothelial Cell Seeding"", EUR. J. ENDOVASC. SURG., vol. 23, 2002, pages 29 - 38;;SCHMIDT ET AL., ARCH PHYS MEDREHABIL., vol. 51, 1970, pages 321 - 7;;CZIRJAK ET AL., RHEUMATOLOLOGY, vol. 47, no. 5, 2008, pages 44 - 45;;SERUP, J., DERMATOLOGY, vol. 171, 1985, pages 41 - 44",PENDING
415,US,A,US 2572687 A,110-740-333-999-96X,1951-10-23,1951,US 75439047 A,1947-06-13,GB 196945 A,1945-01-24,Power-actuated vehicle-moving apparatus,,MAVOR & COULSON LTD,JOHN ANDERSON;;ANDREW FRASER,,https://lens.org/110-740-333-999-96X,Granted Patent,no,5,7,4,4,0,B61J3/00;;B61J3/08;;B61J3/08;;B61J3/00,B61J3/00;;B61J3/08,,0,0,,,,EXPIRED
416,US,A,US 936109 A,150-406-821-319-713,1909-10-05,1909,US 1908/0459051 A,1908-10-22,US 1908/0459051 A,1908-10-22,MACHINE FOR EDGING METALLIC PLATES.,,FRASER JOHN;;GRAY THOMAS,FRASER JOHN;;GRAY THOMAS,,https://lens.org/150-406-821-319-713,Granted Patent,no,0,2,1,1,0,B21B1/224;;Y10T409/50738;;Y10T409/50738;;B21B1/224,B21B1/22,,0,0,,,,EXPIRED
417,US,A1,US 2017/0089899 A1,135-140-286-110-66X,2017-03-30,2017,US 201615278460 A,2016-09-28,US 201615278460 A;;US 201562234017 P,2015-09-28,MICROFLUIDIC CAPTURE AND DETECTION OF BIOLOGICAL ANALYTES,"A microfluidic capture device is described that include a regular macroporous layer comprising a binding molecule, an inlet and outlet port fluidly connected to the regular macroporous layer and configured to add or remove a biological sample to the regular macroporous layer and positioned to allow flow of the biological sample through a flow region in the regular macroporous layer, a first and second electrode positioned on opposite sides of the flow region, and a substrate enclosing the regular macroporous layer, including top and bottom sides on opposite sides of the regular macroporous layer. Methods of using the device to qualitatively and/or quantitatively determine the amount of a biological analyte such as a virus particle in a biological sample obtained from a subject using cyclic voltammetry are also described.",CYCLIC SOLUTIONS LLC,KUNDROD KATHRYN;;FRASER JOHN,CYCLIC SOLUTIONS LLC (2017-06-12),https://lens.org/135-140-286-110-66X,Patent Application,yes,0,5,1,1,0,G01N33/5438;;G01N33/56988;;G01N2333/16;;B01L3/502753;;G01N33/56988;;B01L3/502715;;B01L3/502761;;B01L2300/12;;B01L2300/0887;;B01L2300/0645;;B01L2200/0647;;G01N2333/16;;G01N33/5438,G01N33/569;;B01L3/00;;G01N27/327;;G01N27/416,,0,0,,,,DISCONTINUED
418,DD,A5,DD 211555 A5,140-301-697-034-054,1984-07-18,1984,DD 25333083 A,1983-07-22,GB 8221457 A,1982-07-24,"VERFAHREN ZUR HERSTELLUNG NEUER 4-AMINO-6,7-DIMETHOXYCHINOLIN-DERIVATE",,PFIZER,FRASER SIMON;;DAVID JOHN,,https://lens.org/140-301-697-034-054,Granted Patent,no,0,0,46,53,0,C07C255/00;;C07D215/42;;C07D215/48;;C07D295/195;;C07D401/04;;C07D401/12;;C07D405/12;;C07D413/12;;C07D417/12;;A61P9/12;;C07D215/20;;C07D295/195;;C07D405/12;;C07D401/04;;C07D413/12;;C07D417/12;;C07C255/00;;C07D215/42;;C07D401/12;;C07D215/48,A61K31/47;;C07D215/20;;A61K31/4709;;A61K31/495;;A61K31/50;;A61K31/505;;A61K31/53;;A61P9/12;;C07D215/42;;C07D215/48;;C07D295/195;;C07D401/04;;C07D401/12;;C07D401/14;;C07D405/12;;C07D405/14;;C07D413/12;;C07D413/14;;C07D417/12,,0,0,,,,EXPIRED
419,ES,T3,ES 2641547 T3,172-795-954-073-649,2017-11-10,2017,ES 14845486 T,2014-09-17,US 201361880086 P;;US 201461977466 P;;US 2014/0056145 W,2013-09-19,Métodos de uso de células derivadas de tejido adiposo en el tratamiento del fenómeno de Raynaud asociado con esclerodermia,,CYTORI THERAPEUTICS INC,FRASER JOHN;;MAGALON GUY,,https://lens.org/172-795-954-073-649,Granted Patent,no,0,5,18,18,0,A61K35/35;;A61K35/28;;A61P17/00;;A61P19/02;;A61P25/02;;A61P25/04;;A61P29/00;;A61P37/00;;A61P43/00;;A61K35/35;;A61K35/28;;A61K9/0019,C12N5/077;;A61K35/28;;A61K35/35;;A61P17/00;;A61P37/00;;A61P43/00;;C12N5/0775,,0,0,,,,ACTIVE
420,EP,A1,EP 2347351 A1,040-689-486-318-784,2011-07-27,2011,EP 09802206 A,2009-11-04,IB 2009007348 W;;US 26438108 A,2008-11-04,METHOD AND SYSTEM FOR ARCHIVING AND RETRIEVING ITEMS BASED ON EPISODIC MEMORY OF GROUPS OF PEOPLE,,6S LTD,SHARPE ELIZABETH;;FRASER JOHN,,https://lens.org/040-689-486-318-784,Patent Application,yes,0,0,6,6,0,G06F16/435;;G06F16/489;;G06F16/438;;G06F16/438;;G06F16/489;;G06F16/435,G06F17/30,,0,0,,,,DISCONTINUED
421,CN,A,CN 105934155 A,060-402-208-236-329,2016-09-07,2016,CN 201480063073 A,2014-09-17,US 201361880086 P;;US 201461977466 P;;US 2014/0056145 W,2013-09-19,Methods of using adipose tissue-derived cells in the modulation of pain and/or fibrosis,"Aspects of the present invention relate to the field of medicine, specifically, the effect of adipose tissue and its components on modulating pain and/or fibrosis.",CYTORI THERAPEUTICS INC,FRASER JOHN;;MAGALON GUY,,https://lens.org/060-402-208-236-329,Patent Application,no,2,6,18,18,0,A61K35/35;;A61K35/28;;A61P17/00;;A61P19/02;;A61P25/02;;A61P25/04;;A61P29/00;;A61P37/00;;A61P43/00;;A61K35/35;;A61K35/28;;A61K9/0019,A01N63/00,,0,0,,,,DISCONTINUED
422,EP,A1,EP 0900534 A1,061-708-074-904-085,1999-03-10,1999,EP 98307187 A,1998-09-07,GB 9719046 A,1997-09-08,Device and assembly,"A wiper unit (6) for a cosmetics applicator is provided with resilient fingers (22) at an obtuse angle to the axis of its orifice, and occupying at most 50% of the orifice area.",GEKA MFG LTD,FORDHAM JOHN FRASER WOOD,GEKA BRUSH GMBH (2001-08-16),https://lens.org/061-708-074-904-085,Patent Application,yes,10,8,4,15,0,A45D34/046;;A45D34/046,A45D34/04,,0,0,,,,DISCONTINUED
423,GB,A,GB 1064947 A,082-969-748-037-342,1967-04-12,1967,GB 446564 A,1964-02-03,GB 446564 A,1964-02-03,Improvements relating to thermo-electric devices,"1,064,947. Thermocouples. ASSOCIATED ELECTRICAL INDUSTRIES Ltd. Jan. 13, 1965 [Feb. 3, 1964], No. 4465/64. Heading H1K. Manufacture of a known kind of thermocouple (Fig. 1, not shown), consisting of two dissimilar semi-conductors (e.g. lead telluride and germanium telluride) joined by a metal (e.g. nickel) member to which they are alloyed, is complicated by the fact that the temperature at which one of the semi-conductors alloys with the metal is above the melting point of the other semi-conductor. To avoid this disadvantage the invention provides for the metal member to be replaced by a body consisting of the lower melting point semi-conductor alloyed with a noble metal which further depresses its melting point. In the case of a PbTe-GeTe couple the joining body would be of GeTe alloyed with 1 to 2% by weight of gold (or silver or platinum). Fig. 2 (not shown) depicts a preferred form of couple of this constitution and Figs. 3 and 4 (not shown) depicts a thermopile consisting of a series connected array of such couples. The exposed surfaces of the semi-conductor bodies used in the couples are insulant-coated.",ASS ELECT IND,FRASER MURDO JAMES JOHN,,https://lens.org/082-969-748-037-342,Granted Patent,no,0,0,1,2,0,H10N10/817,H01L35/08,H1K KTB           TB;;H1K K1D6E         TB;;H1K K2R3F         TB;;H1K K2R3Y         TB;;H1K K2S10         TB;;H1K K2S11G        TB;;H1K K2S11S        TB;;H1K K2S13         TB;;H1K K2S22D        TB;;H1K K2S23         TB;;H1K K6T5C1A       TB;;H1K K6T5C1D       TB;;H1K K6T5C1Y       TB;;H1K K6T5EY        TB;;H1K K6T7A4        TB;;H1K K6T7C1        TB;;H1K K6T7D2A       TB,0,0,,,,EXPIRED
424,DE,D1,DE 60022828 D1,084-621-193-096-028,2005-11-03,2005,DE 60022828 T,2000-07-03,GB 9915947 A;;GB 0005503 A,1999-07-07,Kosmetikeinheit und deren Zusammensetzung,,GEKA BRUSH GMBH,FORDHAM JOHN FRASER WOOD,"GEKA GMBH, 91572 BECHHOFEN, DE (2010-12-30)",https://lens.org/084-621-193-096-028,Granted Patent,no,0,0,8,15,0,A45D40/267;;A46B3/18;;A46B9/021;;A46B2200/1053,A45D34/04;;A45D40/26;;A46B3/18;;A46B9/02,,0,0,,,,EXPIRED
425,WO,A3,WO 2007/017775 A3,171-669-365-441-753,2007-08-30,2007,IB 2006052475 W,2006-07-19,US 70639805 P,2005-08-08,ULTRASOUND TRANSDUCER ARRAYS,"An ultrasonic transducer element (104,313) , comprising: an active layer (201) having a first side and a second side; a first electrode (204, 317) connected to the first side and a second electrode (205,319) connected to the first side; and a circuit (315) having a first output (316) connected to the first electrode and a second output (318) connected to the second electrode, wherein the first output provides a first voltage to the first electrode, the second output provides a second voltage to the second electrode and the circuit provides a voltage to the active layer that is equal to approximately a difference between the first voltage and the second voltage.",KONINKL PHILIPS ELECTRONICS NV;;FRASER JOHN;;DUFORT BENOIT,FRASER JOHN;;DUFORT BENOIT,,https://lens.org/171-669-365-441-753,Search Report,yes,5,0,10,10,0,B06B1/0207;;B06B1/0207,B06B1/02,,0,0,,,,PENDING
426,CN,A,CN 101252970 A,029-369-718-609-214,2008-08-27,2008,CN 200680031530 A,2006-08-25,IB 2006052966 W;;US 71231605 P,2005-08-30,Combination imaging and therapy transducer with therapy transducer amplifier,"A combined ultrasound imaging and therapy transducer (10) includes a linear array of imaging transducer elements (14). First and second linear arrays of therapy transducer elements (18, 20) extend longitudinally along respective first and second sides of the imaging transducer elements and are canted inwardly toward each other. The imaging and therapy transducer is used with an ultrasound imaging system to locate clots in a region of interest. After the region of interest has been perfused with a microbubble contrast agent, the therapy transducer elements are driven by an amplifier located in the transducer to dissolve the clot. The use of the imaging transducer elements and the therapy transducer elements can be interleaved so that the therapy can be conditioned on an ultrasound image showing substantial destruction of the contrast agent microbubbles, re-perfusion of microbubbles in the region of interest, or the continued presence of the clot.",KONINKL PHILIPS ELECTRONICS NV,JOHN FRASER;;MICHALAKIS AVERKIOU,,https://lens.org/029-369-718-609-214,Patent Application,no,0,3,7,7,0,A61B8/0833;;A61B8/14;;A61B8/4405;;A61B8/481;;A61B17/22004;;A61B17/2256;;A61B2017/22028;;G01S15/8977;;G01S15/8918;;A61B2090/378;;A61B8/0833;;A61B8/14;;A61B8/4405;;A61B8/481;;A61B17/22004;;A61B17/2256;;A61B2017/22028;;G01S15/8977;;G01S15/8918;;A61B2090/378,A61N7/00;;A61B8/14;;A61B17/22;;A61B19/00,,0,0,,,,ACTIVE
427,CA,A,CA 287133 A,068-282-497-669-231,1929-02-12,1929,CA 287133D A,,CA 287133T A,,AIM INDICATOR,,LAMONT JOHN WILLIAM FRASER,LAMONT JOHN WILLIAM FRASER,,https://lens.org/068-282-497-669-231,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
428,US,B2,US 10920532 B2,089-565-001-561-035,2021-02-16,2021,US 201616061200 A,2016-12-22,GB 201522652 A;;GB 2016054031 W,2015-12-22,Squeeze packer and method of setting a squeeze packer,"A squeeze packer ( 1 ) assembly incorporates a built-in setting tool which removes the need for a separate setting tool. The packer comprises a body comprising a mandrel ( 9 ), a shuttle sleeve ( 7 ), and a stinger ( 2 ) assembly which is lowered into the wellbore on the end of tubing ( 102 ). The shuttle sleeve is housed within the body and incorporates a latch device in the form of a collet comprising a plurality of resilient fingers ( 14 ) to releasably connect to the stinger. A ball seat ( 15 ) allows hydraulic setting of slips ( 3 ). Additional slips ( 4 ) can be set by applying tension on the tubing (FIG. 4 ). Once released, the stinger can open and close the shuttle sleeve by reciprocating in and out of the packer as many times as required during cementing operations.",CORETRAX TECH LIMITED,FONG JASON;;FRASER JOHN,CORETRAX GLOBAL LIMITED (2022-04-21);;CORETRAX TECHNOLOGY LIMITED (2018-07-11),https://lens.org/089-565-001-561-035,Granted Patent,yes,6,0,8,8,0,E21B23/06;;E21B29/00;;E21B33/1293;;E21B33/1294;;E21B43/116;;E21B34/142;;E21B23/06;;E21B29/00;;E21B33/1293;;E21B33/1294;;E21B43/116;;E21B34/142;;E21B23/06;;E21B29/00;;E21B33/1293;;E21B33/1294;;E21B43/116;;E21B34/142;;E21B34/142;;E21B33/1285;;E21B33/1293;;E21B33/14;;E21B34/102,E21B33/129;;E21B33/128;;E21B33/14;;E21B34/10;;E21B34/14,,4,0,,,"Coretrax: “Coretrax—CX-SV Squeeze Packer”, retrieved from the internet: url: https://www.youtube.com/wach?v=yFK9sb41o0M, published on Jun. 22, 2016, retrieved on Feb. 6, 2017, 1 page.;;International Search Report and Written Opinion for International Application No. PCT/GB2016/054031 dated Feb. 16, 2017, 16 pages.;;International Preliminary Report on Patentability for International Application No. PCT/GB2016/054031 dated Jul. 5 26, 2018, 9 pages.;;Halliburton Drillable Service Tools, pp. 3-1 to 3-52, date unknown.",ACTIVE
429,EP,A1,EP 1066771 A1,093-974-658-458-421,2001-01-10,2001,EP 00305609 A,2000-07-03,GB 9915947 A;;GB 0005503 A,1999-07-07,Applicator and assembly,"A cosmetics applicator assembly, especially a mascara brush, comprising a cap 8 to a container having a wiper 6 in its neck 3, has a stop 20 at the end of a rod 12, immediately above the applicator 14, the rod tapering towards the stop. The wiper is provided with fingers 22 which bear against the rod so that as the applicator is withdrawn from the container as the tapered portion passes them they relax until their ends contact the stop which inverts them as it passes, the fingers remaining inturned until the applicator passes them when they will revert to their relaxed state removing any blob of cosmetic from the end of the applicator.",GEKA MFG LTD,FORDHAM JOHN FRASER WOOD,GEKA BRUSH GMBH (2001-08-16),https://lens.org/093-974-658-458-421,Patent Application,yes,9,14,8,15,0,A45D40/267;;A46B3/18;;A46B9/021;;A46B2200/1053,A45D34/04;;A45D40/26;;A46B3/18;;A46B9/02,,0,0,,,,EXPIRED
430,JP,A,JP 2001061547 A,108-980-377-185-539,2001-03-13,2001,JP 2000207283 A,2000-07-07,GB 9915947 A;;GB 0005503 A,1999-07-07,APPLICATOR AND ASSEMBLY,"PROBLEM TO BE SOLVED: To provide an applicator and a rod for cosmetic material, such as mascara and hair dye, and an assembly including the applicator. SOLUTION: This assembly of a cosmetic applicator, particularly a mascara brush, includes a cap 8 for a container, the cap 8 having a wiper 6 in its neck 3 and having a stop 20 immediately above the applicator 14 at the end of the rod 12, with the rod tapered in the direction of the stop 20. The wiper is provided with a finger 22. The finger 22 presses and supports the rod, and when the applicator is drawn out of the container and passing through the tapered part, the finger 22 is relaxed; when their ends come into contact with the stop, they are reversed and held reversed until the applicator passes therethrough. They are returned to relaxed states to remove droplets of cosmetic from the end of the applicator.",GEKA MFG LTD,FORDHAM JOHN FRASER WOOD,,https://lens.org/108-980-377-185-539,Patent Application,no,5,6,8,15,0,A45D40/267;;A46B3/18;;A46B9/021;;A46B2200/1053,A45D34/04;;A45D40/26;;A46B3/18;;A46B9/02,,0,0,,,,EXPIRED
431,DE,A1,DE 1496090 A1,034-648-528-815-01X,1969-06-04,1969,DE 1496090 A,1964-04-17,DE C0032661 A;;NL 6404280 A,1964-04-17,Halbkristalline glaskeramische Koerper,,CORNING GLASS WORKS,FRASER MAC DOWELL JOHN,,https://lens.org/034-648-528-815-01X,Patent Application,no,0,1,4,6,0,C03C10/0027;;C03C10/0009,C03C10/00,,0,0,,,,PENDING
432,US,A,US 1699595 A,046-842-338-859-286,1929-01-22,1929,US 22450627 A,1927-10-06,GB 1699595X A,1927-02-28,Aim-indicating device for small arms,,FRASER LAMONT JOHN WILLIAM,FRASER LAMONT JOHN WILLIAM,,https://lens.org/046-842-338-859-286,Granted Patent,no,0,3,1,1,0,F41A33/02;;F41A33/02,F41A33/02,,0,0,,,,EXPIRED
433,CA,A,CA 478955 A,081-558-404-677-853,1951-11-27,1951,CA 478955D A,,CA 478955T A,,"POWER-ACTUATED VEHICLE-MOVING APPARATUS, PARTICULARLY FOR USE IN COLLIERIES",,MAVOR AND COULSON,FRASER ANDREW;;ANDERSON JOHN,,https://lens.org/081-558-404-677-853,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
434,GB,A,GB 2505165 A,111-243-849-399-243,2014-02-26,2014,GB 201213161 A,2012-07-24,GB 201213161 A,2012-07-24,Pump out plug assembly,A pump out plug assembly suitable for cementing operations consists of check valves and top 12 and bottom 13 rubber plugs. The check valve may be a one way plate valve and the pump out plug may include a shear pin mechanism and a bull nose.,FONG JASON;;FRASER JOHN;;CORETRAX TECHNOLOGY,FONG JASON;;FRASER JOHN,,https://lens.org/111-243-849-399-243,Patent Application,no,3,1,2,2,0,E21B33/16;;E21B21/10;;Y02E10/10;;F24T2010/53;;E21B33/16;;E21B33/16,E21B33/16,,0,0,,,,DISCONTINUED
435,CA,A1,CA 3194188 A1,138-530-088-962-098,2022-04-07,2022,CA 3194188 A,2021-09-27,US 202063084752 P;;US 2021/0052164 W,2020-09-29,WASTEWATER TREATMENT SYSTEM AND METHOD USING AEROBIC GRANULAR SLUDGE WITH IMMERSED MEMBRANE SEPARATION,"A treatment system and method for removal of nutrients and other pollutants to produce a low solid, high quality effluent suitable for discharge or reuse using a combination of aerobic granular sludge (AGS), either in a sequencing batch reactor (SBR) AGS configuration or in a flow through AGS configuration, in combination with immersed/submerged membranes commonly referred to as membrane bio-reactor (MBR) wastewater treatment processes, systems, and methods.",CAROLLO ENG INC,FRASER JOHN;;GILMORE ANDREW,,https://lens.org/138-530-088-962-098,Patent Application,no,0,0,5,5,0,Y02W10/10;;C02F3/301;;C02F3/085;;C02F3/1273;;C02F3/301;;Y02W10/10;;C02F3/085;;C02F3/1273;;C02F3/1273;;C02F3/301;;C02F2305/12,C02F3/08;;C02F3/12;;C02F3/30,,0,0,,,,PENDING
436,GB,A,GB 2312617 A,140-585-984-114-601,1997-11-05,1997,GB 9609339 A,1996-05-03,GB 9609339 A,1996-05-03,Cosmetics applicator; brush wiper,"An applicator for cosmetics; e.g. mascara; has cosmetic container 1, cap 8, applicator brush 14 extending from the cap, and a brush wiper 6 located in the container neck and having an array of resilient fingers extending from a body and spaced around an orifice in the body. Each finger has a part parallel to the axis of the orifice and an inwardly-directed free end, which ends remove the drop of cosmetic from the brush end as it is withdrawn. The finger ends may rest in a groove in brush rod 12.",GEKA MFG LTD,FORDHAM JOHN FRASER WOOD,,https://lens.org/140-585-984-114-601,Patent Application,no,5,18,2,2,0,A45D40/267,A45D40/26,A4K KBA           KBA(C);;A4K K157          KBA(C);;A4K K161          KBA(C);;U1S S1120,0,0,,,,DISCONTINUED
437,CA,A,CA 56474 A,153-136-414-820-465,1897-07-02,1897,CA 56474D A,1897-06-02,CA 56474T A,1897-06-02,TACKLE BLOCK,,CAMPBELL DUNCAN;;FRASER JOHN,CAMPBELL DUNCAN;;FRASER JOHN,,https://lens.org/153-136-414-820-465,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
438,DE,T2,DE 69517310 T2,171-136-266-923-94X,2000-11-23,2000,DE 69517310 T,1995-03-31,GB 9406486 A;;GB 9500734 W,1994-03-31,ABNEHMBARES ABSTURZSICHERUNGSGERÄT,,LATCHWAYS LTD,ATKINSON FRASER;;PATTERSON JOHN,,https://lens.org/171-136-266-923-94X,Granted Patent,no,0,0,12,12,0,A62B35/005;;A62B35/0087;;E06C7/18;;E06C7/186;;A62B35/0087;;A62B35/005;;E06C7/18;;E06C7/186,A62B1/14;;E06C9/14;;A62B35/00;;A62B35/04;;E06C7/18,,0,0,,,,EXPIRED
439,GB,A,GB 2328863 A,193-010-534-116-920,1999-03-10,1999,GB 9719046 A,1997-09-08,GB 9719046 A,1997-09-08,Cosmetics applicator:wiper unit,"In an applicator device for a cosmetic, e.g. mascara, where an applicator such as a rod with an end brush is withdrawn from a cosmetic container in which it is stored, a wiper to remove surplus cosmetic from the applicator has a wiping orifice 18 and resilient fingers extending inwardly at an angle of from 90-120 degrees to the orifice axis. The fingers occupy 50% of the area of the orifice when viewed axially.",GEKA MFG LTD,FORDHAM JOHN FRASER WOOD,,https://lens.org/193-010-534-116-920,Patent Application,no,6,0,4,15,0,A45D34/046;;A45D34/046,A45D34/04,A4K KBA           KBA(C);;A4K K157          KBA(C);;A4K K161          KBA(C);;U1S S1120,0,0,,,,DISCONTINUED
440,DK,T3,DK 3046417 T3,195-336-269-254-486,2017-10-09,2017,DK 14845486 T,2014-09-17,US 201361880086 P;;US 201461977466 P;;US 2014/0056145 W,2013-09-19,FREMGANGSMÅDER TIL ANVENDELSE AF FEDTVÆVSAFLEDTE CELLER TIL BEHANDLING AF RAYNAUDS SYNDROM FORBUNDET MED SCLERODERMIA,,CYTORI THERAPEUTICS INC,FRASER JOHN;;MAGALON GUY,,https://lens.org/195-336-269-254-486,Granted Patent,no,0,5,18,18,0,A61K35/35;;A61K35/28;;A61P17/00;;A61P19/02;;A61P25/02;;A61P25/04;;A61P29/00;;A61P37/00;;A61P43/00;;A61K35/35;;A61K35/28;;A61K9/0019,C12N5/077;;A61K35/28;;A61K35/35;;A61P17/00;;A61P37/00;;A61P43/00;;C12N5/0775,,0,0,,,,ACTIVE
441,WO,A1,WO 2017/081494 A1,063-319-034-415-176,2017-05-18,2017,GB 2016054031 W,2016-12-22,GB 201522652 A,2015-12-22,SQUEEZE PACKER AND METHOD OF SETTING A SQUEEZE PACKER,"A squeeze packer (1) assembly incorporates a built-in setting tool which removes the need for a separate setting tool. The packer comprises a body comprising a mandrel (9), a shuttle sleeve (7), and a stinger (2) assembly which is lowered into the wellbore on the end of tubing (102). The shuttle sleeve is housed within the body and incorporates a latch device in the form of a collet comprising a plurality of resilient fingers (14) to releasably connect to the stinger. A ball seat (15) allows hydraulic setting of slips (3). Additional slips (4) can be set by applying tension on the tubing (fig 4). Once released, the stinger can open and close the shuttle sleeve by reciprocating in and out of the packer as many times as required during cementing operations.",CORETRAX TECH LTD,FONG JASON;;FRASER JOHN,,https://lens.org/063-319-034-415-176,Patent Application,yes,3,3,8,8,0,E21B23/06;;E21B29/00;;E21B33/1293;;E21B33/1294;;E21B43/116;;E21B34/142;;E21B23/06;;E21B29/00;;E21B33/1293;;E21B33/1294;;E21B43/116;;E21B34/142;;E21B23/06;;E21B29/00;;E21B33/1293;;E21B33/1294;;E21B43/116;;E21B34/142;;E21B34/142;;E21B33/1285;;E21B33/1293;;E21B33/14;;E21B34/102,E21B23/06;;E21B29/00;;E21B33/129;;E21B34/14;;E21B43/116,,1,0,,,"CORETRAX: ""Coretrax - CX-SV Squeeze Packer"", 22 June 2016 (2016-06-22), pages 1, XP054977133, Retrieved from the Internet <URL:https://www.youtube.com/watch?v=yFK9sb41o0M> [retrieved on 20170206]",PENDING
442,DE,T2,DE 60022828 T2,068-393-040-329-925,2006-07-06,2006,DE 60022828 T,2000-07-03,GB 9915947 A;;GB 0005503 A,1999-07-07,Kosmetikeinheit und deren Zusammensetzung,,GEKA BRUSH GMBH,FORDHAM JOHN FRASER WOOD,"GEKA GMBH, 91572 BECHHOFEN, DE (2010-12-30)",https://lens.org/068-393-040-329-925,Granted Patent,no,0,3,8,15,0,A45D40/267;;A46B3/18;;A46B9/021;;A46B2200/1053,A45D34/04;;A45D40/26;;A46B3/18;;A46B9/02,,0,0,,,,EXPIRED
443,IL,A,IL 301450 A,101-530-887-261-367,2023-05-01,2023,IL 30145023 A,2023-03-16,US 202063084752 P;;US 2021/0052164 W,2020-09-29,Wastewater treatment system and method using aerobic granular sludge with immersed membrane separation,,CAROLLO ENG INC;;FRASER JOHN;;GILMORE ANDREW,FRASER JOHN;;GILMORE ANDREW,,https://lens.org/101-530-887-261-367,Patent Application,no,0,0,5,5,0,Y02W10/10;;C02F3/301;;C02F3/085;;C02F3/1273;;C02F3/301;;Y02W10/10;;C02F3/085;;C02F3/1273;;C02F3/1273;;C02F3/301;;C02F2305/12,,,0,0,,,,PENDING
444,US,A1,US 2020/0270967 A1,056-692-686-711-984,2020-08-27,2020,US 201616061200 A,2016-12-22,GB 201522652 A;;GB 2016054031 W,2015-12-22,Squeeze Packer and Method of Setting a Squeeze Packer,"A squeeze packer ( 1 ) assembly incorporates a built-in setting tool which removes the need for a separate setting tool. The packer comprises a body comprising a mandrel ( 9 ), a shuttle sleeve ( 7 ), and a stinger ( 2 ) assembly which is lowered into the wellbore on the end of tubing ( 102 ). The shuttle sleeve is housed within the body and incorporates a latch device in the form of a collet comprising a plurality of resilient fmgers ( 14 ) to releasably connect to the stinger. A ball seat ( 15 ) allows hydraulic setting of slips ( 3 ). Additional slips ( 4 ) can be set by applying tension on the tubing (FIG. 4 ). Once released, the stinger can open and close the shuttle sleeve by reciprocating in and out of the packer as many times as required during cementing operations.",CORETRAX TECH LIMITED,FONG JASON;;FRASER JOHN,CORETRAX GLOBAL LIMITED (2022-04-21);;CORETRAX TECHNOLOGY LIMITED (2018-07-11),https://lens.org/056-692-686-711-984,Patent Application,yes,0,7,8,8,0,E21B23/06;;E21B29/00;;E21B33/1293;;E21B33/1294;;E21B43/116;;E21B34/142;;E21B23/06;;E21B29/00;;E21B33/1293;;E21B33/1294;;E21B43/116;;E21B34/142;;E21B23/06;;E21B29/00;;E21B33/1293;;E21B33/1294;;E21B43/116;;E21B34/142;;E21B34/142;;E21B33/1285;;E21B33/1293;;E21B33/14;;E21B34/102,E21B34/14;;E21B33/128;;E21B33/129;;E21B34/10,,0,0,,,,ACTIVE
445,CA,A1,CA 2924883 A1,016-348-634-208-937,2015-03-26,2015,CA 2924883 A,2014-09-17,US 201361880086 P;;US 201461977466 P;;US 2014/0056145 W,2013-09-19,METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS,"Aspects of the present invention relate to the field of medicine, specifically, the effect of adipose tissue and its components on modulating pain and/or fibrosis.",CYTORI THERAPEUTICS INC,FRASER JOHN;;MAGALON GUY,,https://lens.org/016-348-634-208-937,Patent Application,no,0,5,18,18,0,A61K35/35;;A61K35/28;;A61P17/00;;A61P19/02;;A61P25/02;;A61P25/04;;A61P29/00;;A61P37/00;;A61P43/00;;A61K35/35;;A61K35/28;;A61K9/0019,A01N63/00,,0,0,,,,DISCONTINUED
446,CA,A,CA 26650 A,077-140-618-285-895,1887-05-07,1887,CA 26650D A,,CA 26650T A,,WAGGON AND OTHER VEHICLES,,FRASER JOHN;;HALL MICHEAL,FRASER JOHN;;HALL MICHEAL,,https://lens.org/077-140-618-285-895,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
447,GB,A,GB 2561480 A,074-081-299-518-594,2018-10-17,2018,GB 201809215 A,2016-12-22,GB 2016054031 W;;GB 201522652 A,2015-12-22,Squeeze packer and method of setting a squeeze packer,"A squeeze packer (1) assembly incorporates a built-in setting tool which removes the need for a separate setting tool. The packer comprises a body comprising a mandrel (9), a shuttle sleeve (7), and a stinger (2) assembly which is lowered into the wellbore on the end of tubing (102). The shuttle sleeve is housed within the body and incorporates a latch device in the form of a collet comprising a plurality of resilient fingers (14) to releasably connect to the stinger. A ball seat (15) allows hydraulic setting of slips (3). Additional slips (4) can be set by applying tension on the tubing (fig 4). Once released, the stinger can open and close the shuttle sleeve by reciprocating in and out of the packer as many times as required during cementing operations.",CORETRAX TECH LIMITED,JASON FONG;;JOHN FRASER,,https://lens.org/074-081-299-518-594,Patent Application,no,2,0,8,8,0,E21B23/06;;E21B29/00;;E21B33/1293;;E21B33/1294;;E21B43/116;;E21B34/142;;E21B23/06;;E21B29/00;;E21B33/1293;;E21B33/1294;;E21B43/116;;E21B34/142;;E21B23/06;;E21B29/00;;E21B33/1293;;E21B33/1294;;E21B43/116;;E21B34/142;;E21B34/142;;E21B33/1285;;E21B33/1293;;E21B33/14;;E21B34/102,E21B23/06;;E21B29/00;;E21B33/129;;E21B34/14;;E21B43/116,,1,0,,,"Coretrax, ""Coretrax - CX-SV Squeeze Packer"", (20160622), page 1, URL: https://www.youtube.com/watch?v=yFK9sb41o0M, (20170206), XP054977133",ACTIVE
448,AT,B,AT 115718 B,076-680-681-439-587,1930-01-10,1930,AT 115718D A,1926-05-12,GB 115718X A,1925-05-26,Zielkontrolleinrichtung für Feuerwaffen.,,LAMONT JOHN WILLIAM FRASER,LAMONT JOHN WILLIAM FRASER,,https://lens.org/076-680-681-439-587,Granted Patent,no,0,0,1,1,0,,,72F,0,0,,,,EXPIRED
449,US,A1,US 2016/0206661 A1,104-100-119-307-202,2016-07-21,2016,US 201414917441 A,2014-09-17,US 201414917441 A;;US 201361880086 P;;US 201461977466 P;;US 2014/0056145 W,2013-09-19,METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE MODULATION OF PAIN AND/OR FIBROSIS,"Aspects of the present invention relate to the field of medicine, specifically, the effect of adipose tissue and its components on modulating pain and/or fibrosis.",FRASER JOHN;;MAGALON GUY,FRASER JOHN;;MAGALON GUY,CYTORI THERAPEUTICS INC (2014-12-02);;LOREM VASCULAR PTE. LTD (2019-04-24),https://lens.org/104-100-119-307-202,Patent Application,yes,0,3,18,18,0,A61K35/35;;A61K35/28;;A61P17/00;;A61P19/02;;A61P25/02;;A61P25/04;;A61P29/00;;A61P37/00;;A61P43/00;;A61K35/35;;A61K35/28;;A61K9/0019,A61K35/28;;A61K9/00,,0,0,,,,DISCONTINUED
450,EP,B8,EP 3299451 B8,127-642-091-147-147,2019-09-18,2019,EP 17172872 A,2014-09-17,US 201361880086 P;;US 201461977466 P;;EP 14845486 A;;US 2014/0056145 W,2013-09-19,METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF RAYNAUD'S PHENOMENON,,LOREM VASCULAR PTE LTD,FRASER JOHN;;MAGALON GUY,LOREM VASCULAR PTE. LTD. (2019-09-11),https://lens.org/127-642-091-147-147,Amended Patent,yes,1,0,18,18,0,A61K35/35;;A61K35/28;;A61P17/00;;A61P19/02;;A61P25/02;;A61P25/04;;A61P29/00;;A61P37/00;;A61P43/00;;A61K35/35;;A61K35/28;;A61K9/0019,C12N5/077;;A61K35/28;;A61K35/35;;A61P17/00;;A61P37/00;;A61P43/00;;C12N5/0775,,3,0,,,"POZZI M R ET AL: ""AUTOLOGOUS FAT TRANSFER FOR DIGITAL ULCERS TREATMENT IN SYSTEMIC SCLEROSIS"", ANNALS OF THE RHEUMATIC DISEASES, vol. 72, no. Suppl. 3, June 2013 (2013-06) , page 649, XP009190959, & ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY (EULAR); MADRID, SPAIN; JUNE 12 -15, 2013;;SCUDERI N ET AL: ""Human adipose-derived stromal cells for cell-based therapies in the treatment of systemic sclerosis"", CELL TRANSPLANTATION 2013 COGNIZANT COMMUNICATION CORPORATION USA, vol. 22, no. 5, 17 April 2012 (2012-04-17) , pages 779-795, XP002759956, ISSN: 0963-6897;;DAUMAS A ET AL: ""Interests and potentials of adipose tissue in scleroderma"", REVUE DE MEDECINE INTERNE 2013 ELSEVIER MASSON SAS FRA, vol. 34, no. 12, 17 September 2013 (2013-09-17), pages 763-769, XP002759957, ISSN: 0248-8663",ACTIVE
451,FI,A,FI 13040 A,161-181-148-789-292,1930-08-22,1930,FI 13040D A,,FI 13040T A,,Anordning för angivande av en skyttes siktpunkt,,,FRASER LAMONT JOHN WILLIAM,,https://lens.org/161-181-148-789-292,Granted Patent,no,0,0,1,1,0,,F41G3/26,,0,0,,,,EXPIRED
452,GB,A,GB 2567838 A,168-787-954-484-603,2019-05-01,2019,GB 201717561 A,2017-10-25,GB 201717561 A,2017-10-25,Improved inflow test packer for drilling applications,"An improved downhole packer tool 100 includes a bypass channel and a method of reducing or preventing debris from entering the bypass chamber 4. One or more meshes (17, fig 2) filter the fluid entering via the lower port (6, fig 2). When set, the lower body 1 moves downwards with respect to the lower housing 2. Seals 3 prevent the passage of fluid into the chamber 4. The seals may be replaced by filters. ‘Inflow’ or ‘negative’ tests may be carried out when the packer is in place.",CORETRAX TECH LIMITED,JASON FONG;;JOHN FRASER,,https://lens.org/168-787-954-484-603,Patent Application,no,4,0,3,3,0,E21B23/06;;E21B33/12;;E21B33/1243;;E21B33/127;;E21B33/1285;;E21B33/14;;E21B33/12;;E21B33/1243;;E21B33/127;;E21B33/14,E21B33/127;;E21B21/00;;E21B33/12;;E21B33/124;;E21B33/14,,0,0,,,,ACTIVE
453,US,A1,US 2010/0141093 A1,000-786-156-183-729,2010-06-10,2010,US 6318106 A,2006-07-19,US 6318106 A;;US 70639805 P;;IB 2006052475 W,2005-08-08,ULTRASOUND TRANSDUCER ARRAYS,"An ultrasonic transducer ( 104,313 ), transducer array ( 103 ) and an ultrasonic probe ( 100 ) are described.",KONINKL PHILIPS ELECTRONICS NV,FRASER JOHN;;DUFORT BENOIT,KONINKLIJKE PHILIPS ELECTRONICS N.V (2008-01-17),https://lens.org/000-786-156-183-729,Patent Application,yes,13,6,10,10,0,B06B1/0207;;B06B1/0207,H01L41/047,310/334,0,0,,,,INACTIVE
454,CN,B,CN 101237946 B,026-499-280-391-789,2013-03-27,2013,CN 200680029122 A,2006-07-19,IB 2006052475 W;;US 70639805 P,2005-08-08,Ultrasound transducer arrays,,KONINKL PHILIPS ELECTRONICS NV,DUFORT BENOIT;;FRASER JOHN,,https://lens.org/026-499-280-391-789,Granted Patent,no,0,0,10,10,0,B06B1/0207;;B06B1/0207,B06B1/02,,0,0,,,,INACTIVE
455,US,A,US 897256 A,104-696-199-189-647,1908-08-25,1908,US 1908/0417720 A,1908-02-25,US 1908/0417720 A,1908-02-25,MACHINE FOR EDGING METAL PLATES.,,FRASER JOHN;;GRAY THOMAS,FRASER JOHN;;GRAY THOMAS,,https://lens.org/104-696-199-189-647,Granted Patent,no,0,4,1,1,0,B21B2015/0014;;B21B2015/0014;;B21B15/0007,,,0,0,,,,EXPIRED
456,US,A,US 910471 A,156-671-226-093-399,1909-01-19,1909,US 1908/0444858 A,1908-07-22,US 1908/0444858 A,1908-07-22,MACHINE FOR EDGING METAL PLATES.,,FRASER JOHN;;GRAY THOMAS,FRASER JOHN;;GRAY THOMAS,,https://lens.org/156-671-226-093-399,Granted Patent,no,0,2,1,1,0,B21B1/224;;B21B1/224;;Y10T409/50738;;Y10T409/50738,B21B1/22,,0,0,,,,EXPIRED
457,WO,A1,WO 2022/072270 A1,196-498-757-127-628,2022-04-07,2022,US 2021/0052164 W,2021-09-27,US 202063084752 P,2020-09-29,WASTEWATER TREATMENT SYSTEM AND METHOD USING AEROBIC GRANULAR SLUDGE WITH IMMERSED MEMBRANE SEPARATION,"A treatment system and method for removal of nutrients and other pollutants to produce a low solid, high quality effluent suitable for discharge or reuse using a combination of aerobic granular sludge (AGS), either in a sequencing batch reactor (SBR) AGS configuration or in a flow through AGS configuration, in combination with immersed/submerged membranes commonly referred to as membrane bio-reactor (MBR) wastewater treatment processes, systems, and methods.",CAROLLO ENG INC,FRASER JOHN;;GILMORE ANDREW,,https://lens.org/196-498-757-127-628,Patent Application,yes,5,2,5,5,0,Y02W10/10;;C02F3/301;;C02F3/085;;C02F3/1273;;C02F3/301;;Y02W10/10;;C02F3/085;;C02F3/1273;;C02F3/1273;;C02F3/301;;C02F2305/12,C02F3/08;;C02F3/12;;C02F3/30,,0,0,,,,PENDING
458,WO,A1,WO 2020/193976 A1,009-063-864-213-333,2020-10-01,2020,GB 2020050802 W,2020-03-25,GB 201904112 A,2019-03-25,SEAMLESS-SHIFT TRANSMISSION,"A transmission (100) comprising an output shaft (124), a first input shaft (104) carrying one or more wheels (106, 108, 110) for driving the output shaft, a first motor (102) configured to drive the first input shaft, a second input shaft (114) carrying one or more wheels (116, 118, 20) for driving the output shaft, a second motor (112) configured to drive the second input shaft, a coupling mechanism (122) configured to controllably engage to positively connect the first and second input shafts.",MCLAREN AUTOMOTIVE LTD,SUTTON JOHN;;FRASER ALEXANDER,,https://lens.org/009-063-864-213-333,Patent Application,yes,4,1,2,2,0,B60K6/387;;B60K6/48;;B60K6/547;;B60K2006/4825;;B60W10/02;;B60W10/113;;B60W30/19;;F16H3/006;;F16H3/089;;F16H2003/007;;F16H2061/0433;;Y02T10/62,F16H3/00;;B60K1/02;;F16H3/089,,0,0,,,,PENDING
459,WO,A2,WO 2007/017775 A2,020-797-056-738-124,2007-02-15,2007,IB 2006052475 W,2006-07-19,US 70639805 P,2005-08-08,ULTRASOUND TRANSDUCER ARRAYS,"An ultrasonic transducer (104,313), transducer array (103) and an ultrasonic probe (100) are described.",KONINKL PHILIPS ELECTRONICS NV;;FRASER JOHN;;DUFORT BENOIT,FRASER JOHN;;DUFORT BENOIT,,https://lens.org/020-797-056-738-124,Patent Application,yes,0,3,10,10,0,B06B1/0207;;B06B1/0207,,,0,0,,,,PENDING
460,AT,B,AT 119134 B,085-649-645-338-907,1930-09-25,1930,AT 119134D A,1928-02-23,GB 119134X A,1927-02-28,Zielbeleuchtungsvorrichtung für Gewehre.,,FLASH SPOTTER LTD,LAMONT JOHN WILLIAM FRASER,,https://lens.org/085-649-645-338-907,Granted Patent,no,0,0,1,1,0,,,72F,0,0,,,,EXPIRED
461,GB,A,GB 2352167 A,087-756-627-986-878,2001-01-24,2001,GB 0016320 A,2000-07-03,GB 9915947 A;;GB 0005503 A,1999-07-07,Cosmetics applicator,"A cosmetics applicator assembly, especially a mascara brush, comprising a cap 8 to a container having a wiper 6 in its neck 3, has a stop 20 at the end of a rod 12, immediately above the applicator 14, the rod tapering towards the stop. The wiper is provided with fingers 22 which bear against the rod so that as the tapered portion passes them they relax until their ends contact the stop which inverts them as it passes, the fingers remaining inturned until the applicator passes them when they will revert to their relaxed state removing any blob of cosmetic from the end of the applicator.",GEKA MFG LTD,FORDHAM JOHN FRASER WOOD,,https://lens.org/087-756-627-986-878,Patent Application,no,4,2,8,15,0,A45D40/267;;A46B3/18;;A46B9/021;;A46B2200/1053,A45D34/04;;A45D40/26;;A46B3/18;;A46B9/02,A4K KBA           KBA(C);;A4K K157          KBA(C);;A4K K161          KBA(C);;U1S S1120,0,0,,,,DISCONTINUED
462,US,A1,US 2023/0373831 A1,082-675-388-851-485,2023-11-23,2023,US 202118246929 A,2021-09-27,US 202118246929 A;;US 202063084752 P;;US 2021/0052164 W,2020-09-29,Wastewater Treatment System and Method Using Aerobic Granular Sludge With Immersed Membrane Separation,"A treatment system and method for removal of nutrients and other pollutants to produce a low solid, high quality effluent suitable for discharge or reuse using a combination of aerobic granular sludge (AGS), either in a sequencing batch reactor (SBR) AGS configuration or in a flow through AGS configuration, in combination with immersed/submerged membranes commonly referred to as membrane bio-reactor (MBR) wastewater treatment processes, systems, and methods.",CAROLLO ENG INC,FRASER JOHN;;GILMORE ANDREW,CAROLLO ENGINEERS INC (2021-10-26),https://lens.org/082-675-388-851-485,Patent Application,yes,0,0,5,5,0,Y02W10/10;;C02F3/301;;C02F3/085;;C02F3/1273;;C02F3/301;;Y02W10/10;;C02F3/085;;C02F3/1273;;C02F3/1273;;C02F3/301;;C02F2305/12,C02F3/30;;C02F3/12,,0,0,,,,PENDING
463,EP,A2,EP 1915221 A2,114-626-067-593-372,2008-04-30,2008,EP 06780137 A,2006-07-19,IB 2006052475 W;;US 70639805 P,2005-08-08,ULTRASOUND TRANSDUCER ARRAYS,,KONINKL PHILIPS ELECTRONICS NV,FRASER JOHN;;DUFORT BENOIT,KONINKLIJKE PHILIPS N.V. (2013-09-25),https://lens.org/114-626-067-593-372,Patent Application,yes,0,0,10,10,0,B06B1/0207;;B06B1/0207,B06B1/02,,1,0,,,See references of WO 2007017775A3,ACTIVE
464,US,A,US 914369 A,151-747-751-248-535,1909-03-02,1909,US 1908/0434541 A,1908-05-23,US 1908/0434541 A,1908-05-23,PRESS FOR MAKING PIPES.,,FRASER JOHN;;GRAY THOMAS,FRASER JOHN;;GRAY THOMAS,,https://lens.org/151-747-751-248-535,Granted Patent,no,0,0,1,1,0,B21D39/021;;B21D39/021;;Y10T29/53791;;Y10T29/53791,,,0,0,,,,EXPIRED
465,AU,A1,AU 2014/323629 A1,174-109-103-454-259,2016-05-12,2016,AU 2014/323629 A,2014-09-17,US 201461977466 P;;US 201361880086 P;;US 2014/0056145 W,2013-09-19,Methods of using adipose tissue-derived cells in the modulation of pain and/or fibrosis,"Aspects of the present invention relate to the field of medicine, specifically, the effect of adipose tissue and its components on modulating pain and/or fibrosis.",CYTORI THERAPEUTICS INC,FRASER JOHN;;MAGALON GUY,,https://lens.org/174-109-103-454-259,Patent Application,no,0,2,18,18,0,A61K35/35;;A61K35/28;;A61P17/00;;A61P19/02;;A61P25/02;;A61P25/04;;A61P29/00;;A61P37/00;;A61P43/00;;A61K35/35;;A61K35/28;;A61K9/0019,A01N63/00,,0,0,,,,DISCONTINUED
466,EP,A1,EP 3299451 A1,035-445-668-362-581,2018-03-28,2018,EP 17172872 A,2014-09-17,US 201361880086 P;;US 201461977466 P;;EP 14845486 A;;US 2014/0056145 W,2013-09-19,METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF RAYNAUD'S PHENOMENON,"Aspects of the present invention relate to the field of medicine, specifically, the effect of adipose tissue and its components on modulating pain and/or fibrosis.",CYTORI THERAPEUTICS INC,FRASER JOHN;;MAGALON GUY,LOREM VASCULAR PTE. LTD. (2019-09-11),https://lens.org/035-445-668-362-581,Patent Application,yes,31,5,18,18,0,A61K35/35;;A61K35/28;;A61P17/00;;A61P19/02;;A61P25/02;;A61P25/04;;A61P29/00;;A61P37/00;;A61P43/00;;A61K35/35;;A61K35/28;;A61K9/0019,C12N5/077;;A61K35/28;;A61K35/35;;A61P17/00;;A61P37/00;;A61P43/00;;C12N5/0775,,28,23,021-400-102-617-760;;006-485-162-197-149;;028-976-226-158-427;;045-787-458-363-087;;007-126-466-697-398;;068-929-730-624-924;;012-526-554-878-117;;084-476-732-626-801;;032-279-003-745-289;;026-563-150-261-584;;019-810-335-711-889;;113-651-591-024-609;;197-698-560-021-363;;009-852-354-311-269;;023-361-891-946-332;;098-468-861-318-395;;118-594-841-874-424;;158-997-957-027-443;;018-667-753-289-435;;157-994-310-553-91X;;041-201-637-014-038;;108-496-809-984-154;;035-982-850-526-072,22526170;;10.3727/096368912x639017;;24050783;;10.1016/j.revmed.2013.08.007;;11014457;;10.1016/0963-6897(95)00006-j;;7640867;;10.1177/096368979500400306;;10.1016/0304-3835(80)90091-9;;7013975;;10.1016/j.mvr.2004.08.002;;15501245;;12100134;;10.1046/j.1365-2141.2002.03561.x;;12571853;;10.1002/art.10759;;12424614;;10.1038/sj.gt.3301816;;10.1006/mthe.2002.0711;;12409257;;10.1016/s1525-0016(02)90711-2;;9579858;;10.1126/science.2660259;;2660259;;2255890;;10.1038/scientificamerican1190-68;;1608446;;10.1038/357455a0;;10.1161/01.cir.90.4.2070;;7923695;;2299088;;10.1016/s0735-1097(10)80079-8;;8261224;;10.1097/00019501-199305000-00011;;pmc325139;;8180504;;15622378;;10.1016/j.jvs.2004.08.027;;10.1053/ejvs.2001.1532;;11748945;;5423802;;6663597;;10.1159/000249385;;3896883,"POZZI M R ET AL: ""AUTOLOGOUS FAT TRANSFER FOR DIGITAL ULCERS TREATMENT IN SYSTEMIC SCLEROSIS"", ANNALS OF THE RHEUMATIC DISEASES, vol. 72, no. Suppl. 3, June 2013 (2013-06-01), & ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY (EULAR); MADRID, SPAIN; JUNE 12 -15, 2013, pages 649, XP009190959;;SCUDERI N ET AL: ""Human adipose-derived stromal cells for cell-based therapies in the treatment of systemic sclerosis"", CELL TRANSPLANTATION 2013 COGNIZANT COMMUNICATION CORPORATION USA, vol. 22, no. 5, 17 April 2012 (2012-04-17), pages 779 - 795, XP002759956, ISSN: 0963-6897;;DAUMAS A ET AL: ""Interests and potentials of adipose tissue in scleroderma"", REVUE DE MEDECINE INTERNE 2013 ELSEVIER MASSON SAS FRA, vol. 34, no. 12, 17 September 2013 (2013-09-17), pages 763 - 769, XP002759957, ISSN: 0248-8663;;KOLTZENBURG, M., CLIN. J. OF PAIN, vol. 16, 2000, pages S131 - S138;;""Classification of Chronic Pain, International Association for the Study of Pain (IASP) Task Force on Taxonomy"", 1994, IASP PRESS: SEATTLE, pages: 209 - 214;;""Physicians' Desk Reference. 57th ed."", 2003, pages: 1417,183;;WILLIAMS ET AL.: ""Collagenase lot selection and purification for adipose tissue digestion"", CELL TRANSPLANT, vol. 4, no. 3, 1995, pages 281 - 289;;TWENTYMAN ET AL.: ""Use of bacterial neutral protease for disaggregation of mouse tumours and multicellular tumor spheroids"", CANCER LETT., vol. 9, no. 3, 1980, pages 225 - 228;;NG ET AL.: ""Interstitial flow differentially stimulates blood and lymphatic endothelial cell morphogenesis in vitro"", MICROVASC RES., vol. 68, no. 3, November 2004 (2004-11-01), pages 258 - 264;;WATTS ET AL.: ""Variable product purity and functional capacity after CD34 selection: a direct comparison of the CliniMACS (v2.1) and Isolex 300i (v2.5) clinical scale devices"", BR J HAEMATOL., vol. 1 18, no. 1, July 2002 (2002-07-01), pages 117 - 123;;""Remington's Pharmaceutical Sciences"", 1990, MACK PUBL. CO, pages: 1435 - 1712;;GELSE ET AL.: ""Articular cartilage repair by gene therapy using growth factor-producing mesenchymal cells"", ARTHRITIS RHEUM., vol. 48, 2003, pages 430 - 441;;HUARD ET AL.: ""Muscle-derived cell-mediated ex vivo gene therapy for urological dysfunction"", GENE THER., vol. 9, 2002, pages 1617 - 1626;;KIM ET AL.: ""Ex vivo gene delivery of IL-IRa and soluble TNF receptor confers a distal synergistic therapeutic effect in antigen-induced arthritis"", MOL. THER., vol. 6, 2002, pages 591 - 600;;ANDERSON: ""Human Gene Therapy"", NATURE, vol. 392, no. 6679, 1998, pages 25 - 20;;FRIEDMANN: ""Progress toward human gene therapy"", SCIENCE, vol. 244, no. 4910, 1989, pages 1275 - 1281;;VERMA: ""Gene therapy"", SCIENTIFIC AMERICAN, vol. 263, no. 5, 1990, pages 68 - 84;;MILLER: ""Human gene therapy comes of age"", NATURE, vol. 357, 1992, pages 455 - 460;;LINCOFF ET AL.: ""Local drug delivery for the prevention of restenosis. Fact, fancy, and future"", CIRCULATION, vol. 90, 1994, pages 2070 - 2084;;WOLINSKY ET AL.: ""Use of a perforated balloon catheter to deliver concentrated heparin into the wall of the normal canine artery"", J. AM. COLL. CARDIOL., vol. 15, 1990, pages 475 - 481;;LAMBERT ET AL.: ""Local drug delivery catheters: functional comparison of porous and microporous designs"", CORON. ARTERY DIS., vol. 4, 1993, pages 469 - 475;;MAZUR ET AL.: ""Coronary restenosis and gene therapy"", TEXAS HEART INSTITUTE JOURNAL, vol. 21, 1994, pages 104 - 111;;PAVCNIK ET AL.: ""Second-generation percutaneous bioprosthetic valve: a short-term study in sheep"", EUR. J. ENDOVASC. SURG., vol. 40, 2004, pages 1223 - 1227;;ARTS ET AL.: ""Contaminants from the Transplant Contribute to Intimal Hyperplasia Associated with Microvascular Endothelial Cell Seeding"", EUR. J. ENDOVASC. SURG., vol. 23, 2002, pages 29 - 38;;SCHMIDT ET AL., ARCH PHYS MED REHABIL., vol. 51, 1970, pages 321 - 327;;LEE ET AL., J. RHEUMATOL., vol. 10, 1983, pages 930 - 938;;CZIRJAK ET AL., RHEUMATOLOLOGY, vol. 47, no. 5, 2008, pages 44 - 45;;SERUP, J., DERMATOLOGY, vol. 171, 1985, pages 41 - 44",ACTIVE
467,CN,A,CN 101237946 A,067-306-226-047-534,2008-08-06,2008,CN 200680029122 A,2006-07-19,IB 2006052475 W;;US 70639805 P,2005-08-08,Ultrasound transducer arrays,"An ultrasonic transducer element (104,313) , comprising: an active layer (201) having a first side and a second side; a first electrode (204,317) connected to the first side and a second electrode (205,319) connected to the first side; and a circuit (315) having a first output (316) connected to the first electrode and a second output (318) connected to the second electrode, wherein the first output provides a first voltage to the first electrode, the second output provides a second voltage to the second electrode and the circuit provides a voltage to the active layer that is equal to approximately a difference between the first voltage and the second voltage.",KONINKL PHILIPS ELECTRONICS NV,JOHN FRASER;;BENOIT DUFORT,,https://lens.org/067-306-226-047-534,Patent Application,no,0,4,10,10,0,B06B1/0207;;B06B1/0207,B06B1/02,,0,0,,,,INACTIVE
468,EP,B1,EP 3299451 B1,194-300-783-120-113,2019-08-07,2019,EP 17172872 A,2014-09-17,US 201361880086 P;;US 201461977466 P;;EP 14845486 A;;US 2014/0056145 W,2013-09-19,METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF RAYNAUD'S PHENOMENON,,CYTORI THERAPEUTICS INC,FRASER JOHN;;MAGALON GUY,LOREM VASCULAR PTE. LTD. (2019-09-11),https://lens.org/194-300-783-120-113,Granted Patent,yes,1,0,18,18,0,A61K35/35;;A61K35/28;;A61P17/00;;A61P19/02;;A61P25/02;;A61P25/04;;A61P29/00;;A61P37/00;;A61P43/00;;A61K35/35;;A61K35/28;;A61K9/0019,C12N5/077;;A61K35/28;;A61K35/35;;A61P17/00;;A61P37/00;;A61P43/00;;C12N5/0775,,3,0,,,"POZZI M R ET AL: ""AUTOLOGOUS FAT TRANSFER FOR DIGITAL ULCERS TREATMENT IN SYSTEMIC SCLEROSIS"", ANNALS OF THE RHEUMATIC DISEASES, vol. 72, no. Suppl. 3, June 2013 (2013-06) , page 649, XP009190959, & ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY (EULAR); MADRID, SPAIN; JUNE 12 -15, 2013;;SCUDERI N ET AL: ""Human adipose-derived stromal cells for cell-based therapies in the treatment of systemic sclerosis"", CELL TRANSPLANTATION 2013 COGNIZANT COMMUNICATION CORPORATION USA, vol. 22, no. 5, 17 April 2012 (2012-04-17) , pages 779-795, XP002759956, ISSN: 0963-6897;;DAUMAS A ET AL: ""Interests and potentials of adipose tissue in scleroderma"", REVUE DE MEDECINE INTERNE 2013 ELSEVIER MASSON SAS FRA, vol. 34, no. 12, 17 September 2013 (2013-09-17), pages 763-769, XP002759957, ISSN: 0248-8663",ACTIVE
469,EP,A1,EP 3046417 A1,038-909-627-180-708,2016-07-27,2016,EP 14845486 A,2014-09-17,US 201361880086 P;;US 201461977466 P;;US 2014/0056145 W,2013-09-19,METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF RAYNAUD'S PHENOMENON ASSOCIATED WITH SCLERODERMA,,CYTORI THERAPEUTICS INC,FRASER JOHN;;MAGALON GUY,,https://lens.org/038-909-627-180-708,Patent Application,yes,0,0,18,18,0,A61K35/35;;A61K35/28;;A61P17/00;;A61P19/02;;A61P25/02;;A61P25/04;;A61P29/00;;A61P37/00;;A61P43/00;;A61K35/35;;A61K35/28;;A61K9/0019,C12N5/077;;A61K35/28;;A61K35/35;;A61P17/00;;A61P37/00;;A61P43/00;;C12N5/0775,,0,0,,,,ACTIVE
470,GB,B,GB 2567838 B,093-393-666-429-449,2023-03-15,2023,GB 201717561 A,2017-10-25,GB 201717561 A,2017-10-25,An improved inflow test packer for drilling applications,,CORETRAX TECH LIMITED,JASON FONG;;JOHN FRASER,,https://lens.org/093-393-666-429-449,Granted Patent,no,5,0,3,3,0,E21B23/06;;E21B33/12;;E21B33/1243;;E21B33/127;;E21B33/1285;;E21B33/14;;E21B33/12;;E21B33/1243;;E21B33/127;;E21B33/14,E21B33/127;;E21B21/00;;E21B33/12;;E21B33/124;;E21B33/14,,0,0,,,,ACTIVE
471,DE,D1,DE 69517310 D1,129-171-181-779-185,2000-07-06,2000,DE 69517310 T,1995-03-31,GB 9406486 A;;GB 9500734 W,1994-03-31,ABNEHMBARES ABSTURZSICHERUNGSGERÄT,,LATCHWAYS LTD,ATKINSON FRASER;;PATTERSON JOHN,,https://lens.org/129-171-181-779-185,Granted Patent,no,0,0,12,12,0,A62B35/005;;A62B35/0087;;E06C7/18;;E06C7/186;;A62B35/0087;;A62B35/005;;E06C7/18;;E06C7/186,A62B1/14;;E06C9/14;;A62B35/00;;A62B35/04;;E06C7/18,,0,0,,,,EXPIRED
472,CA,A,CA 11485 A,131-323-320-705-98X,1880-07-10,1880,CA 11485D A,,CA 11485T A,,IMPROVEMENTS IN PHOTOGRAPHY,,FRASER JOHN A JR,FRASER JOHN A JR,,https://lens.org/131-323-320-705-98X,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
473,WO,A1,WO 2014/006418 A1,144-238-038-444-806,2014-01-09,2014,GB 2013051787 W,2013-07-05,GB 201212058 A,2012-07-06,CONTAINER AND CLOSURE THEREFOR,"A closure for a wide-mouth container having a circular opening defining an axis, the closure comprising an inner component (11) and an outer component (14), the inner component having a collar portion for locating about the exterior of the container and a sealing portion connected to the collar portion and arranged to close the opening. The sealing portion is resiliently moveable in an axial direction relative to the collar portion, and the outer component is arranged to fit over the inner component to secure the collar portion about the container and so that rotation of the outer component relative to the inner component presses the sealing portion axially into the opening. The container has an outwardly projecting lip (12A) and a plurality of spaced apart cam features beneath the lip, the cam features comprising a first side face (20A) for limiting rotation of an inner component of the closure in the tightening direction relative to the container and a second side face (20B) providing a cam surface for driving radially moveable parts (13) of the closure radially outwards when the inner component is rotated in the loosening direction relative to the container, the inner surface of the container having a frusto-conical lead-in surface (12B) adjacent the circular opening and a plurality of spaced apart venting grooves (21) in said lead-in surface.",THREADLESS CLOSURES LTD,FRASER ANTHONY;;HINE JOHN,,https://lens.org/144-238-038-444-806,Patent Application,no,3,1,2,2,0,B65D41/02;;B65D45/30;;B65D45/325;;B65D51/1688,B65D41/02;;B65D45/30;;B65D45/32;;B65D51/16,,0,0,,,,PENDING
474,US,B2,US 9000653 B2,024-530-610-156-90X,2015-04-07,2015,US 6318106 A,2006-07-19,US 6318106 A;;US 70639805 P;;IB 2006052475 W,2005-08-08,Ultrasound transducer arrays,"A transducer array of micromachined ultrasonic transducer elements is connected to a microbeamformer. Driver circuits of the microbeamformer have a first output coupled to a first electrode of a respective transducer element and a second output coupled to a second electrode of the respective transducer element. The driver circuits apply first and second time varying voltage signals to the electrodes, with one voltage signal being time inverted relative to the other. The peak-to-peak voltage applied to the transducer element is 1.75 to 2.0 times the peak-to-peak voltage of either the first or the second time varying voltage signal.",FRASER JOHN;;DUFORT BENOIT;;KONINKL PHILIPS NV,FRASER JOHN;;DUFORT BENOIT,KONINKLIJKE PHILIPS ELECTRONICS N.V (2008-01-17),https://lens.org/024-530-610-156-90X,Granted Patent,yes,21,0,10,10,0,B06B1/0207;;B06B1/0207,H01L41/09;;B06B1/02,310/322;;310/317;;310/334,0,0,,,,INACTIVE
475,EP,A1,EP 1083384 A1,046-224-498-405-074,2001-03-14,2001,EP 99117836 A,1999-09-10,EP 99117836 A,1999-09-10,Halogen light unit,"The invention of this application relates to the ability to provide a halogen lamp unit, typically for use in an underwater environment such as a swimming pool, which provides the advantages of using halogen bulbs. In one aspect of the invention the halogen bulb unit can be provided of a similar shape to the conventional type of light unit currently used in swimming pools which is referred to as a Par lamp. The similar shape allows the halogen lamp units to be fitted in substitution of a Par lamp unit in the same mounting and to provide the required watertight seal between the halogen lamp unit and the original mounting thus overcoming the need to undertake expensive refitting of the same. The bulb unit for the halogen lamp unit is also a feature of the invention which allows the bulb to be replaced and the bulb unit can be fitted in the lamp unit without the need for the bulb to be electrically connected in situ at the time of fitting.",CERTIKIN INTERNAT LTD,WHITEHOUSE JOHN;;FRASER JAMIE,,https://lens.org/046-224-498-405-074,Patent Application,yes,6,2,1,1,0,F21S8/00;;F21V19/0005;;F21W2131/401,F21S8/00;;F21V19/00,,0,0,,,,DISCONTINUED
476,NO,A1,NO 20180799 A1,078-446-468-277-520,2018-06-08,2018,NO 20180799 A,2018-06-08,GB 201522652 A;;GB 2016054031 W,2015-12-22,Squeeze packer and method of setting a squeeze packer,"A squeeze packer (1) assembly incorporates a built-in setting tool which removes the need for a separate setting tool. The packer comprises a body comprising a mandrel (9), a shuttle sleeve (7), and a stinger (2) assembly which is lowered into the wellbore on the end of tubing (102). The shuttle sleeve is housed within the body and incorporates a latch device in the form of a collet comprising a plurality of resilient fingers (14) to releasably connectto the stinger. A ball seat (15) allows hydraulic setting of slips (3). Additional slips (4) can be set by applying tension on the tubing (fig 4). Once released, the stinger can open and close the shuttle sleeve by reciprocating in and out of the packer as many times as required during cementing operations.",CORETRAX TECH LIMITED,FRASER JOHN;;FONG JASON,"CORETRAX GLOBAL LIMITED, GB (2023-02-13)",https://lens.org/078-446-468-277-520,Patent Application,no,1,0,8,8,0,E21B23/06;;E21B29/00;;E21B33/1293;;E21B33/1294;;E21B43/116;;E21B34/142;;E21B23/06;;E21B29/00;;E21B33/1293;;E21B33/1294;;E21B43/116;;E21B34/142;;E21B23/06;;E21B29/00;;E21B33/1293;;E21B33/1294;;E21B43/116;;E21B34/142;;E21B34/142;;E21B33/1285;;E21B33/1293;;E21B33/14;;E21B34/102,E21B23/06;;E21B29/00;;E21B33/129;;E21B34/14;;E21B43/116,,0,0,,,,PENDING
477,WO,A1,WO 2010/052555 A1,104-165-999-093-616,2010-05-14,2010,IB 2009007348 W,2009-11-04,US 26438108 A,2008-11-04,METHOD AND SYSTEM FOR ARCHIVING AND RETRIEVING ITEMS BASED ON EPISODIC MEMORY OF GROUPS OF PEOPLE,"A method and system are provided for archiving and retrieving digital media items based on episodic memory for predefined associated groups of one or more people. The method and system may comprise identifying one or more groups to which an archiving user belongs; receiving a user input identifying select groups to which a digital media item to be archived; receiving archiving input data identifying the digital media item to be archived for the group; generating index information using the received user archiving input; storing the index information in association with the identified digital media item; repeating the reception of archiving input data, the generation of the index information and the storing of the index information for the digital media item; receiving retrieval input data representing a selection of candidate values; and using the selections and the identified group to retrieve and output digital media items that match the selection.",6S LTD;;SHARPE ELIZABETH;;FRASER JOHN,SHARPE ELIZABETH;;FRASER JOHN,,https://lens.org/104-165-999-093-616,Patent Application,yes,2,0,6,6,0,G06F16/435;;G06F16/489;;G06F16/438;;G06F16/438;;G06F16/489;;G06F16/435,G06F17/30,,2,1,003-831-005-012-93X,10.1145/1027527.1027573,"NAAMAN M ET AL: ""Context data in geo-referenced digital photo collections"", PROCEEDINGS OF THE ACM INTERNATIONAL CONFERENCE ONMULTIMEDIA, NEW YORK, NY, US, 10 October 2004 (2004-10-10), pages 196 - 203, XP002415095;;MARC DAVIS ET AL: ""From Context to Content: Levaraging Context to Infer Media Metadata"", INTERNET CITATION, 16 October 2004 (2004-10-16), pages 1 - 8, XP002374239, Retrieved from the Internet <URL:New York, USA> [retrieved on 20060327]",PENDING
478,WO,A1,WO 2008/029125 A1,075-517-746-702-475,2008-03-13,2008,GB 2007003338 W,2007-09-06,GB 0617716 A,2006-09-08,MOORING FAILURE DETECTION,"A mooring failure detector, for attachment to a mooring chain or wire rope, includes a power source, which is activated by the rupture of a rupture element, caused by a change in depth and hence pressure of the device. Activation of the power source provides power to a transmitter to signal the failure, either by acoustic or radio frequency means. The device can operate on an inclined mooring such that failure above or below the point of attachment results in a failure signal being transmitted.",QINETIQ LTD;;MOODY MARTIN JOHN;;FRASER GRANT;;SUTHERLAND ANDREW FRASER,MOODY MARTIN JOHN;;FRASER GRANT;;SUTHERLAND ANDREW FRASER,,https://lens.org/075-517-746-702-475,Patent Application,yes,10,1,5,5,0,B63B21/22;;B63B21/22;;B63B2021/008;;B63B2021/008;;G01L5/047;;G01L5/047;;H01M6/34;;H01M6/34,G01L5/04,,0,0,,,,PENDING
479,EP,A1,EP 2059778 A1,163-029-102-145-834,2009-05-20,2009,EP 07804143 A,2007-09-06,GB 2007003338 W;;GB 0617716 A,2006-09-08,MOORING FAILURE DETECTION,,QINETIQ LTD,MOODY MARTIN JOHN;;FRASER GRANT;;SUTHERLAND ANDREW FRASER,,https://lens.org/163-029-102-145-834,Patent Application,yes,0,1,5,5,0,B63B21/22;;B63B21/22;;B63B2021/008;;B63B2021/008;;G01L5/047;;G01L5/047;;H01M6/34;;H01M6/34,G01L5/04,,1,0,,,See references of WO 2008029125A1,DISCONTINUED
480,US,A1,US 2010/0269580 A1,147-667-960-044-93X,2010-10-28,2010,US 43800607 A,2007-09-06,GB 0617716 A;;GB 2007003338 W,2006-09-08,MOORING FAILURE DETECTION,"A mooring failure detector, for attachment to a mooring chain or wire rope, includes a power source, which is activated by the rupture of a rupture element, caused by a change in depth and hence pressure of the device. Activation of the power QC source provides power to a transmitter to signal the failure, either by acoustic or radio frequency means. The device can operate on an inclined mooring such that failure above or below the point of attachment results in a failure signal being transmitted.",QINETIQ LTD,MOODY MARTIN JOHN;;SUTHERLAND ANDREW FRASER;;FRASER GRANT,QINETIQ LIMITED (2008-11-02),https://lens.org/147-667-960-044-93X,Patent Application,yes,11,4,5,5,0,B63B21/22;;B63B21/22;;B63B2021/008;;B63B2021/008;;G01L5/047;;G01L5/047;;H01M6/34;;H01M6/34,G01L5/04,73/158,0,0,,,,DISCONTINUED
481,NO,L,NO 20091268 L,112-153-108-124-338,2009-06-03,2009,NO 20091268 A,2009-03-26,GB 0617716 A;;GB 2007003338 W,2006-09-08,Pavisning av svikt ved fortoyning,"Det er beskrevet en fortøyningssviktdetektor (308, 408, 508) for feste på en fortøyningskjetting eller ståltrådkabel (306, 406, 506) og som omfatter en kraftkilde (106) som aktiveres ved brudd i et bruddelement (104) forårsaket av en endring i dybde og derved trykk på anordningen. Aktiveringen av kraftkilden gir kraft til en sender (11 14) for å signalere svikten enten akustisk eller ved hjelp av høyfrekvent radioutstyr. Anordningen kan arbeide på en skrånende fortøyning, slik at svikt over eller under festepunktet fører til at et sviktsignal sendes ut.",QINETIQ LTD,MOODY MARTIN JOHN;;FRASER GRANT;;SUTHERLAND ANDREW FRASER,,https://lens.org/112-153-108-124-338,Abstract,no,0,0,5,5,0,B63B21/22;;B63B21/22;;B63B2021/008;;B63B2021/008;;G01L5/047;;G01L5/047;;H01M6/34;;H01M6/34,G01L5/04;;B63B21/22;;H01M6/34,,0,0,,,,DISCONTINUED
482,WO,A3,WO 2012/160380 A3,079-794-515-754-770,2013-10-03,2013,GB 2012051166 W,2012-05-24,GB 201108724 A,2011-05-24,SUPPORT DEVICE FOR USE IN A WELLBORE AND A METHOD FOR DEPLOYING A BARRIER IN A WELLBORE,"The present invention relates to a downhole support device (100) for use in a wellbore and which is adapted to be run into the wellbore through or run on an elongate member string (2) such as on a string of tubulars, a coiled tubing string or a slickline. The downhole support device comprises an inflatable element (102), which in use is adapted to be selectively connectable to the elongate member string and is further adapted to apply a biasing force in the direction of the wellbore walls. The inflatable element has an inlet (104) for receiving fluid and/or fluidized solids. The support device is further adapted to be selectively disconnectable from the elongate member string.",SMJM LTD;;FRASER JOHN PAUL;;FONG JASON WING HAU;;MURRAY JOHN KENNETH FRASER,FRASER JOHN PAUL;;FONG JASON WING HAU;;MURRAY JOHN KENNETH FRASER,,https://lens.org/079-794-515-754-770,Search Report,yes,5,0,8,8,0,E21B23/06;;E21B33/134;;E21B23/06;;E21B33/134;;E21B23/06;;E21B33/134;;E21B33/127;;E21B33/13,E21B23/06;;E21B33/134,,0,0,,,,PENDING
483,CA,A,CA 155690 A,040-346-250-001-92X,1914-05-19,1914,CA 155690D A,1914-01-12,CA 155690T A,1914-01-12,RAIL FASTENER,,SMITH JOHN ROBERT;;FRASER JOHN S,SMITH JOHN ROBERT;;FRASER JOHN S,,https://lens.org/040-346-250-001-92X,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
484,EP,A2,EP 0319146 A2,058-660-532-284-760,1989-06-07,1989,EP 88310478 A,1988-11-08,US 12592887 A,1987-11-27,Glass-ceramic substrates for electronic packaging and thermally crystallizable glass compositions of use in the production thereof.,"This invention is directed to the preparation of glass-­ceramic materials especially suitable for use in multilayer substrates for integrated circuit packages. The inventive glass-ceramics are derived from thermally crystallizable glasses which, in the form of frit, are capable of being sintered into an integral body at temperatures below 1000°C and essentially concurrently crystallized  in situ  to yield BPO₄ as the predominant crystal phase. The inventive glass-­ceramics exhibit a linear coefficient of thermal expansion between about 30-45 x 10⁻⁷/°C, a dielectric constant less than 5, and consist essentially, in weight percent, of 10-25% B₂O₃, 20-40% P₂O₅, and >50-65% SiO₂.  ",CORNING GLASS WORKS,MACDOWELL JOHN FRASER;;PAISLEY ROBERT JOHN,,https://lens.org/058-660-532-284-760,Patent Application,yes,0,3,5,5,0,C03C10/0054;;H01L23/15;;H01L2924/09701;;H05K1/0306;;H01L2924/0002;;H01L23/00;;H01L23/15;;C03C10/0054;;H05K1/0306;;H01L2924/09701;;H01L2924/0002,C03C10/00;;C03C10/02;;H01L23/15;;H05K1/03;;H05K3/46,,0,0,,,,DISCONTINUED
485,AU,B,AU 364105 B,199-280-016-200-864,1905-11-14,1905,AU 364105 A,1905-07-18,AU 364105 A,1905-07-18,Fuse igniters,,F JOHN FRASER JOHN THOMAS GOOD,F JOHN FRASER JOHN THOMAS GOOD,,https://lens.org/199-280-016-200-864,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
486,CA,A,CA 338348 A,066-195-198-249-810,1934-01-02,1934,CA 338348D A,,CA 338348T A,,STEEL AND ALLOY ANNEALING PROCESS,,INT NICKEL CO,OWENS ROBERT JOHN;;FRASER HUGH JOHN,,https://lens.org/066-195-198-249-810,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
487,US,A,US 1901039 A,088-700-950-856-321,1933-03-14,1933,US 57998331 A,1931-12-09,US 57998331 A,1931-12-09,Process of bright annealing steels and alloys,,INTERNAITONAL NICKEL COMPANY I,JOHN OWENS ROBERT;;JOHN FRASER HUGH,,https://lens.org/088-700-950-856-321,Granted Patent,no,0,6,1,1,0,C23C22/83;;C23C22/83,,,0,0,,,,EXPIRED
488,GB,B,GB 2506292 B,135-672-198-419-322,2018-08-01,2018,GB 201320930 A,2012-05-24,GB 2012051166 W;;GB 201108724 A,2011-05-24,Support device for use in a wellbore and a method for deploying a barrier in a wellbore,,SMJM LTD,JOHN PAUL FRASER;;JASON WING HAU FONG;;JOHN KENNETH FRASER MURRAY,,https://lens.org/135-672-198-419-322,Granted Patent,no,5,0,8,8,0,E21B23/06;;E21B33/134;;E21B23/06;;E21B33/134;;E21B23/06;;E21B33/134;;E21B33/127;;E21B33/13,E21B23/06;;E21B33/134,,0,0,,,,ACTIVE
489,CA,A,CA 366783 A,115-844-595-017-32X,1937-06-15,1937,CA 366783D A,,CA 366783T A,,METALLIC PRODUCT ANNEALING PROCESS AND APPARATUS,,INT NICKEL CO,FRASER HUGH JOHN;;OWENS ROBERT JOHN,,https://lens.org/115-844-595-017-32X,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
490,GB,A,GB 2413195 A,067-986-542-736-608,2005-10-19,2005,GB 0408597 A,2004-04-17,GB 0408597 A,2004-04-17,A memory tag and reader with password protection of tag memory,"A memory tag in the form of a radio frequency identification tag (RFID) includes a memory storing data, an operating program and a current password. The memory tag is operable, in response to a read signal 64 from a tag reader requesting data 67, to run the operating program to check the read signal for inclusion of a token 66 dependent upon the current password. If the token is identified within the reader signal, the memory tag is operable to read the requested data and transmit it to the reader 72, 73. The token may be the password itself, or a derivative of the password. The tag password may be set at the time of manufacture, or updated after each communication from the tag to the reader. Alternatively the tag receives a new password from the reader after transmitting the requested data. The current token and new passwords may be sent in encrypted form.",HEWLETT PACKARD DEVELOPMENT CO,CASTLE ROBERT JOHN;;DICKIN FRASER JOHN,,https://lens.org/067-986-542-736-608,Patent Application,no,8,3,5,5,0,G06K19/0723;;G06K19/0723;;G06K19/07309;;G06K19/07309,G06F12/14;;G06K19/07;;G06K19/073;;H04Q5/22,G4A AAP           AP;;G4A A23A          AP;;G4A A23B          AP;;G4A A23D          AP,0,0,,,,DISCONTINUED
491,CA,A,CA 169648 A,107-668-725-149-68X,1916-05-23,1916,CA 169648D A,1916-04-05,CA 169648T A,1916-04-05,VALVE FOR COMBUSTION ENGINES,,JACKSON JOHN FRASER;;WILSON JOHN PALMER,JACKSON JOHN FRASER;;WILSON JOHN PALMER,,https://lens.org/107-668-725-149-68X,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
492,US,A,US 2057518 A,179-989-540-488-633,1936-10-13,1936,US 74074034 A,1934-08-21,US 74074034 A,1934-08-21,Apparatus for bright annealing metallic products,,INT NICKEL CO,JOHN FRASER HUGH;;JOHN OWENS ROBERT,,https://lens.org/179-989-540-488-633,Granted Patent,no,0,12,1,1,0,C21D9/0043;;C21D9/561;;C21D9/561;;C21D9/0043,C21D9/00;;C21D9/56,,0,0,,,,EXPIRED
493,EP,A3,EP 0319146 A3,010-491-056-908-328,1990-05-16,1990,EP 88310478 A,1988-11-08,US 12592887 A,1987-11-27,GLASS-CERAMIC SUBSTRATES FOR ELECTRONIC PACKAGING AND THERMALLY CRYSTALLIZABLE GLASS COMPOSITIONS OF USE IN THE PRODUCTION THEREOF,"This invention is directed to the preparation of glass-­ceramic materials especially suitable for use in multilayer substrates for integrated circuit packages. The inventive glass-ceramics are derived from thermally crystallizable glasses which, in the form of frit, are capable of being sintered into an integral body at temperatures below 1000°C and essentially concurrently crystallized  in situ  to yield BPO₄ as the predominant crystal phase. The inventive glass-­ceramics exhibit a linear coefficient of thermal expansion between about 30-45 x 10⁻⁷/°C, a dielectric constant less than 5, and consist essentially, in weight percent, of 10-25% B₂O₃, 20-40% P₂O₅, and >50-65% SiO₂.  ",CORNING GLASS WORKS,"MACDOWELL, JOHN FRASER;;PAISLEY, ROBERT JOHN",,https://lens.org/010-491-056-908-328,Search Report,yes,2,0,5,5,0,C03C10/0054;;H01L23/15;;H01L2924/09701;;H05K1/0306;;H01L2924/0002;;H01L23/00;;H01L23/15;;C03C10/0054;;H05K1/0306;;H01L2924/09701;;H01L2924/0002,C03C10/00;;C03C10/02;;H01L23/15;;H05K1/03;;H05K3/46,,0,0,,,,DISCONTINUED
494,GB,A,GB 2413197 A,029-840-542-245-729,2005-10-19,2005,GB 0505188 A,2005-03-15,GB 0408597 A,2004-04-17,A memory tag and reader with password protection of tag memory,"A memory tag in the form of a radio frequency identification tag (RFID) includes a memory storing data, an operating program and a current password. The memory tag is operable, in response to a read signal 64 from a tag reader requesting data 67, to run the operating program to check the read signal for inclusion of a token 66 dependent upon the current password. If the token is identified within the reader signal, the memory tag is operable to read the requested data and transmit it to the reader 72, 73. If the current token is not identified within the reader signal 71, the memory tag does nothing so as to avoid announcing its presence in any way. The token may be the password itself or a derivative of the password. The tag password may be set at the time of manufacture, or updated after each communication from the tag to the reader. Alternatively the tag receives a new password from the reader after transmitting the requested data. The current token and new passwords may be sent in encrypted form.",HEWLETT PACKARD DEVELOPMENT CO,DICKIN FRASER JOHN;;CASTLE ROBERT JOHN,,https://lens.org/029-840-542-245-729,Patent Application,no,4,2,5,5,0,G06K19/0723;;G06K19/0723;;G06K19/07309;;G06K19/07309,G06F12/14;;G06K19/07;;G06K19/073;;H04Q5/22,G4A AAP           AP;;G4A A23A          AP;;G4A A23B          AP;;G4A A23D          AP,0,0,,,,DISCONTINUED
495,CA,A,CA 169495 A,181-778-527-254-48X,1916-05-16,1916,CA 169495D A,1916-04-07,CA 169495T A,1916-04-07,VALVE FOR INTERNAL COMBUSTION ENGINES,,JACKSON JOHN FRASER;;WILSON JOHN PALMER,JACKSON JOHN FRASER;;WILSON JOHN PALMER,,https://lens.org/181-778-527-254-48X,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
496,WO,A2,WO 2012/160380 A2,003-566-210-898-915,2012-11-29,2012,GB 2012051166 W,2012-05-24,GB 201108724 A,2011-05-24,SUPPORT DEVICE FOR USE IN A WELLBORE AND A METHOD FOR DEPLOYING A BARRIER IN A WELLBORE,"The present invention relates to a downhole support device for use in a wellbore and which is adapted to be run into the wellbore through or run on an elongate member string such as on a string of tubulars, a coiled tubing string or a slickline. The downhole support device comprises an inflatable element, which in use is adapted to be selectively connectable to the elongate member string and is further adapted to apply a biasing force in the direction of the wellbore walls. The inflatable element has an inlet for receiving fluid and/or fluidized solids. The support device is further adapted to be selectively disconnectable from the elongate member string.",SMJM LTD;;FRASER JOHN PAUL;;FONG JASON WING HAU;;MURRAY JOHN KENNETH FRASER,FRASER JOHN PAUL;;FONG JASON WING HAU;;MURRAY JOHN KENNETH FRASER,,https://lens.org/003-566-210-898-915,Patent Application,yes,0,9,8,8,0,E21B23/06;;E21B33/134;;E21B23/06;;E21B33/134;;E21B23/06;;E21B33/134;;E21B33/127;;E21B33/13,,,0,0,,,,PENDING
497,US,A1,US 2014/0238694 A1,083-421-331-016-012,2014-08-28,2014,US 201214117408 A,2012-05-24,GB 201108724 A;;GB 2012051166 W,2011-05-24,SUPPORT DEVICE FOR USE IN A WELLBORE AND A METHOD FOR DEPLOYING A BARRIER IN A WELLBORE,"The present invention relates to a downhole support device ( 100 ) for use in a wellbore and which is adapted to be run into the wellbore through or run on an elongate member string ( 2 ) such as on a string of tubulars, a coiled tubing string or a slickline. The downhole support device comprises an inflatable element ( 102 ), which in use is adapted to be selectively connectable to the elongate member string and is further adapted to apply a biasing force in the direction of the wellbore walls. The inflatable element has an inlet ( 104 ) for receiving fluid and/or fluidized solids. The support device is further adapted to be selectively disconnectable from the elongate member string.",FRASER JOHN PAUL;;FONG JASON WING HAU;;MURRAY JOHN KENNETH FRASER;;SMJM LTD,FRASER JOHN PAUL;;FONG JASON WING HAU;;MURRAY JOHN KENNETH FRASER,CORETRAX GLOBAL LIMITED (2022-04-21);;SMJM LIMITED (2012-07-17);;CORETRAX TECHNOLOGY LIMITED (2013-11-12),https://lens.org/083-421-331-016-012,Patent Application,yes,22,17,8,8,0,E21B23/06;;E21B33/134;;E21B23/06;;E21B33/134;;E21B23/06;;E21B33/134;;E21B33/127;;E21B33/13,E21B33/127;;E21B33/13,166/382;;166/179,0,0,,,,ACTIVE
498,GB,A,GB 2506292 A,175-630-653-948-150,2014-03-26,2014,GB 201320930 A,2012-05-24,GB 2012051166 W;;GB 201108724 A,2011-05-24,Support device for use in a wellbore and a method for deploying a barrier in a wellbore,"The present invention relates to a downhole support device for use in a wellbore and which is adapted to be run into the wellbore through or run on an elongate member string such as on a string of tubulars, a coiled tubing string or a slickline. The downhole support device comprises an inflatable element, which in use is adapted to be selectively connectable to the elongate member string and is further adapted to apply a biasing force in the direction of the wellbore walls. The inflatable element has an inlet for receiving fluid and/or fluidized solids. The support device is further adapted to be selectively disconnectable from the elongate member string.",SMJM LTD,FRASER JOHN PAUL;;FONG JASON WING HAU;;MURRAY JOHN KENNETH FRASER,,https://lens.org/175-630-653-948-150,Patent Application,no,5,0,8,8,0,E21B23/06;;E21B33/134;;E21B23/06;;E21B33/134;;E21B23/06;;E21B33/134;;E21B33/127;;E21B33/13,E21B23/06;;E21B33/134,,0,0,,,,ACTIVE
499,US,B2,US 9422787 B2,018-520-929-200-371,2016-08-23,2016,US 201214117408 A,2012-05-24,GB 201108724 A;;GB 2012051166 W,2011-05-24,Support device for use in a wellbore and a method for deploying a barrier in a wellbore,"The present invention relates to a downhole support device ( 100 ) for use in a wellbore and which is adapted to be run into the wellbore through an elongate member string ( 2 ) such as on a string of tubulars, a coiled tubing string or a slickline. The downhole support device comprises an inflatable element ( 102 ), which in use is adapted to be selectively connectable to the elongate member string and is further adapted to apply a biasing force in the direction of the wellbore walls. The inflatable element has an inlet ( 104 ) for receiving fluid and/or fluidized solids. The support device is further adapted to be selectively disconnectable from the elongate member string.",FRASER JOHN PAUL;;FONG JASON WING HAU;;MURRAY JOHN KENNETH FRASER;;SMJM LTD,FRASER JOHN PAUL;;FONG JASON WING HAU;;MURRAY JOHN KENNETH FRASER,CORETRAX GLOBAL LIMITED (2022-04-21);;SMJM LIMITED (2012-07-17);;CORETRAX TECHNOLOGY LIMITED (2013-11-12),https://lens.org/018-520-929-200-371,Granted Patent,yes,27,4,8,8,0,E21B23/06;;E21B33/134;;E21B23/06;;E21B33/134;;E21B23/06;;E21B33/134;;E21B33/127;;E21B33/13,E21B33/13;;E21B23/06;;E21B33/12;;E21B33/127;;E21B33/134,,1,0,,,"Manolache, I., ""International Search Report"" for PCT/GB2012/051166, as mailed Jul. 26, 2013, 5 pages.",ACTIVE
500,GB,A,GB 189614783 A,012-679-690-919-056,1897-05-15,1897,GB 189614783D A,1896-07-03,GB 189614783T A,1896-07-03,"Improvements in Closing or Stoppering Bottles, Jars, and the like.",,PALMER THOMAS CASSIENET;;FRASER WILLIAM JOHN;;FRASER FRANK HAZEL;;FRASER LESLIE MCGREGOR,PALMER THOMAS CASSIENET;;FRASER WILLIAM JOHN;;FRASER FRANK HAZEL;;FRASER LESLIE MCGREGOR,,https://lens.org/012-679-690-919-056,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
501,NZ,A,NZ 576699 A,048-736-457-869-245,2011-12-22,2011,NZ 57669910 A,2010-04-30,NZ 57669910 A,2010-04-30,A seat for an emergency response fire fighting vehicle formed from two spaced apart generally L shaped columns that accomodates operator backpack equipment,"A method of forming a column for a vehicle seat, a method of forming a seat for an emergency response vehicle, and an emergency response vehicle seat is disclosed. The emergency response vehicle seat has a seat base portion and a seat back portion including: (a) a pair of spaced apart generally L shaped columns, each formed from two halves formed of folded sheet metal, each half including: (i) a planar generally L shaped body; (ii) first tabs extending from the planar generally L shaped body in a first direction with respect to the body; and (iii) second tabs extending from the planar generally L shaped body in a second direction with respect to the body, wherein tabs of the column halves are secured together face to face; (b) cross members securing the generally L shaped columns in spaced apart relationship; and (c) cushioning applied to the seat base and seat back portions. The pair of spaced apart columns define a cavity between the columns in the seat back portion suitable for accommodating a pressurised fluid container of the type forming a typical emergency backpack.",FRASER FIRE & RESCUE LTD,MARTIN SIMPSON;;JOHN JAMES FRASER,,https://lens.org/048-736-457-869-245,Patent Application,no,0,0,1,1,0,,B60N2/24;;B60N2/42;;B60N2/68,,0,0,,,,PENDING
502,JP,A,JP 2012143233 A,059-966-138-361-826,2012-08-02,2012,JP 2012040561 A,2012-02-27,US 57599704 P;;US 63922204 P,2004-06-01,COMPOSITION AND METHOD TO PREVENT AAV VECTOR AGGREGATION,"PROBLEM TO BE SOLVED: To provide compositions and methods for preparing concentrated stock solutions of AAV virions without aggregation.SOLUTION: Formulations for AAV preparation and storage are high ionic strength solutions (e.g. μ-500 mM) that are nonetheless isotonic with the intended target tissue. This combination of high ionic strength and modest osmolarity is achieved using salts of high valency, such as sodium citrate. AAV stock solutions up to 6.4x10vg/mL are possible using the formulations, with no aggregation being observed even after ten freeze-thaw cycles. The surfactant Pluronic(R) F68 may be added at 0.001% to prevent losses of virions to surfaces during handling. Virion preparations can also be treated with nucleases to eliminate small nucleic acid strands on virions surfaces that exacerbate aggregation.",GENZYME CORP,WRIGHT JOHN FRASER;;QU GUANG,,https://lens.org/059-966-138-361-826,Patent Application,no,1,1,33,34,0,C12N2750/14151;;C12N7/00;;C12N2750/14151;;C12N7/00;;C12N2750/14111,C12N7/00;;A61K9/08;;A61K35/76;;A61K47/02;;C12N7/02,,2,0,,,"JPN6011008947; Ｊｏｕｒｎａｌ ｏｆ Ｇｅｎｅｒａｌ Ｖｉｒｏｌｏｇｙ Ｖｏｌ．７８, 1997, ｐｐ．１４５３-１４６２;;JPN6011008926; Ｍｏｌｅｃｕｌａｒ Ｔｈｅｒａｐｙ Ｖｏｌ．９， Ｓｕｐ．１, 200405, ｐ．Ｓ１６３， ＃４２５",ACTIVE
503,US,B2,US 7261544 B2,073-525-911-758-307,2007-08-28,2007,US 85168804 A,2004-05-21,US 85168804 A;;US 47238403 P;;US 54975604 P,2003-05-21,Methods for producing preparations of recombinant AAV virions substantially free of empty capsids,Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.,GENZYME CORP,QU GUANG;;WRIGHT JOHN FRASER,AVIGEN INC (2004-08-27);;GENZYME CORPORATION (2007-09-25),https://lens.org/073-525-911-758-307,Granted Patent,yes,5,13,40,41,0,C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N15/86;;C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N2710/16651;;C12N2710/10351;;C12N2760/16051;;C12N15/86,C12N/;;C12N7/02;;C12N15/00;;C12N15/86;;C12N15/864,425/239;;435/69.1;;435/320.1,22,22,003-351-517-641-454;;051-418-497-856-216;;042-838-870-694-53X;;141-768-814-445-684;;082-256-886-757-890;;040-850-901-799-916;;038-473-596-759-623;;131-849-343-621-830;;001-855-353-292-660;;088-196-754-870-804;;135-987-388-625-166;;004-717-207-320-786;;127-234-167-778-680;;156-118-146-118-185;;020-844-173-544-686;;165-644-511-657-053;;056-315-332-834-967;;045-942-479-095-293;;063-793-003-971-602;;040-850-901-799-916;;036-117-611-735-723;;008-227-308-422-865,10.1089/104303400750001390;;11044910;;12459331;;10.1016/s0958-1669(02)00369-5;;9445046;;10.1128/jvi.72.2.1438-1445.1998;;pmc124624;;10.1089/10430349950018427;;10223736;;10.1016/s1525-0016(02)90719-7;;12436964;;10.1006/mthe.2002.0719;;10.1089/104303402320139014;;12133276;;12413414;;10.1016/s1046-2023(02)00220-7;;10.1016/s0076-6879(02)46069-7;;11883083;;10.1016/s1525-0016(16)41455-3;;15963933;;10.1016/j.ymthe.2005.02.021;;10.1016/s1525-0016(02)00019-9;;12573625;;10455443;;10.1038/sj.gt.3300946;;10.1016/s1525-0016(16)42976-x;;10.1016/0005-2795(70)90310-7;;5534305;;10.1016/j.jviromet.2004.07.001;;15381358;;10.1007/bf03187263;;10.1016/s0166-0934(99)00150-0;;0010716335;;10716335;;11589834;;10.1089/104303401753153974;;10.1038/sj.gt.3300938;;10455399;;10.1089/104303402320139014;;12133276;;19649903;;10821405;;10.1016/s0378-4347(00)00100-6,"Gao, G., G. Qu, et al., Purification of recombinant adeno-associated virus vectors by column chromatography and its performance in vivo., Human Gene Therapy, Oct. 10, 2000, 2079-91, vol. 11.;;Snyder, R. O. and T. R. Flotte, Production of clinical-grade recombinant adeno-associated virus vectors., Current Opinion in Biotechnology, 2002, 418-23, vol. 13.;;Summerford, C. and R. J. Samulski, Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions., Journal of Virology, Feb. 1998, 1438-45, vol. 72.;;Clark, K. R., X. Liu, et al., Highly purified recombinant adeno-associated virus vectors are biologially active and free of detectable helper and wild-type viruses., Human Gene Therapy, Apr. 10, 1999, 1031-9. vol. 10.;;Brument, N., R. Morenweiser, et al., A versatile and scalable two-step ion-exchange chromatography process for the purification of recombinant adeno-associated virus serotypes-2 and -5., Molecular Therapy, Nov. 2002, 678-86, vol. 6, No. 5.;;Kaludov, N., B. Handelman, et al., Scalable purification of adeno-associated virus type 2, 4, or 5 using ion-exchange chromatography., Human Gene Therapy, Jul. 1, 2000, 1235-43, vol. 13.;;Zolotukhin, S., M. Potter, et al., Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors, Methods, Jul. 15, 2002, 158-67, vol. 28.;;Potter, M., K. Chesnut, et al., Streamlined large-scale production of recombinant adeno-associated virus (rAAV) vectors., Methods in Enzymology, 2002, 413-430, vol. 346.;;Parker A., Nagy D., Vargas J., Anand V., Qu G., Sommer J., Wright F., Couto L., In vivo performance of AAV-2 vectors purified by CsCl gradient centrifugation or column chromatography., Molecular Therapy, 2003, S390 vol. 7.;;Wright, J. F., T. Le, et al., Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and forumulation., Molecular Therapy, Jul. 2005, 171-8, vol. 12, No. 1.;;Sommer, JM., P. H. Smith, et al., Quantification of adeno-associated virus particles and empty capsids by optical density measurement., Molecular Therapy, Jan. 2003, 122-8, vol. 7, No. 1.;;Grimm, D., A. Kern, et al., Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2., Gene Therapy, 1999, 1322-30, vol. 6.;;Qu G., et al., Characterization of AAV Vectors Expressing Human Coagulation Factor IX Produced at Intermediate Scale., Molecular Therapy, May 2002, S50, vol. 5.;;Lewis, U. J., E. V. Cheever, et al., Kinetic study of the deamidation of growth hormone and prolactin., Biochimica et Biophysica Acta, 1970, 498-508, vol. 214.;;Davidoff, A. M., C. Y. NG, et al., Purification of recombinant adeno-associated virus type 8 vectors by ion exchange chromatography generates clinical grade vector stock., Journal of Virological Methods, 2004, 209-15, 121.;;Wu, Xaiobing, et al., A novel method for purification of recombinant adeno-associated virus vectors on a large scale., Chinese Science Bulletin, 2001, 485-489, vol. 46.;;Anderson, et al., A Method for the Preparation of Highly Purified Adeno<SUB>-</SUB>Associated Virus Using Affinity Column Chromatography, Protease Digestion and Solvent Extraction, Journal of Viralogical Methods 85:23-34 (2000).;;Vellekamp, et al., ""Empty Capsids in Column-Purified Recombinant Adenovirus Preparations,"" Human Gene Therapy 12:1923-1936 (2001).;;Zoluthkin, et al., ""Recombinant Adeno-Associated Virus Purification Using Novel Methods Improves Infectious Titer and Yield,"" Gene Therapy 6:973-985 (1999).;;Kaludov et al., ""Scalable Purification of Adeno-Associated Virus Type 2, 4, or 5 Using Ion-Exchange Chromatography,"" Human Gene Therapy, 13:1235-1243 (2002).;;Qu et al., ""Scaling-Up Production of Recombinant AAV Vectors for Clinical Applications,"" Current Opinion in Drug Discovery & Development, 3(6):750-755 (2000).;;Debelak, et al, ""Cation-Exchange High-Performance Liquid Chromatography of Recombinant Adeno-Associated Virus Type 2,"" J. Chromat.B, 740:195-202 (2000).",ACTIVE
504,EP,A1,EP 0766785 A1,095-758-476-152-591,1997-04-09,1997,EP 94900943 A,1993-11-30,GB 9225005 A;;GB 9302458 W,1992-11-30,IMPROVEMENTS IN OR RELATING TO FLUID-FLOW CONTROL VALVES,,PERKINS LTD,WALLACE IAN FRASER;;STAMFORD JOHN,,https://lens.org/095-758-476-152-591,Patent Application,yes,0,2,12,12,0,F02M65/005;;F02M2200/245;;Y10T137/8242;;F02M65/00;;Y10T137/8242;;F02M65/005;;F02M2200/245,B05B5/00;;F02M51/06;;F02M65/00;;F16K31/02,,0,0,,,,EXPIRED
505,US,A1,US 2018/0135097 A1,096-995-459-578-078,2018-05-17,2018,US 201715806136 A,2017-11-07,US 201715806136 A;;US 201662418637 P,2016-11-07,RAB ESCORT PROTEIN POTENCY ASSAY,"Methods for measuring REP-1 and REP-2 activity are provided. In certain embodiments, a method includes: (a) contacting cells that do not express endogenous functional REP-1 or REP-2 protein with an adeno-associated viral (AAV) vector comprising a CHM gene encoding a REP-1 protein or CHM like gene encoding a REP-2 protein under conditions allowing cell transduction; (b) incubating transduced cells under conditions allowing expression of the encoded REP-1 or REP-2 protein; (c) lysing the transduced cells to produce an extract comprising the encoded REP-1 or REP-2 protein and Rab small GTPase (Rabs); (d) incubating said extract with a Rab substrate for a period of time and under conditions allowing prenylation of the Rab thereby forming prenylated Rab; and (e) detecting and/or quantifying the prenylated Rab, wherein the amount of prenylated Rab reflects REP-1 or REP-2 activity thereby measuring REP-1 or REP-2 activity.",SPARK THERAPEUTICS INC,WRIGHT JOHN FRASER;;SUMAROKA MARINA,SPARK THERAPEUTICS INC (2017-11-14),https://lens.org/096-995-459-578-078,Patent Application,yes,0,0,11,11,0,C12Y205/0106;;C12Q1/48;;G01N2333/91171;;C12N9/1085;;C12Q1/48;;G01N2333/91171;;C12Y205/0106,C12Q1/48,,0,0,,,,ACTIVE
506,DK,T3,DK 2277996 T3,136-351-201-426-339,2014-10-20,2014,DK 10179750 T,2004-05-21,US 47238403 P;;US 54975604 P;;EP 04776068 A,2003-05-21,"FREMGANGSMÅDER TIL FREMSTILLING AF PRÆPARATIONER AF REKOMBINANTE AAV-VIRIONER, DER I HOVEDSAGEN ER FRI FOR TOMME CAPSIDER",Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.,GENZYME CORP,QU GUANG;;WRIGHT JOHN FRASER,,https://lens.org/136-351-201-426-339,Granted Patent,no,0,0,40,41,0,C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N15/86;;C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N2710/16651;;C12N2710/10351;;C12N2760/16051;;C12N15/86,C12N7/02;;B01D15/00;;B01D15/04;;C02F1/42;;C12N/;;C12N15/86;;C12N15/864,,0,0,,,,ACTIVE
507,US,A1,US 2011/0076744 A1,171-165-123-804-380,2011-03-31,2011,US 66155310 A,2010-03-19,US 66155310 A;;US 14199605 A;;US 57599704 P;;US 63922204 P,2004-06-01,Compositions and methods to prevent AAV vector aggregation,"Compositions and methods are provided for preparation of concentrated stock solutions of AAV virions without aggregation. Formulations for AAV preparation and storage are high ionic strength solutions (e.g. μ˜500 mM) that are nonetheless isotonic with the intended target tissue. This combination of high ionic strength and modest osmolarity is achieved using salts of high valency, such as sodium citrate. AAV stock solutions up to 6.4×10 13 vg/mL are possible using the formulations of the invention, with no aggregation being observed even after ten freeze-thaw cycles. The surfactant Pluronic® F68 may be added at 0.001% to prevent losses of virions to surfaces during handling. Virion preparations can also be treated with nucleases to eliminate small nucleic acid strands on virions surfaces that exacerbate aggregation.",WRIGHT JOHN FRASER;;QU GUANG,WRIGHT JOHN FRASER;;QU GUANG,AVIGEN INC (2005-10-04);;GENZYME CORPORATION (2005-12-19),https://lens.org/171-165-123-804-380,Patent Application,yes,6,12,33,34,0,C12N2750/14151;;C12N7/00;;C12N2750/14151;;C12N7/00;;C12N2750/14111,C12N7/00;;C12N7/02;;C12N15/63,435/239;;435/320.1;;435/235.1,1,1,120-644-541-568-817,pmc109439;;9420290;;10.1128/jvi.72.1.802-806.1998,"VIHINEN-RANTA M. et al., Intracellular Route of Canine Parvovirus Entry, JOURNAL OF VIROLOGY, Jan. 1998, vol. 72, No. 1, pages 802-806.",ACTIVE
508,EP,A4,EP 1625210 A4,011-356-279-403-102,2006-07-12,2006,EP 04776068 A,2004-05-21,US 2004/0015958 W;;US 47238403 P;;US 54975604 P,2003-05-21,METHODS FOR PRODUCING PREPARATIONS OF RECOMBINANT AAV VIRIONS SUBSTANTIALLY FREE OF EMPTY CAPSIDS,Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.,AVIGEN INC,QU GUANG;;WRIGHT JOHN FRASER,,https://lens.org/011-356-279-403-102,Search Report,no,2,0,40,41,0,C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N15/86;;C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N2710/16651;;C12N2710/10351;;C12N2760/16051;;C12N15/86,C12N/;;C12N7/02;;C12N15/86;;C12N15/864,,6,6,040-850-901-799-916;;036-117-611-735-723;;045-942-479-095-293;;056-315-332-834-967;;063-793-003-971-602;;133-796-772-596-115,10.1089/104303402320139014;;12133276;;19649903;;11589834;;10.1089/104303401753153974;;10.1016/s0166-0934(99)00150-0;;0010716335;;10716335;;10.1038/sj.gt.3300938;;10455399;;10.1016/j.ymthe.2004.06.346,"KALUDOV NIKOLA ET AL: ""Scalable purification of adeno-associated virus type 2, 4, or 5 using ion-exchange chromatography"", HUMAN GENE THERAPY, vol. 13, no. 10, 1 July 2002 (2002-07-01), pages 1235 - 1243, XP002382732, ISSN: 1043-0342;;QU G ET AL: ""SCALING-UP PRODUCTION OF RECOMBINANT AAV VECTORS FOR CLINICAL APPLICATIONS"", CURRENT OPINION IN DRUG DISCOVERY AND DEVELOPMENT, CURRENT DRUGS, LONDON, GB, vol. 3, no. 6, 2000, pages 750 - 755, XP001041966, ISSN: 1367-6733;;VELLEKAMP GARY ET AL: ""Empty capsids in column-purified recombinant adenovirus preparations"", HUMAN GENE THERAPY, vol. 12, no. 15, 10 October 2001 (2001-10-10), pages 1923 - 1936, XP002382733, ISSN: 1043-0342;;ANDERSON R ET AL: ""A METHOD FOR THE PREPARATION OF HIGHLY PURIFIED ADENO-ASSOCIATED VIRUS USING AFFINITY COLUMN CHROMATOGRAPHY, PROTEASE DIGESTION AND SOLVENT EXTRACTION"", JOURNAL OF VIROLOGICAL METHODS, AMSTERDAM, NL, vol. 85, no. 1-2, March 2000 (2000-03-01), pages 23 - 34, XP000982643, ISSN: 0166-0934;;ZOLOTUKHIN ET AL: ""Recombinant adeno -associated virus purification using novel methods improves infectious titer and yield"", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 6, no. 6, June 1999 (1999-06-01), pages 973 - 985, XP002116593, ISSN: 0969-7128;;""Development of a scalable column chromatography-based purification process to manufacure empty capsid-free AAV vectors"", MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA,, US, vol. 9, May 2004 (2004-05-01), pages 162, XP004634790, ISSN: 1525-0016",ACTIVE
509,DE,T2,DE 69316934 T2,020-444-989-775-150,1998-08-27,1998,DE 69316934 T,1993-11-30,GB 9225005 A;;GB 9302458 W,1992-11-30,VERBESSERUNGEN AN DURCHFLUSSREGELVENTILEN,,PERKINS LTD,WALLACE IAN FRASER;;STAMFORD JOHN,"PERKINS ENGINES CO., LTD., DESFORD, LEICESTER, GB (2000-12-07)",https://lens.org/020-444-989-775-150,Granted Patent,no,0,2,12,12,0,F02M65/005;;F02M2200/245;;Y10T137/8242;;F02M65/00;;Y10T137/8242;;F02M65/005;;F02M2200/245,F02M51/06;;B05B5/00;;F02M65/00;;F16K31/02,,0,0,,,,EXPIRED
510,US,A,US 2450423 A,033-078-195-666-061,1948-10-05,1948,US 54762244 A,1944-08-01,US 54762244 A,1944-08-01,Terminal structure,,FRASER JOHN W;;LOUIS GORDON,FRASER JOHN W;;LOUIS GORDON,,https://lens.org/033-078-195-666-061,Granted Patent,no,14,9,1,1,0,H01G4/35;;H01G4/35,H01G4/35,,0,0,,,,EXPIRED
511,US,A1,US 2021/0102448 A1,025-826-507-380-603,2021-04-08,2021,US 202017062314 A,2020-10-02,US 202017062314 A;;US 201962911002 P,2019-10-04,ADAPTOR APPARATUSES AND METHODS FOR ARTIFICIAL LIFT SYSTEMS,"The disclosure provides an adaptor apparatus for a downhole artificial lift system. The apparatus includes an upper adaptor section and a base adaptor section. The upper adaptor section includes a top connector portion for connecting to first equipment, and a neck portion below the top connector portion. The base adaptor section includes a bottom connector portion for connecting to second equipment. The base adaptor section and the neck section define a longitudinal fluid passage therethrough. The upper adaptor section includes slots extending from the fluid passage to an outer surface of the neck. The upper adaptor section also includes a plurality of fluid channels recessed in the outer surface of the upper adaptor piece.",FRASER GARTH JOHN;;COYES CORBIN,FRASER GARTH JOHN;;COYES CORBIN,Q2 ARTIFICIAL LIFT SERVICES ULC (2020-10-02),https://lens.org/025-826-507-380-603,Patent Application,yes,0,4,4,4,0,E21B43/127;;E21B17/02;;E21B43/127,E21B43/12,,0,0,,,,ACTIVE
512,EP,A1,EP 1735334 A1,047-508-812-673-87X,2006-12-27,2006,EP 04808912 A,2004-12-07,NZ 2004000317 W;;AU 2004/901570 A,2004-03-24,SET1 PROTEINS AND USES THEREFOR,,AUCKLAND UNISERVICES LTD,FRASER JOHN DAVID;;LANGLEY RIES,,https://lens.org/047-508-812-673-87X,Patent Application,yes,0,0,5,5,13,C07K14/31;;C07K14/31;;C07K16/1271;;C07K16/1271,C07K1/14;;C07K14/31;;C07K16/12;;C12N15/11;;C12N15/31,,0,0,,,,DISCONTINUED
513,WO,A1,WO 2010/021993 A1,050-114-456-832-016,2010-02-25,2010,US 2009/0054055 W,2009-08-17,US 9018608 P,2008-08-19,METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF THE LYMPHATIC SYSTEM AND MALIGNANT DISEASE,"Aspects of the invention provides methods for preparing and using adipose-tissue-derived stem and progenitor cells, adipose-tissue-derived lymphatic endothelial cells, and cells capable of differentiating into lymphatic endothelial cells to treat disorders of the lymphatic system and to modulate expansion, repair, and/or regeneration of the lymphatic system. The invention further provides using adipose-tissue-derived lymphatic endothelial cells and cells capable of differentiating into lymphatic endothelial cells for delivery of therapeutic agents to tumor cells as a means for treating malignant disease, and assays to screen for drugs that modulate lymphatic system expansion, repair or regeneration.",CYTORI THERAPEUTICS INC;;ALFONSO ZENI;;FRASER JOHN K,ALFONSO ZENI;;FRASER JOHN K,,https://lens.org/050-114-456-832-016,Patent Application,yes,4,41,6,6,0,A61K35/12;;A61K35/12;;A61K35/28;;A61K35/28;;A61K35/35;;A61K35/35;;A61K45/06;;A61K2035/124;;A61P3/06;;A61P9/00;;A61P35/04;;C12N5/0651;;C12N5/0651;;C12N5/0667;;C12N5/069;;C12N5/069,C12N5/00;;A61K35/12;;A61K35/28;;A61K35/35,,0,0,,,,PENDING
514,CA,A1,CA 2849201 A1,079-577-277-082-225,2003-07-03,2003,CA 2849201 A,2002-12-09,US 33885601 P;;CA 2469370 A,2001-12-07,ADIPOSE-DERIVED CELL PROCESSING UNIT,Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient.,MACROPORE BIOSURGERY INC,FRASER JOHN;;HEDRICK MARC H,,https://lens.org/079-577-277-082-225,Patent Application,no,0,0,65,221,0,A61K35/28;;A61K35/28;;A61K48/00;;A61B10/0283;;A61B10/0283;;A61K9/0019;;A61K9/0019;;A61K35/32;;A61K35/35;;A61K35/35;;A61K35/36;;A61M1/76;;A61M2202/08;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/00;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;A61P43/00;;C12M47/04;;C12N5/0667;;C12N5/0667;;C12N5/069;;C12N5/069;;C12N2506/1384;;C12N2506/1384,A61K35/12;;A61M1/00;;A61K8/98;;A61K31/436;;A61K35/02;;A61K35/28;;A61K35/35;;A61K35/36;;A61K38/00;;A61K38/16;;A61K45/00;;A61L27/00;;A61P1/00;;A61P1/16;;A61P3/00;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P19/00;;A61P19/02;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;C12M3/06;;C12N5/0775,,0,0,,,,DISCONTINUED
515,US,A1,US 2003/0207439 A1,093-247-319-539-939,2003-11-06,2003,US 44070403 A,2003-05-19,US 44070403 A;;US 63383400 A,2000-08-07,Large-scale recombinant adeno-associated virus (rAAV) production and purification,"
   Methods are provided for large-scale purification of recombinant AAV (rAAV) virions that were produced in the absence of infectious adenovirus. Preferably, the rAAV is produced in a host cell line via triple-transfection with an accessory function vector, an AAV vector, and an AAV helper vector. The methods include preparing a lysate from the host cell line and passing that lysate over various combination of ion exchange chromatography media and/or affinity chromatography media. The affinity chromatography medium is an AAV receptor or an antibody with binding affinity for AAV, e.g., heparin sulfate. A variety of cation exchange and anion exchange media are contemplated by the present invention. In certain embodiment, optional purification steps may be included, such as filtering the lysate through one or more filters, or treating the lysate with a nuclease. 
",WRIGHT JOHN FRASER;;QU QUANG,WRIGHT JOHN FRASER;;QU QUANG,AVIGEN INC (2001-11-27);;GENZYME CORPORATION (2007-11-06),https://lens.org/093-247-319-539-939,Patent Application,yes,4,21,4,4,0,C12N7/00;;C12N2750/14151;;C12N7/00;;C12N2750/14151,C12N7/02,435/239,0,0,,,,DISCONTINUED
516,KR,A,KR 20080103611 A,082-543-393-844-816,2008-11-27,2008,KR 20087027860 A,2002-12-09,US 0239465 W;;US 33885601 P,2001-12-07,SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS,Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient.,CYTORI THERAPEUTICS INC,FRASER JOHN;;HENDRICK MARC H,,https://lens.org/082-543-393-844-816,Patent Application,no,0,5,65,221,0,A61K35/28;;A61K35/28;;A61K48/00;;A61B10/0283;;A61B10/0283;;A61K9/0019;;A61K9/0019;;A61K35/32;;A61K35/35;;A61K35/35;;A61K35/36;;A61M1/76;;A61M2202/08;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/00;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;A61P43/00;;C12M47/04;;C12N5/0667;;C12N5/0667;;C12N5/069;;C12N5/069;;C12N2506/1384;;C12N2506/1384,A61K48/00;;A61M1/00;;A61K31/436;;A61K35/02;;A61K35/12;;A61K35/28;;A61K35/32;;A61K35/35;;A61K35/36;;A61K38/00;;A61K38/16;;A61K45/00;;A61L27/00;;A61P1/00;;A61P1/16;;A61P3/00;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P19/00;;A61P19/02;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;C12M3/06;;C12N5/0775,,0,0,,,,EXPIRED
517,CN,C,CN 1267505 C,108-087-862-531-579,2006-08-02,2006,CN 02823422 A,2002-11-19,EP 01811152 A,2001-11-28,Fluorescent pigments,,CIBA SC HOLDING AG,JOHN FRASER IAN FRANK MACPHERS,,https://lens.org/108-087-862-531-579,Granted Patent,no,0,0,13,13,0,C09B35/105;;C09B35/105;;C09B35/18;;C09B35/18;;C09B35/18,C07D319/06;;C09B35/10;;C08K5/00;;C09B35/18;;C09D11/02;;C09K11/06,,0,0,,,,EXPIRED
518,BR,B1,BR PI0511764 B1,107-898-922-222-78X,2017-10-24,2017,BR PI0511764 A,2005-06-01,US 57599704 P;;US 63922204 P;;US 2005/0019235 W,2004-06-01,método de prevenção de agregação de vírions de vírus adeno-associado recombinante (raav) em uma preparação purificada de virions raav,"composições e métodos para prevenir a agregação de vetor de aav. a presente invenção refere-se a composições e a métodos que são fornecidos para a preparação de soluções de matéria-prima concentradas de vírions de aav sem a agregação. as formulações para a preparação e armazenagem de aav são soluções de força iônica elevada (por exemplo, <109> ~500mm) que são apesar de tudo isotônicas com o tecido-alvo pretendido. esta combinação, de força iônica elevada e osmolaridade modesta, são obtidas empregando sais de valência elevada, tal como citrato de sódio. as soluções de matéria-prima aav acima de 6,4x10^ ¹³^ são possíveis empregando as formulações da invenção, com nenhuma agregação sendo observada mesmo após dez ciclos de congelamento-descongelamento. o tensoativo pluronic<32>f68 pode ser adicionado em 0,001% para impedir perdas de vírions para superfícies durante o manuseio. as preparações de vírions podem também ser tratadas com nucleases para eliminar pequenos filamentos de ácido nucléico em superfícies de vírions que exacerba a agregação.",AVIGEN INC,GUANG QU;;JOHN FRASER WRIGHT,,https://lens.org/107-898-922-222-78X,Granted Patent,no,0,0,33,34,0,C12N2750/14151;;C12N7/00;;C12N2750/14151;;C12N7/00;;C12N2750/14111,C12N7/02,,0,0,,,,ACTIVE
519,US,A,US 1836364 A,109-727-654-687-842,1931-12-15,1931,US 13851526 A,1926-09-29,US 13851526 A,1926-09-29,Sheet glass grinding and polishing apparatus,,LIBBEY OWENSFORD GLASS COMPANY,DRAKE JOHN L;;FRANK FRASER,,https://lens.org/109-727-654-687-842,Granted Patent,no,0,3,1,1,0,B24B7/244;;B24B7/244,B24B7/24,,0,0,,,,EXPIRED
520,US,B2,US 10633689 B2,107-215-753-023-425,2020-04-28,2020,US 201715806136 A,2017-11-07,US 201715806136 A;;US 201662418637 P,2016-11-07,Rab Escort Protein potency assay,"Methods for measuring REP-1 and REP-2 activity are provided. In certain embodiments, a method includes: (a) contacting cells that do not express endogenous functional REP-1 or REP-2 protein with an adeno-associated viral (AAV) vector comprising a CHM gene encoding a REP-1 protein or CHM like gene encoding a REP-2 protein under conditions allowing cell transduction; (b) incubating transduced cells under conditions allowing expression of the encoded REP-1 or REP-2 protein; (c) lysing the transduced cells to produce an extract comprising the encoded REP-1 or REP-2 protein and Rab small GTPase (Rabs); (d) incubating said extract with a Rab substrate for a period of time and under conditions allowing prenylation of the Rab thereby forming prenylated Rab; and (e) detecting and/or quantifying the prenylated Rab, wherein the amount of prenylated Rab reflects REP-1 or REP-2 activity thereby measuring REP-1 or REP-2 activity.",SPARK THERAPEUTICS INC,WRIGHT JOHN FRASER;;SUMAROKA MARINA,SPARK THERAPEUTICS INC (2017-11-14),https://lens.org/107-215-753-023-425,Granted Patent,yes,2,0,11,11,0,C12Y205/0106;;C12Q1/48;;G01N2333/91171;;C12N9/1085;;C12Q1/48;;G01N2333/91171;;C12Y205/0106,C12Q1/48,,2,2,060-944-441-451-240;;060-944-441-451-240,pmc3646845;;10.1371/journal.pone.0061396;;23667438;;pmc3646845;;10.1371/journal.pone.0061396;;23667438,"Vasireddy et al in “AAV-Mediated Gene Therapy for Choroideremia: Preclinical Studies in Personalized Models” (PLOS One May 2013 vol. 8, No. 5, pp. 1-13. (Year: 2013).;;Vasireddy, et al., AAV-Mediated Gene Therapy for Choroideremia: Preclinical Studies in Personalized Models, PLoS One, 2013, 8(5)1-13, Article e61396.",ACTIVE
521,EP,A1,EP 1141000 A1,109-346-817-687-240,2001-10-10,2001,EP 99962603 A,1999-12-24,NZ 9900228 W;;NZ 33358998 A,1998-12-24,SUPERANTIGENS,,AUCKLAND UNISERVICES LTD,FRASER JOHN DAVID;;PROFT THOMAS,,https://lens.org/109-346-817-687-240,Patent Application,yes,0,0,7,10,8,A61K38/00;;A61K39/00;;A61P35/00;;A61P37/02;;C07K14/315,G01N33/569;;A61K38/00;;A61K39/00;;A61K39/09;;A61K39/395;;A61K47/48;;A61P35/00;;A61P37/02;;C07K14/315;;C07K16/12;;C12N15/09;;C12Q1/68,,0,0,,,,DISCONTINUED
522,WO,A3,WO 2003/053346 A3,112-931-131-058-672,2006-08-17,2006,US 0239465 W,2002-12-09,US 33885601 P,2001-12-07,SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS,Cells present in processed lipoaspirate tissue are used to treat patients&period; Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient&period; The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient&period; Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient&period;,MACROPORE BIOSURGERY INC;;FRASER JOHN;;HENDRICK MARC H,FRASER JOHN;;HENDRICK MARC H,,https://lens.org/112-931-131-058-672,Search Report,yes,2,0,65,221,0,A61K35/28;;A61K35/28;;A61K48/00;;A61B10/0283;;A61B10/0283;;A61K9/0019;;A61K9/0019;;A61K35/32;;A61K35/35;;A61K35/35;;A61K35/36;;A61M1/76;;A61M2202/08;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/00;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;A61P43/00;;C12M47/04;;C12N5/0667;;C12N5/0667;;C12N5/069;;C12N5/069;;C12N2506/1384;;C12N2506/1384,A61K35/00;;A61M1/00;;A61K31/436;;A61K35/02;;A61K35/12;;A61K35/28;;A61K35/35;;A61K35/36;;A61K38/00;;A61K38/16;;A61K45/00;;A61L27/00;;A61P1/00;;A61P1/16;;A61P3/00;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P19/00;;A61P19/02;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;C12M3/06;;C12N5/0775,,2,1,010-094-842-952-554,10.1089/107632701300062859;;11304456,"ZUK P.A. ET AL: ""Multilineage Cells from Human Adipose Issue: Implications for Cell-based Therapies"", TISSUE ENGINEERING, vol. 7, no. 2, April 2001 (2001-04-01), pages 211 - 228, XP002198710;;See also references of EP 1572071A4",PENDING
523,US,A,US 756950 A,129-279-727-029-437,1904-04-12,1904,US 1903/0137813 A,1903-01-05,US 1903/0137813 A,1903-01-05,DRIVING MECHANISM FOR SIEVE BOLTING-MACHINES.,,FRASER JOHN;;MATHER ALLAN G,FRASER JOHN;;MATHER ALLAN G,,https://lens.org/129-279-727-029-437,Granted Patent,no,0,6,1,1,0,B07B1/42;;B07B1/42,,,0,0,,,,EXPIRED
524,ES,T3,ES 2932278 T3,139-857-034-224-664,2023-01-17,2023,ES 17186206 T,2005-06-01,US 57599704 P;;US 63922204 P,2004-06-01,Composiciones y métodos para prevenir la agregación del vector AAV,"Se proporcionan composiciones y métodos para la preparación de soluciones madre concentradas de viriones AAV sin agregación. Las formulaciones para la preparación y el almacenamiento de AAV son soluciones de alta fuerza iónica (p. ej., μ ∼ 500 mM) que, no obstante, son isotónicas con el tejido objetivo previsto. Esta combinación de fuerza iónica alta y osmolaridad modesta se logra utilizando sales de alta valencia, como el citrato de sodio. Las soluciones madre de AAV de hasta 6,4x1013 vg/mL son posibles usando las formulaciones de la invención, sin que se observe agregación incluso después de diez ciclos de congelación-descongelación. Se puede agregar el surfactante Pluronic® F68 al 0.001% para evitar pérdidas de viriones a las superficies durante la manipulación. Las preparaciones de viriones también se pueden tratar con nucleasas para eliminar las pequeñas cadenas de ácido nucleico en las superficies de los viriones que exacerban la agregación. (Traducción automática con Google Translate, sin valor legal)",GENZYME CORP,WRIGHT JOHN FRASER;;QU GUANG,,https://lens.org/139-857-034-224-664,Granted Patent,no,0,0,33,34,0,C12N2750/14151;;C12N7/00;;C12N2750/14151;;C12N7/00;;C12N2750/14111,C12N7/00;;C12N7/02,,0,0,,,,ACTIVE
525,US,B2,US 11699332 B2,149-806-851-808-267,2023-07-11,2023,US 202217690259 A,2022-03-09,US 202217690259 A;;US 202117238390 A,2021-04-23,"Apparatus, system, and method for bulk currency note deposits",A Self-Service Terminal (SST) that provides valuable media deposit features is enhanced with an apparatus fastened to an outside surface of the SST. The apparatus is adapted to receive an externally provided valuable media cassette and connect/interface a port of the cassette to an unload infeed port. A transaction interface is enhanced to identify the cassette as a source device for obtaining valuable media during a deposit transaction. The SST feeds the valuable media from the externally connected cassette through media validation and transport modules of the SST into cassettes of a safe and the SST returns rejected media for the deposit transaction back through the modules to return rejected media to the externally interfaced cassette.,NCR CORP,FRASER GRANT BUCHANAN;;MANNION JOHN,NCR CORPORATION (2021-04-23),https://lens.org/149-806-851-808-267,Granted Patent,yes,3,0,4,4,0,G07F19/205;;G07F19/202;;G07F19/205;;G07F19/202,G07F19/00,,0,0,,,,ACTIVE
526,CH,A,CH 453343 A,145-760-664-883-468,1968-06-14,1968,CH 688864 A,1964-05-26,GB 2108463 A,1963-05-27,Verfahren zur Oxydation von Cyclohexan,,ICI LTD,CYRIL GARDNER;;JOHN FRASER PRESCOTT,,https://lens.org/145-760-664-883-468,Granted Patent,no,0,0,7,8,0,C07C51/313;;C07C51/313;;C07C45/33;;C07C45/33;;C07C51/316;;C07C51/316,C07C45/33;;C07C51/31,"12O,25",0,0,,,,EXPIRED
527,WO,A1,WO 2005/118792 A1,009-656-101-301-021,2005-12-15,2005,US 2005/0019235 W,2005-06-01,US 57599704 P;;US 63922204 P,2004-06-01,COMPOSITIONS AND METHODS TO PREVENT AAV VECTOR AGGREGATION,"Compositions and methods are provided for preparation of concentrated stock solutions of AAV virions without aggregation. Formulations for AAV preparation and storage are high ionic strength solutions (e.g. 쎽 500mM) that are nonetheless isotonic with the intended target tissue. This combination of high ionic strength and modest osmolarity is achieved using salts of high valency, such as sodium citrate. AAV stock solutions up to 6.4x1013 vg/mL are possible using the formulations of the invention, with no aggregation being observed even after ten freeze-thaw cycles. The surfactant Pluronicꡞ F68 may be added at 0.001% to prevent losses of virions to surfaces during handling. Virion preparations can also be treated with nucleases to eliminate small nucleic acid strands on virions surfaces that exacerbate aggregation.",AVIGEN INC;;WRIGHT JOHN FRASER;;QU GUANG,WRIGHT JOHN FRASER;;QU GUANG,,https://lens.org/009-656-101-301-021,Patent Application,yes,0,46,33,34,0,C12N2750/14151;;C12N7/00;;C12N2750/14151;;C12N7/00;;C12N2750/14111,C12N7/02,,9,7,036-117-611-735-723;;089-800-605-790-418;;135-987-388-625-166;;017-602-964-237-703;;056-841-143-148-239;;028-383-058-454-759;;089-786-895-898-348,19649903;;11269337;;10.1002/1521-2254(2000)9999:9999<::aid-jgm152>3.0.co;2-u;;10.1016/s1525-0016(02)00019-9;;12573625;;10.1002/jps.2600831204;;7891291;;10.1002/jps.20079;;15124199;;10.1016/s0378-5173(99)00152-0;;10460913;;15488616;;10.1016/j.jviromet.2004.07.007,"QU G. ET AL: ""Scaling up production of recombinant AAV vectors for clinical applications"", CURR. OPINION IN DRUG DISCOVERY & DEVELOPMENT, vol. 3, no. 6, 2000, pages 750 - 755, XP001041966;;DRITTANTI L. ET AL: ""Optimized helper virus-free production of high-quality adeno-associated virus vectors"", THE JOURNAL OF GENE MEDICINE, vol. 3, pages 59 - 71, XP009033855;;SOMMER J.M. ET AL: ""Quantification of adeno-associated virus particles and enmty capsids by optical density measurement"", MOLECULAR THERAPY, vol. 7, no. 1, January 2003 (2003-01-01), pages 122 - 128, XP002965707;;CHEN, B. ET AL., J. PHARM. SCI., vol. 83, 1994, pages 1657 - 1661;;SHIRE, S. J. ET AL., J. PHARM. SCI, vol. 93, 2004, pages 1390 - 1402;;WANG, W., INT. J. PHARM, vol. 185, 1999, pages 129 - 188;;WON, C. M. ET AL., INT. J. PHARM, vol. 167, 1998, pages 25 - 36;;SMITH, P. ET AL., MOL. THERAPY, vol. 7, 2003, pages S348;;XIE, Q. ET AL., J. VIROL. METHODS, vol. 122, 2004, pages 17 - 27",PENDING
528,EP,A2,EP 2277996 A2,051-021-261-514-45X,2011-01-26,2011,EP 10179750 A,2004-05-21,EP 04776068 A;;US 47238403 P;;US 54975604 P,2003-05-21,Methods for producing preparations of recombinant AAV virions substantially free of empty capsids,"Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.
",GENZYME CORP,QU GUANG;;WRIGHT JOHN FRASER,,https://lens.org/051-021-261-514-45X,Patent Application,yes,12,0,40,41,0,C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N15/86;;C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N2710/16651;;C12N2710/10351;;C12N2760/16051;;C12N15/86,C12N7/02;;B01D15/00;;B01D15/04;;C02F1/42;;C12N/;;C12N15/86;;C12N15/864,,49,33,010-713-990-772-82X;;040-850-901-799-916;;074-652-424-954-106;;010-092-025-424-218;;042-769-724-026-529;;036-751-136-233-342;;004-906-146-072-928;;005-904-093-105-315;;118-781-394-705-963;;017-939-992-695-836;;087-005-980-063-276;;001-107-410-887-879;;034-454-872-268-857;;075-206-291-455-245;;072-366-322-919-406;;010-519-409-512-153;;056-196-064-755-971;;039-999-144-232-460;;019-953-149-793-444;;061-166-732-363-142;;056-196-064-755-971;;030-079-213-874-071;;039-151-553-495-992;;008-587-496-850-953;;058-452-600-692-672;;061-166-732-363-142;;040-212-003-832-140;;009-499-373-901-710;;066-928-563-719-899;;011-646-571-801-437;;010-284-533-720-722;;004-717-207-320-786;;045-303-142-874-063,10.1038/nbt0395-222;;9634764;;10.1089/104303402320139014;;12133276;;10.1128/jvi.63.9.3822-3828.1989;;pmc250975;;2547998;;pmc240929;;10.1128/jvi.65.6.2936-2945.1991;;2033660;;10.1099/0022-1317-9-3-243;;5498444;;10.1016/0042-6822(71)90141-3;;5000131;;6305001;;10.1016/s0042-6822(83)80008-7;;10.1128/jvi.41.3.868-876.1982;;6284977;;pmc256823;;pmc319248;;6262830;;10.1073/pnas.78.3.1925;;10.1016/0042-6822(80)90354-2;;6249041;;10.1099/0022-1317-29-2-239;;213533;;pmc319472;;6265925;;10.1073/pnas.78.5.2927;;6256359;;10.1016/s0021-9258(19)70007-6;;10.1128/jvi.62.1.206-210.1988;;pmc250520;;2824848;;4705382;;10.1016/0042-6822(73)90341-3;;6263759;;10.1016/0378-1119(81)90008-1;;10.1089/hum.1994.5.7-793;;7981305;;10.1128/mcb.8.10.3988;;pmc365467;;2847025;;10.1128/mcb.8.10.3988-3996.1988;;10.1016/0958-1669(92)90082-t;;1369403;;1316261;;10.1007/978-3-642-75608-5_5;;10.1089/hum.1994.5.7-793;;7981305;;7584077;;pmc2191525;;7515101;;10.1084/jem.179.6.1867;;886304;;10.1099/0022-1317-36-1-59;;452423;;10.1016/0042-6822(79)90476-8;;1316261;;10.1007/978-3-642-75608-5_5;;10.1006/viro.1994.1535;;8091661;;6270377;;pmc256613;;10.1128/jvi.40.1.241-247.1981;;2998066;;10.1016/0042-6822(85)90243-0;;3012864;;10.1016/0042-6822(86)90376-4;;10.1089/1043034041361262;;15298029;;10455443;;10.1038/sj.gt.3300946;;10982375;;pmc102127;;10.1128/jvi.74.19.9281-9293.2000,"C. P. HODGSON, BIOTECHNOLOGY, vol. 13, 1995, pages 222 - 225;;QU; WRIGHT, CUR. OPIN. DRUG DISC. AND DEVELOP., vol. 3, 2000, pages 750 - 755;;KALUDOV ET AL., HUM. GENE THER., vol. 13, 2002, pages 1235 - 1243;;D. GLOVER: ""DNA Cloning: A Practical Approach"", vol. I, II;;P. TIJSSEN,: ""CRC Handbook of Parvoviruses"", vol. I, II;;B.N. FIELDS AND D.M. KNIPE: ""Fundamental Virology2nd Edition,"", vol. I, II;;FRESHNEY: ""Culture of Animal Cells, A Manual of Basic Technique,Third Edition"", WILEY-LISS;;AUSUBEL ET AL.: ""Current Protocols in Molecular Biology"", 1991, WILEY INTERSCIENCE;;SAMULSKI ET AL., J. VIROL., vol. 63, 1989, pages 3822 - 3828;;MCCARTY ET AL., J. VIROL., vol. 65, 1991, pages 2936 - 2945;;ITO ET AL., J. GEN. VIROL., vol. 9, 1970, pages 243;;ISHIBASHI ET AL., VIROLOGY, vol. 45, 1971, pages 317;;CARTER ET AL., VIROLOGY, vol. 126, 1983, pages 505;;LAUGHLIN ET AL., J. VIROL., vol. 41, 1982, pages 868;;JANIK ET AL., PROC. NATL. ACAD. SCI. USA, vol. 78, 1981, pages 1925;;OSTROVE ET AL., VIROLOGY, vol. 104, 1980, pages 502;;HANDA ET AL., J. GEN. VIROL., vol. 29, 1975, pages 239;;STRAUSS ET AL., J. VIROL., vol. 17, 1976, pages 140;;MYERS ET AL., J. VIROL., vol. 35, 1980, pages 665;;JAY ET AL., PROC. NATL. ACAD. SCI. USA, vol. 78, 1981, pages 2927;;MYERS ET AL., J. BIOL. CHEM., vol. 256, 1981, pages 567;;CARTER: ""I CRC Handbook of Parvoviruses"", 1990, article ""Adeno-Associated Virus Helper Functions"";;SAMULSKI ET AL., J. VIROL., vol. 62, 1988, pages 206 - 210;;MATSHUSHITA ET AL., GENE THERAPY, vol. 5, 1998, pages 938 - 945;;GRAHAM ET AL., VIROLOGY, vol. 52, 1973, pages 456;;SAMBROOK ET AL.: ""Molecular Cloning, : a laboratory manual"", 1989, COLD SPRING HARBOR LABORATORIES;;DAVIS ET AL.: ""Basic Methods in Molecular Biology"", 1986, ELSEVIER;;CHU ET AL., GENE, vol. 13, 1981, pages 197;;KOTIN, R.M., HUMAN GENE THERAPY, vol. 5, 1994, pages 793 - 801;;BERNS, K.I.: ""Fundamental Virology, 2nd Edition,"", article ""Parvoviridae and their Replication"";;LEBKOWSKI ET AL., MOLEC. CELL. BIOL., vol. 8, 1988, pages 3988 - 3996;;VINCENT ET AL.: ""Vaccines"", vol. 90, 1990, COLD SPRING HARBOR LABORATORY PRESS;;CARTER, CURRENT OPINION IN BIOTECHNOLOGY, vol. 3, 1992, pages 533 - 539;;MUZYCZKA, CURRENT TOPICS IN MICROBIOL. AND IMMUNOL., vol. 158, 1992, pages 97 - 129;;KOTIN, HUMAN GENE THERAPY, vol. 5, 1994, pages 793 - 801;;SHELLING; SMITH, GENE THERAPY, vol. 1, 1994, pages 165 - 169;;ZHOU ET AL., J EXP. MED., vol. 179, 1994, pages 1867 - 1875;;GRAHAM ET AL., J. GEN. VIROL., vol. 36, 1977, pages 59;;AIELLO ET AL., VIROLOGY, vol. 94, 1979, pages 460;;MUZYCZKA, N., CURRENT TOPICS IN MICROBIOL. AND IMMUNOL., vol. 158, 1992, pages 97 - 129;;THOMSON ET AL., VIROLOGY, vol. 204, 1994, pages 304 - 311;;SAMULSKI ET AL., J VIROL., vol. 63, 1989, pages 3822 - 3828;;BULLER ET AL., J. VIROL., vol. 40, 1981, pages 241 - 247;;MCPHERSON ET AL., VIROLOGY, vol. 147, 1985, pages 217 - 222;;SCHLEHOFER ET AL., VIROLOGY, vol. 152, 1986, pages 110 - 117;;ZHEN ET AL.: ""An Infectious Titer Assay for Adeno-associated Virus (AAV) Vectors with Sensitivity Sufficient to Detect Single Infectious Events"", HUM. GENE THER., 2004;;GRIMM ET AL., GENE THERAPY, vol. 6, 1999, pages 1322 - 1330;;SOMMER ET AL., MOLEC. THER., vol. 2, 2003, pages 122 - 128;;WOBUS ET AL., J. VIROL., vol. 74, 2000, pages 9281 - 9293",ACTIVE
529,EP,A3,EP 2305276 A3,052-531-522-741-877,2011-09-21,2011,EP 10183690 A,2002-12-09,EP 02805565 A;;US 33885601 P,2001-12-07,Processed lipoaspirate cells for use in therapy,Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patent. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient.,CYTORI THERAPEUTICS INC,FRASER JOHN;;HEDRICK MARC H,,https://lens.org/052-531-522-741-877,Search Report,yes,3,0,65,221,0,A61K35/28;;A61K35/28;;A61K48/00;;A61B10/0283;;A61B10/0283;;A61K9/0019;;A61K9/0019;;A61K35/32;;A61K35/35;;A61K35/35;;A61K35/36;;A61M1/76;;A61M2202/08;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/00;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;A61P43/00;;C12M47/04;;C12N5/0667;;C12N5/0667;;C12N5/069;;C12N5/069;;C12N2506/1384;;C12N2506/1384,A61K35/12;;A61M1/00;;A61K31/436;;A61K35/02;;A61K35/28;;A61K35/35;;A61K35/36;;A61K38/00;;A61K38/16;;A61K45/00;;A61L27/00;;A61P1/00;;A61P1/16;;A61P3/00;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P19/00;;A61P19/02;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;C12M3/06;;C12N5/071;;C12N5/0775,,2,1,010-094-842-952-554,10.1089/107632701300062859;;11304456,"ZUK P A ET AL: ""Multilineage cells from human adipose tissue: implications for cell-based therapies."", TISSUE ENGINEERING APR 2001, vol. 7, no. 2, April 2001 (2001-04-01), pages 211 - 228, XP002198710, ISSN: 1076-3279;;HAUNER H ET AL: ""CULTURES OF HUMAN ADIPOSE PRECURSOR CELLS"", METHODS IN MOLECULAR BIOLOGY, HUMANA PRESS INC, NJ, US, vol. 155, 1 January 2001 (2001-01-01), pages 239 - 247, XP001153827, ISSN: 1064-3745",DISCONTINUED
530,CY,T1,CY 1115788 T1,051-676-491-867-012,2017-01-25,2017,CY 141100981 T,2014-11-26,EP 10179750 A;;US 47238403 P;;US 54975604 P,2003-05-21,ΜΕΘΟΔΟΙ ΓΙΑ ΠΑΡΑΓΩΓΗ ΠΑΡΑΣΚΕΥΑΣΜΑΤΩΝ ΑΝΑΣΥΝΔΥΑΣΜΕΝΩΝ AAV ΙΟΣΩΜΑΤΙΩΝ ΟΥΣΙΑΣΤΙΚΑ ΑΠΑΛΛΑΓΜΕΝΩΝ ΑΠΟ ΚΕΝΑ ΚΑΨΙΔΙΑ,Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.,GENZYME CORP,QU GUANG;;WRIGHT JOHN FRASER,,https://lens.org/051-676-491-867-012,Granted Patent,no,0,0,40,41,0,C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N15/86;;C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N2710/16651;;C12N2710/10351;;C12N2760/16051;;C12N15/86,C12N7/02;;B01D15/00;;B01D15/04;;C02F1/42;;C12N/;;C12N15/86;;C12N15/864,,0,0,,,,ACTIVE
531,BR,A2,BR 112013014422 A2,058-852-500-299-876,2017-03-21,2017,BR 112013014422 A,2011-12-08,IB 2011055546 W;;US 42247910 P,2010-12-13,sistema de formação de imagem diagnóstica ltrassônica para análise de onda de cisalhamento e método para ajustar a medição de uma característica de onda de cisalhamento medida em uma região do tecido,"sistema de formação de imagem diagnóstica ltrassônica para análise de onda de cisalhamento e método para ajustar a medição de uma característica de onda de cisalhamento medida em uma região do tecido um sistema de formação de imagem diagnóstica, ultrassônica para medição de onda de cisalhamento transmite pulsos de impulso no tecido para a geração de ondas de cisalhamento. as características das ondas de cisalhamento, como sua velocidade de passagem através do tecido, são medidas para avaliar propriedades, como rigidez do tecido. as medições são compensadas para efeitos de movimento de base ao amostrar sinais de eco do tecido em diferentes momentos e comparar as amostras para detectar a presença de movimento relativo entre a sonda de ultrassom e a região de interesse, onde as ondas de cisalhamento são detectadas. o movimento de base sentido é utilizado para ajustar as características de onda de cisalhamento medidas.",KONINIKLIJKE PHILIPS ELECTRONICS N V,HUA XIE;;JOHN DOUGLAS FRASER,KONINKLIJKE PHILIPS N.V. (NL) (2017-05-02),https://lens.org/058-852-500-299-876,Patent Application,no,0,0,14,14,0,A61B8/0825;;A61B8/4488;;A61B8/5276;;G01S7/52036;;G01S7/52042;;G01S7/5205;;G01S7/52095;;G01S15/8925;;A61B8/485;;A61B8/4488;;A61B8/485;;G01S7/52036;;A61B8/4488;;A61B8/5276;;G01S7/52036;;A61B8/0825;;G01S7/52042;;G01S7/5205;;G01S7/52095;;G01S15/8925;;A61B8/485,A61B8/00;;G01S7/52,,0,0,,,,PENDING
532,ES,T3,ES 2681434 T3,089-463-184-295-86X,2018-09-13,2018,ES 14762249 T,2014-03-17,US 201361787818 P;;US 2014/0030370 W,2013-03-15,Procedimiento de fabricación escalable para producir vectores lentivirales recombinantes en un sistema de cultivo celular en suspensión libre de suero,"Procedimiento para la purificación de vectores lentivirales recombinantes (rLV) a gran escala, que comprende; a) recolectar vectores virales recombinantes que comprenden un transgén a partir de un cultivo en suspensión libre de suero; b) clarificar la cosecha de la etapa a) por medio de filtración; c) recolectar el filtrado de la etapa b) y opcionalmente exponer dicho filtrado a digestión con nucleasas para eliminar impurezas de ADN/ARN; d) someter el filtrado de la etapa c) a cromatografía en columna de intercambio aniónico modulada por PEG, aislando de este modo dichos vectores rLV; e) purificar adicionalmente los vectores rLV obtenidos de la etapa d) por medio de filtración de flujo tangencial para reducir el volumen e intercambiar el tampón; f) someter el filtrado de la etapa e) a cromatografía en columna de exclusión molecular para purificar adicionalmente dichos vectores rLV; g) someter los vectores rLV de la etapa f) a filtración de flujo tangencial, y obtener de este modo el título de vectores final; h) filtrar la disolución de vectores rLV obtenida de la etapa g) a través de un filtro de diámetro de poro de 0,20 a 0,5 μm; y i) recoger vectores rLV purificados.",CHILDRENS HOSPITAL PHILADELPHIA,QU GUANG;;WRIGHT JOHN FRASER,,https://lens.org/089-463-184-295-86X,Granted Patent,no,0,0,29,29,0,C12N7/00;;C12N2740/15043;;C12N2740/15051;;A61K48/0091;;A61K48/0091;;C12N2740/15043;;C12N2740/15051;;C12N7/00;;A61K48/0091;;C12N7/00;;C12N7/00;;C12N2740/15043;;C12N2740/15051;;A61K48/0091,C12N7/02,,0,0,,,,ACTIVE
533,EP,A3,EP 0322090 A3,113-495-647-111-698,1989-07-26,1989,EP 88308971 A,1988-09-28,GB 8707544 A;;GB 8724616 A,1987-03-30,REINFORCING A GRASSED SURFACE,"It is highly desirable to reinforce the grassed surface layer of a sports ground in order to reduce damage to the surface, e.g. from horse racing or from playing football. In order to provide a good surface layer, a biaxially-orientated, integrally-extruded plastics material mesh structure layer is laid on a base of sand 2 strengthened with small, flexible, randomly-placed, plastics material mesh pieces. A top dressing 3 is put on top of the mesh structure layer, grass 4 is seeded or planted, and a machine is then used after the grass has grown to slit the mesh structure layer into pieces 1 which may be e.g. 100 x 100 mm or 150 x 150 mm, each having a number of complete mesh openings. If a piece 1 is caught by a horse's hoof or by an footballer's stud, it may be ripped out, but the whole mesh layer is not ripped out.  ",THE ROYAL HONG KONG JOCKEY CLUB;;NETLON LIMITED,"HALLIDAY, JOHN;;MARTIN KEITH FRASER",,https://lens.org/113-495-647-111-698,Search Report,yes,5,0,10,13,0,E01C13/083;;E01C13/083;;F02B1/04;;F02B1/04,A01G13/00;;A01G1/00;;E01C13/08;;F02B1/04,,0,0,,,,DISCONTINUED
534,US,A1,US 2009/0183091 A1,118-406-607-638-772,2009-07-16,2009,US 26438108 A,2008-11-04,US 26438108 A;;US 67063500 A,2000-09-26,METHOD AND SYSTEM FOR ARCHIVING AND RETRIEVING ITEMS BASED ON EPISODIC MEMORY OF GROUPS OF PEOPLE,"A method and system are provided for archiving and retrieving digital media items based on episodic memory for predefined associated groups of one or more people. The method and system may comprise identifying one or more groups to which an archiving user belongs; receiving a user input identifying select groups to which a digital media item to be archived; receiving archiving input data identifying the digital media item to be archived for the group; generating index information using the received user archiving input; storing the index information in association with the identified digital media item; repeating the reception of archiving input data, the generation of the index information and the storing of the index information for the digital media item; receiving retrieval input data representing a selection of candidate values; and using the selections and the identified group to retrieve and output digital media items that match the selection.",6S LTD,SHARPE ELIZABETH;;FRASER JOHN LESLIE,6S LIMITED (2009-03-24),https://lens.org/118-406-607-638-772,Patent Application,yes,33,20,6,6,0,G06F16/435;;G06F16/489;;G06F16/438;;G06F16/438;;G06F16/489;;G06F16/435,G06F12/00;;G06F3/048;;G06F12/16;;G06F17/30;;G06F21/00;;H04L9/32,715/761;;715/764;;726/3;;707/204;;715/810;;X707E1701;;X707E17101;;X707E17059;;X707E17044;;X707E17009,0,0,,,,EXPIRED
535,US,A,US 4060875 A,130-526-329-777-211,1977-12-06,1977,US 70349576 A,1976-07-08,US 70349576 A,1976-07-08,Apparatus for cutting stuffed sausage casing,"An apparatus and method for cutting stuffed sausage casing into individual lengths in the area of a linkage is described. Chilled casing which is stuffed with sausage meat and linked at predetermined points is guided through the apparatus, a forked blade is positioned over a first linkage and the casing is advanced towards a cutting zone. The forked blade is pivotally mounted on a carriage assembly which is slidably moveable along the direction of the chilled casing. The casing is cut in the area of the linkage by cooperation of a cutting blade with the forked blade in the cutting zone. The carriage assembly is then withdrawn from the cutting zone and the forked blade pivoted forward and upward out of the way of the casing. The forked blade is drawn over the surface of the casing until a second linkage is contacted.",UNION CARBIDE CANADA LTD,GOSLING LINCOLN JOHN;;FRASER GRAHAM,,https://lens.org/130-526-329-777-211,Granted Patent,yes,5,41,1,1,0,A22C11/006;;Y10T83/4635;;Y10T83/4635;;A22C11/006,A22C11/00;;A22C11/02,17  1F,0,0,,,,EXPIRED
536,JP,A,JP 2016073322 A,128-784-982-732-083,2016-05-12,2016,JP 2016020659 A,2016-02-05,US 47238403 P;;US 54975604 P,2003-05-21,METHODS FOR PRODUCING PREPARATIONS OF RECOMBINANT AAV VIRIONS SUBSTANTIALLY FREE OF EMPTY CAPSIDS,PROBLEM TO BE SOLVED: To provide a novel method for enhancing productivity by removing empty capsids or reducing the number of empty capsids from an AAV vector particle stock.SOLUTION: The invention is based on the development of an efficient and commercially viable method for preparing a stock of rAAV virions with a reduced amount of empty capsids. The inventors herein have found that empty capsids can be separated from rAAV virions containing genetic materials (AAV vector particles) by using a column chromatography technique. Described herein is a method for separating AAV empty capsids from a mixture of AAV vector particles and AAV empty capsids. This method uses a column chromatography technique to provide recombinant AAV virions at a commercially viable level.SELECTED DRAWING: None,GENZYME CORP,QU GUANG;;WRIGHT JOHN FRASER,,https://lens.org/128-784-982-732-083,Patent Application,no,0,0,40,41,0,C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N15/86;;C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N2710/16651;;C12N2710/10351;;C12N2760/16051;;C12N15/86,C12N7/02;;C12N/;;C12N15/86;;C12N15/864,,0,0,,,,DISCONTINUED
537,CA,A,CA 46258 A,137-615-562-884-899,1894-06-05,1894,CA 46258D A,,CA 46258T A,,COMBINED CHURN AND BUTTER WORKER,,FRASER THOMAS;;SMITH ELLIOTT JOHN,FRASER THOMAS;;SMITH ELLIOTT JOHN,,https://lens.org/137-615-562-884-899,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
538,CA,A1,CA 2569244 A1,164-944-011-586-429,2005-12-15,2005,CA 2569244 A,2005-06-01,US 57599704 P;;US 63922204 P;;US 2005/0019235 W,2004-06-01,COMPOSITIONS AND METHODS TO PREVENT AAV VECTOR AGGREGATION,,AVIGEN INC,QU GUANG;;WRIGHT JOHN FRASER,,https://lens.org/164-944-011-586-429,Patent Application,no,0,0,33,34,0,C12N2750/14151;;C12N7/00;;C12N2750/14151;;C12N7/00;;C12N2750/14111,C12N7/02,,0,0,,,,ACTIVE
539,US,B2,US 8701022 B2,156-833-835-844-783,2014-04-15,2014,US 26438108 A,2008-11-04,US 26438108 A;;US 67063500 A,2000-09-26,Method and system for archiving and retrieving items based on episodic memory of groups of people,"A method and system are provided for archiving and retrieving digital media items based on episodic memory for predefined associated groups of one or more people. The method and system may comprise identifying one or more groups to which an archiving user belongs; receiving a user input identifying select groups to which a digital media item to be archived; receiving archiving input data identifying the digital media item to be archived for the group; generating index information using the received user archiving input; storing the index information in association with the identified digital media item; repeating the reception of archiving input data, the generation of the index information and the storing of the index information for the digital media item; receiving retrieval input data representing a selection of candidate values; and using the selections and the identified group to retrieve and output digital media items that match the selection.",SHARPE ELIZABETH;;FRASER JOHN LESLIE;;6S LTD,SHARPE ELIZABETH;;FRASER JOHN LESLIE,6S LIMITED (2009-03-24),https://lens.org/156-833-835-844-783,Granted Patent,yes,43,5,6,6,0,G06F16/435;;G06F16/489;;G06F16/438;;G06F16/438;;G06F16/489;;G06F16/435,G06F3/048,715/761;;715/764,5,4,130-915-722-387-120;;023-993-018-529-724;;149-865-423-447-055;;003-831-005-012-93X,10.1145/319878.319921;;10.1109/icme.2000.869606;;10.1016/b978-155860915-0/50011-1;;10.1145/1027527.1027573,"Alexander C. Loui and Mark D. Wood, A Software System for Automatic Albuming of Consumer Pictures, pp. 159-162.;;K. Priyantha Hewagamage and Masahito Hirakawa, Augmented Album: Situation-dependant System for a Personal Digital Video/Image Collection, pp. 323-326.;;Shneiderman et al. (Direct Annotation: A Drag-and-Drop Strategy for Labeling Photos, Aug. 2000.;;Naaman, Mor, et al., ""Context Data in Geo-Referenced Digital Photo Collections"", Proceedings of the ACM International Conference on Multimedia, NY, NY, Oct. 10, 2004, pp. 196-203.;;Davis, Marc, et al., ""From Context to Content: Leveraging Context to Infer Media Metadata"", Internet Citation, Oct. 16, 2004, pp. 1-8.",EXPIRED
540,EP,B1,EP 2651307 B1,178-612-967-217-131,2017-11-15,2017,EP 11813561 A,2011-12-08,US 42247910 P;;IB 2011055546 W,2010-12-13,ADJUSTING MEASUREMENTS OF THE EFFECTS OF ACOUSTIC RADIATION FORCE FOR BACKGROUND MOTION EFFECTS,,KONINKLIJKE PHILIPS NV,FRASER JOHN DOUGLAS;;XIE HUA,,https://lens.org/178-612-967-217-131,Granted Patent,yes,3,0,14,14,0,A61B8/0825;;A61B8/4488;;A61B8/5276;;G01S7/52036;;G01S7/52042;;G01S7/5205;;G01S7/52095;;G01S15/8925;;A61B8/485;;A61B8/4488;;A61B8/485;;G01S7/52036;;A61B8/4488;;A61B8/5276;;G01S7/52036;;A61B8/0825;;G01S7/52042;;G01S7/5205;;G01S7/52095;;G01S15/8925;;A61B8/485,A61B8/08;;A61B8/00;;G01S7/52;;G01S15/89,,0,0,,,,ACTIVE
541,EP,B1,EP 3290513 B1,170-462-257-623-045,2022-09-07,2022,EP 17186206 A,2005-06-01,US 57599704 P;;US 63922204 P;;EP 05755269 A;;US 2005/0019235 W,2004-06-01,COMPOSITIONS AND METHODS TO PREVENT AAV VECTOR AGGREGATION,,GENZYME CORP,WRIGHT JOHN FRASER;;QU GUANG,GENZYME CORPORATION (2018-07-18),https://lens.org/170-462-257-623-045,Granted Patent,yes,2,0,33,34,0,C12N2750/14151;;C12N7/00;;C12N2750/14151;;C12N7/00;;C12N2750/14111,C12N7/00;;C12N7/02,,4,0,,,"WRIGHT J.F., ET AL: ""425. Formulation Development for AAV2 Vectors: Identification of Excipients That Inhibit Vector Aggregation"", MOLECULAR THERAPY , vol. 9, no. S1 May 2004 (2004-05), pages S163-S163, XP002461847, ISSN: 1525-0016, DOI: 10.1016/j.ymthe.2004.06.356 Retrieved from the Internet: URL:http://www.cell.com/molecular-therapy- family/molecular-therapy/pdf/S1525-0016%28 04%2900655-0.pdf [retrieved on 2017-12-11];;STEINBACH S ET AL: ""Assembly of adeno-associated virus type 2 capsids in vitro"", JOURNAL OF GENERAL VIROLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, SPENCERS WOOD, GB, vol. 78, no. 6, 1997, pages 1453-1462, XP002346582, ISSN: 0022-1317;;XIE Q ET AL: ""Large-scale production, purification and crystallization of wild-type adeno-associated virus-2"", JOURNAL OF VIROLOGICAL METHODS, AMSTERDAM, NL, vol. 122, no. 1, 1 December 2004 (2004-12-01), pages 17-27, XP004603069, ISSN: 0166-0934;;WRIGHT J F ET AL: ""Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulation"", MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA,, US, vol. 12, no. 1, July 2005 (2005-07), pages 171-178, XP004974961, ISSN: 1525-0016",ACTIVE
542,FR,B1,FR 2613391 B1,171-599-524-306-444,1991-01-04,1991,FR 8804183 A,1988-03-30,GB 8707544 A;;GB 8724616 A,1987-03-30,ARMATURE POUR SURFACE ENGAZONNEE,,NETLON LTD;;HALLIDAY JOHN,HALLIDAY JOHN;;MARTIN KEITH FRASER,,https://lens.org/171-599-524-306-444,Granted Patent,no,0,0,10,13,0,E01C13/083;;E01C13/083;;F02B1/04;;F02B1/04,A01G13/00;;A01G1/00;;E01C13/08;;F02B1/04,,0,0,,,,EXPIRED
543,US,A1,US 2022/0343738 A1,181-487-704-781-118,2022-10-27,2022,US 202217690259 A,2022-03-09,US 202217690259 A;;US 202117238390 A,2021-04-23,"APPARATUS, SYSTEM, AND METHOD FOR BULK CURRENCY NOTE DEPOSITS",A Self-Service Terminal (SST) that provides valuable media deposit features is enhanced with an apparatus fastened to an outside surface of the SST. The apparatus is adapted to receive an externally provided valuable media cassette and connect/interface a port of the cassette to an unload infeed port. A transaction interface is enhanced to identify the cassette as a source device for obtaining valuable media during a deposit transaction. The SST feeds the valuable media from the externally connected cassette through media validation and transport modules of the SST into cassettes of a safe and the SST returns rejected media for the deposit transaction back through the modules to return rejected media to the externally interfaced cassette.,NCR CORP,FRASER GRANT BUCHANAN;;MANNION JOHN,NCR CORPORATION (2021-04-23),https://lens.org/181-487-704-781-118,Patent Application,yes,3,2,4,4,0,G07F19/205;;G07F19/202;;G07F19/205;;G07F19/202,G07F19/00,,0,0,,,,ACTIVE
544,GB,A,GB 1068907 A,179-633-431-018-053,1967-05-17,1967,GB 2108463 A,1963-05-27,GB 2108463 A,1963-05-27,Oxidation of cyclohexane,"Cyclohexane is oxidized in the liquid phase with mixtures of oxygen and gases inert with respect to the reactants and products of the process, the proportion of oxygen in the gaseous mixtures being varied during the course of the oxidation, preferably being increased as the oxidation proceeds. An oxidation catalyst, e.g. cobalt naphthenate may be employed. The mixture of oxidation products obtained by the process of the invention may be further oxidized with nitric acid to form adipic acid.",ICI LTD,GARDNER CYRIL;;PRESCOTT JOHN FRASER,,https://lens.org/179-633-431-018-053,Granted Patent,no,0,0,7,8,0,C07C51/313;;C07C51/313;;C07C45/33;;C07C45/33;;C07C51/316;;C07C51/316,C07C45/33;;C07C51/31,C2C CCS;;C2C CUE;;C2C CWY;;C2C C20Y;;C2C C22Y;;C2C C22Y;;C2C C221;;C2C C221;;C2C C225;;C2C C225;;C2C C227;;C2C C227;;C2C C295;;C2C C297;;C2C C297;;C2C C299;;C2C C30Y;;C2C C30Y;;C2C C30Y;;C2C C351;;C2C C353;;C2C C36Y;;C2C C360;;C2C C362;;C2C C366;;C2C C367;;C2C C37X;;C2C C386;;C2C C40Y;;C2C C409;;C2C C409;;C2C C409;;C2C C41Y;;C2C C41Y;;C2C C410;;C2C C410;;C2C C413;;C2C C414;;C2C C46X;;C2C C46X;;C2C C46Y;;C2C C46Y;;C2C C490;;C2C C50Y;;C2C C509;;C2C C569;;C2C C623;;C2C C625;;C2C C638;;C2C C65Y;;C2C C662;;C2C C69Y,0,0,,,,EXPIRED
545,GB,A,GB 189716692 A,178-855-083-379-270,1898-06-25,1898,GB 189716692D A,1897-07-14,GB 189716692T A,1897-07-14,Improvements in Marking or Applying Labels or the like to Tobacco.,"16,692. Cope, T. H., and Fraser, J. July 14. Labels for tobacco. A label b, in the form of a strip of paper, metal foil, or canvas, is intertwined with a rope of tobacco a made up in a roll, in such a way as to prevent the removal of the label without undoing the roll Letters, figures, or the like are printed or impressed on the paper so as to be easily seen. Instead of a special strip, the binding-strip ordinarily used may be employed as a label in the same way.",COPE THOMAS HENRY;;FRASER JOHN,COPE THOMAS HENRY;;FRASER JOHN,,https://lens.org/178-855-083-379-270,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
546,CN,A,CN 103260525 A,018-211-892-143-932,2013-08-21,2013,CN 201180059600 A,2011-12-08,IB 2011055546 W;;US 42247910 P,2010-12-13,Adjusting measurements of the effects of acoustic radiation force for background motion effects,An ultrasonic diagnostic imaging system for shear wave measurement transmits push pulses into tissue for the generation of shear waves. Characteristics of the shear waves such as their velocity of passage through the tissue are measured to assess properties such as tissue stiffness. The measurements are compensated for effects of background motion by sampling echo signals from the tissue at different times and comparing the samples to detect the presence of relative motion between the ultrasound probe and the region of interest where shear waves are detected. Sensed background motion is used to adjust measured shear wave characteristics.,KONINKL PHILIPS ELECTRONICS NV,FRASER JOHN DOUGLAS;;H XIE,,https://lens.org/018-211-892-143-932,Patent Application,no,4,3,14,14,0,A61B8/0825;;A61B8/4488;;A61B8/5276;;G01S7/52036;;G01S7/52042;;G01S7/5205;;G01S7/52095;;G01S15/8925;;A61B8/485;;A61B8/4488;;A61B8/485;;G01S7/52036;;A61B8/4488;;A61B8/5276;;G01S7/52036;;A61B8/0825;;G01S7/52042;;G01S7/5205;;G01S7/52095;;G01S15/8925;;A61B8/485,A61B8/00;;G01S7/52,,0,0,,,,ACTIVE
547,US,A1,US 2022/0364111 A1,018-524-356-025-294,2022-11-17,2022,US 202217579281 A,2022-01-19,US 202217579281 A;;US 201916538664 A;;US 201816019139 A;;US 201615351725 A;;US 201213368167 A;;US 80965507 A;;US 85168804 A;;US 54975604 P;;US 47238403 P,2003-05-21,METHODS FOR PRODUCING PREPARATIONS OF RECOMBINANT AAV VIRIONS SUBSTANTIALLY FREE OF EMPTY CAPSIDS,Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.,GENZYME CORP,QU GUANG;;WRIGHT JOHN FRASER,,https://lens.org/018-524-356-025-294,Patent Application,yes,1,0,40,41,0,C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N15/86;;C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N2710/16651;;C12N2710/10351;;C12N2760/16051;;C12N15/86,C12N15/86;;C12N/;;C12N7/00;;C12N7/02;;C12N15/864,,0,0,,,,PENDING
548,EP,B1,EP 1572071 B1,044-853-918-754-350,2018-10-03,2018,EP 02805565 A,2002-12-09,US 0239465 W;;US 33885601 P,2001-12-07,METHODS FOR PREPARING FRESH ADIPOSE TISSUE-DERIVED CELLS AND USES IN TREATING PATIENTS,,CYTORI THERAPEUTICS INC,FRASER JOHN;;HEDRICK MARC H,"CYTORI THERAPEUTICS, INC. (2006-11-29)",https://lens.org/044-853-918-754-350,Granted Patent,yes,2,0,65,221,0,A61B10/0283;;A61K9/0019;;C12N5/0667;;C12N5/069;;C12N2506/1384;;A61K35/28;;A61K35/35;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P3/00;;A61P3/06;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;A61K35/32;;A61K48/00;;A61K35/36;;A61B10/0283;;A61K9/0019;;C12N5/0667;;C12N5/069;;C12N2506/1384;;A61M1/76;;A61K35/28;;A61K35/35;;C12M47/04;;A61M2202/08,A61K35/00;;A61K31/436;;A61M1/00;;A61K35/02;;A61K35/12;;A61K35/28;;A61K35/35;;A61K35/36;;A61K38/00;;A61K38/16;;A61K45/00;;A61L27/00;;A61P1/00;;A61P1/16;;A61P3/00;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P19/00;;A61P19/02;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;C12M3/06;;C12N5/00;;C12N5/0775,,5,5,007-121-277-775-438;;047-798-816-795-67X;;094-646-193-890-460;;014-900-457-930-702;;100-845-809-931-986,10.1097/00006534-200102000-00047;;11214080;;10553215;;10.1016/s0094-1298(20)32659-6;;10.1038/labinvest.3780360;;11598159;;16322640;;10.1634/stemcells.2005-0234;;15833829;;10.1158/0008-5472.can-04-4194,"KATZ A.J. ET AL.,: ""A novel device for the simple and efficient refinement of liposuctioned tissue"", PLASTIC AND RECONSTRUCTIVE SURGERY, vol. 107, no. 2, 2001 - 1 February 2001 (2001-02-01), pages 595 - 597, XP002966149;;KATZ A.J. ET AL: ""EMERGING APPROACHES TO THE TISSUE ENGINEERING OF FAT"", CLINICS IN PLASTIC SURGERY, vol. 26, no. 4, 1999 - 1 October 1999 (1999-10-01), pages 587 - 603, XP009061485;;ARTS C H P ET AL: ""A novel method for isolating pure microvascular endothelial cells from subcutaneous fat tissue ideal for direct cell seeding"", LABORATORY INVESTIGATION, NATURE PUBLISHING GROUP, THE UNITED STATES AND CANADIAN ACADEMY OF PATHOLOGY, INC, vol. 81, no. 10, 1 January 2001 (2001-01-01), pages 1461 - 1465, XP002515273, ISSN: 0023-6837;;MITCHELL JAMES B ET AL: ""Immunophenotype of human adipose-derived cells: Temporal changes in stromal-associated and stem cell-associated markers"", STEM CELLS (MIAMISBURG), vol. 24, no. 2, February 2006 (2006-02-01), pages 376 - 385, ISSN: 1066-5099;;RUBIO DANIEL ET AL: ""Spontaneous human adult stem cell transformation."", CANCER RESEARCH 15 APR 2005, vol. 65, no. 8, 15 April 2005 (2005-04-15), pages 3035 - 3039, ISSN: 0008-5472",EXPIRED
549,AT,T1,AT E490307 T1,041-184-199-412-164,2010-12-15,2010,AT 04776068 T,2004-05-21,US 47238403 P;;US 54975604 P;;US 2004/0015958 W,2003-05-21,"VERFAHREN ZUR HERSTELLUNG VON PRÄPARATIONEN REKOMBINANTER AAV-VIRIONEN, DIE WEITGEHEND FREI VON LEEREN CAPSIDEN SIND",Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.,GENZYME CORP,QU GUANG;;WRIGHT JOHN FRASER,,https://lens.org/041-184-199-412-164,Granted Patent,no,0,0,40,41,0,C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N15/86;;C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N2710/16651;;C12N2710/10351;;C12N2760/16051;;C12N15/86,C12N/;;C12N7/02;;C12N15/86;;C12N15/864,,0,0,,,,INACTIVE
550,CA,C,CA 2904366 C,066-556-641-832-578,2023-07-04,2023,CA 2904366 A,2014-03-17,US 201361787818 P;;US 2014/0030370 W,2013-03-15,SCALABLE MANUFACTURING PROCESS TO PRODUCE RECOMBINANT LENTIVIRAL VECTORS IN SERUM-FREE SUSPENSION CELL CULTURE SYSTEM,Methods for preparing highly purified rLV vector formulations at the scale needed to meet anticipated demand for human gene therapy are provided.,CHILDRENS HOSPITAL PHILADELPHIA,QU GUANG;;WRIGHT JOHN FRASER,,https://lens.org/066-556-641-832-578,Granted Patent,no,0,0,29,29,0,C12N7/00;;C12N2740/15043;;C12N2740/15051;;A61K48/0091;;A61K48/0091;;C12N2740/15043;;C12N2740/15051;;C12N7/00;;A61K48/0091;;C12N7/00;;C12N7/00;;C12N2740/15043;;C12N2740/15051;;A61K48/0091,C12N7/02,,0,0,,,,PENDING
551,CN,A,CN 1630526 A,075-613-870-286-78X,2005-06-22,2005,CN 02827968 A,2002-12-09,US 0239465 W;;US 33885601 P,2001-12-07,Systems and methods for treating patients with processed lipoaspirate cells,,MACROPORE BIOSURGERY INC,JOHN FRASER;;HEDRICK MARC H,,https://lens.org/075-613-870-286-78X,Patent Application,no,0,10,65,221,0,A61K35/28;;A61K35/28;;A61K48/00;;A61B10/0283;;A61B10/0283;;A61K9/0019;;A61K9/0019;;A61K35/32;;A61K35/35;;A61K35/35;;A61K35/36;;A61M1/76;;A61M2202/08;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/00;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;A61P43/00;;C12M47/04;;C12N5/0667;;C12N5/0667;;C12N5/069;;C12N5/069;;C12N2506/1384;;C12N2506/1384,A61M1/00;;A61K31/436;;A61K35/02;;A61K35/12;;A61K35/28;;A61K35/35;;A61K35/36;;A61K38/00;;A61K38/16;;A61K45/00;;A61L27/00;;A61P1/00;;A61P1/16;;A61P3/00;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P19/00;;A61P19/02;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;C12M3/06;;C12N5/0775,,0,0,,,,EXPIRED
552,EP,A4,EP 1141000 A4,069-912-450-755-124,2004-09-15,2004,EP 99962603 A,1999-12-24,NZ 9900228 W;;NZ 33358998 A,1998-12-24,SUPERANTIGENS,,AUCKLAND UNISERVICES LTD,FRASER JOHN DAVID;;PROFT THOMAS,,https://lens.org/069-912-450-755-124,Search Report,no,0,0,7,10,0,A61K38/00;;A61K39/00;;A61P35/00;;A61P37/02;;C07K14/315,G01N33/569;;A61K38/00;;A61K39/00;;A61K39/09;;A61K39/395;;A61K47/48;;A61P35/00;;A61P37/02;;C07K14/315;;C07K16/12;;C12N15/09;;C12Q1/68,,2,1,011-267-960-143-490,10.1128/iai.65.9.3828-3833.1997;;9284159;;pmc175546,"KAMEZAWA YUKIO ET AL: ""Streptococcal mitogenic exotoxin Z, a novel acidic superantigenic toxin produced by a T1 strain of Streptococcus pyogenes"", INFECTION AND IMMUNITY, vol. 65, no. 9, 1997, pages 3828 - 3833, XP002288932, ISSN: 0019-9567;;See also references of WO 0039159A1",DISCONTINUED
553,US,A,US 3365491 A,107-830-330-066-698,1968-01-23,1968,US 36786264 A,1964-05-15,GB 2108463 A,1963-05-27,Oxidation of cyclohexane,,ICI LTD,CYRIL GARDNER;;FRASER PRESCOTT JOHN,,https://lens.org/107-830-330-066-698,Granted Patent,no,1,0,7,8,0,C07C51/313;;C07C51/313;;C07C45/33;;C07C45/33;;C07C51/316;;C07C51/316,C07C45/33;;C07C51/31,260/533,0,0,,,,EXPIRED
554,CA,A,CA 29984 A,145-647-349-523-054,1888-10-13,1888,CA 29984D A,,CA 29984T A,,AUTOMATIC WAGGON BRAKE,,FRASER JOHN;;UPPER G A,FRASER JOHN;;UPPER G A,,https://lens.org/145-647-349-523-054,Granted Patent,no,0,5,1,1,0,,,,0,0,,,,EXPIRED
555,EP,A2,EP 1625210 A2,138-045-143-123-934,2006-02-15,2006,EP 04776068 A,2004-05-21,US 2004/0015958 W;;US 47238403 P;;US 54975604 P,2003-05-21,METHODS FOR PRODUCING PREPARATIONS OF RECOMBINANT AAV VIRIONS SUBSTANTIALLY FREE OF EMPTY CAPSIDS,Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.,AVIGEN INC,QU GUANG;;WRIGHT JOHN FRASER,,https://lens.org/138-045-143-123-934,Patent Application,yes,0,0,40,41,0,C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N15/86;;C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N2710/16651;;C12N2710/10351;;C12N2760/16051;;C12N15/86,C12N7/02;;B01D15/00;;B01D15/04;;C02F1/42;;C12N/;;C12N15/86;;C12N15/864,,0,0,,,,ACTIVE
556,KR,A,KR 20100029272 A,166-671-428-108-643,2010-03-16,2010,KR 20107002719 A,2002-12-09,US 0239465 W;;US 33885601 P,2001-12-07,SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS,Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient.,CYTORI THERAPEUTICS INC,FRASER JOHN;;HENDRICK MARC H,,https://lens.org/166-671-428-108-643,Patent Application,no,0,7,65,221,0,A61K35/28;;A61K35/28;;A61K48/00;;A61B10/0283;;A61B10/0283;;A61K9/0019;;A61K9/0019;;A61K35/32;;A61K35/35;;A61K35/35;;A61K35/36;;A61M1/76;;A61M2202/08;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/00;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;A61P43/00;;C12M47/04;;C12N5/0667;;C12N5/0667;;C12N5/069;;C12N5/069;;C12N2506/1384;;C12N2506/1384,A61K35/36;;A61M1/00;;A61K31/436;;A61K35/02;;A61K35/12;;A61K35/28;;A61K35/32;;A61K35/35;;A61K38/00;;A61K38/16;;A61K45/00;;A61K48/00;;A61L27/00;;A61P1/00;;A61P1/16;;A61P3/00;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P19/00;;A61P19/02;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;C12M3/06;;C12N5/0775,,0,0,,,,EXPIRED
557,KR,A,KR 20120003961 A,166-991-213-591-255,2012-01-11,2012,KR 20117028207 A,2002-12-09,US 33885601 P,2001-12-07,SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS,,CYTORI THERAPEUTICS INC,FRASER JOHN;;HENDRICK MARC H,,https://lens.org/166-991-213-591-255,Patent Application,no,0,5,65,221,0,A61K35/28;;A61K35/28;;A61K48/00;;A61B10/0283;;A61B10/0283;;A61K9/0019;;A61K9/0019;;A61K35/32;;A61K35/35;;A61K35/35;;A61K35/36;;A61M1/76;;A61M2202/08;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/00;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;A61P43/00;;C12M47/04;;C12N5/0667;;C12N5/0667;;C12N5/069;;C12N5/069;;C12N2506/1384;;C12N2506/1384,A61M1/00;;A61K31/436;;A61K35/00;;A61K35/02;;A61K35/12;;A61K35/28;;A61K35/32;;A61K35/35;;A61K35/36;;A61K38/00;;A61K38/16;;A61K45/00;;A61L27/00;;A61P1/00;;A61P1/16;;A61P3/00;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P19/00;;A61P19/02;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;C12M3/06;;C12N5/0775,,0,0,,,,DISCONTINUED
558,US,A1,US 2023/0230459 A1,171-512-070-720-653,2023-07-20,2023,US 202318125479 A,2023-03-23,US 202318125479 A;;US 202217690259 A;;US 202117238390 A,2021-04-23,"APPARATUS, SYSTEM, AND METHOD FOR BULK CURRENCY NOTE DEPOSITS",A Self-Service Terminal (SST) that provides valuable media deposit features is enhanced with an apparatus fastened to an outside surface of the SST. The apparatus is adapted to receive an externally provided valuable media cassette and connect/interface a port of the cassette to an unload infeed port. A transaction interface is enhanced to identify the cassette as a source device for obtaining valuable media during a deposit transaction. The SST feeds the valuable media from the externally connected cassette through media validation and transport modules of the SST into cassettes of a safe and the SST returns rejected media for the deposit transaction back through the modules to return rejected media to the externally interfaced cassette.,NCR CORP,FRASER GRANT BUCHANAN;;MANNION JOHN,NCR CORPORATION (2021-04-23),https://lens.org/171-512-070-720-653,Patent Application,yes,2,0,4,4,0,G07F19/205;;G07F19/202;;G07F19/205;;G07F19/202,G07F19/00,,0,0,,,,PENDING
559,DK,T3,DK 1751275 T3,173-758-944-837-178,2017-11-27,2017,DK 05755269 T,2005-06-01,US 57599704 P;;US 63922204 P;;US 2005/0019235 W,2004-06-01,SAMMENSÆTNINGER OG FREMGANGSMÅDER TIL FOREBYGGELSE AF AGGREGERING AF AAV-VEKTORER,,AVIGEN INC,WRIGHT JOHN FRASER;;QU GUANG,,https://lens.org/173-758-944-837-178,Granted Patent,no,0,0,33,34,0,C12N2750/14151;;C12N7/00;;C12N2750/14151;;C12N7/00;;C12N2750/14111,C12N7/00;;C12N7/02,,0,0,,,,ACTIVE
560,JP,A,JP 2014111625 A,012-451-027-140-328,2014-06-19,2014,JP 2014014070 A,2014-01-29,US 57599704 P;;US 63922204 P,2004-06-01,COMPOSITIONS AND METHODS TO PREVENT AAV VECTOR AGGREGATION,"PROBLEM TO BE SOLVED: To provide compositions and methods for preparation of concentrated stock solutions of virions, particularly adeno-associated virus (AAV) virions, without aggregation.SOLUTION: A method of preventing aggregation of virions in a preparation of virions comprises adding one or more excipients to the preparation of virions to achieve an ionic strength of at least about 200 mM. This combination of the high ionic strength and modest osmolarity is achieved using salts of high valency, such as sodium citrate.",GENZYME CORP,WRIGHT JOHN FRASER;;QU GUANG,,https://lens.org/012-451-027-140-328,Patent Application,no,0,0,33,34,0,C12N2750/14151;;C12N7/00;;C12N2750/14151;;C12N7/00;;C12N2750/14111,A61K9/10;;A61K47/12;;C12N7/00;;C12N7/02;;C12N15/09,,1,0,,,"JPN6011008926; Ｍｏｌｅｃｕｌａｒ Ｔｈｅｒａｐｙ Ｖｏｌ．９， Ｓｕｐ．１, 200405, ｐ．Ｓ１６３， ＃４２５",PENDING
561,EP,A1,EP 2651307 A1,003-788-438-881-101,2013-10-23,2013,EP 11813561 A,2011-12-08,US 42247910 P;;IB 2011055546 W,2010-12-13,ADJUSTING MEASUREMENTS OF THE EFFECTS OF ACOUSTIC RADIATION FORCE FOR BACKGROUND MOTION EFFECTS,,KONINKL PHILIPS NV,FRASER JOHN DOUGLAS;;XIE HUA,,https://lens.org/003-788-438-881-101,Patent Application,yes,0,0,14,14,0,A61B8/0825;;A61B8/4488;;A61B8/5276;;G01S7/52036;;G01S7/52042;;G01S7/5205;;G01S7/52095;;G01S15/8925;;A61B8/485;;A61B8/4488;;A61B8/485;;G01S7/52036;;A61B8/4488;;A61B8/5276;;G01S7/52036;;A61B8/0825;;G01S7/52042;;G01S7/5205;;G01S7/52095;;G01S15/8925;;A61B8/485,A61B8/08;;A61B8/00;;G01S7/52;;G01S15/89,,0,0,,,,ACTIVE
562,GB,A,GB 2206611 A,029-122-215-270-402,1989-01-11,1989,GB 8807522 A,1988-03-30,GB 8707544 A;;GB 8724616 A,1987-03-30,REINFORCED GRASS SURFACE; TEARABLE FABRIC,,HALLIDAY JOHN;;NETLON LTD,HALLIDAY JOHN;;MARTIN KEITH FRASER,,https://lens.org/029-122-215-270-402,Patent Application,no,1,0,10,13,0,E01C13/083;;E01C13/083;;F02B1/04;;F02B1/04,A01G13/00;;A01G1/00;;E01C13/08;;F02B1/04,A1E EAF           EAF;;A1E EF9           EAF;;A6D DTN           DTN;;A6D D39X          D39;;D1R RBA           RBA;;E1F FWDJB         FWDJB,0,0,,,,EXPIRED
563,MX,B,MX 364690 B,013-782-135-462-706,2019-05-06,2019,MX 2015012450 A,2014-03-17,US 201361787818 P;;US 2014/0030370 W,2013-03-15,SCALABLE MANUFACTURING PROCESS TO PRODUCE RECOMBINANT LENTIVIRAL VECTORS IN SERUM-FREE SUSPENSION CELL CULTURE SYSTEM.,Methods for preparing highly purified rLV vector formulations at the scale needed to meet anticipated demand for human gene therapy are provided.,CHILDRENS HOSPITAL PHILADELPHIA,GUANG QU;;JOHN FRASER WRIGHT,,https://lens.org/013-782-135-462-706,Granted Patent,no,0,0,29,29,0,C12N7/00;;C12N2740/15043;;C12N2740/15051;;A61K48/0091;;A61K48/0091;;C12N2740/15043;;C12N2740/15051;;C12N7/00;;A61K48/0091;;C12N7/00;;C12N7/00;;C12N2740/15043;;C12N2740/15051;;A61K48/0091,C12N7/02;;A61K48/00,,0,0,,,,ACTIVE
564,US,B2,US 11446006 B2,036-365-168-084-518,2022-09-20,2022,US 201916666646 A,2019-10-29,US 201916666646 A;;US 201313990201 A;;IB 2011055546 W;;US 42247910 P,2010-12-13,Adjusting measurements of the effects of acoustic radiation force for background motion effects,An ultrasonic diagnostic imaging system for shear wave measurement transmits push pulses into tissue for the generation of shear waves. Characteristics of the shear waves such as their velocity of passage through the tissue are measured to assess properties such as tissue stiffness. The measurements are compensated for effects of background motion by sampling echo signals from the tissue at different times and comparing the samples to detect the presence of relative motion between the ultrasound probe and the region of interest where shear waves are detected. Sensed background motion is used to adjust measured shear wave characteristics.,KONINKLIJKE PHILIPS NV,FRASER JOHN DOUGLAS;;XIE HUA,,https://lens.org/036-365-168-084-518,Granted Patent,yes,9,0,14,14,0,A61B8/0825;;A61B8/4488;;A61B8/5276;;G01S7/52036;;G01S7/52042;;G01S7/5205;;G01S7/52095;;G01S15/8925;;A61B8/485;;A61B8/4488;;A61B8/485;;G01S7/52036;;A61B8/4488;;A61B8/5276;;G01S7/52036;;A61B8/0825;;G01S7/52042;;G01S7/5205;;G01S7/52095;;G01S15/8925;;A61B8/485,A61B8/00;;A61B8/08;;G01S7/52;;G01S15/89,,6,6,056-705-091-710-181;;070-586-234-728-521;;000-361-577-809-810;;139-454-483-530-353;;166-054-203-736-266;;015-443-234-271-768,10.1121/1.1378344;;11508987;;10.1016/s0301-5629(98)00110-0;;10385964;;10.1109/tuffc.2009.1097;;pmc2756029;;19406703;;pmc3764610;;19213633;;10.1109/tuffc.2009.1006;;10.1126/science.280.5360.82;;9525861;;10.1016/j.ultrasmedbio.2007.10.009;;18222031;;pmc2362504,"Nightingale et al: “On the Feasibility of Remote Palpation Using Acoustic Radiation Force”; 2001 Acoustical Society of America, vol. 110, No. 1, pp. 625-634.;;Sarvazyan et al: “Shear Wave Elasticity Imaging: a New Ultrasonic Technology of Medical Diagnostics”; Ultrasound in Medicine and Biology, vol. 24, No. 9, pp. 1419-1435, 1998.;;Urban et al: “Error in Estimates of Tissue Material Properties From Shear Wave Dispersion Ultrasound Vibrometry:” IEEE Transactions in Ultrason Ferroelectric Freq Control, Apr. 2009, 56(4): pp. 748-758.;;Bouchard et al: “Image Quality, Tissue Heating, and Frame Rate Trade-Off in Acoustic Radiation Force Impulse Imaging”; IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, vol. 56, No. 1, Jan. 2009, pp. 63-76.;;Fatemi et al: “Ultrasound-Stimulated Vibro-Acoustic Spectrography”; Science 280, 1998, pp. 82-85.;;Palmeri et al: “Quantifying Hepatic Shear Modulus in Vivo Using Acoustic Radiation Force”; Ultrasound Meical Biology, Apr. 2008, 34(4): pp. 546-558.",ACTIVE
565,US,A1,US 2014/0289222 A1,048-886-482-959-019,2014-09-25,2014,US 201414192583 A,2014-02-27,US 201414192583 A;;US 26438108 A;;US 67063500 A,2000-09-26,METHOD AND SYSTEM FOR ARCHIVING AND RETRIEVING ITEMS BASED ON EPISODIC MEMORY OF GROUPS OF PEOPLE,"A method and system are provided for archiving and retrieving digital media items based on episodic memory for predefined associated groups of one or more people. The method and system may comprise identifying one or more groups to which an archiving user belongs; receiving a user input identifying select groups to which a digital media item to be archived; receiving archiving input data identifying the digital media item to be archived for the group; generating index information using the received user archiving input; storing the index information in association with the identified digital media item; repeating the reception of archiving input data, the generation of the index information and the storing of the index information for the digital media item; receiving retrieval input data representing a selection of candidate values; and using the selections and the identified group to retrieve and output digital media items that match the selection.",SHARPE ELIZABETH;;FRASER JOHN LESLIE;;6S LTD,SHARPE ELIZABETH;;FRASER JOHN LESLIE,,https://lens.org/048-886-482-959-019,Patent Application,yes,10,30,6,6,0,G06F16/435;;G06F16/489;;G06F16/438;;G06F16/438;;G06F16/489;;G06F16/435,G06F17/30,707/722,0,0,,,,DISCONTINUED
566,AU,A1,AU 2022/221593 A1,057-521-007-467-052,2023-08-31,2023,AU 2022/221593 A,2022-02-18,US 202163150797 P;;CA 2022050237 W,2021-02-18,SODIUM SULFATE BY-PRODUCT PROCESSING IN LITHIUM AND BATTERY CHEMICAL PRODUCTION,"A process for battery chemical production, where a sodium sulfate stream is treated with an ion exchange process to provide potassium sulfate and sodium chloride. The sodium chloride may be treated with a chlor-alkali to produce sodium hydroxide for use upstream in the battery chemical production process.",HATCH LTD,FRASER ROBERT JOHN;;STAMATIOU EVANGELOS,,https://lens.org/057-521-007-467-052,Patent Application,no,0,0,8,8,0,C01D3/04;;C01D1/04;;C01D5/00;;C25B1/34;;C25B15/081;;Y02E60/10;;C01D1/04;;C01D5/00;;C25B1/46;;C25B9/23;;Y02E60/10;;B01J49/57;;B01J41/04;;B01J41/12;;C01D1/20;;C01D3/04;;C01D5/02;;C01P2006/40,C01D5/00;;B01J49/30;;C01B17/96;;C01D1/04;;C01D3/04;;C25B1/34;;C25B15/08,,0,0,,,,PENDING
567,CA,C,CA 2569244 C,064-249-569-317-762,2017-02-14,2017,CA 2569244 A,2005-06-01,US 57599704 P;;US 63922204 P;;US 2005/0019235 W,2004-06-01,COMPOSITIONS AND METHODS TO PREVENT AAV VECTOR AGGREGATION,"Compositions and methods are provided for preparation of concentrated stock solutions of AAV virions without aggregation. Formulations for AAV preparation and storage are high ionic strength solutions (e.g. ~ ~500mM) that are nonetheless isotonic with the intended target tissue. This combination of high ionic strength and modest osmolarity is achieved using salts of high valency, such as sodium citrate. AAV stock solutions up to 6.4x1013 vg/mL are possible using the formulations of the invention, with no aggregation being observed even after ten freeze-thaw cycles. The surfactant Pluronic® F68 may be added at 0.001% to prevent losses of virions to surfaces during handling. Virion preparations can also be treated with nucleases to eliminate small nucleic acid strands on virions surfaces that exacerbate aggregation.",AVIGEN INC,WRIGHT JOHN FRASER;;QU GUANG,,https://lens.org/064-249-569-317-762,Granted Patent,no,0,0,33,34,0,C12N2750/14151;;C12N7/00;;C12N2750/14151;;C12N7/00;;C12N2750/14111,C12N7/02,,0,0,,,,ACTIVE
568,WO,A1,WO 1994/019733 A1,062-612-935-329-685,1994-09-01,1994,US 9401988 W,1994-02-22,US 2306093 A,1993-02-25,APPARATUS AND METHOD FOR DRIVING A LEADSCREW,"A leadscrew driving arrangement which is corrected to eliminate the effect of pitch errors. The leadscrew (32) is mapped to create a table of differences between the leadscrew angular of a perfect leadscrew which has been advanced the same axial distance. The differences are used to create a correction table which is stored in a PROM (44). During operation of the leadscrew (32), the correction table is used to adjust the leadscrew driving signal.",OHIO ELECTRONIC ENGRAVERS INC,FRASER JOHN W;;WOODS CURTIS,,https://lens.org/062-612-935-329-685,Patent Application,yes,4,0,6,6,0,G05B19/404;;G05B19/404;;G05B19/186;;G05B19/186;;G05B2219/41036;;G05B2219/41036;;G05B2219/41038;;G05B2219/41038;;G05B2219/41055;;G05B2219/41055;;G05B2219/41077;;G05B2219/41077;;G05B2219/45212;;G05B2219/45212,G05B19/18;;G05B19/404;;G05D3/00;;G05D3/12,,0,0,,,,PENDING
569,NZ,A,NZ 511943 A,082-078-707-988-935,2003-07-25,2003,NZ 51194399 A,1999-12-24,NZ 51194399 A;;NZ 33358998 A;;NZ 9900228 W,1998-12-24,Superantigens,"A superantigen selected from any one of SMEZ-2, SPE-G, SPE-H and SPE-J and polynucleotides which encode them. Diagnostic and therapeutic applications of these superantigens are described.",AUCKLAND UNISERVICES LTD,PROFT THOMAS;;FRASER JOHN DAVID,,https://lens.org/082-078-707-988-935,Patent Application,no,0,0,1,10,0,,A61K35/74;;A61K39/09;;C07H19/00;;C07K14/315;;C07K16/12;;C12N1/20;;C12Q1/68,,0,0,,,,DISCONTINUED
570,US,A1,US 2017/0260545 A1,088-224-177-721-010,2017-09-14,2017,US 201615351725 A,2016-11-15,US 201615351725 A;;US 201213368167 A;;US 80965507 A;;US 85168804 A;;US 47238403 P;;US 54975604 P,2003-05-21,METHODS FOR PRODUCING PREPARATIONS OF RECOMBINANT AAV VIRIONS SUBSTANTIALLY FREE OF EMPTY CAPSIDS,Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.,GENZYME CORP,QU GUANG;;WRIGHT JOHN FRASER,AVIGEN INC (2004-08-27);;GENZYME CORPORATION (2007-09-25),https://lens.org/088-224-177-721-010,Patent Application,yes,0,13,40,41,0,C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N15/86;;C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N2710/16651;;C12N2710/10351;;C12N2760/16051;;C12N15/86,C12N15/86;;C12N/;;C12N7/00;;C12N7/02;;C12N15/864,,0,0,,,,DISCONTINUED
571,MX,A,MX 2015012450 A,084-854-380-517-104,2016-04-25,2016,MX 2015012450 A,2014-03-17,US 201361787818 P;;US 2014/0030370 W,2013-03-15,SCALABLE MANUFACTURING PROCESS TO PRODUCE RECOMBINANT LENTIVIRAL VECTORS IN SERUM-FREE SUSPENSION CELL CULTURE SYSTEM.,Methods for preparing highly purified rLV vector formulations at the scale needed to meet anticipated demand for human gene therapy are provided.,PHILADELPHIA CHILDREN HOSPITAL,QU GUANG;;WRIGHT JOHN FRASER,,https://lens.org/084-854-380-517-104,Patent Application,no,0,0,29,29,0,C12N7/00;;C12N2740/15043;;C12N2740/15051;;A61K48/0091;;A61K48/0091;;C12N2740/15043;;C12N2740/15051;;C12N7/00;;A61K48/0091;;C12N7/00;;C12N7/00;;C12N2740/15043;;C12N2740/15051;;A61K48/0091,C12N7/02,,0,0,,,,ACTIVE
572,AU,A1,AU 2017/355714 A1,091-504-853-116-92X,2019-05-30,2019,AU 2017/355714 A,2017-11-07,US 201662418637 P;;US 2017/0060413 W,2016-11-07,Rab escort protein potency assay,"Methods for measuring REP-1 and REP-2 activity are provided. In certain embodiments, a method includes: (a) contacting cells that do not express endogenous functional REP-1 or REP-2 protein with an adeno-associated viral (AAV) vector comprising a CHM gene encoding a REP-1 protein or CHM like gene encoding a REP-2 protein under conditions allowing cell transduction; (b) incubating transduced cells under conditions allowing expression of the encoded REP-1 or REP-2 protein; (c) lysing the transduced cells to produce an extract comprising the encoded REP-1 or REP-2 protein and Rab small GTPase (Rabs); (d) incubating said extract with a Rab substrate for a period of time and under conditions allowing prenylation of the Rab thereby forming prenylated Rab; and (e) detecting and/or quantifying the prenylated Rab, wherein the amount of prenylated Rab reflects REP-1 or REP-2 activity thereby measuring REP-1 or REP-2 activity.",SPARK THERAPEUTICS INC,WRIGHT JOHN FRASER;;SUMAROKA MARINA,,https://lens.org/091-504-853-116-92X,Patent Application,no,0,0,11,11,0,C12Y205/0106;;C12Q1/48;;G01N2333/91171;;C12N9/1085;;C12Q1/48;;G01N2333/91171;;C12Y205/0106,A61K48/00;;C12N15/86,,0,0,,,,PENDING
573,HU,T2,HU E035418 T2,090-738-948-670-830,2018-05-02,2018,HU E05755269 A,2005-06-01,US 57599704 P;;US 63922204 P,2004-06-01,COMPOSITIONS AND METHODS TO PREVENT AAV VECTOR AGGREGATION,,GENZYME CORP,WRIGHT JOHN FRASER;;QU GUANG,,https://lens.org/090-738-948-670-830,Amended Patent,no,0,0,33,34,0,C12N2750/14151;;C12N7/00;;C12N2750/14151;;C12N7/00;;C12N2750/14111,C12N7/00;;C12N7/02,,0,0,,,,PENDING
574,ZA,B,ZA 201506478 B,099-252-923-179-401,2021-09-29,2021,ZA 201506478 A,2015-09-03,US 201361787818 P;;US 2014/0030370 W,2013-03-15,SCALABLE MANUFACTURING PROCESS TO PRODUCE RECOMBINANT LENTIVIRAL VECTORS IN SERUM-FREE SUSPENSION CELL CULTURE SYSTEM,,CHILDRENS HOSPITAL PHILADELPHIA,QU GUANG;;WRIGHT JOHN FRASER,,https://lens.org/099-252-923-179-401,Granted Patent,no,0,0,29,29,0,C12N7/00;;C12N2740/15043;;C12N2740/15051;;A61K48/0091;;A61K48/0091;;C12N2740/15043;;C12N2740/15051;;C12N7/00;;A61K48/0091;;C12N7/00;;C12N7/00;;C12N2740/15043;;C12N2740/15051;;A61K48/0091,,,0,0,,,,ACTIVE
575,EP,A4,EP 2970920 A4,145-937-117-855-784,2016-09-14,2016,EP 14762249 A,2014-03-17,US 201361787818 P;;US 2014/0030370 W,2013-03-15,SCALABLE MANUFACTURING PROCESS TO PRODUCE RECOMBINANT LENTIVIRAL VECTORS IN SERUM-FREE SUSPENSION CELL CULTURE SYSTEM,,PHILADELPHIA CHILDREN HOSPITAL,QU GUANG;;WRIGHT JOHN FRASER,THE CHILDREN'S HOSPITAL OF PHILADELPHIA (2018-08-29),https://lens.org/145-937-117-855-784,Search Report,no,2,0,29,29,0,C12N7/00;;C12N2740/15043;;C12N2740/15051;;A61K48/0091;;A61K48/0091;;C12N2740/15043;;C12N2740/15051;;C12N7/00;;A61K48/0091;;C12N7/00;;C12N7/00;;C12N2740/15043;;C12N2740/15051;;A61K48/0091,C12N7/02,,1,0,,,See also references of WO 2014145578A1,ACTIVE
576,US,A1,US 2014/0323556 A1,147-334-107-729-127,2014-10-30,2014,US 201414216778 A,2014-03-17,US 201414216778 A;;US 201361787818 P,2013-03-15,SCALABLE MANUFACTURING PROCESS TO PRODUCE RECOMBINANT LENTIVIRAL VECTORS IN SERUM-FREE SUSPENSION CELL CULTURE SYSTEM,Methods for preparing highly purified rLV vector formulations at the scale needed to meet anticipated demand for human gene therapy are provided.,PHILADELPHIA CHILDREN HOSPITAL,QU GUANG;;WRIGHT JOHN FRASER,,https://lens.org/147-334-107-729-127,Patent Application,yes,4,11,29,29,0,C12N7/00;;C12N2740/15043;;C12N2740/15051;;A61K48/0091;;A61K48/0091;;C12N2740/15043;;C12N2740/15051;;C12N7/00;;A61K48/0091;;C12N7/00;;C12N7/00;;C12N2740/15043;;C12N2740/15051;;A61K48/0091,A61K48/00,514 44 R;;435/320.1,2,1,005-528-896-894-93X,10.1038/gt.2010.162;;21248790,"Benati, C, Production and purification of lentiviral vector for pre-clinical and clinical application, ASGCT/ESGCT Joint Clinical Trials Training, 2012, pages 1-17;;Lesch et al, Production and purification of lentiviral vectors generated in 293T suspension cells with baculoviral vectors, Gene Therapy (2011) 18, 531-538",DISCONTINUED
577,US,B2,US 7838244 B2,158-122-480-930-982,2010-11-23,2010,US 59429104 A,2004-12-07,AU 2004/901570 A;;NZ 2004000317 W,2004-03-24,SET1 proteins and uses thereof,"The invention relates to methods of use of SET1 proteins or functional equivalents thereof. More particularly the invention relates to the use of SET1 proteins or functional equivalents thereof in procedure, for identification and/or isolation of IgA and the scrum complement factor C5.",AUCKLAND UNISERVICES LTD,FRASER JOHN DAVID;;LANGLEY RIES,AUCKLAND UNISERVICES LIMITED (2006-09-21),https://lens.org/158-122-480-930-982,Granted Patent,yes,5,1,5,5,18,C07K14/31;;C07K14/31;;C07K16/1271;;C07K16/1271,G01N33/53;;C07K1/14;;C07K14/31;;C07K16/12;;C12N15/11;;C12N15/31,435/7.1;;435/7.2,16,14,118-098-590-537-796;;023-005-371-477-893;;005-195-979-619-105;;125-353-444-304-889;;094-489-464-583-037;;019-724-810-371-350;;071-873-997-625-73X;;083-788-244-996-439;;010-433-136-463-335;;158-656-971-858-862;;029-098-741-026-533;;018-506-745-539-708;;023-005-371-477-893;;000-219-638-800-282,9398665;;10.1091/mbc.8.12.2421;;pmc25717;;15728504;;10.4049/jimmunol.174.5.2926;;10.1016/j.jmb.2005.09.014;;16213522;;16242332;;10.1016/j.tim.2005.10.002;;10.1016/s0165-5728(99)00245-3;;10696909;;10.1002/eji.200535324;;16874740;;10.1093/intimm/3.12.1373;;1777426;;1559978;;10.1016/s0021-9258(18)42524-0;;12082105;;10.1074/jbc.m203914200;;10.1016/s0140-6736(02)08713-5;;12044378;;10.1073/pnas.0402521101;;pmc470752;;15213324;;10.1016/s0140-6736(00)04403-2;;11418146;;15728504;;10.4049/jimmunol.174.5.2926;;10.1128/iai.68.8.4407-4415.2000;;pmc98335;;10899837,"Nislow et al. Molecular Biology of the Cell 1997, vol. 8, p. 2421-2436.;;Langley, Ries, et al, ""The Staphylococcal Superantigen-Like Protein 7 Binds IgA and Complement C5 and Inhibits IgA-FcalphaRI Binding and Serum Killing of Bacteria."" Journal of Immunology, 2005, 174:2926-2933.;;Haas, Pieter-Jan, et al, ""The Structure of the C5a Receptor-blocking Domain of Chemotaxs Inhibitory Protein of Staphylococcus aureus is Related to a Group of Immune Evasive Molecules."" J. Mol. Biol. (2005) 353, 859-872.;;Rooijakkers, Suzan H.M., et al, ""Staphylococcal Innate Immune Evasion."", TRENDS in Microbiology vol. 13 No. 12 Dec. 2005, pp. 596-601.;;Kanwar, Jagat R., et al; ""beta7 Integrins Contribute to Demyelinating Disease of the Central Nervous System""; Journal of Neuroimmunology (103) (2000) 146-152.;;Krissansen, Geoffrey W., et al, A Pseudosymmetric Cell Adhesion Regulatory Domain in the beta7 Tail of the Integrin alpha4beta7 That Interacts With Focal Adhesion Kinase and SRC, Eur. J. Immunol. 2006. 36:2203-2214.;;Yuan et al. ""Cloning and sequence analysis of a novel beta 2-related integrin transcript form T lymphocytes: homology of intergrin cysteine-rich repeats to domain III of lamini B chains,"" Int Immunol. 1990;2(11):1097-108, Erratum in: Int Immunol. Dec. 1991;3(12);1373-4.;;Yuan et al. ""Molecular Cloning of the mouse Integrin beta 7 Subunit"" J Biol Chem. Apr. 15, 1992;267(11):7352-8.;;Arcus et al., ""The Three-Dimensional Structure of a Superantigen-like Protein, SET3, from a Pathogenicity Island of the Staphylococcus aureus Genome"", The Journal of Biological chemistry 277:32274-32281, 2002.;;Baba et al, ""Genome and Virulence Determinants of High Virulence Community-Acquired MRSA"", The Lancet 359:1819-1827, 2002.;;Fraser et al., ""The Staphylococcal SETs-Superantigen Like Virulence Factors Targeting IgA and Complement Factors."", Conference Presentation, Australian Society for Immunology 2003, Perth, Western Australia, Abstract submitted Sep. 15, 2003; Conference opened Jul. 12, 2003; oral presentation delivered Oct. 12, 2003. Abstract and PowerPoint(TM) presentation attached.;;Holden et al., ""Complete Genomes of Two Clinical Staphylococcus aureus Strains: Evidence for the Rapid Evolution of Virulence and Drug Resistance"", Proceedings of the National Academy of Sciences (USA) 101:9786-9791, 2004.;;Kuroda et al., ""Whole Genome Sequencing of Meticillin-Resistant Staphylococcus aureus"", The Lancet 357:1225-1240, 2001.;;Langley et al., ""The Staphylococcal Superantigen-Like Protein 7 Binds IgA and Complement C5 and Inhibits IgA-FcRI Binding and Serum Killing of Bacteria"", The Journal of Immunology 174:2926-2933, 2005.;;Williams et al., ""Identification of a Novel Gene Cluster Encoding Staphylococcal Exotoxin-Like Proteins: Characterization of the Prototypic Gene and Its Protein Product, SET1"", Infection and Immunity 68:4407-4415, 2002.;;TrEMBLE Accession No. Q8NY48. Set22 protein. Oct. 1, 2002. Baba et al., (94% identical (Blastp) to Applicant's Seq ID 6).",INACTIVE
578,EP,A4,EP 1572071 A4,153-449-593-029-851,2007-08-01,2007,EP 02805565 A,2002-12-09,US 0239465 W;;US 33885601 P,2001-12-07,SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS,,CYTORI THERAPEUTICS INC,FRASER JOHN;;HENDRICK MARC H,"CYTORI THERAPEUTICS, INC. (2006-11-29)",https://lens.org/153-449-593-029-851,Search Report,no,5,0,65,221,0,A61B10/0283;;A61K9/0019;;C12N5/0667;;C12N5/069;;C12N2506/1384;;A61K35/28;;A61K35/35;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P3/00;;A61P3/06;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;A61K35/32;;A61K48/00;;A61K35/36;;A61B10/0283;;A61K9/0019;;C12N5/0667;;C12N5/069;;C12N2506/1384;;A61M1/76;;A61K35/28;;A61K35/35;;C12M47/04;;A61M2202/08,A61K31/436;;A61K35/02;;A61K35/12;;A61K35/28;;A61M1/00;;A61K35/35;;A61K35/36;;A61K38/00;;A61K38/16;;A61K45/00;;A61L27/00;;A61P1/00;;A61P1/16;;A61P3/00;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P19/00;;A61P19/02;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;C12M3/06;;C12N5/0775,,2,1,010-094-842-952-554,10.1089/107632701300062859;;11304456,"ZUK P A ET AL: ""Multilineage cells from human adipose tissue: implications for cell-based therapies."", TISSUE ENGINEERING APR 2001, vol. 7, no. 2, April 2001 (2001-04-01), pages 211 - 228, XP002198710, ISSN: 1076-3279;;See also references of WO 03053346A2",EXPIRED
579,KR,A,KR 20070089254 A,171-736-994-440-734,2007-08-30,2007,KR 20077018245 A,2002-12-09,US 0239465 W;;US 33885601 P,2001-12-07,SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS,Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient.,CYTORI THERAPEUTICS INC,FRASER JOHN;;HENDRICK MARC H,,https://lens.org/171-736-994-440-734,Patent Application,no,0,5,65,221,0,A61K35/28;;A61K35/28;;A61K48/00;;A61B10/0283;;A61B10/0283;;A61K9/0019;;A61K9/0019;;A61K35/32;;A61K35/35;;A61K35/35;;A61K35/36;;A61M1/76;;A61M2202/08;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/00;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;A61P43/00;;C12M47/04;;C12N5/0667;;C12N5/0667;;C12N5/069;;C12N5/069;;C12N2506/1384;;C12N2506/1384,A61K35/12;;A61M1/00;;A61K31/436;;A61K35/02;;A61K35/28;;A61K35/32;;A61K35/35;;A61K35/36;;A61K38/00;;A61K38/16;;A61K45/00;;A61L27/00;;A61P1/00;;A61P1/16;;A61P3/00;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P19/00;;A61P19/02;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;C12M3/06;;C12N5/0775,,0,0,,,,EXPIRED
580,WO,A2,WO 2004/113494 A2,173-738-594-338-302,2004-12-29,2004,US 2004/0015958 W,2004-05-21,US 47238403 P;;US 54975604 P,2003-05-21,METHODS FOR PRODUCING PREPARATIONS OF RECOMBINANT AAV VIRIONS SUBSTANTIALLY FREE OF EMPTY CAPSIDS,Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.,AVIGEN INC;;QU GUANG;;WRIGHT JOHN FRASER,QU GUANG;;WRIGHT JOHN FRASER,,https://lens.org/173-738-594-338-302,Patent Application,yes,0,43,40,41,0,C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N15/86;;C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N2710/16651;;C12N2710/10351;;C12N2760/16051;;C12N15/86,C12N/;;C12N7/02;;C12N15/86;;C12N15/864,,0,0,,,,PENDING
581,GB,A,GB 1077374 A,190-267-239-954-969,1967-07-26,1967,GB 2108363 A,1963-05-27,GB 2108363 A,1963-05-27,The manufacture of adipic acid,"In the process for the preparation of adipic acid by the liquid phase oxidation of cyclohexane with molecular oxygen followed by further oxidation of this oxidation product by nitric acid after the removal of cyclohexane, adipic acid (0.01 to 5%) is added to the cyclohexane used in the liquid phase oxidation with molecular oxygen. The adipic acid may be added in the form of an aqueous solution, a finely divided solid or as a water-soluble salt.",ICI LTD,GARDNER CYRIL;;PRESCOTT JOHN FRASER,,https://lens.org/190-267-239-954-969,Granted Patent,no,0,0,1,1,0,C07C51/316,C07C51/31,C2C CCS;;C2C C20Y;;C2C C265;;C2C C294;;C2C C299;;C2C C30Y;;C2C C366;;C2C C367;;C2C C37X;;C2C C409;;C2C C46Y;;C2C C490;;C2C C569;;C2C C638;;C2C C65Y,0,0,,,,EXPIRED
582,JP,A,JP 2016195587 A,007-922-923-882-001,2016-11-24,2016,JP 2016058761 A,2016-03-23,US 57599704 P;;US 63922204 P,2004-06-01,COMPOSITIONS AND METHODS TO PREVENT AAV VECTOR AGGREGATION,"PROBLEM TO BE SOLVED: To provide compositions and methods for preparing highly concentrated stock solutions of AAV virion without aggregation.SOLUTION: Formulations for AAV preparation and storage are high ionic strength solutions (e.g. μ 500 mM) that are nonetheless isotonic with an intended target tissue. This combination of high ionic strength and modest osmolarity is achieved using a salt of high valency, such as sodium citrate. AAV stock solutions up to 6.4×10vg/mL are possible using the formulations of the invention, with no aggregation being observed even after ten freeze-thaw cycles. The surfactant Pluronic [registered trademark] F68 is added at 0.001% to prevent losses caused by binding to the surface of the virion during handling. If a virion formulation is treated with a nuclease, a small nucleic acid strand on the virion surface that exacerbates aggregation can be eliminated.SELECTED DRAWING: None",GENZYME CORP,WRIGHT JOHN FRASER;;QU GUANG,,https://lens.org/007-922-923-882-001,Patent Application,no,0,0,33,34,0,C12N2750/14151;;C12N7/00;;C12N2750/14151;;C12N7/00;;C12N2750/14111,C12N7/00;;C12N7/02,,1,0,,,"MOLECULAR THERAPY, vol. Vol.9, Sup.1, JPN6011008926, May 2004 (2004-05-01), pages p.S163, #425",PENDING
583,GB,A,GB 2303556 A,010-368-943-013-295,1997-02-26,1997,GB 9615146 A,1996-07-19,GB 9514973 A,1995-07-21,Controlling gas supply to a patient,"A system for controlling the gas supply to, and the removal of expired gas from, a patient includes a control valve 10 having a gas supply passage 12 and an expired gas passage 14, a connector 28 connecting the control system to a breathing pathway of the patient, at least one inspiratory port 32 and at least one expiratory port 34 between the respective gas passage and the connector and means controlling the opening and closing of the ports to permit inspiration and expiration. Such means may comprise a flexible valve disc 38 which is movable into and out of engagement with an annular seat 30 defining the port 32 and into and out of sealing engagement with a ring of expired gas ports 34 leading to passage 14 via a one-way valve including a valve ring 44.",MALIN JOHN;;WILLIAMS NEIL FRASER,MALIN JOHN;;WILLIAMS NEIL FRASER,,https://lens.org/010-368-943-013-295,Patent Application,no,6,6,3,3,0,A61M16/20;;A61M16/0825;;A61M16/201;;A61M16/208;;A61M16/209,A61M16/20,A5T TV            TV;;A5T T255          TV;;A5T T263          TV;;F2V VR3           VR3,0,0,,,,DISCONTINUED
584,EP,A1,EP 2781596 A1,028-218-792-207-905,2014-09-24,2014,EP 14163759 A,2004-05-21,US 47238403 P;;US 54975604 P;;EP 10179750 A;;EP 04776068 A,2003-05-21,Methods for producing prepartions of recombinant AAVvirions substantially free of empty capsids,"Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.
",GENZYME CORP,QU GUANG;;WRIGHT JOHN FRASER,GENZYME CORPORATION (2018-07-18),https://lens.org/028-218-792-207-905,Patent Application,yes,14,1,40,41,0,C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N15/86;;C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N2710/16651;;C12N2710/10351;;C12N2760/16051;;C12N15/86,C12N7/02;;B01D15/00;;B01D15/04;;C02F1/42;;C12N/;;C12N15/86;;C12N15/864,,56,40,040-850-901-799-916;;003-351-517-641-454;;082-256-886-757-890;;036-117-611-735-723;;045-942-479-095-293;;056-315-332-834-967;;063-793-003-971-602;;133-796-772-596-115;;010-713-990-772-82X;;040-850-901-799-916;;074-652-424-954-106;;010-092-025-424-218;;042-769-724-026-529;;036-751-136-233-342;;004-906-146-072-928;;005-904-093-105-315;;118-781-394-705-963;;017-939-992-695-836;;087-005-980-063-276;;001-107-410-887-879;;034-454-872-268-857;;075-206-291-455-245;;056-196-064-755-971;;039-999-144-232-460;;019-953-149-793-444;;061-166-732-363-142;;056-196-064-755-971;;030-079-213-874-071;;039-151-553-495-992;;008-587-496-850-953;;058-452-600-692-672;;061-166-732-363-142;;040-212-003-832-140;;074-652-424-954-106;;009-499-373-901-710;;066-928-563-719-899;;011-646-571-801-437;;010-284-533-720-722;;004-717-207-320-786;;045-303-142-874-063,10.1089/104303402320139014;;12133276;;10.1089/104303400750001390;;11044910;;10.1016/s1525-0016(02)90719-7;;12436964;;10.1006/mthe.2002.0719;;19649903;;11589834;;10.1089/104303401753153974;;10.1016/s0166-0934(99)00150-0;;0010716335;;10716335;;10.1038/sj.gt.3300938;;10455399;;10.1016/j.ymthe.2004.06.346;;10.1038/nbt0395-222;;9634764;;10.1089/104303402320139014;;12133276;;10.1128/jvi.63.9.3822-3828.1989;;pmc250975;;2547998;;pmc240929;;10.1128/jvi.65.6.2936-2945.1991;;2033660;;10.1099/0022-1317-9-3-243;;5498444;;10.1016/0042-6822(71)90141-3;;5000131;;6305001;;10.1016/s0042-6822(83)80008-7;;10.1128/jvi.41.3.868-876.1982;;6284977;;pmc256823;;pmc319248;;6262830;;10.1073/pnas.78.3.1925;;10.1016/0042-6822(80)90354-2;;6249041;;10.1099/0022-1317-29-2-239;;213533;;pmc319472;;6265925;;10.1073/pnas.78.5.2927;;6256359;;10.1016/s0021-9258(19)70007-6;;10.1128/jvi.62.1.206-210.1988;;pmc250520;;2824848;;10.1089/hum.1994.5.7-793;;7981305;;10.1128/mcb.8.10.3988;;pmc365467;;2847025;;10.1128/mcb.8.10.3988-3996.1988;;10.1016/0958-1669(92)90082-t;;1369403;;1316261;;10.1007/978-3-642-75608-5_5;;10.1089/hum.1994.5.7-793;;7981305;;7584077;;pmc2191525;;7515101;;10.1084/jem.179.6.1867;;886304;;10.1099/0022-1317-36-1-59;;452423;;10.1016/0042-6822(79)90476-8;;1316261;;10.1007/978-3-642-75608-5_5;;10.1006/viro.1994.1535;;8091661;;10.1128/jvi.63.9.3822-3828.1989;;pmc250975;;2547998;;6270377;;pmc256613;;10.1128/jvi.40.1.241-247.1981;;2998066;;10.1016/0042-6822(85)90243-0;;3012864;;10.1016/0042-6822(86)90376-4;;10.1089/1043034041361262;;15298029;;10455443;;10.1038/sj.gt.3300946;;10982375;;pmc102127;;10.1128/jvi.74.19.9281-9293.2000,"KALUDOV NIKOLA ET AL: ""Scalable purification of adeno-associated virus type 2, 4, or 5 using ion-exchange chromatography"", HUMAN GENE THERAPY, vol. 13, no. 10, 1 July 2002 (2002-07-01), pages 1235 - 1243, XP002382732, ISSN: 1043-0342;;GAO G ET AL: ""Purification of Recombinant Adeno-Associated Virus Vectors by Column Chromatography and Its Performance In Vivo"", HUMAN GENE THERAPY, MARY ANN LIEBERT, NEW YORK ,NY, US, vol. 11, no. 15, 1 October 2000 (2000-10-01), pages 2079 - 2091, XP008090776, ISSN: 1043-0342;;BRUMENT N ET AL: ""A versatile and scalable two-step ion exchange chromatography process for the purification of recombinant adeno-associated virus serotypes-2 and -5"", MOLECULAR THERAPY, NATURE PUBLISHING GROUP, GB, vol. 6, no. 5, 1 November 2002 (2002-11-01), pages 678 - 686, XP002969618, ISSN: 1525-0016, DOI: 10.1016/S1525-0016(02)90719-7;;QU G ET AL: ""SCALING-UP PRODUCTION OF RECOMBINANT AAV VECTORS FOR CLINICAL APPLICATIONS"", CURRENT OPINION IN DRUG DISCOVERY AND DEVELOPMENT, CURRENT DRUGS, LONDON, GB, vol. 3, no. 6, 2000, pages 750 - 755, XP001041966, ISSN: 1367-6733;;VELLEKAMP GARY ET AL: ""Empty capsids in column-purified recombinant adenovirus preparations"", HUMAN GENE THERAPY, vol. 12, no. 15, 10 October 2001 (2001-10-10), pages 1923 - 1936, XP002382733, ISSN: 1043-0342;;ANDERSON R ET AL: ""A METHOD FOR THE PREPARATION OF HIGHLY PURIFIED ADENO-ASSOCIATED VIRUS USING AFFINITY COLUMN CHROMATOGRAPHY, PROTEASE DIGESTION AND SOLVENT EXTRACTION"", JOURNAL OF VIROLOGICAL METHODS, AMSTERDAM, NL, vol. 85, no. 1-2, March 2000 (2000-03-01), pages 23 - 34, XP000982643, ISSN: 0166-0934;;ZOLOTUKHIN ET AL: ""Recombinant adeno -associated virus purification using novel methods improves infectious titer and yield"", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 6, no. 6, June 1999 (1999-06-01), pages 973 - 985, XP002116593, ISSN: 0969-7128;;""Development of a scalable column chromatography-based purification process to manufacure empty capsid-free AAV vectors"", MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA,, US, vol. 9, May 2004 (2004-05-01), pages 162, XP004634790, ISSN: 1525-0016;;C. P. HODGSON, BIOTECHNOLOGY, vol. 13, 1995, pages 222 - 225;;QU; WRIGHT, CUR. OPIN. DRUG DISC. AND DEVELOP., vol. 3, 2000, pages 750 - 755;;KALUDOV ET AL., HUM. GENE THER., vol. 13, 2002, pages 1235 - 1243;;SAMULSKI ET AL., J. VIRAL., vol. 63, 1989, pages 3822 - 3828;;MCCARTY ET AL., J. VIROL., vol. 65, 1991, pages 2936 - 2945;;ITO ET AL., J GEN. VIROL., vol. 9, 1970, pages 243;;ISHIBASHI ET AL., VIROLOGY, vol. 45, 1971, pages 317;;CARTER ET AL., VIROLOGY, vol. 126, 1983, pages 505;;LAUGHLIN ET AL., J VIROL., vol. 41, 1982, pages 868;;JANIK ET AL., PROC. NATL. ACAD. SCI. USA, vol. 78, 1981, pages 1925;;OSTROVE ET AL., VIROLOGY, vol. 104, 1980, pages 502;;HANDA ET AL., J. GEN. VIROL., vol. 29, 1975, pages 239;;STRAUSS ET AL., J. VIRAL, vol. 17, 1976, pages 140;;MYERS ET AL., J. VIROL., vol. 35, 1980, pages 665;;JAY ET AL., PROC. NATL. ACAD SCI. USA, vol. 78, 1981, pages 2927;;MYERS ET AL., J BIOL. CHEM., vol. 256, 1981, pages 567;;CARTER, ADENO-ASSOCIATED VIRUS HELPER FUNCTIONS: ""I CRC Handbook of Parvoviruses"", 1990;;SAMULSKI ET AL., J VIROL., vol. 62, 1988, pages 206 - 210;;MATSHUSHITA ET AL., GENE THERAPY, vol. 1, 1998, pages 938 - 945;;KOTIN, R.M., HUMAN GENE THERAPY, vol. 5, 1994, pages 793 - 801;;BEMS, K.I: ""Fundamental Virology"", article ""Parvoviridae and their Replication"";;LEBKOWSKI ET AL., MOLEC. CELL. BIOL., vol. 8, 1988, pages 3988 - 3996;;VINCENT ET AL.: ""Vaccines"", vol. 90, 1990, COLD SPRING HARBOR LABORATORY PRESS;;CARTER, CURRENT OPINION IN BIOTECHNOLOGY, vol. 3, 1992, pages 533 - 539;;MUZYCZKA, CURRENT TOPICS IN MICROBIOL. AND IMMUNOL., vol. 158, 1992, pages 97 - 129;;KOTIN, HUMAN GENE THERAPY, vol. 5, 1994, pages 793 - 801;;SHELLING; SMITH, GENE THERAPY, vol. 1, 1994, pages 165 - 169;;ZHOU ET AL., J. EXP. MED., vol. 179, 1994, pages 1867 - 1875;;GRAHAM ET AL., J. GEN. VIROL., vol. 36, 1977, pages 59;;AIELLO ET AL., VIROLOGY, vol. 94, 1979, pages 460;;MUZYCZKA, N., CURRENT TOPICS IN MICROBIAL. AND IMMUNOL., vol. 158, 1992, pages 97 - 129;;THOMSON ET AL., VIROLOGY, vol. 204, 1994, pages 304 - 311;;SAMULSKI ET AL., J. VIROL., vol. 63, 1989, pages 3822 - 3828;;BULLER ET AL., J. VIROL., vol. 40, 1981, pages 241 - 247;;MCPHERSON ET AL., VIROLOGY, vol. 147, 1985, pages 217 - 222;;SCHLEHOFER ET AL., VIROLOGY, vol. 152, 1986, pages 110 - 117;;ITO ET AL., J. GEN. VIROL., vol. 9, 1970, pages 243;;LAUGHLIN ET AL., J. VIROL., vol. 41, 1982, pages 868;;STRAUSS ET AL., J. VIROL., vol. 17, 1976, pages 140;;MYERS ET AL., J VIROL., vol. 35, 1980, pages 665;;MYERS ET AL., J. BIOL. CHEM., vol. 256, 1981, pages 567;;CARTER: ""Adeno-Associated Virus Helper Functions, in I CRC Handbook of Parvoviruses"", 1990;;SAMULSKI ET AL., J. VIROL., vol. 62, 1988, pages 206 - 210;;MATSHUSHITA ET AL., GENE THERAPY, vol. 5, 1998, pages 938 - 945;;ZHEN ET AL.: ""An Infectious Titer Assay for Adeno-associated Virus (AAV) Vectors with Sensitivity Sufficient to Detect Single Infectious Events"", HUM. GENE THER., 2004;;GRIMM ET AL., GENE THERAPY, vol. 6, 1999, pages 1322 - 1330;;SOMMER ET AL., MOLEC. HER., vol. 7, 2003, pages 122 - 128;;WOBUS ET AL., J. VIROL., vol. 74, 2000, pages 9281 - 9293",DISCONTINUED
585,WO,A1,WO 2018/191507 A1,024-261-707-970-059,2018-10-18,2018,US 2018/0027317 W,2018-04-12,EP 17000619 A,2017-04-12,FIRE RETARDANT COMPOSITE,"This disclosure relates to a fire-retardant composite material comprising a fibre-reinforced plastic covered by an aluminium foil and its application in passenger transport industries such as aerospace, railway or marine.",HUNTSMAN ADV MAT LICENSING SWITZERLAND GMBH,DE VERCLOS OLIVIER;;FRASER JOHN,,https://lens.org/024-261-707-970-059,Patent Application,yes,5,0,8,8,0,B32B15/14;;B32B27/38;;B32B3/12;;B32B5/022;;B32B5/024;;B32B5/26;;B32B15/092;;B32B15/20;;B32B15/20;;B32B19/041;;B32B19/06;;B32B2260/023;;B32B2260/046;;B32B2262/02;;B32B2262/0269;;B32B2262/101;;B32B2262/106;;B32B2307/3065;;B32B2311/24;;B32B2363/00;;B32B2451/00;;B32B2605/00,B32B5/02;;B32B3/12;;B32B5/26;;B32B15/14;;B32B15/20;;B32B19/04;;B32B19/06,,0,0,,,,PENDING
586,BR,A2,BR 112015022292 A2,038-168-947-436-180,2017-07-18,2017,BR 112015022292 A,2014-03-17,US 2014/0030370 W;;US 201361787818 P,2013-03-15,processo de fabricação escalonável para produzir vetores lentivirais recombinantes em um sistema de cultura celular em suspensão sem soro,"resumo patente de invenção: ""processo de fabricação escalonável para produzir vetores lentivirais recombinantes em um sistema de cultura celular em suspensão sem soro"". são fornecidos métodos para a preparação de formulações de vetor rlv altamente purificado em uma escala necessária para atingir a demanda antecipada para a terapia de gene.",CHILDRENS HOSPITAL PHILADELPHIA,GUANG QU;;JOHN FRASER WRIGHT,,https://lens.org/038-168-947-436-180,Patent Application,no,0,0,29,29,0,C12N7/00;;C12N2740/15043;;C12N2740/15051;;A61K48/0091;;A61K48/0091;;C12N2740/15043;;C12N2740/15051;;C12N7/00;;A61K48/0091;;C12N7/00;;C12N7/00;;C12N2740/15043;;C12N2740/15051;;A61K48/0091,C12N7/02,,0,0,,,,DISCONTINUED
587,EP,B1,EP 1028272 B1,049-667-785-561-143,2004-03-17,2004,EP 00300556 A,2000-01-26,US 24874799 A,1999-02-12,Torque converter bypass clutch,,LAWRENCE TECHNOLOGICAL UNIVERS,MACDONALD FRASER JOHN;;HARGRAVE DAVID,LAWRENCE TECHNOLOGICAL UNIVERSITY (2003-06-25),https://lens.org/049-667-785-561-143,Granted Patent,yes,5,0,6,6,0,F16H45/02;;F16H45/02;;F16H2045/0294;;F16H2045/0294,F16H45/02,,1,0,,,"FROSLIE, MILEK, SMITH: ""Design Practices- Passenger Car Automatic Transmissions Part I"" 1962 , SAE , NEW YORK XP000905044 * page 81 - page 99 *",EXPIRED
588,US,A1,US 2010/0015104 A1,054-708-109-040-130,2010-01-21,2010,US 37500507 A,2007-07-25,US 37500507 A;;US 83356106 P;;US 2007/0016750 W,2006-07-26,GENERATION OF ADIPOSE TISSUE AND ADIPOCYTES,"The invention provides novel methods by which adipose tissue, preadipocytes, and adipocytes can be generated for research purposes, and methods for identifying cell populations that can proliferate and differentiate into adipocytes in vivo. The invention further provides a means for the in vivo derivation of “designer” or “customized” adipose tissue, preadipocytes, and adipocytes. Also provided are methods for identifying agents that affect adipocytes and adipose tissue, as well as the agents themselves. In particular, the present invention allows for creation of tissues and cells that can be used to screen for agents useful for treating human disorders associated with adipose tissue, including obesity, metabolic syndrome, and diabetes.",CYTORI THERAPEUTICS INC,FRASER JOHN K;;DEEMIDIO MICHAEL,CYTORI THERAPEUTICS INC (2009-03-17);;LOREM VASCULAR PTE. LTD (2019-04-24),https://lens.org/054-708-109-040-130,Patent Application,yes,99,630,3,3,0,A61K35/12;;C12N5/0653;;C12N2501/599;;C12N2503/02;;A61P3/00;;C12N5/0653;;A61K35/12;;C12N2501/599;;C12N2503/02,A61P3/00;;A61K35/12;;C12N5/077;;C12Q1/02;;C12Q1/04,424/93.7;;435/34;;435/29,0,0,,,,DISCONTINUED
589,US,A1,US 2017/0368201 A1,081-055-953-476-056,2017-12-28,2017,US 201715699613 A,2017-09-08,US 201715699613 A;;US 201414216778 A;;US 201361787818 P,2013-03-15,SCALABLE MANUFACTURING PROCESS TO PRODUCE RECOMBINANT LENTIVIRAL VECTORS IN SERUM-FREE SUSPENSION CELL CULTURE SYSTEM,Methods for preparing highly purified rLV vector formulations at the scale needed to meet anticipated demand for human gene therapy are provided.,THE CHILDREN'S HOSPITAL OF PHILADELPHIA,QU GUANG;;WRIGHT JOHN FRASER,THE CHILDREN'S HOSPITAL OF PHILADELPHIA (2021-04-11),https://lens.org/081-055-953-476-056,Patent Application,yes,0,1,29,29,0,C12N7/00;;C12N2740/15043;;C12N2740/15051;;A61K48/0091;;A61K48/0091;;C12N2740/15043;;C12N2740/15051;;C12N7/00;;A61K48/0091;;C12N7/00;;C12N7/00;;C12N2740/15043;;C12N2740/15051;;A61K48/0091,A61K48/00;;C12N7/00,,0,0,,,,ACTIVE
590,US,A,US 3149162 A,083-561-153-574-330,1964-09-15,1964,US 9638861 A,1961-03-17,GB 1026160 A,1961-03-17,Purification of hydrogenation products,,ICI LTD,CYRIL GARDNER;;FRASER PRESCOTT JOHN,,https://lens.org/083-561-153-574-330,Granted Patent,no,2,7,2,2,0,C07C209/84;;C07C211/50;;C07C209/84,,,0,0,,,,EXPIRED
591,CA,A1,CA 3174164 A1,107-323-172-287-842,2022-08-25,2022,CA 3174164 A,2022-02-18,US 202163150797 P;;CA 2022050237 W,2021-02-18,SODIUM SULFATE BY-PRODUCT PROCESSING IN LITHIUM AND BATTERY CHEMICAL PRODUCTION,"A process for battery chemical production, where a sodium sulfate stream is treated with an ion exchange process to provide potassium sulfate and sodium chloride. The sodium chloride may be treated with a chlor-alkali to produce sodium hydroxide for use upstream in the battery chemical production process.",HATCH LTD,FRASER ROBERT JOHN;;STAMATIOU EVANGELOS,,https://lens.org/107-323-172-287-842,Patent Application,no,0,0,8,8,0,C01D3/04;;C01D1/04;;C01D5/00;;C25B1/34;;C25B15/081;;Y02E60/10;;C01D1/04;;C01D5/00;;C25B1/46;;C25B9/23;;Y02E60/10;;B01J49/57;;B01J41/04;;B01J41/12;;C01D1/20;;C01D3/04;;C01D5/02;;C01P2006/40,C01D5/00;;B01J49/30;;C01B17/96;;C01D1/04;;C01D3/04;;C25B1/34;;C25B15/08,,0,0,,,,PENDING
592,EP,A2,EP 1323076 A2,107-816-095-084-026,2003-07-02,2003,EP 01969995 A,2001-09-26,GB 0104302 W;;GB 0023584 A,2000-09-26,METHOD AND SYSTEM FOR ARCHIVING AND RETRIEVING ITEMS BASED ON EPISODIC MEMORY OF GROUPS OF PEOPLE,,6S LTD,FRASER JOHN LESLIE;;SHARPE ELIZABETH,,https://lens.org/107-816-095-084-026,Patent Application,yes,0,0,8,8,0,G06F16/9535;;G06F16/951,G06F17/30,,0,0,,,,DISCONTINUED
593,JP,A,JP 2010155868 A,111-963-458-504-283,2010-07-15,2010,JP 2010089074 A,2010-04-07,US 47238403 P;;US 54975604 P,2003-05-21,METHOD FOR PRODUCING PREPARATION OF RECOMBINANT AAV VIRION SUBSTANTIALLY FREE OF EMPTY CAPSID,"<P>PROBLEM TO BE SOLVED: To provide a new method for removing AAV empty capsids from AAV vector particle stock or decreasing the number of AAV empty capsids, to improve production capacity. <P>SOLUTION: An efficient and commercially achievable method for preparing rAAV virion stock decreased in empty capsid amount is developed. It is found out that the empty capsids can be separated from the rAAV virion (""AAV vector particle"") containing genetic materials by using column chromatography techniques. A method for separating empty capsids from a mixture of AAV vector and AAV empty capsids is provided. The method uses column chromatography techniques and provides for commercially achievable levels of recombinant AAV virions. <P>COPYRIGHT: (C)2010,JPO&INPIT",GENZYME CORP,QU GUANG;;WRIGHT JOHN FRASER,,https://lens.org/111-963-458-504-283,Patent Application,no,2,0,40,41,0,C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N15/86;;C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N2710/16651;;C12N2710/10351;;C12N2760/16051;;C12N15/86,C07K14/075;;C12N/;;C12N7/02;;C12N15/09;;C12N15/86;;C12N15/864,,4,0,,,"JPN5006016005; ＧＡＯ． Ｇ．: ＨＵＭＡＮ ＧＥＮＥ ＴＨＥＲＡＰＹ Ｖ１１, 200010, Ｐ２０７９-２０９１;;JPN5006016006; ＤＥＢＥＬＡＫ． Ｄ．: Ｊ． ＣＨＲＯＭＡＴ． Ｂ． Ｖ７４０, 200004, Ｐ１９５-２０２;;JPN5006016007; ＢＲＵＭＥＮＴ． Ｎ．: ＭＯＬＥＣＵＬＡＲ ＴＨＥＲＡＰＹ Ｖ６ Ｎ５, 200211, Ｐ６７８-６８６;;JPN6010005004; Ｈｕｍａｎ Ｇｅｎｅ Ｔｈｅｒａｐｙ， （２００２）， Ｖｏｌ． １３， ｐ． １２３５-１２４３",ACTIVE
594,US,A1,US 2023/0052881 A1,119-551-334-891-330,2023-02-16,2023,US 202217977523 A,2022-10-31,US 202217977523 A;;CA 2022050237 W;;US 202163150797 P,2021-02-18,SODIUM SULFATE BY-PRODUCT PROCESSING IN LITHIUM AND BATTERY CHEMICAL PRODUCTION,"A process for battery chemical production, where a sodium sulfate stream is treated with an ion exchange process to provide potassium sulfate and sodium chloride. The sodium chloride may be treated with a chlor-alkali to produce sodium hydroxide for use upstream in the battery chemical production process.",HATCH LTD,FRASER ROBERT JOHN;;STAMATIOU EVANGELOS,HATCH LTD (2023-02-07),https://lens.org/119-551-334-891-330,Patent Application,yes,1,0,8,8,0,C01D3/04;;C01D1/04;;C01D5/00;;C25B1/34;;C25B15/081;;Y02E60/10;;C01D1/04;;C01D5/00;;C25B1/46;;C25B9/23;;Y02E60/10;;B01J49/57;;B01J41/04;;B01J41/12;;C01D1/20;;C01D3/04;;C01D5/02;;C01P2006/40,C01D1/20;;B01J41/04;;B01J41/12;;B01J49/57;;C01D3/04;;C01D5/02,,0,0,,,,PENDING
595,US,B2,US 8137948 B2,121-239-685-360-393,2012-03-20,2012,US 80965507 A,2007-06-01,US 80965507 A;;US 85168804 A;;US 47238403 P;;US 54975604 P,2003-05-21,Methods for producing preparations of recombinant AAV virions substantially free of empty capsids,Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.,QU GUANG;;WRIGHT JOHN FRASER;;GENZYME CORP,QU GUANG;;WRIGHT JOHN FRASER,AVIGEN INC (2004-08-27);;GENZYME CORPORATION (2007-09-25),https://lens.org/121-239-685-360-393,Granted Patent,yes,8,116,40,41,0,C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N15/86;;C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N2710/16651;;C12N2710/10351;;C12N2760/16051;;C12N15/86,C12N7/02;;C12N/;;C12N15/00;;C12N15/86;;C12N15/864,435/239;;435/320.1,23,22,024-206-805-530-75X;;056-315-332-834-967;;082-256-886-757-890;;141-768-814-445-684;;020-844-173-544-686;;008-227-308-422-865;;003-351-517-641-454;;004-717-207-320-786;;040-850-901-799-916;;156-118-146-118-185;;001-855-353-292-660;;131-849-343-621-830;;127-234-167-778-680;;036-117-611-735-723;;051-418-497-856-216;;135-987-388-625-166;;042-838-870-694-53X;;045-942-479-095-293;;088-196-754-870-804;;165-644-511-657-053;;063-793-003-971-602;;133-796-772-596-115,15975005;;10.2174/1566523054065011;;10.1016/s0166-0934(99)00150-0;;0010716335;;10716335;;10.1016/s1525-0016(02)90719-7;;12436964;;10.1006/mthe.2002.0719;;10.1089/10430349950018427;;10223736;;10.1016/j.jviromet.2004.07.001;;15381358;;10821405;;10.1016/s0378-4347(00)00100-6;;10.1089/104303400750001390;;11044910;;10455443;;10.1038/sj.gt.3300946;;10.1089/104303402320139014;;12133276;;10.1016/0005-2795(70)90310-7;;5534305;;10.1016/s1525-0016(16)41455-3;;10.1016/s0076-6879(02)46069-7;;11883083;;10.1016/s1525-0016(16)42976-x;;19649903;;12459331;;10.1016/s0958-1669(02)00369-5;;10.1016/s1525-0016(02)00019-9;;12573625;;9445046;;10.1128/jvi.72.2.1438-1445.1998;;pmc124624;;11589834;;10.1089/104303401753153974;;15963933;;10.1016/j.ymthe.2005.02.021;;10.1007/bf03187263;;10.1038/sj.gt.3300938;;10455399;;10.1016/j.ymthe.2004.06.346,"Timpe et al. Current Gene Therapy, 2005, vol. 5, pp. 273-284.;;Feit et al. 2003, J. Pat. Trade. Off. Soc., vol. 85, No. 1, pp. 5-21.;;Anderson, et al., ""A Method for the Preparation of Highly Purified Adeno-Associated Virus Using Affinity Column Chromatography, Protease Digestion, and Solvent Extraction,"" Journal of Viralogical Methods 85:23-34 (2000).;;Brument, et al., ""A Versitile and Scalable Two-Step Ion-Exchange Chromatography Process for the Purification of Recombinant Adeno-Associated Virus Serotype-2 and -5,"" Molecular Therapy 6(5):678-686 (2002).;;Clark, et al., ""Highly Purified Recombinant Adeno-Associated Virus Vectors are Biologically Active and Free of Detectable Helper and Wild-Type Viruses,"" Human Gene Therapy 10:1031-1039 (1999).;;Davidoff, et al., ""Purification of Recombinant Adeno-Associated Virus Type 8 Vectors by Ion Exchange Chromatography Generates Clinical Grade Vector Stock,"" Journal of Virilogical Methods 121:209-215 (2004).;;Debelak, et al., ""Cation-Exchange High-Performance Liquid Chromatography of Recombinant Adeno-Associated Virus Type-2,"" J Chromat B 740:195-202 (2000).;;Gao, et al., ""Purification of Recombinant Adeno-Associated Virus Vectors by Column Chromatography and It's Performance in Vivo,"" Human Gene Therapy 11:2079-2091 (2000).;;Grimm, et al., ""Titration of AAV-2 Particles Via a Novel Capsid ELISA: Packaging of Genomes Can Limit Production of Recombinant AAV-2,"" Gene Therapy 6:1322-1330 (1999).;;Kaludov, et al., ""Scalable Purification of Adeno-Associated Virus Type 2,4, or 5 Using Ion-Exchange Chromatography,"" Human Gene Therapy 13:1235-1243 (2002).;;Lewis, et al., ""Kinetic Study of the Deamidation of Growth Hormone and Prolatin,"" Biochimica et Biophysica Acta 214:498-508 (1970).;;Parker, et al., ""In Vivo Performance of AAV-2 Vectors Purified by CsCI Gradient Centrifugation or column Chromatography,"" Molecular Therapy 7:S390 (2003).;;Potter, et al., ""Streamlined Large-Scale Production of Recombinant Adeno-Associated Virus (rAAV) Vectors,"" Methods in Enzymology 346:413-430 (2002).;;Qu, et al., Characterization of AAV Vectors Expressing Human Coagulation Factor IX Produced At Intermediate Scale, Molecular Therapy 5:S50 (2002).;;Qu, et al., ""Scaling-Up Production of Recombinant AAV Vectors for Clinical Applications,"" Current Opinion in Drug Discovery & Development 3(6):750-755 (2000).;;Snyder, et al., ""Production of Clinical-Grade Recombinant Adeno-Associated Virus Vectors,"" Current Opinion in Biotechnology 13:418-423 (2002).;;Sommer, et al., ""Quantification of Adeno-Associated Virus Particles and Empty Capsids by Optical Density Measuremnt,"" Molecular Therapy 7:122-128 (2003).;;Summerford, et al., Membrane-Associated Heperan Sulfate Proteoglycan is a Receptor for Adeno-Associated Viruse Type 2 Virions, Journal of Virology 72:1438-1445 (1998).;;Vellekamp, et al., ""Empty Capsids in Column-Purified Recombinant Adenovirus Preparations,"" Human Gene Therapy 12:1923-1936 (2001).;;Wright, et al., ""Identification of Factors That Contribute to Recombinant AAV2 Particle Aggregation and Methods to Prevent Its Occurance During Vector Purification and Formulation,"" Molecular Therapy12:171-178 (2005).;;Wu, et al., ""A Novel Method for Purification of Recombinant Adeno-Associated Virus Vectors on a Large Scale,"" Chinese Science Bulletine 46:485-489 (2001).;;Zoluthkin, et al., ""Recombinant Adeno-Addociated Virus Purification Using Novel Methods Improves Infectious Titer and Yield,"" Gene Therapy 6:973-985 (1999).;;Qu, et al., ""Development of a Scalable Column Chromatography-Based Purification Process to Manufacture Empty Capsid-Free AAV Vectors,"" Mol Ther 9:S162 Abst.# 424 (2004).",ACTIVE
596,CA,C,CA 3095034 C,120-701-463-974-235,2023-02-28,2023,CA 3095034 A,2020-10-02,US 201962911002 P,2019-10-04,ADAPTOR APPARATUSES AND METHODS FOR ARTIFICIAL LIFT SYSTEMS,"The disclosure provides an adaptor apparatus for a downhole artificial lift system. The apparatus includes an upper adaptor section and a base adaptor section. The upper adaptor section includes a top connector portion for connecting to first equipment, and a neck portion below the top connector portion. The base adaptor section includes a bottom connector portion for connecting to second equipment. The base adaptor section and the neck section define a longitudinal fluid passage therethrough. The upper adaptor section includes slots extending from the fluid passage to an outer surface of the neck. The upper adaptor section also includes a plurality of fluid channels recessed in the outer surface of the upper adaptor piece.",Q2 ARTIFICIAL LIFT SERVICES ULC,FRASER GARTH JOHN;;COYES CORBIN,,https://lens.org/120-701-463-974-235,Granted Patent,no,0,0,4,4,0,E21B43/127;;E21B17/02;;E21B43/127,E21B17/042,,0,0,,,,PENDING
597,AU,B2,AU 2014/232879 B2,124-307-307-158-199,2020-03-05,2020,AU 2014/232879 A,2014-03-17,US 201361787818 P;;US 2014/0030370 W,2013-03-15,Scalable manufacturing process to produce recombinant lentiviral vectors in serum-free suspension cell culture system,Methods for preparing highly purified rLV vector formulations at the scale needed to meet anticipated demand for human gene therapy are provided.,CHILDRENS HOSPITAL PHILADELPHIA,QU GUANG;;WRIGHT JOHN FRASER,,https://lens.org/124-307-307-158-199,Granted Patent,no,1,0,29,29,0,C12N7/00;;C12N2740/15043;;C12N2740/15051;;A61K48/0091;;A61K48/0091;;C12N2740/15043;;C12N2740/15051;;C12N7/00;;A61K48/0091;;C12N7/00;;C12N7/00;;C12N2740/15043;;C12N2740/15051;;A61K48/0091,C12N7/02,,1,1,016-991-047-300-811,10.1016/j.jviromet.2011.01.013;;21295608,"ZHOU ET AL., ""PEG-modulated column chromatography for purification of recombinant adeno- associated virus serotype 9."", J VIROL METHODS, (2011-04), vol. 173, no. 1, pages 99 - 107",ACTIVE
598,PT,T,PT 2970920 T,139-547-583-386-910,2018-07-30,2018,PT 14762249 T,2014-03-17,US 201361787818 P,2013-03-15,SCALABLE MANUFACTURING PROCESS TO PRODUCE RECOMBINANT LENTIVIRAL VECTORS IN SERUM-FREE SUSPENSION CELL CULTURE SYSTEM,,CHILDRENS HOSPITAL PHILADELPHIA,GUANG QU;;JOHN FRASER WRIGHT,,https://lens.org/139-547-583-386-910,Patent Application,no,0,0,29,29,0,C12N7/00;;C12N2740/15043;;C12N2740/15051;;A61K48/0091;;A61K48/0091;;C12N2740/15043;;C12N2740/15051;;C12N7/00;;A61K48/0091;;C12N7/00;;C12N7/00;;C12N2740/15043;;C12N2740/15051;;A61K48/0091,C12N7/02,,0,0,,,,PENDING
599,EP,B1,EP 0766785 B1,195-520-032-817-041,1998-02-04,1998,EP 94900943 A,1993-11-30,GB 9225005 A;;GB 9302458 W,1992-11-30,IMPROVEMENTS IN OR RELATING TO FLUID-FLOW CONTROL VALVES,,PERKINS LTD,WALLACE IAN FRASER;;STAMFORD JOHN,,https://lens.org/195-520-032-817-041,Granted Patent,yes,3,1,12,12,0,F02M65/005;;F02M2200/245;;Y10T137/8242;;F02M65/00;;Y10T137/8242;;F02M65/005;;F02M2200/245,B05B5/00;;F02M51/06;;F02M65/00;;F16K31/02,,0,0,,,,EXPIRED
600,SG,A,SG 11201908725Q A,011-755-404-223-900,2019-10-30,2019,SG 11201908725Q A,2018-04-12,EP 17000619 A;;US 2018/0027317 W,2017-04-12,FIRE RETARDANT COMPOSITE,"INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 18 October 2018 (18.10.2018) WIPO I PCT omit VIII °nolo mu OH 100 Imo oimIE (10) International Publication Number WO 2018/191507 Al (51) International Patent Classification: B32B 5/02 (2006.01) B32B 19/04 (2006.01) B32B 5/26 (2006.01) B32B 19/06 (2006.01) B32B 15/14 (2006.01) B32B 3/12 (2006.01) B32B 15/20 (2006.01) (21) International Application Number: PCT/US2018/027317 (22) International Filing Date: 12 April 2018 (12.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17000619.1 12 April 2017 (12.04.2017) EP (71) Applicant: HUNTSMAN ADVANCED MATERIALS LICENSING (SWITZERLAND) GMBH [CH/CH]; Le- gal Services Department, Klybeckstrasse 200, 4057 Basel (CH). (72) Inventors: DE VERCLOS, Olivier; HUNTSMAN AD- VANCED MATERIALS LICENSING (SWITZERLAND) GMBH, Legal Services Department, Klybeckstrasse 200, 4057 Basel (CH). FRASER, John; Concordia House, Gle- narm Road, Wynyard Park, Billingham TS22 5FB (GB). (74) Agent: RAUB, Monique; Huntsman International LLC, 10003 Woodloch Forest Drive, The Woodlands, Texas 77380 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, O N TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) 00 (54) Title: FIRE RETARDANT COMPOSITE 0 (57) : This disclosure relates to a fire-retardant composite material comprising a fibre-reinforced plastic covered by an alu- \"" minium foil and its application in passenger transport industries such as aerospace, railway or marine.",HUNTSMAN ADV MAT LICENSING SWITZERLAND GMBH,DE VERCLOS OLIVIER;;FRASER JOHN,,https://lens.org/011-755-404-223-900,Unknown,no,0,0,8,8,0,B32B15/14;;B32B27/38;;B32B3/12;;B32B5/022;;B32B5/024;;B32B5/26;;B32B15/092;;B32B15/20;;B32B15/20;;B32B19/041;;B32B19/06;;B32B2260/023;;B32B2260/046;;B32B2262/02;;B32B2262/0269;;B32B2262/101;;B32B2262/106;;B32B2307/3065;;B32B2311/24;;B32B2363/00;;B32B2451/00;;B32B2605/00,B32B5/02;;B32B3/12;;B32B5/26;;B32B15/14;;B32B15/20;;B32B19/04;;B32B19/06,,0,0,,,,PENDING
601,EP,A2,EP 2305276 A2,053-826-812-763-585,2011-04-06,2011,EP 10183690 A,2002-12-09,EP 02805565 A;;US 33885601 P,2001-12-07,Processed lipoaspirate cells for use in therapy,"Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patent. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient.
",CYTORI THERAPEUTICS INC,FRASER JOHN;;HEDRICK MARC H,,https://lens.org/053-826-812-763-585,Patent Application,yes,25,5,65,221,0,A61B10/0283;;A61K9/0019;;C12N5/0667;;C12N5/069;;C12N2506/1384;;A61K35/28;;A61K35/35;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P3/00;;A61P3/06;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;A61K35/32;;A61K48/00;;A61K35/36;;A61B10/0283;;A61K9/0019;;C12N5/0667;;C12N5/069;;C12N2506/1384;;A61M1/76;;A61K35/28;;A61K35/35;;C12M47/04;;A61M2202/08,A61K35/12;;A61M1/00;;A61K31/436;;A61K35/02;;A61K35/28;;A61K35/35;;A61K35/36;;A61K38/00;;A61K38/16;;A61K45/00;;A61L27/00;;A61P1/00;;A61P1/16;;A61P3/00;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P19/00;;A61P19/02;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;C12M3/06;;C12N5/071;;C12N5/0775,,107,103,075-488-030-671-490;;095-913-934-904-672;;084-816-629-310-620;;045-787-458-363-087;;007-126-466-697-398;;079-406-902-735-361;;063-511-874-896-881;;013-836-055-730-839;;050-826-336-424-654;;009-733-473-349-276;;037-681-158-746-769;;012-526-554-878-117;;039-145-123-882-385;;055-386-526-071-218;;080-727-563-346-048;;002-402-322-729-764;;114-069-508-870-517;;017-174-141-941-136;;072-127-656-734-286;;113-681-236-526-978;;047-891-267-991-075;;072-231-000-479-884;;033-479-118-598-189;;054-323-134-654-049;;114-479-047-988-820;;076-090-834-573-016;;015-875-842-431-592;;106-603-013-159-878;;154-284-578-210-365;;102-202-551-812-472;;015-757-459-694-093;;048-302-189-004-430;;087-309-466-182-005;;056-351-892-637-02X;;106-909-648-526-709;;079-304-670-311-107;;060-789-622-695-335;;018-221-020-974-252;;008-093-251-887-096;;047-771-701-165-31X;;078-144-091-568-913;;020-837-486-216-522;;019-939-051-494-816;;006-004-203-029-468;;008-115-130-355-40X;;027-810-214-593-214;;124-936-001-314-170;;119-279-899-568-792;;015-599-406-080-089;;054-506-496-484-990;;000-726-416-179-570;;010-094-842-952-554;;054-783-391-382-440;;111-021-439-383-245;;072-217-283-816-738;;034-785-794-270-260;;119-899-790-379-397;;035-339-813-605-916;;017-611-155-476-581;;072-093-532-186-924;;015-599-406-080-089;;010-094-842-952-554;;115-114-291-514-621;;101-659-159-373-595;;014-944-849-240-553;;008-093-251-887-096;;050-826-336-424-654;;086-462-532-224-686;;094-547-639-217-227;;012-100-750-932-039;;155-317-023-938-779;;024-543-293-226-152;;053-378-748-216-731;;104-867-388-312-53X;;005-046-972-638-291;;055-939-072-605-234;;006-388-312-315-426;;100-021-019-543-442;;055-939-072-605-234;;060-346-109-363-548;;123-676-259-156-005;;013-585-462-742-366;;022-168-856-452-360;;071-429-593-853-516;;015-065-365-556-91X;;047-253-510-312-524;;036-252-293-129-219;;016-725-607-839-435;;012-100-750-932-039;;062-596-462-103-530;;073-024-866-252-802;;013-619-248-169-661;;008-689-173-407-727;;011-805-902-464-128;;038-374-873-783-178;;042-752-396-214-211;;047-615-077-646-421;;053-378-748-216-731;;000-409-808-541-605;;002-574-351-412-169;;052-138-454-301-405;;073-243-305-396-996;;020-575-119-732-157,11329932;;10.1038/nm0901-1035;;pmc2818999;;11533707;;11156872;;10.1161/01.cir.103.5.634;;10.1016/0963-6897(95)00006-j;;7640867;;10.1177/096368979500400306;;10.1016/0304-3835(80)90091-9;;7013975;;182647;;10.1002/ijc.2910180309;;3966975;;10.1038/bjc.1985.13;;pmc1976821;;7357534;;7995370;;10.1089/15258160260194875;;12201961;;10.1080/146532402317381848;;12006209;;12100134;;10.1046/j.1365-2141.2002.03561.x;;4028127;;10.1007/bf00217172;;10.1002/bit.1043;;11255159;;10.1046/j.1423-0410.2001.00078.x;;11555470;;10225738;;10.1111/j.1744-9987.1997.tb00137.x;;10.1016/s0171-2985(82)80064-8;;6984421;;9770361;;10.1006/excr.1998.4163;;9390271;;9592680;;10.1007/s004050050045;;10.1016/s0165-022x(98)00006-2;;9711500;;11359674;;10.1089/15258160151134980;;11205918;;9597573;;10.1089/scd.1.1998.7.159;;11675329;;10.1182/blood.v98.9.2615;;10448662;;10.1016/s0344-0338(99)80049-1;;12135677;;10.1016/s0301-472x(02)00812-3;;1689854;;10.1007/bf02739694;;10.1007/s004040050273;;10834322;;12037404;;10.1159/000058006;;10.1016/s0165-2427(01)00375-0;;11604158;;10.1515/cclm.2000.092;;11028769;;11835415;;10.1002/jca.1032;;12144534;;10.1034/j.1600-0609.2002.01682.x;;9027589;;10.1002/(sici)1097-4644(199702)64:2<295::aid-jcb12>3.0.co;2-i;;10.1002/(sici)1097-4644(199702)64:2<295::aid-jcb12>3.3.co;2-6;;12411045;;12456961;;10.1634/stemcells.20-6-530;;10.1097/00003086-200010001-00011;;11039755;;10983732;;10.2165/00003495-200060020-00002;;10998427;;10.3892/ijmm.6.4.363;;9852198;;10.3892/ijmm.1.1.55;;7593260;;10.1002/jcb.240580312;;7628536;;10.1006/excr.1995.1221;;9618145;;10.1002/(sici)1097-4652(199807)176:1<57::aid-jcp7>3.0.co;2-7;;10546632;;10.1097/00003086-199910001-00003;;10556859;;10.1002/(sici)1097-4636(1999)48:6<913::aid-jbm22>3.0.co;2-0;;10102814;;10.1126/science.284.5411.143;;10.1016/s1471-4914(01)02016-0;;11378515;;11284885;;10.1046/j.1525-1594.2001.025003187.x;;11518286;;10.1016/s0736-0266(00)00054-1;;10.1089/107632701300062859;;11304456;;10.1097/00006534-200201000-00030;;11786812;;10.1080/17453674.1998.11744808;;9333121;;10.1359/jbmr.1997.12.10.1606;;10.1002/jor.1100160309;;9671928;;9262062;;11711826;;10.1097/00001665-200111000-00015;;10.1038/79449;;10973216;;11506726;;10.1089/10763270152436427;;10.1016/s1471-4914(01)02016-0;;11378515;;10.1089/107632701300062859;;11304456;;10.1111/j.1749-6632.1990.tb24327.x;;2291566;;9728332;;10.1023/a:1005462804271;;10738576;;10.1002/(sici)1521-2254(199903/04)1:2<121::aid-jgm26>3.0.co;2-j;;10.1097/00003086-200010001-00011;;11039755;;7995370;;10.1007/bf00453875;;8526158;;10.1016/s0094-1298(20)32343-9;;11248861;;1896551;;10.1097/00006534-199110000-00038;;11134993;;10.1046/j.1524-4725.2000.00277.x;;10.1046/j.1524-4725.2000.t01-1-00277.x;;10.1007/s002669900055;;8849432;;10.1007/bf02390315;;9048302;;10.1089/end.1997.11.67;;11125386;;10.1097/00005392-200101000-00037;;10.1046/j.1365-2613.1996.00964.x;;8762864;;pmc2691621;;10.1016/s0940-2993(99)80076-1;;10048720;;10488710;;10.1016/s0168-8278(99)80043-9;;10.1016/0270-9139(95)90478-6;;7539398;;10.1002/hep.1840210632;;10.1016/s0940-2993(99)80076-1;;10048720;;pmc507709;;8958214;;10.1172/jci119070;;11287958;;10.1038/35070587;;11326230;;10.1067/mtc.2001.112937;;10.1161/01.cir.0000034046.87607.1c;;12370212;;10086387;;10.1038/6529;;10.1182/blood.v97.5.1227;;11222364;;11594767;;10.1006/bbrc.2001.5712;;11487017;;6382294;;1896551;;10.1097/00006534-199110000-00038;;10.1097/00003086-199810001-00026;;9917645;;11884830;;10.1097/00006534-200203000-00037;;10.1152/ajpendo.2001.281.5.e1037;;11595661;;pmc370387;;6306056;;10.1172/jci110937;;12160849;;10.1016/s0301-472x(02)00867-6;;10.1016/s0736-0266(00)00010-3;;11332607;;11877271;;10.1182/blood.v99.6.1995;;10.1111/j.1749-6632.2001.tb03592.x;;11458511;;9048302;;10.1089/end.1997.11.67;;11105688;;10.1016/s0079-6123(00)28026-6;;10.1182/blood.v92.2.362.414k38_362_367;;9657732;;10.1182/blood.v92.2.362;;10.1038/7434;;10202935;;7881356;;10.1002/stem.5530120602;;pmc3839126;;24312129;;10.1155/2013/534263,"MASUDA, H.; C. KALKA; T. ASAHARA: ""Endothelial progenitor cells for regeneration"", HUM CELL, vol. 13, no. 4, 2000, pages 153 - 60;;KAUSHAL, S. ET AL.: ""Functional small-diameter neovessels created using endothelial progenitor cells expanded ex vivo"", NAT MED, vol. 7, no. 9, 2001, pages 1035 - 40;;KAWAMOTO, A. ET AL.: ""Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia"", CIRCULATION, vol. 103, no. 5, 2001, pages 634 - 7;;WILLIAMS, S. K.; S. MCKENNEY ET AL.: ""Collagenase lot selection and purification for adipose tissue digestion"", CELL TRANSPLANT, vol. 4, no. 3, 1995, pages 281 - 9;;TWENTYMAN, P. R.; J. M. YUHAS: ""Use of bacterial neutral protease for disaggregation of mouse tumours and multicellular tumor spheroids"", CANCER LETT, vol. 9, no. 3, 1980, pages 225 - 8;;RUSSELL, S. W.; W. F. DOE ET AL.: ""Inflammatory cells in solid murine neoplasms. 1. Tumor disaggregation and identification of constituent inflammatory cells"", INT J CANCER, vol. 18, no. 3, 1976, pages 322 - 30;;ENGELHOLM, S. A.; M. SPANG-THOMSEN ET AL.: ""Disaggregation of human solid tumours by combined mechanical and enzymatic methods"", BR J CANCER, vol. 51, no. 1, 1985, pages 93 - 8;;HEMSTREET, G. P., 3RD; P. G. ENOCH ET AL.: ""Tissue disaggregation of human renal cell carcinoma with further isopylcnic and isokinetic gradient purification"", CANCER RES, vol. 40, no. 4, 1980, pages 1043 - 9;;SCHWEITZER, C. M. ET AL.: ""Isolation and culture of human bone marrow endothelial cells"", EXL3 HEMATOL, vol. 23, no. 1, 1995, pages 41 - 8;;GRYN, J.; R. K. SHADDUCK ET AL.: ""Factors affecting purification of CD34(+) peripheral blood stem cells using the Baxter Isolex 300i"", J HEMATOTHER STEM CELL RES, vol. 11, no. 4, 2002, pages 719 - 30;;PRINCE, H. M.; J. BASHFORD ET AL.: ""Isolex 300i CD34-selected cells to support multiple cycles of high-dose therapy"", CYTOTHERAPY, vol. 4, no. 2, 2002, pages 137 - 45;;WATTS, M. J.; T. C. SOMERVAILLE ET AL.: ""Variable product purity and functional capacity after CD34 selection: a direct comparison of the CliniMACS (v2.1) and Isolex 300i (v2.5) clinical scale devices"", BR J HAEMATOL, vol. 118, no. 1, 2002, pages 117 - 23;;MAINWARING, G.; A. F. ROWLEY: ""Separation of leucocytes in the dogfish (Scyliorhinus canicula) using density gradient centrifugation and differential adhesion to glass coverslips"", CELL TISSUE RES, vol. 241, no. 2, 1985, pages 283 - 90;;GREENBERG, A. W.; D. A. HAMMER: ""Cell separation mediated by differential rolling adhesion"", BIOTECHNOL BIOENG, vol. 73, no. 2, 2001, pages 111 - 24;;SOLI, M. ET AL.: ""A multicentre evaluation of a new filtration protocol for leucocyte depletion of high-haematocrit red blood cells collected by an automated blood collection system"", VOX SANG, vol. 81, no. 2, 2001, pages 108 - 12;;SMITH, J.W.: ""Apheresis techniques and cellular immunomodulation"", THER APHER, vol. 1, no. 3, 1997, pages 203 - 6;;BERDEL, W.E. ET AL.: ""Purification of human monocytes by adherence to polymeric fluorocarbon. Characterization of the monocyte-enriched cell fraction"", IMMUNOBIOLOGY, vol. 163, no. 5, 1982, pages 511 - 20;;BICKENBACH, J.R.; E. CHISM: ""Selection and extended growth of murine epidermal stem cells in culture"", EXP CELL RES, vol. 244, no. 1, 1998, pages 184 - 95;;GEISELHART, A. ET AL.: ""Positive selection of CD56+ lymphocytes by magnetic cell sorting"", NAT HNMUN, vol. 15, no. 5, 1996, pages 227 - 33;;FORMANEK, M. ET AL.: ""Magnetic cell separation for purification of human oral keratinocytes: an effective method for functional studies without prior cell subcultivation"", EUR ARCH OTORHINOLARYNGOL, vol. 255, no. 4, 1998, pages 211 - 5;;GRAEPLER, F.; U. LAUER; M. GREGOR: ""Magnetic cell sorting for parietal cell purification using a new monoclonal antibody without influence on cell function"", J BIOCHEM BIOPHYS METHODS, vol. 36, no. 2-3, 1998, pages 143 - 55;;KOBARI, L. ET AL.: ""CD133+ cell selection is an alternative to CD34+ cell selection for ex vivo expansion of hematopoietic stem cells"", J HEMATOTHER STEM CELL RES, vol. 10, no. 2, 2001, pages 273 - 81;;MOHR, M. ET AL.: ""Simultaneous immunomagnetic CD34+ cell selection and B-cell depletion in peripheral blood progenitor cell samples of patients suffering from B-cell non-Hodgkin's lymphoma"", CLIN CANCER RES, vol. 7, no. 1, 2001, pages 51 - 7;;PUGH, R.E. ET AL.: ""CD19 selection improves the sensitivity of B cell lymphoma detection"", J HEMATOTHER, vol. 7, no. 2, 1998, pages 159 - 68;;REYES, M. ET AL.: ""Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells"", BLOOD, vol. 98, no. 9, 2001, pages 2615 - 25;;JOYNER, C.J. ET AL.: ""Development of a monoclonal antibody to the aP2 protein to identify adipocyte precursors in tumours of adipose differentiation"", PATHOL RES PRACT, vol. 195, no. 7, 1999, pages 461 - 6;;QUIRICI, N. ET AL.: ""Isolation of bone marrow mesenchymal stem cells by anti-nerve growth factor receptor antibodies"", EXP HEMATOL, vol. 30, no. 7, 2002, pages 783 - 91;;CIVIN, C.I ET AL.: ""Positive stem cell selection--basic science"", PROG CLIN BIOL RES, vol. 333, no. 387, 1990, pages 387 - 401;;QIAN, X.; L. JIN; R.V. LLOYD: ""Percoll Density Gradient-Enriched Populations of Rat Pituitary Cells: Interleukin 6 Secretion, Proliferative Activity, and Nitric Oxide Synthase Expression"", ENDOCR PATHOL, vol. 9, no. 1, 1998, pages 339 - 346;;SMITS, G.; W. HOLZGREVE; S. HAHN: ""An examination of different Percoll density gradients and magnetic activated cell sorting (MACS) for the enrichment of fetal erythroblasts from maternal blood"", ARCH GYNECOL OBSTET, vol. 263, no. 4, 2000, pages 160 - 3;;LEHNER, M.; W. HOLTER: ""Endotoxin-free purification of monocytes for dendritic cell generation via discontinuous density gradient centrifugation based on diluted Ficoll-Paque Plus"", INT ARCH ALLERGY IMMUNOL, vol. 128, no. 1, 2002, pages 73 - 6;;VAN MERRIS, V. ET AL.: ""Separation of bovine bone marrow into maturation-related myeloid cell fractions"", VET IMMUNOL IMMUNOPATHOL, vol. 83, no. 1-2, 2001, pages 11 - 7;;LASCH, J.; G. KULLERTZ; J.R. OPALKA: ""Separation of erythrocytes into age-related fractions by density or size? Counterflow centrifugation"", CLIN CHEM LAB MED, vol. 38, no. 7, 2000, pages 629 - 32;;ITO, Y.; K. SHINOMIYA: ""A new continuous-flow cell separation method based on cell density: principle, apparatus, and preliminary application to separation of human buffy coat"", J CLIN APHERESIS, vol. 16, no. 4, 2001, pages 186 - 91;;DLUBEK, D. ET AL.: ""Enrichment of normal progenitors in counter-flow centrifugal elutriation (CCE) fractions of fresh chronic myeloid leukemia leukapheresis products"", EUR J HAEMATOL, vol. 68, no. 5, 2002, pages 281 - 8;;JAISWAL, N. ET AL.: ""Osteogenic differentiation of purified, culture-expanded human mesenchymal stem cells in vitro"", J CELL BIOCHEM, vol. 64, no. 2, 1997, pages 295 - 312;;HOU, L. ET AL.: ""Study of in vitro expansion and differentiation into neuron-like cells of human umbilical cord blood mesenchymal stem cells"", ZHONGHUA XUE YE XUE ZA ZHI, vol. 23, no. 8, 2002, pages 415 - 9;;SEKIYA, I. ET AL.: ""Expansion of Human Adult Stem Cells from Bone Marrow Stroma: Conditions that Maximize the Yields of Early Progenitors and Evaluate Their Quality"", STEM CELLS, vol. 20, no. 6, 2002, pages 530 - 41;;MOSCA, J. D.; J. K. HENDRICKS ET AL.: ""Mesenchymal stem cells as vehicles for gene delivery"", CLIN ORTHOP, vol. 379, 2000, pages 71 - 90;;WALTHER, W.; U. STEIN: ""Viral vectors for gene transfer: a review of their use in the treatment of human diseases"", DRUGS, vol. 60, no. 2, 2000, pages 249 - 71;;ATHANASOPOULOS, T.; S. FABB ET AL.: ""Gene therapy vectors based on adeno-associated virus: characteristics and applications to acquired and inherited diseases (review)"", INT J MOL MED, vol. 6, no. 4, 2000, pages 363 - 75;;MURAMATSU, T.; A. NAKAMURA ET AL.: ""In vivo electroporation: a powerful and convenient means of nonviral gene transfer to tissues of living animals (Review)"", INT J MOL MED, vol. 1, no. 1, 1998, pages 55 - 62;;GIMBLE, J. M.; C. MORGAN ET AL.: ""Bone morphogenetic proteins inhibit adipocyte differentiation by bone marrow stromal cells"", J CELL BIOCHEM, vol. 58, no. 3, 1995, pages 393 - 402;;LENNON, D. P.; S. E. HAYNESWORTH ET AL.: ""A chemically defined medium supports in vitro proliferation and maintains the osteochondral potential of rat marrow-derived mesenchymal stem cells"", EXP CELL RES, vol. 219, no. 1, 1995, pages 211 - 22;;MAJUMDAR, M. K.; M. A. THIEDE ET AL.: ""Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (MSCs) and stromal cells"", J CELL PHYSIOL, vol. 176, no. 1, 1998, pages 57 - 66;;CAPLAN, A. I.; V. M. GOLDBERG: ""Principles of tissue engineered regeneration of skeletal tissues"", CLIN ORTHOP, vol. 367, 1999, pages 12 - 6;;OHGUSHI, H.; A. I. CAPLAN: ""Stem cell technology and bioceramics: from cell to gene engineering"", J BIOMED MATER RES, vol. 48, no. 6, 1999, pages 913 - 27;;PITTENGER, M. F.; A. M. MACKAY ET AL.: ""Multilineage potential of adult human mesenchymal stem cells"", SCIENCE, vol. 284, no. 5411, 1999, pages 143 - 7;;CAPLAN, A. 1.; S. P. BRUDER: ""Mesenchymal stem cells: building blocks for molecular medicine in the 21st century"", TRENDS MOL MED, vol. 7, no. 6, 2001, pages 259 - 64;;FUKUDA, K.: ""Development of regenerative cardiomyocytes from mesenchymal stem cells for cardiovascular tissue engineering"", ARTIF ORGANS, vol. 25, no. 3, 2001, pages 187 - 93;;WORSTER, A. A.; B. D. BROWER-TOLAND ET AL.: ""Chondrocytic differentiation of mesenchymal stem cells sequentially exposed to transforming growth factor-betal in monolayer and insulin- like growth factor-I in a three-dimensional matrix"", J ORTHOP RES, vol. 19, no. 4, 2001, pages 738 - 49;;ZUK, P. A.; M. ZHU ET AL.: ""Multilineage cells from human adipose tissue: implications for cell- based therapies"", TISSUE ENG, vol. 7, no. 2, 2001, pages 211 - 28;;MIZUNO, H.; P. A. ZUK ET AL.: ""Myogenic differentiation by human processed lipoaspirate cells"", PLAST RECONSTR SURG, vol. 109, no. 1, 2002, pages 199 - 209;;LIND, M.: ""Growth factor stimulation of bone healing. Effects on osteoblasts, osteomies, and implants fixation"", ACTA ORTHOP SCAND SUPPL, vol. 283, 1998, pages 2 - 37;;HANADA, K.; J.E. DENNIS; A.I. CAPLAN: ""Stimulatory effects of basic fibroblast growth factor and bone morphogenetic protein-2 on osteogenic differentiation of rat bone marrow-derived mesenchymal stem cells"", J BONE MINER RES, vol. 12, no. 10, 1997, pages 1606 - 14;;LIEBERMAN, J.R. ET AL.: ""Regional gene therapy with a BMP-2-producing murine stromal cell line induces heterotopic and orthotopic bone formation in rodents"", J ORTHOP RES, vol. 16, no. 3, 1998, pages 330 - 9;;JEAN, J.L.; S.J. WANG; M.K. AU: ""Treatment of a large segmental bone defect with allograft and autogenous bone marrow graft"", J FORMOS MED ASSOC, vol. 96, no. 7, 1997, pages 553 - 7;;SAADEH, P.B. ET AL.: ""Repair of a Critical Size Defect in the Rat Mandible Using Allogenic Type I Collagen"", J CRANIOFAC SURG, vol. 12, no. 6, 2001, pages 573 - 579;;PETITE, H. ET AL.: ""Tissue-engineered bone regeneration"", NAT BIOTECHNOL, vol. 18, no. 9, 2000, pages 959 - 63;;GAO, J. ET AL.: ""Tissue-Engineered Fabrication of an Osteochondral Composite Graft Using Rat Bone Marrow-Derived Mesenchymal Stem Cells"", TISSUE ENG, vol. 7, no. 4, 2001, pages 363 - 71;;OHGUSHI, H.; A.I. CAPLAN: ""Stem cell technology and bioceramics: from cell to gene engineering"", J BIOMED MATER RES, vol. 48, no. 6, 1999, pages 913 - 27;;CAPLAN, A.I.; V.M. GOLDBERG: ""Principles of tissue engineered regeneration of skeletal tissues"", CLIN ORTHOP, vol. 367, 1999, pages 12 - 6;;CAPLAN, A.I.; S.P. BRUDER: ""Mesenchymal stem cells: building blocks for molecular medicine in the 21st century"", TRENDS MOL MED, vol. 7, no. 6, 2001, pages 259 - 64;;ZUK, P.A. ET AL.: ""Multilineage cells from human adipose tissue: implications for cell- based therapies"", TISSUE ENG, vol. 7, no. 2, 2001, pages 211 - 28;;LUSKEY, B.D. ET AL.: ""Gene transfer into murine hematopoietic stem cells and bone marrow stromal cells"", ANN N Y ACAD SCI, vol. 612, no. 398, 1990, pages 398 - 406;;GROMPE, M. ET AL.: ""Therapeutic trials in the murine model of hereditary tyrosinaemia type I: a progress report"", J INHERIT METAB DIS, vol. 21, no. 5, 1998, pages 518 - 31;;GAZIT, D. ET AL.: ""Engineered pluripotent mesenchymal cells integrate and differentiate in regenerating bone: a novel cell-mediated gene therapy"", J GENE MED, vol. 1, no. 2, 1999, pages 121 - 33;;MOSCA, J.D. ET AL.: ""Mesenchymal stem cells as vehicles for gene delivery"", CLIN ORTHOP, vol. 379, 2000, pages 71 - 90;;GREENBERG, A.W.; D.A. HAMMER: ""Cell separation mediated by differential rolling adhesion"", BIOTECHNOL BIOENG, vol. 73, no. 2, 2001, pages 111 - 24;;MAINWARING, G.; A.F. ROWLEY: ""Separation of leucocytes in the dogfish (Scyliorhinus canicula) using density gradient centrifugation and differential adhesion to glass coverslips"", CELL TISSUE RES, vol. 241, no. 2, 1985, pages 283 - 90;;SCHWEITZER, C.M. ET AL.: ""Isolation and culture of-human bone marrow endothelial cells"", EXP HEMATOL, vol. 23, no. 1, 1995, pages 41 - 8;;COLEMAN, S. R.: ""Long-term survival of fat transplants: controlled demonstrations"", AESTHETIC PLAST SURG, vol. 19, no. 5, 1995, pages 421 - 5;;COLEMAN, S. R.: ""Structural fat grafts: the ideal filler?"", CLIN PLAST SURG, vol. 28, no. 1, 2001, pages 111 - 9;;COLEMAN, W. P.: ""Plast Reconstr Surg"", vol. 88, 1991, article ""Autologous fat transplantation"", pages: 736;;EREMIA, S.; N. NEWMAN: ""Long-term follow-up after autologous fat grafting: analysis of results from 116 patients followed at least 12 months after receiving the last of a minimum of two treatments"", DERMATOL SURG, vol. 26, no. 12, 2000, pages 1150 - 8;;GUERREROSANTOS, J.; A. GONZALEZ-MENDOZA ET AL.: ""Long-term survival of free fat grafts in muscle: an experimental study in rats"", AESTHETIC PLAST SURG, vol. 20, no. 5, 1996, pages 403 - 8;;PALMA, P. C.; C. L. RICCETTO ET AL.: ""Repeated lipoinjections for stress urinary incontinence"", J ENDOUROL, vol. 11, no. 1, 1997, pages 67 - 70;;LEE, P. E.; R. C. KUNG ET AL.: ""Periurethral autologous fat injection as treatment for female stress urinary incontinence: a randomized double-blind controlled trial"", J UROL, vol. 165, no. 1, 2001, pages 153 - 8;;LEE, J. H.; Z. ILIC ET AL.: ""Cell kinetics of repair after allyl alcohol-induced liver necrosis in mice"", INT J EXP PATHOL, vol. 77, no. 2, 1996, pages 63 - 72;;WERLICH, T.; K. J. STILLER ET AL.: ""Experimental studies on the stem cell concept of liver regeneration. n"", EXP TOXICOL PATHOL, vol. 51, no. 1, 1999, pages 93 - 8;;YIN, L.; D. LYNCH ET AL.: ""Participation of different cell types in the restitutive response of the rat liver to periportal injury induced by allyl alcohol"", J HEPATOL, vol. 31, no. 3, 1999, pages 497 - 507;;YAVORKOVSKY, L.; E. LAI ET AL.: ""Participation of small intraportal stem cells in the restitutive response of the liver to periportal necrosis induced by allyl alcohol"", HEPATOLOGY, vol. 21, no. 6, 1995, pages 1702 - 12;;WERLICH, T.; K. J. STILLER ET AL.: ""Experimental studies on the stem cell concept of liver regeneration. II"", EXP TOXICOL PATHOL, vol. 51, no. 1, 1999, pages 93 - 8;;MURRY, C. E.; R. W. WISEMAN ET AL.: ""Skeletal myoblast transplantation for repair of myocardial necrosis"", J CLIN INVEST, vol. 98, no. 11, 1996, pages 2512 - 23;;ORLIC, D.; J. KAJSTURA ET AL.: ""Bone marrow cells regenerate infarcted myocardium"", NATURE, vol. 410, no. 6829, 2001, pages 701 - 5;;RAJNOCH, C.; J. C. CHACHQUES ET AL.: ""Cellular therapy reverses myocardial dysfunction"", J THORAC CARDIOVASC SURG, vol. 121, no. 5, 2001, pages 871 - 8;;STRAUER, B. E.; M. BREHM ET AL.: ""Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans"", CIRCULATION, vol. 106, no. 15, 2002, pages 1913 - 8;;HORWITZ, E. M.; D. J. PROCKOP ET AL.: ""Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta"", NAT MED, vol. 5, no. 3, 1999, pages 309 - 13;;HORWITZ, E. M.; D. J. PROCKOP ET AL.: ""Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta"", BLOOD, vol. 97, no. 5, 2001, pages 1227 - 31;;AVITAL, L; D. INDERBITZIN ET AL.: ""Isolation, characterization, and transplantation of bone marrow-derived hepatocyte stem cells"", BIOCHEM BIOPHYS RES COMMUN, vol. 288, no. 1, 2001, pages 156 - 64;;CARMELIET, P.; A. LUTTUN: ""The emerging role of the bone marrow-derived stem cells in (therapeutic) angiogenesis"", THROMB HAEMOST, vol. 86, no. 1, 2001, pages 289 - 97;;CASTRO-MALASPINA, H.; W. EBELL ET AL.: ""Human bone marrow fibroblast colony-forming units (CFU-F)"", PROG CLINBIOL RES, vol. 154, 1984, pages 209 - 36;;COLEMAN, W. P., 3RD: ""Autologous fat transplantation"", PLAST RECONSTR SURG, vol. 88, no. 4, 1991, pages 736;;CONNOLLY, J. F.: ""Clinical use of marrow osteoprogenitor cells to stimulate osteogenesis"", CLIN ORTHOP, vol. 355, 1998, pages 257 - 66;;HUANG, J. L; S. R. BEANES ET AL.: ""Rat extramedullary adipose tissue as a source of osteochondrogenic progenitor cells"", PLAST RECONSTR SURG, vol. 109, no. 3, 2002, pages 1033 - 41;;HUTLEY, L. J.; A. C. HERINGTON ET AL.: ""Human adipose tissue endothelial cells promote preadipocyte proliferation"", AM J PHYSIOL ENDOCRINOL METAB, vol. 281, no. 5, 2001, pages 037 - 44;;KERN, P. A.; A. KNEDLER ET AL.: ""Isolation and culture of microvascular endothelium from human adipose tissue"", J CLIN INVEST, vol. 71, no. 6, 1983, pages 1822 - 9;;MURAYAMA, T.; O. M. TEPPER ET AL.: ""Determination of bone marrow-derived endothelial progenitor cell significance in angiogenic growth factor-induced neovascularization in vivo"", EXP HEMATOL, vol. 30, no. 8, 2002, pages 967 - 72;;MUSCHLER, G. F.; H. NITTO ET AL.: ""Age- and gender-related changes in the cellularity of human bone marrow and the prevalence of osteoblastic progenitors"", J ORTHOP RES, vol. 19, no. 1, 2001, pages 117 - 25;;NISHIMORI, M.; Y. YAMADA ET AL.: ""Health-related quality of life of unrelated bone marrow donors in Japan"", BLOOD, vol. 99, no. 6, 2002, pages 1995 - 2001;;ORLIC, D.; J. KAJSTURA ET AL.: ""Transplanted adult bone marrow cells repair myocardial infarcts in mice"", ANN N Y ACAD SCI, vol. 938, 2001, pages 221 - 9;;PAHNA, P. C.; C. L. RICCETTO ET AL.: ""Repeated lipoinjections for stress urinary incontinence"", J ENDOUROL, vol. 11, no. 1, 1997, pages 67 - 70;;PROCKOP, D. J.; S. A. AZIZI ET AL.: ""Potential use of marrow stromal cells as therapeutic vectors for diseases of the central nervous system"", PROG BRAIN RES, vol. 128, 2000, pages 293 - 7;;SHI, Q.; S. RAFII ET AL.: ""Evidence for circulating bone marrow-derived endothelial cells"", BLOOD, vol. 92, no. 2, 1998, pages 362 - 7;;TAKAHASHI, T.; C. KALKA ET AL.: ""Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization"", NAT MED, vol. 5, no. 4, 1999, pages 434 - 8;;THOMAS, E. D.: ""Stem Cell Transplantation: Past, Present and Future"", STEM CELLS, vol. 12, 1994, pages 539 - 544;;KOELLENSPERGER EVA ET AL: ""Human adipose tissue derived stem cells promote liver regeneration in a rat model of toxic injury."", STEM CELLS INTERNATIONAL 2013, vol. 2013, 2013, pages 534263, ISSN: 1687-966X",DISCONTINUED
602,DK,T3,DK 3290513 T3,063-406-886-291-13X,2022-12-12,2022,DK 17186206 T,2005-06-01,US 57599704 P;;US 63922204 P;;EP 05755269 A,2004-06-01,SAMMENSÆTNINGER OG FREMGANGSMÅDER TIL FORHINDRING AF AAV-VEKTORAGGREGERING,,GENZYME CORP,WRIGHT JOHN FRASER;;QU GUANG,,https://lens.org/063-406-886-291-13X,Granted Patent,no,0,0,33,34,0,C12N2750/14151;;C12N7/00;;C12N2750/14151;;C12N7/00;;C12N2750/14111,C12N7/00;;C12N7/02,,0,0,,,,ACTIVE
603,US,A1,US 2005/0042740 A1,065-730-416-094-163,2005-02-24,2005,US 85168804 A,2004-05-21,US 85168804 A;;US 47238403 P;;US 54975604 P,2003-05-21,Methods for producing preparations of recombinant AAV virions substantially free of empty capsids,Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.,QU GUANG;;WRIGHT JOHN FRASER,QU GUANG;;WRIGHT JOHN FRASER,AVIGEN INC (2004-08-27);;GENZYME CORPORATION (2007-09-25),https://lens.org/065-730-416-094-163,Patent Application,yes,1,8,40,41,0,C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N15/86;;C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N2710/16651;;C12N2710/10351;;C12N2760/16051;;C12N15/86,C12N/;;C12N7/02;;C12N15/86;;C12N15/864,435/239;;435/456,0,0,,,,ACTIVE
604,EP,A4,EP 3534967 A4,071-269-626-719-39X,2020-07-22,2020,EP 17866596 A,2017-11-07,US 201662418637 P;;US 2017/0060413 W,2016-11-07,RAB ESCORT PROTEIN POTENCY ASSAY,,SPARK THERAPEUTICS INC,WRIGHT JOHN FRASER;;SUMAROKA MARINA,,https://lens.org/071-269-626-719-39X,Search Report,no,0,0,11,11,0,C12Y205/0106;;C12Q1/48;;G01N2333/91171;;C12N9/1085;;C12Q1/48;;G01N2333/91171;;C12Y205/0106,C12Q1/48;;A61K48/00;;C12N9/10;;C12N15/86,,4,4,065-428-410-152-230;;037-561-168-178-287;;060-944-441-451-240;;099-610-276-486-903,pmc4362346;;10.1038/mtm.2014.11;;26015956;;10.1007/s00109-013-1006-4;;pmc3695676;;23756766;;pmc3646845;;10.1371/journal.pone.0061396;;23667438;;10.1016/s0042-6989(02)00389-9;;12668061,"NICOLAS CERESO ET AL: ""Proof of concept for AAV2/5-mediated gene therapy in iPSC-derived retinal pigment epithelium of a choroideremia patient"", MOLECULAR THERAPY - METHODS & CLINICAL DEVELOP, vol. 1, 1 January 2014 (2014-01-01), GB, pages 14011, XP055699447, ISSN: 2329-0501, DOI: 10.1038/mtm.2014.11;;TANYA TOLMACHOVA ET AL: ""Functional expression of Rab escort protein 1 following AAV2-mediated gene delivery in the retina of choroideremia mice and human cells ex vivo"", JOURNAL OF MOLECULAR MEDICINE, vol. 91, no. 7, 12 June 2013 (2013-06-12), pages 825 - 837, XP055110987, ISSN: 0946-2716, DOI: 10.1007/s00109-013-1006-4;;VIDYULLATHA VASIREDDY ET AL: ""AAV-Mediated Gene Therapy for Choroideremia: Preclinical Studies in Personalized Models"", PLOS ONE, vol. 8, no. 5, 7 May 2013 (2013-05-07), pages 1 - 13, XP055111001, DOI: 10.1371/journal.pone.0061396;;VIBHA ANAND ET AL: ""Gene therapy for choroideremia: in vitro rescue mediated by recombinant adenovirus"", VISION RESEARCH, vol. 43, no. 8, 1 April 2003 (2003-04-01), AMSTERDAM, NL, pages 919 - 926, XP055495142, ISSN: 0042-6989, DOI: 10.1016/S0042-6989(02)00389-9",PENDING
605,GB,A,GB 1120038 A,076-811-320-426-42X,1968-07-17,1968,GB 2413465 A,1965-06-08,GB 2413465 A,1965-06-08,A method of and apparatus for the manufacture of candlewick fabric,"1,120,038. Tufting apparatus; pile fabrics; finishing fabrics. DOUGLAS FRASER & SONS (MANUFACTURING). 1 Sept., 1966 [8 June, 1965], No. 24134/65. Headings D1G, D1K and D1S. A double-sided candlewick fabric is made by forming a first series of rows of tufting on one side of a base fabric on a multi-needle tufting machine and then forming a second series of rows of tufting on the reverse side of the fabric, alternating between the first series of rows, on a multi-needle machine employing a presser foot 2 having ribs 3 with holes 5 for the passage of the tufting needles and channels 4 for the free passage of the first series of rows of tufts. The loops passed through the base fabric are engaged by a looper and cut. The base fabric may be muslin and the pile a heavy cotton yarn. The pile fabric may be dampened and tumble dried to shrink the base fabric about the tufts which burst to give a bloom to the finished material.",DOUGLAS FRASER & SONS MFG LTD,FRASER KEITH HAMILTON;;CHERRIE JOHN,,https://lens.org/076-811-320-426-42X,Granted Patent,no,0,2,1,1,0,D05C15/00,D05C15/00,D1G GDA           GDA;;D1G GE            GE;;D1G G1F6          -;;D1G G2H1A         -;;D1G G5            -;;D1K K20F          -;;D1S S10           -;;D1S S18           -,0,0,,,,EXPIRED
606,WO,A1,WO 2014/145578 A1,074-948-058-917-913,2014-09-18,2014,US 2014/0030370 W,2014-03-17,US 201361787818 P,2013-03-15,SCALABLE MANUFACTURING PROCESS TO PRODUCE RECOMBINANT LENTIVIRAL VECTORS IN SERUM-FREE SUSPENSION CELL CULTURE SYSTEM,Methods for preparing highly purified rLV vector formulations at the scale needed to meet anticipated demand for human gene therapy are provided.,PHILADELPHIA CHILDREN HOSPITAL,QU GUANG;;WRIGHT JOHN FRASER,,https://lens.org/074-948-058-917-913,Patent Application,yes,6,14,29,29,0,C12N7/00;;C12N2740/15043;;C12N2740/15051;;A61K48/0091;;A61K48/0091;;C12N2740/15043;;C12N2740/15051;;C12N7/00;;A61K48/0091;;C12N7/00;;C12N7/00;;C12N2740/15043;;C12N2740/15051;;A61K48/0091,C12N7/02,,4,3,016-991-047-300-811;;083-247-370-685-779;;074-175-001-656-837,10.1016/j.jviromet.2011.01.013;;21295608;;10.1016/j.bej.2009.10.017;;10352135;;10.2741/klimatcheva,"ZHOU ET AL.: ""PEG-modulated column chromatography for purification of recombinant adeno- associated virus serotype 9."", J VIROL METHODS, vol. 173, no. 1, April 2011 (2011-04-01), pages 99 - 107, XP028174767;;ANSORGE ET AL.: ""Recent progress in lentiviral vector mass production."", BIOCHEMICAL ENGINEERING JOURNAL, vol. 48, no. 3, 15 February 2010 (2010-02-15), pages 362 - 377, XP026886643;;KLIMATCHEVA ET AL.: ""Frontiers in Bioscience"", vol. 4, 1999, pages: 481 - 496;;See also references of EP 2970920A4",PENDING
607,DE,T2,DE 60008945 T2,095-640-238-647-018,2005-01-27,2005,DE 60008945 T,2000-01-26,US 24874799 A,1999-02-12,Drehmomentwandler-Überbrückungskupplung,,LAWRENCE TECHNOLOGICAL UNIVERS,MACDONALD FRASER JOHN;;HARGRAVE DAVID,,https://lens.org/095-640-238-647-018,Granted Patent,no,0,0,6,6,0,F16H45/02;;F16H45/02;;F16H2045/0294;;F16H2045/0294,F16H45/02,,0,0,,,,EXPIRED
608,US,A1,US 2020/0060655 A1,100-803-057-477-593,2020-02-27,2020,US 201916666646 A,2019-10-29,US 201916666646 A;;US 201313990201 A;;IB 2011055546 W;;US 42247910 P,2010-12-13,ADJUSTING MEASUREMENTS OF THE EFFECTS OF ACOUSTIC RADIATION FORCE FOR BACKGROUND MOTION EFFECTS,An ultrasonic diagnostic imaging system for shear wave measurement transmits push pulses into tissue for the generation of shear waves. Characteristics of the shear waves such as their velocity of passage through the tissue are measured to assess properties such as tissue stiffness. The measurements are compensated for effects of background motion by sampling echo signals from the tissue at different times and comparing the samples to detect the presence of relative motion between the ultrasound probe and the region of interest where shear waves are detected. Sensed background motion is used to adjust measured shear wave characteristics.,KONINKLIJKE PHILIPS NV,FRASER JOHN DOUGLAS;;XIE HUA,,https://lens.org/100-803-057-477-593,Patent Application,yes,0,1,14,14,0,A61B8/0825;;A61B8/4488;;A61B8/5276;;G01S7/52036;;G01S7/52042;;G01S7/5205;;G01S7/52095;;G01S15/8925;;A61B8/485;;A61B8/4488;;A61B8/485;;G01S7/52036;;A61B8/4488;;A61B8/5276;;G01S7/52036;;A61B8/0825;;G01S7/52042;;G01S7/5205;;G01S7/52095;;G01S15/8925;;A61B8/485,A61B8/08;;A61B8/00;;G01S7/52,,0,0,,,,ACTIVE
609,JP,A,JP 2014031389 A,101-602-541-429-652,2014-02-20,2014,JP 2013242179 A,2013-11-22,US 33885601 P,2001-12-07,SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS,PROBLEM TO BE SOLVED: To treat patients by using cells present in processed lipoaspirate tissue.SOLUTION: Methods of treating patients comprise processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to the patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient.,CYTORI THERAPEUTICS INC,FRASER JOHN;;HENDRICK MARC H,,https://lens.org/101-602-541-429-652,Patent Application,no,3,6,65,221,0,A61K35/28;;A61K35/28;;A61K48/00;;A61B10/0283;;A61B10/0283;;A61K9/0019;;A61K9/0019;;A61K35/32;;A61K35/35;;A61K35/35;;A61K35/36;;A61M1/76;;A61M2202/08;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/00;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;A61P43/00;;C12M47/04;;C12N5/0667;;C12N5/0667;;C12N5/069;;C12N5/069;;C12N2506/1384;;C12N2506/1384,A61K35/12;;A61M1/00;;A61K31/436;;A61K35/02;;A61K35/28;;A61K35/35;;A61K35/36;;A61K38/00;;A61K38/16;;A61K45/00;;A61L27/00;;A61P1/00;;A61P1/16;;A61P3/00;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;A61P43/00;;C12M3/06;;C12N5/0775,,2,0,,,"JPN6012048561; ＳＯＭＭＥＲ，Ｂ． ｅｔ ａｌ: 'Ｃｕｒｒｅｎｔ ｃｏｎｃｅｐｔｓ ｏｆ ｆａｔ ｇｒａｆｔ ｓｕｒｖｉｖａｌ： ｈｉｓｔｏｌｏｇｙ ｏｆ ａｓｐｉｒａｔｅｄ ａｄｉｐｏｓｅ ｔｉｓｓｕｅ ａｎｄ ｒｅｖｉｅｗ ｏｆ ｔｈｅ ｌｉｔｅ' Ｄｅｒｍａｔｏｌｏｇｉｃ ｓｕｒｇｅｒｙ Ｖｏｌ．２６， Ｎｏ．１２, 2000, ｐ．１１５９-１１６６;;JPN6012048564; ＺＵＫ，Ｐ．Ａ． ｅｔ ａｌ: 'Ｍｕｌｔｉｌｉｎｅａｇｅ ｃｅｌｌｓ ｆｒｏｍ ｈｕｍａｎ ａｄｉｐｏｓｅ ｔｉｓｓｕｅ： ｉｍｐｌｉｃａｔｉｏｎｓ ｆｏｒ ｃｅｌｌ-ｂａｓｅｄ ｔｈｅｒａｐｉｅｓ' Ｔｉｓｓｕｅ Ｅｎｇ Ｖｏｌ．７， Ｎｏ．２, 200104, ｐ．２１１-２８",INACTIVE
610,BR,A2,BR 112019020217 A2,105-943-968-621-353,2020-04-22,2020,BR 112019020217 A,2018-04-12,US 2018/0027317 W;;EP 17000619 A,2017-04-12,material compósito retardador de fogo,"essa descrição refere-se a um material compósito retardador de fogo que compreende um plástico reforçado com fibra coberto por uma folha de alumínio e sua aplicação em indústrias de transporte de passageiros, como aeroespacial, ferroviário ou marítimo.",HUNTSMAN ADV MAT LICENSING SWITZERLAND GMBH,JOHN FRASER;;OLIVIER DE VERCLOS,,https://lens.org/105-943-968-621-353,Patent Application,no,0,0,8,8,0,B32B15/14;;B32B27/38;;B32B3/12;;B32B5/022;;B32B5/024;;B32B5/26;;B32B15/092;;B32B15/20;;B32B15/20;;B32B19/041;;B32B19/06;;B32B2260/023;;B32B2260/046;;B32B2262/02;;B32B2262/0269;;B32B2262/101;;B32B2262/106;;B32B2307/3065;;B32B2311/24;;B32B2363/00;;B32B2451/00;;B32B2605/00,B32B3/12;;B32B5/02;;B32B5/26;;B32B15/14;;B32B15/20;;B32B19/04;;B32B19/06,,0,0,,,,DISCONTINUED
611,EP,A1,EP 4170024 A1,124-211-974-984-922,2023-04-26,2023,EP 22193904 A,2005-06-01,US 57599704 P;;US 63922204 P;;EP 17186206 A;;EP 05755269 A;;US 2005/0019235 W,2004-06-01,COMPOSITIONS AND METHODS TO PREVENT AAV VECTOR AGGREGATION,"Compositions and methods are provided for preparation of concentrated stock solutions of AAV virions without aggregation. Formulations for AAV preparation and storage are high ionic strength solutions (e.g. µ ~500 mM) that are nonetheless isotonic with the intended target tissue. This combination of high ionic strength and modest osmolarity is achieved using salts of high valency, such as sodium citrate. AAV stock solutions up to 6.4x1013 vg/mL are possible using the formulations of the invention, with no aggregation being observed even after ten freeze-thaw cycles. The surfactant Pluronic ®  F68 may be added at 0.001% to prevent losses of virions to surfaces during handling. Virion preparations can also be treated with nucleases to eliminate small nucleic acid strands on virions surfaces that exacerbate aggregation.",GENZYME CORP,WRIGHT JOHN FRASER;;QU GUANG,,https://lens.org/124-211-974-984-922,Patent Application,yes,4,0,33,34,0,C12N2750/14151;;C12N7/00;;C12N2750/14151;;C12N7/00;;C12N2750/14111,C12N7/00;;C12N7/02,,27,18,001-478-717-191-668;;186-530-405-960-936;;072-653-024-592-144;;088-196-754-870-804;;012-648-145-502-050;;035-752-925-068-093;;029-321-799-330-385;;060-601-673-062-602;;008-498-374-187-896;;072-653-024-592-144;;089-786-895-898-348;;049-155-615-380-092;;081-231-772-265-33X;;010-284-533-720-722;;017-602-964-237-703;;056-841-143-148-239;;028-383-058-454-759;;020-396-894-870-872,10.1016/s1525-0016(16)42996-5;;10.1016/s1525-0016(16)40961-5;;12669452;;15963933;;10.1016/j.ymthe.2005.02.021;;10.1089/10430349950016799;;10543610;;10.1111/j.1749-6632.2001.tb11361.x;;11795424;;10.1146/annurev.genom.2.1.177;;11701648;;10.1073/pnas.162250899;;pmc124927;;12136130;;10.1038/sj.gt.3301527;;11571564;;12669452;;15488616;;10.1016/j.jviromet.2004.07.007;;10.12665/j13.bowe;;9358564;;10.1023/a:1012193326789;;10.1089/1043034041361262;;15298029;;10.1002/jps.2600831204;;7891291;;10.1002/jps.20079;;15124199;;10.1016/s0378-5173(99)00152-0;;10460913;;10.1038/sj.gt.3300680;;9813665,"QUICKR KAYLA S ET AL: ""166. Dynamic Light Scattering as a Useful Tool for the Physical Characterization of Recombinant Viral Vectors during Production and Development"", MOLECULAR THERAPY, VOL 5, NO 5, SUPPLEMENT, 1 May 2002 (2002-05-01), pages S56 - S57, XP093027911, Retrieved from the Internet <URL:https://www.cell.com/action/showPdf?pii=S1525-0016%2816%2942996-5> [retrieved on 20230301], DOI: 2;;SMITH JONATHAN ET AL: ""519. A Dynamic Light Scattering (DLS) Assay for the Analysis of Aggregated Adenovector Particles"", MOLECULAR THERAPY, VOL. 7, NO. 5, SUPPLEMENT, 1 May 2003 (2003-05-01), pages S202 - S203, XP093027928, Retrieved from the Internet <URL:https://www.cell.com/action/showPdf?pii=S1525-0016%2816%2940961-5> [retrieved on 20230301];;WRIGHT J FRASER ET AL: ""Recombinant adeno-associated virus: formulation challenges and strategies for a gene therapy vector."", CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT MAR 2003, vol. 6, no. 2, March 2003 (2003-03-01), pages 174 - 178, XP009092903, ISSN: 1367-6733;;WRIGHT J F ET AL: ""Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulation"", MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA,, US, vol. 12, no. 1, July 2005 (2005-07-01), pages 171 - 178, XP004974961, ISSN: 1525-0016;;GRIMM, D.KLEINSCHMIDT, J. A., HUM GENE THER., vol. 10, 1999, pages 2445 - 2450;;HIGH, K. A., ANN. N. Y. ACAD. SCI., vol. 953, 2001, pages 64 - 67;;PFEIFER, A.VERMA, I. M., ANN. REV. GENOMICS HUM. GENET., vol. 2, 2001, pages 177 - 211;;BERNS, K. I., FIELDS VIROLOGY, 1996, pages 2173 - 2197;;XIE, Q. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 99, 2002, pages 10405 - 10410;;CROYLE, M. A. ET AL., GENE THERAPY, vol. 8, 2001, pages 1281 - 1290;;HUANG, J ET AL.: ""1"", MOL. THERAPY, 2000, pages S286;;WRIGHT, J. F. ET AL., CURR. OPIN. DRUG DISC. DEV., vol. 6, 2003, pages 174 - 178;;XIE, Q. ET AL., J. VIROL. METHODS, vol. 122, 2004, pages 17 - 27;;XIE, Q. ET AL.: ""122"", J. VIRAL. METHODS, 2004, pages 17 - 27;;ADADEVOH, K. ET AL., BIOPROCESSING, vol. 1, no. 2, 2002, pages 62 - 69;;BRAUN, A. ET AL., PHARM. RES., vol. 14, 1997, pages 1472 - 1478;;CHENUAUD, P. ET AL., BLOOD, vol. 104, 2004, pages 121a - 3302;;FLOTTE, T. R., HUMAN GENE THER, 2004;;ZHEN, Z. ET AL., HUMAN GENE THER., vol. 15, 2004, pages 709 - 715;;MEIJER, K. D. F.MOLEMA, G., SEM. LIVER DIS, vol. 15, 1995, pages 206;;HUANG, J. ET AL., MOL. THERAPY, vol. 1, 2000, pages S286;;CHEN, B. ET AL., J. PHARM. SCI., vol. 83, 1994, pages 1657 - 1661;;SHIRE, S. J. ET AL., J. PHARM. SCI., vol. 93, 2004, pages 1390 - 1402;;WANG, W., INT. J. PHARM., vol. 185, 1999, pages 129 - 188;;WON, C. M. ET AL., INT. J. PHARM., vol. 167, 1998, pages 25 - 36;;SOMMER, J. M. ET AL., MOL. THERAPY, vol. 7, 2003, pages S348 - 128;;MATSUSHITA, T. ET AL., GENE THERAPY, vol. 5, 1998, pages 938 - 945",PENDING
612,US,B2,US 8784801 B2,147-507-879-507-228,2014-07-22,2014,US 201113031031 A,2011-02-18,US 201113031031 A;;US 2009/0054055 W;;US 9018608 P,2008-08-19,Methods of using adipose tissue-derived cells in the treatment of the lymphatic system and malignant disease,"Aspects of the invention provides methods for preparing and using adipose-tissue-derived stem and progenitor cells, adipose-tissue-derived lymphatic endothelial cells, and cells capable of differentiating into lymphatic endothelial cells to treat disorders of the lymphatic system and to modulate expansion, repair, and/or regeneration of the lymphatic system. The invention further provides using adipose-tissue-derived lymphatic endothelial cells and cells capable of differentiating into lymphatic endothelial cells for delivery of therapeutic agents to tumor cells as a means for treating malignant disease, and assays to screen for drugs that modulate lymphatic system expansion, repair or regeneration.",ALFONSO ZENI;;FRASER JOHN K;;CYTORI THERAPEUTICS INC,ALFONSO ZENI;;FRASER JOHN K,CYTORI THERAPEUTICS INC (2011-03-30);;LOREM VASCULAR PTE. LTD (2019-04-24),https://lens.org/147-507-879-507-228,Granted Patent,yes,103,10,6,6,0,A61K35/12;;A61K35/12;;A61K35/28;;A61K35/28;;A61K35/35;;A61K35/35;;A61K45/06;;A61K2035/124;;A61P3/06;;A61P9/00;;A61P35/04;;C12N5/0651;;C12N5/0651;;C12N5/0667;;C12N5/069;;C12N5/069,C12N5/00;;A61K35/12;;A61K35/28;;A61K35/35,424/93.7;;435/366,99,96,070-839-046-502-27X;;010-540-013-256-049;;134-654-757-212-403;;032-404-259-701-837;;001-174-850-465-856;;059-588-500-547-821;;042-989-386-993-552;;019-810-335-711-889;;014-008-860-336-482;;029-946-078-457-714;;075-284-732-479-861;;157-994-310-553-91X;;101-877-952-875-22X;;116-024-403-014-056;;071-709-364-692-057;;011-072-762-416-590;;027-803-020-078-075;;173-002-914-257-594;;007-172-022-414-518;;078-144-091-568-913;;047-253-510-312-524;;023-961-417-626-568;;116-871-349-386-357;;007-886-031-008-735;;030-049-294-751-075;;097-867-342-595-907;;015-569-025-003-488;;090-815-773-677-26X;;094-359-459-035-479;;004-182-422-100-243;;043-014-435-315-202;;007-742-922-258-989;;019-679-035-676-507;;106-649-915-724-737;;078-698-146-972-599;;020-939-213-381-300;;000-625-008-142-215;;114-069-508-870-517;;033-642-914-335-547;;160-132-718-714-712;;069-962-637-789-469;;008-762-489-429-146;;000-247-718-432-449;;113-062-358-749-472;;014-595-660-154-907;;091-397-407-383-437;;019-368-227-595-121;;042-772-099-513-918;;076-945-814-976-839;;149-453-463-380-579;;023-684-957-851-237;;005-376-980-059-70X;;035-961-317-498-39X;;006-652-397-889-647;;022-459-651-150-57X;;017-165-339-699-387;;018-369-175-290-657;;043-947-449-038-108;;055-646-074-155-100;;027-339-475-967-163;;125-995-223-966-197;;070-522-011-983-995;;031-206-044-096-031;;015-599-406-080-089;;108-799-353-449-53X;;069-205-374-732-453;;036-607-251-048-680;;003-264-302-978-919;;036-252-293-129-219;;019-888-471-790-198;;000-503-988-011-572;;009-545-708-254-047;;031-856-752-899-649;;123-956-839-153-069;;016-725-607-839-435;;023-915-407-391-147;;014-294-149-065-780;;068-189-597-689-823;;000-156-231-629-318;;003-050-327-178-826;;015-055-316-845-193;;033-814-301-870-318;;030-847-714-444-597;;060-272-195-296-337;;011-995-010-843-384;;028-547-919-869-891;;004-509-498-015-514;;020-498-500-483-165;;044-955-100-185-726;;042-873-767-839-626;;106-603-013-159-878;;063-946-362-236-807;;101-420-359-134-80X;;069-042-212-344-227;;086-462-532-224-686;;094-547-639-217-227,10.1002/jcp.10174;;12384991;;7540405;;10.1016/8756-3282(94)00044-1;;198274;;10.1016/0012-1606(77)90110-5;;6352350;;10.1051/rnd:19850201;;3887522;;10.1002/mus.880120705;;2674704;;15869434;;10.1089/ten.2005.11.556;;9579858;;10611546;;10.1089/ten.1999.5.545;;pmc1219645;;10.1042/bj3330787;;9677341;;9519353;;10.1159/000019544;;10.1053/ejvs.2001.1532;;11748945;;10.1038/nm747;;12161747;;10.1097/01.prs.0000055043.62589.05;;12711954;;10.1111/j.1524-4725.1990.tb01561.x;;2229639;;7646489;;10.1006/bbrc.1995.2141;;11181551;;10.1210/endo.142.3.8006;;10.1210/en.142.3.1325;;10.2337/diabetes.50.8.1691;;11473026;;10.1161/01.cir.0000043246.74879.cd;;12473544;;10998427;;10.3892/ijmm.6.4.363;;11594767;;10.1006/bbrc.2001.5712;;10.1002/jcp.10260;;12811816;;10.1016/s1043-2760(02)00010-3;;12475611;;10.1007/s002239900683;;10441651;;10.1083/jcb.144.4.789;;pmc2132933;;10037799;;11697641;;10.3109/10428190109097705;;10.1080/15513819809168768;;9566278;;10.1182/blood.v97.10.2957;;11342417;;10228193;;10.1056/nejm199905063401807;;10548503;;10.1006/bbrc.1999.1620;;10.1177/019459989010200402;;2136268;;6866054;;10.1056/nejm198308043090509;;10.1002/jbmr.5650111114;;8915778;;pmc6517823;;10.1111/j.1582-4934.2000.tb00125.x;;12067460;;2292654;;10.1182/blood.v77.12.2591.bloodjournal77122591;;1710512;;10.1182/blood.v77.12.2591.2591;;1757497;;10.1242/jcs.99.1.131;;10.1016/s0171-2985(82)80064-8;;6984421;;3489608;;10.1210/endo-119-4-1776;;6043938;;10.1016/0006-291x(85)91209-4;;2415129;;10.1093/hmg/ddi295;;16081467;;10.1016/j.stem.2008.03.002;;pmc2613570;;18397751;;11094627;;10.1126/science.283.5401.534;;9915700;;10.1016/s0022-2275(20)34799-4;;6252272;;10.1016/s0022-2275(20)41303-3;;206638;;10.1097/00005392-200301000-00098;;12478183;;10.1016/s0022-5347(05)64118-3;;5337892;;10.1016/s0007-1226(67)80033-x;;10.1001/archopht.1988.01060130181012;;3341968;;10.1016/j.peptides.2005.03.039;;16042991;;12115867;;10.1002/path.1158;;10.1007/bf02557680;;3922598;;8040190;;10.1002/jcp.1041600214;;10027397;;pmc1849992;;10.1016/s0002-9440(10)65285-6;;9027588;;10.1002/(sici)1097-4644(199702)64:2<278::aid-jcb11>3.0.co;2-f;;9621889;;10.1002/jor.1100160202;;10961917;;10.1042/0300-5127:0280350;;10.1042/bst0280350;;0010961917;;11248860;;10.1016/s0094-1298(20)32342-7;;10.1161/01.cir.0000074209.17561.99;;12835229;;2144412;;10.1007/bf00174624;;10.1097/00003086-199609000-00031;;8804298;;6370890;;10.1016/s0074-7696(08)62444-4;;10.1016/s1471-4914(01)02016-0;;11378515;;1870029;;10.1002/jor.1100090504;;10.1016/s0094-1298(20)31020-8;;7924141;;10.1016/s1359-6446(03)02866-6;;14643161;;10.1038/74651;;10742145;;11487017;;10.1007/bf00444241;;8122570;;10541768;;10.1007/s002239900721;;pmc3097937;;21607134;;10.4252/wjsc.v3.i4.25;;12193778;;10.1126/science.297.5585.1299;;10.1126/science.1080631;;10.1126/science.1079318;;12595675;;6382294;;10.1111/j.1524-475x.2006.00182.x;;17244317;;16731010;;10.1016/j.cellbi.2005.12.009;;10.1016/s0021-9258(18)41732-2;;1326540;;pmc1397798;;10.1167/iovs.05-0975;;16303945;;12609969;;10.1161/01.res.0000063425.51108.8d;;12949903;;10.1002/jnr.10691;;6300083;;10.1016/s0021-9258(18)32630-9;;10.1016/s0167-4889(97)00083-9;;9409810;;10.1210/endo.134.1.8275945;;8275945;;10.1210/en.134.1.277;;10213083;;15621248;;10.1016/j.biomaterials.2004.09.013;;16690020;;10.1016/j.bbrc.2006.04.089;;10.1016/j.biomaterials.2005.02.022;;15949551;;10.1016/j.bbrc.2006.04.128;;16696950;;10.1210/endo-114-2-477;;6690287;;1689854;;11532401;;10.1016/s0959-437x(00)00235-5;;17016179;;10.1097/01.prs.0000221037.34883.0a;;10.1111/j.1524-4725.1993.tb00996.x;;8245302;;10.1007/bf00453875;;8526158;;10.1016/s0094-1298(20)32343-9;;11248861,"Abbate, A., Biondi-Zoccai, G.G. and Baldi, A. (2002) ""Pathophysiologic role of myocardial apoptosis in post-infarction left ventricular remodeling"" J Cell Physiol 193, 145-53.;;Aharinejad, S., Mars, S.C., Jr., Bock P., Mason-Savas, A., MacKay, C.A. Larson, E.K., Jackson, M.E., Luftensteiner, M. and Weisbauer, E. (1995) ""CSF-1 treatment promotes angiogenesis in the metaphysics of osteopetrotic (toothless, tl) rats"" Bone 16, 315-324.;;Ahrens, Patricia Buckley et al., ""Stage-Related Capacity for Limb Chondrogenesis in Cell Culture,"" Developmental Biology, 1977, 60:69-82.;;Ailhaud, et al., 1983, ""Hormonal requirements for growth and differentiation of OB17 preadipocyte cells in vitro,"" Diabete & Metabolisme, vol. 9:125-133.;;Ailhaud, et al., 1985, ""Lipoprotiene lipase et differenciation adipocytaire,"" Reprod. Nutr. Develop., vol. 25:153-158.;;Alameddine, Hala S. et al., ""Regeneration of Skeletal Muscle Fibers from Autologous Satellite Cells Multiplied in Vitro. An Experimental Model for Testing Cultured Cell Myogenicity,"" Muscle & Nerve, 1989, 12:544-55.;;Alhadlaq et al. ""Engineered adipose tissue from human mesenchymal stem cells maintains predefined shape and dimension: implications in soft tissue augmentation and reconstruction."" Tissue Eng 11, 556-566 (2005).;;Anderson, Apr. 30, 1998, Human Gene Therapy, Nature, 392 Supp (6679):25-30.;;Angele, P. et al., ""Engineering of Osteochondral Tissue with Bone Marrow Mesenchymal Progenitor Cells in a Derivatized Hyaluronan-Gelatin Composite Sponge,"" Tissue Engineering, 1999, 5:545-53.;;Ankrom, Michael A., ""Age-related changes in human oestrogen receptor function and levels in osteoblasts,"" Biochem J. 333:787-794.;;Aragona, F., L. D'Urso et al (1998) ""Immunologic aspects of bovine injectable collagen in humans. A review"" Eur Urol 33(2): 129-33.;;Arts et al., 2002, Contaminants from the Transplant Contribute to Intimal Hyperplasia Associated with Microvascular Endothelial Cell Seeding, Eur. J. Endovasc. Surg. 23:29-38.;;Arvidsson, A., Collin, T., Kirk, D., Kokaia, Z., and Lindvall, O. (2002) ""Neuronal replacement from endogenous precursors in the adult brain after stroke"" Nat Med 8, 963-70.;;Ashjian, P.H. Elbarbary, A.S., Edmonds, B., DeUgarte, D., Zhu, M., Zuk, P.A., Lorenz, H.P., Benhaim, P., and Hedrick, M.H. (2003). ""In vitro differentiation of human processed lipoaspirate cells into early neural progenitors"" Plast Reconstr Surg 111 1922-31.;;Asken, S. (1990) ""Microliposuction and autologous fat transplantation for aesthetic enhancement of the aging face"" J Dermatol Surg Oncol 16(10): 965-72.;;Aso, Hisashi, et al., ""A Preadipocyte Clonal Line from bovine Intramuscular Adipose Tissue: Nonexpression of GLUT-4 protein during Adipocyte Differentiation,"" Biochem. Biophys. Res. Commun. 213:369-375.;;Asou, Y., Riffling, S.R., Yoshitake, H., Tsuji, K., Shinomiya, K., Nifuji, A., Denhardt, D.T., and Noda, M. (2001) ""Osteopontin facilitates angiogenesis, accumulation of osteoclasts, and resorption in ectopic bone"" Endocrinology 142, 1325-1332.;;Assady, S., Maor, G., Amit, M., Itskovitz-Eldor, J., Skorecki, K.L., and Tzukerman, M. (2001) ""Insulin production by human embryonic stem cells"" Diabetes 50, 1691-7.;;Assmus, B., Schachinger, V., Teupe, C., Britten,M., Lehmann, R., Dobert, N., Grunwald, F., Aicher, A., Urbich, C., Martin, H., Hoelzer, D., Dimeler, S., and Zeiher, A.M. (2002) Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI) Circulation 106, 3009-17.;;Athanasopoulos, T., Fabb, S., and Dickson, G. (2000) ""Gene therapy vectors based on adeno-associated virus: characteristics and applications to acquired and inherited diseases (review)"" Int J Mol Med 6, 363-75.;;ATTC Preservation Methods: Freezing and Free-Drying, ATCC, 2nd Edition, 1991.;;Avital, I., D. Inderbitzin, et al. (2001) ""Isolation, characterization and transplantation of bone marrow-derived hepatocyte stem cells"" Biochem Biophys Res Commun 288(1): 156-64.;;Badiavas, et al. ""Participation of bone marrow derived cells in cutaneous would healing."" Journal of Cellular Physiology. 196(2): 245-250 (2003).;;Bagnato et al., Jan. 2002, Emerging role of endothelin-1 in tumor angiogenesis, Trends in Endocrinology and Metabolism, 14(1):44-50.;;Bailey, A. J. et al., ""Age-Related Changes in the Biochemical Properties of Human Cancellous Bone Collagen: Relationship to Bone Strength,"" Calcified Tissue International, 1999, 65:203-10.;;Banerji et al., Feb. 22, 1999, LYVE-1, a New Homologue of the CD44 Glycoprotein, Is a Lymph-specific Receptor for Hyaluronan, J. Cell Biology, 144(4):789-801.;;Banfi, A., Bianchi, G., Galotto, M., Cancedda, R., and Quarto, R. (2001) ""Bone marrow stromal damage after chemo/radiotherapy: occurrence, consequences and possibilities of treatment"" Leuk Lymphoma 42, 863-70.;;Barghorn, A. et al., ""a-Smooth Muscle Actin Distribution in the Pulmonary Vasculature Comparing Hypoplastic and Normal Fetal Lungs,"" Pediatric Pathology & Laboratory Medicine, 1998, 18:5-22.;;Barker, J.N., Davies, S.M., DeFor, T., Ramsay, N.K., Weisdorf, D.J. and Wagner, J.E. (2001) ""Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of huan leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis"" Blood 97, 2957-61.;;Baron et al., 1999, Acute Necrotizing Pancreatitis, The New Engl. J. Med. 340:1412-1417.;;Barry, F.P., Boynton, R.E., Haynesworth, S., Murphy, J.M., and Zaia, J. (1999) ""The monoclonal antibody SH-2, raised against human mesenchymal stem cells, recognizes an epitope on endoglin (CD105)"" Biochem Biophys Res Commun 265, 134-9.;;Bartynski, J.M., S. Marion et al. (1990) ""Histopathologic evaluation of adipose autografts in a rabit ear model"" Otolaryngol Hea Neck Surg 102(4): 314-21.;;Bastard, J. P. et al., ""A Mini-Liposuction Technique Adapted to the Study of Human Adipocyte Glucose Transport System,"" Diabetologia, 36(Suppl. 1):A135, 1993.;;Baylink, David J., ""Glucocorticoid-Induced Osteoporosis,"" The New England Journal of Medicine, 1983, 309:306-8.;;Becerra, José et al., ""Demineralized Bone Matrix Mediates Differentiation of Bone Marrow Stromal Cells In Vitro: Effect of Age of Cell Donor,"" Journal of Bone and Mineral Research, 1996, 11:1703-14.;;Beecken, W.D., Kramer, W., and Jonas, D. (2000) ""New molecular mediators in tumor angiogenesis"" J Cell Mol Med 4, 262-269.;;Beiser, Ian H. and Irvin O. Kanat, ""Subchondral Bone Drilling: A Treatment for Cartilage Defects,"" Journal of Foot Surgery, 1990, 29:595-601.;;Bender et al., 1991, Identification and comparison of CD34-positive cells and their subpopulations from normal peripheral blood and bone marrow using multicolor flow cytometry, Blood 77(12): 2591-2596.;;Bennett, JH, et al., 1991 J. Cell Sci. ""Adipocytic cells cultured from marrow have osteogenic potential,"" 99(Pt1):131-139.;;Berdel, W.E., Fink, U., Thiel, E., Stunkel, K., Greiner, E., Schwarzkopf, G., Reichert, A. and Rastetter, J. (1982) ""Purification of human monocytes by adherence to polymeric fluorocarbon. Characterization of the monocyte-enriched cell fraction"" Immunobiology 163, 511-520.;;Beresford, et al., 1986 Endo. ""1,25- Dihydroxyvitamin D3 and Human Bone-Derived Cells in Vitro: Effects on Alkaline Phosphatase, Type I Collagen and Proliferation,"" 119:1776-1785.;;Bergeon, M.T. (1967) ""Collagen: a review"" J Okla State Med Assoc 60(6): 330-2.;;Bernlohr, David A. et al., ""Tissue Specific Expression of p422 protein , A putative Lipid Carrier, In Mouse Adipocytes,"" Biochem. Biophys. Res. Comun. 1985 132:850-855.;;Berry et al., 2005, The Establishment of a Predictive Mutational Model of the Forkhead Domain through the Analyses of FOXC2 Missense Mutations Identified in Patients with Hereditary Lymphedema with Distichiasis, Human Molecular Genetics 14(18):2619-2627.;;Bianco et al., Apr. 2008, Mesenchymal stem cells: revisiting history, concepts, and assays, Cell Stem Cell, 2:313-319.;;Bickenbach, J.R. and Dunnwald, M. (2000) ""Epidermal stem cells: characteristics and use in tissue engineering and gene therapy"" Adv Dermatol 16, 159-83.;;Bjornson, et al., 1999 Science ""Turning Brain into Blood: A Hematopoetic Fate Adopted by Adult Neural Stem Cells in Vivo,"" 283:534-537.;;Bjorntorp et al., 1980, Differentiation and function of rat adipocyte precursor cells in primary culture, J. Lipid Research 21:714-723.;;Björntrop, et al. ""Isolation and characterization of cells from rat adipose tissue developing into adipocytes."" J. Lipid Res. 19:316-324 (1978).;;Block, C.A., C.S. Cooper (2003) ""Long-term Efficacy of periurethral collagen injection for the treatment of urinary incontinence secondary to myelomeningocele"" J Urol 169(1): 327-329.;;Boering, G. and A.J. Huffstadt (1967) ""The use of derma-fat grafts in the face"" Br J Plast Surg 20(2): 172-8.;;Boerner, C.F. (1988) ""Allergic response to a porcine collagen corneal shield. Case report"" Arch Opthalmol 106(2): 171.;;Boghossian et al, 2005, Suppression of fat deposition for the life time with gene therapy, Peptides 26(8):1512-1519.;;Bond et al., 1999, ""Human Subcutaneouspreadipocytes Differentiate Into osteoblasts,"" FASEB Journal 13:600A.;;Bonner-Weir, S. and Sharma, A. (2002) ""Pancreatic stem cells"" J Pathol 197, 519-526.;;Boskey, et al., 1985, ""The Effect of Osteocalcin on In Vitro Lipid-Induced Hydroxyapatite Formation and Seeded Hydroxyapatite Growth,"" Calc. Tiss. Int. 37:75.;;Breen, Ellen C. et al., ""TGFb Alters Growth and Differentiation Related Gene Expression in Proliferating Osteoblasts In Vitro, Preventing Development of the Mature Bone Phenotype,"" Journal of Cellular Physiology, 1994, 160:323-35.;;Breiteneder-Geleff et al., Feb. 1999, Angiosarcomas Express Mixed Endothelial Phenotypes of Blood and Lymphatic Capillaries, Am. J. Path. 154(2): 385-394.;;Bruder, et al., 1997 J. Cell Biochem. ""Growth Kinetics, Self-Renewal, and the Osteogenic Potential of Purified Human Mesenchymal Stem Cells During Extensive Subcultivation and Following Cryopreservation,"" 64:278-294.;;Bruder, Scott P. et al., ""Bone Regeneration by Implantation of Purified, Culture-Expanded Human Mesenchymal Stem Cells,"" Journal of Orthopaedic Research, 1998, 16:155-62.;;Bulleid, J.J., D.C. John et al (2000) ""Recombinant expression systems for the production of collagen"" Biochem Soc Trans 28(4): 350-3.;;Burres, S. (2001) ""Soft-tissue augmentation with fascian"" Clin Plast Surg 28(1): 101-10.;;Buschmann, I.R. Busch, H.J., Mies, G., and Hossmann, K.A. (2003) ""Therapeutic induction of arteriogenesis in hypoperfused rat brain via granulocyte-macrophage colony-stimulating factor"" Circulation 108, 610-615.;;Butler-Browne, et al., 1990 Anat. Embryol. (Berl) ""Myosin heavy and light chain expression during human skeletal muscle development and precocious muscle maturation induced by thyroid hormone,"" 181:513-522.;;Butnariu-Ephrat, Miriam et al., ""Resurfacing of Goat Articular Cartilage by Chondrocytes Derived From Bone Marrow,"" Clinical Orthopaedics and Related Research, 1996, 330:234-43.;;Campion, Dennis R., ""The Muscle Satellite Cell: A Review,"" Internationals Review of Cytology, 1984, 87:225-51.;;Caplan, A.I. and Bruder, S.P. (2001) ""Mesenchymal stem cells: building blocks for molecular medicine in the 21st century"" Trends Mol Med 7, 259-64.;;Caplan, Arnold I., ""Mesenchymal Stem Cells,"" Journal of Orthopaedic Research, 1991, 9:641-50.;;Caplan, Arnold I., ""The Mesengenic Process,"" Clinics in Plastic Surgery, 21:429-35, 1994.;;Carano, R.A. and Filvaroff, E.H. (2003) ""Angiogenesis and bone repair"" Drug Discov. Today 8, 980-989.;;Carmeliet, P. (2000) ""Mechamisms of angiogenesis and arteriogenesis"" Nat Med 6, 389-395.;;Carmeliet, P. and A. Luttun (2001) ""The emerging role of the bone marrow-derived stem cells in (therapeutic angiogenesis"" Thromb Haemost 86(1): 289-97.;;Carpandena, C.A. ""Collagen alterations in adipose autograft's."" Aesthetic Plastic Surgery vol. 18, 11-15 (1994).;;Carranza-Bencano, A. et al., ""Comparative Study of the Reconstruction of Articular Cartilage Defects with Free Costal Perichondrial Grafts and Free Tibial Periosteal Grafts: An Experimental Study on Rabbits,"" Calcified Tissue International, 1999, 65:402-7.;;Casteilla et al., Apr. 26, 2011, Adipose-derived stromal cells: their identity and uses in clinical trials, an update, World J. Stem Cells, 3(4):25-33.;;Castro, et al. ""Failure of Bone Marrow Cells to Transdifferentiate into Neural Cells in Vivo."" Science. 297:1299 (2002).;;Castro, et al. ""Response to Comment on 'Failure of Bone Marrow Cells to Transdifferentiate into Neural Cells in Vivo.'"" Science. 299:1184c (2003).;;Castro-Malaspina, H., W. Ebell, et al. (1984) ""Human bone marrow fibroblast colony-forming units (CFU-F ""Prog Clin Ciol Res 154: 209-36.;;Cavallini, 2007, Autologous Fibroblasts to Treat Deep and Complicated Leg Ulcers in Diabetic Patients, Wound Repair Regen. 15(1):35-8.;;Chang et al., Jan. 2006, Characterization of two populations of mesenchymal progenitor cells in umbilical cord blood, Cell Biology International, 40:495-499.;;Cheifetz, S. et al., ""Endoglin Is a Component of the Transforming Growth Factor-beta Receptor System in Human Endothelial Cells,"" J. Biol. Chem., 1992 267:19027-19030.;;Chen et al., Dec. 2005, Novel Expression and Characterization of Lymphatic Vessel Endothelial Hyaluronate Receptor 1 (LYVE-1) by Conjunctival Cells, Invest. Ophthalmol. Vis. Sci. 46(12):4536-4540.;;Chen, J. et al. Intravenous Administration of Human Bone Marrow Stromal Cells Induces Angiogenesis in the Ischemic Boundary Zone After Stroke in Rats, Circulation Research, Apr. 2003, vol. 92, pp. 692-699.;;Chen, J. et al. Intravenous Bone Marrow Stromal Cell Therapy Reduces Apoptosis and Promotes Endogenous Cell Proliferation After Stroke in Femal Rat, J. Neuroscience Research, Sep. 2003, vol. 73 pp. 778-786.;;Chen, Theresa L. et al., ""1alpha,25-Dihydroxyvitamin D3 Receptors in Cultured Rat osteoblast-like Cells,"" J. Biol. Chem. 1983 258:4350-4355.;;Chen, Xiaoli et al., ""Differentiation-dependent expression of obese (ob) gene by preadipocytes and adipocytes in primary cultures of porcine stromal-vascular cells,"" Biochimica et Biophysica Acta, 1997, 1359:136-42.;;Cheng S-L., et al., 1994 Endo ""Differentiation of Human Bone Marrow Osteogenic Stromal Cells in Vitro: Induction of the Osteoblast Phenotype by Dexamethasone,"" 134: 277-286.;;Chimal-Monroy, Jesús and Lino Díaz de León, ""Expression of N-cadherin, N-CAM, fibronectin tenascin is stimulated by TGF-b1, b2, b3 and b5 during the formation of precartilage condensations,"" The International Journal of Developmental Biology, 1999, 43:59-67.;;Cho,S.W. et al. ""Engineering of volume-stable adipose tissues."" Biomaterials 26, 3577-3585 (2005).;;Cho,S.W. et al. ""Enhancement of adipose tissue formation by implantation of adipogenic-differentiated preadipocytes."" Biochem Biophys Res Commun 345, 588-594 (2006).;;Choi et al. ""Adipose tissue engineering using mesenchymal stem cells attached to injectable PLGA spheres."" Biomaterials 26, 5855-5863 (2005).;;Choi,Y.S. et al. ""Adipogenic differentiation of adipose tissue derived adult stem cells in nude mouse."" Biochem Biophys Res Commun 345, 631-637 (2006).;;Chyun, et al., 1984 Endo. ""Cortisol Decreases Bone Formation by Inhibiting Periosteal Cell Proliferation,"" 114:477-480.;;Civin, C.I., Strauss, L.C., Fackler, M.J., Trischmann, T.M., Wiley, J.M., and Loken, M.R. (1990) ""Positive stem cell selection-basic science"" Prog Clin Biol Res 333, 387-401.;;Clarke, D. and Frisen, J. (2001) ""Differentiation potential of adult stem cells"" Curr Opin Genet Dev 11, 575-80.;;Clavijo-Alvarez,J.A. et al. ""A novel perfluoroelastomer seeded with adipose-derived stem cells for soft-tissue repair."" Plast Reconstr Surg 118, 1132-1142 (2006).;;Coleman III, et al. ""Autologous Collagen? Lipocytic Dermal Augmentation. A Histopathologic Study"". J. Dermatol Surg Oncol. vol. 19, 1032-1040 (1993).;;Coleman, S.R. (1995) ""Long-term survival of fat transplants: controlled demonstrations"" Aesthetic Plast Surg 19(5): 421-5.;;Coleman, S.R. (2001). ""Structural fat grafts: the ideal filler?"" Clin Plast Surg 28(1): 111-9.",INACTIVE
613,EP,A3,EP 1028272 A3,146-644-149-723-740,2001-04-11,2001,EP 00300556 A,2000-01-26,US 24874799 A,1999-02-12,Torque converter bypass clutch,"A hydrokinetic torque converter includes an impeller cover (12) and a bypass clutch. A drive ring (74) is located between adjacent surfaces of the cover (12) and a clutch piston (60), which deflects flexurally axially. The piston (60) is welded to the cover (12) at a radially inner position, which is supported at another radial location on the cover (12). The piston (60) deflects into engagement with the drive ring (74), and the drive ring (74) engages with the cover (12). When clutch apply pressure is reduced, energy, in the form of elastic bending potential energy stored in the piston (60), is used to move the piston out of engagement with the drive ring (74) and cover (12).",FORD GLOBAL TECH INC,MACDONALD FRASER JOHN;;HARGRAVE DAVID,LAWRENCE TECHNOLOGICAL UNIVERSITY (2003-06-25),https://lens.org/146-644-149-723-740,Search Report,yes,5,0,6,6,0,F16H45/02;;F16H2045/0294;;F16H45/02;;F16H2045/0294,F16H45/02,,1,0,,,"FROSLIE, MILEK, SMITH: ""Design Practices- Passenger Car Automatic Transmissions Part I"", 1962, SAE, NEW YORK, XP000905044",EXPIRED
614,HK,A1,HK 1219978 A1,149-972-651-513-53X,2017-04-21,2017,HK 16107978 A,2016-07-08,US 2014/0030370 W;;US 201361787818 P,2013-03-15,SCALABLE MANUFACTURING PROCESS TO PRODUCE RECOMBINANT LENTIVIRAL VECTORS IN SERUM-FREE SUSPENSION CELL CULTURE SYSTEM,,CHILDRENS HOSPITAL PHILADELPHIA,QU GUANG;;WRIGHT JOHN FRASER,,https://lens.org/149-972-651-513-53X,Patent Application,no,0,0,29,29,0,C12N7/00;;C12N2740/15043;;C12N2740/15051;;A61K48/0091;;A61K48/0091;;C12N2740/15043;;C12N2740/15051;;C12N7/00;;A61K48/0091;;C12N7/00;;C12N7/00;;C12N2740/15043;;C12N2740/15051;;A61K48/0091,C12N/,,0,0,,,,PENDING
615,ES,T3,ES 2521682 T3,152-477-240-757-249,2014-11-13,2014,ES 10179750 T,2004-05-21,US 47238403 P;;US 54975604 P,2003-05-21,Procedimientos para producir preparaciones de viriones de AAV recombinantes sustancialmente exentas de cápsidas vacías,Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.,GENZYME CORP,QU GUANG;;WRIGHT JOHN FRASER,,https://lens.org/152-477-240-757-249,Granted Patent,no,0,0,40,41,0,C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N15/86;;C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N2710/16651;;C12N2710/10351;;C12N2760/16051;;C12N15/86,C12N7/02;;B01D15/00;;B01D15/04;;C02F1/42;;C12N/;;C12N15/86;;C12N15/864,,0,0,,,,ACTIVE
616,PL,T3,PL 1625210 T3,173-695-646-639-40X,2011-05-31,2011,PL 04776068 T,2004-05-21,US 47238403 P;;US 54975604 P;;EP 04776068 A;;US 2004/0015958 W,2003-05-21,METHODS FOR PRODUCING PREPARATIONS OF RECOMBINANT AAV VIRIONS SUBSTANTIALLY FREE OF EMPTY CAPSIDS,Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.,GENZYME CORP,QU GUANG;;WRIGHT JOHN FRASER,,https://lens.org/173-695-646-639-40X,Patent Application,no,0,0,40,41,0,C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N15/86;;C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N2710/16651;;C12N2710/10351;;C12N2760/16051;;C12N15/86,C12N7/02;;B01D15/00;;B01D15/04;;C02F1/42;;C12N/;;C12N15/86;;C12N15/864,,0,0,,,,PENDING
617,WO,A1,WO 2000/039159 A1,198-767-760-804-613,2000-07-06,2000,NZ 9900228 W,1999-12-24,NZ 33358998 A,1998-12-24,SUPERANTIGENS,"The invention provides superantigens SMEZ-2, SPE-G, SPE-H and SPE-J, as well as polynucleotides which encode them. Such superantigens have, inter alia, diagnostic and therapeutic applications.",AUCKLAND UNISERVICES LTD;;FRASER JOHN DAVID;;PROFT THOMAS,FRASER JOHN DAVID;;PROFT THOMAS,,https://lens.org/198-767-760-804-613,Patent Application,yes,1,2,7,10,0,A61K38/00;;A61K39/00;;A61P35/00;;A61P37/02;;C07K14/315,G01N33/569;;A61K38/00;;A61K39/00;;A61K39/09;;A61K39/395;;A61K47/48;;A61P35/00;;A61P37/02;;C07K14/315;;C07K16/12;;C12N15/09;;C12Q1/68,,14,8,013-657-500-788-251;;050-832-500-731-869;;026-674-097-624-885;;125-129-352-164-907;;018-614-372-193-465;;003-664-229-208-813;;051-933-738-521-473;;035-933-364-762-730,9874566;;pmc1887688;;10.1084/jem.189.1.89;;9632603;;10.1128/iai.66.7.3337-3348.1998;;pmc108350;;9720870;;10.1046/j.1365-2958.1998.00947.x;;3045005;;10.1128/iai.56.9.2518-2520.1988;;pmc259600;;10.1038/nsb0897-635;;9253413;;9447589;;10.1038/nbt0198-27;;2185544;;10.1126/science.2185544;;pmc239452;;10.1128/mr.60.3.473-482.1996;;8840782,"PROFT. ET. AL.: ""Indentification and characterization of novel superantigens from Streptococcus pyogenes."", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 189, no. 1, 1999, pages 89 - 101, XP002905208;;DATABASE GENPEPT 29 July 1999 (1999-07-29), GERLACH, D, WAGNER, M, FLEISCHER, B, SCHMIDT, KH, VETTERMANN, S, REICHARDT, W., XP001052798;;DATABASE GENPEPT 19 July 1999 (1999-07-19), GERLACH, D, WAGNER, M, FLEISCHER, B, SCHMIDT, KH, VETTERMANN, S, REICHARDT, W., XP002905301;;DATABASE GENPEPT 19 July 1999 (1999-07-19), GERLACH, D, WAGNER, M, FLEISCHER, B, SCHMIDT, KH, VETTERMANN, S, REICHARDT, W., XP002905302;;MUNSON, SH, ET. AL.: ""Identification and Characterization of Staphylococcal Enterotoxin Types G and I from Staphylococcus aureus."", INFECTION AND IMMUNITY, vol. 66, no. 7, 1998, pages 3337 - 3348, XP002092808;;LINDSAY, JA. ET. AL: ""The gene for toxic shock toxin is carried by a family of mobi le pathogenicity islands in staphylococcus aureus."", MOLECULAR MICROBIOLOGY, vol. 29, no. 2, 1998, pages 527 - 543, XP002905209;;GOSHORN, SC. AND SCHLIEVERT, PM.: ""Nucleotide Sequence of Streptococcal Pyrogenic Exotoxin Type C"", INFECTION AND IMMUNITY, vol. 56, no. 9, 1998, pages 2518 - 2520, XP002066997;;DATABASE MEDLINE 1 January 1900 (1900-01-01), ""SPEC STRPY; EXOTOXIN TYPE C (PRECURSOR)"", XP001052797, Database accession no. P13380;;DATABASE MEDLINE 1 January 1900 (1900-01-01), SCHLIEVERT P M, ET AL: ""PYROENIC EXOTOXIN C"", XP002905303, Database accession no. AAB59091;;See also references of EP 1141000A4;;ROUSSEL ET AL., NAT. STR-UCT. BIOL., vol. 4, no. 8, 1997, pages 635 - 43;;MARSHALL; HODGSON, NATURE BIOTECHNOLOGY, vol. 16, 1998, pages 27 - 31;;MARRACK, P.; J. KAPPLER.: ""The staphylococcal enterotoxins and their relatives"", SCIENCE, vol. 248, 1990, pages 705 - 711, XP002138564, DOI: doi:10.1126/science.2185544;;HUBER, B.T.; P.N. HSU; N. SUTKOWSKI.: ""Virus-encoded superantigens"", MICROBIOL. REV., vol. 60, no. 3, 1996, pages 473 - 82",PATENTED
618,GB,A,GB 2367158 A,006-592-685-383-518,2002-03-27,2002,GB 0023584 A,2000-09-26,GB 0023584 A,2000-09-26,Archiving and retrieving items based on episodic memory of groups of people,"A method for archiving and retrieving digital media items such as images, audio, text based on episodic memory of predefined associated groups of one or more people comprises: receiving an input identifying a group to which the user belongs; receiving user archiving input identifying a digital media item to be archived for the group, selecting zero or more group event types 56 from a predetermined plurality of group event types for the group, selecting zero or more persons 55 in the group, and selecting a time 57; generating index information using the received user archiving input; storing the indexed information in association with the identified digital item; repeating the reception of user archiving input, the generation of the index information and the storing of the index information for a plurality of digital media items; receiving a user retrieval input selecting or automatically selecting: zero or more groups of event types from the predetermined plurality of group event types for the group, zero or more persons in the group, and a time period; and using the selections and the identified group to retrieve and output digital media items that match the selection. Trails may be defined 59 which define a logical or meaningful route through the digital media items. An item may be specified as a high point 58. The method may be used for nustalgia purposes 62.",6S LTD,FRASER JOHN LESLIE;;SHARPE ELIZABETH,,https://lens.org/006-592-685-383-518,Patent Application,no,11,12,8,8,0,G06F16/9535;;G06F16/951,G06F17/30,G4A AUDB          UDB,0,0,,,,EXPIRED
619,CA,C,CA 2469370 C,024-585-733-813-664,2014-07-08,2014,CA 2469370 A,2002-12-09,US 33885601 P;;US 0239465 W,2001-12-07,ADIPOSE-DERIVED CELL PROCESSING UNIT,Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient.,MACROPORE BIOSURGERY INC,HEDRICK MARC H;;FRASER JOHN,,https://lens.org/024-585-733-813-664,Granted Patent,no,0,0,65,221,0,A61B10/0283;;A61K9/0019;;C12N5/0667;;C12N5/069;;C12N2506/1384;;A61K35/28;;A61K35/35;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P3/00;;A61P3/06;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;A61K35/32;;A61K48/00;;A61K35/36;;A61B10/0283;;A61K9/0019;;C12N5/0667;;C12N5/069;;C12N2506/1384;;A61M1/76;;A61K35/28;;A61K35/35;;C12M47/04;;A61M2202/08,A61M1/00;;C12M3/06;;A61K31/436;;A61K35/02;;A61K35/12;;A61K35/28;;A61K35/35;;A61K35/36;;A61K38/00;;A61K38/16;;A61K45/00;;A61L27/00;;A61P1/00;;A61P1/16;;A61P3/00;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P19/00;;A61P19/02;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;C12N5/0775,,0,0,,,,EXPIRED
620,EP,B1,EP 2277996 B1,047-202-675-947-587,2014-09-03,2014,EP 10179750 A,2004-05-21,EP 04776068 A;;US 47238403 P;;US 54975604 P,2003-05-21,Methods for producing preparations of recombinant AAV virions substantially free of empty capsids,Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.,GENZYME CORP,QU GUANG;;WRIGHT JOHN FRASER,,https://lens.org/047-202-675-947-587,Granted Patent,yes,1,0,40,41,0,C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N15/86;;C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N2710/16651;;C12N2710/10351;;C12N2760/16051;;C12N15/86,C12N7/02;;B01D15/00;;B01D15/04;;C02F1/42;;C12N/;;C12N15/86;;C12N15/864,,8,8,082-256-886-757-890;;068-982-043-431-314;;089-800-605-790-418;;040-850-901-799-916;;071-415-183-497-398;;133-796-772-596-115;;012-005-260-781-965;;004-363-049-230-746,10.1016/s1525-0016(02)90719-7;;12436964;;10.1006/mthe.2002.0719;;14625046;;10.1016/j.jviromet.2003.09.002;;11269337;;10.1002/1521-2254(2000)9999:9999<::aid-jgm152>3.0.co;2-u;;10.1089/104303402320139014;;12133276;;17196264;;10.1016/j.jviromet.2006.11.019;;10.1016/j.ymthe.2004.06.346;;6277875;;10.1093/oxfordjournals.jbchem.a133632;;6721144;;10.1016/0003-2697(84)90241-0,"BRUMENT ET AL.: ""A versatile and scalable two-step ion exchange chromatography process for the purification of recombinant adeno-associated virus serotype-2 and - 5''."", MOL. THER., vol. 6, no. 5, 5 November 2002 (2002-11-05), pages 678 - 686, XP002969618;;SMITH ET AL.: ""Serum-free production and column purification of adeno-associated virus type 5''."", J. VIROL. METHODS., vol. 114, no. 2, December 2003 (2003-12-01), pages 115 - 124, XP055316815;;DRITTANTI ET AL.: ""Optimised helper virus-free production of high-quality adeno- associated virus vectors''."", J. GENE . MED., vol. 3, 2001, pages 59 - 71, XP009033855, [retrieved on 20001009];;KALUDOV ET AL.: ""Scalable purification of adeno-associated virus type 2, 4, or 5 using ion-exchange chromatography''."", HUM. GENE . THER., vol. 13, no. 10, 1 July 2002 (2002-07-01), pages 1235 - 43, XP002382732;;QU ET AL.: ""Separation of adeno-associated virus type 2 empty particles from genome containing vectors by anion-exchange column chromatography''."", J . VIROL. METH., vol. 140, 2007, pages 183 - 192, XP005870426, [retrieved on 20061228];;AMERICAN SOCIETY OF GENE THERAPY: ""Development of a scalable column chromatography-based purification process to manufacture empty capsid-free AAV vectors''."", MOL. THER., vol. 9, no. S1, May 2004 (2004-05-01), pages 162, XP004634790;;TAKAHASHI-NAKAMURA ET AL.: ""Purification and characterization of an inhibitor of calcium-activated neutral protease from rabbit skeletal muscle''."", J. BIOCHEM., vol. 90, no. 6, October 1981 (1981-10-01), pages 1583 - 1589, XP055316818;;GORBUNOFF ET AL.: ""The interaction of proteins with hydroxyapatite: III . Mechanism''."", ANAL. BIOCH., vol. 136, 1983, pages 440 - 445, XP024825294, [retrieved on 19840201]",ACTIVE
621,WO,A3,WO 2010/126385 A3,048-829-598-596-079,2010-12-23,2010,NZ 2010000085 W,2010-04-30,NZ 57669909 A,2009-05-01,IMPROVEMENTS IN OR RELATING TO VEHICLE SEATS,An emergency response vehicle seat including a cavity for accommodating a pressurised fluid container and methods of forming the seat columns and seat. The seat includes a pair of spaced apart generally L shaped columns each formed from two halves formed of folded sheet metal. The columns are formed by bending two column half blanks so as to each form two walls of the generally L shaped column and secure them together to form a generally L shaped column. The pair of columns are secured together in spaced apart relationship to define a cavity between the columns in the seat back portion suitable for accommodating a pressurised fluid container of the type forming part of a typical emergency back pack.,FRASER FIRE & RESCUE LTD;;SIMPSON MARTIN;;FRASER JOHN JAMES,SIMPSON MARTIN;;FRASER JOHN JAMES,,https://lens.org/048-829-598-596-079,Search Report,yes,3,0,2,2,0,A62B9/04;;A62B25/00;;B60N2/68;;B60N2/24,B60N2/24;;B60N2/42;;B60N2/68,,0,0,,,,PENDING
622,EP,A2,EP 2308963 A2,034-924-925-389-93X,2011-04-13,2011,EP 10183737 A,2002-12-09,EP 02805565 A;;US 33885601 P,2001-12-07,System for processing lipoaspirate cells,"Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patent. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient.
",CYTORI THERAPEUTICS INC,FRASER JOHN;;HEDRICK MARC H,,https://lens.org/034-924-925-389-93X,Patent Application,yes,25,5,65,221,0,A61B10/0283;;A61K9/0019;;C12N5/0667;;C12N5/069;;C12N2506/1384;;A61K35/28;;A61K35/35;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P3/00;;A61P3/06;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;A61K35/32;;A61K48/00;;A61K35/36;;A61B10/0283;;A61K9/0019;;C12N5/0667;;C12N5/069;;C12N2506/1384;;A61M1/76;;A61K35/28;;A61K35/35;;C12M47/04;;A61M2202/08,A61K35/00;;A61M1/00;;A61K31/436;;A61K35/02;;A61K35/12;;A61K35/28;;A61K35/35;;A61K35/36;;A61K38/00;;A61K38/16;;A61K45/00;;A61L27/00;;A61P1/00;;A61P1/16;;A61P3/00;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P19/00;;A61P19/02;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;C12M3/06;;C12N5/071;;C12N5/0775,,119,113,125-457-618-257-610;;075-488-030-671-490;;095-913-934-904-672;;084-816-629-310-620;;045-787-458-363-087;;007-126-466-697-398;;079-406-902-735-361;;063-511-874-896-881;;013-836-055-730-839;;050-826-336-424-654;;009-733-473-349-276;;037-681-158-746-769;;012-526-554-878-117;;039-145-123-882-385;;055-386-526-071-218;;080-727-563-346-048;;002-402-322-729-764;;114-069-508-870-517;;017-174-141-941-136;;072-127-656-734-286;;113-681-236-526-978;;047-891-267-991-075;;072-231-000-479-884;;033-479-118-598-189;;054-323-134-654-049;;114-479-047-988-820;;076-090-834-573-016;;015-875-842-431-592;;106-603-013-159-878;;154-284-578-210-365;;102-202-551-812-472;;015-757-459-694-093;;048-302-189-004-430;;087-309-466-182-005;;056-351-892-637-02X;;106-909-648-526-709;;079-304-670-311-107;;060-789-622-695-335;;018-221-020-974-252;;008-093-251-887-096;;047-771-701-165-31X;;078-144-091-568-913;;020-837-486-216-522;;019-939-051-494-816;;006-004-203-029-468;;008-115-130-355-40X;;027-810-214-593-214;;124-936-001-314-170;;119-279-899-568-792;;015-599-406-080-089;;054-506-496-484-990;;000-726-416-179-570;;010-094-842-952-554;;054-783-391-382-440;;111-021-439-383-245;;072-217-283-816-738;;034-785-794-270-260;;119-899-790-379-397;;035-339-813-605-916;;017-611-155-476-581;;072-093-532-186-924;;015-599-406-080-089;;010-094-842-952-554;;115-114-291-514-621;;101-659-159-373-595;;014-944-849-240-553;;008-093-251-887-096;;039-145-123-882-385;;050-826-336-424-654;;086-462-532-224-686;;094-547-639-217-227;;012-100-750-932-039;;155-317-023-938-779;;024-543-293-226-152;;053-378-748-216-731;;104-867-388-312-53X;;005-046-972-638-291;;055-939-072-605-234;;006-388-312-315-426;;100-021-019-543-442;;055-939-072-605-234;;060-346-109-363-548;;123-676-259-156-005;;013-585-462-742-366;;022-168-856-452-360;;071-429-593-853-516;;015-065-365-556-91X;;047-253-510-312-524;;036-252-293-129-219;;016-725-607-839-435;;062-596-462-103-530;;073-024-866-252-802;;013-619-248-169-661;;008-689-173-407-727;;104-867-388-312-53X;;011-805-902-464-128;;038-374-873-783-178;;042-752-396-214-211;;047-615-077-646-421;;053-378-748-216-731;;000-409-808-541-605;;002-574-351-412-169;;052-138-454-301-405;;073-243-305-396-996;;048-726-894-033-877;;025-339-980-161-109;;057-358-490-774-177;;104-466-330-440-670;;008-093-816-253-155;;080-113-880-774-779;;013-275-636-250-211;;031-353-044-011-130;;107-600-824-332-374,12475952;;10.1091/mbc.e02-02-0105;;pmc138633;;11329932;;10.1038/nm0901-1035;;pmc2818999;;11533707;;11156872;;10.1161/01.cir.103.5.634;;10.1016/0963-6897(95)00006-j;;7640867;;10.1177/096368979500400306;;10.1016/0304-3835(80)90091-9;;7013975;;182647;;10.1002/ijc.2910180309;;3966975;;10.1038/bjc.1985.13;;pmc1976821;;7357534;;7995370;;10.1089/15258160260194875;;12201961;;10.1080/146532402317381848;;12006209;;12100134;;10.1046/j.1365-2141.2002.03561.x;;4028127;;10.1007/bf00217172;;10.1002/bit.1043;;11255159;;10.1046/j.1423-0410.2001.00078.x;;11555470;;10225738;;10.1111/j.1744-9987.1997.tb00137.x;;10.1016/s0171-2985(82)80064-8;;6984421;;9770361;;10.1006/excr.1998.4163;;9390271;;9592680;;10.1007/s004050050045;;10.1016/s0165-022x(98)00006-2;;9711500;;11359674;;10.1089/15258160151134980;;11205918;;9597573;;10.1089/scd.1.1998.7.159;;11675329;;10.1182/blood.v98.9.2615;;10448662;;10.1016/s0344-0338(99)80049-1;;12135677;;10.1016/s0301-472x(02)00812-3;;1689854;;10.1007/bf02739694;;10.1007/s004040050273;;10834322;;12037404;;10.1159/000058006;;10.1016/s0165-2427(01)00375-0;;11604158;;10.1515/cclm.2000.092;;11028769;;11835415;;10.1002/jca.1032;;12144534;;10.1034/j.1600-0609.2002.01682.x;;9027589;;10.1002/(sici)1097-4644(199702)64:2<295::aid-jcb12>3.0.co;2-i;;10.1002/(sici)1097-4644(199702)64:2<295::aid-jcb12>3.3.co;2-6;;12411045;;12456961;;10.1634/stemcells.20-6-530;;10.1097/00003086-200010001-00011;;11039755;;10983732;;10.2165/00003495-200060020-00002;;10998427;;10.3892/ijmm.6.4.363;;9852198;;10.3892/ijmm.1.1.55;;7593260;;10.1002/jcb.240580312;;7628536;;10.1006/excr.1995.1221;;9618145;;10.1002/(sici)1097-4652(199807)176:1<57::aid-jcp7>3.0.co;2-7;;10546632;;10.1097/00003086-199910001-00003;;10556859;;10.1002/(sici)1097-4636(1999)48:6<913::aid-jbm22>3.0.co;2-0;;10102814;;10.1126/science.284.5411.143;;10.1016/s1471-4914(01)02016-0;;11378515;;11284885;;10.1046/j.1525-1594.2001.025003187.x;;11518286;;10.1016/s0736-0266(00)00054-1;;10.1089/107632701300062859;;11304456;;10.1097/00006534-200201000-00030;;11786812;;10.1080/17453674.1998.11744808;;9333121;;10.1359/jbmr.1997.12.10.1606;;10.1002/jor.1100160309;;9671928;;9262062;;11711826;;10.1097/00001665-200111000-00015;;10.1038/79449;;10973216;;11506726;;10.1089/10763270152436427;;10.1016/s1471-4914(01)02016-0;;11378515;;10.1089/107632701300062859;;11304456;;10.1111/j.1749-6632.1990.tb24327.x;;2291566;;9728332;;10.1023/a:1005462804271;;10738576;;10.1002/(sici)1521-2254(199903/04)1:2<121::aid-jgm26>3.0.co;2-j;;10.1097/00003086-200010001-00011;;11039755;;4028127;;10.1007/bf00217172;;7995370;;10.1007/bf00453875;;8526158;;10.1016/s0094-1298(20)32343-9;;11248861;;1896551;;10.1097/00006534-199110000-00038;;11134993;;10.1046/j.1524-4725.2000.00277.x;;10.1046/j.1524-4725.2000.t01-1-00277.x;;10.1007/s002669900055;;8849432;;10.1007/bf02390315;;9048302;;10.1089/end.1997.11.67;;11125386;;10.1097/00005392-200101000-00037;;10.1046/j.1365-2613.1996.00964.x;;8762864;;pmc2691621;;10.1016/s0940-2993(99)80076-1;;10048720;;10488710;;10.1016/s0168-8278(99)80043-9;;10.1016/0270-9139(95)90478-6;;7539398;;10.1002/hep.1840210632;;10.1016/s0940-2993(99)80076-1;;10048720;;pmc507709;;8958214;;10.1172/jci119070;;11287958;;10.1038/35070587;;11326230;;10.1067/mtc.2001.112937;;10.1161/01.cir.0000034046.87607.1c;;12370212;;10086387;;10.1038/6529;;10.1182/blood.v97.5.1227;;11222364;;11594767;;10.1006/bbrc.2001.5712;;11487017;;6382294;;10.1097/00003086-199810001-00026;;9917645;;11884830;;10.1097/00006534-200203000-00037;;10.1152/ajpendo.2001.281.5.e1037;;11595661;;pmc370387;;6306056;;10.1172/jci110937;;11125386;;10.1097/00005392-200101000-00037;;12160849;;10.1016/s0301-472x(02)00867-6;;10.1016/s0736-0266(00)00010-3;;11332607;;11877271;;10.1182/blood.v99.6.1995;;10.1111/j.1749-6632.2001.tb03592.x;;11458511;;9048302;;10.1089/end.1997.11.67;;11105688;;10.1016/s0079-6123(00)28026-6;;10.1182/blood.v92.2.362.414k38_362_367;;9657732;;10.1182/blood.v92.2.362;;10.1038/7434;;10202935;;7881356;;10.1002/stem.5530120602;;12031117;;10.1089/107632702753725049;;10.1089/10763270050044452;;10941222;;12695078;;10.1016/s0142-9612(03)00049-8;;10.1016/j.biomaterials.2005.04.065;;15964623;;10.1016/s0142-9612(00)00186-1;;11214753;;15165469;;10.1089/107632704323061889;;15378584;;10.1002/micr.20056;;10.1097/01.prs.0000095942.71618.9d;;14707645;;10.1177/1090820x11415976;;21813882,"ZUK ET AL.: ""Human Adipose Tissue Is A Source Of Multipotent Stem Cells"", MOLECULAR BIOLOGY OF THE CELL;;MASUDA, H.; C. KALKA; T. ASAHARA: ""Endothelial progenitor cells for regeneration"", HUM CELL, vol. 13, no. 4, 2000, pages 153 - 60;;KAUSHAL, S. ET AL.: ""Functional small-diameter neovessels created using endothelial progenitor cells expanded ex vivo"", NAT MED, vol. 7, no. 9, 2001, pages 1035 - 40, XP001156248, DOI: doi:10.1038/nm0901-1035;;KAWAMOTO, A. ET AL.: ""Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia"", CIRCULATION, vol. 103, no. 5, 2001, pages 634 - 7;;WILLIAMS, S. K.; S. MCKENNEY ET AL.: ""Collagenase lot selection and purification for adipose tissue digestion."", CELL TRANSPLANT, vol. 4, no. 3, 1995, pages 281 - 9;;TWENTYMAN, P. R.; J. M. YUHAS: ""Use of bacterial neutral protease for disaggregation of mouse tumours and multicellular tumor spheroids."", CANCER LETT, vol. 9, no. 3, 1980, pages 225 - 8, XP023162513, DOI: doi:10.1016/0304-3835(80)90091-9;;RUSSELL, S. W.; W. F. DOE ET AL.: ""Inflammatory cells in solid murine neoplasms. 1. Tumor disaggregation and identification of constituent inflammatory cells."", INT J CANCER, vol. 18, no. 3, 1976, pages 322 - 30;;ENGELHOLM, S. A.; M. SPANG-THOMSEN ET AL.: ""Disaggregation of human solid tumours by combined mechanical and enzymatic methods."", BR J CANCER, vol. 51, no. 1, 1985, pages 93 - 8, XP055005214, DOI: doi:10.1038/bjc.1985.13;;HEMSTREET, G. P., 3RD; P. G. ENOCH ET AL.: ""Tissue disaggregation of human renal cell carcinoma with further isopylcnic and isokinetic gradient purification."", CANCER RES, vol. 40, no. 4, 1980, pages 1043 - 9, XP055086908;;SCHWEITZER, C. M., VAN ET AL.: ""Isolation and culture of human bone marrow endothelial cells."", EXL3 HEMATOL, vol. 23, no. 1, 1995, pages 41 - 8;;GRYN, J.; R. K. SHADDUCK ET AL.: ""Factors affecting purification of CD34(+) peripheral blood stem cells using the Baxter Isolex 300i."", J HEMATOTHER STEM CELL RES, vol. 11, no. 4, 2002, pages 719 - 30;;PRINCE, H. M.; J. BASHFORD ET AL.: ""Isolex 300i CD34-selected cells to support multiple cycles of high-dose therapy."", CYTOTHERAPY, vol. 4, no. 2, 2002, pages 137 - 45;;WATTS, M. J.; T. C. SOMERVAILLE ET AL.: ""Variable product purity and functional capacity after CD34 selection: a direct comparison of the CliniMACS (v2.1) and Isolex 300i (v2.5) clinical scale devices."", BR J HAEMATOL, vol. 118, no. 1, 2002, pages 117 - 23, XP002524812, DOI: doi:10.1046/j.1365-2141.2002.03561.x;;MAINWARING, G.; A. F. ROWLEY: ""Separation of leucocytes in the dogfish (Scyliorhinus canicula) using density gradient centrifugation and differential adhesion to glass coverslips."", CELL TISSUE RES, vol. 241, no. 2, 1985, pages 283 - 90;;GREENBERG, A. W.; D. A. HAMMER: ""Cell separation mediated by differential rolling adhesion."", BIOTECHNOL BIOENG, vol. 73, no. 2, 2001, pages 111 - 24, XP002506839, DOI: doi:10.1002/bit.1043;;SOLI, M. ET AL.: ""A multicentre evaluation of a new filtration protocol for leucocyte depletion of high-haematocrit red blood cells collected by an automated blood collection system"", VOX SANG, vol. 81, no. 2, 2001, pages 108 - 12;;SMITH, J.W.: ""Apheresis techniques and cellular immunomodulation"", THER APHER, vol. 1, no. 3, 1997, pages 203 - 6;;BERDEL, W.E. ET AL.: ""Purification of human monocytes by adherence to polymeric fluorocarbon. Characterization of the monocyte-enriched cell fraction"", IMMUNOBIOLOGY, vol. 163, no. 5, 1982, pages 511 - 20;;BICKENBACH, J.R.; E. CHISM: ""Selection and extended growth of murine epidermal stem cells in culture"", EXP CELL RES, vol. 244, no. 1, 1998, pages 184 - 95, XP002182785, DOI: doi:10.1006/excr.1998.4163;;GEISELHART, A. ET AL.: ""Positive selection of CD56+ lymphocytes by magnetic cell sorting"", NAT HNMUN, vol. 15, no. 5, 1996, pages 227 - 33;;FORMANEK, M. ET AL.: ""Magnetic cell separation for purification of human oral keratinocytes: an effective method for functional studies without prior cell subcultivation"", EUR ARCH OTORHINOLARYNGOL, vol. 255, no. 4, 1998, pages 211 - 5;;GRAEPLER, F.; U. LAUER; M. GREGOR: ""Magnetic cell sorting for parietal cell purification using a new monoclonal antibody without influence on cell function"", J BIOCHEM BIOPHYS METHODS, vol. 36, no. 2-3, 1998, pages 143 - 55;;KOBARI, L. ET AL.: ""CD133+ cell selection is an alternative to CD34+ cell selection for ex vivo expansion of hematopoietic stem cells"", J HEMATOTHER STEM CELL RES, vol. 10, no. 2, 2001, pages 273 - 81, XP008077591, DOI: doi:10.1089/15258160151134980;;MOHR, M. ET AL.: ""Simultaneous immunomagnetic CD34+ cell selection and B-cell depletion in peripheral blood progenitor cell samples of patients suffering from B-cell non-Hodgkin's lymphoma"", CLIN CANCER RES, vol. 7, no. 1, 2001, pages 51 - 7;;PUGH, R.E. ET AL.: ""CD19 selection improves the sensitivity of B cell lymphoma detection"", J HEMATOTHER, vol. 7, no. 2, 1998, pages 159 - 68;;REYES, M. ET AL.: ""Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells"", BLOOD, vol. 98, no. 9, 2001, pages 2615 - 25, XP001153222, DOI: doi:10.1182/blood.V98.9.2615;;JOYNER, C.J. ET AL.: ""Development of a monoclonal antibody to the aP2 protein to identify adipocyte precursors in tumours of adipose differentiation"", PATHOL RES PRACT, vol. 195, no. 7, 1999, pages 461 - 6;;QUIRICI, N. ET AL.: ""Isolation of bone marrow mesenchymal stem cells by anti-nerve growth factor receptor antibodies"", EXP HEMATOL, vol. 30, no. 7, 2002, pages 783 - 91, XP002973273, DOI: doi:10.1016/S0301-472X(02)00812-3;;CIVIN, C.I ET AL.: ""Positive stem cell selection--basic science"", PROG CLIN BIOL RES, vol. 333, no. 387, 1990, pages 387 - 401;;QIAN, X.; L. JIN; R.V. LLOYD: ""Percoll Density Gradient-Enriched Populations of Rat Pituitary Cells: Interleukin 6 Secretion, Proliferative Activity, and Nitric Oxide Synthase Expression"", ENDOCR PATHOL, vol. 9, no. 1, 1998, pages 339 - 346;;SMITS, G.; W. HOLZGREVE; S. HAHN: ""An examination of different Percoll density gradients and magnetic activated cell sorting (MACS) for the enrichment of fetal erythroblasts from maternal blood"", ARCH GYNECOL OBSTET, vol. 263, no. 4, 2000, pages 160 - 3;;LEHNER, M.; W. HOLTER: ""Endotoxin-free purification of monocytes for dendritic cell generation via discontinuous density gradient centrifugation based on diluted Ficoll-Paque Plus"", INT ARCH ALLERGY IMMUNOL, vol. 128, no. 1, 2002, pages 73 - 6;;VAN MERRIS, V. ET AL.: ""Separation of bovine bone marrow into maturation-related myeloid cell fractions"", VET IMMUNOL IMMUNOPATHOL, vol. 83, no. 1-2, 2001, pages 11 - 7;;LASCH, J.; G. KULLERTZ; J.R. OPALKA: ""Separation of erythrocytes into age-related fractions by density or size? Counterflow centrifugation"", CLIN CHEM LAB MED, vol. 38, no. 7, 2000, pages 629 - 32;;ITO, Y.; K. SHINOMIYA: ""A new continuous-flow cell separation method based on cell density: principle, apparatus, and preliminary application to separation of human buffy coat"", J CLIN APHERESIS, vol. 16, no. 4, 2001, pages 186 - 91;;DLUBEK, D. ET AL.: ""Enrichment of normal progenitors in counter-flow centrifugal elutriation (CCE) fractions of fresh chronic myeloid leukemia leukapheresis products"", EUR J HAEMATOL, vol. 68, no. 5, 2002, pages 281 - 8;;JAISWAL, N. ET AL.: ""Osteogenic differentiation of purified, culture-expanded human mesenchymal stem cells in vitro"", J CELL BIOCHEM, vol. 64, no. 2, 1997, pages 295 - 312, XP002193569, DOI: doi:10.1002/(SICI)1097-4644(199702)64:2<295::AID-JCB12>3.0.CO;2-I;;HOU, L. ET AL.: ""Study of in vitro expansion and differentiation into neuron-like cells of human umbilical cord blood mesenchymal stem cells"", ZHONGHUA XUE YE XUE ZA ZHI, vol. 23, no. 8, 2002, pages 415 - 9;;SEKIYA, I. ET AL.: ""Expansion of Human Adult Stem Cells from Bone Marrow Stroma: Conditions that Maximize the Yields of Early Progenitors and Evaluate Their Quality"", STEM CELLS, vol. 20, no. 6, 2002, pages 530 - 41, XP009092467, DOI: doi:10.1634/stemcells.20-6-530;;MOSCA, J. D.; J. K. HENDRICKS ET AL.: ""Mesenchymal stem cells as vehicles for gene delivery."", CLIN ORTHOP, vol. 379, 2000, pages 71 - 90;;WALTHER, W.; U. STEIN: ""Viral vectors for gene transfer: a review of their use in the treatment of human diseases."", DRUGS, vol. 60, no. 2, 2000, pages 249 - 71, XP000979501, DOI: doi:10.2165/00003495-200060020-00002;;ATHANASOPOULOS, T.; S. FABB ET AL.: ""Gene therapy vectors based on adeno-associated virus: characteristics and applications to acquired and inherited diseases (review)."", INT J MOL MED, vol. 6, no. 4, 2000, pages 363 - 75, XP001034010;;MURAMATSU, T.; A. NAKAMURA ET AL.: ""In vivo electroporation: a powerful and convenient means of nonviral gene transfer to tissues of living animals (Review)."", INT J MOL MED, vol. 1, no. 1, 1998, pages 55 - 62, XP009000374;;GIMBLE, J. M.; C. MORGAN ET AL.: ""Bone morphogenetic proteins inhibit adipocyte differentiation by bone marrow stromal cells."", J CELL BIOCHEM, vol. 58, no. 3, 1995, pages 393 - 402, XP001094236, DOI: doi:10.1002/jcb.240580312;;LENNON, D. P.; S. E. HAYNESWORTH ET AL.: ""A chemically defined medium supports in vitro proliferation and maintains the osteochondral potential of rat marrow-derived mesenchymal stem cells."", EXP CELL RES, vol. 219, no. 1, 1995, pages 211 - 22, XP001180075, DOI: doi:10.1006/excr.1995.1221;;MAJUMDAR, M. K.; M. A. THIEDE ET AL.: ""Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (MSCs) and stromal cells."", J CELL PHYSIOL, vol. 176, no. 1, 1998, pages 57 - 66, XP000857632, DOI: doi:10.1002/(SICI)1097-4652(199807)176:1<57::AID-JCP7>3.0.CO;2-7;;CAPLAN, A. I.; V. M. GOLDBERG: ""Principles of tissue engineered regeneration of skeletal tissues."", CLIN ORTHOP, vol. 367, 1999, pages 12 - 6;;OHGUSHI, H.; A. I. CAPLAN: ""Stem cell technology and bioceramics: from cell to gene engineering."", J BIOMED MATER RES, vol. 48, no. 6, 1999, pages 913 - 27, XP000996617, DOI: doi:10.1002/(SICI)1097-4636(1999)48:6<913::AID-JBM22>3.0.CO;2-0;;PITTENGER, M.; F., A. M. MACKAY ET AL.: ""Multilineage potential of adult human mesenchymal stem cells."", SCIENCE, vol. 284, no. 5411, 1999, pages 143 - 7, XP002942313, DOI: doi:10.1126/science.284.5411.143;;CAPLAN, A. 1.; S. P. BRUDER: ""Mesenchymal stem cells: building blocks for molecular medicine in the 21st century."", TRENDS MOL MED, vol. 7, no. 6, 2001, pages 259 - 64, XP001156351, DOI: doi:10.1016/S1471-4914(01)02016-0;;FUKUDA, K.: ""Development of regenerative cardiomyocytes from mesenchymal stem cells for cardiovascular tissue engineering."", ARTIF ORGANS, vol. 25, no. 3, 2001, pages 187 - 93, XP002285275, DOI: doi:10.1046/j.1525-1594.2001.025003187.x;;WORSTER, A. A.; B. D. BROWER-TOLAND ET AL.: ""Chondrocytic differentiation of mesenchymal stem cells sequentially exposed to transforming growth factor-betal in monolayer and insulin- like growth factor-I in a three-dimensional matrix."", J ORTHOP RES, vol. 19, no. 4, 2001, pages 738 - 49, XP055071743, DOI: doi:10.1016/S0736-0266(00)00054-1;;ZUK, P. A.; M. ZHU ET AL.: ""Multilineage cells from human adipose tissue: implications for cell- based therapies."", TISSUE ENG, vol. 7, no. 2, 2001, pages 211 - 28, XP002746115, DOI: doi:10.1089/107632701300062859;;MIZUNO, H.; P. A. ZUK ET AL.: ""Myogenic differentiation by human processed lipoaspirate cells."", PLAST RECONSTR SURG, vol. 109, no. 1, 2002, pages 199 - 209, XP009151040;;LIND, M.: ""Growth factor stimulation of bone healing. Effects on osteoblasts, osteomies, and implants fixation"", ACTA ORTHOP SCAND SUPPL, vol. 283, 1998, pages 2 - 37;;HANADA, K.; J.E. DENNIS; A.I. CAPLAN: ""Stimulatory effects of basic fibroblast growth factor and bone morphogenetic protein-2 on osteogenic differentiation of rat bone marrow-derived mesenchymal stem cells"", J BONE MINER RES, vol. 12, no. 10, 1997, pages 1606 - 14, XP002919088, DOI: doi:10.1359/jbmr.1997.12.10.1606;;LIEBERMAN, J.R. ET AL.: ""Regional gene therapy with a BMP-2-producing murine stromal cell line induces heterotopic and orthotopic bone formation in rodents"", J ORTHOP RES, vol. 16, no. 3, 1998, pages 330 - 9, XP002089723, DOI: doi:10.1002/jor.1100160309;;JEAN, J.L.; S.J. WANG; M.K. AU: ""Treatment of a large segmental bone defect with allograft and autogenous bone marrow graft"", J FORMOS MED ASSOC, vol. 96, no. 7, 1997, pages 553 - 7;;SAADEH, P.B. ET AL.: ""Repair of a Critical Size Defect in the Rat Mandible Using Allogenic Type I Collagen"", J CRANIOFAC SURG, vol. 12, no. 6, 2001, pages 573 - 579;;PETITE, H. ET AL.: ""Tissue-engineered bone regeneration"", NAT BIOTECHNOL, vol. 18, no. 9, 2000, pages 959 - 63, XP001157176, DOI: doi:10.1038/79449;;GAO, J. ET AL.: ""Tissue-Engineered Fabrication of an Osteochondral Composite Graft Using Rat Bone Marrow-Derived Mesenchymal Stem Cells"", TISSUE ENG, vol. 7, no. 4, 2001, pages 363 - 71, XP008005883, DOI: doi:10.1089/10763270152436427;;OHGUSHI, H.; A.I. CAPLAN: ""Stem cell technology and bioceramics: from cell to gene engineering"", J BIOMED MATER RES, vol. 48, no. 6, 1999, pages 913 - 27, XP000996617, DOI: doi:10.1002/(SICI)1097-4636(1999)48:6<913::AID-JBM22>3.0.CO;2-0;;CAPLAN, A.I.; V.M. GOLDBERG: ""Principles of tissue engineered regeneration of skeletal tissues"", CLIN ORTHOP, vol. 367, 1999, pages 12 - 6;;CAPLAN, A.I.; S.P. BRUDER: ""Mesenchymal stem cells: building blocks for molecular medicine in the 21st century"", TRENDS MOL MED, vol. 7, no. 6, 2001, pages 259 - 64, XP001156351, DOI: doi:10.1016/S1471-4914(01)02016-0;;ZUK, P.A. ET AL.: ""Multilineage cells from human adipose tissue: implications for cell- based therapies"", TISSUE ENG, vol. 7, no. 2, 2001, pages 211 - 28, XP002746115, DOI: doi:10.1089/107632701300062859;;LUSKEY, B.D. ET AL.: ""Gene transfer into murine hematopoietic stem cells and bone marrow stromal cells"", ANN N Y ACAD SCI, vol. 612, no. 398, 1990, pages 398 - 406;;GROMPE, M. ET AL.: ""Therapeutic trials in the murine model of hereditary tyrosinaemia type I: a progress report"", J INHERIT METAB DIS, vol. 21, no. 5, 1998, pages 518 - 31;;GAZIT, D. ET AL.: ""Engineered pluripotent mesenchymal cells integrate and differentiate in regenerating bone: a novel cell-mediated gene therapy"", J GENE MED, vol. 1, no. 2, 1999, pages 121 - 33, XP001010376, DOI: doi:10.1002/(SICI)1521-2254(199903/04)1:2<121::AID-JGM26>3.0.CO;2-J;;MOSCA, J.D. ET AL.: ""Mesenchymal stem cells as vehicles for gene delivery"", CLIN ORTHOP, vol. 379, 2000, pages 71 - 90;;GREENBERG, A.W.; D.A. HAMMER: ""Cell separation mediated by differential rolling adhesion"", BIOTECHNOL BIOENG, vol. 73, no. 2, 2001, pages 111 - 24, XP002506839, DOI: doi:10.1002/bit.1043;;CELL TISSUE RES, vol. 241, no. 2, 1985, pages 283 - 90;;SCHWEITZER, C.M. ET AL.: ""Isolation and culture of-human bone marrow endothelial cells"", EXP HEMATOL, vol. 23, no. 1, 1995, pages 41 - 8;;COLEMAN, S. R.: ""Long-term survival of fat transplants: controlled demonstrations."", AESTHETIC PLAST SURG, vol. 19, no. 5, 1995, pages 421 - 5;;COLEMAN, S. R.: ""Structural fat grafts: the ideal filler?"", CLIN PLAST SURG, vol. 28, no. 1, 2001, pages 111 - 9;;COLEMAN, W. P., 3RD: ""Autologous fat transplantation."", PLAST RECONSTR SURG, vol. 88, no. 4, 1991, pages 736;;EREMIA, S.; N. NEWMAN: ""Long-term follow-up after autologous fat grafting: analysis of results from 116 patients followed at least 12 months after receiving the last of a minimum of two treatments."", DERMATOL SURG, vol. 26, no. 12, 2000, pages 1150 - 8;;GUERREROSANTOS, J.; A. GONZALEZ-MENDOZA ET AL.: ""Long-term survival of free fat grafts in muscle: an experimental study in rats."", AESTHETIC PLAST SURG, vol. 20, no. 5, 1996, pages 403 - 8, XP009151094;;PALMA, P. C.; C. L. RICCETTO ET AL.: ""Repeated lipoinjections for stress urinary incontinence."", J ENDOUROL, vol. 11, no. 1, 1997, pages 67 - 70;;LEE, P. E.; R. C. KUNG ET AL.: ""Periurethral autologous fat injection as treatment for female stress urinary incontinence: a randomized double-blind controlled trial."", J UROL, vol. 165, no. L, 2001, pages 153 - 8, XP005554356, DOI: doi:10.1097/00005392-200101000-00037;;LEE, J. H.; Z. ILIC ET AL.: ""Cell kinetics of repair after allyl alcohol-induced liver necrosis in mice."", INT J EXP PATHOL, vol. 77, no. 2, 1996, pages 63 - 72;;WERLICH, T.; K. J. STILLER ET AL.: ""Experimental studies on the stem cell concept of liver regeneration. n."", EXP TOXICOL PATHOL, vol. 51, no. 1, 1999, pages 93 - 8;;YIN, L.; D. LYNCH ET AL.: ""Participation of different cell types in the restitutive response of the rat liver to periportal injury induced by allyl alcohol."", J HEPATOL, vol. 31, no. 3, 1999, pages 497 - 507, XP001159743, DOI: doi:10.1016/S0168-8278(99)80043-9;;YAVORKOVSKY, L.; E. LAI ET AL.: ""Participation of small intraportal stem cells in the restitutive response of the liver to periportal necrosis induced by allyl alcohol."", HEPATOLOGY, vol. 21, no. 6, 1995, pages 1702 - 12;;WERLICH, T.; K. J. STILLER ET AL.: ""Experimental studies on the stem cell concept of liver regeneration. II."", EXP TOXICOL PATHOL, vol. 51, no. 1, 1999, pages 93 - 8;;MURRY, C. E.; R. W. WISEMAN ET AL.: ""Skeletal myoblast transplantation for repair of myocardial necrosis."", J CLIN INVEST, vol. 98, no. 11, 1996, pages 2512 - 23, XP002078686, DOI: doi:10.1172/JCI119070;;ORLIC, D.; J. KAJSTURA ET AL.: ""Bone marrow cells regenerate infarcted myocardium."", NATURE, vol. 410, no. 6829, 2001, pages 701 - 5, XP002965971, DOI: doi:10.1038/35070587;;RAJNOCH, C.; J. C. CHACHQUES ET AL.: ""Cellular therapy reverses myocardial dysfunction."", J THORAC CARDIOVASC SURG, vol. 121, no. 5, 2001, pages 871 - 8, XP002316435, DOI: doi:10.1067/mtc.2001.112937;;STRAUER, B. E.; M. BREHM ET AL.: ""Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans."", CIRCULATION, vol. 106, no. 15, 2002, pages 1913 - 8, XP002364839, DOI: doi:10.1161/01.CIR.0000034046.87607.1C;;HORWITZ, E. M.; D. J. PROCKOP ET AL.: ""Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta."", NAT MED, vol. 5, no. 3, 1999, pages 309 - 13, XP002924802, DOI: doi:10.1038/6529;;HORWITZ, E. M.; D. J. PROCKOP ET AL.: ""Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta"", BLOOD, vol. 97, no. 5, 2001, pages 1227 - 31;;AVITAL, L, D. INDERBITZIN ET AL.: ""Isolation, characterization, and transplantation of bone marrow-derived hepatocyte stem cells."", BIOCHEM BIOPHYS RES COMMUN, vol. 288, no. 1, 2001, pages 156 - 64, XP002340918, DOI: doi:10.1006/bbrc.2001.5712;;CARMELIET, P.; A. LUTTUN: ""The emerging role of the bone marrow-derived stem cells in (therapeutic) angiogenesis."", THROMB HAEMOST, vol. 86, no. 1, 2001, pages 289 - 97, XP009014929;;CASTRO-MALASPINA, H.; W. EBELL ET AL.: ""Human bone marrow fibroblast colony-forming units (CFU-F)."", PROG CLINBIOL RES, vol. 154, 1984, pages 209 - 36;;CONNOLLY, J. F.: ""Clinical use of marrow osteoprogenitor cells to stimulate osteogenesis."", CLIN ORTHOP, vol. 355, 1998, pages 257 - 66;;GUERREROSANTOS, J.; A. GONZALEZ-MENDOZA ET AL.: ""Long-term survival of free fat grafts in muscle: an experimental study in rats"", AESTHETIC PLAST SURG, vol. 20, no. 5, 1996, pages 403 - 8, XP009151094;;HORWITZ, E. M.; D. J. PROCKOP ET AL.: ""Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta."", BLOOD, vol. 97, no. 5, 2001, pages 1227 - 31;;HUANG, J. L; S. R. BEANES ET AL.: ""Rat extramedullary adipose tissue as a source of osteochondrogenic progenitor cells."", PLAST RECONSTR SURG, vol. 109, no. 3, 2002, pages 1033 - 41;;HUTLEY, L. J.; A. C. HERINGTON ET AL.: ""Human adipose tissue endothelial cells promote preadipocyte proliferation."", AM J PHYSIOL ENDOCRINOL METAB, vol. 281, no. 5, 2001, pages EL 037 - 44;;KERN, P. A.; A. KNEDLER ET AL.: ""Isolation and culture of microvascular endothelium from human adipose tissue."", J CLIN INVEST, vol. 71, no. 6, 1983, pages 1822 - 9;;LEE, P. E.; R. C. KUNG ET AL.: ""Periurethral autologous fat injection as treatment for female stress urinary incontinence: a randomized double-blind controlled trial."", J UROL, vol. 165, no. 1, 2001, pages 153 - 8, XP005554356, DOI: doi:10.1097/00005392-200101000-00037;;MURAYAMA, T.; O. M. TEPPER ET AL.: ""Determination of bone marrow-derived endothelial progenitor cell significance in angiogenic growth factor-induced neovascularization in vivo."", EXP HEMATOL, vol. 30, no. 8, 2002, pages 967 - 72, XP002985415, DOI: doi:10.1016/S0301-472X(02)00867-6;;MUSCHLER, G. F.; H. NITTO ET AL.: ""Age- and gender-related changes in the cellularity of human bone marrow and the prevalence of osteoblastic progenitors."", J ORTHOP RES, vol. 19, no. 1, 2001, pages 117 - 25;;NISHIMORI, M.; Y. YAMADA ET AL.: ""Health-related quality of life of unrelated bone marrow donors in Japan."", BLOOD, vol. 99, no. 6, 2002, pages 1995 - 2001;;ORLIC, D.; J. KAJSTURA ET AL.: ""Transplanted adult bone marrow cells repair myocardial infarcts in mice"", ANN N Y ACAD SCI, vol. 938, 2001, pages 221 - 9;;PAHNA, P. C.; C. L. RICCETTO ET AL.: ""Repeated lipoinjections for stress urinary incontinence."", J ENDOUROL, vol. 11, no. 1, 1997, pages 67 - 70;;PITTENGER, M. F.; A. M. MACKAY ET AL.: ""Multilineage potential of adult human mesenchymal stem cells."", SCIENCE, vol. 284, no. 5411, 1999, pages 143 - 7, XP002942313, DOI: doi:10.1126/science.284.5411.143;;PROCKOP, D. J.; S. A. AZIZI ET AL.: ""Potential use of marrow stromal cells as therapeutic vectors for diseases of the central nervous system."", PROG BRAIN RES, vol. 128, 2000, pages 293 - 7, XP009091457, DOI: doi:10.1016/S0079-6123(00)28026-6;;SHI, Q.; S. RAFII ET AL.: ""Evidence for circulating bone marrow-derived endothelial cells."", BLOOD, vol. 92, no. 2, 1998, pages 362 - 7;;TAKAHASHI, T.; C. KALKA ET AL.: ""Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization."", NAT MED, vol. 5, no. 4, 1999, pages 434 - 8, XP002918947, DOI: doi:10.1038/8462;;THOMAS, E. D.: ""Stem Cell Transplantation: Past, Present and Future."", STEM CELLS, vol. 12, 1994, pages 539 - 544;;PATRICK C W JR ET AL: ""Long-term implantation of preadipocyte-seeded PLGA scaffolds."", TISSUE ENGINEERING APR 2002, vol. 8, no. 2, April 2002 (2002-04-01), pages 283 - 293, ISSN: 1076-3279;;Y TABATA ET AL: ""De novo formation of adipose tissue by controlled release of basic fibroblast growth factor"", TISSUE ENGINEERING, 1 June 2000 (2000-06-01), UNITED STATES, pages 279, XP055086762, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pubmed/10941222> DOI: 10.1089/10763270050044452;;KIMURA YU ET AL: ""Adipose tissue engineering based on human preadipocytes combined with gelatin microspheres containing basic fibroblast growth factor."", BIOMATERIALS JUN 2003, vol. 24, no. 14, June 2003 (2003-06-01), pages 2513 - 2521, XP004419996, ISSN: 0142-9612, DOI: 10.1016/S0142-9612(03)00049-8;;HEMMRICH KARSTEN ET AL: ""Implantation of preadipocyte-loaded hyaluronic acid-based scaffolds into nude mice to evaluate potential for soft tissue engineering."", BIOMATERIALS DEC 2005, vol. 26, no. 34, December 2005 (2005-12-01), pages 7025 - 7037, ISSN: 0142-9612;;VON HEIMBURG D ET AL: ""Human preadipocytes seeded on freeze-dried collagen scaffolds investigated in vitro and in vivo."", BIOMATERIALS MAR 2001, vol. 22, no. 5, March 2001 (2001-03-01), pages 429 - 438, XP004227888, ISSN: 0142-9612, DOI: 10.1016/S0142-9612(00)00186-1;;MASUDA TEIICHI ET AL: ""Photocured, styrenated gelatin-based microspheres for de novo adipogenesis through corelease of basic fibroblast growth factor, insulin, and insulin-like growth factor I."", TISSUE ENGINEERING, vol. 10, no. 3-4, March 2004 (2004-03-01), pages 523 - 535, XP055086755, ISSN: 1076-3279, DOI: 10.1089/107632704323061889;;WALTON ROBERT L ET AL: ""De novo adipose formation in a vascularized engineered construct."", MICROSURGERY 2004, vol. 24, no. 5, 2004, pages 378 - 384, ISSN: 0738-1085;;CRONIN KEVIN J ET AL: ""New murine model of spontaneous autologous tissue engineering, combining an arteriovenous pedicle with matrix materials."", PLASTIC AND RECONSTRUCTIVE SURGERY JAN 2004, vol. 113, no. 1, January 2004 (2004-01-01), pages 260 - 269, ISSN: 0032-1052;;STERODIMAS ARIS ET AL: ""Autologous fat transplantation versus adipose-derived stem cell-enriched lipografts: a study."", AESTHETIC SURGERY JOURNAL AUG 2011, vol. 31, no. 6, August 2011 (2011-08-01), pages 682 - 693, ISSN: 1527-330X",DISCONTINUED
623,AU,A,AU 1988/014013 A,061-811-136-318-379,1988-09-29,1988,AU 1988/014013 A,1988-03-30,GB 8707544 A;;GB 8724616 A,1987-03-30,REINFORCING A GRASSED SURFACE,,NETLON LTD;;ROYAL HONG KONG JOCKEY CLUB THE,HALLIDAY JOHN;;MARTIN KEITH FRASER,,https://lens.org/061-811-136-318-379,Patent Application,no,0,1,10,13,0,E01C13/083;;F02B1/04;;E01C13/083;;F02B1/04,A01G13/00;;A01G1/00;;E01C13/08;;F02B1/04,,0,0,,,,DISCONTINUED
624,GB,A,GB 909054 A,093-138-794-851-793,1962-10-24,1962,GB 1026160 A,1961-03-17,GB 1026160 A,1961-03-17,Purification of tolylene diamines,"A process for the purification of mixed tolylene diamines obtained by the reduction of the dinitro compounds produced by the direct nitration of toluene comprises treating the diamines with a solvent of a temperature of from 20 DEG C. to -20 DEG C. preferably from 0 DEG C. to -20 DEG C. and removing the undissolved purified aromatic diamines from the solution. Suitable solvents are water, alcohols such as methanol, ethanol and isopropanol, and mixtures of such alcohols with water, and mixtures of chloroform, carbon tetrachloride and aromatic hydrocarbons such as benzene, toluene and xylene, with aliphatic hydrocarbons such as hexane, heptane, isooctane, cyclohexane and mixtures thereof, for example light petroleum (boiling point 40 DEG to 60 DEG C.) and o-dichlorobenzene. The solvent is preferably used in an amount from half to ten times the weight of the diamines to be purified. The process may be carried out by mixing the aromatic diamines, preferably in a finely divided form, with the solvent at the desired temperature, and agitating the mixture until all soluble material has dissolved. Alternatively the diamines and solvent may be mixed at an elevated temperature, for example at 50 DEG to 100 DEG C. until all soluble material has dissolved, and then cooling the mixture to the desired temperature range, when the undissolved purified diamines are removed by, for example, filtration or centrifugal means. Examples are given of removing the ortho isomers as impurities in a mixture of 2:4 and 2:6 isomers of diaminotoluenes using isopropanol and ortho-dichlorobenzene as solvents.",ICI LTD,GARDNER CYRIL;;PRESCOTT JOHN FRASER,,https://lens.org/093-138-794-851-793,Granted Patent,no,0,1,2,2,0,C07C209/84;;C07C211/50;;C07C209/84,,C2C CNH;;C2C C22Y;;C2C C220;;C2C C227;;C2C C30Y;;C2C C32Y;;C2C C321;;C2C C43X;;C2C C630;;C2C C660;;C2C C774;;C2C C776,0,0,,,,EXPIRED
625,US,A,US 758907 A,099-628-332-569-240,1904-05-03,1904,US 1903/0165617 A,1903-07-15,US 1903/0165617 A,1903-07-15,SIEVE BOLTING-MACHINE.,,FRASER JOHN;;MATHER ALLAN G,FRASER JOHN;;MATHER ALLAN G,,https://lens.org/099-628-332-569-240,Granted Patent,no,0,7,1,1,0,B07B1/38;;B07B1/38,,,0,0,,,,EXPIRED
626,CA,A1,CA 3043013 A1,148-722-361-850-548,2018-05-11,2018,CA 3043013 A,2017-11-07,US 201662418637 P;;US 2017/0060413 W,2016-11-07,RAB ESCORT PROTEIN POTENCY ASSAY,"Methods for measuring REP-1 and REP-2 activity are provided. In certain embodiments, a method includes: (a) contacting cells that do not express endogenous functional REP-1 or REP-2 protein with an adeno-associated viral (AAV) vector comprising a CHM gene encoding a REP-1 protein or CHM like gene encoding a REP-2 protein under conditions allowing cell transduction; (b) incubating transduced cells under conditions allowing expression of the encoded REP-1 or REP-2 protein; (c) lysing the transduced cells to produce an extract comprising the encoded REP-1 or REP-2 protein and Rab small GTPase (Rabs); (d) incubating said extract with a Rab substrate for a period of time and under conditions allowing prenylation of the Rab thereby forming prenylated Rab; and (e) detecting and/or quantifying the prenylated Rab, wherein the amount of prenylated Rab reflects REP-1 or REP-2 activity thereby measuring REP-1 or REP-2 activity.",SPARK THERAPEUTICS INC,WRIGHT JOHN FRASER;;SUMAROKA MARINA,,https://lens.org/148-722-361-850-548,Patent Application,no,0,0,11,11,0,C12Y205/0106;;C12Q1/48;;G01N2333/91171;;C12N9/1085;;C12Q1/48;;G01N2333/91171;;C12Y205/0106,A61K48/00;;C12N15/86,,0,0,,,,PENDING
627,JP,A,JP 2012235788 A,150-131-049-232-400,2012-12-06,2012,JP 2012170066 A,2012-07-31,US 47238403 P;;US 54975604 P,2003-05-21,METHOD FOR PRODUCING PREPARATION OF RECOMBINANT AAV VIRION SUBSTANTIALLY FREE OF EMPTY CAPSID,"PROBLEM TO BE SOLVED: To provide new methods for enhancing manufacturing capability by removing empty capsids from stocks of AAV vector particles or reducing the numbers of empty capsids.SOLUTION: The empty capsids can be separated from rAAV virions (""AAA vector particles"") containing genetic material using column chromatography techniques. Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.",GENZYME CORP,QU GUANG;;WRIGHT JOHN FRASER,,https://lens.org/150-131-049-232-400,Patent Application,no,1,0,40,41,0,C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N15/86;;C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N2710/16651;;C12N2710/10351;;C12N2760/16051;;C12N15/86,C12N7/00;;C12N/;;C12N7/02;;C12N15/09;;C12N15/86;;C12N15/864,,4,0,,,"JPN6010005001; Ｍｏｌｅｃｕｌａｒ Ｔｈｅｒａｐｙ， （２００２）， Ｖｏｌ． ６， Ｎｏ． ５， ｐ． ６７８-６８６;;JPN5006016005; ＧＡＯ． Ｇ．: ＨＵＭＡＮ ＧＥＮＥ ＴＨＥＲＡＰＹ Ｖ１１, 200010, Ｐ２０７９-２０９１;;JPN6010005004; Ｈｕｍａｎ Ｇｅｎｅ Ｔｈｅｒａｐｙ， （２００２）， Ｖｏｌ． １３， ｐ． １２３５-１２４３;;JPN5007009046; ＱＵ，Ｇ．: ＣＵＲＲ．ＯＰＩＮＩＯＮ ＩＮ ＤＲＵＧ ＤＩＳＣＯＶＥＲＹ ＆ ＤＥＶＥＬＯＰＭＥＮＴ Ｖ３ Ｎ６, 2000, Ｐ７５０-７５５",DISCONTINUED
628,KR,A,KR 20230145474 A,143-781-962-119-265,2023-10-17,2023,KR 20237031927 A,2022-02-18,US 202163150797 P;;CA 2022050237 W,2021-02-18,리튬 및 배터리 화학물질 생성 시 황산나트륨 부산물 가공,"배터리 화학물질 생성을 위한 방법으로서, 황산나트륨 스트림을 이온 교환 공정으로 처리하여 황산칼륨 및 염화나트륨을 제공하는, 방법. 염화나트륨은 클로르-알칼리로 처리되어, 배터리 화학물질 생성 공정의 상류에서 사용하기 위한 수산화나트륨을 생성할 수 있다.",HATCH LTD,FRASER ROBERT JOHN;;STAMATIOU EVANGELOS,,https://lens.org/143-781-962-119-265,Patent Application,no,0,0,8,8,0,C01D3/04;;C01D1/04;;C01D5/00;;C25B1/34;;C25B15/081;;Y02E60/10;;C01D1/04;;C01D5/00;;C25B1/46;;C25B9/23;;Y02E60/10;;B01J49/57;;B01J41/04;;B01J41/12;;C01D1/20;;C01D3/04;;C01D5/02;;C01P2006/40,C01D1/04;;C01D5/00;;C25B1/46;;C25B9/23,,0,0,,,,PENDING
629,BR,A,BR 0214772 A,160-286-264-850-585,2007-01-09,2007,BR 0214772 A,2002-12-09,US 33885601 P;;US 0239465 W,2001-12-07,sistemas e métodos para o tratamento de pacientes com células lipoaspiradas processadas,"""SISTEMAS E MéTODOS PARA O TRATAMENTO DE PACIENTES COM CéLULAS LIPOASPIRADAS PROCESSADAS"". As células presentes em um tecido lipoaspirado processado são usadas para tratar pacientes. Os métodos de tratamento de pacientes incluem o processamento de um tecido adiposo de modo a fornecer uma quantidade concentrada de células-tronco obtidas do tecido adiposo para um paciente. os métodos podem ser praticados em um sistema fechado de modo que as células não fiquem expostas a um ambiente externo antes de serem administradas a um paciente. As composições que são administradas a um paciente incluem uma mistura de tecido adiposo e células-tronco de modo que a composição apresente uma concentração maior de células tronco do que quando o tecido adiposo foi retirado do paciente.",MACROPORE BIOSURGERY INC,FRASER JOHN;;HENDRICK MARC H,,https://lens.org/160-286-264-850-585,Patent Application,no,0,0,65,221,0,A61K35/28;;A61K35/28;;A61K48/00;;A61B10/0283;;A61B10/0283;;A61K9/0019;;A61K9/0019;;A61K35/32;;A61K35/35;;A61K35/35;;A61K35/36;;A61M1/76;;A61M2202/08;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/00;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;A61P43/00;;C12M47/04;;C12N5/0667;;C12N5/0667;;C12N5/069;;C12N5/069;;C12N2506/1384;;C12N2506/1384,A61M1/00;;A61K31/436;;A61K35/02;;A61K35/12;;A61K35/28;;A61K35/35;;A61K35/36;;A61K38/00;;A61K38/16;;A61K45/00;;A61L27/00;;A61P1/00;;A61P1/16;;A61P3/00;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P19/00;;A61P19/02;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;C12M3/06;;C12N5/0775,,0,0,,,,DISCONTINUED
630,AU,A,AU 1980/064941 A,182-752-412-673-570,1982-04-29,1982,AU 1980/064941 A,1980-12-01,US 19846080 A,1980-10-20,CELLULOSIC FUEL PELLETS,,TRANS WORLD ENTERPRISES,JOHNSTON IAN FRASER;;HOUSEMAN JOHN,,https://lens.org/182-752-412-673-570,Patent Application,no,0,0,5,5,0,Y02E50/10;;Y02E50/30,C10L/;;C10L5/14;;C10L5/44,,0,0,,,,DISCONTINUED
631,CN,B,CN 103260525 B,195-299-967-278-506,2015-07-15,2015,CN 201180059600 A,2011-12-08,IB 2011055546 W;;US 42247910 P,2010-12-13,Adjusting measurements of the effects of acoustic radiation force for background motion effects,,KONINKL PHILIPS ELECTRONICS NV,FRASER JOHN DOUGLAS;;H XIE,,https://lens.org/195-299-967-278-506,Granted Patent,no,0,0,14,14,0,A61B8/0825;;A61B8/4488;;A61B8/5276;;G01S7/52036;;G01S7/52042;;G01S7/5205;;G01S7/52095;;G01S15/8925;;A61B8/485;;A61B8/4488;;A61B8/485;;G01S7/52036;;A61B8/4488;;A61B8/5276;;G01S7/52036;;A61B8/0825;;G01S7/52042;;G01S7/5205;;G01S7/52095;;G01S15/8925;;A61B8/485,A61B8/00;;G01S7/52,,0,0,,,,ACTIVE
632,GB,A,GB 190007716 A,018-127-249-935-875,1901-03-30,1901,GB 190007716D A,1900-04-26,GB 190007716T A,1900-04-26,Improved Hygienic Heel Support.,"7716. Galloway, W., and MacGregor, J. F. April 26. Heels socks; ventilating.-Relates to elastic heel pads for reducing shock in walking, preventing the heel from wearing unevenly, and promoting ventilation. Fig. 1 shows a plan, Fig. 2 an underview, and Fig. 6 a longitudinal section of one. It is composed of india-rubber or other elastic material, and has on its upper face a number of projections c perforated at j. These perforations lead into cells d, which open into recesses communicating with annular grooves e. These grooves are connected by channels g, h leading into openings i at the front of the pad. During walking, the cells d are alternately compressed and expanded, so that air is pumped in and out, and the boot well ventilated. The upper surface of the pad may be protected by chamois leather, perforated over the openings j, and the lower surface may be covered by a strip of canvas k. The pad may be thickened by india-rubber lifts l, Fig. 6, perforated over the cells.",GALLOWAY WILLIAM;;MACGREGOR JOHN FRASER,GALLOWAY WILLIAM;;MACGREGOR JOHN FRASER,,https://lens.org/018-127-249-935-875,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
633,US,B2,US 11261463 B2,037-505-483-571-162,2022-03-01,2022,US 201916538664 A,2019-08-12,US 201916538664 A;;US 201816019139 A;;US 201615351725 A;;US 201213368167 A;;US 80965507 A;;US 85168804 A;;US 54975604 P;;US 47238403 P,2003-05-21,Methods for producing preparations of recombinant AAV virions substantially free of empty capsids,Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.,GENZYME CORP,QU GUANG;;WRIGHT JOHN FRASER,AVIGEN INC (2004-08-27);;GENZYME CORPORATION (2007-09-25),https://lens.org/037-505-483-571-162,Granted Patent,yes,24,1,40,41,0,C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N15/86;;C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N2710/16651;;C12N2710/10351;;C12N2760/16051;;C12N15/86,C12N15/86;;C12N/;;C12N7/00;;C12N7/02;;C12N15/864,,37,32,056-315-332-834-967;;082-256-886-757-890;;117-352-835-844-351;;136-631-017-232-397;;031-924-489-357-130;;141-768-814-445-684;;020-844-173-544-686;;008-227-308-422-865;;089-800-605-790-418;;003-351-517-641-454;;004-717-207-320-786;;040-850-901-799-916;;001-346-905-665-504;;156-118-146-118-185;;083-686-476-906-538;;001-855-353-292-660;;131-849-343-621-830;;071-415-183-497-398;;133-796-772-596-115;;036-117-611-735-723;;127-234-167-778-680;;068-982-043-431-314;;051-418-497-856-216;;135-987-388-625-166;;042-838-870-694-53X;;024-206-805-530-75X;;127-947-112-426-944;;045-942-479-095-293;;008-767-212-664-381;;088-196-754-870-804;;165-644-511-657-053;;063-793-003-971-602,10.1016/s0166-0934(99)00150-0;;0010716335;;10716335;;10.1016/s1525-0016(02)90719-7;;12436964;;10.1006/mthe.2002.0719;;16231055;;10.1038/sj.gt.3302611;;17764561;;10.1186/1471-2199-8-74;;pmc2064930;;10.1016/j.toxicon.2005.11.004;;16386282;;10.1089/10430349950018427;;10223736;;10.1016/j.jviromet.2004.07.001;;15381358;;10821405;;10.1016/s0378-4347(00)00100-6;;11269337;;10.1002/1521-2254(2000)9999:9999<::aid-jgm152>3.0.co;2-u;;10.1089/104303400750001390;;11044910;;10455443;;10.1038/sj.gt.3300946;;10.1089/104303402320139014;;12133276;;10.1038/ng1386;;15220920;;10.1016/0005-2795(70)90310-7;;5534305;;10.1016/s0962-8924(98)01360-9;;9789330;;10.1016/s1525-0016(16)41455-3;;10.1016/s0076-6879(02)46069-7;;11883083;;17196264;;10.1016/j.jviromet.2006.11.019;;10.1016/j.ymthe.2004.06.346;;19649903;;10.1016/s1525-0016(16)42976-x;;14625046;;10.1016/j.jviromet.2003.09.002;;12459331;;10.1016/s0958-1669(02)00369-5;;10.1016/s1525-0016(02)00019-9;;12573625;;9445046;;10.1128/jvi.72.2.1438-1445.1998;;pmc124624;;15975005;;10.2174/1566523054065011;;10.1016/j.ymthe.2005.11.024;;16473554;;10.1016/j.ymthe.2006.08.1217;;11589834;;10.1089/104303401753153974;;28548061;;10.3390/biomedicines2010080;;pmc5423478;;15963933;;10.1016/j.ymthe.2005.02.021;;10.1007/bf03187263;;10.1038/sj.gt.3300938;;10455399,"Anderson, et al. “A Method For The Preparation Of Highly Purified Adeno-Associated Virus Using Affinity col. Chromatography, Protease Digestion, And Solvent Extraction,” Journal of Viralogical Methods 85:23-34 (2000).;;Brument, et al. “A Versitile And Scalable Two-Step Ion-Exchange Chromatography Process For The Purification Of Recombinant Adeno-Associated Virus Serotype-2 And -5,” Molecular Therapy §.(5):678-686 (2002).;;Burova, et al. “Chromatographic Purification of Recombinant Adenoviral and Adena-Associated Viral Vectors: Methods and Implications,” Gene Therapy vol. 12, S5-S17, 2005.;;Chalmel, et al. “Rod-derived Cone Viability Factor-2 is a Novel Bifunctional-thioredoxin-like Protein with Therapeutic Potential,” BMC Molecular Biology 2007, 8:74, 12 pages.;;Chen et al. “Isolation and Cloning ofExendin Precursor cDNAs from Single Samples of Venom from the Mexican Beaded Lizard (Heloderma rorridum) and the Gila Monster Heloderma suspectum),” Toxicon Mar. 2006, 47(3):288-295.;;Clark, et al. “Highly Purified Recombinant Adeno-Associated Virus Vectors Are Biologically Active And Free of Detectable Helper And Wild-Type Viruses,” Human Gene Therapy 10:1031-1039 (1999).;;Davidoff, et al. “Purification Of Recombinant Adeno-Associated Virus Type 8 Vectors By Ion Exchange Chromatography Generates Clinical Grade Vector Stock,” Journal of Virilogical Methods 121:209-215 (2004).;;Debelak, et al. “Cation-Exchange High-Performance Liquid Chromatography Of Recombinant Adeno-Associated Virus Type-2,” J Chroma! B 740: 195-202 (2000).;;Drittanti, et al. “Optimised Helper Virus-Free Production of High-Quality Adena-Associated Virus Vectors,” This Journal of Gene Medicine, vol. 3, pp. 59-71 (2001).;;Feit, et al. 2003, J. Pat. Trade. Off. Soc., vol. 85, No. 1, pp. 5-21.;;Gao, et al. “Purification Of Recombinant Adeno-Associated Virus Vectors By Column Chromatography And It's Performance In Vivo,” Human Gene Therapy 11:2079-2091 (2000).;;Grimm, et al. “Titration Of AA V-2 Particles Via A Novel Capsid ELISA: Packaging Of Genomes Can Limit Production Of Recombinant AA V-2,” Gene Therapy §.:1322-1330 (1999).;;Kaludov, et al. “Scalable Purification Of Adeno-Associated Virus Type 2,4, Or 5 Using Ion-Exchange Chromatography,” Human Gene Therapy II:I235-1243 (2002).;;Leveillard, et al. “Identification and Characterization of Rod-derived Cone Viability Factor,” Nature Genetics, (2004), 36(7):755-759.;;Lewis, et al. “Kinetic Study Of The Deamidation Of Growth Hormone And Prolatin,” Biochimica et Biophysica Acta 214:498-508 (1970).;;Martoglio et al., Signal Sequences: 1-15 more than just greasy peptides, Trends in Cell Biology, 8(10):410-415 (1998).;;Notice of Opposition to a European patent, patent No. EP2277996 dated Jun. 3, 2015.;;Parker, et al. “In Vivo Performance Of AA V-2 Vectors Purified By CsCI Gradient Centrifugation Or Column Chromatography,” Molecular Therapy I:S390 (2003).;;Potter, et al. “Streamlined Large-Scale Production Of Recombinant Adeno-Associated Virus (rAA V) Vectors,” Methods In Enzymology 346:413-430 (2002).;;Qu, et al. Separation of Adena-Associated Virus Type 2 Empty Particles from Genome Containing Vectors by Anion-Exchange Column Chromatography, Journal of Virological Methods, vol. 140, pp. 183-192 (2007).;;Qu, et al. “Development of a Scalable Column Chromatography-Based Purification Process to Manufacture Empty Capsid-Free AA V Vectors,” Mot Ther 2:SI62 Abst.# 424 (2004).;;Qu, et al. “Scaling-Up Production Of Recombinant AA V Vectors For Clinical Applications,” Current Opinion In Drug Discovery & Development ;1(6):750-755 (2000).;;Qu, et al. Characterization Of AA V Vectors Expressing Human Coagulation Factor IX Produced At Intermediate Scale, Molecular Therapy 5:S50 (2002).;;Response from the Applicant in the US proceedings on Apr. 2011 original file name: D13-U.S. Pat. No. 8,137,948—Response from Applicant.;;Smith, et al. Serum-Free Production and Column Purification of Adena-Associated Virus Type 5, Journal of Virological Methods, vol. 114, pp. 115-124 (2003).;;Snyder, et al. “Production Of Clinical-Grade Recombinant Adena-Associated Virus Vectors,” Current Opinion In Biotechnology .LI.:418-423 (2002).;;Sommer, et al. “Quantification Of Adena-Associated Virus Particles And Empty Capsids By Optical Density Measuremnt,” Molecular Therapy 1: 122-128 (2003).;;Summerford, et al. Membrane-Associated Heperan Sulfate Proteoglycan Is A Receptor For Adena-Associated Viruse Type 2 Virions, Journal of Virology 72:1438-1445 (1998).;;Timpe et al. Current Gene Therapy, 2005, vol. 5, pp. 273-284.;;Urabe, et al. “Removal of Empty Capsids from Type 1 Adena-Associated Virus Vector Stocks by Anion-Exchange Chromatography Potentiates Transgene Expression,” Molecular Therapy, vol. 13, No. 4, pp. 823-828.;;US Priority Document 1—U.S. Appl. No. 60/472,384, filed May 2003 original file name: D2—Priority Document 2003—US472384.;;US Priority Document 2—U.S. Appl. No. 60/549,756, filed Mar. 2004 original file name: D3—Priority Document 2004—US549756.;;Vellekamp, et al. “Empty Capsids In Column-Purified Recombinant Adenovirus Preparations,” Human Gene Therapy 12:1923-1936 (2001).;;Wright, et al. “Product-Related Impurities in Clinical-Grade Recombinant AAV Vectors: Characterization and Risk Assessment,” Biomedicines, vol. 2, pp. 80-97 (2014).;;Wright, et al. “Identification Of Factors That Contribute To Recombinant AA V2 Particle Aggregation And Methods To Prevent Its Occurance During Vector Purification And Formulation,” Molecular Therapy] 2: 171-178 (2005).;;Wu, et al. “A Novel Method For Purification Of Recombinant Adena-Associated Virus Vectors On A Large Scale,” Chinese Science Bulletine 46:485-489 (2001).;;Zoluthkin, et al. “Recombinant Adeno-Addociated Virus Purification Using Novel Methods Improves Infectious Titer And Yield,” Gene Therapy 2:973-985 (1999).",ACTIVE
634,EP,A4,EP 1751275 A4,047-011-297-002-073,2008-01-23,2008,EP 05755269 A,2005-06-01,US 2005/0019235 W;;US 57599704 P;;US 63922204 P,2004-06-01,COMPOSITIONS AND METHODS TO PREVENT AAV VECTOR AGGREGATION,,AVIGEN INC,WRIGHT JOHN FRASER;;QU GUANG,"GENZYME CORPORATION, US (2018-07-31);;GENZYME CORPORATION; US (2018-03-23);;GENZYME CORPORATION (2018-07-18);;GENZYME CORPORATION, CAMBRIDGE, US (2018-01-19)",https://lens.org/047-011-297-002-073,Search Report,no,1,0,33,34,0,C12N2750/14151;;C12N7/00;;C12N2750/14151;;C12N7/00;;C12N2750/14111,C12N7/02,,4,4,090-258-715-508-987;;024-082-216-460-229;;089-786-895-898-348;;088-196-754-870-804,10.1016/j.ymthe.2004.06.356;;9191943;;10.1099/0022-1317-78-6-1453;;15488616;;10.1016/j.jviromet.2004.07.007;;15963933;;10.1016/j.ymthe.2005.02.021,"WRIGHT J.F., ET AL: ""425. Formulation Development for AAV2 Vectors: Identification of Excipients That Inhibit Vector Aggregation"", MOLECULAR THERAPY, vol. 9, no. S1, May 2004 (2004-05-01), pages S163 - S163, XP002461847, ISSN: 1525-0016, Retrieved from the Internet <URL:doi: 10.1016/j.ymthe.2004.06.356>;;STEINBACH S ET AL: ""Assembly of adeno-associated virus type 2 capsids in vitro"", JOURNAL OF GENERAL VIROLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, SPENCERS WOOD, GB, vol. 78, no. 6, 1997, pages 1453 - 1462, XP002346582, ISSN: 0022-1317;;XIE Q ET AL: ""Large-scale production, purification and crystallization of wild-type adeno-associated virus-2"", JOURNAL OF VIROLOGICAL METHODS, AMSTERDAM, NL, vol. 122, no. 1, 1 December 2004 (2004-12-01), pages 17 - 27, XP004603069, ISSN: 0166-0934;;WRIGHT J F ET AL: ""Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulation"", MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA,, US, vol. 12, no. 1, July 2005 (2005-07-01), pages 171 - 178, XP004974961, ISSN: 1525-0016",ACTIVE
635,US,B2,US 9486484 B2,048-908-309-542-986,2016-11-08,2016,US 201414336755 A,2014-07-21,US 201414336755 A;;US 201113031031 A;;US 2009/0054055 W;;US 9018608 P,2008-08-19,Methods of using adipose tissue-derived cells in the treatment of the lymphatic system and malignant disease,"Aspects of the invention provides methods for preparing and using adipose-tissue-derived stem and progenitor cells, adipose-tissue-derived lymphatic endothelial cells, and cells capable of differentiating into lymphatic endothelial cells to treat disorders of the lymphatic system and to modulate expansion, repair, and/or regeneration of the lymphatic system. The invention further provides using adipose-tissue-derived lymphatic endothelial cells and cells capable of differentiating into lymphatic endothelial cells for delivery of therapeutic agents to tumor cells as a means for treating malignant disease, and assays to screen for drugs that modulate lymphatic system expansion, repair or regeneration.",CYTORI THERAPEUTICS INC,ALFONSO ZENI;;FRASER JOHN K,CYTORI THERAPEUTICS INC (2014-08-12);;LOREM VASCULAR PTE. LTD (2019-04-24),https://lens.org/048-908-309-542-986,Granted Patent,yes,101,4,6,6,0,A61K35/12;;A61K35/12;;A61K35/28;;A61K35/28;;A61K35/35;;A61K35/35;;A61K45/06;;A61K2035/124;;A61P3/06;;A61P9/00;;A61P35/04;;C12N5/0651;;C12N5/0651;;C12N5/0667;;C12N5/069;;C12N5/069,C12N5/00;;A61K35/12;;A61K35/28;;A61K35/35;;A61K45/06;;C12N5/071;;C12N5/078,,99,95,070-839-046-502-27X;;010-540-013-256-049;;134-654-757-212-403;;032-404-259-701-837;;001-174-850-465-856;;059-588-500-547-821;;042-989-386-993-552;;019-810-335-711-889;;014-008-860-336-482;;029-946-078-457-714;;075-284-732-479-861;;157-994-310-553-91X;;101-877-952-875-22X;;116-024-403-014-056;;071-709-364-692-057;;011-072-762-416-590;;027-803-020-078-075;;173-002-914-257-594;;007-172-022-414-518;;078-144-091-568-913;;047-253-510-312-524;;023-961-417-626-568;;116-871-349-386-357;;007-886-031-008-735;;030-049-294-751-075;;097-867-342-595-907;;015-569-025-003-488;;090-815-773-677-26X;;094-359-459-035-479;;004-182-422-100-243;;043-014-435-315-202;;007-742-922-258-989;;019-679-035-676-507;;106-649-915-724-737;;078-698-146-972-599;;020-939-213-381-300;;000-625-008-142-215;;114-069-508-870-517;;033-642-914-335-547;;063-197-629-720-396;;160-132-718-714-712;;069-962-637-789-469;;008-762-489-429-146;;015-065-494-491-841;;000-247-718-432-449;;113-062-358-749-472;;014-595-660-154-907;;091-397-407-383-437;;019-368-227-595-121;;092-482-123-514-901;;042-772-099-513-918;;076-945-814-976-839;;149-453-463-380-579;;023-684-957-851-237;;005-376-980-059-70X;;035-961-317-498-39X;;006-652-397-889-647;;022-459-651-150-57X;;017-165-339-699-387;;018-369-175-290-657;;043-947-449-038-108;;055-646-074-155-100;;027-339-475-967-163;;125-995-223-966-197;;070-522-011-983-995;;031-206-044-096-031;;027-810-214-593-214;;015-599-406-080-089;;108-799-353-449-53X;;069-205-374-732-453;;036-607-251-048-680;;003-264-302-978-919;;036-252-293-129-219;;019-888-471-790-198;;000-503-988-011-572;;009-545-708-254-047;;031-856-752-899-649;;123-956-839-153-069;;016-725-607-839-435;;023-915-407-391-147;;014-294-149-065-780;;053-963-206-893-495;;068-189-597-689-823;;000-156-231-629-318;;003-050-327-178-826;;015-055-316-845-193;;033-814-301-870-318;;030-847-714-444-597;;060-272-195-296-337;;011-995-010-843-384;;028-547-919-869-891;;004-509-498-015-514;;020-498-500-483-165;;044-955-100-185-726;;042-873-767-839-626,10.1002/jcp.10174;;12384991;;7540405;;10.1016/8756-3282(94)00044-1;;198274;;10.1016/0012-1606(77)90110-5;;6352350;;10.1051/rnd:19850201;;3887522;;10.1002/mus.880120705;;2674704;;15869434;;10.1089/ten.2005.11.556;;9579858;;10611546;;10.1089/ten.1999.5.545;;pmc1219645;;10.1042/bj3330787;;9677341;;9519353;;10.1159/000019544;;10.1053/ejvs.2001.1532;;11748945;;10.1038/nm747;;12161747;;10.1097/01.prs.0000055043.62589.05;;12711954;;10.1111/j.1524-4725.1990.tb01561.x;;2229639;;7646489;;10.1006/bbrc.1995.2141;;11181551;;10.1210/endo.142.3.8006;;10.1210/en.142.3.1325;;10.2337/diabetes.50.8.1691;;11473026;;10.1161/01.cir.0000043246.74879.cd;;12473544;;10998427;;10.3892/ijmm.6.4.363;;11594767;;10.1006/bbrc.2001.5712;;10.1002/jcp.10260;;12811816;;10.1016/s1043-2760(02)00010-3;;12475611;;10.1007/s002239900683;;10441651;;10.1083/jcb.144.4.789;;pmc2132933;;10037799;;11697641;;10.3109/10428190109097705;;10.1080/15513819809168768;;9566278;;10.1182/blood.v97.10.2957;;11342417;;10228193;;10.1056/nejm199905063401807;;10548503;;10.1006/bbrc.1999.1620;;10.1177/019459989010200402;;2136268;;6866054;;10.1056/nejm198308043090509;;10.1002/jbmr.5650111114;;8915778;;pmc6517823;;10.1111/j.1582-4934.2000.tb00125.x;;12067460;;2292654;;10.1182/blood.v77.12.2591.bloodjournal77122591;;1710512;;10.1182/blood.v77.12.2591.2591;;1757497;;10.1242/jcs.99.1.131;;10.1016/s0171-2985(82)80064-8;;6984421;;3489608;;10.1210/endo-119-4-1776;;8695822;;10.1182/blood.v88.2.731.bloodjournal882731;;6043938;;10.1016/0006-291x(85)91209-4;;2415129;;10.1093/hmg/ddi295;;16081467;;15110761;;10.1016/j.bbrc.2004.03.192;;10.1016/j.stem.2008.03.002;;pmc2613570;;18397751;;11094627;;10.1126/science.283.5401.534;;9915700;;10.1016/s0022-2275(20)34799-4;;6252272;;10.1016/s0022-2275(20)41303-3;;206638;;10931522;;10.1002/1097-4547(20000815)61:4<364::aid-jnr2>3.0.co;2-c;;10.1002/1097-4547(20000815)61:4<364::aid-jnr2>3.3.co;2-3;;10.1097/00005392-200301000-00098;;12478183;;10.1016/s0022-5347(05)64118-3;;5337892;;10.1016/s0007-1226(67)80033-x;;10.1001/archopht.1988.01060130181012;;3341968;;10.1016/j.peptides.2005.03.039;;16042991;;12115867;;10.1002/path.1158;;10.1007/bf02557680;;3922598;;8040190;;10.1002/jcp.1041600214;;10027397;;pmc1849992;;10.1016/s0002-9440(10)65285-6;;9027588;;10.1002/(sici)1097-4644(199702)64:2<278::aid-jcb11>3.0.co;2-f;;9621889;;10.1002/jor.1100160202;;10961917;;10.1042/0300-5127:0280350;;10.1042/bst0280350;;0010961917;;11248860;;10.1016/s0094-1298(20)32342-7;;10.1161/01.cir.0000074209.17561.99;;12835229;;2144412;;10.1007/bf00174624;;10.1097/00003086-199609000-00031;;8804298;;6370890;;10.1016/s0074-7696(08)62444-4;;10546632;;10.1097/00003086-199910001-00003;;10.1016/s1471-4914(01)02016-0;;11378515;;1870029;;10.1002/jor.1100090504;;10.1016/s0094-1298(20)31020-8;;7924141;;10.1016/s1359-6446(03)02866-6;;14643161;;10.1038/74651;;10742145;;11487017;;10.1007/bf00444241;;8122570;;10541768;;10.1007/s002239900721;;pmc3097937;;21607134;;10.4252/wjsc.v3.i4.25;;12193778;;10.1126/science.297.5585.1299;;10.1126/science.1080631;;10.1126/science.1079318;;12595675;;6382294;;10.1111/j.1524-475x.2006.00182.x;;17244317;;16731010;;10.1016/j.cellbi.2005.12.009;;9541256;;10.1111/j.1600-0722.1998.tb02206.x;;10.1016/s0021-9258(18)41732-2;;1326540;;pmc1397798;;10.1167/iovs.05-0975;;16303945;;12609969;;10.1161/01.res.0000063425.51108.8d;;12949903;;10.1002/jnr.10691;;6300083;;10.1016/s0021-9258(18)32630-9;;10.1016/s0167-4889(97)00083-9;;9409810;;10.1210/endo.134.1.8275945;;8275945;;10.1210/en.134.1.277;;10213083;;15621248;;10.1016/j.biomaterials.2004.09.013;;16690020;;10.1016/j.bbrc.2006.04.089;;10.1016/j.biomaterials.2005.02.022;;15949551;;10.1016/j.bbrc.2006.04.128;;16696950;;10.1210/endo-114-2-477;;6690287,"Abbate, A., Biondi-Zoccai, G.G. and Baldi, A. (2002) ""Pathophysiologic role of myocardial apoptosis in post-infarction left ventricular remodeling"" J Cell Physiol 193, 145-53.;;Aharinejad, S., Mars, S.C., Jr., Bock P., Mason-Savas, A., MacKay, C.A. Larson, E.K., Jackson, M.E., Luftensteiner, M. and Weisbauer, E. (1995) ""CSF-1 treatment promotes angiogenesis in the metaphysics of osteopetrotic (toothless, tl) rats"" Bone 16, 315-324.;;Ahrens, Patricia Buckley et al., ""Stage-Related Capacity for Limb Chondrogenesis in Cell Culture,"" Developmental Biology, 1977, 60:69-82.;;Ailhaud, et al., 1983, ""Hormonal requirements for growth and differentiation of OB17 preadipocyte cells in vitro,"" Diabete & Metabolisme, vol. 9:125-133.;;Ailhaud, et al., 1985, ""Lipoprotiene lipase et differenciation adipocytaire,"" Reprod. Nutr. Develop., vol. 25:153-158.;;Alameddine, Hale S. et al., ""Regeneration of Skeletal Muscle Fibers from Autologous Satellite Cells Multiplied In Vitro. An Experimental Model for Testing Cultured Cell Myogenicity,"" Muscle & Nerve, 1989, 12:544-55.;;Alhadlaq et al. ""Engineered adipose tissue from human mesenchymal stem cells maintains predefined shape and dimension: implications in soft tissue augmentation and reconstruction."" Tissue Eng 11, 556-566 (2005).;;Anderson, Apr. 30, 1998, Human Gene Therapy, Nature, 392 Supp (6679):25-30.;;Angele, P. et al., ""Engineering of Osteochondral Tissue with Bone Marrow Mesenchymal Progenitor Cells in a Derivatized Hyaluronan-Gelatin Composite Sponge,"" Tissue Engineering, 1999, 5:545-53.;;Ankrom et al., 1998, Age-related changes in human oestrogen receptor function and levels in osteoblasts, Biochem J. 333:787-794.;;Aragona, F., L. D'Urso et al (1998) ""Immunologic aspects of bovine injectable collagen in humans. A review"" Eur Urol 33(2): 129-33.;;Arts et al., 2002, Contaminants from the Transplant Contribute to Intimal Hyperplasia Associated with Microvascular Endothelial Cell Seeding, Eur. J. Endovasc. Surg. 23:29-38.;;Arvidsson, A., Collin, T., Kirik, D., Kokaia, Z., and Lindvall, O. (2002) ""Neuronal replacement from endogenous precursors in the adult brain after stroke"" Nat Med 8, 963-70.;;Ashjian et al., 2003, In vitro differentiation of human processed lipoaspirate cells into early neural progenitors Plast Reconstr Surg 111 1922-1931.;;Asken, S. (1990) ""Microliposuction and autologous fat transplantation for aesthetic enhancement of the aging face"" J Dermatol Surg Oncol 16(10): 965-72.;;Aso et al., Aug. 15, 1995, A Preadipocyte Clonal Line from bovine Intramuscular Adipose Tissue: Nonexpression of GLUT-4 protein during Adipocyte Differentiation, Biochem. Biophys. Res. Commun. 213:369-375.;;Asou, Y., Rittling, S.R., Yoshitake, H., Tsuji, K., Shinomiya, K., Nifuji, A., Denhardt, D.T., and Noda, M. (2001) ""Osteopontin facilitates angiogenesis, accumulation of osteoclasts, and resorption in ectopic bone"" Endocrinology 142, 1325-1332.;;Assady, S., Maor, G., Amit, M., ltskovitz-Eldor, J., Skorecki, K.L., and Tzukerman, M. (2001) ""Insulin production by human embryonic stem cells"" Diabetes 50, 1691-7.;;Assmus et al., 2002, Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI) Circulation 106, pp. 3009-3017.;;Athanasopoulos, T., Fabb, S., and Dickson, G. (2000) ""Gene therapy vectors based on adeno-associated virus: characteristics and applications to acquired and inherited diseases (review)"" Int J Mol Med 6, 363-75.;;ATTC Preservation Methods: Freezing and Free-Drying, ATCC, 2nd Edition, 1991.;;Avital, I. D. lnderbitzin, et al. (2001) ""Isolation, characterization and transplantation of bone marrow-derived hepatocyte stem cells"" Biochem Biophys Res Commun 288(1): 156-64.;;Badiavas, et al. ""Participation of bone marrow derived cells in cutaneous would healing."" Journal of Cellular Physiology. 196(2): 245-250 (2003).;;Bagnato et al., Jan. 2002, Emerging role of endothelin-1 in tumor angiogenesis, Trends in Endocrinology and Metabolism, 14(1):44-50.;;Bailey, A. J. et al., ""Age-Related Changes in the Biochemical Properties of Human Cancellous Bone Collagen: Relationship to Bone Strength,"" Calcified Tissue International, 1999, 65:203-10.;;Banerji et al., Feb. 22, 1999, LYVE-1, a New Homologue of the CD44 Glycoprotein, Is a Lymph-specific Receptor for Hyaluronan, J. Cell Biology, 144(4):789-801.;;Banfi, A., Bianchi, G., Galotto, M., Cancedda, R., and Quarto, R. (2001) ""Bone marrow stromal damage after chemo/radiotherapy: occurrence, consequences and possibilities of treatment"" Leuk Lymphoma 42, 863-70.;;Barghorn, A. et al., ""a-Smooth Muscle Actin Distribution in the Pulmonary Vasculature Comparing Hypoplastic and Normal Fetal Lungs,"" Pediatric Pathology & Laboratory Medicine, 1998, 18:5-22.;;Barker et al., 2001, Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of huan leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis, Blood, 97:2957-61.;;Baron et al., 1999, Acute Necrotizing Pancreatitis, The New Engl. J. Med. 340:1412-1417.;;Barry et al., (1999) ""The monoclonal antibody SH-2, raised against human mesenchymal stem cells, recognizes an epitope on endoglin (CD105)"" Biochem Biophys Res Commun 265, 134-9.;;Bartynski, J.M., S. Marion et al. (1990) ""Histopathologic evaluation of adipose autografts in a rabbit ear model"" Otolaryngol Hea Neck Surg 102(4): 314-21.;;Bastard, J. P. et al., ""A Mini-Liposuction Technique Adapted to the Study of Human Adipocyte Glucose Transport System,"" Diabetologia, 36(Suppl. 1):A135, 1993.;;Baylink, David J., ""Glucocorticoid-Induced Osteoporosis,"" The New England Journal of Medicine, 1983, 309:306-8.;;BD Biosciences, Feb. 15, 2002, Product Specification Sheet: BD Matrigel(TM) Basement Membrane Matrix, 3 pp.;;Becerra, José et al., ""Demineralized Bone Matrix Mediates Differentiation of Bone Marrow Stromal Cells In Vitro: Effect of Age of Cell Donor,"" Journal of Bone and Mineral Research, 1996, 11:1703-14.;;Beecken, W.D., Kramer, W., and Jonas, D. (2000) ""New molecular mediators in tumor angiogenesis"" J Cell Mol Med 4, 262-269.;;Geiser, Ian H. and Irvin O. Kanat, ""Subchondral Bone Drilling: a Treatment for Cartilage Defects,"" Journal of Foot Surgery, 1990, 29:595-601.;;Bender et al., 1991, Identification and comparison of CD34-positive cells and their subpopulations from normal peripheral blood and bone marrow using multicolor flow cytometry, Blood 77(12): 2591-2596.;;Bennett, JH, et al., 1991 J. Cell Sci. ""Adipocytic cells cultured from marrow have osteogenic potential,"" 99(Pt1):131-139.;;Berdel et al., 1982, Purification of human monocytes by adherence to polymeric fluorocarbon. Characterization of the monocyte-enriched cell fraction, Immunobiology, 163:511-520.;;Beresford, et al., 1986 Endo. ""1,25-Dihydroxyvitamin D3 and Human Bone-Derived Cells in Vitro: Effects on Alkaline Phosphatase, Type I Collagen and Proliferation,"" 119:1776-1785.;;Bergan et al., 1996, Electroporation of synthetic oligodeoxynucleotides: a novel technique for ex vivo bone marrow purging, Blood, 88(2):731-741.;;Bergeon, M.T. (1967) ""Collagen: a review"" J Okla State Med Assoc 60(6): 330-2.;;Bernlohr, David A. et al., ""Tissue Specific Expression of p422 protein , a putative Lipid Carrier, in Mouse Adipocytes,"" Biochem. Biophys. Res. Commun. 1985 132:850-855.;;Berry et al., 2005, The Establishment of a Predictive Mutational Model of the Forkhead Domain through the Analyses of FOXC2 Missense Mutations Identified in Patients with Hereditary Lymphedema with Distichiasis, Human Molecular Genetics 14(18):2619-2627.;;Bhagavati, et al., 2004, Isolation and enrichment of skeletal muscle progenitor cells from mouse bone marrow, Biochem. Biophys. Res. Comm. 318(1):318-24.;;Bianco et al., Apr. 2008, Mesenchymal stem cells: revisiting history, concepts, and assays, Cell Stem Cell, 2:313-319.;;Bickenbach, J.R. and Dunnwald, M. (2000) ""Epidermal stem cells: characteristics and use in tissue engineering and gene therapy"" Adv Dermatol 16, 159-83.;;Bjornson, et al., 1999 Science ""Turning Brain into Blood: A Hematopoetic Fate Adopted by Adult Neural Stem Cells in Vivo,"" 283:534-537.;;Bjorntorp et al., 1980, Differentiation and function of rat adipocyte precursor cells in primary culture, J. Lipid Research 21:714-723.;;Björntrop, et al. ""Isolation and characterization of cells from rat adipose tissue developing into adipocytes."" J. Lipid Res. 19:316-324 (1978).;;Black et al., 2000, Adult Rat and Human Bone Marrow Stromal cells Differentiate Into Neurons, J. Neurosci. Res. Science 61:364-370.;;Block, C.A., C.S. Cooper (2003) ""Long-term Efficacy of periurethral collagen injection for the treatment of urinary incontinence secondary to myelomeningocele"" J Urol 169(1): 327-329.;;Boering, G. and A.J. Huffstadt (1967) ""The use of derma-fat grafts in the face"" Br J Plast Surg 20(2): 172-8.;;Boerner, C.F. (1988) ""Allergic response to a porcine collagen corneal shield. Case report"" Arch Ophthalmol 106(2): 171.;;Boghossian et al, 2005, Suppression of fat deposition for the life time with gene therapy, Peptides 26(8):1512-1519.;;Bond et al., 1999, ""Human Subcutaneou spreadipocytes Differentiate Into osteoblasts,"" FASEB Journal 13:600A.;;Bonner-Weir, S. and Sharma, A. (2002) ""Pancreatic stem cells"" J Pathol 197, 519-526.;;Boskey, et al., 1985, ""The Effect of Osteocalcin on In Vitro Lipid-Induced Hydroxyapatite Formation and Seeded Hydroxyapatite Growth,"" Calc. Tiss. Int. 37:75.;;Breen, Ellen C. et al., ""TGFb Alters Growth and Differentiation Related Gene Expression in Proliferating Osteoblasts In Vitro, Preventing Development of the Mature Bone Phenotype,"" Journal of Cellular Physiology, 1994, 160:323-35.;;Breiteneder-Geleff et al., Feb. 1999, Angiosarcomas Express Mixed Endothelial Phenotypes of Blood and Lymphatic Capillaries, Am. J. Path. 154(2): 385-394.;;Bruder, et al., 1997 J. Cell Biochem. ""Growth Kinetics, Self-Renewal, and the Osteogenic Potential of Purified Human Mesenchymal Stem Cells During Extensive Subcultivation and Following Cryopreservation,"" 64:278-294.;;Bruder, Scott P. et al., ""Bone Regeneration by Implantation of Purified, Culture-Expanded Human Mesenchymal Stem Cells,"" Journal of Orthopaedic Research, 1998, 16:155-62.;;Bulleid, J.J., D.C. John et al (2000) ""Recombinant expression systems for the production of collagen"" Biochem Soc Trans 28(4): 350-3.;;Burres, S. (2001) ""Soft-tissue augmentation with fascian"" Clin Plast Surg 28(1): 101-10.;;Buschmann, I.R. Busch, H.J., Mies, G., and Hossmann, K.A. (2003) ""Therapeutic induction of arteriogenesis in hypoperfused rat brain via granulocyte-macrophage colony-stimulating factor"" Circulation 108, 610-615.;;Butler-Browne, et al., 1990 Anat. Embryol. (Berl) ""Myosin heavy and light chain expression during human skeletal muscle development and precocious muscle maturation induced by thyroid hormone,"" 181:513-522.;;Butnariu-Ephrat, Miriam et al., ""Resurfacing of Goat Articular Cartilage by Chondrocytes Derived From Bone Marrow,"" Clinical Orthopaedics and Related Research, 1996, 330:234-43.;;Campion, Dennis R., ""The Muscle Satellite Cell: A Review,"" Internationals Review of Cytology, 1984, 87:225-51.;;Caplan and Goldberg, 1999, Principles of tissue engineered regeneration of skeletal tissues, Clin Orthop Suppl. 367: 12-16.;;Caplan, A.I. and Bruder, S.P. (2001) ""Mesenchymal stem cells: building blocks for molecular medicine in the 21st century"" Trends Mol Med 7, 259-64.;;Caplan, Arnold I., ""Mesenchymal Stem Cells,"" Journal of Orthopaedic Research, 1991, 9:641-50.;;Caplan, Arnold I., ""The Mesengenic Process,"" Clinics in Plastic Surgery, 21:429-35, 1994.;;Carano, R.A. and Filvaroff, E.H. (2003) ""Angiogenesis and bone repair"" Drug Discov. Today 8, 980-989.;;Carmeliet, P. (2000) ""Mechamisms of angiogenesis and arteriogenesis"" Nat Med 6, 389-395.;;Carmeliet, P. and A. Luttun (2001) ""The emerging role of the bone marrow-derived stem cells in (therapeutic angiogenesis"" Thromb Haemost 86(1): 289-97.;;Carpandena, C.A. ""Collagen alterations in adipose autograft's."" Aesthetic Plastic Surgery vol. 18, 11-15 (1994).;;Carranza-Bencano, A. et al., ""Comparative Study of the Reconstruction of Articular Cartilage Defects with Free Costal Perichondrial Grafts and Free Tibial Periosteal Grafts: An Experimental Study on Rabbits,"" Calcified Tissue International, 1999, 65:402-7.;;Casteilla et al., Apr. 26, 2011, Adipose-derived stromal cells: their identity and uses in clinical trials, an update, World J. Stem Cells, 3(4):25-33.;;Castro, et al. ""Failure of Bone Marrow Cells to Transdifferentiate into Neural Cells in Vivo."" Science. 297:1299 (2002).;;Castro, et al. ""Response to Comment on 'Failure of Bone Marrow Cells to Transdifferentiate into Neural Cells in Vivo.'"" Science. 299:1184c (2003).;;Castro-Malaspina, H., W. Ebell, et al. (1984) ""Human bone marrow fibroblast colony-forming units (CFU-F"" Prog Clin Ciol Res 154: 209-36.;;Cavallini, 2007, Autologous Fibroblasts to Treat Deep and Complicated Leg Ulcers in Diabetic Patients, Wound Repair Regen. 15(1):35-8.;;Chang et al., Jan. 2006, Characterization of two populations of mesenchymal progenitor cells in umbilical cord blood, Cell Biology International, 40:495-499.;;Cheifetz et al., 1988, Analysis of intracellular osteopontin as a marker of osteoblastic cell differentiation and mesenchymal cell migration,European Journal of Oral Sciences, 106(Supp. 1):401-7.;;Cheifetz, S. et al., ""Endoglin Is a Component of the Transforming Growth Factor-beta Receptor System in Human Endothelial Cells,"" J. Biol. Chem., 1992 267:19027-19030.;;Chen et al., Dec. 2005, Novel Expression and Characterization of Lymphatic Vessel Endothelial Hyaluronate Receptor 1 (LYVE-1) by Conjunctival Cells, Invest. Ophthalmol. Vis. Sci. 46(12):4536-4540.;;Chen, J. et al. Intravenous Administration of Human Bone Marrow Stromal Cells Induces Angiogenesis in the Ischemic Boundary Zone After Stroke in Rats, Circulation Research, Apr. 2003, vol. 92, pp. 692-699.;;Chen, J. et al. Intravenous Bone Marrow Stromal Cell Therapy Reduces Apoptosis and Promotes Endogenous Cell Proliferation After Stroke in Femal Rat, J. Neuroscience Research, Sep 2003, vol. 73 pp. 778-786.;;Chen, Theresa L. et al., ""1alpha,25-Dihydroxyvitamin D3 Receptors in Cultured Rat osteoblast-like Cells,"" J. Biol. Chem. 1983 258:4350-4355.;;Chen, Xiaoli et al., ""Differentiation-dependent expression of obese (ob) gene by preadipocytes and adipocytes in primary cultures of porcine stromal-vascular cells,"" Biochimica et Biophysica Acta, 1997, 1359:136-42.;;Cheng S-L., et al., 1994 Endo ""Differentiation of Human Bone Marrow Osteogenic Stromal Cells in Vitro: Induction of the Osteoblast Phenotype by Dexamethasone,"" 134: 277-286.;;Chimal-Monroy et al., 1999, Expression of N-cadherin, N-CAM, fibronectin tenascin is stimulated by TGF-b1, b2, b3 and b5 during the formation of precartilage condensations, The International Journal of Developmental Biology, 43:59-67.;;Cho. et al. ""Engineering of volume-stable adipose tissues."" Biomaterials 26, 3577-3585 (2005).;;Cho. et al. ""Enhancement of adipose tissue formation by implantation of adipogenic-differentiated preadipocytes."" Biochem Biophys Res Commun 345, 588-594 (2006).;;Choi et al. ""Adipose tissue engineering using mesenchymal stem cells attached to injectable PLGA spheres."" Biomaterials 26, 5855-5863 (2005).;;Choi. et al. ""Adipogenic differentiation of adipose tissue derived adult stem cells in nude mouse."" Biochem Biophys Res Commun 345, 631-637 (2006).;;Chyun, et al., 1984 Endo. ""Cortisol Decreases Bone Formation by Inhibiting Periosteal Cell Proliferation,"" 114:477-480.",INACTIVE
636,ES,T3,ES 2647477 T3,061-621-784-292-325,2017-12-21,2017,ES 05755269 T,2005-06-01,US 57599704 P;;US 63922204 P;;US 2005/0019235 W,2004-06-01,Composiciones y métodos para prevenir la agregación del vector AAV,"Un método para prevenir la agregación de viriones de AAV2 (virus adenoasociado tipo 2) en una preparación de dichos viriones, que comprende añadir uno o más excipientes a viriones de AAV2 para producir una preparación isotónica de viriones con una fuerza iónica de al menos 250 mM, en donde la concentración de viriones de AAV2 dentro de la preparación supera 1x1013 vg/ml, y en donde uno o más de los excipientes comprende un ion multivalente.",GENZYME CORP,WRIGHT JOHN FRASER;;QU GUANG,,https://lens.org/061-621-784-292-325,Granted Patent,no,0,0,33,34,0,C12N2750/14151;;C12N7/00;;C12N2750/14151;;C12N7/00;;C12N2750/14111,C12N7/02;;C12N7/00,,0,0,,,,ACTIVE
637,AU,B2,AU 764650 B2,062-698-869-644-475,2003-08-28,2003,AU 2000/019010 A,1999-12-24,NZ 33358998 A;;NZ 9900228 W,1998-12-24,Superantigens,,AUCKLAND UNISERVICES LTD,FRASER JOHN DAVID;;PROFT THOMAS,,https://lens.org/062-698-869-644-475,Granted Patent,no,1,0,7,10,0,A61K38/00;;A61K39/00;;A61P35/00;;A61P37/02;;C07K14/315,G01N33/569;;A61K38/00;;A61K39/00;;A61K39/09;;A61K39/395;;A61K47/48;;A61P35/00;;A61P37/02;;C07K14/315;;C07K16/12;;C12N15/09;;C12Q1/68,,0,0,,,,EXPIRED
638,JP,A,JP 2019058177 A,064-011-139-365-73X,2019-04-18,2019,JP 2018218970 A,2018-11-22,US 57599704 P;;US 63922204 P,2004-06-01,COMPOSITIONS AND METHODS TO PREVENT AAV VECTOR AGGREGATION,"To provide compositions and methods for preparation of concentrated stock solutions of virions such as AAV without aggregation.SOLUTION: A method of preventing aggregation of virions in a preparation of virions, comprises adding one or more excipients such as multivalent ions to the preparation of virions, to achieve the ionic strength of at least about 200 mM.SELECTED DRAWING: None",GENZYME CORP,WRIGHT JOHN FRASER;;QU GUANG,,https://lens.org/064-011-139-365-73X,Patent Application,no,0,0,33,34,0,C12N2750/14151;;C12N7/00;;C12N2750/14151;;C12N7/00;;C12N2750/14111,C12N7/02;;C12N7/00,,0,0,,,,PENDING
639,GB,B,GB 2367158 B,073-334-809-639-131,2004-10-20,2004,GB 0023584 A,2000-09-26,GB 0023584 A,2000-09-26,Method and system for archiving and retrieving items based on episodic memory of groups of people,,6S LTD,FRASER JOHN LESLIE;;SHARPE ELIZABETH,,https://lens.org/073-334-809-639-131,Granted Patent,no,11,0,8,8,0,G06F16/9535;;G06F16/951,G06F17/30,G4A AUDB          UDB,0,0,,,,EXPIRED
640,HU,T2,HU E060433 T2,083-634-500-682-083,2023-03-28,2023,HU E17186206 A,2005-06-01,US 57599704 P;;US 63922204 P,2004-06-01,COMPOSITIONS AND METHODS TO PREVENT AAV VECTOR AGGREGATION,,GENZYME CORP,WRIGHT JOHN FRASER;;QU GUANG,,https://lens.org/083-634-500-682-083,Amended Patent,no,0,0,33,34,0,C12N2750/14151;;C12N7/00;;C12N2750/14151;;C12N7/00;;C12N2750/14111,C12N7/00;;C12N7/02,,0,0,,,,PENDING
641,DK,T3,DK 2970920 T3,111-271-012-686-45X,2018-08-06,2018,DK 14762249 T,2014-03-17,US 201361787818 P;;US 2014/0030370 W,2013-03-15,SKALERBAR FREMSTILLINGSPROCESS TIL FREMSTILLING AF REKOMBINANT LENTIVIRALE VEKTORER I SERUMFRIT SUSPENSIONSCELLEKULTURSYSTEM,,CHILDRENS HOSPITAL PHILADELPHIA,WRIGHT JOHN FRASER;;QU GUANG,,https://lens.org/111-271-012-686-45X,Granted Patent,no,0,0,29,29,0,C12N7/00;;C12N2740/15043;;C12N2740/15051;;A61K48/0091;;A61K48/0091;;C12N2740/15043;;C12N2740/15051;;C12N7/00;;A61K48/0091;;C12N7/00;;C12N7/00;;C12N2740/15043;;C12N2740/15051;;A61K48/0091,C12N7/02,,0,0,,,,ACTIVE
642,CA,A,CA 134907 A,104-058-701-302-574,1911-08-15,1911,CA 134907D A,1910-07-04,CA 134907T A,1910-07-04,LOCK,,FRASER JOHN R;;SCHLICHTING HENRY,FRASER JOHN R;;SCHLICHTING HENRY,,https://lens.org/104-058-701-302-574,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
643,AU,A,AU 1971/033358 A,099-789-871-692-835,1973-03-15,1973,AU 1971/033358 A,1970-09-15,AU 1971/033358 A,1970-09-15,FILM PROJECTORS,,BOLGAR F,BOLGAR FRANCIS;;FRASER JOHN JAMES,,https://lens.org/099-789-871-692-835,Patent Application,no,0,0,2,2,0,G03B21/11,G03B21/11,,0,0,,,,EXPIRED
644,US,A1,US 2021/0101380 A1,106-342-122-132-460,2021-04-08,2021,US 201816500110 A,2018-04-12,EP 17000619 A;;US 2018/0027317 W,2017-04-12,FIRE RETARDANT COMPOSITE,"This disclosure relates to a fire-retardant composite material comprising a fibre-reinforced plastic covered by an aluminium foil and its application in passenger transport industries such as aerospace, railway or marine.",HUNTSMAN ADV MAT LICENSING SWITZERLAND GMBH,DE VERCLOS OLIVER;;FRASER JOHN,,https://lens.org/106-342-122-132-460,Patent Application,yes,0,0,8,8,0,B32B15/14;;B32B27/38;;B32B3/12;;B32B5/022;;B32B5/024;;B32B5/26;;B32B15/092;;B32B15/20;;B32B15/20;;B32B19/041;;B32B19/06;;B32B2260/023;;B32B2260/046;;B32B2262/02;;B32B2262/0269;;B32B2262/101;;B32B2262/106;;B32B2307/3065;;B32B2311/24;;B32B2363/00;;B32B2451/00;;B32B2605/00,B32B27/38;;B32B15/092;;B32B15/20,,0,0,,,,DISCONTINUED
645,AU,A,AU 2000/019010 A,107-314-139-059-229,2000-07-31,2000,AU 2000/019010 A,1999-12-24,NZ 33358998 A;;NZ 9900228 W,1998-12-24,Superantigens,,AUCKLAND UNISERVICES LTD,FRASER JOHN DAVID;;PROFT THOMAS,,https://lens.org/107-314-139-059-229,Patent Application,no,0,0,7,10,0,A61K38/00;;A61K39/00;;C07K14/315;;A61P35/00;;A61P37/02,G01N33/569;;A61K38/00;;A61K39/00;;A61K39/09;;A61K39/395;;A61K47/48;;A61P35/00;;A61P37/02;;C07K14/315;;C07K16/12;;C12N15/09;;C12Q1/68,,0,0,,,,EXPIRED
646,AT,T1,AT E442856 T1,153-038-571-797-052,2009-10-15,2009,AT 01999384 T,2001-12-04,US 25124300 P;;NZ 0100267 W,2000-12-04,IMMUNMODULATORISCHE KONSTRUKTIONEN UND IHRE VERWENDUNG,,AUCKLAND UNISERVICES LTD,FRASER JOHN DAVID;;NICHOLSON MELISSA,,https://lens.org/153-038-571-797-052,Granted Patent,no,0,0,12,12,0,A61K39/092;;A61K39/385;;A61K2039/5154;;A61K2039/57;;A61K2039/6068;;C07K14/31;;C07K14/315;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61K39/385;;A61K39/092;;A61K2039/5154;;A61K2039/57;;A61K2039/6068;;C07K14/31;;C07K14/315,C12N15/09;;A61K39/00;;A61K39/085;;A61K39/09;;A61K39/385;;A61K45/00;;A61K48/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;C07K14/31;;C07K14/315;;C12N15/31,,0,0,,,,EXPIRED
647,EP,A1,EP 1751275 A1,146-939-017-648-476,2007-02-14,2007,EP 05755269 A,2005-06-01,US 2005/0019235 W;;US 57599704 P;;US 63922204 P,2004-06-01,COMPOSITIONS AND METHODS TO PREVENT AAV VECTOR AGGREGATION,,AVIGEN INC,WRIGHT JOHN FRASER;;QU GUANG,"GENZYME CORPORATION, US (2018-07-31);;GENZYME CORPORATION; US (2018-03-23);;GENZYME CORPORATION (2018-07-18);;GENZYME CORPORATION, CAMBRIDGE, US (2018-01-19)",https://lens.org/146-939-017-648-476,Patent Application,yes,0,0,33,34,0,C12N2750/14151;;C12N7/00;;C12N2750/14151;;C12N7/00;;C12N2750/14111,C12N7/00;;C12N7/02,,0,0,,,,ACTIVE
648,CN,A,CN 1901802 A,166-884-049-006-03X,2007-01-24,2007,CN 200480010610 A,2004-02-20,US 2004/0005117 W;;US 44927903 P;;US 46291103 P,2003-02-20,Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions,,MACROPORE BIOSURGERY INC,ISABELLA FRASER JOHN K HEDRICK,,https://lens.org/166-884-049-006-03X,Patent Application,no,0,2,3,221,0,,A01N63/00;;C12N5/00,,0,0,,,,EXPIRED
649,MX,A,MX 2019006353 A,161-913-656-611-256,2022-06-27,2022,MX 2019006353 A,2006-11-30,US 57599704 P;;US 63922204 P,2004-06-01,COMPOSITIONS AND METHODS TO PREVENT AAV VECTOR AGGREGATION.,"Compositions and methods are provided for preparation of concentrated stock solutions of AAV virions without aggregation. Formulations for AAV preparation and storage are high ionic strength solutions (e.g. µ ~500mM) that are nonetheless isotonic with the intended target tissue. This combination of high ionic strength and modest osmolarity is achieved using salts of high valency, such as sodium citrate. AAV stock solutions up to 6.4x1013 vg/mL are possible using the formulations of the invention, with no aggregation being observed even after ten freeze-thaw cycles. The surfactant Pluronic® F68 may be added at 0.001% to prevent losses of virions to surfaces during handling. Virion preparations can also be treated with nucleases to eliminate small nucleic acid strands on virions surfaces that exacerbate aggregation.",GENZYME CORP,WRIGHT JOHN FRASER;;QU GUANG,,https://lens.org/161-913-656-611-256,Patent Application,no,0,0,33,34,0,C12N2750/14151;;C12N7/00;;C12N2750/14151;;C12N7/00;;C12N2750/14111,C12N7/02,,0,0,,,,PENDING
650,US,A,US 1607492 A,160-943-205-072-565,1926-11-16,1926,US 8976926 A,1926-02-20,GB 1607492X A,1924-10-21,Manufacture of dyestuffs and intermediates,,SCOTTISH DYES LTD,FRASER THOMSON ROBERT;;JOHN THOMAS,,https://lens.org/160-943-205-072-565,Granted Patent,no,0,0,1,1,0,C09B3/06;;C09B3/24;;C09B3/24;;C09B3/06,C09B3/06;;C09B3/24,,0,0,,,,EXPIRED
651,US,A1,US 2012/0143511 A1,173-553-152-786-318,2012-06-07,2012,US 201113287809 A,2011-11-02,US 201113287809 A;;US 84853410 A;;US 201061425679 P;;US 23600009 P,2009-08-21,REMOVING GROUND ROLL FROM GEOPHYSICAL DATA,"Methods and systems for processing geophysical data are disclosed. In one embodiment, interferometry and modeling are used to generate and then remove estimates of ground roll between a source and one or more boundary locations.",HALLIDAY DAVID FRASER;;QUIGLEY JOHN,HALLIDAY DAVID FRASER;;QUIGLEY JOHN,WESTERNGECO L.L.C (2012-01-16),https://lens.org/173-553-152-786-318,Patent Application,yes,5,2,1,5,0,G01V1/364;;G01V2210/3246;;G01V1/364;;G01V2210/3246,G06F19/00;;G01V1/28,702/17,0,0,,,,DISCONTINUED
652,US,A1,US 2009/0215195 A1,179-757-902-989-396,2009-08-27,2009,US 59429104 A,2004-12-07,AU 2004/901570 A;;NZ 2004000317 W,2004-03-24,Set1 proteins and uses thereof,"The invention relates to methods of use of SET1 proteins or functional equivalents thereof. More particularly the invention relates to the use of SET1 proteins or functional equivalents thereof in procedure, for identification and/or isolation of IgA and the scrum complement factor C5.",FRASER JOHN DAVID;;LANGLEY RIES,FRASER JOHN DAVID;;LANGLEY RIES,AUCKLAND UNISERVICES LIMITED (2006-09-21),https://lens.org/179-757-902-989-396,Patent Application,yes,0,1,5,5,13,C07K14/31;;C07K14/31;;C07K16/1271;;C07K16/1271,G01N33/566;;C07K1/00;;C07K1/14;;C07K14/00;;C07K14/31;;C07K16/12;;C12N15/11;;C12N15/31,436/501;;530/413;;530/350;;536/23.1,0,0,,,,INACTIVE
653,US,A1,US 2015/0045983 A1,004-112-965-332-573,2015-02-12,2015,US 201313961797 A,2013-08-07,US 201313961797 A,2013-08-07,"Methods, Systems and Devices for Obtaining and Utilizing Vehicle Telematics Data","Certain embodiments of this disclosure include methods, systems and devices for obtaining and utilizing vehicle telematics data. According to one embodiment, a method is provided. The method may include: (i) obtaining, from at least one sensor located in a telematics device, telematics device sensor data, wherein the telematics device sensor data comprises data describing one or more characteristics of a vehicle associated with the telematics device; (ii) transmitting, by the telematics device, the telematics device sensor data to a mobile device; (iii) obtaining, from at least one sensor located in the mobile device, mobile device sensor data, wherein the mobile device sensor data comprises data describing one or more different characteristics of the vehicle; and (iv) transmitting, by the mobile device, the telematics device sensor data and the mobile device sensor data to a remote computing device for processing.",DRIVEFACTOR,FRASER MACGREGOR;;WALTERS JOHN MILAM,DRIVEFACTOR INC (2015-04-16),https://lens.org/004-112-965-332-573,Patent Application,yes,9,194,1,1,0,G07C5/0841;;G07C5/008;;G07C5/008;;G07C5/0841,G07C5/00,701/1,0,0,,,,DISCONTINUED
654,US,A,US 4064373 A,003-319-362-268-930,1977-12-20,1977,US 62793575 A,1975-11-03,CA 175971 A;;US 45605574 A,1973-07-09,Line circuit for key telephone systems,"A line circuit for providing line control between a central office or PBX line and the key telephone station subscriber instruments. The line circuit responds to ring currents to activate suitable signalling at stations having access to the called line. The circuit responds to a station going off-hook following ringing to provide the well-known responses. Call holding is also controlled by the line circuit. Within the circuit, the ring response is activated by a capacitor, the same capacitor being used to time out and terminate ring on a failure to respond and also to time the release of the circuit from the central office line.",INT STANDARD ELECTRIC CORP,PINEDE EDOUARD;;LITSER JOHN FRASER,ALCATEL N.V. DE LAIRESSESTRAAT 153 1075 HK AMSTERDAM THE NETHERLANDS A CORP OF THE NETHERLANDS (1987-03-11),https://lens.org/003-319-362-268-930,Granted Patent,yes,5,6,1,2,0,H04M9/006;;H04M9/006,H04M9/00,179/99,0,0,,,,EXPIRED
655,ZA,B,ZA 943045 B,035-492-884-074-105,1995-01-30,1995,ZA 943045 A,1994-05-03,ZA 943045 A,1994-05-03,FLuid-flow control valves,,PERKINS LTD,WALLACE IAN FRASER;;STAMFORD JOHN,,https://lens.org/035-492-884-074-105,Granted Patent,no,0,0,1,1,0,,F16K/,,0,0,,,,EXPIRED
656,US,A1,US 2017/0114325 A1,037-659-183-963-625,2017-04-27,2017,US 201615345294 A,2016-11-07,US 201615345294 A;;US 201414336755 A;;US 201113031031 A;;US 2009/0054055 W;;US 9018608 P,2008-08-19,METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF THE LYMPHATIC SYSTEM AND MALIGNANT DISEASE,"Aspects of the invention provides methods for preparing and using adipose-tissue-derived stem and progenitor cells, adipose-tissue-derived lymphatic endothelial cells, and cells capable of differentiating into lymphatic endothelial cells to treat disorders of the lymphatic system and to modulate expansion, repair, and/or regeneration of the lymphatic system. The invention further provides using adipose-tissue-derived lymphatic endothelial cells and cells capable of differentiating into lymphatic endothelial cells for delivery of therapeutic agents to tumor cells as a means for treating malignant disease, and assays to screen for drugs that modulate lymphatic system expansion, repair or regeneration.",CYTORI THERAPEUTICS INC,ALFONSO ZENI;;FRASER JOHN K,CYTORI THERAPEUTICS INC (2017-01-26);;LOREM VASCULAR PTE. LTD (2019-04-24),https://lens.org/037-659-183-963-625,Patent Application,yes,3,2,6,6,0,A61K35/12;;A61K35/12;;A61K35/28;;A61K35/28;;A61K35/35;;A61K35/35;;A61K45/06;;A61K2035/124;;A61P3/06;;A61P9/00;;A61P35/04;;C12N5/0651;;C12N5/0651;;C12N5/0667;;C12N5/069;;C12N5/069,C12N5/078;;A61K35/12;;A61K35/28;;A61K35/35;;C12N5/071;;C12N5/0775,,0,0,,,,DISCONTINUED
657,AU,A1,AU 2018/250668 A1,047-482-081-719-842,2019-10-10,2019,AU 2018/250668 A,2018-04-12,EP 17000619 A;;US 2018/0027317 W,2017-04-12,Fire retardant composite,"This disclosure relates to a fire-retardant composite material comprising a fibre-reinforced plastic covered by an aluminium foil and its application in passenger transport industries such as aerospace, railway or marine.",HUNTSMAN ADV MAT LICENSING SWITZERLAND GMBH,DE VERCLOS OLIVIER;;FRASER JOHN,,https://lens.org/047-482-081-719-842,Patent Application,no,0,0,8,8,0,B32B5/022;;B32B5/024;;B32B5/26;;B32B15/14;;B32B15/20;;B32B19/041;;B32B19/06;;B32B3/12;;B32B2260/023;;B32B2260/046;;B32B2262/02;;B32B2262/0269;;B32B2262/101;;B32B2262/106;;B32B2307/3065;;B32B2451/00;;B32B2605/00;;B32B15/092;;B32B15/20;;B32B27/38;;B32B2311/24;;B32B2363/00,B32B5/02;;B32B3/12;;B32B5/26;;B32B15/14;;B32B15/20;;B32B19/04;;B32B19/06,,0,0,,,,DISCONTINUED
658,BR,B8,BR PI0511764 B8,095-408-640-572-003,2021-05-25,2021,BR PI0511764 A,2005-06-01,US 57599704 P;;US 63922204 P;;US 2005/0019235 W,2004-06-01,método de prevenção de agregação de vírions de vírus adeno-associado recombinante (raav) em uma preparação purificada de virions raav,"composições e métodos para prevenir a agregação de vetor de aav. a presente invenção refere-se a composições e a métodos que são fornecidos para a preparação de soluções de matéria-prima concentradas de vírions de aav sem a agregação. as formulações para a preparação e armazenagem de aav são soluções de força iônica elevada (por exemplo, <109> ~500mm) que são apesar de tudo isotônicas com o tecido-alvo pretendido. esta combinação, de força iônica elevada e osmolaridade modesta, são obtidas empregando sais de valência elevada, tal como citrato de sódio. as soluções de matéria-prima aav acima de 6,4x10^ ¹³^ são possíveis empregando as formulações da invenção, com nenhuma agregação sendo observada mesmo após dez ciclos de congelamento-descongelamento. o tensoativo pluronic<32>f68 pode ser adicionado em 0,001% para impedir perdas de vírions para superfícies durante o manuseio. as preparações de vírions podem também ser tratadas com nucleases para eliminar pequenos filamentos de ácido nucléico em superfícies de vírions que exacerba a agregação.",AVIGEN INC,GUANG QU;;JOHN FRASER WRIGHT,,https://lens.org/095-408-640-572-003,Amended Patent,no,0,0,33,34,0,C12N2750/14151;;C12N7/00;;C12N2750/14151;;C12N7/00;;C12N2750/14111,C12N7/02,,0,0,,,,ACTIVE
659,WO,A2,WO 2010/126385 A2,102-241-931-079-251,2010-11-04,2010,NZ 2010000085 W,2010-04-30,NZ 57669909 A,2009-05-01,IMPROVEMENTS IN OR RELATING TO VEHICLE SEATS,An emergency response vehicle seat including a cavity for accommodating a pressurised fluid container and methods of forming the seat columns and seat. The seat includes a pair of spaced apart generally L shaped columns each formed from two halves formed of folded sheet metal. The columns are formed by bending two column half blanks so as to each form two walls of the generally L shaped column and secure them together to form a generally L shaped column. The pair of columns are secured together in spaced apart relationship to define a cavity between the columns in the seat back portion suitable for accommodating a pressurised fluid container of the type forming part of a typical emergency back pack.,FRASER FIRE & RESCUE LTD;;SIMPSON MARTIN;;FRASER JOHN JAMES,SIMPSON MARTIN;;FRASER JOHN JAMES,,https://lens.org/102-241-931-079-251,Patent Application,no,0,1,2,2,0,A62B9/04;;A62B25/00;;B60N2/68;;B60N2/24,,,0,0,,,,PENDING
660,BR,A,BR PI0511764 A,118-051-474-563-673,2008-01-08,2008,BR PI0511764 A,2005-06-01,US 57599704 P;;US 63922204 P;;US 2005/0019235 W,2004-06-01,composições e métodos para prevenir a agregação de vetor de aav,"COMPOSIçõES E MéTODOS PARA PREVENIR A AGREGAçãO DE VETOR DE AAV. A presente invenção refere-se a composições e a métodos que são fornecidos para a preparação de soluções de matéria-prima concentradas de vírions de AAV sem a agregação. As formulações para a preparação e armazenagem de AAV são soluções de força iónica elevada (por exemplo, <109> ~500mM) que são apesar de tudo isotónicas com o tecido-alvo pretendido. Esta combinação, de força iónica elevada e osmolaridade modesta, são obtidas empregando sais de valência elevada, tal como citrato de sódio. As soluções de matéria-prima AAV acima de 6,4x10¬ ¹³¬ são possíveis empregando as formulações da invenção, com nenhuma agregação sendo observada mesmo após dez ciclos de congelamento-descongelamento. O tensoativo Pluronic<32>F68 pode ser adicionado em 0,001% para impedir perdas de vírions para superfícies durante o manuseio. As preparações de vírions podem também ser tratadas com nucleases para eliminar pequenos filamentos de ácido nucléico em superfícies de vírions que exacerba a agregação.",AVIGEN INC,WRIGHT JOHN FRASER;;QU GUANG,,https://lens.org/118-051-474-563-673,Patent Application,no,0,0,33,34,0,C12N2750/14151;;C12N7/00;;C12N2750/14151;;C12N7/00;;C12N2750/14111,C12N7/02,,0,0,,,,ACTIVE
661,EP,A4,EP 1735334 A4,132-746-688-633-129,2007-09-05,2007,EP 04808912 A,2004-12-07,NZ 2004000317 W;;AU 2004/901570 A,2004-03-24,SET1 PROTEINS AND USES THEREFOR,,AUCKLAND UNISERVICES LTD,FRASER JOHN DAVID;;LANGLEY RIES,,https://lens.org/132-746-688-633-129,Search Report,no,1,0,5,5,0,C07K14/31;;C07K16/1271;;C07K14/31;;C07K16/1271,C07K14/31;;C07K1/14;;C07K16/12;;C12N15/11;;C12N15/31,,4,3,023-005-371-477-893;;005-195-979-619-105;;125-353-444-304-889,15728504;;10.4049/jimmunol.174.5.2926;;10.1016/j.jmb.2005.09.014;;16213522;;16242332;;10.1016/j.tim.2005.10.002,"LANGLEY RIES ET AL: ""The staphylococcal superantigen-like protein 7 binds IgA and complement C5 and inhibits IgA-Fc alpha RI binding and serum killing of bacteria."", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 MAR 2005, vol. 174, no. 5, 1 March 2005 (2005-03-01), pages 2926 - 2933, XP002443450, ISSN: 0022-1767;;HAAS ET AL: ""The Structure of the C5a Receptor-blocking Domain of Chemotaxis Inhibitory Protein of Staphylococcus aureus is Related to a Group of Immune Evasive Molecules"", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 353, no. 4, 4 November 2005 (2005-11-04), pages 859 - 872, XP005118796, ISSN: 0022-2836;;ROOIJAKKERS ET AL: ""Staphylococcal innate immune evasion"", TRENDS IN MICROBIOLOGY, ELSEVIER SCIENCE LTD., KIDLINGTON, GB, vol. 13, no. 12, December 2005 (2005-12-01), pages 596 - 601, XP005175685, ISSN: 0966-842X;;See also references of WO 2005090381A1",DISCONTINUED
662,DE,D1,DE 60008945 D1,124-123-672-067-264,2004-04-22,2004,DE 60008945 T,2000-01-26,US 24874799 A,1999-02-12,Drehmomentwandler-Überbrückungskupplung,,LAWRENCE TECHNOLOGICAL UNIVERS,MACDONALD FRASER JOHN;;HARGRAVE DAVID,,https://lens.org/124-123-672-067-264,Granted Patent,no,0,0,6,6,0,F16H45/02;;F16H45/02;;F16H2045/0294;;F16H2045/0294,F16H45/02,,0,0,,,,EXPIRED
663,EP,A2,EP 1028272 A2,142-226-819-598-049,2000-08-16,2000,EP 00300556 A,2000-01-26,US 24874799 A,1999-02-12,Torque converter bypass clutch,"A hydrokinetic torque converter includes an impeller cover (12) and a bypass clutch. A drive ring (74) is located between adjacent surfaces of the cover (12) and a clutch piston (60), which deflects flexurally axially. The piston (60) is welded to the cover (12) at a radially inner position, which is supported at another radial location on the cover (12). The piston (60) deflects into engagement with the drive ring (74), and the drive ring (74) engages with the cover (12). When clutch apply pressure is reduced, energy, in the form of elastic bending potential energy stored in the piston (60), is used to move the piston out of engagement with the drive ring (74) and cover (12).",FORD GLOBAL TECH INC,MACDONALD FRASER JOHN;;HARGRAVE DAVID,LAWRENCE TECHNOLOGICAL UNIVERSITY (2003-06-25),https://lens.org/142-226-819-598-049,Patent Application,yes,2,0,6,6,0,F16H45/02;;F16H45/02;;F16H2045/0294;;F16H2045/0294,F16H45/02,,0,0,,,,EXPIRED
664,MX,A,MX 2019005334 A,156-870-436-760-163,2019-10-04,2019,MX 2019005334 A,2017-11-07,US 201662418637 P;;US 2017/0060413 W,2016-11-07,RAB ESCORT PROTEIN POTENCY ASSAY.,"Methods for measuring REP-1 and REP-2 activity are provided. In certain embodiments, a method includes: (a) contacting cells that do not express endogenous functional REP-1 or REP-2 protein with an adeno-associated viral (AAV) vector comprising a CHM gene encoding a REP-1 protein or CHM like gene encoding a REP-2 protein under conditions allowing cell transduction; (b) incubating transduced cells under conditions allowing expression of the encoded REP-1 or REP-2 protein; (c) lysing the transduced cells to produce an extract comprising the encoded REP-1 or REP-2 protein and Rab small GTPase (Rabs); (d) incubating said extract with a Rab substrate for a period of time and under conditions allowing prenylation of the Rab thereby forming prenylated Rab; and (e) detecting and/or quantifying the prenylated Rab, wherein the amount of prenylated Rab reflects REP-1 or REP-2 activity thereby measuring REP-1 or REP-2 activity.",SPARK THERAPEUTICS INC,JOHN FRASER WRIGHT;;MARINA SUMAROKA,,https://lens.org/156-870-436-760-163,Patent Application,no,0,0,11,11,0,C12Y205/0106;;C12Q1/48;;G01N2333/91171;;C12N9/1085;;C12Q1/48;;G01N2333/91171;;C12Y205/0106,A61K48/00;;C12N15/86,,0,0,,,,PENDING
665,WO,A1,WO 2002/012455 A1,147-569-390-462-056,2002-02-14,2002,US 0118443 W,2001-06-07,US 63383400 A,2000-08-07,LARGE-SCALE RECOMBINANT ADENO-ASSOCIATED VIRUS (rAAV) PRODUCTION AND PURIFICATION,"Methods are provided for large-scale purification of recombinant AAV (rAAV) virions that were produced in the absence of infectious adenovirus. Preferably, the rAAV is produced in a host cell line via triple-transfection with an accessory function vector, an AAV vector, and an AAV helper vector. The methods include preparing a lysate from the host cell line and passing that lysate over various combinations of ion exchange chromatography media and/or affinity chromatography media. The affinity chromatography medium is an AAV receptor or an antibody with binding affinity for AAV, e.g., heparin sulfate. A variety of cation exchange and anion exchange media are contemplated by the present invention. In certain embodiments, optional purification steps may be included, such as filtering the lysate through one or more filters, or treating the lysate with a nuclease.",AVIGEN INC,WRIGHT JOHN FRASER;;QU GUANG,,https://lens.org/147-569-390-462-056,Patent Application,yes,2,84,4,4,0,C12N7/00;;C12N2750/14151;;C12N7/00;;C12N2750/14151,C12N7/02,,3,3,076-649-834-185-907;;056-315-332-834-967;;036-117-611-735-723,10.1038/8470;;10229239;;10.1016/s0166-0934(99)00150-0;;0010716335;;10716335;;19649903,"SUMMERFORD, CANDACE ET AL: ""Viral receptors and vector purification: new approaches for generating clinical-grade reagents"", NAT. MED. (N. Y.) (1999), 5(5), 587-588, - 1999, XP002185298;;ANDERSON R ET AL: ""A METHOD FOR THE PREPARATION OF HIGHLY PURIFIED ADENO-ASSOCIATED VIRUS USING AFFINITY COLUMN CHROMATOGRAPHY, PROTEASE DIGESTION AND SOLVENT EXTRACTION"", JOURNAL OF VIROLOGICAL METHODS, AMSTERDAM, NL, vol. 85, no. 1-2, March 2000 (2000-03-01), pages 23 - 34, XP000982643, ISSN: 0166-0934;;QU G. ET AL: ""Scaling-up production of recombinant AAV vectors for clinical applications."", CURRENT OPINION IN DRUG DISCOVERY AND DEVELOPMENT, (2000) 3/6 (750-755)., - 2000, XP001041966",PENDING
666,EP,A1,EP 2970920 A1,150-700-022-984-765,2016-01-20,2016,EP 14762249 A,2014-03-17,US 201361787818 P;;US 2014/0030370 W,2013-03-15,SCALABLE MANUFACTURING PROCESS TO PRODUCE RECOMBINANT LENTIVIRAL VECTORS IN SERUM-FREE SUSPENSION CELL CULTURE SYSTEM,,PHILADELPHIA CHILDREN HOSPITAL,QU GUANG;;WRIGHT JOHN FRASER,THE CHILDREN'S HOSPITAL OF PHILADELPHIA (2018-08-29),https://lens.org/150-700-022-984-765,Patent Application,yes,0,1,29,29,0,C12N7/00;;C12N2740/15043;;C12N2740/15051;;A61K48/0091;;A61K48/0091;;C12N2740/15043;;C12N2740/15051;;C12N7/00;;A61K48/0091;;C12N7/00;;C12N7/00;;C12N2740/15043;;C12N2740/15051;;A61K48/0091,C12N7/02,,0,0,,,,ACTIVE
667,CN,A,CN 110177579 A,159-955-644-376-790,2019-08-27,2019,CN 201780082482 A,2017-11-07,US 201662418637 P;;US 2017/0060413 W,2016-11-07,RAB ESCORT PROTEIN POTENCY ASSAY,"Methods for measuring REP-1 and REP-2 activity are provided. In certain embodiments, a method includes: (a) contacting cells that do not express endogenous functional REP-1 or REP-2 protein with an adeno-associated viral (AAV) vector comprising a CHM gene encoding a REP-1 protein or CHM like gene encoding a REP-2 protein under conditions allowing cell transduction; (b) incubating transduced cellsunder conditions allowing expression of the encoded REP-1 or REP-2 protein; (c) lysing the transduced cells to produce an extract comprising the encoded REP-1 or REP-2 protein and Rab small GTPase (Rabs); (d) incubating said extract with a Rab substrate for a period of time and under conditions allowing prenylation of the Rab thereby forming prenylated Rab; and (e) detecting and/or quantifying theprenylated Rab, wherein the amount of prenylated Rab reflects REP-1 or REP-2 activity thereby measuring REP-1 or REP-2 activity.",SPARK THERAPEUTICS INC,WRIGHT JOHN FRASER;;SUMAROKA MARINA,,https://lens.org/159-955-644-376-790,Patent Application,no,3,0,11,11,0,C12Y205/0106;;C12Q1/48;;G01N2333/91171;;C12N9/1085;;C12Q1/48;;G01N2333/91171;;C12Y205/0106,A61K48/00;;C12N15/86,,2,0,,,"TANYA TOLMACHOVA等: ""Functional expression of Rab escort protein 1 following AAV2-mediated gene delivery in the retina of choroideremia mice and human cells ex vivo"", 《JOURNAL OF MOLECULAR MEOICINE》;;NICOLAS CERESO等: ""Proof of concept for AAV2/5-mediated gene therapy in iPSC-derived retinal pigment epithelium of a choroideremia patient"", 《MOL THER METHODS CLIN DEV.》",PENDING
668,GB,A,GB 823914 A,162-032-178-772-122,1959-11-18,1959,GB 1113658 A,1958-04-08,GB 1113658 A,1958-04-08,Improvements in penicillin-sulphonamide tablets,"A penicillin-sulphonamide tablet comprises a core containing a granular mixture of penicillin, or a penicillin salt, at least one substantially water-insoluble sulphonamide drug, and ammoniated polyvinyl acetate phthalate, and a concentric outer shell containing conventional excipients and the same therapeutic agents. The core contains at least half (e.g. 60% to 95%) of the total penicillin and less than half (e.g. 10% to 35%) of the total sulphonamide. The ammoniated polyvinyl acetate phthalate may have a degree of polymerization of 600 to 800, an acetyl content of 4% to 15% and a phthalyl content of 40% to 70%, the amount used being 5% to 20% (preferably 8% to 10%) of the total core weight. A process for making the tablets is described. An example of a tablet given contains as the core, sodium penicillin G 18 mgm. (30,000 I.U.), sulphadiazine, sulphamerazine, sulphathiazole 26.7 mgm. of each, corn starch 6 mgm, ammoniated polyvinyl acetate phthalate 9.6 mgm., magnesium stearate 1.4 mgms.; and as the shell, sodium penicillin G 12 mgm. (20,000 I.V.), the sulphonamide, 56.6 mgm. of each, calcium citrate 90 mgm. corn starch 19 mgm., sodium carboxy methyl cellulose (of high viscosity) 3.3 mgm., magnesium stearate 2.7 mgms., and polyvinylpyrrolidone as binder. Examples of other sulphonamides given which may be used are: sulphapyridine, sulphamethazine, sulphanilamide, sulphaguanidine, sulphacetamide, sulphisoxazole, sulphadimetine.",FROSST & CO CHARLES E,MILLAR JOHN FRASER;;LINDNER GERHARD,,https://lens.org/162-032-178-772-122,Granted Patent,no,0,0,1,1,0,A61K9/209,A61K9/24,A5B BKB           BKB;;A5B B75Y          -;;A5B B750          L;;A5B B757          L;;A5B B764          L,0,0,,,,EXPIRED
669,WO,A1,WO 2022/174350 A1,182-538-368-788-970,2022-08-25,2022,CA 2022050237 W,2022-02-18,US 202163150797 P,2021-02-18,SODIUM SULFATE BY-PRODUCT PROCESSING IN LITHIUM AND BATTERY CHEMICAL PRODUCTION,"A process for battery chemical production, where a sodium sulfate stream is treated with an ion exchange process to provide potassium sulfate and sodium chloride. The sodium chloride may be treated with a chlor-alkali to produce sodium hydroxide for use upstream in the battery chemical production process.",HATCH LTD,FRASER ROBERT JOHN;;STAMATIOU EVANGELOS,,https://lens.org/182-538-368-788-970,Patent Application,yes,3,0,8,8,0,C01D3/04;;C01D1/04;;C01D5/00;;C25B1/34;;C25B15/081;;Y02E60/10;;C01D1/04;;C01D5/00;;C25B1/46;;C25B9/23;;Y02E60/10;;B01J49/57;;B01J41/04;;B01J41/12;;C01D1/20;;C01D3/04;;C01D5/02;;C01P2006/40,C01D5/00;;B01J49/30;;C01B17/96;;C01D1/04;;C01D3/04;;C25B1/34;;C25B15/08,,0,0,,,,PENDING
670,EP,A3,EP 2308963 A3,174-194-493-825-13X,2011-09-21,2011,EP 10183737 A,2002-12-09,EP 02805565 A;;US 33885601 P,2001-12-07,System for processing lipoaspirate cells,Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patent. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient.,CYTORI THERAPEUTICS INC,FRASER JOHN;;HEDRICK MARC H,,https://lens.org/174-194-493-825-13X,Search Report,yes,2,0,65,221,0,A61K35/28;;A61K35/28;;A61K48/00;;A61B10/0283;;A61B10/0283;;A61K9/0019;;A61K9/0019;;A61K35/32;;A61K35/35;;A61K35/35;;A61K35/36;;A61M1/76;;A61M2202/08;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/00;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;A61P43/00;;C12M47/04;;C12N5/0667;;C12N5/0667;;C12N5/069;;C12N5/069;;C12N2506/1384;;C12N2506/1384,A61K35/00;;A61M1/00;;A61K31/436;;A61K35/02;;A61K35/12;;A61K35/28;;A61K35/35;;A61K35/36;;A61K38/00;;A61K38/16;;A61K45/00;;A61L27/00;;A61P1/00;;A61P1/16;;A61P3/00;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P19/00;;A61P19/02;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;C12M3/06;;C12N5/071;;C12N5/0775,,3,3,010-094-842-952-554;;001-750-270-620-541;;039-605-949-551-683,10.1089/107632701300062859;;11304456;;11134994;;10.1046/j.1524-4725.2000.00278.x;;10.1046/j.1524-4725.2000.t01-1-00278.x;;10.1016/j.biocel.2003.10.018;;15010330,"ZUK P A ET AL: ""Multilineage cells from human adipose tissue: implications for cell-based therapies."", TISSUE ENGINEERING APR 2001, vol. 7, no. 2, April 2001 (2001-04-01), pages 211 - 228, XP002198710, ISSN: 1076-3279;;BORIS SOMMER ET AL: ""Current Concepts of Fat Graft Survival: Histology of Aspirated Adipose Tissue and Review of the Literature"", DERMATOLOGIC SURGERY, vol. 26, no. 12, 1 December 2000 (2000-12-01), pages 1159 - 1166, XP055004275, ISSN: 1076-0512, DOI: 10.1046/j.1524-4725.2000.00278.x;;JOHN K FRASER ET AL: ""Adult stem cell therapy for the heart"", THE INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, vol. 36, no. 4, 1 April 2004 (2004-04-01), pages 658 - 666, XP055004200, ISSN: 1357-2725, DOI: 10.1016/j.biocel.2003.10.018",DISCONTINUED
671,KR,A,KR 20160024841 A,187-721-545-641-687,2016-03-07,2016,KR 20157029322 A,2014-03-17,US 201361787818 P;;US 2014/0030370 W,2013-03-15,SCALABLE MANUFACTURING PROCESS TO PRODUCE RECOMBINANT LENTIVIRAL VECTORS IN SERUM-FREE SUSPENSION CELL CULTURE SYSTEM,인간 유전자 요법에 기대되는 요건을 충족시키는데 필요한 규모로 고도로 정제된 rLV 벡터 제형을 제조하는 방법이 제공된다.,PHILADELPHIA CHILDREN HOSPITAL,QU GUANG;;WRIGHT JOHN FRASER,,https://lens.org/187-721-545-641-687,Patent Application,no,3,1,29,29,0,C12N7/00;;C12N2740/15043;;C12N2740/15051;;A61K48/0091;;A61K48/0091;;C12N2740/15043;;C12N2740/15051;;C12N7/00;;A61K48/0091;;C12N7/00;;C12N7/00;;C12N2740/15043;;C12N2740/15051;;A61K48/0091,A61K48/00;;B01D15/36,,1,1,016-991-047-300-811,10.1016/j.jviromet.2011.01.013;;21295608,"J. VIROL. METHODS. 2011, vol. 173, no. 1, pages 99-107.",ACTIVE
672,CN,A,CN 105378074 A,196-539-189-102-454,2016-03-02,2016,CN 201480016236 A,2014-03-17,US 2014/0030370 W;;US 201361787818 P,2013-03-15,Scalable manufacturing process to produce recombinant lentiviral vectors in serum-free suspension cell culture system,Methods for preparing highly purified rLV vector formulations at the scale needed to meet anticipated demand for human gene therapy are provided.,THE CHILDREN'S HOSPITAL OF PHILADELPHIA,QU GUANG;;WRIGHT JOHN FRASER,,https://lens.org/196-539-189-102-454,Patent Application,no,3,12,29,29,0,C12N7/00;;C12N2740/15043;;C12N2740/15051;;A61K48/0091;;A61K48/0091;;C12N2740/15043;;C12N2740/15051;;C12N7/00;;A61K48/0091;;C12N7/00;;C12N7/00;;C12N2740/15043;;C12N2740/15051;;A61K48/0091,C12N7/02,,1,0,,,"ZHOU JINGMIN 等: ""PEG-modulated column chromatography for purification of recombinant adeno-associated virus serotype 9"", 《JOURNAL OF VIROLOGICAL METHODS》",PENDING
673,US,B2,US 11428084 B2,010-133-274-885-873,2022-08-30,2022,US 202017062314 A,2020-10-02,US 202017062314 A;;US 201962911002 P,2019-10-04,Adaptor apparatuses and methods for artificial lift systems,"The disclosure provides an adaptor apparatus for a downhole artificial lift system. The apparatus includes an upper adaptor section and a base adaptor section. The upper adaptor section includes a top connector portion for connecting to first equipment, and a neck portion below the top connector portion. The base adaptor section includes a bottom connector portion for connecting to second equipment. The base adaptor section and the neck section define a longitudinal fluid passage therethrough. The upper adaptor section includes slots extending from the fluid passage to an outer surface of the neck. The upper adaptor section also includes a plurality of fluid channels recessed in the outer surface of the upper adaptor piece.",Q2 ARTIFICIAL LIFT SERVICES ULC,FRASER GARTH JOHN;;COYES CORBIN,Q2 ARTIFICIAL LIFT SERVICES ULC (2020-10-02),https://lens.org/010-133-274-885-873,Granted Patent,yes,11,2,4,4,0,E21B43/127;;E21B17/02;;E21B43/127,E21B43/12,,0,0,,,,ACTIVE
674,ES,T3,ES 2357131 T3,022-953-725-682-549,2011-04-19,2011,ES 04776068 T,2004-05-21,US 47238403 P,2003-05-21,PROCEDIMIENTOS PARA PRODUCIR PREPARACIONES DE VIRIONES DE AAV RECOMBINANTES SUSTANCIALMENTE EXENTAS DE CAPSIDAS VACIAS.,"Un procedimiento para purificar partículas de vectores de AAV procedentes de una preparación de AAV que comprende partículas de vectores de AAV y cápsidas vacías de AAV, para proporcionar un producto sustancialmente exento de cápsidas vacías de AAV, comprendiendo dicho procedimiento: a) proporcionar una célula hospedadora que comprende partículas de vectores de AAV; b) lisar dicha célula hospedadora para obtener un lisado celular bruto que comprende partículas de vectores de AAV y cápsidas vacías de AAV; c) aplicar dicho lisado celular bruto a una primera columna de cromatografía de intercambio catiónico en condiciones en las que dichas partículas de vectores de AAV y dichas cápsidas vacías de AAV se unen a la columna; d) eluir dichas partículas de vectores de AAV y dichas cápsidas vacías de AAV en condiciones de no separación para proporcionar una preparación de AAV que comprende partículas de vectores de AAV y cápsidas vacías de AAV; e) aplicar la preparación de AAV procedente de (d) a una segunda columna de cromatografía de intercambio catiónico en condiciones en las que dichas partículas de vectores de AAV y dichas cápsidas vacías de AAV se unen a la columna; f) añadir un tampón bajo en sal a la columna de (e) en condiciones en las que las partículas de vectores de AAV se eluyen y las cápsidas vacías de AAV permanecen unidas a la columna; y g) recoger las fracciones eluidas de (f) que comprenden partículas de vectores de AAV para proporcionar un producto de AAV sustancialmente exento de cápsidas vacías de AAV.",GENZYME CORP,QU GUANG;;WRIGHT JOHN FRASER,,https://lens.org/022-953-725-682-549,Granted Patent,no,0,0,1,41,0,,C12N7/02;;B01D15/00;;B01D15/04;;C02F1/42;;C12N15/864,,0,0,,,,ACTIVE
675,US,A1,US 2011/0206646 A1,040-867-897-902-79X,2011-08-25,2011,US 201113031031 A,2011-02-18,US 201113031031 A;;US 2009/0054055 W;;US 9018608 P,2008-08-19,METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF THE LYMPHATIC SYSTEM AND MALIGNANT DISEASE,"Aspects of the invention provides methods for preparing and using adipose-tissue-derived stem and progenitor cells, adipose-tissue-derived lymphatic endothelial cells, and cells capable of differentiating into lymphatic endothelial cells to treat disorders of the lymphatic system and to modulate expansion, repair, and/or regeneration of the lymphatic system. The invention further provides using adipose-tissue-derived lymphatic endothelial cells and cells capable of differentiating into lymphatic endothelial cells for delivery of therapeutic agents to tumor cells as a means for treating malignant disease, and assays to screen for drugs that modulate lymphatic system expansion, repair or regeneration.",ALFONSO ZENI;;FRASER JOHN K,ALFONSO ZENI;;FRASER JOHN K,CYTORI THERAPEUTICS INC (2011-03-30);;LOREM VASCULAR PTE. LTD (2019-04-24),https://lens.org/040-867-897-902-79X,Patent Application,yes,99,58,6,6,0,A61K35/12;;A61K35/12;;A61K35/28;;A61K35/28;;A61K35/35;;A61K35/35;;A61K45/06;;A61K2035/124;;A61P3/06;;A61P9/00;;A61P35/04;;C12N5/0651;;C12N5/0651;;C12N5/0667;;C12N5/069;;C12N5/069,A61K35/12;;A61K35/28;;A61K35/35;;A61P3/06;;A61P9/00;;A61P35/04,424/93.7,0,0,,,,INACTIVE
676,CA,A1,CA 3095034 A1,057-231-974-196-117,2021-04-04,2021,CA 3095034 A,2020-10-02,US 201962911002 P,2019-10-04,ADAPTOR APPARATUSES AND METHODS FOR ARTIFICIAL LIFT SYSTEMS,"The disclosure provides an adaptor apparatus for a downhole artificial lift system. The apparatus includes an upper adaptor section and a base adaptor section. The upper adaptor section includes a top connector portion for connecting to first equipment, and a neck portion below the top connector portion. The base adaptor section includes a bottom connector portion for connecting to second equipment. The base adaptor section and the neck section define a longitudinal fluid passage therethrough. The upper adaptor section includes slots extending from the fluid passage to an outer surface of the neck. The upper adaptor section also includes a plurality of fluid channels recessed in the outer surface of the upper adaptor piece.",Q2 ARTIFICIAL LIFT SERVICES ULC,FRASER GARTH JOHN;;COYES CORBIN,,https://lens.org/057-231-974-196-117,Patent Application,no,0,0,4,4,0,E21B43/127;;E21B17/02;;E21B43/127,E21B17/042,,0,0,,,,PENDING
677,WO,A1,WO 1994/012788 A1,065-983-738-760-670,1994-06-09,1994,GB 9302458 W,1993-11-30,GB 9225005 A,1992-11-30,IMPROVEMENTS IN OR RELATING TO FLUID-FLOW CONTROL VALVES,"A fluid flow control valve comprises first (12) and second (14) electrically conductive body members separated by an electrically active means (16) having electrical resistance. A valve actuation member (20) slidably locates within the second body (14) member making a sliding electrical contact therewith. The valve actuation member (20) can move from a first position spaced from the first body (12) member to a second position electrically connecting the first body (12) member with the second body (14) member thus forming a low resistance electrical connection. In its first position spaced from the first body member (12), the resistance of the electrical connection between the body members (12, 14) depends on the electrical resistance of the separation means (16). An electrical circuit connected across the body members (12, 14) including a current limiting resistor (R3) forms a voltage splitter circuit with the separation means (16) to enable an output voltage signal indicative of contact of the valve actuation member (20) with the first body member (12) to be obtained.",PERKINS LTD;;WALLACE IAN FRASER;;STAMFORD JOHN,WALLACE IAN FRASER;;STAMFORD JOHN,,https://lens.org/065-983-738-760-670,Patent Application,yes,3,7,12,12,0,F02M65/005;;F02M2200/245;;Y10T137/8242;;F02M65/00;;Y10T137/8242;;F02M65/005;;F02M2200/245,B05B5/00;;F02M51/06;;F02M65/00;;F16K31/02,,0,0,,,,PATENTED
678,US,A1,US 2016/0083694 A1,079-720-272-238-381,2016-03-24,2016,US 201514702008 A,2015-05-01,US 201514702008 A;;US 66155310 A;;US 14199605 A;;US 57599704 P;;US 63922204 P,2004-06-01,COMPOSITIONS AND METHODS TO PREVENT AAV VECTOR AGGREGATION,"Compositions and methods are provided for preparation of concentrated stock solutions of AAV virions without aggregation. Formulations for AAV preparation and storage are high ionic strength solutions (e.g. μ˜500 mM) that are nonetheless isotonic with the intended target tissue. This combination of high ionic strength and modest osmolarity is achieved using salts of high valency, such as sodium citrate. AAV stock solutions up to 6.4×10 13 vg/mL are possible using the formulations of the invention, with no aggregation being observed even after ten freeze-thaw cycles. The surfactant Pluronic® F 68 may be added at 0.001% to prevent losses of virions to surfaces during handling. Virion preparations can also be treated with nucleases to eliminate small nucleic acid strands on virions surfaces that exacerbate aggregation.",GENZYME CORP,WRIGHT JOHN FRASER;;QU GUANG,,https://lens.org/079-720-272-238-381,Patent Application,yes,0,0,33,34,0,C12N2750/14151;;C12N7/00;;C12N2750/14151;;C12N7/00;;C12N2750/14111,C12N7/00;;C12N7/02,,0,0,,,,DISCONTINUED
679,CN,A,CN 1942531 A,100-006-998-195-334,2007-04-04,2007,CN 200580012093 A,2005-03-30,EP 2005051428 W;;EP 04101410 A,2004-04-06,Pigment compositions for inks with improved rheology,,CIBA SC HOLDING AG,JOHN HAGGATA STEPHEN FRASER IA,,https://lens.org/100-006-998-195-334,Patent Application,no,0,1,9,9,0,C09B63/005;;C09B67/002;;C09D11/037;;C09B67/002;;C09B67/006;;C09D17/00;;C09D11/037;;C09B67/002;;C09D11/037;;C09B63/005,C09B67/18;;C09B63/00;;C09D11/02,,0,0,,,,INACTIVE
680,EP,A3,EP 2281877 A3,099-364-025-973-829,2011-06-01,2011,EP 10179749 A,2004-05-21,EP 04776068 A;;US 47238403 P;;US 54975604 P,2003-05-21,Methods for producing preparations of recombinant AAV virions substantially free of empty capsids,"Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.
",GENZYME CORP,QU GUANG;;WRIGHT JOHN FRASER,,https://lens.org/099-364-025-973-829,Search Report,yes,2,0,40,41,0,C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N15/86;;C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N2710/16651;;C12N2710/10351;;C12N2760/16051;;C12N15/86,C12N7/02;;B01D15/00;;B01D15/04;;C02F1/42;;C12N/;;C12N15/86;;C12N15/864,,8,8,040-850-901-799-916;;036-117-611-735-723;;045-942-479-095-293;;056-315-332-834-967;;063-793-003-971-602;;003-351-517-641-454;;082-256-886-757-890;;133-796-772-596-115,10.1089/104303402320139014;;12133276;;19649903;;11589834;;10.1089/104303401753153974;;10.1016/s0166-0934(99)00150-0;;0010716335;;10716335;;10.1038/sj.gt.3300938;;10455399;;10.1089/104303400750001390;;11044910;;10.1016/s1525-0016(02)90719-7;;12436964;;10.1006/mthe.2002.0719;;10.1016/j.ymthe.2004.06.346,"KALUDOV NIKOLA ET AL: ""Scalable purification of adeno-associated virus type 2, 4, or 5 using ion-exchange chromatography"", HUMAN GENE THERAPY, vol. 13, no. 10, 1 July 2002 (2002-07-01), pages 1235 - 1243, XP002382732, ISSN: 1043-0342;;QU G ET AL: ""SCALING-UP PRODUCTION OF RECOMBINANT AAV VECTORS FOR CLINICAL APPLICATIONS"", CURRENT OPINION IN DRUG DISCOVERY AND DEVELOPMENT, CURRENT DRUGS, LONDON, GB, vol. 3, no. 6, 2000, pages 750 - 755, XP001041966, ISSN: 1367-6733;;VELLEKAMP GARY ET AL: ""Empty capsids in column-purified recombinant adenovirus preparations"", HUMAN GENE THERAPY, vol. 12, no. 15, 10 October 2001 (2001-10-10), pages 1923 - 1936, XP002382733, ISSN: 1043-0342;;ANDERSON R ET AL: ""A METHOD FOR THE PREPARATION OF HIGHLY PURIFIED ADENO-ASSOCIATED VIRUS USING AFFINITY COLUMN CHROMATOGRAPHY, PROTEASE DIGESTION AND SOLVENT EXTRACTION"", JOURNAL OF VIROLOGICAL METHODS, AMSTERDAM, NL, vol. 85, no. 1-2, March 2000 (2000-03-01), pages 23 - 34, XP000982643, ISSN: 0166-0934;;ZOLOTUKHIN ET AL: ""Recombinant adeno -associated virus purification using novel methods improves infectious titer and yield"", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 6, no. 6, June 1999 (1999-06-01), pages 973 - 985, XP002116593, ISSN: 0969-7128;;GAO G ET AL: ""Purification of Recombinant Adeno-Associated Virus Vectors by Column Chromatography and Its Performance In Vivo"", HUMAN GENE THERAPY, MARY ANN LIEBERT, NEW YORK ,NY, US, vol. 11, no. 15, 1 October 2000 (2000-10-01), pages 2079 - 2091, XP008090776, ISSN: 1043-0342;;BRUMENT N ET AL: ""A versatile and scalable two-step ion exchange chromatography process for the purification of recombinant adeno-associated virus serotypes-2 and -5"", MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 6, no. 5, 1 November 2002 (2002-11-01), pages 678 - 686, XP002969618, ISSN: 1525-0016, DOI: 10.1016/S1525-0016(02)90719-7;;""Development of a scalable column chromatography-based purification process to manufacure empty capsid-free AAV vectors"", MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA,, US, vol. 9, May 2004 (2004-05-01), pages 162, XP004634790, ISSN: 1525-0016",DISCONTINUED
681,CN,A,CN 1118194 A,104-726-561-967-072,1996-03-06,1996,CN 94191287 A,1994-02-22,US 2306093 A,1993-02-25,Apparatus and method for driving a leadscrew,,OHIO ELECTRONIC ENGRAVERS INC,FRASER JOHN W;;WOODS CURTIS,,https://lens.org/104-726-561-967-072,Patent Application,no,0,1,6,6,0,G05B19/404;;G05B19/404;;G05B19/186;;G05B19/186;;G05B2219/41036;;G05B2219/41036;;G05B2219/41038;;G05B2219/41038;;G05B2219/41055;;G05B2219/41055;;G05B2219/41077;;G05B2219/41077;;G05B2219/45212;;G05B2219/45212,G05B19/18;;G05B19/404;;G05D3/00;;G05D3/12,,0,0,,,,DISCONTINUED
682,US,A,US 3211181 A,131-970-138-968-880,1965-10-12,1965,US 32836263 A,1963-12-05,US 32836263 A,1963-12-05,Single handle faucet,,SPEAKMAN CO,JAMES FRASER;;PECIS JOHN G,,https://lens.org/131-970-138-968-880,Granted Patent,no,6,3,1,1,0,F16K11/0565;;F16K11/0565;;F16K11/078;;F16K11/078;;Y10T137/86549;;Y10T137/86549,F16K11/056;;F16K11/078,,0,0,,,,EXPIRED
683,WO,A1,WO 2012/080913 A1,143-738-364-865-045,2012-06-21,2012,IB 2011055546 W,2011-12-08,US 42247910 P,2010-12-13,ADJUSTING MEASUREMENTS OF THE EFFECTS OF ACOUSTIC RADIATION FORCE FOR BACKGROUND MOTION EFFECTS,An ultrasonic diagnostic imaging system for shear wave measurement transmits push pulses into tissue for the generation of shear waves. Characteristics of the shear waves such as their velocity of passage through the tissue are measured to assess properties such as tissue stiffness. The measurements are compensated for effects of background motion by sampling echo signals from the tissue at different times and comparing the samples to detect the presence of relative motion between the ultrasound probe and the region of interest where shear waves are detected. Sensed background motion is used to adjust measured shear wave characteristics.,KONINKL PHILIPS ELECTRONICS NV;;FRASER JOHN DOUGLAS;;XIE HUA,FRASER JOHN DOUGLAS;;XIE HUA,,https://lens.org/143-738-364-865-045,Patent Application,yes,3,13,14,14,0,A61B8/0825;;A61B8/4488;;A61B8/5276;;G01S7/52036;;G01S7/52042;;G01S7/5205;;G01S7/52095;;G01S15/8925;;A61B8/485;;A61B8/4488;;A61B8/485;;G01S7/52036;;A61B8/4488;;A61B8/5276;;G01S7/52036;;A61B8/0825;;G01S7/52042;;G01S7/5205;;G01S7/52095;;G01S15/8925;;A61B8/485,G01S7/52;;A61B8/00,,6,6,056-705-091-710-181;;070-586-234-728-521;;015-443-234-271-768;;166-054-203-736-266;;139-454-483-530-353;;000-361-577-809-810,10.1121/1.1378344;;11508987;;10.1016/s0301-5629(98)00110-0;;10385964;;10.1016/j.ultrasmedbio.2007.10.009;;18222031;;pmc2362504;;10.1126/science.280.5360.82;;9525861;;pmc3764610;;19213633;;10.1109/tuffc.2009.1006;;10.1109/tuffc.2009.1097;;pmc2756029;;19406703,"NIGHTINGALE, K.R. ET AL.: ""On the feasibility of remote palpation using acoustic radiation force"", J. ACOUST. SOC. AM., vol. 110, no. 1, 2001, pages 625 - 34, XP012002408, DOI: doi:10.1121/1.1378344;;SARVAZYAN, A. ET AL.: ""Shear wave elasticity imaging: A new ultrasonic technology of medical diagnostics"", ULTRASOUND MED. BIOL., vol. 24, 1998, pages 1419 - 1435, XP004295295, DOI: doi:10.1016/S0301-5629(98)00110-0;;""Quantifying Hepatic Shear Modulus In Vivo Using Acoustic Radiation Force"", ULTRASOUND IN MED. BIOL., vol. 34, 2008;;FATEMI, M. ET AL.: ""Ultrasound-stimulated vibro- acoustic spectrography"", SCIENCE, vol. 280, 1998, pages 82 - 85, XP055025546, DOI: doi:10.1126/science.280.5360.82;;BOUCHARD, R. ET AL.: ""Image Quality, Tissue Heating, and Frame Rate Trade-offs in Acoustic Radiation Force Impulse Imaging"", IEEE TRANS. UFFC, vol. 56, 2009, pages 63 - 76, XP011267404, DOI: doi:10.1109/TUFFC.2009.1006;;URBAN ET AL.: ""Error in Estimates of Tissue Material Properties from Shear Wave Dispersion Ultrasound Vibrometry"", IEEE TRANS. UFFC, vol. 56, no. 4, April 2009 (2009-04-01), XP011255657",PENDING
684,WO,A2,WO 2003/053346 A2,145-532-353-661-409,2003-07-03,2003,US 0239465 W,2002-12-09,US 33885601 P,2001-12-07,SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS,Cells present in processed lipoaspirate tissue are used to treat patients&period; Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient&period; The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient&period; Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient&period;,MACROPORE BIOSURGERY INC;;FRASER JOHN;;HENDRICK MARC H,FRASER JOHN;;HENDRICK MARC H,,https://lens.org/145-532-353-661-409,Patent Application,yes,5,0,65,221,0,A61K35/28;;A61K35/28;;A61K48/00;;A61B10/0283;;A61B10/0283;;A61K9/0019;;A61K9/0019;;A61K35/32;;A61K35/35;;A61K35/35;;A61K35/36;;A61M1/76;;A61M2202/08;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/00;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;A61P43/00;;C12M47/04;;C12N5/0667;;C12N5/0667;;C12N5/069;;C12N5/069;;C12N2506/1384;;C12N2506/1384,A61M1/00;;A61K31/436;;A61K35/02;;A61K35/12;;A61K35/28;;A61K35/35;;A61K35/36;;A61K38/00;;A61K38/16;;A61K45/00;;A61L27/00;;A61P1/00;;A61P1/16;;A61P3/00;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P19/00;;A61P19/02;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;C12M3/06;;C12N5/0775,,12,11,047-798-816-795-67X;;002-402-322-729-764;;087-309-466-182-005;;056-351-892-637-02X;;106-909-648-526-709;;079-304-670-311-107;;060-789-622-695-335;;018-221-020-974-252;;100-021-019-543-442;;006-388-312-315-426;;010-094-842-952-554,10553215;;10.1016/s0094-1298(20)32659-6;;10225738;;10.1111/j.1744-9987.1997.tb00137.x;;10.1515/cclm.2000.092;;11028769;;11835415;;10.1002/jca.1032;;12144534;;10.1034/j.1600-0609.2002.01682.x;;9027589;;10.1002/(sici)1097-4644(199702)64:2<295::aid-jcb12>3.0.co;2-i;;10.1002/(sici)1097-4644(199702)64:2<295::aid-jcb12>3.3.co;2-6;;12411045;;12456961;;10.1634/stemcells.20-6-530;;10.1016/0270-9139(95)90478-6;;7539398;;10.1002/hep.1840210632;;10488710;;10.1016/s0168-8278(99)80043-9;;10.1089/107632701300062859;;11304456,"KATZ, A.J. ET AL.: ""Emerging approaches to the tissue engineering of fat"", CLIN PLAST SURG, vol. 26, no. 4, October 1999 (1999-10-01), pages 587 - 603, XP009061485;;SMITH, J.W.: ""Apheresis techniques and cellular immunomodulation"", THER APHER, vol. 1, no. 3, 1997, pages 203 - 6;;LASCH, J.; G. KULLERTZ; J.R. OPALKA: ""Separation of erythrocytes into age-related fractions by density or size? Counterflow centrifugation"", CLIN CHEM LAB MED, vol. 38, no. 7, 2000, pages 629 - 32;;ITO, Y.; K. SHINOMIYA: ""A new continuous-flow cell separation method based on cell density: principle, apparatus, and preliminary application to separation of human buffy coat"", J CLIN APHERESIS, vol. 16, no. 4, 2001, pages 186 - 91;;DLUBEK, D. ET AL.: ""Enrichment of normal progenitors in counter-flow centrifugal elutriation (CCE) fractions of fresh chronic myeloid leukemia leukapheresis products"", EUR J HAEMATOL, vol. 68, no. 5, 2002, pages 281 - 8;;JAISWAL, N. ET AL.: ""Osteogenic differentiation of purified, culture-expanded human mesenchymal stem cells in vitro"", J CELL BIOCHEM, vol. 64, no. 2, 1997, pages 295 - 312, XP002193569, DOI: doi:10.1002/(SICI)1097-4644(199702)64:2<295::AID-JCB12>3.0.CO;2-I;;HOU, L. ET AL.: ""Study of in vitro expansion and differentiation into neuron-like cells of human umbilical cord blood mesenchymal stem cells"", ZHONGHUA XUE YE XUE ZA ZHI, vol. 23, no. 8, 2002, pages 415 - 9;;SEKIYA, 1. ET AL.: ""Expansion of Human Adult Stem Cells from Bone Marrow Stroma: Conditions that Maximize the Yields of Early Progenitors and Evaluate Their Quality"", STEM CELLS, vol. 20, no. 6, 2002, pages 530 - 41, XP009092467, DOI: doi:10.1634/stemcells.20-6-530;;YAVORKOVSKY, L.; E. LAI ET AL.: ""Participation of small intraportal stem cells in the restitutive response of the liver to periportal necrosis induced by allyl alcohol."", HEPATOLOGY, vol. 21, no. 6, 1995, pages 1702 - 12;;YIN, L.; D. LYNCH ET AL.: ""Participation of different cell types in the restitutive response of the rat liver to periportal injury induced by allyl alcohol."", J HEPATOL, vol. 31, no. 3, 1999, pages 497 - 507, XP001159743, DOI: doi:10.1016/S0168-8278(99)80043-9;;ZUK, P. A.; M. ZHU ET AL.: ""Multilineage cells from human adipose tissue: implications for cell-based therapies."", TISSUE ENG, vol. 7, no. 2, 2001, pages 211 - 28, XP002746115, DOI: doi:10.1089/107632701300062859;;See also references of EP 1572071A4",PENDING
685,DE,B,DE 1288582 B,145-086-377-453-148,1969-02-06,1969,DE I0025916 A,1964-05-26,GB 2108463 A,1963-05-27,Verfahren zur Herstellung von Adipinsaeure,,ICI LTD,CYRIL GARDNER;;FRASER PRECOTT JOHN,,https://lens.org/145-086-377-453-148,Patent Application,no,3,0,7,8,0,C07C51/313;;C07C51/313;;C07C45/33;;C07C45/33;;C07C51/316;;C07C51/316,C07C45/33;;C07C51/31,,0,0,,,,DISCONTINUED
686,GB,A,GB 2218748 A,153-858-647-150-508,1989-11-22,1989,GB 8908798 A,1989-04-19,GB 8809478 A,1988-04-21,A regenerative pump,"A regenerative pump includes a circular impeller 2 having spaced radially extending blades 4 which define channels 24 therebetween. The impeller 2 is rotatably mounted in a pump casing 8 to enable the blades 4 to pass along an annular chamber 6. A part of this chamber 6 is of reduced cross-section and forms a barrier 10. The longitudinal axis 29 of each channel 24 is inclined outwardly and rearwardly with respect to the direction of rotation of the impeller 2, and this axis may be appropriately curved. The barrier 10 may be formed by two opposed side portions of different lengths (one may subtend an angle 30 DEG greater than the other), and these side portions may be staggered at both the inlet and outlet of the barrier 10. The channels 24 may be formed in opposed side walls of the impeller 2 to extend across only part of the impeller 2, and the channels on one side may be offset in relation to those on the other side (Fig 5). <IMAGE>",MYSON GROUP PLC,FRASER JOHN IAN;;SEREMAK RICHARD,,https://lens.org/153-858-647-150-508,Patent Application,no,6,12,4,4,0,F04D29/188;;F04D5/002,F04D5/00;;F04D29/18,F1C CE            CE;;F1C CFE           CFE;;F1C C109          CE;;F1C C109          CFE;;F1V VB            VB;;F1V V120          VB;;F1V V200          VB;;F1V V210          VB;;U1S S2005,0,0,,,,EXPIRED
687,US,B1,US 7461099 B1,177-603-568-000-516,2008-12-02,2008,US 67063500 A,2000-09-26,US 67063500 A,2000-09-26,Method and system for archiving and retrieving items based on episodic memory of groups of people,"A method and system for archiving and retrieving digital media items based on episodic memory of predefined associated groups of one or more people comprises: receiving an input identifying a group to which the user belongs; receiving user archiving input identifying a digital media item to be archived for the group, selecting zero or more group event types from a predetermined plurality of group event tapes for the group, selecting zero or more persons in the group, and selecting a time; generating index information using the received user archiving input; storing the indexed information in association with the identified digital item; repeating the reception of user archiving input, the generation of the index information and the storing of the index information for a plurality of digital media items; receiving a user retrieval input selecting or automatically selecting: zero or more groups of event types from the predetermined plurality of group event types for the group, zero or more persons in the group, and a time period; and using the selections and the identified group to retrieve and output digital media items that match the selection.",6S LTD,SHARPE ELIZABETH;;FRASER JOHN LESLIE,6S LIMITED (2001-01-08),https://lens.org/177-603-568-000-516,Granted Patent,yes,24,32,1,1,0,G06F16/907;;G06F16/907;;Y10S707/99955;;Y10S707/99933,G06F17/30,707/204;;707/3;;707/10,3,3,149-865-423-447-055;;130-915-722-387-120;;023-993-018-529-724,10.1016/b978-155860915-0/50011-1;;10.1145/319878.319921;;10.1109/icme.2000.869606,"Shneiderman et al. (Direct Annotation: A Drag-and-Drop Strategy for Labeling Photos, Aug. 2000.;;Alexander C. Loui and Mark D. Wood, A Software System For Automatic Albuming Of Consumer Pictures, pp. 159-162.;;K. Priyantha Hewagamage and Masahito Hirakawa, Augmented Album: Situation-dependant System For A Personal Digital Video/Image Collection, pp. 323-326.",EXPIRED
688,EP,B1,EP 1625210 B1,191-666-421-906-896,2010-12-01,2010,EP 04776068 A,2004-05-21,US 2004/0015958 W;;US 47238403 P;;US 54975604 P,2003-05-21,METHODS FOR PRODUCING PREPARATIONS OF RECOMBINANT AAV VIRIONS SUBSTANTIALLY FREE OF EMPTY CAPSIDS,Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.,GENZYME CORP,QU GUANG;;WRIGHT JOHN FRASER,,https://lens.org/191-666-421-906-896,Granted Patent,yes,4,0,40,41,0,C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N15/86;;C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N2710/16651;;C12N2710/10351;;C12N2760/16051;;C12N15/86,C12N7/02;;B01D15/00;;B01D15/04;;C02F1/42;;C12N/;;C12N15/86;;C12N15/864,,9,0,,,"KALUDOV NIKOLA ET AL: ""Scalable purification of adeno-associated virus type 2, 4, or 5 using ion-exchange chromatography"" HUMAN GENE THERAPY, vol. 13, no. 10, 1 July 2002 (2002-07-01), pages 1235-1243, XP002382732 ISSN: 1043-0342;;QU G ET AL: ""SCALING-UP PRODUCTION OF RECOMBINANT AAV VECTORS FOR CLINICAL APPLICATIONS"" CURRENT OPINION IN DRUG DISCOVERY AND DEVELOPMENT, CURRENT DRUGS, LONDON, GB, vol. 3, no. 6, 2000, pages 750-755, XP001041966 ISSN: 1367-6733;;VELLEKAMP GARY ET AL: ""Empty capsids in column-purified recombinant adenovirus preparations"" HUMAN GENE THERAPY, vol. 12, no. 15, 10 October 2001 (2001-10-10), pages 1923-1936, XP002382733 ISSN: 1043-0342;;ANDERSON R ET AL: ""A METHOD FOR THE PREPARATION OF HIGHLY PURIFIED ADENO-ASSOCIATED VIRUS USING AFFINITY COLUMN CHROMATOGRAPHY, PROTEASE DIGESTION AND SOLVENT EXTRACTION"" JOURNAL OF VIROLOGICAL METHODS, AMSTERDAM, NL, vol. 85, no. 1-2, March 2000 (2000-03), pages 23-34, XP000982643 ISSN: 0166-0934;;ZOLOTUKHIN ET AL: ""Recombinant adeno -associated virus purification using novel methods improves infectious titer and yield"" GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 6, no. 6, June 1999 (1999-06), pages 973-985, XP002116593 ISSN: 0969-7128;;""Development of a scalable column chromatography-based purification process to manufacure empty capsid-free AAV vectors"" MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA,, US, vol. 9, May 2004 (2004-05), page 162, XP004634790 ISSN: 1525-0016;;GAO G ET AL: 'Purification of Recombinant Adeno-Associated Virus Vectors by Column Chromatography and its Performance in Vivo.' HUMAN GENE THERAPY. vol. 11, no. 15, October 2000, pages 2080 - 2084, XP002993010;;DEBELAK D. ET AL: 'Cation-exchange high-performance liquid chromatography of recombinant adeno-associated virus type 2.' J CROMAT B. vol. 740, no. 2, April 2000, pages 195 - 202, XP004195010;;BRUMENT N ET AL: 'A Versatile and Scalable Two-Step Ion Exchange Chromatography Process for the Purification of Recombinant Adeno-associated Virus Serotype-2 and -5.' MOLECULAR THERAPY. vol. 6, no. 5, November 2002, pages 678 - 686, XP002969618",ACTIVE
689,CA,A1,CA 3059632 A1,023-641-677-205-505,2018-10-17,2018,CA 3059632 A,2018-04-12,EP 17000619 A;;US 2018/0027317 W,2017-04-12,FIRE RETARDANT COMPOSITE,"This disclosure relates to a fire-retardant composite material comprising a fibre-reinforced plastic covered by an aluminium foil and its application in passenger transport industries such as aerospace, railway or marine.",HUNTSMAN ADV MAT LICENSING SWITZERLAND GMBH,DE VERCLOS OLIVIER;;FRASER JOHN,,https://lens.org/023-641-677-205-505,Patent Application,no,0,0,8,8,0,B32B5/022;;B32B5/024;;B32B5/26;;B32B15/14;;B32B15/20;;B32B19/041;;B32B19/06;;B32B3/12;;B32B2260/023;;B32B2260/046;;B32B2262/02;;B32B2262/0269;;B32B2262/101;;B32B2262/106;;B32B2307/3065;;B32B2451/00;;B32B2605/00;;B32B15/092;;B32B15/20;;B32B27/38;;B32B2311/24;;B32B2363/00,B32B5/02;;B32B3/12;;B32B5/26;;B32B15/14;;B32B15/20;;B32B19/04;;B32B19/06,,0,0,,,,DISCONTINUED
690,WO,A3,WO 2002/027545 A3,035-008-423-259-038,2003-03-13,2003,GB 0104302 W,2001-09-26,GB 0023584 A,2000-09-26,METHOD AND SYSTEM FOR ARCHIVING AND RETRIEVING ITEMS BASED ON EPISODIC MEMORY OF GROUPS OF PEOPLE,"A method and system for archiving and retrieving digital media items based on episodic memory of predefined associated groups of one or more people comprises: receiving an input identifying a group to which the user belongs; receiving user archiving input identifying a digital media item to be archived for the group, selecting zero or more group event types from a predetermined plurality of group event types for the group, selecting zero or more persons in the group, and selecting a time; generating index information using the received user archiving input; storing the indexed information in associated using the received user archiving input; storing the indexed information in association with the identifying digital item; repeating the reception of user archiving input, the generating of the index information and the storing of the index information for a pluralty of digital media items; receiving a user retrieval input selecting or automatically selecting: zero or more groups of event types from the predetermined plurality of group event types for the group, zero or more persons in the group, and a time period; and using the selections and the identified group to retrieve and output digital media items that match the selection.",6S LTD;;FRASER JOHN LESLIE;;SHARPE ELIZABETH,FRASER JOHN LESLIE;;SHARPE ELIZABETH,,https://lens.org/035-008-423-259-038,Search Report,yes,3,0,8,8,0,G06F16/9535;;G06F16/951,G06F17/30,,2,2,130-915-722-387-120;;023-993-018-529-724,10.1145/319878.319921;;10.1109/icme.2000.869606,"ALEXANDER C., LOUI AND MARK D. WOOD: ""A Software System for Automatic Albuming of Consumer Pictures"", PROCEEDINGS OF THE SEVENTH ACM INTERNATIONAL CONFERENCE ON MULTIMEDIA, 1999, Orlando, FL, USA, pages 159 - 162, XP002220769, Retrieved from the Internet <URL:http://portal.acm.org/citation.cfm?id=319921&coll=portal&dl=ACM&CFID=5712302&CFTOKEN=4850483> [retrieved on 20021114];;HEWAGAMAGE, K.P.; HIRAKAWA, M.: ""Augmented Album: situation-dependent system for a personal digital video/image collection"", MULTIMEDIA AND EXPO, 2000. ICME 2000. 2000 IEEE INTERNATIONAL CONFERENCE ON, vol. 1, 30 July 2000 (2000-07-30) - 2 August 2000 (2000-08-02), NY, USA, pages 323 - 326, XP002220770, Retrieved from the Internet <URL:http://ieeexplore.ieee.org/iel5/6974/18800/00869606.pdf?isNumber=18800&prod=CNF&arnumber=869606&arSt=323&ared=326+vol.1&arAuthor=Hewagamage%2C+K.P.%3B+Hirakawa%2C+M.> [retrieved on 20021114]",PENDING
691,AU,A1,AU 2002/357135 A1,073-912-140-889-471,2003-07-09,2003,AU 2002/357135 A,2002-12-09,US 33885601 P;;US 0239465 W,2001-12-07,SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS,,MACROPORE BIOSURGERY INC,FRASER JOHN;;HENDRICK MARC H,,https://lens.org/073-912-140-889-471,Patent Application,no,0,0,65,221,0,A61K35/28;;A61K35/28;;A61K48/00;;A61B10/0283;;A61B10/0283;;A61K9/0019;;A61K9/0019;;A61K35/32;;A61K35/35;;A61K35/35;;A61K35/36;;A61M1/76;;A61M2202/08;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/00;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;A61P43/00;;C12M47/04;;C12N5/0667;;C12N5/0667;;C12N5/069;;C12N5/069;;C12N2506/1384;;C12N2506/1384,A61M1/00;;A61K31/436;;A61K35/02;;A61K35/12;;A61K35/28;;A61K35/35;;A61K35/36;;A61K38/00;;A61K38/16;;A61K45/00;;A61L27/00;;A61P1/00;;A61P1/16;;A61P3/00;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P19/00;;A61P19/02;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;C12M3/06;;C12N5/0775,,0,0,,,,EXPIRED
692,JP,A,JP 2012149088 A,105-868-577-637-406,2012-08-09,2012,JP 2012091080 A,2012-04-12,US 33885601 P,2001-12-07,SYSTEM AND METHOD FOR TREATMENT OF PATIENT BY USING PROCESSED LIPOASPIRATE CELL,"PROBLEM TO BE SOLVED: To treat a patient by using a cell that exists in a processed lipoaspirate tissue.SOLUTION: The method of treatment includes a step that delivers to the patient a concentrated amount of stem cell obtained from the adipose tissue adipose. The stem cell is not exposed to an outside environment before it is administered to the patient because this method is enforceable in a closed system. Since a composition administered to the patient contains a mixture of the adipose tissue and the stem cell, the composition has a higher density stem cell than when the adipose tissue is removed from the patient.",CYTORI THERAPEUTICS INC,FRASER JOHN;;HENDRICK MARC H,,https://lens.org/105-868-577-637-406,Patent Application,no,1,6,65,221,0,A61K35/28;;A61K35/28;;A61K48/00;;A61B10/0283;;A61B10/0283;;A61K9/0019;;A61K9/0019;;A61K35/32;;A61K35/35;;A61K35/35;;A61K35/36;;A61M1/76;;A61M2202/08;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/00;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;A61P43/00;;C12M47/04;;C12N5/0667;;C12N5/0667;;C12N5/069;;C12N5/069;;C12N2506/1384;;C12N2506/1384,A61K35/28;;A61M1/00;;A61K31/436;;A61K35/02;;A61K35/12;;A61K35/35;;A61K35/36;;A61K38/00;;A61K38/16;;A61K45/00;;A61L27/00;;A61P1/00;;A61P1/16;;A61P3/00;;A61P3/06;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;C12M3/06;;C12N5/0775,,0,0,,,,INACTIVE
693,US,B2,US 9051542 B2,126-566-193-379-91X,2015-06-09,2015,US 66155310 A,2010-03-19,US 66155310 A;;US 14199605 A;;US 57599704 P;;US 63922204 P,2004-06-01,Compositions and methods to prevent AAV vector aggregation,"Compositions and methods are provided for preparation of concentrated stock solutions of AAV virions without aggregation. Formulations for AAV preparation and storage are high ionic strength solutions (e.g. μ˜500 mM) that are nonetheless isotonic with the intended target tissue. This combination of high ionic strength and modest osmolarity is achieved using salts of high valency, such as sodium citrate. AAV stock solutions up to 6.4×10 13 vg/mL are possible using the formulations of the invention, with no aggregation being observed even after ten freeze-thaw cycles. The surfactant Pluronic® F68 may be added at 0.001% to prevent losses of virions to surfaces during handling. Virion preparations can also be treated with nucleases to eliminate small nucleic acid strands on virions surfaces that exacerbate aggregation.",WRIGHT JOHN FRASER;;QU GUANG;;GENZYME CORP,WRIGHT JOHN FRASER;;QU GUANG,AVIGEN INC (2005-10-04);;GENZYME CORPORATION (2005-12-19),https://lens.org/126-566-193-379-91X,Granted Patent,yes,7,31,33,34,0,C12N2750/14151;;C12N7/00;;C12N2750/14151;;C12N7/00;;C12N2750/14111,C12N7/00;;C12N7/02,,27,22,120-644-541-568-817;;049-155-615-380-092;;081-231-772-265-33X;;017-602-964-237-703;;150-063-089-564-168;;008-498-374-187-896;;089-800-605-790-418;;025-599-305-407-591;;052-632-297-810-831;;027-720-586-974-158;;073-559-929-212-99X;;036-117-611-735-723;;056-841-143-148-239;;135-987-388-625-166;;024-082-216-460-229;;028-383-058-454-759;;147-049-565-078-568;;072-653-024-592-144;;088-196-754-870-804;;089-786-895-898-348;;060-601-673-062-602;;010-284-533-720-722,pmc109439;;9420290;;10.1128/jvi.72.1.802-806.1998;;10.12665/j13.bowe;;9358564;;10.1023/a:1012193326789;;10.1002/jps.2600831204;;7891291;;14739218;;10.1182/blood-2003-11-3845;;10.1038/sj.gt.3301527;;11571564;;11269337;;10.1002/1521-2254(2000)9999:9999<::aid-jgm152>3.0.co;2-u;;15242531;;10.1089/1043034041361190;;10.1182/blood-2003-11-3852;;14695227;;7491504;;10.1055/s-2007-1007278;;10.1016/s1525-0016(16)41343-2;;19649903;;10.1002/jps.20079;;15124199;;10.1016/s1525-0016(02)00019-9;;12573625;;9191943;;10.1099/0022-1317-78-6-1453;;10.1016/s0378-5173(99)00152-0;;10460913;;10.1016/s0378-5173(98)00038-6;;12669452;;15963933;;10.1016/j.ymthe.2005.02.021;;15488616;;10.1016/j.jviromet.2004.07.007;;10.1073/pnas.162250899;;pmc124927;;12136130;;10.1089/1043034041361262;;15298029,"Vihinen-Ranta M. et al., Intracellular Route of Canine Parvovirus Entry, Journal of Virology, Jan. 1998, vol. 72, No. 1, pp. 802-806.;;Adadeyoh et al., ""Short-Term Field Use and Shipping Stability Study of a Wild Type AD5 Adenoviral Reference Material,"" BioProcessing, 1(3):62-9 (2002).;;Braun et al., ""Protein Aggregates Seem to Play a Key Role Among the Parameters Influencing The Antigenicity of Interferon Alpha (IFN-Alpha) in Normal and Transgenic Mice,"" Pharm. Res. 14(10):1472-1478 (1997).;;Chen et al., ""Strategies to Suppress Aggregation of Recombinant Keratinocyte Growth Factor During Liquid Formulation Development,"" J. Pharm. Sci. 83(12):1657-1661 (1994).;;Chenuaud et al., ""Autoimmune Anemia in Macaques Following Erythropoietin Gene Therapy,"" Blood 103(9):3303-3304 (2004).;;Croyle et al., ""Development of Formulations That Enhance Physical Stability of Viral Vectors for Gene Therapy,"" Gene Therapy 8(17):1281-1290 (2001).;;Drittanti et al., ""Optimised Helper Virus-Free Production of High Quality Adeno-Associated Virus Vectors"", The Journal of Gene Medicine, 3:59-71 (2001).;;Flotte, T. R., ""Immune Responses to Recombinant Adeno-Associated Virus Vectors: Putting Preclinical Findings Into Perspective,"" Human Gene Ther. 15(7):716-717 (2004).;;Gao et al., ""Erythropoietin Gene Therapy Leads to Autoimmune Anemia in Macaques,"" Blood 103(9):3300-3302 (2004).;;High et al., ""Human Immune Responses to AAV-2 Capsid May Limit Duration of Expression in Liver-Directed Gene Transfer in Human With Hemophilis beta,"" Blood, 104(11):121a, Abstract No. 413 (2004).;;Huang et al., ""ADAAV Support High-Titer Production of RAAV But Not Stable,"" Mol. Therapy 1:S286 (2000).;;Meijer et al., ""Targeting of Drugs to the Liver,"" Sem. Liver Dis. 15(3):202-256 (1995).;;Qu et al., ""Evidence That Ionic Interactions Are Involved in Concentration-Induced Aggregation of Recombinant Adeno-Associated Virus,"" Molecular Therapy, 7(5):S348, abstract No. 901 (2003).;;Qu et al., ""Scaling Up Production of Recombinant AAV Vectors for Clinical Applications,"" Curr Opin Drug Disc Dev. 3(6):750-755 (2000).;;Shire et al., ""Challenges in The Development of High Protein Concentration Formulations,"" J. Pharm. Sci. 93(6):1390-1402 (2004).;;Sommer et al., ""Quantification of Adeno-Associated Virus Particles and Empty Capsids by Optical Density Measurement,"" Mol Ther 7(1):122-128 (2003).;;Steinbach et al., ""Assembly of Adeno-Associated Virus Type 2 Capsids in Vitro,"" J Gen. Virol. 78(6):1453-1462 (1997).;;Wang, W., ""Instability, Stabilization, and Formulation of Liquid Protein Pharmaceuticals,"" Int. J. Pharm. 185(2):129-188 (1999).;;Won et al., ""Stabilizers Against Heat-Induced Aggregation of RPR 114849, An Acidic Fibroblast Growth Factor (AFGF,"" Int. J. Pharm. 167:25-36 (1998).;;Wright et al., ""Recombinant Adeno-Associated Virus: Formulation Challenges and Strategies for a Gene Therapy Vector,"" Curr. Opin. Drug Disc. Dev. 6(2):174-178 (2003).;;Wright et al., ""425. Formulation Development for AAV2 Vectors: Identification of Excipients That Inhibit Vector Aggregation,"" Mol. Ther. [Online] 9(S1):S163-S163 (2004).;;Wright et al., ""Identification of Factors That Contribute to Recombinant AAV2 Particle Aggregation and Methods to Prevent Its Occurrence During Vector Purification and Formulation,"" Mol. Ther. 12(1):171-178 (2005).;;Xie et al., ""Large-Scale Production, Purification and Crystallization of Wild-Type Adeno-Associated Virus-2,"" J. Virol. Methods 122(1):17-27 (2004).;;Xie et al., ""The Atomic Structure of Adeno-Associated Virus (AAV-2), A Vector for Human Gene Therapy,"" Proc. Natl. Acad. Sci. U.S.A. 99(16):10405-10410 (2002).;;Zhen et al., ""Infectious Titer Assay for Adeno-Associated Virus Vectors With Sufficient to Detect Single Infectious Events,"" Human Gene Ther. 15:709-715 (2004).;;The Term ""Purify"" and ""About"", Merriam-Webster Online Dictionary, at the web-http://www.m-w.com, p. 1 and p. 2, Accessed on Nov. 30, 2006, Dec. 1, 2006.;;The Definition of the Term ""Ionic Strength"", Answer.com, at the web-http://www.answers.com, p. 1, Accessed on Nov. 30, 2006.",ACTIVE
694,AU,A,AU 1994/055710 A,124-963-948-828-987,1994-06-22,1994,AU 1994/055710 A,1993-11-30,GB 9225005 A;;GB 9302458 W,1992-11-30,Improvements in or relating to fluid-flow control valves,,PERKINS LTD,WALLACE IAN FRASER;;STAMFORD JOHN,,https://lens.org/124-963-948-828-987,Patent Application,no,0,0,12,12,0,F02M65/005;;F02M2200/245;;Y10T137/8242;;F02M65/00;;Y10T137/8242;;F02M65/005;;F02M2200/245,F02M51/06;;B05B5/00;;F02M65/00;;F16K31/02,,0,0,,,,PENDING
695,CN,B,CN 1630526 B,116-918-558-361-274,2010-05-05,2010,CN 02827968 A,2002-12-09,US 0239465 W;;US 33885601 P,2001-12-07,Systems and methods for treating patients with processed lipoaspirate cells,Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositionsthat are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient.,MACROPORE BIOSURGERY INC,JOHN FRASER;;HEDRICK MARC H,,https://lens.org/116-918-558-361-274,Granted Patent,no,0,1,65,221,0,A61K35/28;;A61K35/28;;A61K48/00;;A61B10/0283;;A61B10/0283;;A61K9/0019;;A61K9/0019;;A61K35/32;;A61K35/35;;A61K35/35;;A61K35/36;;A61M1/76;;A61M2202/08;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/00;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;A61P43/00;;C12M47/04;;C12N5/0667;;C12N5/0667;;C12N5/069;;C12N5/069;;C12N2506/1384;;C12N2506/1384,A61M1/00;;C12N5/00;;A61K31/436;;A61K35/02;;A61K35/12;;A61K35/28;;A61K35/35;;A61K35/36;;A61K38/00;;A61K38/16;;A61K45/00;;A61L27/00;;A61P1/00;;A61P1/16;;A61P3/00;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P19/00;;A61P19/02;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;C12M3/06;;C12N5/0775,,0,0,,,,EXPIRED
696,WO,A2,WO 2002/027545 A2,117-769-852-146-217,2002-04-04,2002,GB 0104302 W,2001-09-26,GB 0023584 A,2000-09-26,METHOD AND SYSTEM FOR ARCHIVING AND RETRIEVING ITEMS BASED ON EPISODIC MEMORY OF GROUPS OF PEOPLE,"A method and system for archiving and retrieving digital media items based on episodic memory of predefined associated groups of one or more people comprises: receiving an input identifying a group to which the user belongs; receiving user archiving input identifying a digital media item to be archived for the group, selecting zero or more group event types from a predetermined plurality of group event types for the group, selecting zero or more persons in the group, and selecting a time; generating index information using the received user archiving input; storing the indexed information in associated using the received user archiving input; storing the indexed information in association with the identifying digital item; repeating the reception of user archiving input, the generating of the index information and the storing of the index information for a pluralty of digital media items; receiving a user retrieval input selecting or automatically selecting: zero or more groups of event types from the predetermined plurality of group event types for the group, zero or more persons in the group, and a time period; and using the selections and the identified group to retrieve and output digital media items that match the selection.",6S LTD;;FRASER JOHN LESLIE;;SHARPE ELIZABETH,FRASER JOHN LESLIE;;SHARPE ELIZABETH,,https://lens.org/117-769-852-146-217,Patent Application,yes,0,2,8,8,0,G06F16/9535;;G06F16/951,G06F17/30,,0,0,,,,PENDING
697,AU,A,AU 2001/069757 A,125-063-319-715-392,2002-02-18,2002,AU 2001/069757 A,2001-06-07,US 63383400 A;;US 0118443 W,2000-08-07,Large-scale recombinant adeno-associated virus (raav) production and purification,,AVIGEN INC,WRIGHT JOHN FRASER;;QU GUANG,,https://lens.org/125-063-319-715-392,Patent Application,no,0,0,4,4,0,C12N7/00;;C12N2750/14151;;C12N7/00;;C12N2750/14151,C12N7/02,,0,0,,,,PENDING
698,US,A1,US 2017/0247664 A1,137-216-898-382-632,2017-08-31,2017,US 201615287037 A,2016-10-06,US 201615287037 A;;US 201514702008 A;;US 66155310 A;;US 14199605 A;;US 57599704 P;;US 63922204 P,2004-06-01,COMPOSITIONS AND METHODS TO PREVENT AAV VECTOR AGGREGATION,"Compositions and methods are provided for preparation of concentrated stock solutions of AAV virions without aggregation. Formulations for AAV preparation and storage are high ionic strength solutions (e.g. μ˜500 mM) that are nonetheless isotonic with the intended target tissue. This combination of high ionic strength and modest osmolarity is achieved using salts of high valency, such as sodium citrate. AAV stock solutions up to 6.4×10 13 vg/mL are possible using the formulations of the invention, with no aggregation being observed even after ten freeze-thaw cycles. The surfactant Pluronic® F68 may be added at 0.001% to prevent losses of virions to surfaces during handling. Virion preparations can also be treated with nucleases to eliminate small nucleic acid strands on virions surfaces that exacerbate aggregation.",GENZYME CORP,WRIGHT JOHN FRASER;;QU GUANG,AVIGEN INC (2005-10-04);;GENZYME CORPORATION (2005-12-19),https://lens.org/137-216-898-382-632,Patent Application,yes,0,13,33,34,0,C12N2750/14151;;C12N7/00;;C12N2750/14151;;C12N7/00;;C12N2750/14111,C12N7/00;;C12N7/02,,0,0,,,,DISCONTINUED
699,EP,B1,EP 1751275 B1,137-422-327-806-435,2017-08-16,2017,EP 05755269 A,2005-06-01,US 2005/0019235 W;;US 57599704 P;;US 63922204 P,2004-06-01,COMPOSITIONS AND METHODS TO PREVENT AAV VECTOR AGGREGATION,,AVIGEN INC,WRIGHT JOHN FRASER;;QU GUANG,"GENZYME CORPORATION, US (2018-07-31);;GENZYME CORPORATION; US (2018-03-23);;GENZYME CORPORATION (2018-07-18);;GENZYME CORPORATION, CAMBRIDGE, US (2018-01-19)",https://lens.org/137-422-327-806-435,Granted Patent,yes,1,0,33,34,0,C12N2750/14151;;C12N7/00;;C12N2750/14151;;C12N7/00;;C12N2750/14111,C12N7/02;;C12N7/00,,7,0,,,"WRIGHT J.F., ET AL: ""425. Formulation Development for AAV2 Vectors: Identification of Excipients That Inhibit Vector Aggregation"" MOLECULAR THERAPY, [Online] vol. 9, no. S1, May 2004 (2004-05), pages S163-S163, XP002461847 ISSN: 1525-0016 Retrieved from the Internet: URL:doi: 10.1016/j.ymthe.2004.06.356>;;STEINBACH S ET AL: ""Assembly of adeno-associated virus type 2 capsids in vitro"" JOURNAL OF GENERAL VIROLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, SPENCERS WOOD, GB, vol. 78, no. 6, 1997, pages 1453-1462, XP002346582 ISSN: 0022-1317;;XIE Q ET AL: ""Large-scale production, purification and crystallization of wild-type adeno-associated virus-2"" JOURNAL OF VIROLOGICAL METHODS, AMSTERDAM, NL, vol. 122, no. 1, 1 December 2004 (2004-12-01), pages 17-27, XP004603069 ISSN: 0166-0934;;WRIGHT J F ET AL: ""Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulation"" MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA,, US, vol. 12, no. 1, July 2005 (2005-07), pages 171-178, XP004974961 ISSN: 1525-0016;;QU G. ET AL: 'Scaling up production of recombinant AAV vectors for clinical applications' CURR. OPINION IN DRUG DISCOVERY & DEVELOPMENT vol. 3, no. 6, 2000, pages 750 - 755, XP001041966;;DRITTANTI L. ET AL: 'Optimized helper virus-free production of high-quality adeno-associated virus vectors' THE JOURNAL OF GENE MEDICINE vol. 3, pages 59 - 71, XP009033855;;SOMMER J.M. ET AL: 'Quantification of adeno-associated virus particles and enmty capsids by optical density measurement' MOLECULAR THERAPY vol. 7, no. 1, January 2003, pages 122 - 128, XP002965707",ACTIVE
700,US,A,US 3458758 A,156-019-101-337-903,1969-07-29,1969,US 3458758D A,1965-10-26,GB 4387364 A,1964-10-24,GAS-FILLED ELECTRIC DISCHARGE DEVICE WITH IMPROVED RECOVERY,,M O VALVE CO LTD,FRASER DAVID ALEXANDER;;GOWAR JOHN,,https://lens.org/156-019-101-337-903,Granted Patent,no,8,3,2,2,0,H01J17/04;;H01J17/04;;H01J17/56;;H01J17/56,H01J17/04;;H01J17/56,315/102,0,0,,,,EXPIRED
701,MX,B,MX 360727 B,172-903-418-182-273,2018-11-14,2018,MX 2014006734 A,2005-06-01,US 57599704 P;;US 63922204 P;;US 2005/0019235 W,2004-06-01,COMPOSITIONS AND METHODS TO PREVENT AAV VECTOR AGGREGATION.,"Compositions and methods are provided for preparation of concentrated stock solutions of AAV virions without aggregation. Formulations for AAV preparation and storage are high ionic strength solutions (e.g. µ ~500mM) that are nonetheless isotonic with the intended target tissue. This combination of high ionic strength and modest osmolarity is achieved using salts of high valency, such as sodium citrate. AAV stock solutions up to 6.4x1013 vg/mL are possible using the formulations of the invention, with no aggregation being observed even after ten freeze-thaw cycles. The surfactant Pluronic® F68 may be added at 0.001% to prevent losses of virions to surfaces during handling. Virion preparations can also be treated with nucleases to eliminate small nucleic acid strands on virions surfaces that exacerbate aggregation.",GENZYME CORP,WRIGHT JOHN FRASER;;QU GUANG,,https://lens.org/172-903-418-182-273,Granted Patent,no,0,0,33,34,0,C12N2750/14151;;C12N7/00;;C12N2750/14151;;C12N7/00;;C12N2750/14111,C12N7/02;;C12N7/00,,0,0,,,,ACTIVE
702,CA,A1,CA 2356755 A1,185-963-121-270-033,2000-07-06,2000,CA 2356755 A,1999-12-24,NZ 33358998 A;;NZ 9900228 W,1998-12-24,SUPERANTIGENS,"The invention provides superantigens SMEZ-2, SPE-G, SPE-H and SPE-J, as well as polynucleotides which encode them. Such superantigens have, inter alia, diagnostic and therapeutic applications.",AUCKLAND UNISERVICES LTD,PROFT THOMAS;;FRASER JOHN DAVID,,https://lens.org/185-963-121-270-033,Patent Application,no,0,0,7,10,4,A61K38/00;;A61K39/00;;A61P35/00;;A61P37/02;;C07K14/315,G01N33/569;;A61K38/00;;A61K39/00;;A61K39/09;;A61K39/395;;A61K47/48;;A61P35/00;;A61P37/02;;C07K14/315;;C07K16/12;;C12N15/09;;C12Q1/68,,0,0,,,,DISCONTINUED
703,JP,A,JP 2018082721 A,199-533-685-723-382,2018-05-31,2018,JP 2018018391 A,2018-02-05,US 47238403 P;;US 54975604 P,2003-05-21,METHODS FOR PRODUCING PREPARATIONS OF RECOMBINANT AAV VIRIONS SUBSTANTIALLY FREE OF EMPTY CAPSIDS,PROBLEM TO BE SOLVED: To provide a novel method for enhancing productivity by removing empty capsids or reducing the number of empty capsids from an AAV vector particle stock.SOLUTION: The invention is based on the development of an efficient and commercially viable method for preparing a stock of rAAV virions with a reduced amount of empty capsids. The inventors herein have found that empty capsids can be separated from rAAV virions containing genetic materials (AAV vector particles) by using a column chromatography technique. Described herein is a method for separating AAV empty capsids from a mixture of AAV vector particles and AAV empty capsids. This method uses a column chromatography technique to provide recombinant AAV virions at a commercially viable level.SELECTED DRAWING: None,GENZYME CORP,QU GUANG;;WRIGHT JOHN FRASER,,https://lens.org/199-533-685-723-382,Patent Application,no,0,0,40,41,0,C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N15/86;;C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N2710/16651;;C12N2710/10351;;C12N2760/16051;;C12N15/86,C12N7/02;;C12N/;;C12N15/86;;C12N15/864,,0,0,,,,DISCONTINUED
704,CN,A,CN 117098727 A,196-378-410-801-533,2023-11-21,2023,CN 202280026319 A,2022-02-18,US 202163150797 P;;CA 2022050237 W,2021-02-18,Sodium sulfate by-product processing in lithium and battery chemical production,A process for chemical production of batteries in which a sodium sulfate stream is treated with an ion exchange process to provide potassium sulfate and sodium chloride. The sodium chloride may be treated with chlor-alkali to produce sodium hydroxide for use upstream of a battery chemical production process.,HATCH LTD,FRASER ROBERT JOHN;;STAMATIOU EVANGELOS,,https://lens.org/196-378-410-801-533,Patent Application,no,0,0,8,8,0,C01D3/04;;C01D1/04;;C01D5/00;;C25B1/34;;C25B15/081;;Y02E60/10;;C01D1/04;;C01D5/00;;C25B1/46;;C25B9/23;;Y02E60/10;;B01J49/57;;B01J41/04;;B01J41/12;;C01D1/20;;C01D3/04;;C01D5/02;;C01P2006/40,C01D5/00,,0,0,,,,PENDING
705,US,A,US 1607491 A,020-281-275-003-593,1926-11-16,1926,US 8976826 A,1926-02-20,GB 1607491X A,1924-10-21,Dibenzanthronyl product and preparation thereof,,SCOTTISH DYES LTD,FRASER THOMSON ROBERT;;JOHN THOMAS,,https://lens.org/020-281-275-003-593,Granted Patent,no,0,0,1,1,0,C09B3/06;;C09B3/12;;C09B3/12;;C09B3/06,C09B3/06;;C09B3/12,,0,0,,,,EXPIRED
706,JP,A,JP 2020048586 A,024-963-154-138-356,2020-04-02,2020,JP 2020000279 A,2020-01-06,US 47238403 P;;US 54975604 P,2003-05-21,METHODS FOR PRODUCING PREPARATIONS OF RECOMBINANT AAV VIRIONS SUBSTANTIALLY FREE OF EMPTY CAPSIDS,"To provide novel methods for eliminating empty capsids from stocks of AAV vector particles or reducing the number of empty capsids to promote production capacity.SOLUTION: The invention is based on that an efficient and commercially realizable method for preparing a stock of rAAV virions with a reduced amount of empty capsids has been developed. The inventors have found, as shown herein, that empty capsids can be separated from rAAV virions containing genetic materials (AAV vector particles) by column chromatography techniques. Disclosed herein is a method for separating AAV empty capsids from a mixture of AAV vector particles and AAV empty capsids. This method uses column chromatography techniques to provide recombinant AAV virions at a commercially feasible level.SELECTED DRAWING: None",GENZYME CORP,QU GUANG;;WRIGHT JOHN FRASER,,https://lens.org/024-963-154-138-356,Patent Application,no,0,0,40,41,0,C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N15/86;;C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N2710/16651;;C12N2710/10351;;C12N2760/16051;;C12N15/86,C12N/;;C12N7/02;;C12N15/86;;C12N15/864,,0,0,,,,PENDING
707,GB,A,GB 893825 A,040-605-668-549-62X,1962-04-11,1962,GB 1780259 A,1959-05-25,GB 1780259 A,1959-05-25,Decorative laminates,"A melamine-urea-formaldehyde resin may be modified with 10% of a resin produced by reacting a mixture of o-toluenesulphonamide and p-toluenesulphonamide with formaldehyde, and a melamine-formaldehyde resin may be modified with 15% of the same resin. Tris-hydroxymethylaminomethane may also be used as the modifier. The formaldehyde-melamine mol. ratio in the resin may be between 2:1 and 2,25:1.",FORMICA INT,FRASER JOHN;;LOWE DENNIS CHARLES,,https://lens.org/040-605-668-549-62X,Granted Patent,no,0,1,3,3,0,B32B27/00;;B29C59/026;;B29C2059/027;;B29K2061/20;;B29K2995/0022;;B29K2995/0024;;B44C5/0469,B29C59/02;;B32B27/00;;B44C5/04,B5S S17Y;;B5S S189;;B5S S239;;B5S S25X;;B5S S250;;B5S S253;;B5S S30X;;B5S S300;;B5S S303;;B5S S304;;B5S S305;;B5S S476;;B5S S507;;B5S S508;;B5S S52X;;B5S S54X;;B5S S55X;;B5S S62Y;;B5S S620;;B5S S629;;B5S S663;;B5S S666;;B5S S67X;;B5S S670;;B5S S671;;B5S S679;;B5S S735;;B5S S754;;B6G GLB           GLB;;B6G G102          GLB;;B6G G142          GLB;;C3M MB            MB;;C3M M116          MB;;C3M M117          MB,0,0,,,,EXPIRED
708,EP,A3,EP 1921133 A3,039-383-749-798-613,2008-05-28,2008,EP 07124088 A,2002-12-09,EP 02805565 A;;US 33885601 P,2001-12-07,System for processing lipoaspirate cells,"Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. The system comprises a first filter adapted to retain adipose-derived stem cells and a cell concentrator comprising a centrifuge or a spinning membrane.
",CYTORI THERAPEUTICS INC,FRASER JOHN;;HEDRICK MARC H,"CYTORI THERAPEUTICS, INC. (2010-12-29)",https://lens.org/039-383-749-798-613,Search Report,yes,3,0,65,221,0,A61K35/28;;A61K35/28;;A61K48/00;;A61B10/0283;;A61B10/0283;;A61K9/0019;;A61K9/0019;;A61K35/32;;A61K35/35;;A61K35/35;;A61K35/36;;A61M1/76;;A61M2202/08;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/00;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;A61P43/00;;C12M47/04;;C12N5/0667;;C12N5/0667;;C12N5/069;;C12N5/069;;C12N2506/1384;;C12N2506/1384,A61M1/00;;C12M3/06;;A61K31/436;;A61K35/02;;A61K35/12;;A61K35/28;;A61K35/35;;A61K35/36;;A61K38/00;;A61K38/16;;A61K45/00;;A61L27/00;;A61P1/00;;A61P1/16;;A61P3/00;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P19/00;;A61P19/02;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;C12N5/0775,,1,1,010-094-842-952-554,10.1089/107632701300062859;;11304456,"ZUK P A ET AL: ""Multilineage cells from human adipose tissue: Implications for cell-based therapies"", TISSUE ENGINEERING, LARCHMONT, NY, US, vol. 7, no. 2, April 2001 (2001-04-01), pages 211 - 228, XP002198710, ISSN: 1076-3279",EXPIRED
709,CA,A,CA 403148 A,070-648-005-713-28X,1942-03-03,1942,CA 403148D A,,CA 403148T A,,CLAY GUN,,MILES JOHN;;FRASER JAMES S,MILES JOHN;;FRASER JAMES S,,https://lens.org/070-648-005-713-28X,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
710,US,B2,US 10261919 B2,080-896-000-680-090,2019-04-16,2019,US 201615205326 A,2016-07-08,US 201615205326 A,2016-07-08,Selective memory encryption,"In one example in accordance with the present disclosure, a method may include receiving, by a processor on a system on a chip (SoC), a request to encrypt a subset of data accessed by a process. The method may also include receiving, at a page encryption hardware unit of the SoC, a system call from an operating system on behalf of the process, to generate an encrypted memory page corresponding to the subset of data. The method may also include generating, by the page encryption hardware unit, an encryption/decryption key for the first physical memory address. The encryption/decryption key may not be accessible by the operating system. The method may also include encrypting, by the page encryption hardware unit, the subset of data to the physical memory address using the encryption/decryption key and storing, by the page encryption hardware unit, the encryption/decryption key in a key store.",HEWLETT PACKARD ENTPR DEV LP,NDU GEOFFREY;;DICKIN FRASER JOHN,HEWLETT PACKARD ENTERPRISE DEVELOPMENT LP (2016-07-01),https://lens.org/080-896-000-680-090,Granted Patent,yes,17,3,2,2,0,G09C1/00;;H04L9/0894;;G06F21/602;;G06F21/78;;G06F12/1408;;G06F12/1466;;G06F12/0891;;G09C1/00;;H04L9/0894;;G06F21/602;;G06F21/78,G09C1/00;;G06F12/0891;;G06F12/14;;G06F21/60;;G06F21/78;;H04L9/08,,5,4,121-840-298-602-636;;007-972-774-435-771;;071-266-908-232-957;;065-210-791-866-197,10.1109/date.2008.4484834;;10.1109/ccst.2011.6095942;;10.1109/hicss.2006.114;;10.1109/ism.2008.29,"X. Chen, R. P. Dick and A. Choudhary, “Operating System Controlled Processor—Memory Bus Encryption,” 2008 Design, Automation and Test in Europe, Munich, 2008, pp. 1154-1159. (Year: 2008).;;C. Maaser and H. Baier, “A concept for monitoring self-transforming code using memory page access control management,” 2011 Carnahan Conference on Security Technology, Barcelona, 2011, pp. 1-7. (Year: 2011).;;Kaplan, D., et al., “AMD Memory Encryption,” White Paper, Advanced Micro Devices, Inc., Apr. 21, 2016, 12 pages.;;Mahar, A.J. et al., “Design and Characterization of a Hardware Encryption Management Unit for Secure Computing Platforms,” (Research Paper), Proceedings of the 29th Hawaii International Conference on System Sciences, 2006, 10 pages.;;Massoudi, A. et al., “Secure and Low Cost Selective Encryption for Jpeg2000,” (Research Paper), Multimedia, Jun. 30, 2008, Tenth IEEE International Symposium on, 8 pages.",ACTIVE
711,EP,A2,EP 1572071 A2,107-706-912-745-49X,2005-09-14,2005,EP 02805565 A,2002-12-09,US 0239465 W;;US 33885601 P,2001-12-07,METHODS FOR PREPARING FRESH ADIPOSE TISSUE-DERIVED CELLS AND USES IN TREATING PATIENTS,,MACROPORE BIOSURGERY INC,FRASER JOHN;;HEDRICK MARC H,"CYTORI THERAPEUTICS, INC. (2006-11-29)",https://lens.org/107-706-912-745-49X,Patent Application,yes,0,2,65,221,0,A61K35/28;;A61K35/28;;A61K48/00;;A61B10/0283;;A61B10/0283;;A61K9/0019;;A61K9/0019;;A61K35/32;;A61K35/35;;A61K35/35;;A61K35/36;;A61M1/76;;A61M2202/08;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/00;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;A61P43/00;;C12M47/04;;C12N5/0667;;C12N5/0667;;C12N5/069;;C12N5/069;;C12N2506/1384;;C12N2506/1384,A61K35/00;;A61M1/00;;A61K31/436;;A61K35/02;;A61K35/12;;A61K35/28;;A61K35/35;;A61K35/36;;A61K38/00;;A61K38/16;;A61K45/00;;A61L27/00;;A61P1/00;;A61P1/16;;A61P3/00;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P19/00;;A61P19/02;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;C12M3/06;;C12N5/00;;C12N5/0775,,0,0,,,,EXPIRED
712,PL,T3,PL 2277996 T3,121-458-500-030-68X,2015-03-31,2015,PL 10179750 T,2004-05-21,US 47238403 P;;US 54975604 P;;EP 10179750 A;;EP 04776068 A,2003-05-21,Methods for producing preparations of recombinant AAV virions substantially free of empty capsids,Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.,GENZYME CORP,QU GUANG;;WRIGHT JOHN FRASER,,https://lens.org/121-458-500-030-68X,Patent Application,no,0,0,40,41,0,C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N15/86;;C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N2710/16651;;C12N2710/10351;;C12N2760/16051;;C12N15/86,B01D15/00;;C12N7/02;;B01D15/04;;C02F1/42;;C12N/;;C12N15/86;;C12N15/864,,0,0,,,,PENDING
713,AU,B,AU 1910/020282 B,155-066-565-357-617,1911-04-04,1911,AU 1910/020282 A,1910-12-24,AU 1910/020282 A,1910-12-24,Improved baton,,JOHN HUNT ER GWILLIAM FRASER,JOHN HUNT ER GWILLIAM FRASER,,https://lens.org/155-066-565-357-617,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
714,SI,T1,SI 2277996 T1,152-543-571-917-553,2014-12-31,2014,SI 200432199 T,2004-05-21,US 47238403 P;;US 54975604 P;;EP 10179750 A,2003-05-21,Methods for producing preparations of recombinant AAV virions substantially free of empty capsids,Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.,GENZYME CORP,QU GUANG;;WRIGHT JOHN FRASER,,https://lens.org/152-543-571-917-553,Granted Patent,no,0,0,40,41,0,C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N15/86;;C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N2710/16651;;C12N2710/10351;;C12N2760/16051;;C12N15/86,C12N7/00;;B01D15/00;;C02F1/00;;C12N/;;C12N7/02;;C12N15/00;;C12N15/86;;C12N15/864,,0,0,,,,ACTIVE
715,HK,A1,HK 1078009 A1,187-012-650-874-085,2006-03-03,2006,HK 05110006 A,2005-11-09,US 0239465 W;;US 33885601 P,2001-12-07,SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS,,CYTORI THERAPEUTICS INC,FRASER JOHN;;HENDRICK MARC H,,https://lens.org/187-012-650-874-085,Patent Application,no,0,5,65,221,0,A61K35/28;;A61K35/28;;A61K48/00;;A61B10/0283;;A61B10/0283;;A61K9/0019;;A61K9/0019;;A61K35/32;;A61K35/35;;A61K35/35;;A61K35/36;;A61M1/76;;A61M2202/08;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/00;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;A61P43/00;;C12M47/04;;C12N5/0667;;C12N5/0667;;C12N5/069;;C12N5/069;;C12N2506/1384;;C12N2506/1384,A61M1/00;;A61K31/436;;A61K35/02;;A61K35/12;;A61K35/28;;A61K35/35;;A61K35/36;;A61K38/00;;A61K38/16;;A61K45/00;;A61L27/00;;A61M/;;A61P1/00;;A61P1/16;;A61P3/00;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P19/00;;A61P19/02;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;C12M3/06;;C12N5/0775,,0,0,,,,DISCONTINUED
716,EP,B1,EP 2970920 B1,004-983-762-961-090,2018-04-25,2018,EP 14762249 A,2014-03-17,US 201361787818 P;;US 2014/0030370 W,2013-03-15,SCALABLE MANUFACTURING PROCESS TO PRODUCE RECOMBINANT LENTIVIRAL VECTORS IN SERUM-FREE SUSPENSION CELL CULTURE SYSTEM,,CHILDRENS HOSPITAL PHILADELPHIA,QU GUANG;;WRIGHT JOHN FRASER,THE CHILDREN'S HOSPITAL OF PHILADELPHIA (2018-08-29),https://lens.org/004-983-762-961-090,Granted Patent,yes,6,0,29,29,0,C12N7/00;;C12N2740/15043;;C12N2740/15051;;A61K48/0091;;A61K48/0091;;C12N2740/15043;;C12N2740/15051;;C12N7/00;;A61K48/0091;;C12N7/00;;C12N7/00;;C12N2740/15043;;C12N2740/15051;;A61K48/0091,C12N7/02,,2,0,,,"ZHOU ET AL.: 'PEG-modulated column chromatography for purification of recombinant adeno- associated virus serotype 9.' J VIROL METHODS vol. 173, no. 1, April 2011, pages 99 - 107, XP028174767;;ANSORGE ET AL.: 'Recent progress in lentiviral vector mass production.' BIOCHEMICAL ENGINEERING JOURNAL vol. 48, no. 3, 15 February 2010, pages 362 - 377, XP026886643",ACTIVE
717,CA,A1,CA 2469370 A1,017-754-176-226-74X,2003-07-03,2003,CA 2469370 A,2002-12-09,US 33885601 P;;US 0239465 W,2001-12-07,SYSTEMS AND METHODS FOR TREATING PATIENTS WITH PROCESSED LIPOASPIRATE CELLS,Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient.,MACROPORE BIOSURGERY INC,HENDRICK MARC H;;FRASER JOHN,,https://lens.org/017-754-176-226-74X,Patent Application,no,0,2,65,221,0,A61K35/28;;A61K35/28;;A61K48/00;;A61B10/0283;;A61B10/0283;;A61K9/0019;;A61K9/0019;;A61K35/32;;A61K35/35;;A61K35/35;;A61K35/36;;A61M1/76;;A61M2202/08;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/00;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;A61P43/00;;C12M47/04;;C12N5/0667;;C12N5/0667;;C12N5/069;;C12N5/069;;C12N2506/1384;;C12N2506/1384,A61M1/00;;A61K31/436;;A61K35/02;;A61K35/12;;A61K35/28;;A61K35/35;;A61K35/36;;A61K38/00;;A61K38/16;;A61K45/00;;A61L27/00;;A61P1/00;;A61P1/16;;A61P3/00;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P19/00;;A61P19/02;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;C12M3/06;;C12N5/0775,,0,0,,,,EXPIRED
718,AU,A1,AU 2014/232879 A1,045-620-223-421-137,2015-09-24,2015,AU 2014/232879 A,2014-03-17,US 201361787818 P;;US 2014/0030370 W,2013-03-15,Scalable manufacturing process to produce recombinant lentiviral vectors in serum-free suspension cell culture system,Methods for preparing highly purified rLV vector formulations at the scale needed to meet anticipated demand for human gene therapy are provided.,CHILDRENS HOSPITAL PHILADELPHIA,QU GUANG;;WRIGHT JOHN FRASER,,https://lens.org/045-620-223-421-137,Patent Application,no,0,0,29,29,0,C12N7/00;;C12N2740/15043;;C12N2740/15051;;A61K48/0091;;A61K48/0091;;C12N2740/15043;;C12N2740/15051;;C12N7/00;;A61K48/0091;;C12N7/00;;C12N7/00;;C12N2740/15043;;C12N2740/15051;;A61K48/0091,C12N7/02,,0,0,,,,ACTIVE
719,US,B2,US 10485514 B2,043-990-607-849-058,2019-11-26,2019,US 201113990201 A,2011-12-08,US 201113990201 A;;US 42247910 P;;IB 2011055546 W,2010-12-13,Adjusting measurements of the effects of acoustic radiation force for background motion effects,An ultrasonic diagnostic imaging system for shear wave measurement transmits push pulses into tissue for the generation of shear waves. Characteristics of the shear waves such as their velocity of passage through the tissue are measured to assess properties such as tissue stiffness. The measurements are compensated for effects of background motion by sampling echo signals from the tissue at different times and comparing the samples to detect the presence of relative motion between the ultrasound probe and the region of interest where shear waves are detected. Sensed background motion is used to adjust measured shear wave characteristics.,FRASER JOHN DOUGLAS;;XIE HUA;;KONINKLIJKE PHILIPS NV,FRASER JOHN DOUGLAS;;XIE HUA,KONINKLIJKE PHILIPS ELECTRONICS N.V (2013-05-05),https://lens.org/043-990-607-849-058,Granted Patent,yes,8,0,14,14,0,A61B8/0825;;A61B8/4488;;A61B8/5276;;G01S7/52036;;G01S7/52042;;G01S7/5205;;G01S7/52095;;G01S15/8925;;A61B8/485;;A61B8/4488;;A61B8/485;;G01S7/52036;;A61B8/4488;;A61B8/5276;;G01S7/52036;;A61B8/0825;;G01S7/52042;;G01S7/5205;;G01S7/52095;;G01S15/8925;;A61B8/485,A61B8/00;;A61B8/08,,6,6,056-705-091-710-181;;070-586-234-728-521;;000-361-577-809-810;;139-454-483-530-353;;166-054-203-736-266;;015-443-234-271-768,10.1121/1.1378344;;11508987;;10.1016/s0301-5629(98)00110-0;;10385964;;10.1109/tuffc.2009.1097;;pmc2756029;;19406703;;pmc3764610;;19213633;;10.1109/tuffc.2009.1006;;10.1126/science.280.5360.82;;9525861;;10.1016/j.ultrasmedbio.2007.10.009;;18222031;;pmc2362504,"Nightingale et al: “On the Feasibility of Remote Palpation Using Acoustic Radiation Force”; 2001 Acoustical Society of America, vol. 110, No. 1, pp. 625-634.;;Sarvazyan et al: “Shear Wave Elasticity Imaging: A New Ultrasonic Technology of Medical Diagnostics”; Ultrasound in Medicine and Biology, vol. 24, No. 9, pp. 1419-1435, 1998.;;Urban et al: “Error in Estimates of Tissue Material Properties From Shear Wave Dispersion Ultrasound Vibrometry:” IEEE Transactions in Ultrason Ferroelectric Freq Control, Apr. 2009, 56(4): pp. 748-758.;;Bouchard et al: “Image Quality, Tissue Heating, and Frame Rate Trade-Off in Acoustic Radiation Force Impulse Imaging”; IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, vol. 56, No. 1, Jan. 2009, pp. 63-76.;;Fatemi et al: “Ultrasound-Stimulated Vibro-Acoustic Spectrography”; Science 280, 1998, pp. 82-85.;;Palmeri et al: “Quantifying Hepatic Shear Modulus in Vivo Using Acoustic Radiation Force”; Ultrasound Meical Biology, Apr. 2008, 34(4): pp. 546-558.",ACTIVE
720,US,A1,US 2019/0032081 A1,046-594-280-660-249,2019-01-31,2019,US 201816019139 A,2018-06-26,US 201816019139 A;;US 201615351725 A;;US 201213368167 A;;US 80965507 A;;US 85168804 A;;US 47238403 P;;US 54975604 P,2003-05-21,METHODS FOR PRODUCING PREPARATIONS OF RECOMBINANT AAV VIRIONS SUBSTANTIALLY FREE OF EMPTY CAPSIDS,Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.,GENZYME CORP,QU GUANG;;WRIGHT JOHN FRASER,AVIGEN INC (2004-08-27);;GENZYME CORPORATION (2007-09-25),https://lens.org/046-594-280-660-249,Patent Application,yes,0,0,40,41,0,C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N15/86;;C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N2710/16651;;C12N2710/10351;;C12N2760/16051;;C12N15/86,C12N15/86;;C12N/;;C12N7/00;;C12N7/02;;C12N15/864,,0,0,,,,DISCONTINUED
721,DE,D1,DE 602004030327 D1,088-468-996-528-186,2011-01-13,2011,DE 602004030327 T,2004-05-21,US 47238403 P;;US 54975604 P;;US 2004/0015958 W,2003-05-21,"VERFAHREN ZUR HERSTELLUNG VON PRÄPARATIONEN REKOMBINANTER AAV-VIRIONEN, DIE WEITGEHEND FREI VON LEEREN CAPSIDEN SIND",Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.,GENZYME CORP,QU GUANG;;WRIGHT JOHN FRASER,,https://lens.org/088-468-996-528-186,Granted Patent,no,0,0,40,41,0,C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N15/86;;C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N2710/16651;;C12N2710/10351;;C12N2760/16051;;C12N15/86,C12N7/02;;B01D15/00;;B01D15/04;;C02F1/42;;C12N/;;C12N15/86;;C12N15/864,,0,0,,,,ACTIVE
722,AU,B2,AU 2002/357135 B2,103-074-648-341-075,2008-07-31,2008,AU 2002/357135 A,2002-12-09,US 33885601 P;;US 0239465 W,2001-12-07,Systems and methods for treating patients with processed lipoaspirate cells,,MACROPORE BIOSURGERY INC,HENDRICK MARC H;;FRASER JOHN,,https://lens.org/103-074-648-341-075,Granted Patent,no,0,3,65,221,0,A61K35/28;;A61K35/28;;A61K48/00;;A61B10/0283;;A61B10/0283;;A61K9/0019;;A61K9/0019;;A61K35/32;;A61K35/35;;A61K35/35;;A61K35/36;;A61M1/76;;A61M2202/08;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/00;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;A61P43/00;;C12M47/04;;C12N5/0667;;C12N5/0667;;C12N5/069;;C12N5/069;;C12N2506/1384;;C12N2506/1384,A61K35/02;;A61M1/00;;A61K31/436;;A61K35/12;;A61K35/28;;A61K35/35;;A61K35/36;;A61K38/00;;A61K38/16;;A61K45/00;;A61L27/00;;A61P1/00;;A61P1/16;;A61P3/00;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P19/00;;A61P19/02;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;C12M3/06;;C12N5/0775,,2,1,010-094-842-952-554,10.1089/107632701300062859;;11304456,"Zuk P A et al, Tissue Eng., 2001 Apr, 7(2):211-28;;References cited in WO 03/053346",EXPIRED
723,WO,A1,WO 2019/168685 A1,112-700-996-595-209,2019-09-06,2019,US 2019/0018176 W,2019-02-15,US 201862635685 P,2018-02-27,IMPROVEMENT OF ENDOTHELIAL CELL FUNCTION,"Provided herein are compositions and methods for improving endothelial cell function, e.g. , in a subject in need thereof. In some aspects, the compositions and methods involve enhancing or preserving endothelial cell viability. In some aspects, the compositions and methods involve improving leakiness of the endothelial cell barrier, or mitigating or improving vascular leak. In some aspects, the compositions and methods improve or enhance endothelial cell migration. In some aspects, the compositions and methods mitigate or dampen improper endothelial cell activation.",CYTORI THERAPEUTICS INC,FRASER JOHN K;;NAKAGAWA YOSHIHIRO,,https://lens.org/112-700-996-595-209,Patent Application,yes,2,0,1,1,0,A61K35/12;;A61K35/28;;A61K35/48,A01N63/00;;A61K35/12;;A61K35/14;;A61K35/32;;A61K35/50;;A61K45/00;;C12N5/071,,3,3,065-290-843-099-595;;005-758-369-671-578;;062-722-585-120-650,27343194;;pmc5504427;;10.1152/ajplung.00393.2015;;pmc4483164;;25977568;;10.1161/atvbaha.115.305519;;10.1177/2045893217743950,"AMAN ET AL.: ""Using cultured endothelial cells to study endothelial barrier dysfunction: Challenges and opportunities"", AMERICAN JOURNAL OF PHYSIOLOGY - LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, vol. 311, no. 2, 2016, pages L453 - 66, XP055635172;;MAO ET AL.: ""Resident Endothelial Cells and Endothelial Progenitor Cells Restore Endothelial Barrier Function After Inflammatory Lung Injury"", ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, vol. 35, no. 7, 2015, pages 1635 - 1644, XP055635176;;YODER: ""Endothelial stem and progenitor cells (stem cells): (2017 Grover Conference Series)"", PULMONARY CIRCULATION 2012 APR-JUN, vol. 8, no. 1, 3 November 2017 (2017-11-03), pages 1 - 9, XP055635178",PENDING
724,MX,A,MX PA06014030 A,140-261-189-594-254,2007-10-08,2007,MX PA06014030 A,2005-06-01,US 57599704 P;;US 63922204 P;;US 2005/0019235 W,2004-06-01,COMPOSITIONS AND METHODS TO PREVENT AAV VECTOR AGGREGATION.,"Compositions and methods are provided for preparation of concentrated stock solutions of AAV virions without aggregation. Formulations for AAV preparation and storage are high ionic strength solutions (e.g. µ ~500mM) that are nonetheless isotonic with the intended target tissue. This combination of high ionic strength and modest osmolarity is achieved using salts of high valency, such as sodium citrate. AAV stock solutions up to 6.4x1013 vg/mL are possible using the formulations of the invention, with no aggregation being observed even after ten freeze-thaw cycles. The surfactant Pluronic?? F68 may be added at 0.001% to prevent losses of virions to surfaces during handling. Virion preparations can also be treated with nucleases to eliminate small nucleic acid strands on virions surfaces that exacerbate aggregation.",GENZYME CORP,WRIGHT JOHN FRASER;;QU GUANG,,https://lens.org/140-261-189-594-254,Patent Application,no,0,0,33,34,0,C12N2750/14151;;C12N7/00;;C12N2750/14151;;C12N7/00;;C12N2750/14111,C12N7/00;;C12N7/02,,0,0,,,,ACTIVE
725,PT,E,PT 1625210 E,141-509-512-442-81X,2011-03-15,2011,PT 04776068 T,2004-05-21,US 47238403 P;;US 54975604 P,2003-05-21,METHODS FOR PRODUCING PREPARATIONS OF RECOMBINANT AAV VIRIONS SUBSTANTIALLY FREE OF EMPTY CAPSIDS,Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.,GENZYME CORP,QU GUANG;;WRIGHT JOHN FRASER,,https://lens.org/141-509-512-442-81X,Granted Patent,no,0,0,40,41,0,C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N15/86;;C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N2710/16651;;C12N2710/10351;;C12N2760/16051;;C12N15/86,C12N7/02;;B01D15/00;;B01D15/04;;C02F1/42;;C12N/;;C12N15/86;;C12N15/864,,0,0,,,,ACTIVE
726,AU,C1,AU 2002/357135 C1,151-165-958-829-61X,2009-01-22,2009,AU 2002/357135 A,2002-12-09,US 33885601 P;;US 0239465 W,2001-12-07,Systems and methods for treating patients with processed lipoaspirate cells,,MACROPORE BIOSURGERY INC,HENDRICK MARC H;;FRASER JOHN,,https://lens.org/151-165-958-829-61X,Amended Patent,no,0,0,65,221,0,A61K35/28;;A61K35/28;;A61K48/00;;A61B10/0283;;A61B10/0283;;A61K9/0019;;A61K9/0019;;A61K35/32;;A61K35/35;;A61K35/35;;A61K35/36;;A61M1/76;;A61M2202/08;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/00;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;A61P43/00;;C12M47/04;;C12N5/0667;;C12N5/0667;;C12N5/069;;C12N5/069;;C12N2506/1384;;C12N2506/1384,A61K35/00;;A61M1/00;;A61K31/436;;A61K35/02;;A61K35/12;;A61K35/28;;A61K35/35;;A61K35/36;;A61K38/00;;A61K38/16;;A61K45/00;;A61L27/00;;A61P1/00;;A61P1/16;;A61P3/00;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P19/00;;A61P19/02;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;C12M3/06;;C12N5/0775,,2,1,010-094-842-952-554,10.1089/107632701300062859;;11304456,"Zuk P A et al, Tissue Eng., 2001 Apr, 7(2):211-28;;References cited in WO 03/053346",EXPIRED
727,WO,A1,WO 2018/085844 A1,166-832-644-721-412,2018-05-11,2018,US 2017/0060413 W,2017-11-07,US 201662418637 P,2016-11-07,RAB ESCORT PROTEIN POTENCY ASSAY,"Methods for measuring REP-1 and REP-2 activity are provided. In certain embodiments, a method includes: (a) contacting cells that do not express endogenous functional REP-1 or REP-2 protein with an adeno-associated viral (AAV) vector comprising a CHM gene encoding a REP-1 protein or CHM like gene encoding a REP-2 protein under conditions allowing cell transduction; (b) incubating transduced cells under conditions allowing expression of the encoded REP-1 or REP-2 protein; (c) lysing the transduced cells to produce an extract comprising the encoded REP-1 or REP-2 protein and Rab small GTPase (Rabs); (d) incubating said extract with a Rab substrate for a period of time and under conditions allowing prenylation of the Rab thereby forming prenylated Rab; and (e) detecting and/or quantifying the prenylated Rab, wherein the amount of prenylated Rab reflects REP-1 or REP-2 activity thereby measuring REP-1 or REP-2 activity.",SPARK THERAPEUTICS INC,WRIGHT JOHN FRASER;;SUMAROKA MARINA,,https://lens.org/166-832-644-721-412,Patent Application,yes,2,0,11,11,0,C12Y205/0106;;C12Q1/48;;G01N2333/91171;;C12N9/1085;;C12Q1/48;;G01N2333/91171;;C12Y205/0106,A61K48/00;;C12N15/86,,1,1,060-944-441-451-240,pmc3646845;;10.1371/journal.pone.0061396;;23667438,"VASIREDDY ET AL.: ""AAV-Mediated Gene Therapy for Choroideremia: Preclinical Studies in Personalized Models"", PLOS ONE, vol. 8, no. 5, 7 May 2013 (2013-05-07), pages 1 - 13, XP055111001",PENDING
728,JP,A,JP 2010095531 A,164-948-131-988-850,2010-04-30,2010,JP 2010001420 A,2010-01-06,US 33885601 P,2001-12-07,SYSTEM AND METHOD FOR TREATING PATIENT WITH PROCESSED LIPOASPIRATE CELL,"<P>PROBLEM TO BE SOLVED: To treat patients with cells present in a processed lipoaspirate tissue. <P>SOLUTION: A method for treating patients includes a delivery process of a concentrated amount of stem cells obtained from processed adipose tissue. The method can be performed in a closed system, thus no stem cell is exposed to the exterior environment before administration to the patient. The composition administered to the patient includes a mixture of the adipose tissue and the stem cells, and includes higher concentration of stem cells than when the adipose tissue was removed from the patient. <P>COPYRIGHT: (C)2010,JPO&INPIT",CYTORI THERAPEUTICS INC,FRASER JOHN;;HENDRICK MARC H,,https://lens.org/164-948-131-988-850,Patent Application,no,1,5,65,221,0,A61K35/28;;A61K35/28;;A61K48/00;;A61B10/0283;;A61B10/0283;;A61K9/0019;;A61K9/0019;;A61K35/32;;A61K35/35;;A61K35/35;;A61K35/36;;A61M1/76;;A61M2202/08;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/00;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;A61P43/00;;C12M47/04;;C12N5/0667;;C12N5/0667;;C12N5/069;;C12N5/069;;C12N2506/1384;;C12N2506/1384,A61K35/28;;A61M1/00;;A61K31/436;;A61K35/02;;A61K35/12;;A61K35/34;;A61K35/35;;A61K35/36;;A61K38/00;;A61K38/16;;A61K45/00;;A61L27/00;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/00;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;C12M3/06;;C12N5/0775,,2,0,,,"JPN6012048564; ＺＵＫ，Ｐ．Ａ． ｅｔ ａｌ: 'Ｍｕｌｔｉｌｉｎｅａｇｅ ｃｅｌｌｓ ｆｒｏｍ ｈｕｍａｎ ａｄｉｐｏｓｅ ｔｉｓｓｕｅ： ｉｍｐｌｉｃａｔｉｏｎｓ ｆｏｒ ｃｅｌｌ-ｂａｓｅｄ ｔｈｅｒａｐｉｅｓ' Ｔｉｓｓｕｅ Ｅｎｇ Ｖｏｌ．７， Ｎｏ．２, 200104, ｐ．２１１-２８;;JPN6012048561; ＳＯＭＭＥＲ，Ｂ． ｅｔ ａｌ: 'Ｃｕｒｒｅｎｔ ｃｏｎｃｅｐｔｓ ｏｆ ｆａｔ ｇｒａｆｔ ｓｕｒｖｉｖａｌ： ｈｉｓｔｏｌｏｇｙ ｏｆ ａｓｐｉｒａｔｅｄ ａｄｉｐｏｓｅ ｔｉｓｓｕｅ ａｎｄ ｒｅｖｉｅｗ ｏｆ ｔｈｅ ｌｉｔｅ' Ｄｅｒｍａｔｏｌｏｇｉｃ ｓｕｒｇｅｒｙ Ｖｏｌ．２６， Ｎｏ．１２, 2000, ｐ．１１５９-１１６６",INACTIVE
729,US,B2,US 7704721 B2,179-555-560-046-957,2010-04-27,2010,US 14199605 A,2005-06-01,US 14199605 A;;US 57599704 P;;US 63922204 P,2004-06-01,Compositions and methods to prevent AAV vector aggregation,"Compositions and methods are provided for preparation of concentrated stock solutions of AAV virions without aggregation. Formulations for AAV preparation and storage are high ionic strength solutions (e.g. μ˜500 mM) that are nonetheless isotonic with the intended target tissue. This combination of high ionic strength and modest osmolarity is achieved using salts of high valency, such as sodium citrate. AAV stock solutions up to 6.4×10 13 vg/mL are possible using the formulations of the invention, with no aggregation being observed even after ten freeze-thaw cycles. The surfactant Pluronic® F68 may be added at 0.001% to prevent losses of virions to surfaces during handling. Virion preparations can also be treated with nucleases to eliminate small nucleic acid strands on virions surfaces that exacerbate aggregation.",GENZYME CORP,WRIGHT JOHN FRASER;;QU GUANG,AVIGEN INC (2005-10-04);;GENZYME CORPORATION (2005-12-19),https://lens.org/179-555-560-046-957,Granted Patent,yes,5,55,33,34,0,C12N2750/14151;;C12N7/00;;C12N2750/14151;;C12N7/00;;C12N2750/14111,C12N7/02,435/239,27,22,089-800-605-790-418;;073-559-929-212-99X;;081-231-772-265-33X;;017-602-964-237-703;;150-063-089-564-168;;008-498-374-187-896;;025-599-305-407-591;;052-632-297-810-831;;027-720-586-974-158;;056-841-143-148-239;;028-383-058-454-759;;147-049-565-078-568;;072-653-024-592-144;;089-786-895-898-348;;060-601-673-062-602;;010-284-533-720-722;;049-155-615-380-092;;073-559-929-212-99X;;036-117-611-735-723;;024-082-216-460-229;;135-987-388-625-166;;088-196-754-870-804,11269337;;10.1002/1521-2254(2000)9999:9999<::aid-jgm152>3.0.co;2-u;;10.1016/s1525-0016(16)41343-2;;9358564;;10.1023/a:1012193326789;;10.1002/jps.2600831204;;7891291;;14739218;;10.1182/blood-2003-11-3845;;10.1038/sj.gt.3301527;;11571564;;15242531;;10.1089/1043034041361190;;10.1182/blood-2003-11-3852;;14695227;;7491504;;10.1055/s-2007-1007278;;10.1002/jps.20079;;15124199;;10.1016/s0378-5173(99)00152-0;;10460913;;10.1016/s0378-5173(98)00038-6;;12669452;;15488616;;10.1016/j.jviromet.2004.07.007;;10.1073/pnas.162250899;;pmc124927;;12136130;;10.1089/1043034041361262;;15298029;;10.12665/j13.bowe;;10.1016/s1525-0016(16)41343-2;;19649903;;9191943;;10.1099/0022-1317-78-6-1453;;10.1016/s1525-0016(02)00019-9;;12573625;;15963933;;10.1016/j.ymthe.2005.02.021,"Drittanti L. et al. Optimised helper virus-free production of high quality adeno-associated virus vectors, The Journal of Gene Medicine, 2001, 3: 59-71. entire document.;;Qu G. et al. Evidence that ionic interactions are involved in concentration-induced aggregation of recombinant adeno-associated virus, Molecular Therapy, 2003, 7(5): S348, abstract No. 901.;;The term ""Purify"" and ""About"" Merriam-Webster Online Dictionary, at the web- http://www.m-w.com, p. 1 and p. 2.;;The definition of the term ""Ionic strength"", Answer.com, at the web- http://www.answers.com, p. 1.;;Braun, A. et al., ""Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice,"" (1997) Pharm. Res. 14(10):1472-8.;;Chen, B. et al., ""Strategies to suppress aggregation of recombinant keratinocyte growth factor during liquid formulation development,"" (1994) J. Pharm. Sci. 83(12):1657-1661.;;Chenuaud, P. et al., ""Autoimmune anemia in macaques following erythropoietin gene therapy,"" (2004) Blood 103(9):3303-4.;;Croyle, M. A. et al., ""Development of formulations that enhance physical stability of viral vectors for gene therapy,"" (2001) Gene Therapy 8(17):1281-90.;;Flotte, T. R., ""Immune responses to recombinant adeno-associated virus vectors: putting preclinical findings into perspective,"" (2004) Human Gene Ther. 15(7):716-7.;;Gao, G. et al., ""Erythropoietin gene therapy leads to autoimmune anemia in macaques,"" (2004) Blood 103(9):3300-2.;;Huang, J. et al. ""AdAAV support High-titer Production of rAAV but not Stable,"" (2000) Mol. Therapy 1:S286.;;Meijer, et al., ""Targeting of drugs to the liver,"" (1995) Sem. Liver Dis. 15(3):202-56.;;Shire, S. J. et al., ""Challenges in the development of high protein concentration formulations,"" (2004) J. Pharm. Sci. 93(6):1390-402.;;Wang, W., ""Instability, stabilization, and formulation of liquid protein pharmaceuticals,"" (1999) Int. J. Pharm. 185(2):129-188.;;Won, C. M. et al., ""Stabilizers against heat-induced aggregation of RPR 114849, an acidic fibroblast growth factor (aFGF),"" (1998) Int. J. Pharm. 167:25-36.;;Wright, J. F. et al., ""Recombinant adeno-associated virus: formulation challenges and strategies for a gene therapy vector,"" (2003) Curr. Opin. Drug Disc. Dev. 6(2):174-8.;;Xie, Q. et al., ""Large-scale production, purification and crystallization of wild-type adeno-associated virus-2,"" (2004) J. Virol. Methods 122(1):17-27.;;Xie, Q. et al., ""The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy,"" (2002) Proc. Natl. Acad. Sci. U.S.A. 99(16):10405-10.;;Zhen, Z. et al., ""Infectious Titer Assay for Adeno-Associated Virus Vectors with Sensitivity Sufficient to Detect Single Infectious Events,"" (2004) Human Gene Ther. 15:709-15.;;Adadevoh et al., ""Short-Term Field Use and Shipping Stability Study of a Wild Type AD5 Adenoviral Reference Material,"" BioProcessing, 1(3):62-9 (2002).;;High, K. A. et al., ""Human Immune Responses to AAV-2 Capsid May Limit Duration of Expression in Liver-Directed Gene Transfer in Human With Hemophilis beta,"" Blood, 104(11):121a, Abstract No. 413 (2004).;;Qu, G. et al., ""Evidence That Ionic Interactions Are Involved in Concentration-Induced Aggregation of Recombinant Adeno-Associated Virus,"" Mol. Therapy 7(5):S348, Abstract No. 901 (2003).;;Qu, et al., ""Scaling Up Production of Recombinant AAV Vectors for Clinical Applications,"" Curr Opin Drug Disc Dev 3(6):750-755 (2000).;;Steinbach, et al., ""Assembly of Adeno-Associated Virus Type 2 Capsids In Vitro,"" J Gen Virol 78(6):1453-1462 (1997).;;Sommer, et al., ""Quantification of Adeno-Associated Virus Particles and Empty Capsids By Optical Density Measurement,"" Mol Ther 7(1):122-128 (2003).;;Wright, et al., ""425. Formulation Development for AAV2 Vectors: Identification of Excipients that Inhibit Vector Aggregation,"" Mol Ther [Online] 9(S1):S163-S163 (2004).;;Wright, et al., ""Identification of Factors that Contribute to Recombinant AAV2 Particle Aggregation and Methods to Prevent its Occurrence During Vector Purification and Formulation,"" Mol Ther 12(1):171-178 (2005).",ACTIVE
730,US,A,US 1831691 A,184-291-622-209-876,1931-11-10,1931,US 18217227 A,1927-04-08,GB 1831691X A,1926-04-22,Process of preparing dyestuffs and intermediates from benzanthrone derivatives,,SCOTTISH DYES LTD,FRASER THOMSON ROBERT;;JOHN THOMAS,,https://lens.org/184-291-622-209-876,Granted Patent,no,0,0,1,1,0,C09B3/06;;C09B3/06,C09B3/06,,0,0,,,,EXPIRED
731,US,A1,US 2013/0296698 A1,190-958-588-717-497,2013-11-07,2013,US 201113990201 A,2011-12-08,US 201113990201 A;;US 42247910 P;;IB 2011055546 W,2010-12-13,ADJUSTING MEASUREMENTS OF THE EFFECTS OF ACOUSTIC RADIATION FORCE FOR BACKGROUND MOTION EFFECTS,An ultrasonic diagnostic imaging system for shear wave measurement transmits push pulses into tissue for the generation of shear waves. Characteristics of the shear waves such as their velocity of passage through the tissue are measured to assess properties such as tissue stiffness. The measurements are compensated for effects of background motion by sampling echo signals from the tissue at different times and comparing the samples to detect the presence of relative motion between the ultrasound probe and the region of interest where shear waves are detected. Sensed background motion is used to adjust measured shear wave characteristics.,FRASER JOHN DOUGLAS;;XIE HUA;;KONINKL PHILIPS ELECTRONICS NV,FRASER JOHN DOUGLAS;;XIE HUA,KONINKLIJKE PHILIPS ELECTRONICS N.V (2013-05-05),https://lens.org/190-958-588-717-497,Patent Application,yes,6,27,14,14,0,A61B8/0825;;A61B8/4488;;A61B8/5276;;G01S7/52036;;G01S7/52042;;G01S7/5205;;G01S7/52095;;G01S15/8925;;A61B8/485;;A61B8/4488;;A61B8/485;;G01S7/52036;;A61B8/4488;;A61B8/5276;;G01S7/52036;;A61B8/0825;;G01S7/52042;;G01S7/5205;;G01S7/52095;;G01S15/8925;;A61B8/485,A61B8/08,600/438,0,0,,,,ACTIVE
732,GB,B,GB 2206611 B,014-393-025-558-384,1990-11-21,1990,GB 8807522 A,1988-03-30,GB 8707544 A;;GB 8724616 A,1987-03-30,REINFORCING A GRASSED SURFACE,,HALLIDAY JOHN;;NETLON LTD;;ROYAL HONG KONG JOCKEY CLUB,HALLIDAY JOHN;;MARTIN KEITH FRASER,,https://lens.org/014-393-025-558-384,Granted Patent,no,1,0,10,13,0,E01C13/083;;E01C13/083;;F02B1/04;;F02B1/04,A01G13/00;;A01G1/00;;E01C13/08;;F02B1/04,A1E EAF           EAF;;A1E EF9           EAF;;A6D D39X          D39;;D1R RBA           RBA;;E1F FWDJB         FWDJB,0,0,,,,EXPIRED
733,EP,A1,EP 3534967 A1,017-128-350-124-717,2019-09-11,2019,EP 17866596 A,2017-11-07,US 201662418637 P;;US 2017/0060413 W,2016-11-07,RAB ESCORT PROTEIN POTENCY ASSAY,,SPARK THERAPEUTICS INC,WRIGHT JOHN FRASER;;SUMAROKA MARINA,,https://lens.org/017-128-350-124-717,Patent Application,yes,0,0,11,11,0,C12Y205/0106;;C12Q1/48;;G01N2333/91171;;C12N9/1085;;C12Q1/48;;G01N2333/91171;;C12Y205/0106,A61K48/00;;C12N15/86,,0,0,,,,PENDING
734,US,A,US 6006878 A,019-197-743-702-567,1999-12-28,1999,US 24874799 A,1999-02-12,US 24874799 A,1999-02-12,Torque converter bypass clutch having elastically flexible piston,"A hydrokinetic torque converter includes an impeller cover and a bypass clutch. A drive ring is located between adjacent surfaces of the cover and a clutch piston, which deflects flexurally axially. The piston is welded to the cover at a radially inner position, which is supported at another radial location on the cover. The piston deflects into engagement with the drive ring, and the drive ring engages with the cover. When clutch apply pressure is reduced, energy, in the form of elastic bending potential energy stored in the piston, is used to move the piston out of engagement with the drive ring and cover.",FORD GLOBAL TECH INC,MACDONALD FRASER JOHN;;HARGRAVE DAVID,REGAN STEVE (2002-12-18);;FORD GLOBAL TECHNOLOGIES INC. A MICHIGAN CORPORATION (1999-02-01),https://lens.org/019-197-743-702-567,Granted Patent,yes,9,20,6,6,0,F16H45/02;;F16H45/02;;F16H2045/0294;;F16H2045/0294,F16H45/02,192/3.29;;192/212,0,0,,,,EXPIRED
735,CN,A,CN 101018858 A,036-903-529-941-104,2007-08-15,2007,CN 200580017618 A,2005-06-01,US 57599704 P,2004-06-01,Compositions and methods to prevent AAV vector aggregation,"Compositions and methods are provided for preparation of concentrated stock solutions of AAV virions without aggregation. Formulations for AAV preparation and storage are high ionic strength solutions (e.g. mu~500mM) that are nonetheless isotonic with the intended target tissue. This combination of high ionic strength and modest osmolarity is achieved using salts of high valency, such as sodium citrate. AAV stock solutions up to 6.4x10<13> vg/mL are possible using the formulations of the invention, with no aggregation being observed even after ten freeze-thaw cycles. The surfactant Pluronic(R) F68 may be added at 0.001% to prevent losses of virions to surfaces during handling. Virion preparations can also be treated with nucleases to eliminate small nucleic acid strands on virions surfaces that exacerbate aggregation.",AVIGEN INC,GUANG WRIGHT JOHN FRASER QU,,https://lens.org/036-903-529-941-104,Patent Application,no,0,4,1,34,0,,C12N7/02,,0,0,,,,DISCONTINUED
736,FR,A1,FR 2613391 A1,042-573-638-735-666,1988-10-07,1988,FR 8804183 A,1988-03-30,GB 8707544 A;;GB 8724616 A,1987-03-30,ARMATURE POUR SURFACE ENGAZONNEE,"<P>A) SUR UNE BASE DE SABLE 2 RENFORCEE AVEC DES PETITES PIECES DE PLASTIQUE SOUPLE PLACEES EN DISTRIBUTION STATISTIQUE, ON POSE UNE COUCHE A STRUCTURE MAILLEE EN MATERIAU PLASTIQUE, ORIENTEE BIAXIALEMENT ET EXTRUDEE D'UNE SEULE PIECE. PAR DESSUS LA COUCHE A STRUCTURE MAILLEE ON POSE UNE COUVERTURE 3, ON SEME OU ON PLANTE DU GAZON 4, PUIS, APRES QUE LE GAZON A POUSSE, ON UTILISE UNE MACHINE POUR REFENDRE LA COUCHE A STRUCTURE MAILLEE EN PIECE 1 DE DIMENSION PAR EXEMPLE 100 X 100 MM OU 150 X 150 MM, PRESENTANT CHACUNE UN CERTAIN NOMBRE D'OUVERTURES DE MAILLE COMPLETES.</P><P>B) SI LA PIECE 1 EST ATTRAPEE PAR LE SABOT D'UN CHEVAL OU LE CRAMPON D'UN FOOTBALLEUR, ELLE PEUT ETRE ARRACHEE, MAIS CE N'EST PAS LA TOTALITE DE LA COUCHE A STRUCTURE MAILLEE QUI EST ARRACHEE.</P>",NETLON LTD;;HALLIDAY JOHN,HALLIDAY JOHN;;MARTIN KEITH FRASER,,https://lens.org/042-573-638-735-666,Patent Application,no,5,4,10,13,0,E01C13/083;;E01C13/083;;F02B1/04;;F02B1/04,A01G13/00;;A01G1/00;;E01C13/08;;F02B1/04,,0,0,,,,EXPIRED
737,US,A1,US 2005/0153376 A1,051-161-866-765-440,2005-07-14,2005,US 99769004 A,2004-11-24,US 99769004 A;;NZ 33358998 A;;NZ 9900228 W;;US 86913601 A,1998-12-24,Superantigens,"The invention provides superantigens SMEZ-2, SPE-G, SPE-H and SPE-J, as well as polynucleotides which encode them. Such superantigens have, inter alia, diagnostic and therapeutic application.",FRASER JOHN D.;;PROFT THOMAS,FRASER JOHN D;;PROFT THOMAS,AUCKLAND UNISERVICES LIMITED (2005-02-23),https://lens.org/051-161-866-765-440,Patent Application,yes,25,4,2,10,25,A61K38/00;;A61K39/00;;C07K14/315;;C07K14/315;;A61K38/00;;A61K39/00,A61K38/00;;A61K39/00;;C07K14/315,435/7.32;;530/395,0,0,,,,EXPIRED
738,CA,A1,CA 2904366 A1,085-292-778-610-709,2014-09-18,2014,CA 2904366 A,2014-03-17,US 201361787818 P;;US 2014/0030370 W,2013-03-15,SCALABLE MANUFACTURING PROCESS TO PRODUCE RECOMBINANT LENTIVIRAL VECTORS IN SERUM-FREE SUSPENSION CELL CULTURE SYSTEM,Methods for preparing highly purified rLV vector formulations at the scale needed to meet anticipated demand for human gene therapy are provided.,PHILADELPHIA CHILDREN HOSPITAL,QU GUANG;;WRIGHT JOHN FRASER,,https://lens.org/085-292-778-610-709,Patent Application,no,0,0,29,29,0,C12N7/00;;C12N2740/15043;;C12N2740/15051;;A61K48/0091;;A61K48/0091;;C12N2740/15043;;C12N2740/15051;;C12N7/00;;A61K48/0091;;C12N7/00;;C12N7/00;;C12N2740/15043;;C12N2740/15051;;A61K48/0091,C12N7/02,,0,0,,,,PENDING
739,EP,A2,EP 0322090 A2,086-888-559-478-609,1989-06-28,1989,EP 88308971 A,1988-09-28,GB 8707544 A;;GB 8724616 A,1987-03-30,Reinforcing a grassed surface.,"It is highly desirable to reinforce the grassed surface layer of a sports ground in order to reduce damage to the surface, e.g. from horse racing or from playing football. In order to provide a good surface layer, a biaxially-orientated, integrally-extruded plastics material mesh structure layer is laid on a base of sand 2 strengthened with small, flexible, randomly-placed, plastics material mesh pieces. A top dressing 3 is put on top of the mesh structure layer, grass 4 is seeded or planted, and a machine is then used after the grass has grown to slit the mesh structure layer into pieces 1 which may be e.g. 100 x 100 mm or 150 x 150 mm, each having a number of complete mesh openings. If a piece 1 is caught by a horse's hoof or by an footballer's stud, it may be ripped out, but the whole mesh layer is not ripped out.  ",ROYAL HONG KONG JOCKEY CLUB;;NETLON LTD,HALLIDAY JOHN;;MARTIN KEITH FRASER,,https://lens.org/086-888-559-478-609,Patent Application,yes,0,5,10,13,0,E01C13/083;;E01C13/083;;F02B1/04;;F02B1/04,A01G13/00;;A01G1/00;;E01C13/08;;F02B1/04,,0,0,,,,DISCONTINUED
740,GB,B,GB 2218748 B,102-135-803-663-323,1992-10-14,1992,GB 8908798 A,1989-04-19,GB 8809478 A,1988-04-21,A REGENERATIVE PUMP,,MYSON GROUP PLC,FRASER JOHN IAN;;SEREMAK RICHARD,,https://lens.org/102-135-803-663-323,Granted Patent,no,6,0,4,4,0,F04D29/188;;F04D5/002,F04D5/00;;F04D29/18,F1C CE            CE;;F1C CFE           CFE;;F1C C109          CE;;F1C C109          CFE;;F1V VB            VB;;F1V V120          VB;;F1V V200          VB;;F1V V210          VB;;U1S S2005,0,0,,,,EXPIRED
741,EP,A3,EP 2277996 A3,132-603-733-753-27X,2011-06-01,2011,EP 10179750 A,2004-05-21,EP 04776068 A;;US 47238403 P;;US 54975604 P,2003-05-21,Methods for producing preparations of recombinant AAV virions substantially free of empty capsids,"Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.
",GENZYME CORP,QU GUANG;;WRIGHT JOHN FRASER,,https://lens.org/132-603-733-753-27X,Search Report,yes,2,0,40,41,0,C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N15/86;;C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N2710/16651;;C12N2710/10351;;C12N2760/16051;;C12N15/86,C12N7/02;;B01D15/00;;B01D15/04;;C02F1/42;;C12N/;;C12N15/86;;C12N15/864,,8,8,040-850-901-799-916;;036-117-611-735-723;;045-942-479-095-293;;056-315-332-834-967;;063-793-003-971-602;;133-796-772-596-115;;003-351-517-641-454;;082-256-886-757-890,10.1089/104303402320139014;;12133276;;19649903;;11589834;;10.1089/104303401753153974;;10.1016/s0166-0934(99)00150-0;;0010716335;;10716335;;10.1038/sj.gt.3300938;;10455399;;10.1016/j.ymthe.2004.06.346;;10.1089/104303400750001390;;11044910;;10.1016/s1525-0016(02)90719-7;;12436964;;10.1006/mthe.2002.0719,"KALUDOV NIKOLA ET AL: ""Scalable purification of adeno-associated virus type 2, 4, or 5 using ion-exchange chromatography"", HUMAN GENE THERAPY, vol. 13, no. 10, 1 July 2002 (2002-07-01), pages 1235 - 1243, XP002382732, ISSN: 1043-0342;;QU G ET AL: ""SCALING-UP PRODUCTION OF RECOMBINANT AAV VECTORS FOR CLINICAL APPLICATIONS"", CURRENT OPINION IN DRUG DISCOVERY AND DEVELOPMENT, CURRENT DRUGS, LONDON, GB, vol. 3, no. 6, 2000, pages 750 - 755, XP001041966, ISSN: 1367-6733;;VELLEKAMP GARY ET AL: ""Empty capsids in column-purified recombinant adenovirus preparations"", HUMAN GENE THERAPY, vol. 12, no. 15, 10 October 2001 (2001-10-10), pages 1923 - 1936, XP002382733, ISSN: 1043-0342;;ANDERSON R ET AL: ""A METHOD FOR THE PREPARATION OF HIGHLY PURIFIED ADENO-ASSOCIATED VIRUS USING AFFINITY COLUMN CHROMATOGRAPHY, PROTEASE DIGESTION AND SOLVENT EXTRACTION"", JOURNAL OF VIROLOGICAL METHODS, AMSTERDAM, NL, vol. 85, no. 1-2, March 2000 (2000-03-01), pages 23 - 34, XP000982643, ISSN: 0166-0934;;ZOLOTUKHIN ET AL: ""Recombinant adeno -associated virus purification using novel methods improves infectious titer and yield"", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 6, no. 6, June 1999 (1999-06-01), pages 973 - 985, XP002116593, ISSN: 0969-7128;;""Development of a scalable column chromatography-based purification process to manufacure empty capsid-free AAV vectors"", MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA,, US, vol. 9, May 2004 (2004-05-01), pages 162, XP004634790, ISSN: 1525-0016;;GAO G ET AL: ""Purification of Recombinant Adeno-Associated Virus Vectors by Column Chromatography and Its Performance In Vivo"", HUMAN GENE THERAPY, MARY ANN LIEBERT, NEW YORK ,NY, US, vol. 11, no. 15, 1 October 2000 (2000-10-01), pages 2079 - 2091, XP008090776, ISSN: 1043-0342;;BRUMENT N ET AL: ""A versatile and scalable two-step ion exchange chromatography process for the purification of recombinant adeno-associated virus serotypes-2 and -5"", MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 6, no. 5, 1 November 2002 (2002-11-01), pages 678 - 686, XP002969618, ISSN: 1525-0016, DOI: 10.1016/S1525-0016(02)90719-7",ACTIVE
742,US,A,US 5329215 A,164-660-252-320-168,1994-07-12,1994,US 2306093 A,1993-02-25,US 2306093 A,1993-02-25,Apparatus and method for driving a leadscrew,"A leadscrew driving arrangement which is corrected to eliminate the effect of pitch errors. The leadscrew is mapped to create a table of differences between the leadscrew angular position and the corresponding angular position of a perfect leadscrew which has been advanced the same axial distance. The differences are used to create a correction table which is stored in a PROM. During operation of the leadscrew, the correction table is used to adjust the leadscrew driving signal.",OHIO ELECTRONIC ENGRAVERS INC,FRASER JOHN W;;WOODS CURTIS,OHIO ELECTRONIC ENGRAVERS INC (1993-02-25);;MDC MAX DAETWYLER AG (2000-05-11),https://lens.org/164-660-252-320-168,Granted Patent,yes,12,28,6,6,0,G05B19/404;;G05B19/404;;G05B19/186;;G05B19/186;;G05B2219/41036;;G05B2219/41036;;G05B2219/41038;;G05B2219/41038;;G05B2219/41055;;G05B2219/41055;;G05B2219/41077;;G05B2219/41077;;G05B2219/45212;;G05B2219/45212,G05B19/18;;G05B19/404;;G05D3/00;;G05D3/12,318/603;;318/632,3,0,,,"D twyler , Max Daetwyler Corporation, 13420 West Reese Blvd., Huntersville, N.C. 28078, undated brochure.;;Twin Pilot , Maschinenfabrik Kaspar Walter GmbH & Co. KG, Plinganserstrasse 22, 8000 Munchen 70, Germany, undated brochure.;;American Machinist, Feb. 1993 Magazine Article, Laser Technology, Getting Better Accuracy With Non Precision Ball Screws , pp. 50,51.",EXPIRED
743,WO,A1,WO 2005/090381 A1,170-975-721-614-796,2005-09-29,2005,NZ 2004000317 W,2004-12-07,AU 2004/901570 A,2004-03-24,SET1 PROTEINS AND USES THEREFOR,The invention relates to methods of use of SET1 proteins or functional equivalents thereof. More particularly the invention relates to the use of SET1 proteins or functional equivalents thereof in procedures for identification and/or isolation of IgA and the serum complement factor C5.,AUCKLAND UNISERVICES LTD;;FRASER JOHN DAVID;;LANGLEY RIES,FRASER JOHN DAVID;;LANGLEY RIES,,https://lens.org/170-975-721-614-796,Patent Application,yes,2,5,5,5,0,C07K14/31;;C07K14/31;;C07K16/1271;;C07K16/1271,C07K1/14;;C07K14/31;;C07K16/12;;C12N15/11;;C12N15/31,,7,5,029-098-741-026-533;;010-433-136-463-335;;158-656-971-858-862;;018-506-745-539-708;;000-219-638-800-282,10.1073/pnas.0402521101;;pmc470752;;15213324;;12082105;;10.1074/jbc.m203914200;;10.1016/s0140-6736(02)08713-5;;12044378;;10.1016/s0140-6736(00)04403-2;;11418146;;10.1128/iai.68.8.4407-4415.2000;;pmc98335;;10899837,"HOLDEN M.T. ET AL: ""Complete genomes of two clinical Staphylococcus aureus strains: Evidence for the rapid evolution of virulence and drug resistance."", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCE., vol. 101, no. 26, 2004, pages 9786 - 9791, XP002322486;;ARCUS V.L. ET AL: ""The three-dimensional structure of a superantigen-like protein, SET3, from a pathogenicity island of the Staphylococcus aureus genome."", THE JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 277, no. 35, 2002, pages 32274 - 32281, XP003016383;;DATABASE TREMBLE [online] 1 October 2002 (2002-10-01), BABA T. ET AL, XP003017513, Database accession no. (Q8NY48);;BABA T. ET AL: ""Genome and virulence determinants of high virulence community acquired MRSA."", THE LANCET., vol. 359, 2001, pages 1819 - 1827, XP002269809;;KURODA M. ET AL: ""Whole genome sequencing of meticillin-resistant Staphylococcus aureus."", THE LANCET., vol. 357, 2001, pages 1225 - 1240, XP002229662;;WILLIAMS R.J. ET AL: ""Identification of a novel gene cluster encoding Staphylococca exotoxin-like proteins: characterization of the prototypic gene and its protein product."", INFECTION AND IMMUNITY., vol. 68, no. 8, 2000, pages 4407 - 4415, XP003016384;;See also references of EP 1735334A4",PENDING
744,EP,A1,EP 3290513 A1,177-939-117-349-54X,2018-03-07,2018,EP 17186206 A,2005-06-01,US 57599704 P;;US 63922204 P;;EP 05755269 A;;US 2005/0019235 W,2004-06-01,COMPOSITIONS AND METHODS TO PREVENT AAV VECTOR AGGREGATION,"Compositions and methods are provided for preparation of concentrated stock solutions of AAV virions without aggregation. Formulations for AAV preparation and storage are high ionic strength solutions (e.g. µ ∼500 mM) that are nonetheless isotonic with the intended target tissue. This combination of high ionic strength and modest osmolarity is achieved using salts of high valency, such as sodium citrate. AAV stock solutions up to 6.4x1013 vg/mL are possible using the formulations of the invention, with no aggregation being observed even after ten freeze-thaw cycles. The surfactant Pluronic® F68 may be added at 0.001% to prevent losses of virions to surfaces during handling. Virion preparations can also be treated with nucleases to eliminate small nucleic acid strands on virions surfaces that exacerbate aggregation.",GENZYME CORP,WRIGHT JOHN FRASER;;QU GUANG,GENZYME CORPORATION (2018-07-18),https://lens.org/177-939-117-349-54X,Patent Application,yes,3,0,33,34,0,C12N2750/14151;;C12N7/00;;C12N2750/14151;;C12N7/00;;C12N2750/14111,C12N7/00;;C12N7/02,,30,22,090-258-715-508-987;;024-082-216-460-229;;089-786-895-898-348;;088-196-754-870-804;;012-648-145-502-050;;035-752-925-068-093;;029-321-799-330-385;;060-601-673-062-602;;008-498-374-187-896;;072-653-024-592-144;;089-786-895-898-348;;049-155-615-380-092;;081-231-772-265-33X;;150-063-089-564-168;;025-599-305-407-591;;052-632-297-810-831;;010-284-533-720-722;;017-602-964-237-703;;056-841-143-148-239;;028-383-058-454-759;;020-396-894-870-872;;135-987-388-625-166,10.1016/j.ymthe.2004.06.356;;9191943;;10.1099/0022-1317-78-6-1453;;15488616;;10.1016/j.jviromet.2004.07.007;;15963933;;10.1016/j.ymthe.2005.02.021;;10.1089/10430349950016799;;10543610;;10.1111/j.1749-6632.2001.tb11361.x;;11795424;;10.1146/annurev.genom.2.1.177;;11701648;;10.1073/pnas.162250899;;pmc124927;;12136130;;10.1038/sj.gt.3301527;;11571564;;12669452;;15488616;;10.1016/j.jviromet.2004.07.007;;10.12665/j13.bowe;;9358564;;10.1023/a:1012193326789;;14739218;;10.1182/blood-2003-11-3845;;15242531;;10.1089/1043034041361190;;10.1182/blood-2003-11-3852;;14695227;;10.1089/1043034041361262;;15298029;;10.1002/jps.2600831204;;7891291;;10.1002/jps.20079;;15124199;;10.1016/s0378-5173(99)00152-0;;10460913;;10.1038/sj.gt.3300680;;9813665;;10.1016/s1525-0016(02)00019-9;;12573625,"WRIGHT J.F., ET AL: ""425. Formulation Development for AAV2 Vectors: Identification of Excipients That Inhibit Vector Aggregation"", vol. 9, no. S1, May 2004 (2004-05-01), pages S163 - S163, XP002461847, ISSN: 1525-0016, Retrieved from the Internet <URL:http://www.cell.com/molecular-therapy-family/molecular-therapy/pdf/S1525-0016%2804%2900655-0.pdf> [retrieved on 20171211], DOI: 10.1016/j.ymthe.2004.06.356;;STEINBACH S ET AL: ""Assembly of adeno-associated virus type 2 capsids in vitro"", JOURNAL OF GENERAL VIROLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, SPENCERS WOOD, GB, vol. 78, no. 6, 1997, pages 1453 - 1462, XP002346582, ISSN: 0022-1317;;XIE Q ET AL: ""Large-scale production, purification and crystallization of wild-type adeno-associated virus-2"", JOURNAL OF VIROLOGICAL METHODS, AMSTERDAM, NL, vol. 122, no. 1, 1 December 2004 (2004-12-01), pages 17 - 27, XP004603069, ISSN: 0166-0934;;WRIGHT J F ET AL: ""Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulation"", MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA,, US, vol. 12, no. 1, July 2005 (2005-07-01), pages 171 - 178, XP004974961, ISSN: 1525-0016;;GRIMM, D.; KLEINSCHMIDT, J. A., HUM GENE THER., vol. 10, 1999, pages 2445 - 2450;;HIGH, K. A., ANN. N. Y. ACAD. SCI., vol. 953, 2001, pages 64 - 67;;PFEIFER, A.; VERMA, I. M., ANN. REV. GENOMICS HUM. GENET., vol. 2, 2001, pages 177 - 211;;BERNS, K. I.: ""Fields Virology"", 1996, LIPPINCOTT-RAVEN PUBLISHERS, pages: 2173 - 2197;;XIE, Q. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 99, 2002, pages 10405 - 10410;;CROYLE, M. A. ET AL., GENE THERAPY, vol. 8, 2001, pages 1281 - 1290;;HUANG, J. ET AL., MOL. THERAPY, vol. 1, 2000, pages S286;;WRIGHT, J. F. ET AL., CURR. OPIN. DRUG DISC. DEV., vol. 6, 2003, pages 174 - 178;;XIE, Q. ET AL., J. VIROL. METHODS, vol. 122, 2004, pages 17 - 27;;XIE, Q. ET AL., J. VIRAL. METHODS, vol. 122, 2004, pages 17 - 27;;ADADEVOH, K. ET AL., BIOPROCESSING, vol. 1, no. 2, 2002, pages 62 - 69;;BRAUN, A. ET AL., PHARM. RES., vol. 14, 1997, pages 1472 - 1478;;CHENUAUD, P. ET AL., BLOOD, vol. 103, 2004, pages 3303 - 3304;;FLOTTE, T. R., HUMAN GENE THER., vol. 15, 2004, pages 716 - 717;;GAO, G. ET AL., BLOOD, vol. 103, 2004, pages 3300 - 3302;;HIGH, K. A. ET AL., BLOOD, vol. 104, 2004, pages 121a;;ZHEN, Z. ET AL., HUMAN GENE THER., vol. 15, 2004, pages 709 - 715;;MEIJER, K. D. F.; MOLEMA, G., SEM. LIVER DIS., vol. 15, 1995, pages 206;;CHEN, B. ET AL., J. PHARM. SCI., vol. 83, 1994, pages 1657 - 1661;;SHIRE, S. J. ET AL., J. PHARM. SCI., vol. 93, 2004, pages 1390 - 1402;;WANG, W., INT. J. PHARM., vol. 185, 1999, pages 129 - 188;;WON, C. M. ET AL., INT. J. PHARM., vol. 167, 1998, pages 25 - 36;;QU, G. ET AL., MOL. THERAPY, vol. 7, 2003, pages S238;;SMITH, P. ET AL., MOL. THERAPY, vol. 7, 2003, pages S348;;MATSUSHITA, T. ET AL., GENE THERAPY, vol. 5, 1998, pages 938 - 945;;SOMMER, J. M. ET AL., MOL. THERAPY, vol. 7, 2003, pages 122 - 128",ACTIVE
745,WO,A3,WO 2004/113494 A3,169-112-883-280-144,2006-01-26,2006,US 2004/0015958 W,2004-05-21,US 47238403 P;;US 54975604 P,2003-05-21,METHODS FOR PRODUCING PREPARATIONS OF RECOMBINANT AAV VIRIONS SUBSTANTIALLY FREE OF EMPTY CAPSIDS,Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.,AVIGEN INC;;QU GUANG;;WRIGHT JOHN FRASER,QU GUANG;;WRIGHT JOHN FRASER,,https://lens.org/169-112-883-280-144,Search Report,yes,2,1,40,41,0,C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N15/86;;C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N2710/16651;;C12N2710/10351;;C12N2760/16051;;C12N15/86,C12N/;;C12N7/02;;C12N15/86;;C12N15/864,,3,3,003-351-517-641-454;;008-227-308-422-865;;082-256-886-757-890,10.1089/104303400750001390;;11044910;;10821405;;10.1016/s0378-4347(00)00100-6;;10.1016/s1525-0016(02)90719-7;;12436964;;10.1006/mthe.2002.0719,"GAO G ET AL: ""Purification of Recombinant Adeno-Associated Virus Vectors by Column Chromatography and its Performance in Vivo."", HUMAN GENE THERAPY., vol. 11, no. 15, October 2000 (2000-10-01), pages 2080 - 2084, XP002993010;;DEBELAK D. ET AL: ""Cation-exchange high-performance liquid chromatography of recombinant adeno-associated virus type 2."", J CROMAT B., vol. 740, no. 2, April 2000 (2000-04-01), pages 195 - 202, XP004195010;;BRUMENT N ET AL: ""A Versatile and Scalable Two-Step Ion Exchange Chromatography Process for the Purification of Recombinant Adeno-associated Virus Serotype-2 and -5."", MOLECULAR THERAPY., vol. 6, no. 5, November 2002 (2002-11-01), pages 678 - 686, XP002969618",PENDING
746,CN,A,CN 1114023 A,182-997-805-979-752,1995-12-27,1995,CN 94106938 A,1994-05-05,CN 94106938 A,1994-05-05,Improvements in or relating to fluid-flow control valves,"The controlling valve consists of first and second conductor casings, which are insulated by the resistive active element. A conducting valve operation device and the second casing make conducting contact and the former can slide on the latter. The operation device can move from the first position isolated from the first casing to the second position contacting to the first casing. In this time the conducting contact impedance formed by first and second casings is less than the resistance of the resistive active element insulated between them. At the first poistion isolated from the first casing, the resistance between casings is determined by the resistance of separating element. There is a circuit connecting to the casing, which consists of a current limiting resistor to form a voltage dividing circuit with the separating element, thus it can deliver the signal indicating the contact of the operation device and the first casing.",PERKINS LTD,WALLACE IAN FRASER;;STAMFORD JOHN,,https://lens.org/182-997-805-979-752,Patent Application,no,0,2,2,2,0,,F02M61/04;;F02M65/00;;F16K3/26,,0,0,,,,EXPIRED
747,DE,D1,DE 69316934 D1,196-447-821-454-958,1998-03-12,1998,DE 69316934 T,1993-11-30,GB 9225005 A;;GB 9302458 W,1992-11-30,VERBESSERUNGEN AN DURCHFLUSSREGELVENTILEN,,PERKINS LTD,WALLACE IAN FRASER;;STAMFORD JOHN,"PERKINS ENGINES CO., LTD., DESFORD, LEICESTER, GB (2000-12-07)",https://lens.org/196-447-821-454-958,Granted Patent,no,0,0,12,12,0,F02M65/005;;F02M2200/245;;Y10T137/8242;;F02M65/00;;Y10T137/8242;;F02M65/005;;F02M2200/245,F02M51/06;;B05B5/00;;F02M65/00;;F16K31/02,,0,0,,,,EXPIRED
748,US,A1,US 2014/0369970 A1,008-390-805-635-204,2014-12-18,2014,US 201414336755 A,2014-07-21,US 201414336755 A;;US 201113031031 A;;US 2009/0054055 W;;US 9018608 P,2008-08-19,METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF THE LYMPHATIC SYSTEM AND MALIGNANT DISEASE,"Aspects of the invention provides methods for preparing and using adipose-tissue-derived stem and progenitor cells, adipose-tissue-derived lymphatic endothelial cells, and cells capable of differentiating into lymphatic endothelial cells to treat disorders of the lymphatic system and to modulate expansion, repair, and/or regeneration of the lymphatic system. The invention further provides using adipose-tissue-derived lymphatic endothelial cells and cells capable of differentiating into lymphatic endothelial cells for delivery of therapeutic agents to tumor cells as a means for treating malignant disease, and assays to screen for drugs that modulate lymphatic system expansion, repair or regeneration.",CYTORI THERAPEUTICS INC,ALFONSO ZENI;;FRASER JOHN K,CYTORI THERAPEUTICS INC (2014-08-12);;LOREM VASCULAR PTE. LTD (2019-04-24),https://lens.org/008-390-805-635-204,Patent Application,yes,2,7,6,6,0,A61K35/12;;A61K35/12;;A61K35/28;;A61K35/28;;A61K35/35;;A61K35/35;;A61K45/06;;A61K2035/124;;A61P3/06;;A61P9/00;;A61P35/04;;C12N5/0651;;C12N5/0651;;C12N5/0667;;C12N5/069;;C12N5/069,A61K35/28;;A61K35/12;;A61K35/35;;A61K45/06,424/93.7,0,0,,,,INACTIVE
749,AU,A,AU 1977/024562 A,020-907-326-866-383,1978-11-02,1978,AU 1977/024562 A,1977-04-26,CA 251104 A,1976-04-27,CUTTING STUFFED SAUSAGE CASING,,UNION CARBIDE CANADA LTD,GOSLING LINCOLN JOHN;;FRASER GRAHAM,,https://lens.org/020-907-326-866-383,Patent Application,no,0,0,6,6,0,A22C11/006,A22C11/00,,0,0,,,,EXPIRED
750,US,B2,US 10994028 B2,038-545-443-444-903,2021-05-04,2021,US 201715699613 A,2017-09-08,US 201715699613 A;;US 201414216778 A;;US 201361787818 P,2013-03-15,Scalable manufacturing process to produce recombinant lentiviral vectors in serum-free suspension cell culture system,Methods for preparing highly purified rLV vector formulations at the scale needed to meet anticipated demand for human gene therapy are provided.,CHILDRENS HOSPITAL PHILADELPHIA,QU GUANG;;WRIGHT JOHN FRASER,THE CHILDREN'S HOSPITAL OF PHILADELPHIA (2021-04-11),https://lens.org/038-545-443-444-903,Granted Patent,yes,18,0,29,29,0,C12N7/00;;C12N2740/15043;;C12N2740/15051;;A61K48/0091;;A61K48/0091;;C12N2740/15043;;C12N2740/15051;;C12N7/00;;A61K48/0091;;C12N7/00;;C12N7/00;;C12N2740/15043;;C12N2740/15051;;A61K48/0091,C12N7/02;;A61K48/00;;C12N7/00;;C12N15/867,,7,4,028-169-109-894-328;;083-247-370-685-779;;005-528-896-894-93X;;016-991-047-300-811,10.1517/14712598.2013.779249;;23590247;;10.1016/j.bej.2009.10.017;;10.1038/gt.2010.162;;21248790;;10.1016/j.jviromet.2011.01.013;;21295608,"Segura et al, New developments in lentiviral vector design, production and purification, Expert Opin. Biol. Ther. (2013) 13(7):987-1011.;;Millipore, Protein Concentration and Diafiltration by Tangential Flow Filtration, pp. 1-24, downloaded Jun. 22, 2020.;;Ansorge, et al., Recent progress in lentiviral vector mass production, Biochemical Engineering Journal, 2010, 48(3):362-377.;;Benati, C., Production and purification of lentiviral vector for pre-clinical and clinical application, ASGCT/ESGCT Joint Clinical Trials Training, 2012, pp. 1-17.;;Lesch, H.P., et al., Production and purification of lentiviral vectors generated in 293T suspension cells with baculoviral vectors, Gene Therapy, 2011, 18:531-538.;;Zhou, et al., PEG-modulated column chromatography for purification of recombinant adeno-associated virus serotype 9, J. Virol. Methods, 2011, 173(1):99-107.;;PCT International Application No. PCT/US14/30370, International Search Report dated Aug. 25, 2014.",ACTIVE
751,US,B2,US 9528126 B2,043-630-999-543-04X,2016-12-27,2016,US 201213368167 A,2012-02-07,US 201213368167 A;;US 80965507 A;;US 85168804 A;;US 47238403 P;;US 54975604 P,2003-05-21,Methods for producing preparations of recombinant AAV virions substantially free of empty capsids,Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.,QU GUANG;;WRIGHT JOHN FRASER;;GENZYME CORP,QU GUANG;;WRIGHT JOHN FRASER,AVIGEN INC (2004-08-27);;GENZYME CORPORATION (2007-09-25),https://lens.org/043-630-999-543-04X,Granted Patent,yes,12,24,40,41,0,C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N15/86;;C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N2710/16651;;C12N2710/10351;;C12N2760/16051;;C12N15/86,C12N7/02;;C12N/;;C12N7/00;;C12N15/82;;C12N15/86;;C12N15/864,,34,29,003-351-517-641-454;;056-315-332-834-967;;082-256-886-757-890;;141-768-814-445-684;;020-844-173-544-686;;008-227-308-422-865;;003-351-517-641-454;;004-717-207-320-786;;040-850-901-799-916;;156-118-146-118-185;;001-855-353-292-660;;131-849-343-621-830;;127-234-167-778-680;;036-117-611-735-723;;133-796-772-596-115;;051-418-497-856-216;;135-987-388-625-166;;042-838-870-694-53X;;024-206-805-530-75X;;045-942-479-095-293;;088-196-754-870-804;;165-644-511-657-053;;063-793-003-971-602;;117-352-835-844-351;;089-800-605-790-418;;071-415-183-497-398;;068-982-043-431-314;;127-947-112-426-944;;008-767-212-664-381,10.1089/104303400750001390;;11044910;;10.1016/s0166-0934(99)00150-0;;0010716335;;10716335;;10.1016/s1525-0016(02)90719-7;;12436964;;10.1006/mthe.2002.0719;;10.1089/10430349950018427;;10223736;;10.1016/j.jviromet.2004.07.001;;15381358;;10821405;;10.1016/s0378-4347(00)00100-6;;10.1089/104303400750001390;;11044910;;10455443;;10.1038/sj.gt.3300946;;10.1089/104303402320139014;;12133276;;10.1016/0005-2795(70)90310-7;;5534305;;10.1016/s1525-0016(16)41455-3;;10.1016/s0076-6879(02)46069-7;;11883083;;10.1016/s1525-0016(16)42976-x;;19649903;;10.1016/j.ymthe.2004.06.346;;12459331;;10.1016/s0958-1669(02)00369-5;;10.1016/s1525-0016(02)00019-9;;12573625;;9445046;;10.1128/jvi.72.2.1438-1445.1998;;pmc124624;;15975005;;10.2174/1566523054065011;;11589834;;10.1089/104303401753153974;;15963933;;10.1016/j.ymthe.2005.02.021;;10.1007/bf03187263;;10.1038/sj.gt.3300938;;10455399;;16231055;;10.1038/sj.gt.3302611;;11269337;;10.1002/1521-2254(2000)9999:9999<::aid-jgm152>3.0.co;2-u;;17196264;;10.1016/j.jviromet.2006.11.019;;14625046;;10.1016/j.jviromet.2003.09.002;;10.1016/j.ymthe.2005.11.024;;16473554;;10.1016/j.ymthe.2006.08.1217;;28548061;;10.3390/biomedicines2010080;;pmc5423478,"Gao et al. Human Gene Therapy 2000, vol. 11, pp. 2079-2091.;;Anderson, et al., ""A Method for the Preparation of Highly Purified Adeno-Associated Virus Using Affinity Column Chromatography, Protease Digestion, and Solvent Extraction,"" Journal of Viralogical Methods 85:23-34 (2000).;;Brument, et al., ""A Versitile and Scalable Two-Step Ion-Exchange Chromatography Process for the Purification of Recombinant Adeno-Associated Virus Serotype-2 and -5,"" Molecular Therapy 6(5):678-686 (2002).;;Clark, et al., ""Highly Purified Recombinant Adeno-Associated Virus Vectors Are Biologically Active and Free of Detectable Helper and Wild-Type Viruses,"" Human Gene Therapy 10:1031-1039 (1999).;;Davidoff, et al., ""Purification of Recombinant Adeno-Associated Virus Type 8 Vectors by Ion Exchange Chromatography Generates Clinical Grade Vector Stock,"" Journal of Virilogical Methods 121:209-215 (2004).;;Debelak, et al., ""Cation-Exchange High-Performance Liquid Chromatography of Recombinant Adeno-Associated Virus Type-2,"" J Chromat B 740:195-202 (2000).;;Feit et al., J. Pat. Trade. Off. Soc., 85(1):5-21 (2003).;;Gao, et al., ""Purification of Recombinant Adeno-Associated Virus Vectors by Column Chromatography and It's Performance In Vivo,"" Human Gene Therapy 11:2079-2091 (2000).;;Grimm, et al., ""Titration of AAV-2 Particles Via a Novel Capsid ELISA: Packaging of Genomes Can Limit Production of Recombinant AAV-2,"" Gene Therapy 6:1322-1330 (1999).;;Kaludov, et al., ""Scalable Purification of Adeno-Associated Virus Type 2,4, or 5 Using Ion-Exchange Chromatography,"" Human Gene Therapy 13:1235-1243 (2002).;;Lewis, et al., ""Kinetic Study of the Deamidation of Growth Hormone and Prolatin,"" Biochimica et Biophysica Acta 214:498-508 (1970).;;Parker, et al., ""In Vivo Performance of AAV-2 Vectors Purified by CsCI Gradient Centrifugation or column Chromatography,"" Molecular Therapy 7:S390 (2003).;;Potter, et al., ""Streamlined Large-Scale Production of Recombinant Adeno-Associated Virus (rAAV) Vectors,"" Methods in Enzymology 346:413-430 (2002).;;Qu, et al., Characterization of AAV Vectors Expressing Human Coagulation Factor IX Produced At Intermediate Scale, Molecular Therapy 5:S50 (2002).;;Qu, et al., ""Scaling-Up Production of Recombinant AAV Vectors for Clinical Applications,"" Current Opinion in Drug Discovery & Development 3(6):750-755 (2000).;;Qu, et al., ""Development of a Scalable column Chromatography-Based Purification Process to Manufacture Empty Capsid-Free AAV Vectors,"" Mol Ther 9:S162 Abst.# 424 (2004).;;Snyder, et al., ""Production of Clinical-Grade Recombinant Adeno-Associated Virus Vectors,"" Current Opinion in Biotechnology 13:418-423 (2002).;;Sommer, et al., ""Quantification of Adeno-Associated Virus Particles and Empty Capsids by Optical Density Measuremnt,"" Molecular Therapy 7:122-128 (2003).;;Summerford, et al., Membrane-Associated Heperan Sulfate Proteoglycan Is a Receptor for Adeno-Associated Viruse Type 2 Virions, Journal of Virology 72:1438-1445 (1998).;;Timpe et al., Current Gene Therapy 5:273-284 (2005).;;Vellekamp, et al., ""Empty Capsids in Column-Purified Recombinant Adenovirus Preparations,"" Human Gene Therapy 12:1923-1936 (2001).;;Wright, et al., ""Identification of Factors That Contribute to Recombinant AAV2 Particle Aggregation and Methods to Prevent Its Occurance During Vector Purification and Formulation,"" Molecular Therapy12:171-178 (2005).;;Wu, et al., ""A Novel Method for Purification of Recombinant Adeno-Associated Virus Vectors on a Large Scale,"" Chinese Science Bulletine 46:485-489 (2001).;;Zoluthkin, et al., ""Recombinant Adeno-Addociated Virus Purification Using Novel Methods Improves Infectious Titer and Yield,"" Gene Therapy 6:973-985 (1999).;;US Priority Document 1-U.S. Appl. No. 60/472,384, filed May 2003 original file name: D2-Priority Document 2003-U.S. Pat. No. 472384.;;US Priority Document 2-U.S. Appl. No. 60/549,756, filed Mar. 2004 original file name: D3-Priority Document 2004-U.S. Pat. No. 549756.;;Response from the Applicant in the US proceedings on Apr. 2011 original file name: D13-U.S. Pat. No. 8137948-Response from Applicant.;;Burova et al., Chromatographic Purification of Recombinant Adenoviral and Adeno-Associated Viral Vectors: Methods and Implications, Gene Therapy, vol. 12, S5-S17, 2005.;;Drittanti et al., Optimised Helper Virus-Free Production of High-Quality Adeno-Associated Virus Vectors, The Journal of Gene Medicine, vol. 3, pp. 59-71 (2001).;;Qu et al., Separation of Adeno-Associated Virus Type 2 Empty Particles from Genome Containing Vectors by Anion-Exchange Column Chromatography, Journal of Virological Methods, vol. 140, pp. 183-192 (2007).;;Smith et al., Serum-Free Production and column Purification of Adeno-Associated Virus Type 5, Journal of Virological Methods, vol. 114, pp. 115-124 (2003).;;Urabe et al., Removal of Empty Capsids from Type 1 Adeno-Associated Virus Vector Stocks by Anion-Exchange Chromatography Potentiates Transgene Expression, Molecular Therapy, vol. 13, No. 4, pp. 823-828.;;Wright et al., Product-Related Impurities in Clinical-Grade Recombinant AAV Vectors: Characterization and Risk Assessment, Biomedicines, vol. 2, pp. 80-97 (2014).;;Notice of Opposition to a European patent, patent No. EP2277996 dated Jun. 3, 2015.",ACTIVE
752,IN,B,IN 181513 B,039-553-453-998-64X,1998-07-04,1998,IN 68CA1994 A,1994-02-02,IN 68CA1994 A,1994-02-02,A control system for driving a lead screw,,OHIO ELECTRONIC ENGRAVERS INC,FRASER JOHN W;;WOODS CURTIS,,https://lens.org/039-553-453-998-64X,Granted Patent,no,0,0,1,1,0,,B44B1/00,,0,0,,,,EXPIRED
753,BR,A,BR 9405799 A,055-887-080-569-593,1995-12-12,1995,BR 9405799 A,1994-02-22,US 2306093 A;;US 9401988 W,1993-02-25,Aparelho e processo para acionar um fuso guia roscado e aparelho de gravação,,OHIO ELECTRONIC ENGRAVERS INC,FRASER JOHN W;;WOODS CURTIS,,https://lens.org/055-887-080-569-593,Patent Application,no,0,0,6,6,0,G05B19/404;;G05B19/404;;G05B19/186;;G05B19/186;;G05B2219/41036;;G05B2219/41036;;G05B2219/41038;;G05B2219/41038;;G05B2219/41055;;G05B2219/41055;;G05B2219/41077;;G05B2219/41077;;G05B2219/45212;;G05B2219/45212,G05B19/18;;G05B19/404;;G05D3/00;;G05D3/12,,0,0,,,,DISCONTINUED
754,US,B2,US 7491402 B2,056-437-182-332-982,2009-02-17,2009,US 99769004 A,2004-11-24,US 99769004 A;;NZ 33358998 A;;NZ 9900228 W;;US 86913601 A,1998-12-24,"Superantigens SMEZ-2, SPE-G, SPE-H and SPE-J and uses thereof","The invention provides superantigens SMEZ-2, SPE-G, SPE-H and SPE-J, as well as polynucleotides which encode them. Such superantigens have, inter alia, diagnostic and therapeutic application.",AUCKLAND UNISERVICES LTD,FRASER JOHN DAVID;;PROFT THOMAS,AUCKLAND UNISERVICES LIMITED (2005-02-23),https://lens.org/056-437-182-332-982,Granted Patent,yes,43,0,2,10,25,A61K38/00;;A61K39/00;;C07K14/315;;C07K14/315;;A61K38/00;;A61K39/00,A61K39/00;;A61K38/00;;A61K39/02;;A61K39/09;;A61K39/38;;C07H21/02;;C07K1/00;;C07K14/00;;C07K14/315;;C07K17/00;;G01N33/53;;G01N33/569,424/237.1;;424/184.1;;424/185.1;;424/190.1;;530/350;;435/7.34;;435/7.1;;536/23.1;;536/23.7;;536/24.32,46,34,040-823-616-248-951;;082-064-132-996-59X;;163-575-353-925-024;;028-667-798-214-333;;066-479-652-348-611;;108-662-066-771-537;;018-781-067-577-962;;116-631-246-043-105;;012-894-393-907-51X;;116-549-244-556-588;;003-849-961-384-35X;;007-822-064-014-928;;016-557-802-749-662;;048-188-266-680-461;;125-129-352-164-907;;143-049-316-142-287;;143-049-316-142-287;;026-674-097-624-885;;055-947-916-757-829;;050-832-500-731-869;;013-657-500-788-251;;013-657-500-788-251;;018-614-372-193-465;;033-421-192-576-509;;040-811-602-314-323;;027-823-002-465-547;;029-465-313-002-422;;072-117-375-070-090;;014-056-638-943-210;;031-731-686-337-306;;038-849-700-470-356;;031-731-686-337-306;;047-697-710-569-516;;013-657-500-788-251,10.1128/jcm.43.7.3570-3573.2005;;16000510;;pmc1169092;;10.1074/jbc.m605544200;;16980693;;8805648;;15247241;;10.1074/jbc.m406695200;;14609454;;pmc3033064;;10.3201/eid0910.030042;;15272401;;10.1086/422697;;12720278;;10.1002/jmr.612;;11335140;;10.1111/j.1574-695x.2001.tb01572.x;;10.1016/s0928-8244(01)00220-6;;10.1016/s0378-1097(03)00842-5;;14680708;;11917108;;10.1073/pnas.062526099;;pmc123705;;1699952;;pmc2116333;;10.1083/jcb.111.5.2129;;10.1128/mcb.8.3.1247-1252.1988;;10.1128/mcb.8.3.1247;;pmc363269;;3285178;;10.1073/pnas.87.4.1337;;1689484;;pmc53470;;2315699;;10.1126/science.2315699;;3045005;;10.1128/iai.56.9.2518-2520.1988;;pmc259600;;10.1111/j.1574-6968.2000.tb09187.x;;10.1016/s0378-1097(00)00229-9;;10913699;;10.1111/j.1574-6968.2000.tb09187.x;;10.1016/s0378-1097(00)00229-9;;10913699;;9720870;;10.1046/j.1365-2958.1998.00947.x;;1500157;;pmc257353;;10.1128/iai.60.9.3513-3517.1992;;9632603;;10.1128/iai.66.7.3337-3348.1998;;pmc108350;;9874566;;pmc1887688;;10.1084/jem.189.1.89;;9874566;;pmc1887688;;10.1084/jem.189.1.89;;10.1038/nsb0897-635;;9253413;;9500784;;10.1084/jem.187.6.819;;pmc2212197;;10.4049/jimmunol.165.4.2306;;10925320;;10.1006/jmbi.2000.3725;;10860729;;10689316;;10.1016/s1357-4310(99)01657-3;;pmc2212189;;9500785;;10.1084/jem.187.6.823;;10.1016/s1074-7613(00)80646-9;;9881971;;pmc2193151;;10811869;;10.1084/jem.191.10.1765;;12193726;;10.4049/jimmunol.169.5.2561;;pmc2193151;;10811869;;10.1084/jem.191.10.1765;;10.1128/iai.71.3.1361-1369.2003;;pmc148831;;12595453;;9874566;;pmc1887688;;10.1084/jem.189.1.89,"Yang et al, J. Clinical Microbiology, Jul. 2005, 43/7:3570-3573 abstract only.;;Nooh et al, JBC, Nov. 16, 2006, 281/46:35281-35288.;;Stevens et al, J. Immunology, 1996, 157:2479-2487.;;Baker et al, JBC, 2004, 279/37:38571-38576 abstract only.;;Proft et al, Emerging Infectious Diseases, Oct. 2003, 9/10:1211-1218.;;Banks et al, J. Infectious Diseases, 2004, 190:727-738.;;Hong-Geller et al, J. Molecular Recognition, 2003, 16:91-101.;;Gerlach et al, FEMS Immunology and Medical Microbiology, 2001, 30:209-216.;;Igwe et al, FEMS Microbiology Letters, 2003, 229:259-264.;;Smoot et al, PNAS, Apr. 2, 2002, 99/7:4668-4673.;;Nosoh et al, Protein Stability and Stabilization through protein engineering, 1991, pp. 197-217.;;Protein Structure, a practical approach, T.E. Creighton, 1990, pp. 184-186.;;Burgess et al, JCB, 1990, 111:2129-2138.;;Lazar et al, Molecular and Cellular Biology, 1988, 8:1247-1252.;;Kumar et al, PNAS, 1990, 87:1337-1341.;;Bixler et al, Synthetic Vaccines, 1987, pp. 39-71.;;Bowie et al, Science, Mar. 16, 1990 247:1306-1310.;;Houghten et al, Vaccines86, 1986, pp. 21-25.;;Proteins, T. E. Creighton, 1984, pp. 314-315.;;Stephen C. Goshorn et al. ""Nucleotide Sequence of Streptococcal Pyrogenic Exotoxin Type C"". Database Swissprot Accession No. P13380. Infection and Immunity 56(9):2518-2520, 1988.;;D. Gerlach et al. ""Purification and biochemical characterization of a basic superantigen (SPEX/SMEZ3) from Streptococcus pyogenes"". Database GenPept, Accession No. CAB51744, Jul. 29, 1999.;;D. Gerlach et al. ""Biochemical purification and characterization of a basic superantigen of Streptococcus pyogenes"". Database GenPept, Accession No. CAB51332, Jul. 19, 1999.;;D. Gerlach et al. ""Purification and biochemical characterization of a basic superantigen (SPEX/SMEZ3) from Streptococcus pyogenes"". Database GenPept, Accession No. CAB51142, Jul. 19, 1999.;;Goshorn, et al. ""Nucleotide sequence of streptoccal Pyrogenic Exotoxin type C"". Database Swiss-Prot, Locus SPEC-STRPY, Accession No. P13380, Jan. 1990.;;Goshorn, et al. ""Nucleotide sequence of streptococcal Pyrogenic Exotoxin type C"". Database GenPept, Accession No. AAB 59091, 1988.;;Jodi A. Lindsay et al. ""The gene for toxic shock toxin is carried by the family of mobile pathogenicity islands in Staphylococcus aureus"". Molecular Microbiology 29(2):527-543, 1998.;;Vivek Kapur et al. ""Molecular Population Genetic Evidence of Horizontal Spread of two Alleles of the Pyrogenic Exotoxin C Gene (speC) among Pathogenic Clones of Streptococcus pyogenes"". Infection and Immunity 60(9):3513-3517, Sep. 1992.;;Sibyl H. Munson et al. ""Identification and Characterization of Staphylococcal Enterotoxin Types G and I from Staphlococcus aureus"". Infection and Immunity 66(7):3337-3348, 1998.;;Thomas Proft, et al. ""Identification and characterization of novel superantigens from Streptococcus pyogenes"". Journal of Experimental Medicine 189(1):89-101, 1999.;;Thomas Proft, et al. Accession No. AAD52087. ""Identification and characterization of novel superantigens from Streptococcus pyogenes"". Journal of Experimental Medicine 189(1):89-101, 1999.;;Alain Roussel et al. ""Crystal structure of the streptococcal superantigen SPE-C: dimerization and zinc binding suggest a novel mode of interaction with MHC class II molecules"". Nature Structural Biology 4(8):635-643, Aug. 1997.;;Thomas Proft, et al. Superantigens: Just Like Peptides Only Different. J. Exp. Med. 187(6):819-821, Mar. 1998.;;John K. McCormick, et al. Development of Streptococcal Pyrogenic Exotoxin C Vaccine Toxoids That Are Protective in the Rabbit Model of Toxic Shock Syndrome. Journal of Immunology, 165:2306-2312, 2000.;;Arcus et al. ""Conservation and variation in superantigen structure and activity highlighted by the three-dimensional structures of two new superantigens from Streptococcus pyogens"". J. Molecular Biology 299:157-168, 2000.;;Fraser et al. ""Superantigens-powerful modifiers of the immune system"". Molecular Medicine 6:125-132, Mar. 2000.;;Leder et al. ""A mutational analysis of the binding of staphylococcal enterotoxins B and C3 to the T cell receptor beta chain and major histocompatibility complex class II"". J. Exp. Med. 187(6):823-833, Mar. 1998.;;Li et al. ""Three-dimensional structure of the complex between a T cell receptor beta chain and the superantigen staphylococcal enterotoxin B"". Immunity 9:807-816, Dec. 1998.;;Proft et al. ""The streptococcal superantigen SMEZ exhibits wide allelic variation, mosaic structure, and significant antigenic variation"". J. Exp. Med. 191(10):1765-1776, May 2000.;;Unnikrishnan et al. ""The bacterial superantigen streptococcal mitogenic exotoxin Z is the major immunoactive agent of Streptococcus pyogenes"". The Journal of Immunology 169:2561-2569, 2002.;;Thomas Proft, et al. ""The Streptococcal Superantigen SMEZ Exhibits Wide Allelic Variation, Mosaic Structure, and Significant Antigenic Variation"". J. Exp. Med (C) The Rockefeller University Press .vol. 191, No. 10, May 15, 2000 1765-1776.;;Thomas Proft, et al. ""Two Novel Superantigens Found in Both Group A and Group C Streptococcus"". Infection and Immunity, Mar. 2003, p. 1361-1369.;;GenBank, Accession No. AAD52087, Authors: Proft, T, Fleming, N and Fraser JD.;;GenBank, Accession No. AAD30988, Authors: Proft, T, Fleming, N and Fraser JD.;;GenBank, Accession No. AAL31570, Authors: Proft T, Moffatt, SL, Berkahn, CJ and Fraser, JD.;;GenBank, Accession No. AAD30989, Authors: Proft, T, Moffatt, SL, Berkahn, CJ and Frser, JD.;;Thomas Proft, et al. ""Identification and Characterization of Novel Superantigens from Streptococcus pyogenes"". J. Exp. Med. (C) The Rockefeller University Press . vol. 189, No. 1, Jan. 4, 1999 89-101.",EXPIRED
755,US,A1,US 2012/0135515 A1,075-413-070-674-884,2012-05-31,2012,US 201213368167 A,2012-02-07,US 201213368167 A;;US 80965507 A;;US 85168804 A;;US 47238403 P;;US 54975604 P,2003-05-21,METHODS FOR PRODUCING PREPARATIONS OF RECOMBINANT AAV VIRIONS SUBSTANTIALLY FREE OF EMPTY CAPSIDS,Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.,QU GUANG;;WRIGHT JOHN FRASER,QU GUANG;;WRIGHT JOHN FRASER,AVIGEN INC (2004-08-27);;GENZYME CORPORATION (2007-09-25),https://lens.org/075-413-070-674-884,Patent Application,yes,2,35,40,41,0,C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N15/86;;C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N2710/16651;;C12N2710/10351;;C12N2760/16051;;C12N15/86,C12N/;;C12N15/63;;C12N7/02;;C12N15/86;;C12N15/864,435/320.1,1,1,003-351-517-641-454,10.1089/104303400750001390;;11044910,"Gao et al. Human Gene Therapy 2000, Vol. 11, pp. 2079-2091.",ACTIVE
756,US,A,US 1835035 A,074-321-553-178-899,1931-12-08,1931,US 29856728 A,1928-08-09,US 29856728 A,1928-08-09,Return trap,,MILWAUKEE VALVE CO,FRASER JR JOHN;;FRANK HUTCHINSON,,https://lens.org/074-321-553-178-899,Granted Patent,no,0,1,1,1,0,F24D19/081;;Y10T137/7391;;Y10T137/2965;;Y10T137/7391;;Y10T137/2965;;F24D19/081,F24D19/08,,0,0,,,,EXPIRED
757,US,A,US 3888576 A,104-687-796-383-099,1975-06-10,1975,US 50864774 A,1974-09-23,US 50864774 A;;US 27819672 A,1972-08-07,Film projectors,"Apparatus is disclosed for enlarging and back-projecting an image on microfilm onto an essentially horizontal screen set at a fixed distance from the microfilm, the distance between reflecting surfaces and projecting lens and screen being alterable while a corresponding adjusting movement of the projecting lens, to maintain the image in focus, is effected by means of a pair of vertical camming members along which a framework supporting the reflecting surfaces moves.",BOLGAR FRANCIS;;FRASER JOHN JAMES,BOLGAR FRANCIS;;FRASER JOHN JAMES,,https://lens.org/104-687-796-383-099,Granted Patent,no,5,7,1,1,0,G03B21/11;;G03B21/11,G03B21/11,G2J J41           J41,0,0,,,,EXPIRED
758,ES,T3,ES 2114167 T3,105-875-912-183-209,1998-05-16,1998,ES 94900943 T,1993-11-30,GB 9225005 A;;GB 9302458 W,1992-11-30,MEJORAS RELATIVAS A VALVULAS DE CONTROL DEL FLUJO DE FLUIDOS,"UNA VALVULA DE CONTROL DEL FLUJO DE UN FLUIDO COMPRENDE UN PRIMER (12) Y UN SEGUNDO (14) ELECTRICAMENTE CONDUCTOR SEPARADOS POR UN MEDIO ELECTRICAMENTE ACTIVO (16) QUE TIENE RESISTENCIA ELECTRICA. UN MIEMBRO DE ACCIONAMIENTO DE VALVULA (20) SE SITUA DE FORMA DESLIZABLE DENTRO DEL SEGUNDO CUERPO (14) EFECTUANDO UN CONTACTO ELECTRICO DESLIZANTE EN EL INTERIOR DEL MISMO. EL MIEMBRO DE ACCIONAMIENTO DE LA VALVULA (20) PUEDE MOVERSE DESDE UNA PRIMERA POSICION SEPARADA DEL PRIMER CUERPO (12) HASTA UNA SEGUNDA POSICION QUE CONECTA ELECTRICAMENTE EL PRIMER CUERPO (12) CON EL SEGUNDO CUERPO (14) FORMANDO DE ESTA FORMA UNA CONEXION DE BAJA RESISTENCIA ELECTRICA. EN SU PRIMERA POSICION SEPARADA DEL PRIMER CUERPO (12), LA RESISTENCIA DE LA CONEXION ELECTRICA ENTRE LOS CUERPOS (12, 14) DEPENDE DE LA RESISTENCIA ELECTRICA DEL MEDIO DE SEPARACION (16). UN CIRCUITO ELECTRICO CONECTADO A TRAVES DE LOS CUERPOS (12, 14) QUE INCLUYE UN RESISTOR DE LIMITACION DE CORRIENTE (R3) FORMA UN CIRCUITO DE DIVISION DE TENSION CON EL MEDIO DE SEPARACION (16) PARA HACER POSIBLE QUE SE OBTENGA UNA SEÑAL DE TENSION DE SALIDA INDICATIVA DEL CONTACTO DEL MIEMBRO DE ACCIONAMIENTO DE VALVULA (20) CON EL PRIMER CUERPO (12).",PERKINS LTD,WALLACE IAN FRASER;;STAMFORD JOHN,,https://lens.org/105-875-912-183-209,Granted Patent,no,0,0,12,12,0,F02M65/005;;F02M2200/245;;Y10T137/8242;;F02M65/00;;Y10T137/8242;;F02M65/005;;F02M2200/245,B05B5/00;;F02M51/06;;F02M65/00;;F16K31/02,,0,0,,,,EXPIRED
759,GB,A,GB 1077454 A,090-771-334-766-090,1967-07-26,1967,GB 2770063 A,1963-07-12,GB 2770063 A,1963-07-12,Process for the oxidation of cycloalkanes,"A process for the liquid phase oxidation of cycloalkanes to product mixtures containing cycloalkanols with gases containing molecular oxygen is characterized in that a borate ester of an alcohol corresponding to the cycloalkane is introduced into the reaction zone before or during the oxidation, such ester being formed outside the oxidation zone. An example describes the production of cyclohexanol from cyclohexane, the borate ester being cyclohexyl metaborate.",ICI LTD,GARDNER CYRIL;;PRESCOTT JOHN FRASER,,https://lens.org/090-771-334-766-090,Granted Patent,no,0,0,2,3,0,C07C51/316;;C07C29/52;;C07C2601/14,C07C29/52;;C07C51/31,C2C CWY;;C2C C22Y;;C2C C221;;C2C C225;;C2C C227;;C2C C297;;C2C C30Y;;C2C C36Y;;C2C C360;;C2C C362;;C2C C409;;C2C C41Y;;C2C C410;;C2C C413;;C2C C414;;C2C C416;;C2C C417;;C2C C46Y;;C2C C460;;C2C C50Y;;C2C C509;;C2C C623;;C2C C662;;C2C C69Y,0,0,,,,EXPIRED
760,US,A,US 1818510 A,099-722-426-395-203,1931-08-11,1931,US 21679027 A,1927-08-31,GB 1818510X A,1926-09-24,Manufacture of dyestuffs and intermediates,,SCOTTISH DYES LTD,FRASER THOMSON ROBERT;;JOHN THOMAS,,https://lens.org/099-722-426-395-203,Granted Patent,no,0,0,1,1,0,C09B3/30;;C09B3/30,C09B3/30,,0,0,,,,EXPIRED
761,AU,A,AU 2001/090115 A,115-607-250-604-626,2002-04-08,2002,AU 2001/090115 A,2001-09-26,GB 0023584 A;;GB 0104302 W,2000-09-26,Method and system for archiving and retrieving items based on episodic memory ofgroups of people,,6S LTD,FRASER JOHN LESLIE;;SHARPE ELIZABETH,,https://lens.org/115-607-250-604-626,Patent Application,no,0,0,8,8,0,G06F16/9535;;G06F16/951,G06F17/30,,0,0,,,,PENDING
762,US,B1,US 11328563 B1,114-874-307-153-732,2022-05-10,2022,US 202117238390 A,2021-04-23,US 202117238390 A,2021-04-23,"Apparatus, system, and method for bulk currency note deposits",A Self-Service Terminal (SST) that provides valuable media deposit features is enhanced with an apparatus fastened to an outside surface of the SST. The apparatus is adapted to receive an externally provided valuable media cassette and connect/interface a port of the cassette to an unload infeed port. A transaction interface is enhanced to identify the cassette as a source device for obtaining valuable media during a deposit transaction. The SST feeds the valuable media from the externally connected cassette through media validation and transport modules of the SST into cassettes of a safe and the SST returns rejected media for the deposit transaction back through the modules to return rejected media to the externally interfaced cassette.,NCR CORP,FRASER GRANT BUCHANAN;;MANNION JOHN,NCR CORPORATION (2021-04-23),https://lens.org/114-874-307-153-732,Granted Patent,yes,8,4,4,4,0,G07F19/205;;G07F19/202;;G07F19/205;;G07F19/202,G07F19/00,,0,0,,,,ACTIVE
763,EP,A1,EP 4294762 A1,119-089-729-634-315,2023-12-27,2023,EP 22755449 A,2022-02-18,US 202163150797 P;;CA 2022050237 W,2021-02-18,SODIUM SULFATE BY-PRODUCT PROCESSING IN LITHIUM AND BATTERY CHEMICAL PRODUCTION,,HATCH LTD,FRASER ROBERT JOHN;;STAMATIOU EVANGELOS,,https://lens.org/119-089-729-634-315,Patent Application,yes,0,0,8,8,0,C01D3/04;;C01D1/04;;C01D5/00;;C25B1/34;;C25B15/081;;Y02E60/10;;C01D1/04;;C01D5/00;;C25B1/46;;C25B9/23;;Y02E60/10;;B01J49/57;;B01J41/04;;B01J41/12;;C01D1/20;;C01D3/04;;C01D5/02;;C01P2006/40,C01D5/00;;B01J49/30;;C01B17/96;;C01D1/04;;C01D3/04;;C25B1/34;;C25B15/08,,0,0,,,,PENDING
764,EP,A2,EP 2281877 A2,130-627-222-834-282,2011-02-09,2011,EP 10179749 A,2004-05-21,EP 04776068 A;;US 47238403 P;;US 54975604 P,2003-05-21,Methods for producing preparations of recombinant AAV virions substantially free of empty capsids,"Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.
",GENZYME CORP,QU GUANG;;WRIGHT JOHN FRASER,,https://lens.org/130-627-222-834-282,Patent Application,yes,12,0,40,41,0,C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N15/86;;C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N2710/16651;;C12N2710/10351;;C12N2760/16051;;C12N15/86,C12N7/02;;B01D15/00;;B01D15/04;;C02F1/42;;C12N/;;C12N15/86;;C12N15/864,,51,34,010-713-990-772-82X;;040-850-901-799-916;;077-494-681-161-754;;074-652-424-954-106;;010-092-025-424-218;;042-769-724-026-529;;036-751-136-233-342;;004-906-146-072-928;;005-904-093-105-315;;118-781-394-705-963;;017-939-992-695-836;;087-005-980-063-276;;001-107-410-887-879;;034-454-872-268-857;;075-206-291-455-245;;072-366-322-919-406;;010-519-409-512-153;;056-196-064-755-971;;039-999-144-232-460;;019-953-149-793-444;;061-166-732-363-142;;056-196-064-755-971;;030-079-213-874-071;;039-151-553-495-992;;008-587-496-850-953;;058-452-600-692-672;;061-166-732-363-142;;040-212-003-832-140;;009-499-373-901-710;;066-928-563-719-899;;011-646-571-801-437;;010-284-533-720-722;;004-717-207-320-786;;045-303-142-874-063,10.1038/nbt0395-222;;9634764;;10.1089/104303402320139014;;12133276;;10.4324/9780203967621-49;;10.1128/jvi.63.9.3822-3828.1989;;pmc250975;;2547998;;pmc240929;;10.1128/jvi.65.6.2936-2945.1991;;2033660;;10.1099/0022-1317-9-3-243;;5498444;;10.1016/0042-6822(71)90141-3;;5000131;;6305001;;10.1016/s0042-6822(83)80008-7;;10.1128/jvi.41.3.868-876.1982;;6284977;;pmc256823;;pmc319248;;6262830;;10.1073/pnas.78.3.1925;;10.1016/0042-6822(80)90354-2;;6249041;;10.1099/0022-1317-29-2-239;;213533;;pmc319472;;6265925;;10.1073/pnas.78.5.2927;;6256359;;10.1016/s0021-9258(19)70007-6;;10.1128/jvi.62.1.206-210.1988;;pmc250520;;2824848;;4705382;;10.1016/0042-6822(73)90341-3;;6263759;;10.1016/0378-1119(81)90008-1;;10.1089/hum.1994.5.7-793;;7981305;;10.1128/mcb.8.10.3988;;pmc365467;;2847025;;10.1128/mcb.8.10.3988-3996.1988;;10.1016/0958-1669(92)90082-t;;1369403;;1316261;;10.1007/978-3-642-75608-5_5;;10.1089/hum.1994.5.7-793;;7981305;;7584077;;pmc2191525;;7515101;;10.1084/jem.179.6.1867;;886304;;10.1099/0022-1317-36-1-59;;452423;;10.1016/0042-6822(79)90476-8;;1316261;;10.1007/978-3-642-75608-5_5;;10.1006/viro.1994.1535;;8091661;;6270377;;pmc256613;;10.1128/jvi.40.1.241-247.1981;;2998066;;10.1016/0042-6822(85)90243-0;;3012864;;10.1016/0042-6822(86)90376-4;;10.1089/1043034041361262;;15298029;;10455443;;10.1038/sj.gt.3300946;;10982375;;pmc102127;;10.1128/jvi.74.19.9281-9293.2000,"C. P. HODGSON, BIOTECHNOLOGY, vol. 13, 1995, pages 222 - 225;;QU; WRIGHT, CUR. OPIN. DRUG DISC. AND DEVELOP., vol. 3, 2000, pages 750 - 755;;KALUDOV ET AL., HUM. GENE THER., vol. 13, 2002, pages 1235 - 1243;;D. GLOVER,: ""DNA Cloning: A Practical Approach"", vol. I, II;;B. HAMES & S. HIGGINS,: ""Nucleic Acid Hybridization"", CURRENT EDITION;;P. TIJSSEN,: ""CRC Handbook of Parvoviruses"", vol. I, II;;B.N. FIELDS AND D.M. KNIPE,: ""Fundamental Virology, 2nd Edition,"", vol. I, II;;AUSUBEL ET AL.: ""Current Protocols in Molecular Biology"", WILEY MERSCIENCE;;SAMULSKI ET AL., J. VIROL., vol. 63, 1989, pages 3822 - 3828;;MCCARTY ET AL., J. VIROL., vol. 65, 1991, pages 2936 - 2945;;ITO ET AL., J. GEN. VIROL., vol. 9, 1970, pages 243;;ISHIBASHI ET AL., VIROLOGY, vol. 45, 1971, pages 317;;CARTER ET AL., VIROLOGY, vol. 126, 1983, pages 505;;LAUGHLIN ET AL., J. VIROL., vol. 41, 1982, pages 868;;JANIK ET AL., PROC. NATL. ACAD. SCI. USA, vol. 78, 1981, pages 1925;;OSTROVE ET AL., VIROLOGY, vol. 104, 1980, pages 502;;HANDA ET AL., J. GEN. VIROL., vol. 29, 1975, pages 239;;STRAUSS ET AL., J. VIROL., vol. 17, 1976, pages 140;;MYERS ET AL., J. VIROL., vol. 35, 1980, pages 665;;JAY ET AL., PROC. NATL. ACAD. SCI. USA, vol. 78, 1981, pages 2927;;MYERS ET AL., J. BIOL. CHEM., vol. 256, 1981, pages 567;;CARTER: ""I CRC Handbook ofParvoviruses"", 1990, article ""Adeno-Associated Virus Helper Functions"";;SAMULSKI ET AL., J. VIROL., vol. 62, 1988, pages 206 - 210;;MATSHUSHITA ET AL., GENE THERAPY, vol. 5, 1998, pages 938 - 945;;GRAHAM ET AL., VIROLOGY, vol. 52, 1973, pages 456;;SAMBROOK ET AL.: ""Molecular Cloning, a laboratory manual"", 1989, COLD SPRING HARBOR LABORATORIES;;DAVIS ET AL.: ""Basic Methods in Molecular Biology"", 1986, ELSEVIER;;CHU ET AL., GENE, vol. 13, 1981, pages 197;;KOTIN, R.M., HUMAN GENE THERAPY, vol. 5, 1994, pages 793 - 801;;BERNS, K.I.: ""Fundamental Virology, 2nd Edition,"", article ""Parvoviridae and their Replication"";;LEBKOWSKI ET AL., MOLEC. CELL. BIOL., vol. 8, 1988, pages 3988 - 3996;;VINCENT ET AL.: ""Vaccines"", vol. 90, 1990, COLD SPRING HARBOR LABORATORY PRESS;;CARTER, CURRENT OPINION IN BIOTECHNOLOGY, vol. 3, 1992, pages 533 - 539;;MUZYCZKA, CURRENT TOPICS IN MICROBIOL. AND IMMUNOL., vol. 158, 1992, pages 97 - 129;;KOTIN, HUMAN GENE THERAPY, vol. 5, 1994, pages 793 - 801;;SHELLING; SMITH, GENE THERAPY, vol. 1, 1994, pages 165 - 169;;ZHOU ET AL., J. EXP. MED., vol. 179, 1994, pages 1867 - 1875;;GRAHAM ET AL., J. GEN. VIROL., vol. 36, 1977, pages 59;;AIELLO ET AL., VIROLOGY, vol. 94, 1979, pages 460;;MUZYCZKA, N., CURRENT TOPICS IN MICROBIOL. AND IMMUNOL., vol. 158, 1992, pages 97 - 129;;THOMSON ET AL., VIROLOGY, vol. 204, 1994, pages 304 - 311;;BULLER ET AL., J. VIROL., vol. 40, 1981, pages 241 - 247;;MCPHERSON ET AL., VIROLOGY, vol. 147, 1985, pages 217 - 222;;SCHLEHOFER ET AL., VIROLOGY, vol. 152, 1986, pages 110 - 117;;LAUGHLIN ET AL., J VIROL., vol. 41, 1982, pages 868;;JAY ET AL., PROC. NATL. ACAD SCI. USA, vol. 78, 1981, pages 2927;;CARTER: ""I CRC Handbook of Parvoviruses"", 1990, article ""Adeno-Associated Virus Helper Functions"";;ZHEN ET AL.: ""An Infectious Titer Assay for Adeno-associated Virus (AAV) Vectors with Sensitivity Sufficient to Detect Single Infectious Events"", HUM. GENE THER., 2004;;GRIMM ET AL., GENE THERAPY, vol. 6, 1999, pages 1322 - 1330;;SOMMER ET AL., MOLEC. THER., vol. 7, 2003, pages 122 - 128;;WOBUS ET AL., J. VIROL., vol. 74, 2000, pages 9281 - 9293",DISCONTINUED
765,US,A1,US 2018/0011802 A1,134-518-620-241-979,2018-01-11,2018,US 201615205326 A,2016-07-08,US 201615205326 A,2016-07-08,SELECTIVE MEMORY ENCRYPTION,"In one example in accordance with the present disclosure, a method may include receiving, by a processor on a system on a chip (SoC), a request to encrypt a subset of data accessed by a process. The method may also include receiving, at a page encryption hardware unit of the SoC, a system call from an operating system on behalf of the process, to generate an encrypted memory page corresponding to the subset of data. The method may also include generating, by the page encryption hardware unit, an encryption/decryption key for the first physical memory address. The encryption/decryption key may not be accessible by the operating system. The method may also include encrypting, by the page encryption hardware unit, the subset of data to the physical memory address using the encryption/decryption key and storing, by the page encryption hardware unit, the encryption/decryption key in a key store.",HEWLETT PACKARD ENTPR DEV LP,NDU GEOFFREY;;DICKIN FRASER JOHN,HEWLETT PACKARD ENTERPRISE DEVELOPMENT LP (2016-07-01),https://lens.org/134-518-620-241-979,Patent Application,yes,0,28,2,2,0,G09C1/00;;H04L9/0894;;G06F21/602;;G06F21/78;;G06F12/1408;;G06F12/1466;;G06F12/0891;;G09C1/00;;H04L9/0894;;G06F21/602;;G06F21/78,G06F12/14;;H04L9/08,,0,0,,,,ACTIVE
766,PT,E,PT 2277996 E,159-382-816-111-970,2014-12-16,2014,PT 10179750 T,2004-05-21,US 47238403 P;;US 54975604 P,2003-05-21,METHODS FOR PRODUCING PREPARATIONS OF RECOMBINANT AAV VIRIONS SUBSTANTIALLY FREE OF EMPTY CAPSIDS,Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.,GENZYME CORP,QU GUANG;;WRIGHT JOHN FRASER,,https://lens.org/159-382-816-111-970,Granted Patent,no,0,0,40,41,0,C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N15/86;;C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N2710/16651;;C12N2710/10351;;C12N2760/16051;;C12N15/86,C12N7/02;;B01D15/00;;B01D15/04;;C02F1/42;;C12N/;;C12N15/86;;C12N15/864,,0,0,,,,ACTIVE
767,US,B1,US 6593123 B1,175-414-306-855-383,2003-07-15,2003,US 63383400 A,2000-08-07,US 63383400 A,2000-08-07,Large-scale recombinant adeno-associated virus (rAAV) production and purification,"
    Methods are provided for large-scale purification of recombinant AAV (rAAV) virions that were produced in the absence of infectious adenovirus. Preferably, the rAAV is produced in a host cell line via triple-transfection with an accessory function vector, an AAV vector, and an AAV helper vector. The methods include preparing a lysate from the host cell line and passing that lysate over various combinations of ion exchange chromatography media and/or affinity chromatography media. The affinity chromatography medium is an AAV receptor or an antibody with binding affinity for AAV, e.g., heparin sulfate. A variety of cation exchange and anion exchange media are contemplated by the present invention. In certain embodiments, optional purification steps may be included, such as filtering the lysate through one or more filters, or treating the lysate with a nuclease. 
",AVIGEN INC,WRIGHT JOHN FRASER;;QU GUANG,AVIGEN INC (2000-07-31);;GENZYME CORPORATION (2007-11-06),https://lens.org/175-414-306-855-383,Granted Patent,yes,7,90,4,4,0,C12N7/00;;C12N2750/14151;;C12N7/00;;C12N2750/14151,C12N7/02,435/239;;435/69.1;;435/230.1;;435/803;;435/235.1;;435/240.2;;435/172.3;;210/656;;210/659;;210/660;;430/369;;430/412;;536/23.1;;536/23.5,8,7,081-836-474-736-131;;014-845-837-270-620;;056-315-332-834-967;;008-320-008-669-74X;;141-768-814-445-684;;042-838-870-694-53X;;044-903-888-619-862,10.1038/nm1197-1295;;9359708;;9499080;;10.1128/jvi.72.3.2224-2232.1998;;pmc109519;;10.1016/s0166-0934(99)00150-0;;0010716335;;10716335;;9874273;;10.1089/hum.1998.9.18-2745;;10.1089/10430349950018427;;10223736;;9445046;;10.1128/jvi.72.2.1438-1445.1998;;pmc124624;;8800745;;10.1089/hum.1996.7.4-507,"Ferrari et al. Nature Medicine 1997, vol. 11, pp. 1295-1297.*;;Xiao et al. J. Virology, 1998 vol. 72, pp. 2224-2232.*;;Qu et al. 219th ACS National Meeting, San Francisco, CA, (Mar. 26-30, 2000), Abstract.*;;Anderson et al., ""A method for the preparation of highly purified adeno-associated virus using affinity column chromatography, protease and solvent extraction"" Journal of Virological Methods 85 (2000) 23-34.;;Dirk Grimm et al., Novel Tools for Production and Purification of Recombinant Adenoassociated Virus Vectors, Human Gene Therapy, vol. 9, Dec. 10, 1998, pp. 2745-2760.;;K. Reed Clark et al., Highly Purified Recombinant Adeno-Associated Virus Vectors Are Biologically Active and Free of Detectable Helper and Wild-Type Viruses, Human Gene Therapy, vol. 10, Apr. 10, 1999, pp. 1031-1039.;;Candace Summerford et al., Membrane-Associated Heparan Sulfate Proteoglycan Is a Receptor for Adeno-Associated Virus Type 2 Virions, Journal of Virology, Feb. 1998, pp. 1438-1445.;;Kenji Tamayose et al., A New Strategy for Large-Scale Preparation of High-Titer Recombinant Adeno-Associated Virus Vectors by Using Packaging Cell Lines and Sulfonated Cellulose Column Chromatography, Human Gene Therapy, vol. 7, Mar. 1, 1996, pp. 507-513.",EXPIRED
768,US,A1,US 2020/0157566 A1,178-262-203-028-026,2020-05-21,2020,US 201916538664 A,2019-08-12,US 201916538664 A;;US 201816019139 A;;US 201615351725 A;;US 201213368167 A;;US 80965507 A;;US 85168804 A;;US 54975604 P;;US 47238403 P,2003-05-21,METHODS FOR PRODUCING PREPARATIONS OF RECOMBINANT AAV VIRIONS SUBSTANTIALLY FREE OF EMPTY CAPSIDS,Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.,GENZYME CORP,QU GUANG;;WRIGHT JOHN FRASER,AVIGEN INC (2004-08-27);;GENZYME CORPORATION (2007-09-25),https://lens.org/178-262-203-028-026,Patent Application,yes,0,1,40,41,0,C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N15/86;;C12N7/00;;C12N2750/14143;;C12N2750/14151;;C12N2710/16651;;C12N2710/10351;;C12N2760/16051;;C12N15/86,C12N15/86;;C12N/;;C12N7/00;;C12N7/02;;C12N15/864,,0,0,,,,ACTIVE
769,DE,T1,DE 4491093 T1,191-746-804-354-101,1996-01-11,1996,DE 4491093 T,1994-02-22,US 2306093 A;;US 9401988 W,1993-02-25,Vorrichtung und Verfahren zum Antreiben einer Leitspindel,,OHIO ELECTRONIC ENGRAVERS INC,FRASER JOHN W;;WOODS CURTIS,"MDC MAX DAETWYLER AG BLEIENBACH, BLEIENBACH, CH (2002-05-29)",https://lens.org/191-746-804-354-101,Patent Application,no,0,2,6,6,0,G05B19/404;;G05B19/404;;G05B19/186;;G05B19/186;;G05B2219/41036;;G05B2219/41036;;G05B2219/41038;;G05B2219/41038;;G05B2219/41055;;G05B2219/41055;;G05B2219/41077;;G05B2219/41077;;G05B2219/45212;;G05B2219/45212,G05B19/18;;G05B19/404;;G05D3/00;;G05D3/12,,0,0,,,,DISCONTINUED
770,GB,A,GB 189414855 A,195-725-676-969-285,1894-09-08,1894,GB 189414855D A,1894-08-02,GB 189414855T A,1894-08-02,Improvements in Pipe Benders.,,SEATON THOMAS;;FRASER JOHN THOMAS,SEATON THOMAS;;FRASER JOHN THOMAS,,https://lens.org/195-725-676-969-285,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
771,EP,A1,EP 0327484 A1,166-781-605-430-826,1989-08-09,1989,EP 89500006 A,1989-01-18,ES 8800105 A;;ES 8803911 A,1988-01-18,Car jack.,"A vehicle jack of the type often known as Y-jacks, which has two support members (1) and (3) pivoted toge­ther, with a base foot (4) on one of them and a vehicle engaging portion (5) on the other, in which the vehicle engaging portion has a member which rotates on this se­cond support and shaped to have a positive fit with the vehicle body, by means of an insert or groove with oppo­sing thickened areas for alignment with the direction of the vehicle. The foot or base (4) has a member which pivots freely on the first support, with rounded support surfa­ces (26). The pivoting member (6) comprises a threaded member which pivots near the base through a boss. There are some studs (24) in the base, which extend through holes to snap into place, thus retaining the base in position and limiting the said rotation.  ",BATZ S COOP LTDA,DALY JOHN;;KENNEDY FRASER;;WHITLOCK PETER JOHN,,https://lens.org/166-781-605-430-826,Patent Application,yes,5,13,5,8,0,B66F3/12,B66F3/12,,0,0,,,,EXPIRED
772,ES,T3,ES 2033126 T3,018-985-591-197-143,1993-03-01,1993,ES 89500006 T,1989-01-18,ES 8800105 A;;ES 8803911 A,1988-01-18,GATO PARA VEHICULOS.,"GATO DE AUTOMOVIL DEL TIPO GENERALMENTE CONOCIDO COMO GATO EN Y, QUE TIENE DOS ELEMENTOS DE SOPORTE (1) Y (3) PIVOTADOS ENTRE SI, CON UN PIE DE BASE (4) EN UNO DE ELLOS Y UNA PARTE DE ACOPLAMIENTO AL VEHICULO (5) SOBRE EL OTRO, EN EL QUE LA PART QUE SE ACOPLA AL VEHICULO TIENE UN ELEMENTO QUE GIRA SOBRE ESTE SEGUNDO SOPORTE Y ESTA CONFORMADO PARA TENER UN AJUSTE POSITIVO CON LA CARROCERIA DEL VEHICULO, MEDIANTE UNA INSERCION O RANURA CON AREAS DE ESPESOR OPUESTAS PARA ALINEARSE CON LA DIRECCION DEL VEHICULO. EL PIE O BASE (4) TIENE UN ELEMENTO QUE PIVOTA LIBREMENTE SOBRE EL PRIMER SOPORTE, CON SUPERFICIES DE SOPORTE REDONDEADAS (26). EL ELEMENTO DE PIVOTAMIENTO (6) CONSTA DE UN ELEMENTO ROSCADO QUE PIVOTA CERCA DE LA BASE A TRAVES DE UN SALIENTE. EN LA BASE HAY UNOS ESPARRAGOS (24), QUE SE EXTIENDEN A TRAVES DE ORIFICIOS PARA ACOPLARSE, RETENIENDO DE ESTA FORMA A LA BASE EN SU SITIO Y LIMITANDO LA ROTACION.","BATZ, S. COOP. LTDA.","DALY, JOHN;;KENNEDY, FRASER;;WHITLOCK, PETER JOHN",,https://lens.org/018-985-591-197-143,Granted Patent,no,0,0,5,8,0,B66F3/12,B66F3/12,,0,0,,,,EXPIRED
773,AT,T1,AT E76622 T1,156-793-684-248-103,1992-06-15,1992,AT 89500006 T,1989-01-18,EP 89500006 A;;ES 8800105 A;;ES 8803911 A,1988-01-18,WAGENHEBER.,,BATZ S COOP LTDA,DALY JOHN;;KENNEDY FRASER;;WHITLOCK PETER JOHN,,https://lens.org/156-793-684-248-103,Granted Patent,no,0,0,1,8,0,,B66F3/12,,0,0,,,,DISCONTINUED
774,ES,Y,ES 1013400 Y,086-071-478-745-924,1992-01-01,1992,ES 9000710 U,1990-03-06,ES 9000710 U,1990-03-06,GATO PARA VEHICULOS.,,"BATZ, S. COOP. LTDA.",DALY JOHN;;KENNEDY FRASER;;WITHLOCK PETER JOHN,,https://lens.org/086-071-478-745-924,Limited Patent,no,0,0,2,2,0,,B66F3/12,,0,0,,,,EXPIRED
775,ES,Y,ES 1017512 Y,185-566-608-506-31X,1992-07-01,1992,ES 9101259 U,1991-04-25,ES 9101259 U,1991-04-25,ELEMENTO DE SOPORTE DE CARGA EN GATOS ELEVADORES.,,"BATZ, S. COOP. LTDA.",KENNEDY FRASER;;WITHLOCK PETER JOHN;;DALY JOHN,,https://lens.org/185-566-608-506-31X,Limited Patent,no,0,0,2,2,0,,B66F5/00,,0,0,,,,EXPIRED
776,CA,A,CA 77645 A,024-996-686-893-126,1902-10-07,1902,CA 77645D A,1902-09-09,CA 77645T A,1902-09-09,GRAIN CONVEYING MECHANISM,,HAVILAND JOHN;;HAVILAND F H;;FRASER JOHN,HAVILAND JOHN;;HAVILAND F H;;FRASER JOHN,,https://lens.org/024-996-686-893-126,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
777,EP,B1,EP 0327484 B1,052-348-850-726-670,1992-05-27,1992,EP 89500006 A,1989-01-18,ES 8800105 A;;ES 8803911 A,1988-01-18,CAR JACK,,"BATZ, S. COOP. LTDA.","DALY, JOHN;;KENNEDY, FRASER;;WHITLOCK, PETER JOHN",,https://lens.org/052-348-850-726-670,Granted Patent,yes,5,0,5,8,0,B66F3/12,B66F3/12,,0,0,,,,EXPIRED
778,ES,U,ES 1013400 U,184-215-130-300-492,1990-12-16,1990,ES 9000710 U,1990-03-06,ES 9000710 U,1990-03-06,"Car jack. (Machine-translation by Google Translate, not legally binding)","Cat car type of having two members support jointly giran, foot or base in one of them and support in the other member, hitching on the vehicle in which both members are rotated by a spindle equipped with two ends with thread conducted in opposite direction and related to two members through manguitos inserted into grooves in each member which essentially is defined because the screw is a unique and open that bonded by your butt crossing the member comprising foot or base, to crank spinning the same, meanwhile the end of collecting another member is completely open and free, being limited travel spindle in the sense of lowering cat, by contact between the lower end of support member fits in the vehicle and other foot support member. (Machine-translation by Google Translate, not legally binding)","BATZ, S. COOP. LTDA.",DALY JOHN;;KENNEDY FRASER;;WITHLOCK PETER JOHN,,https://lens.org/184-215-130-300-492,Patent Application,no,0,0,2,2,0,,B66F3/12,,0,0,,,,EXPIRED
779,DE,D1,DE 68901620 D1,112-908-522-761-327,1992-07-02,1992,DE 68901620 T,1989-01-18,ES 8800105 A;;ES 8803911 A,1988-01-18,WAGENHEBER.,,BATZ S COOP LTDA,DALY JOHN;;KENNEDY FRASER;;WHITLOCK PETER JOHN,,https://lens.org/112-908-522-761-327,Granted Patent,no,0,0,5,8,0,B66F3/12,B66F3/12,,0,0,,,,EXPIRED
780,ES,U,ES 1017512 U,187-863-659-484-839,1992-01-01,1992,ES 9101259 U,1991-04-25,ES 9101259 U,1991-04-25,"Load bearing element in jacks. (Machine-translation by Google Translate, not legally binding)","Element support load gatos lifting a one-piece base generally cylindrical rotatably mounted between the wings of a member of support and equipped with a groove longitudinal to receive the vehicle body with two outgoing lower section on both sides of the central zone of himself through which relies on thickness recesses mostly circular said support member, which is essentially characterized in that the projections have a section periforme with a portion mostly circular and other portion highlighted with two lifts separated by longitudinal slot, which by its foreign contact us in rotation with rounded edges of the recesses part circular arm of the support member. (Machine-translation by Google Translate, not legally binding)","BATZ, S. COOP. LTDA.",KENNEDY FRASER;;WITHLOCK PETER JOHN;;DALY JOHN,,https://lens.org/187-863-659-484-839,Patent Application,no,0,0,2,2,0,,B66F5/00,,0,0,,,,EXPIRED
781,DK,T3,DK 1917349 T3,003-957-949-580-743,2014-01-13,2014,DK 06779217 T,2006-08-25,GB 0517382 A;;GB 2006003186 W,2005-08-26,"Kompleks, der omfatter et mikrobæremiddel med en positiv ladning, der er konjugeret til et negativt ladet tag, hvilket tag er en mikrosfære, og hvilken mikrosfære ikke er coatet med proteiner, og anvendelser deraf",,PLASTICELL LTD,CHOO YEN;;HORNBY FRASER;;GIRDLESTONE JOHN,,https://lens.org/003-957-949-580-743,Granted Patent,no,0,0,16,16,0,G01N33/5008;;G01N33/5023;;G01N33/5073;;Y10T436/2525;;Y10T436/25375;;Y10T436/13;;Y10T436/2525;;Y10T436/25375;;Y10T436/13;;G01N33/5008;;G01N33/5023;;G01N33/5073,C12N5/00;;G01N33/50,,0,0,,,,ACTIVE
782,EP,A2,EP 0903252 A2,007-258-028-821-63X,1999-03-24,1999,EP 98307587 A,1998-09-17,GB 9719804 A,1997-09-17,Bulkhead,"A bulkhead for a load space such as vehicle interior serves to separate air within the interior into separate compartments, and also has means for supplying cooled air to one or more of the compartments. The bulkhead may be used to provide compartments for distribution of chilled goods at different temperatures, with independent control of the temperature either side of the bulkhead. The integration of the cooled air supply within the bulkhead housing allows a substantial reduction in the load space lost with a conventional arrangement in which the cooled air supply is separately provided.",HUBBARD GROUP SERVICES LIMITED,HALE FRASER JOHN;;GUNN KEVIN JAMES,,https://lens.org/007-258-028-821-63X,Patent Application,yes,1,2,4,4,0,B60H1/3232;;B60H1/3232;;B60P3/205;;F25D23/069,B60H1/32;;B60P3/20;;F25D23/06,,0,0,,,,DISCONTINUED
783,NO,C,NO 171594 C,036-815-970-802-930,1993-04-07,1993,NO 832688 A,1983-07-22,GB 8221457 A,1982-07-24,"ANALOGIFREMGANGSMAATE FOR FREMSTILLING AV TERAPEUTISK AKTIVE 2-SUBSTITUERTE 4-AMINO-6,7-DIMETOKSYKINOLINER",,PFIZER,CAMPBELL SIMON FRASER;;HARDSTONE JOHN DAVID,,https://lens.org/036-815-970-802-930,Granted Patent,no,0,0,46,53,0,C07C255/00;;C07D215/42;;C07D215/48;;C07D295/195;;C07D401/04;;C07D401/12;;C07D405/12;;C07D413/12;;C07D417/12;;A61P9/12;;C07D215/20;;C07D295/195;;C07D405/12;;C07D401/04;;C07D413/12;;C07D417/12;;C07C255/00;;C07D215/42;;C07D401/12;;C07D215/48,A61K31/47;;A61K31/4709;;A61K31/495;;C07D215/20;;A61K31/50;;A61K31/505;;A61K31/53;;A61P9/12;;C07D215/42;;C07D215/48;;C07D295/195;;C07D401/04;;C07D401/12;;C07D401/14;;C07D405/12;;C07D405/14;;C07D413/12;;C07D413/14;;C07D417/12,,0,0,,,,EXPIRED
784,DK,T3,DK 0853770 T3,029-576-109-775-040,2001-02-26,2001,DK 96930247 T,1996-09-10,GB 9520384 A;;GB 9602238 W,1995-10-06,Detektor og fremgangsmåde til udførelse af autoradiografi,"There is disclosed an autoradiography system which includes an autoradiography sample, a substantially radioisotope free microchannel plate (MCP), and an MCP signal collection means, wherein the MCP directly measures beta particles from radioisotopes within the sample.",UNIV LEICESTER,GEORGE WILLIAM FRASER;;JOHN ERNEST LEES,,https://lens.org/029-576-109-775-040,Granted Patent,no,0,0,10,10,0,G01T1/28;;G01T1/2942;;G01T1/28;;G01T1/2942,G01T1/28;;G01T1/29,,0,0,,,,EXPIRED
785,US,A1,US 2017/0197764 A1,036-881-567-182-810,2017-07-13,2017,US 201715414205 A,2017-01-24,GB 201413249 A;;GB 201503512 A;;GB 201518819 A;;GB 201522544 A;;GB 201601501 A;;GB 2015052154 W;;GB 2016052215 W,2014-07-25,Container And Closure,"A container and closure includes a closure secured to the container through projections comprising a series of horizontal, circumferentially spaced apart elements arranged so that the elements on the closure can pass though the spaces between the elements on the container and locate beneath them to secure the closure to the container. The elements of the projection on the container are separated from each other in the circumferential direction and do not overlap with each other in the vertical direction and the elements of the projection on the closure are separated from each other in the circumferential direction and do not overlap with each other in the vertical direction. The closure carries a sealing member for providing a seal with either an internal or external sealing surface of the container. The seal is driven down from a lead-in surface to engage the sealing surface as the closure is rotated.",THREADLESS CLOSURES LTD,HEIN JOHN;;FRASER ANTHONY HENRY JOSEPH,,https://lens.org/036-881-567-182-810,Patent Application,yes,0,6,1,40,0,B65D85/72;;B65D85/72;;B65D41/065;;B65D41/065;;B65D51/1688;;B65D51/1688,B65D43/02;;B65D1/02;;B65D1/16;;B65D43/14;;B65D51/16;;B65D85/72,,0,0,,,,DISCONTINUED
786,GB,B,GB 2421092 B,037-950-641-427-613,2008-12-03,2008,GB 0426773 A,2004-12-07,GB 0426773 A,2004-12-07,Bufferless writing of data to memory,,HEWLETT PACKARD DEVELOPMENT CO,DICKIN FRASER JOHN;;LOH WENG WAH,,https://lens.org/037-950-641-427-613,Granted Patent,no,2,0,5,5,0,G06F11/1004;;G06F11/1004,G06F11/00;;G06F11/10,,0,0,,,,INACTIVE
787,US,A,US 1819105 A,039-959-296-662-367,1931-08-18,1931,US 20448027 A,1927-07-09,US 20448027 A,1927-07-09,High frequency luminous tube,,RAINBOW LIGHT INC,ROBERT MACHLETT RAYMOND;;FRASER STOKES JOHN,,https://lens.org/039-959-296-662-367,Granted Patent,no,0,8,1,1,0,H01J65/046;;H01J65/046,H01J65/04,,0,0,,,,EXPIRED
788,DE,D1,DE 3475303 D1,064-219-637-799-947,1988-12-29,1988,DE 3475303 T,1984-10-17,GB 8327793 A,1983-10-18,"HALO((PHENOXYPYRIDYL)METHYL)ESTERS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS INSECTICIDES","Cyclopropane carboxylates of formula (I) are new. In (I) W= halogen; X=H, CN or -C=CH; Y=H, 1-4C alkyl, 1-4C alkoxy, 1-4C alkylthio, 1-4C alkylsulphonyl, trifluoromethyl, 3,4-methylene dioxy, Cl, F or Br; n=1 or 2; Z=H, Cl or F.",ICI PLC,BUSHELL MICHAEL JOHN;;FRASER ALASTAIR MCLAREN,,https://lens.org/064-219-637-799-947,Granted Patent,no,0,0,27,27,0,A01N53/00;;C07D213/647,A01N29/00;;A01N31/00;;A01N53/04;;A01N43/40;;A01N53/00;;A01N53/08;;C07C13/04;;C07C21/00;;C07C25/00;;C07C43/20;;C07D213/00;;C07D213/64;;C07D213/647,,0,0,,,,EXPIRED
789,EP,A1,EP 3908532 A1,065-049-607-752-758,2021-11-17,2021,EP 19701022 A,2019-01-15,GB 2019050100 W;;GB 201800740 A;;GB 201806400 A,2018-01-17,A CONTAINER AND A CLOSURE FOR A CONTAINER,,THREADLESS CLOSURES LTD,FRASER ANTHONY HENRY JOSEPH;;HEIN JOHN,,https://lens.org/065-049-607-752-758,Patent Application,yes,0,0,10,13,0,B65D41/04;;B65D41/0442;;B65D43/0225;;B65D51/1661;;B65D2543/00972;;B29D99/0096;;B65D1/0246;;B65D41/0442;;B65D51/1661;;B67C3/22;;B67C7/00;;B67C2003/227,B65D41/04;;B65D43/02;;B65D51/16,,0,0,,,,PENDING
790,US,B2,US 8556939 B2,072-057-255-457-440,2013-10-15,2013,US 63893009 A,2009-12-15,US 63893009 A;;US 35093609 A;;US 1962208 P;;US 9845608 P;;US 12250608 P;;US 10486208 P;;US 13803108 P,2008-01-08,"Mathematical relationship of strain, neurological dysfunction and abnormal behavior resulting from neurological dysfunction of the brainstem",A therapeutic method for treating a neurological disease by evaluating and correcting an abnormal neuraxial angle that cause abnormal biomechanically induced neuraxial stress and strain.,HENDERSON FRASER CUMMINS;;NEWMAN JOHN W,HENDERSON FRASER CUMMINS;;NEWMAN JOHN W,POLARIS BIOTECHNOLOGY INC (2010-02-04),https://lens.org/072-057-255-457-440,Granted Patent,yes,101,7,2,27,0,A61B17/7055;;A61B17/7055;;A61B17/7011;;A61B17/7011;;A61B17/7043;;A61B17/7043;;A61B17/7044;;A61B17/7044;;A61B17/7049;;A61B17/7049;;A61B17/7052;;A61B17/7052;;A61B17/8061;;A61B17/8061,A61B17/88,606/279;;600/594,92,90,086-443-222-192-080;;050-550-902-973-574;;055-958-696-928-887;;135-058-861-995-343;;136-067-697-112-553;;023-147-592-549-452;;074-611-322-144-195;;040-263-466-037-282;;039-543-792-519-560;;100-395-282-383-024;;124-315-048-566-461;;096-562-248-680-263;;011-506-337-513-408;;058-544-875-340-471;;032-026-262-703-459;;066-629-021-636-984;;159-484-554-916-425;;013-665-423-408-023;;089-108-195-654-622;;022-878-261-499-22X;;015-362-829-154-988;;001-158-263-173-824;;058-107-204-029-425;;082-036-584-986-749;;010-852-616-837-902;;059-765-557-905-401;;053-925-680-701-000;;031-246-060-983-243;;022-633-504-719-923;;070-026-045-321-495;;090-792-868-576-34X;;126-299-114-397-113;;043-938-389-072-632;;043-272-767-469-816;;053-205-864-333-032;;038-227-892-072-048;;008-294-030-163-458;;067-011-505-873-929;;021-467-677-718-315;;035-206-517-188-733;;031-312-506-617-225;;000-186-482-604-016;;014-301-476-970-617;;006-037-018-652-689;;068-910-158-258-010;;096-315-283-501-795;;096-594-686-766-151;;106-953-475-365-262;;101-805-057-542-688;;161-967-379-592-424;;064-961-096-382-140;;025-129-192-071-684;;043-198-740-690-42X;;088-734-006-345-882;;007-966-469-765-837;;039-649-698-711-594;;101-748-145-810-496;;040-014-464-996-263;;022-863-083-303-762;;029-617-806-992-735;;013-523-154-430-463;;128-684-301-596-103;;094-449-008-946-344;;017-573-684-325-696;;046-767-629-817-484;;043-908-717-677-116;;063-950-537-045-263;;029-276-377-046-51X;;077-922-212-784-586;;076-382-054-205-508;;104-688-625-312-979;;001-011-237-647-268;;062-516-251-291-954;;075-209-944-982-485;;048-820-390-374-660;;011-413-665-818-996;;081-895-495-945-67X;;027-129-383-756-144;;030-467-413-752-508;;001-295-323-124-532;;035-750-137-625-101;;019-600-928-503-596;;072-254-793-619-737;;125-003-130-232-501;;085-615-660-336-47X;;038-184-885-142-418;;047-657-310-710-385;;073-700-598-417-439;;003-091-678-382-467;;006-779-111-684-557,3993694;;3158201;;15371512;;10.1523/jneurosci.1362-04.2004;;pmc6729801;;10.1115/1.1324667;;11192383;;8669719;;10.1007/bf02770996;;5521533;;10.1016/0021-9290(70)90046-1;;9171173;;10.3171/jns.1997.86.6.0950;;9075019;;10.1177/088307389701200206;;348703;;10.2106/00004623-197860030-00001;;8420126;;8993707;;10.1111/1469-7610.00022;;11944873;;10.1097/00006123-199510000-00012;;10.1227/00006123-199510000-00012;;8559297;;10.1038/nm0197-73;;8986744;;11463182;;10.1017/s0012162201000901;;9696080;;10.1097/00006123-199808000-00056;;10.1227/00006123-198811000-00008;;3200390;;9647166;;10.3171/jns.1998.89.1.0008;;7052810;;10.1007/bf01531513;;10473304;;10.1017/s0033291799008508;;10.1001/jama.289.1.87;;12503982;;12610643;;10.1038/sj.mp.4001266;;3167146;;10.1016/0006-3223(88)90168-0;;8445893;;10.1115/1.2895464;;10.1016/s0002-9610(39)90309-0;;10.1046/j.1365-2990.2000.026002105.x;;10840273;;1621145;;10.1097/00007632-199205000-00003;;10.1227/00006123-200107000-00010;;11440461;;10.1097/00006123-200107000-00010;;10.1097/00007632-200111150-00014;;11707712;;10.1046/j.1469-7580.2001.19930339.x;;pmc1468336;;11554511;;8239756;;pmc1005138;;10.1136/ard.52.9.629;;10.1227/01.neu.0000157929.85251.7c;;15854260;;11074673;;10.1097/00007632-200011150-00007;;10.1227/00006123-198403000-00010;;6709158;;10.1097/01.brs.0000113874.82587.33;;15129062;;10.1177/1362361397012003;;11284555;;10.1089/08977150151071053;;14563145;;10.3171/spi.2003.99.3.0278;;10.1097/00007632-200207010-00009;;12131739;;10.1523/jneurosci.0515-03.2004;;pmc6729402;;15140932;;9840768;;10.1089/neu.1998.15.955;;10.1017/s0012162201000627;;10.1111/j.1469-8749.2001.tb00214.x;;11368487;;7623948;;10.2176/nmc.35.285;;9419028;;10.1159/000121176;;12454433;;10.1007/978-3-7091-8882-8_59;;10.1089/08977150360547071;;12675969;;3193195;;10.3171/jns.1988.69.6.0895;;10.1097/00006123-199905000-00042;;10232534;;10.1097/00007632-199809150-00006;;10.1007/bf02172225;;8050980;;10.3171/jns.1982.57.1.0032;;7086498;;10.1016/j.humov.2004.08.019;;15541530;;1341941;;8683606;;10.1089/neu.1995.12.555;;10372899;;10.1016/s0387-7604(99)00009-1;;17110689;;pmc2802715;;10.1097/00007632-200207150-00003;;12131706;;10.1093/milmed/160.2.94;;7783927;;10.1017/s0954579402003085;;12349873;;10102725;;10.1111/1469-7610.00423;;10.1017/s0021963098003291;;9183141;;10.1097/00004583-199706000-00023;;14913631;;10.1136/jnnp.21.3.216;;pmc497322;;13576174;;10.1002/(sici)1097-4547(19971201)50:5<798::aid-jnr16>3.3.co;2-#;;10.1002/(sici)1097-4547(19971201)50:5<798::aid-jnr16>3.0.co;2-y;;9418967;;10.1148/66.2.259;;13297990;;7520459;;10.1007/bf02167898;;11086556;;10.1177/070674370004500806;;12543815;;10.1136/bmj.326.7382.173;;pmc1125046;;10.1097/00007632-199410000-00008;;7809750;;660249;;10.3171/jns.1978.48.6.0975;;9500320;;10.1016/s0140-6736(97)11096-0;;10.1007/978-1-4899-0792-9_7;;11245677;;10.1523/jneurosci.21-06-01923.2001;;pmc6762603;;16616445;;10.1016/j.braindev.2006.02.006;;10.1136/jnnp.39.4.381;;pmc492289;;932754;;11408325;;10.1093/brain/124.7.1299;;10.3171/spi.2004.1.3.0281;;15478366;;15478375;;10.4135/9781412961165.n51;;16247236;;10.2176/nmc.45.512;;10069589;;10.1097/00006123-199903000-00053;;10.1097/00006123-199903000-00050;;15835107;;10.3171/ped.2004.101.2.0189;;10.1136/jnnp.62.4.334;;9120444;;pmc1074087;;10.1136/jnnp.36.5.879;;pmc494486;;4753885;;10.1186/1471-2431-7-36;;18005455;;pmc2244616;;8207526;;10.3171/jns.1994.81.1.0043;;pmc460068;;10.1136/thx.40.5.364;;4023990;;16365484;;10.1177/230949900501300303;;10.1097/00007632-199103001-00005;;12590220;;10.1097/01.brs.0000048460.58471.db;;10.1097/00007632-200302150-00019;;10.1159/000056057;;12006755,"Aman, Michael G., et al., ""The Aberrant Behavior Checklist: A Behavior Rating Scale for the Assessment of Treatment Effects"", Am J Ment Defic, 1985: 89(5): 485-491.;;Aman, Michael G., et al., ""Psychometric Characteristics of the Aberrant Behavior Checklist"", Am J Ment Defic, 1985: 89(5): 492-502.;;Arundine, Mark, et al., ""Vulnerability of Central Neurons to Secondary Insults after in Vitro Mechanical Stretch"", J Neurosci, 2004. 24(37): 8106-8123.;;Bain, Allison C., et al., ""Tissue-Level Thresholds for Axonal Damage in an Experimental Model of Central Nervous System White Matter Injury"", J Biomech Eng, 2000. 122: 615-622.;;Bilston, Lynne E., et al., ""The Mechanical Properties of the Human Cervical Spinal Cord in Vitro"", Ann Biomed Eng, 1996. 24: 67-74.;;Breig, A., ""Overstretching of and Circumscribed Pathological Tension in the Spinal Cord-A Basic Cause of Symptoms in Cord Disorders"", J Biomech, 1970. 3: 7-9.;;Sawin, Paul D., et al., ""Basilar invagination in osteogenesis imperfecta and related osteochondrodysplasias: medical and surgical management"", J Neurosurg, 1997. 86: 950-960.;;Brill, Charles B., et al., ""Chiari I Malformation: Association With Seizures and Developmental Disabilities"", J Child Neurog, 1997. 12(2): 101-106.;;Brooks, Arthur L., et al., ""Atlanto-axial arthrodesis by the wedge compression method"", J Bone Joint Surg Am, 1978. 60(3): 279-284.;;Bunge, Richard P., et al., ""Observations on the Pathology of Human Spinal Cord Injury. A Review and Classification of 22 New Cases with Details from a Case of Chronic Cord Compression with Extensive Focal Demyelination"", Adv Neurol, 1993. 59: 75-89.;;Bunge, Richard P., et al., ""Observations on the Pathology of Several Types of Human Spinal Cord Injury, with Emphasis on the Astrocyte Response to Penetrating Injuries"", Adv Neurol, 1997. 72: 305-315.;;Charman, Tony, et al., ""Practitioner Review: Diagnosis of autism spectrum disorder in 2- and 3-year-old children"", J Child Psychol Psychiatry, 2002. 43(3): 289-305.;;Coyne, Terry J., et al., ""C1-C2 Posterior Cervical Fusion: Long-term Evaluation of Results and Efficacy"", Neurosurgery, 1995. 37(4): 688-693.;;Crowe, Maria J., et al., ""Apoptosis and delayed degeneration after spinal cord injury in rats and monkeys"", Nat Med, 1997. 3(1): 73-76.;;Cushing, K E, et al., ""Tethering of the vertebral artery in the congenital arcuate foramen of the atlas vertebra: a possible cause of vertebral artery dissection in children"", Dev Med Child Neurol, 2001. 43(7): 491-496.;;Dickman, Curtis A., et al., ""Posterior C1-C2 Transarticular Screw Fixation for Atlantoaxial Arthrodesis"", Neurosurgery, 1998. 43(2): 275-280.;;Dyste, Gregg N., et al., ""Presentation and Management of Pediatric Chiari Malformations without Myelodysplasia"", Neurosurgery, 1988. 23(5): 589-597.;;Eleraky, Mohammed Aly, et al., ""Posterior atlantoaxial facet screw fixation in rheumatoid arthritis"", J Neurosurg, 1998. 89: 8-12.;;Fein, Deborah, et al., ""Clinical Correlates of Brainstem Dysfunction in Autistic Children"", J Autism and Dev Disorders, 1981. 11(3): 303-315.;;Fombonne, Eric, ""The epidemiology of autism: a review"", Psych Med, 1999. 29: 769-786.;;Fombonne, Eric, ""The Prevalence of Autism"", JAMA, 2003. 289(1): 87-89.;;Fombonne, Eric, et al., ""MMR and autistic enterocolitis: consistent epidemiological failure to find an association"", Mol Psychiatry, 2003. 8: 133-134.;;Gaffney, Gary R., et al., ""Morphological Evidence for Brainstem Involvement in Infantile Autism"", Biol Psychiatry, 1988. 24: 578-586.;;Galbraith, J. A., et al., ""Mechanical and Electrical Responses of the Squid Giant Axon to Simple Elongation"", J Biomech Eng, 1993. 115: 13-22.;;Gallie, W. E., ""Fractures and Dislocations of the Cervical Spine"", Am J Surg, 1939. 46: 495-499.;;Geddes, J. F., et al., ""Traumatic axonal injury: practical issues for diagnosis in medicolegal cases"", Neuorpath Appl Neurobio, 2000. 26: 105-116.;;Grob, Dieter, et al., ""Biomechanical Evaluation of Four Different Posterior Atlantoaxial Fixation Techniques"", Spine, 1992. 17(5): 480-490.;;Haid, Jr., Regis W., et al., ""C1-C2 Transarticular Screw Fixation for Atlantoaxial Instability: a 6-year Experience"", Neurosurgery, 2001. 49(1): 65-70.;;Harms, Jurgen, et al., ""Posterior C1-C2 Fusion With Polyaxial Screw and Rod Fixation"", Spine, 2001. 26(22): 2467-2471.;;Hasan, Mandi, et al., ""Posterolateral tunnels and ponticuli in human atlas vertebrae"", J Anat, 2001. 199(3): 339-343.;;Henderson, Fraser C., et al., ""Neuropathology of the brainstem and spinal cord in end stage rheumatoid arthritis: implications for treatment."", Ann Rheum Dis, 1993. 52(9): 629-637.;;Henderson, Fraser C., et al., ""Stretch-Associated Injury in Cervical Spondylotic Myelopathy: New Concept and Review"", Neurosurgery, 2005. 56(5): 1101-1113.;;Henriques, Thomas, et al., ""Biomechanical Comparison of Five Different Atlantoaxial Posterior Fixation Techniques"", Spine, 2000. 25(22): 2877-2883.;;Holness, Renn O., et al., ""Posterior Stabilization with an Interlaminar Clamp in Cervical Injuries: Technical Note and Review of the Long Term Experience with the Method"", Neurosurgery, 1984. 14(3): 318-322.;;Hong, Xia, et al., ""Posterior Screw Placement on the Lateral Mass of Atlas: An Anatomic Study"", Spine, 2004. 29(5): 500-503.;;Howlin, Patricia, et al., ""Diagnosis in Autism: A Survey of Over 1200 Patients in the UK"", autism, 1997. 1(2): 135-162.;;Ichihara, Kazuhiko, et al., ""Gray Matter of the Bovine Cervical Spinal Cord is Mechanically More Rigid and Fragile than the White Matter"", J Neurotrama, 2001. 18(3): 361-367.;;Ichihara, Kazuhiko, et al., ""Mechanism of the spinal cord injury and the cervical spondylotic myelopathy: new approach based on the mechanical features of the spinal cord white and gray matter"", J Neurosurg: Spine, 2003. 99: 278-285.;;Iwasaki, Motoki, et al., ""Cervical Kyphosis: Predictive Factors for Progression of Kyphosis and Myelopathy"", Spine, 2002. 27(13): 1419-1425.;;Iwata, Akira, et al., ""Traumatic Axonal Injury Induces Proteolytic Cleavage of the Voltage-Gated Sodium Channels Modulated by Tetrodotoxin and Protease Inhibitors"", J Neuroscience, 2004. 24(19): 4605-4613.;;Jafari, Saeed S., et al., ""Axonal Cytoskeletal Changes After Nondisruptive Axonal Inury. II. Intermediate Sized Axons"", J Neurotrama, 1998. 15(11): 955-966.;;Johansson, Maria, et al., ""Autistic spectrum disorders in Mobius sequence: a comprehensive study of 25 individuals"", Dev Med Child Neurology, 2001. 43: 338-345.;;Kitahara, Yukio, et al., ""Effect of Spinal Cord Stretching due to Head Flexion on Intramedullary Pressure"", Neurol Med Chir (Tokyo), 1995. 35: 285-288.;;Kocak, Ayhan, et al. ""A New Model for Tethered Cord Syndrome: A Biochemical, Electrophysiological, and Electron Microscopic Study"", Pediatr Neurosurg, 1997. 26(3): 120-126.;;Le Couteur, Ann, et al., ""National Autism Plan for Children (NAPC)"", National Initiative for Autism: Screening and Assessment (NIASA), 2003.;;Lusardi, Theresa A., et al., ""The separate roles of calcium and mechanical forces in mediating cell death in mechanically injured neurons"", Biorheology, 2003. 40: 401-409.;;Magerl, F., et al., ""Stable Posterior Fusion of the Atlas and Axis by Transarticular Screw Fixation"", Cervical Spine, 1987. 1: 322-327.;;Maxwell, William L., et al., ""Post-Acute Alterations in the Axonal Cytoskeleton after Traumatic Axonal Injury"", J Neurotrama, 2003. 20(2): 151-168.;;Menezes, Arnold H., et al., ""Transoral-transpharyngeal approach to the anterior craniocervical junction. Ten-year experience with 72 patients."", J Neurosurg, 1988. 69: 895-903.;;Milhorat, Thomas H., et al., ""Chiari I Malformation Redefined: Clinical and Radiographic Findings for 364 Symptomatic Patients"", Neurosurgery, 1999. 44(5): 1005-1017.;;Naderi, Sait, et al., ""Biomechanical Comparison of C1-C2 Posterior Fixations: Cable, Graft, and Screw Combinations"", Spine, 1998; 23(18): 1946-1955.;;Osterling, Julie, et al., ""Early Recognition of Children with Autism: A Study of First Birthday Home Videotapes"", J Autism Dev Disorders, 1994: 24(3): 247-257.;;Pang, Dachling, et al., ""Tethered cord syndrome in adults"", J Neurosurg, 1982. 57(1): 32-47.;;Piek, Jan P., et al., ""Sensory-motor deficits in children with developmental coordination disorder, attention deficit hyperactivity disorder and autistic disorder"", Hum Move Science, 2004. 23: 475-488.;;Povlishock, John T., ""Traumatically Induced Axonal Injury: Pathogenesis and Pathobiological Implications"", Brain Pathology, 1992. 2(1): 1-12.;;Povlishock, John T., et al., ""The Pathobiology of Traumatically Induced Axonal Injury in Animals and Humans: A Review of Current Thoughts"", J Neurotrama, 1995. 12(4): 555-564.;;Rapin, Isabelle, ""Appropriate investigations for clinical care versus research in children with autism"", Brain & Develop, 1999. 21: 152-156.;;Reich, D.S., et al., ""Quantitative Characterization of the Corticospinal Tract at 3T"", Am J Neuroradiol, 2006. 27: 2168-2178.;;Resnick, Daniel K., et al., ""Anatomic Suitability of the C1-C2 Complex for Pedicle Screw Fixation"", Spine, 2002. 27 (14): 1494-1498.;;Riggs, Jack E., et al., ""Spastic Quadriparesis, Dysarthria, and Dysphagia following Cervical Hyperextension: A Traumatic Pontomedullary Syndrome"", Military Medicine, 1995. 160(2): 94-95.;;Rodier, Patricia M., ""Converging evidence for brain stem injury on autism"", Develop and Psychopath, 2002. 14: 537-557.;;Rutter, Michael, et al., ""Genetics and Child Psychiatry: II Empirical Research Findings"", J Child Psychol Psychiatry, 1999. 40(1): 19-55.;;Scahill, Lawrence, et al., ""Children's Yale-Brown Obsessive Compulsive Scale: Reliability and Validity"", J Am Acad Child Adol Psychiatry, 1997. 36(6): 844-852.;;Scoville, W. B., et al., ""The Cervical Ruptured Disc; Report of 115 Operative Cases"", Trans Am Neurol Assoc, 1951. 56: 222-224.;;Schneider, Richard C., et al., ""The Syndrome of Acute Central Cervical Spinal Cord Injury"", J Neurol Neurosurg Psychiatry, 1958. 21: 216-227.;;Shuman, Sheri L., et al., ""Apoptosis of Microglia and Ogliodendrocytes After Spinal Cord Contusion in Rats"", J Neurosci Research, 1997. 50: 798-808.;;Smith, C. G., ""Changes in Length and Position of the Segments of the Spinal Cord with Changes in Posture in the Monkey"", Radiology, 1956. 66(2): 259-265.;;Stein, Mark A., et al., ""Psychometric Properties of the Children's Atypical Development Scale"", J Abnorm Child Psych, 1994. 22(2): 167-176.;;Szatmari, Peter, ""The Classification of Autism, Asperger's Syndrome, and Persuasive Developmental Disorder"", Can J Psychiatry, 2000. 45(8): 731-738.;;Szatmari, Peter, ""The causes of autism spectrum disorders"", BMJ, 2003. 326: 173-174.;;Tachibana, Shigekuni, et al., ""Spinal Cord Intramedullary Pressure. A Possible Factor in Syrinx Growth"", Spine, 1994. 19(19): 2174-2179.;;Tunturi, Archie R., ""Elasticity of the spinal cord, pia, and denticulate ligament in the dog"", J Neurosurg, 1978. 48: 975-979.;;Wakefield, A J, et al., ""Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children"", The Lancet, 1998. 351: 637-641.;;Wing, Lorna, ""Chapter 7-The Continuum of Autistic Characteristics"", Diagnosis and Assessment in Autism, 1993. 91-110.;;Wolf, John A., et al., ""Traumatic Axonal Injury Induces Calcium Influx Modulated by Tetrodotoxin-Sensitive Sodium Channels"", J Neurosci, 2001. 21(6): 1923-1930.;;Zeegers, Mijke, et al., ""Radiological findings in autistic and developmentally delayed children"", Brain & Develop, 2006. 28: 495-499.;;Corbett, J. J., et al., ""'Sneeze syncope,' basilar invagination and Arnold-Chiari type 1 malformation"", J Neurol, Neurosurg, and Psych, 1976; 39: 381-384.;;Geddes, J. F., et al., ""Neuropathology of inflicted head injury in children. II: Microscopic brain injury in infants"", Brain, 2001: 124: 1299-1306.;;Goel, Atul, ""Treatment of basilar invaginations by atlantoaxial joint distraction and direct lateral mass fixation"", J Neurosurg, 2004. 3: 281-286.;;Goel, Atul, et al., ""Craniovertebral Junction Realignment for the Treatment of Basilar Invagination With Syringomyelia: Preliminary Report of 12 Cases"", Neurol Med Chir, 2005. 45: 512-518.;;Grabb, Paul A., et al., ""Ventral Brain Stem Compression in Pediatric and Young Adult Patients with Chiari 1 Malformations"", Neurosurgery, 1999. 44(3): 520-528.;;Kim, Louis J., et al., ""Treatment of basilar invagination associated with Chiari 1 malformations in the pediatric population: cervical reduction and posterior occipitocervical fusion"", J Neurosurg, 2004. 101: 189-195.;;Levine, David N., ""Pathogenesis of cervical spondylotic myelopathy"", J Neurol, Neurosrug, and Psych, 1997. 62: 334-340.;;Phillips, Douglas G., ""Surgical treatment of myelopathy with cervical spondylosis"", J Neurol, Neurosrug, and Psych, 1973. 36: 879-884.;;Rossignol, Daniel A., et al., ""The effects on hyperbaric oxygen therapy on oxidative stress, inflammation, and symptoms in children with autism: an open-label pilot study"", BMC Pediatrics, 2007. 7: 36.;;Ryken, Timothy C., et al., ""Cervicomedullary compression in achondroplasia"", J Neurosurg, 1994. 81: 43-48.;;Stradling, J R, et al., ""Changes in ventilation and its components in normal subjects during sleep"", Thorax, 1985. 40: 364-370.;;Tassanwipas, A, et al., ""Magnetic resonance imaging study of the craniocervial junction"", J Ortho Surg, 2005. 13(3): 228-231.;;Grob, D., et al., ""Posterior Occipitocervical Fusion a Preliminary Report of a New Technique,"" Spine, vol. 16, No. 3 Supplement, Jan. 1, 1991, pp. S17-S24.;;Sandhu, Faheem A., MD, PhD, et al., ""Occipitocervical Fusion for Rheumatoid Arthritis Using the Inside-Outside Stabilzation Technique,"" Spine, 2003, pp. 414-419, vol. 28, No. 4.;;Kumar, Raj et al., ""Management of Pediatric Congenital Atlantoaxial Dislocation: A Report of 23 Cases from Northern India,"" Pediatric Neurosurgery, 2002, pp. 197-208, vol. 36.;;Co-Pending U.S. Appl. No. 12/688,848, filed Jan. 15, 2010.",ACTIVE
791,WO,A1,WO 2007/023297 A1,075-894-027-603-028,2007-03-01,2007,GB 2006003186 W,2006-08-25,GB 0517382 A,2005-08-26,METHOD,The present invention relates in one aspect to a method for determining the cell culture history of a cell unit labelled with more than one type of tag comprising the steps of: (a) measuring one or more parameters of each tag that is used to label the cell unit; (b) identifying each tag in the cell unit; and (c) correlating the identity of each tag to the identity of the cell unit and/or the specific cell culture conditions to which the cell unit has been exposed.,PLASTICELL LTD;;CHOO YEN;;HORNBY FRASER;;GIRDLESTONE JOHN,CHOO YEN;;HORNBY FRASER;;GIRDLESTONE JOHN,,https://lens.org/075-894-027-603-028,Patent Application,yes,14,4,16,16,0,G01N33/5008;;G01N33/5023;;G01N33/5073;;Y10T436/2525;;Y10T436/25375;;Y10T436/13;;Y10T436/2525;;Y10T436/25375;;Y10T436/13;;G01N33/5008;;G01N33/5023;;G01N33/5073,G01N33/50;;C12N5/00,,5,5,055-036-952-526-836;;126-480-153-146-743;;025-991-247-187-688;;040-391-987-013-67X;;055-036-952-526-836,10.1126/science.294.5540.137;;11588257;;10.1634/stemcells.20-1-50;;11796922;;10.1016/s0030-5898(05)70167-x;;10882474;;29711495;;10.1002/(sici)1521-3773(19980420)37:7<926::aid-anie926>3.0.co;2-0;;10.1126/science.294.5540.137;;11588257,"NICEWARNER-PENA S R ET AL: ""SUBMICROMETER METALLIC BARCODES"", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 294, no. 5540, 5 October 2001 (2001-10-05), pages 137 - 141, XP001128112, ISSN: 0036-8075;;DEASY B M ET AL: ""MECHANISMS OF MUSCLE STEM CELL EXPANSION WITH CYTOKINES"", STEM CELLS, ALPHAMED PRESS, DAYTON, OH, US, January 2002 (2002-01-01), pages 50 - 60, XP002952762, ISSN: 1066-5099;;GREENBERGER J S ET AL: ""Expansion of hematopoietic stem cells in vitro as a model system for human tissue engineering."", THE ORTHOPEDIC CLINICS OF NORTH AMERICA. JUL 2000, vol. 31, no. 3, July 2000 (2000-07-01), pages 499 - 510, XP009073761, ISSN: 0030-5898;;GUILES, ANGEW. CHEM. INTL ED ENGL, vol. 37, 1998, pages 926;;SCIENCE, vol. 294, 2001, pages 137 - 141",PENDING
792,WO,A1,WO 2023/052772 A1,077-708-223-605-523,2023-04-06,2023,GB 2022052470 W,2022-09-29,GB 202114032 A,2021-09-30,AMIDO DERIVATIVES FOR USE IN THE TREATMENT OF RNA VIRAL INFECTIONS,The present invention concerns compounds suitable as binders of RNA. RNA binders are useful in the treatment of RNA viruses. The present invention concerns compounds of formula (I) (as defined herein) for use in methods of treatment of viruses comprising RNA.,UNIV STRATHCLYDE,SCOTT FRASER JOHN;;SUCKLING COLIN JAMES,,https://lens.org/077-708-223-605-523,Patent Application,yes,7,1,2,2,6,A61K31/4439;;A61K31/4025;;A61K31/4725;;A61K31/428;;A61K31/427;;A61K31/433;;A61K31/5377;;A61K31/454;;A61K31/496;;A61P31/14;;A61P31/16,A61K31/4025;;A61K31/427;;A61K31/428;;A61K31/433;;A61K31/4439;;A61K31/454;;A61K31/4725;;A61K31/496;;A61K31/5377;;A61P31/14;;A61P31/16,,29,25,028-208-502-211-342;;075-097-240-099-850;;184-954-061-658-624;;108-624-039-845-695;;001-427-233-867-924;;072-118-554-397-325;;002-110-829-504-623;;053-564-374-786-842;;071-797-887-854-345;;106-293-037-230-973;;026-558-118-947-475;;109-731-317-831-972;;066-955-323-214-49X;;179-901-374-951-522;;031-341-262-933-530;;095-483-837-832-083;;037-979-323-931-338;;000-577-992-322-498;;078-830-036-842-414;;009-430-947-642-67X;;071-313-101-080-322;;092-106-604-155-453;;012-953-414-333-55X;;062-874-125-914-524;;124-603-220-967-862,10.1016/j.bmcl.2016.06.040;;27349332;;202191;;10.1007/s11008-005-0057-1;;17942232;;10.1016/j.bbagen.2007.08.018;;10.1021/bi00127a010;;1372825;;pmc147084;;10.1093/nar/25.22.4487;;9358156;;7632695;;10.1021/bi00031a019;;21227551;;10.1016/j.ejmech.2010.12.010;;30866557;;pmc6429135;;10.3390/molecules24050946;;11601968;;10.1021/ar000118k;;24357181;;10.1039/c3ob42023j;;pmc4020623;;pmc7169885;;10.1002/wrna.1373;;27307213;;10.1021/ja5012146;;24702247;;pmc4015652;;10.1039/d0cc06796b;;33201954;;pmc7845941;;10.1351/pac199668122287;;pmc2885024;;10.1099/vir.0.006700-0;;19088272;;10.1021/jm070831g;;17960927;;10.1021/acs.jmedchem.8b01847;;30763102;;pmc7478159;;32952999;;10.1039/c9md00268e;;10.1038/s41596-021-00536-y;;33893470;;pmc4862521;;10.1128/aac.02932-15;;26953209;;19397930;;10.1016/j.antiviral.2009.04.007;;15951748;;pmc2918402;;10.1038/nm1268;;25068132;;pmc4110790;;10.1016/j.stemcr.2014.04.018;;22072760;;10.1128/jvi.05452-11;;pmc3255827,"SCOTT FRASER J ET AL: ""An evaluation of Minor Groove Binders as anti-lung cancer therapeutics"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM NL, vol. 26, no. 15, 16 June 2016 (2016-06-16), pages 3478 - 3486, XP029642141, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2016.06.040;;GONCHARSKAYA T YA ET AL: ""Antiviral properties of analogs of distamycin A"", ANTIBIOTIKI, MEDICINA, MOSCOW, RU, 1 January 1977 (1977-01-01), pages 998 - 1002, XP009541140, ISSN: 0003-5637;;ZAKHAROVA O D ET AL: ""Interaction of HIV-1 Reverse Transcriptase with New Minor Groove Binders and Their Conjugates with Oligonucleotides"", MOLECULAR BIOLOGY, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NE, vol. 39, no. 3, 1 May 2005 (2005-05-01), pages 421 - 429, XP019288354, ISSN: 1608-3245;;R. SINHAM. HOSSAINS. KUMAR, BIOCHIMICA ET BIOPHYSICS ACTA,, vol. 1770, 2007, pages 1636 - 1650;;TANIOUS ET AL., BIOCHEMISTRY, vol. 31, 1992, pages 3103 - 3112;;L. DASSONNEVILLE ET AL., NUCLEIC ACIDS RES., vol. 25, no. 22, 1997, pages 4487 - 4492;;D. PILCH ET AL., BIOCHEMISTRY, vol. 34, 1995, pages 9962 - 9976;;I. STOLIC ET AL., EUR. J. MED. CHEM., vol. 46, 2011, pages 743 - 755;;A. PAUL ET AL., MOLECULES,, vol. 24, no. 946, 2019, pages 1 - 22;;J. GALLEGOG VARANI, ACC. CHEM. RES., vol. 34, 2001, pages 836 - 843;;M.D.YILDIRIM, I.CHILDS-DISNEYJ.L, ORG. BIOMOL. CHEM., vol. 12, 2013, pages 1029 - 1039;;HERMANN, T., WIRES RNA,, vol. 7, 2016, pages 726 - 743;;WONGC.-H ET AL., J. AM. CHEM. SOC., vol. 136, 2014, pages 6355 - 6361;;A.E. HARGROVE, CHEM. COMMUN., vol. 56, 2020, pages 15744 - 14756;;A. D. JENKINS ET AL., PURE & APPL. CHEM., vol. 68, 1996, pages 2287 - 2311;;P. H. STAHLC. G. WERMUTH, HANDBOOK OF PHARMACEUTICAL SALTS: PROPERTIES, SELECTION AND USE,, 2002;;WITTEVELDT, J ET AL., J GEN VIROL, vol. 90, 2009, pages 48 - 58;;C.J. SUCKLING ET AL., J. MED. CHEM., vol. 50, 2007, pages 6116 - 6125;;A.I.KHALAF ET AL., EUR. J. MED. CHEM., vol. 56, 2012, pages 39 - 47;;F.J. SCOTT ET AL., BIOORG. MED. CHEM. LETT, vol. 26, 2016, pages 3478 - 3486;;SCOTT, FRASER: ""An Investigation into Nucleic Acid Binding Compounds."", UNIVERSITY OF STRATHCLYDE THESIS, 2013, Retrieved from the Internet <URL:https://suprimo.lib.strath.ac.uk/primo-explore/fulldisplay?docid=SUSTAX_Tsf268508b&context=L&vid=SUNU01&lang=en_US&search_scope=Search%20the%20full%20Library&adaptor=Local%20Search%20Engine&isFrbr=true&tab=fulllibrary&query=any,contains,fraser%20scott&sortby=date&facet=frbrgroupid,include,2906846&offset=0>;;F. GIORDANI ET AL., J. MED. CHEM.,, vol. 62, 2019, pages 3021 - 3035;;R.J.O. NICHOL ET AL., MED. CHEM. COMMUN., vol. 10, 2019, pages 1620 - 1634;;BEWLEY K. R ET AL., NAT. PROTOC, vol. 16, no. 6, 2021, pages 3114 - 3140;;WITTEVELDT, J.MARTIN-GANS, MSIMMONDS, P, ANTIMICROB AGENTS CHEMOTHER, vol. 60, 2016, pages 2981 - 2992;;IRO, M ET AL., ANTIVIRAL RES, vol. 83, 2009, pages 148 - 155;;WAKITA, T ET AL., NATURE MED, vol. 11, 2005, pages 791 - 796;;ZHOU, X ET AL., STEM CELL REP, vol. 3, 2014, pages 204 - 214;;ANGUS, A. G ET AL., J VIROL, vol. 86, 2012, pages 679 - 690",PENDING
793,AU,A,AU 1975/080465 A,094-673-539-818-487,1976-10-28,1976,AU 1975/080465 A,1975-04-23,CA 199202 A,1974-05-07,PREPARATION OF ALKALI METAL AMIDES,,CA ATOMIC ENERGY LTD,PRESCOTT JOHN FRASER;;SANFORD EMERSON CECIL,,https://lens.org/094-673-539-818-487,Patent Application,no,0,0,17,18,0,B01J31/4015;;B01J31/0252;;C01B21/082;;C01B21/0926;;Y02P20/584,C01B4/00;;B01J31/40;;B01J38/00;;C01B21/082;;C01B21/092;;C07F1/00,,0,0,,,,DISCONTINUED
794,FR,A1,FR 2278627 A1,098-778-289-053-827,1976-02-13,1976,FR 7513920 A,1975-05-05,CA 199202 A,1974-05-07,PROCEDE DE RECUPERATION D'ALKYLAMIDURES DE METAL ALCALIN,,CA ATOMIC ENERGY LTD,PRESCOTT JOHN FRASER;;SANFORD EMERSON CECIL,,https://lens.org/098-778-289-053-827,Patent Application,no,0,0,17,18,0,B01J31/4015;;B01J31/0252;;C01B21/082;;C01B21/0926;;Y02P20/584,C01B4/00;;B01J31/40;;B01J38/00;;C01B21/082;;C01B21/092;;C07F1/00,,0,0,,,,EXPIRED
795,IT,A0,IT 8920433 A0,101-497-138-974-341,1989-05-11,1989,IT 2043389 A,1989-05-11,US 12107687 A,1987-11-16,ARTICOLO DI METALLO RIVESTITO,,CORNING GLASS WORKS,ANDRUS RONALD L;;MACDOWELL JOHN FRASER,,https://lens.org/101-497-138-974-341,Patent Application,no,0,0,1,12,0,,,,0,0,,,,PENDING
796,WO,A1,WO 2019/141973 A1,111-702-722-053-376,2019-07-25,2019,GB 2019050100 W,2019-01-15,GB 201800740 A;;GB 201806400 A,2018-01-17,A CONTAINER AND A CLOSURE FOR A CONTAINER,"A container and a closure for the container, the container having a side surface and a rim that defines an opening and an opening axis that is perpendicular to the opening; wherein the closure is configured to close the opening; the container and closure have respective thread portions that cooperate to define movement of the closure relative to the container in a direction parallel to the opening axis as the closure rotates about the opening axis relative to the container; the closure has a seal (14), configured to be able to form a fluid-tight seal against the side surface of the container; and the thread portions of the container and closure are configured such that, as the closure rotates relative to the container, the seal is moved in a direction parallel to the opening axis to contact three regions on the side surface of the container: a first region (31), configured such that, as the seal is moved across the region, the seal changes between states in which it is uncompressed and compressed, respectively, between the container and closure; a second region (32), configured such that fluid can bypass part of the seal; and a third region (33) in which the seal forms a fluid-tight seal between the side surface of the container and the closure. A container and closure wherein the container includes interrupted threads formed from separate thread portions (71, 72, 73) are also described, as well as a container and closure wherein the closure has a second seal (50).",THREADLESS CLOSURES LTD,FRASER ANTHONY HENRY JOSEPH;;HEIN JOHN,,https://lens.org/111-702-722-053-376,Patent Application,yes,3,1,10,13,0,B65D41/04;;B65D41/0442;;B65D43/0225;;B65D51/1661;;B65D2543/00972;;B29D99/0096;;B65D1/0246;;B65D41/0442;;B65D51/1661;;B67C3/22;;B67C7/00;;B67C2003/227,B65D41/04;;B65D43/02;;B65D51/16,,0,0,,,,PENDING
797,CO,A2,CO 2018001523 A2,116-114-025-509-519,2018-04-30,2018,CO 2018001523 A,2018-02-16,GB 2016052215 W;;GB 2015052154 W;;GB 201518819 A;;GB 201522544 A;;GB 201601501 A,2015-07-24,"Sistema de contenedor y tapa modificado, que genera una mejor barrera de gas y no utiliza el sistema de roscado tradicional","Un contenedor de boca ancha de plástico o metal (10) con una tapa de metal, el contenedor tiene una abertura que define un eje y un primer miembro que se proyecta hacia afuera alrededor de la superficie externa del contenedor, el primer miembro comprende una pluralidad de primeras porciones circunferencialmente espaciadas, cada primera porción tiene un elemento con superficies alargadas superior e inferior, las superficies superior e inferior de la misma son sustancialmente horizontales en la dirección circunferencial. La tapa de metal tiene una parte superior y una parte de faldón, la parte de faldón comprende un segundo miembro que se proyecta hacia adentro alrededor de una superficie interna de la misma, el segundo miembro comprende una pluralidad de segundas porciones circunferencialmente espaciadas, cada segunda porción tiene un elemento con superficies alargadas superior e inferior, las superficies superior e inferior de la misma son sustancialmente horizontales en la dirección circunferencial. Los elementos horizontales de las segundas porciones son de una longitud de manera que pueden pasar a través de espacios entre las primeras porciones y se pueden localizar bajo las primeras porciones para asegurar la tapa de metal al contenedor. La tapa tiene un miembro de sellado (23) para proporcionar un sello con una superficie de sellado del contenedor, la superficie de sellado (13) es una superficie sustancialmente vertical alrededor del interior o exterior de una porción de cuello del contenedor y las segundas porciones sobre la tapa tienen un extremo inclinado hacia arriba en un extremo del mismo y un extremo inclinado hacia abajo en el otro extremo del mismo que se extienden más allá de las superficies alargadas superior e inferior del mismo, respectivamente. Rotación de la tapa de metal en una dirección de ajuste impulsa las segundas porciones hacia abajo de los extremos inclinados hacia abajo para mover la tapa hacia abajo y para comprimir el miembro de sello en una dirección sustancialmente horizontal en acoplamiento de sellado con la superficie de sellado vertical. Rotación de la tapa en una dirección de aflojamiento impulsa las segundas porciones hacia arriba de los extremos inclinados hacia arriba para mover el miembro de sellado desde la posición sellada a una posición de ventilación asegurada. Se requiere rotación adicional en la dirección de aflojamiento para remover la tapa del contenedor.",THREADLESS CLOSURES LTD,FRASER ANTHONY HENRY JOSEPH;;HEIN JOHN,,https://lens.org/116-114-025-509-519,Patent Application,no,0,0,10,40,0,B65D41/065;;B65D41/065;;B65D43/0231;;B65D43/0231;;B65D2543/00972;;B65D2543/00972,B65D51/16;;B65D41/06;;B65D43/02,,0,0,,,,PENDING
798,WO,A1,WO 2002/045739 A1,114-362-305-126-248,2002-06-13,2002,NZ 0100267 W,2001-12-04,US 25124300 P,2000-12-04,IMMUNOMODULATORY CONSTRUCTS AND THEIR USES,"An immunomodulator which comprises an antigen-presenting-cell (APC) targeting molecule coupled to an immunomodulatory antigen, wherein said APC-targeting molecule mimics a superantigen but does not include a fully functional T-cell receptor binding site.",AUCKLAND UNISERVICES LTD;;FRASER JOHN DAVID;;NICHOLSON MELISSA JOY,FRASER JOHN DAVID;;NICHOLSON MELISSA JOY,,https://lens.org/114-362-305-126-248,Patent Application,yes,4,3,12,12,0,A61K39/092;;A61K39/385;;A61K2039/5154;;A61K2039/57;;A61K2039/6068;;C07K14/31;;C07K14/315;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61K39/385;;A61K39/092;;A61K2039/5154;;A61K2039/57;;A61K2039/6068;;C07K14/31;;C07K14/315,C12N15/09;;A61K39/00;;A61K39/085;;A61K39/09;;A61K39/385;;A61K45/00;;A61K48/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;C07K14/31;;C07K14/315;;C12N15/31,,2,1,033-421-192-576-509,9500784;;10.1084/jem.187.6.819;;pmc2212197,"PROFT T. AND FRASER J.: ""Superantigens: Just like peptides only different"", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 187, no. 6, 1998, pages 819 - 821, XP002903301;;See also references of EP 1349568A4",PENDING
799,US,A1,US 2009/0029368 A1,120-684-433-362-260,2009-01-29,2009,US 7245708 A,2008-02-25,GB 0517382 A;;GB 2006003186 W,2005-08-26,Method for determining the cell culture history of a cell unit labelled with more than one type of tag,The present invention relates in one aspect to a method for determining the cell culture history of a cell unit labelled with more than one type of tag comprising the steps of: (a) measuring one or more parameters of each tag that is used to label the cell unit; (b) identifying each tag in the cell unit; and (c) correlating the identity of each tag to the identity of the cell unit and/or the specific cell culture conditions to which the cell unit has been exposed.,PLASTICELL LTD,CHOO YEN;;HORNBY FRASER;;GIRDLESTON JOHN,PLASTICELL LIMITED (2008-08-28),https://lens.org/120-684-433-362-260,Patent Application,yes,15,1,16,16,0,G01N33/5008;;G01N33/5023;;G01N33/5073;;Y10T436/2525;;Y10T436/25375;;Y10T436/13;;Y10T436/2525;;Y10T436/25375;;Y10T436/13;;G01N33/5008;;G01N33/5023;;G01N33/5073,C07H1/00;;C12Q1/68;;C12M1/00;;C12N5/06;;C12N9/50;;C12N15/87;;C12P19/34;;C12Q1/02;;G01N33/50,435/6;;435/29;;435/287.1;;435/219;;536/25.3;;435/91.1;;435/375;;435/455;;435/383;;435/377,0,0,,,,ACTIVE
800,GB,A,GB 2498127 A,135-558-633-659-680,2013-07-03,2013,GB 201305319 A,2013-03-22,GB 201209537 A;;US 201213611654 A,2012-05-29,Practice mortar,A practice mortar bomb 100 comprises a pressure vessel 116 and an outlet valve system 122. The pressure vessel 116 is arranged in use to contain compressed fluid and the outlet valve system122 is arranged in use to allow explosive release of the compressed fluid from the pressure vessel 116 upon activation of the valve system 122 by a firing pin in a mortar tube.,EPC UNITED KINGDOM PLC,MACDONALD FRASER;;BUCHANAN AMBROSE SYDNEY JOHN,,https://lens.org/135-558-633-659-680,Patent Application,no,1,0,4,6,0,F42B8/20;;F42B8/20;;F41B11/723,F42B8/20,,0,0,,,,ACTIVE
801,US,A1,US 2016/0107806 A1,141-683-535-646-405,2016-04-21,2016,US 201414787902 A,2014-04-29,GB 201307767 A;;GB 201312536 A;;GB 201400221 A;;GB 201402642 A;;GB 201407157 A;;GB 2014051322 W,2013-04-30,CLOSURE FOR A CONTAINER,"A closure for releasably securing to a container adapted for storing foodstuff or a beverage, the closure comprising closing means ( 14 ) for closing a mouth of the container and securing means ( 22,23 ) for securing it in a closed position, the closing means and the securing means being formed of a plastics material comprising polyoxymethylene so as to provide a substantial gas barrier to the passage of oxygen and/or carbon dioxide therethrough, The closure may have a sealing member ( 18 ) formed of resilient material (compared to the rigid material of the remainder of the closure) for providing a seal between the closure and the container. The sealing member may be provided on a bore component which projects into the container so that, in use, it seals against an internal surface of the container. The sealing member may be an o-ring ( 18 ) formed of an elastomer, e.g. nitrile butadiene rubber. A foodstuff or beverage container, e.g. in the shape of a wine glass or the shape of a beer glass, having such a closure is also described. The use of a plastics material comprising polyoxymethylene for closing a container provides a barrier to the ingress of oxygen and/or to the egress of carbon dioxide to improve the shelf life of the product is also described.",THREADLESS CLOSURES LTD,FRASER ANTHONY HENRY JOSEPH;;HEIN JOHN,KEMIRA OYJ (2013-06-13);;THREADLESS CLOSURES LIMITED (2015-10-27),https://lens.org/141-683-535-646-405,Patent Application,yes,4,7,5,10,0,B65D41/086;;B65D41/165;;B65D41/0421;;B65D41/0428;;B65D41/165;;B65D43/0204;;B65D41/165;;B65D41/086;;A47G19/2205;;B65D45/322;;B65D85/72,B65D45/32;;A47G19/22;;B65D41/16;;B65D85/72,,0,0,,,,DISCONTINUED
802,GB,A,GB 730218 A,139-192-866-440-112,1955-05-18,1955,GB 2623852 A,1952-10-20,GB 2623852 A,1952-10-20,Improvements in or relating to a process and device for converting a continuous tow of artificial filaments into a sliver comprising staple lengths,"730,218. Stapling fibres ; textile combing- machines. IMPERIAL CHEMICAL INDUSTRIES, Ltd. Aug. 14, 1953 [Oct. 20, 1952], No. 26238/52. Classes 120(1) and 120(3). A process for the conversion of a tow of filaments into a sliver of staple fibre comprises repetition of a cycle of operations of combing from the free end in steps of progressively greater length a forwardly metered length of tow, cutting the combed length to staple length and forwardly metering, as measured from the cut end, a sufficient length of tow for combing and cutting to staple length. The machine shown comprises an endless conveyer 11 carried on and driven at a steady speed through wheels 13 and 14 and mounting, by pivoted links 12, flat plates 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, to all except 10 of which are fixed strips of card wire-clothing 17 : the strip on plate 1 is the shortest, that on plates 8 and 9 are equal and slightly larger than the staple length, and intermediate strips are intergraded in length. In operation the plate 10 initially lies beneath a dabber 23 and tow 22 passes through feed rollers 18 and 20 until the free end is at the edge of the dabber remote therefrom. While the feed rollers then remain stationary, the dabber 23 descends each time a plate passes just beyond its edge and presses on to the clothing 17 the tow, increasing lengths of which are combed by successive strips. When the combed tow has been partly drawn through the wire on plate 9, an electrically operated barber's hair clipper 24 descends and severs the end staple lengths or tuft 26 which is carried away by the plate 9 with its trailing end overhanging plate 10 : as the plate 9 moves around the wheel 13 the free end of the tuft 26 falls and is received by a conveyer 27 and is held thereon by a swinging bar 28 : the plate 9 recedes to complete its combing action, the bar 28 lifts, and the conveyer 27 moves a short distance in readiness for the next tuft, the assembly 32 of overlapping tufts being fed forward by delivery rollers, Fig. 2 (not shown). Feed rollers 18 and 20 run to replace the cut length of tow and the cycle of operations recommences. A pinned clearing device 33 reciprocates continuously to free the clothing 17 from the waste fibre.",ICI LTD,STEWART IAN FRASER;;SEED JOHN BRYAN,,https://lens.org/139-192-866-440-112,Granted Patent,no,0,1,1,1,0,D01G1/04,D01G1/04,D1N N5C10H        N1A;;D1N N5C13         N1A;;D1N N5C2A         N1A;;D1N N5C2D         N1A;;D1N N5C6C         N1A,0,0,,,,EXPIRED
803,EP,A1,EP 0145179 A1,150-503-735-820-629,1985-06-19,1985,EP 84307125 A,1984-10-17,GB 8327793 A,1983-10-18,"Halo((phenoxypyridyl)methyl)esters, process for their preparation and their use as insecticides.","Compounds of formula:
  wherein W is halo, X is hydrogen, cyano or. ethynyl, Y represents hydrogen, alkyl, alkoxy, alkylthio, alkane sulphonyl, trifluoromethyl, halo, or 3,4-methylenedioxy, n is 1 or 2 and Z is hydrogen or halo, useful as insecticides characterised by a combination of a board spectrum of activity and extremely rapid knock-down effect against flying insect pests.",ICI PLC,BUSHELL MICHAEL JOHN;;FRASER ALASTAIR MCLAREN,,https://lens.org/150-503-735-820-629,Patent Application,yes,1,2,27,27,0,A01N53/00;;C07D213/647,A01N29/00;;A01N31/00;;A01N53/04;;A01N43/40;;A01N53/00;;A01N53/08;;C07C13/04;;C07C21/00;;C07C25/00;;C07C43/20;;C07D213/00;;C07D213/64;;C07D213/647,,0,0,,,,EXPIRED
804,AR,A1,AR 081580 A1,153-628-656-450-664,2012-10-03,2012,AR P110101923 A,2011-06-03,GB 201009429 A;;GB 201011800 A,2010-06-04,CIERRE PARA UN CONTENEDOR,"Un cierre para un envase que tiene una abertura circular que define un eje, donde el cierre está sujeto al envase a fin de cerrar dicha abertura, donde el cierre tiene una pieza selladora con aro tórico montado sobre sí, con el propósito de proporcionar un sellado con una superficie selladora del envase y, cuando el cierre está sujeto al envase, la superficie selladora se extiende alrededor de una superficie superior o de una superficie interna del envase. El cierre puede comprender una función de perforación la cual, cuando está en uso, se extiende a través de la abertura hacia el interior del envase, y el sellado con aro tórico puede proporcionarse sobre la función de perforación. Se describen diversas formas de cierre, por ejemplo para cerrar un cuello de botella y un cierre de boca ancha. El cierre puede comprender un componente interno y un componente externo, por ejemplo un cierre con tapa o cap-on-collar y el envase, con preferencia, no presenta filamentos de rosca en su exterior para que sea cómodo beber de él.",THREADLESS CLOSURES LTD,HEIN JOHN;;FRASER ANTHONY HENRY JOSEPH,,https://lens.org/153-628-656-450-664,Patent Application,no,0,0,17,39,0,B65D41/04;;B65D41/0442;;B65D41/0442;;B65D41/00;;B65D41/08;;B65D41/08;;B65D41/08;;B65D41/086;;B65D41/086;;B65D41/62;;B65D53/02;;B65D53/02;;B65D53/02;;B65D2543/00564;;B65D2543/00564;;B65D2543/00972;;B65D2543/00972,B65D41/08,,0,0,,,,PENDING
805,GB,B,GB 2182412 B,157-386-338-293-292,1989-09-20,1989,GB 8525727 A,1985-10-18,GB 8525727 A,1985-10-18,PIPES AND METHODS AND APPARATUS FOR THE PRODUCTION OF PIPES,,BAJ LTD,ADLAM JOHN MAURICE;;PATTERSON IAN FRASER,,https://lens.org/157-386-338-293-292,Granted Patent,no,0,0,3,3,0,B29D23/001;;B29C53/585;;B29D1/00,B29C53/58;;B29D1/00;;B29D23/00,B5A AA1           AA1;;B5A A1R214E       AA1;;B5A A1R314C3      AA1;;B5A A1R429B       AA1;;B5A A1R429X       AA1;;B5A A2A1          AA1;;B5A A2A3          AA1;;B5A A2D2          AA1;;B5A A20T11        AA1;;B5A A20T12        AA1;;F2P PR            P2AZ;;F2P P1B3          P2AZ;;F2P P1B7G         P2AZ;;F2P P2A3          P2AZ;;F2P P2A5          P2AZ,0,0,,,,EXPIRED
806,CH,A,CH 320259 A,162-131-439-565-564,1957-03-31,1957,CH 320259D A,1953-10-13,GB 320259X A;;GB 140853X A,1952-10-20,Verfahren zum Umformen eines Stranges endloser Fasern in ein Kammzugband aus Stapelfasern und Vorrichtung zur Durchführung des Verfahrens,,ICI LTD,JAN FRASER STEWART;;JOHN BRYAN SEED,,https://lens.org/162-131-439-565-564,Granted Patent,no,0,0,1,1,0,D01G1/04,D01G1/04,19B,0,0,,,,EXPIRED
807,CA,A,CA 395766 A,162-971-338-103-24X,1941-04-08,1941,CA 395766D A,,CA 395766T A,,SELECTIVE SIGNAL SYSTEM,,WESTERN ELECTRIC CO,FULTON FRASER FOWLER;;RADFORD JOHN BODEN,,https://lens.org/162-971-338-103-24X,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
808,CN,A,CN 101253260 A,181-744-437-517-228,2008-08-27,2008,CN 200680031299 A,2006-08-25,GB 2006003186 W;;GB 0517382 A,2005-08-26,Method,The present invention relates in one aspect to a method for determining the cell culture history of a cell unit labelled with more than one type of tag comprising the steps of: (a) measuring one or more parameters of each tag that is used to label the cell unit; (b) identifying each tag in the cell unit; and (c) correlating the identity of each tag to the identity of the cell unit and/or the specific cell culture conditions to which the cell unit has been exposed.,PLASTICELL LTD,YEN CHOO;;FRASER HORNBY;;JOHN GIRDLESTONE,,https://lens.org/181-744-437-517-228,Patent Application,no,0,2,16,16,0,G01N33/5008;;G01N33/5023;;G01N33/5073;;Y10T436/2525;;Y10T436/25375;;Y10T436/13;;Y10T436/2525;;Y10T436/25375;;Y10T436/13;;G01N33/5008;;G01N33/5023;;G01N33/5073,C12N5/00;;G01N33/50,,0,0,,,,ACTIVE
809,CN,A,CN 106795267 A,178-511-972-533-806,2017-05-31,2017,CN 201580037578 A,2015-07-07,GB 201412053 A;;GB 201417601 A;;GB 2015051960 W,2014-07-07,Polyurethanes for contact lenses,"The present invention provides a poly(ethylene) glycol based polyurethane polymer composition, particularly useful in the production of contact lenses. Generally the reactant mixture used to form the polymer includes a branched chain extender. There is also provided a method of manufacturing a contact lens formed from such a polymer.",OCUTEC LTD,RASHID ABDUL;;HONEYMAN GORDON;;FRASER JOHN,,https://lens.org/178-511-972-533-806,Patent Application,no,3,3,11,13,0,C08G18/4833;;C08G18/4837;;C08G18/61;;C08G18/6517;;C08G18/6677;;C08G18/758;;C08G18/4808;;G02B1/043;;C08G2210/00;;B29D11/00038;;C08G18/4808;;C08G18/4837;;C08G18/61;;C08G18/6517;;C08G18/758;;G02B1/043;;C08J3/075;;G02C7/04;;B29D11/00038;;C08J2205/028;;C08J2205/022;;C08G18/758;;G02B1/043;;C08G2210/00;;C08G18/61;;C08G18/6677;;C08G18/4833;;C08G18/4808;;C08G18/4837;;C08G18/6517;;B29D11/00038;;C08G18/6674;;C08J3/075;;C08J2375/08;;C08K5/13,C08G18/75;;C08G18/48;;C08G18/61;;C08G18/65;;C08G18/66;;G02B1/04,,0,0,,,,DISCONTINUED
810,EP,A2,EP 1921133 A2,171-378-570-787-657,2008-05-14,2008,EP 07124088 A,2002-12-09,EP 02805565 A;;US 33885601 P,2001-12-07,System for processing lipoaspirate cells,"Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient
",CYTORI THERAPEUTICS INC,FRASER JOHN K;;HEDRICK MARC H,"CYTORI THERAPEUTICS, INC. (2010-12-29)",https://lens.org/171-378-570-787-657,Patent Application,yes,24,17,65,221,0,A61K35/28;;A61K35/28;;A61K48/00;;A61B10/0283;;A61B10/0283;;A61K9/0019;;A61K9/0019;;A61K35/32;;A61K35/35;;A61K35/35;;A61K35/36;;A61M1/76;;A61M2202/08;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/00;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;A61P43/00;;C12M47/04;;C12N5/0667;;C12N5/0667;;C12N5/069;;C12N5/069;;C12N2506/1384;;C12N2506/1384,A61M1/00;;C12M3/06;;A61K31/436;;A61K35/02;;A61K35/12;;A61K35/28;;A61K35/35;;A61K35/36;;A61K38/00;;A61K38/16;;A61K45/00;;A61L27/00;;A61P1/00;;A61P1/16;;A61P3/00;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P19/00;;A61P19/02;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;C12N5/07;;C12N5/0775,,112,106,075-488-030-671-490;;095-913-934-904-672;;084-816-629-310-620;;045-787-458-363-087;;007-126-466-697-398;;079-406-902-735-361;;063-511-874-896-881;;013-836-055-730-839;;050-826-336-424-654;;009-733-473-349-276;;037-681-158-746-769;;012-526-554-878-117;;039-145-123-882-385;;055-386-526-071-218;;080-727-563-346-048;;002-402-322-729-764;;114-069-508-870-517;;017-174-141-941-136;;072-127-656-734-286;;113-681-236-526-978;;047-891-267-991-075;;072-231-000-479-884;;033-479-118-598-189;;054-323-134-654-049;;114-479-047-988-820;;076-090-834-573-016;;015-875-842-431-592;;106-603-013-159-878;;154-284-578-210-365;;102-202-551-812-472;;015-757-459-694-093;;048-302-189-004-430;;087-309-466-182-005;;056-351-892-637-02X;;106-909-648-526-709;;079-304-670-311-107;;060-789-622-695-335;;018-221-020-974-252;;008-093-251-887-096;;047-771-701-165-31X;;078-144-091-568-913;;020-837-486-216-522;;019-939-051-494-816;;006-004-203-029-468;;008-115-130-355-40X;;027-810-214-593-214;;124-936-001-314-170;;119-279-899-568-792;;015-599-406-080-089;;054-506-496-484-990;;000-726-416-179-570;;010-094-842-952-554;;054-783-391-382-440;;111-021-439-383-245;;072-217-283-816-738;;034-785-794-270-260;;119-899-790-379-397;;035-339-813-605-916;;017-611-155-476-581;;072-093-532-186-924;;124-936-001-314-170;;015-599-406-080-089;;010-094-842-952-554;;115-114-291-514-621;;101-659-159-373-595;;014-944-849-240-553;;008-093-251-887-096;;050-826-336-424-654;;086-462-532-224-686;;094-547-639-217-227;;012-100-750-932-039;;155-317-023-938-779;;024-543-293-226-152;;053-378-748-216-731;;104-867-388-312-53X;;005-046-972-638-291;;055-939-072-605-234;;006-388-312-315-426;;100-021-019-543-442;;055-939-072-605-234;;060-346-109-363-548;;123-676-259-156-005;;013-585-462-742-366;;022-168-856-452-360;;071-429-593-853-516;;015-065-365-556-91X;;047-253-510-312-524;;036-252-293-129-219;;016-725-607-839-435;;062-596-462-103-530;;155-317-023-938-779;;054-506-496-484-990;;073-024-866-252-802;;013-619-248-169-661;;008-689-173-407-727;;005-046-972-638-291;;104-867-388-312-53X;;011-805-902-464-128;;060-346-109-363-548;;038-374-873-783-178;;042-752-396-214-211;;047-615-077-646-421;;000-409-808-541-605;;002-574-351-412-169;;052-138-454-301-405;;073-243-305-396-996,11329932;;10.1038/nm0901-1035;;pmc2818999;;11533707;;11156872;;10.1161/01.cir.103.5.634;;10.1016/0963-6897(95)00006-j;;7640867;;10.1177/096368979500400306;;10.1016/0304-3835(80)90091-9;;7013975;;182647;;10.1002/ijc.2910180309;;3966975;;10.1038/bjc.1985.13;;pmc1976821;;7357534;;7995370;;10.1089/15258160260194875;;12201961;;10.1080/146532402317381848;;12006209;;12100134;;10.1046/j.1365-2141.2002.03561.x;;4028127;;10.1007/bf00217172;;10.1002/bit.1043;;11255159;;10.1046/j.1423-0410.2001.00078.x;;11555470;;10225738;;10.1111/j.1744-9987.1997.tb00137.x;;10.1016/s0171-2985(82)80064-8;;6984421;;9770361;;10.1006/excr.1998.4163;;9390271;;9592680;;10.1007/s004050050045;;10.1016/s0165-022x(98)00006-2;;9711500;;11359674;;10.1089/15258160151134980;;11205918;;9597573;;10.1089/scd.1.1998.7.159;;11675329;;10.1182/blood.v98.9.2615;;10448662;;10.1016/s0344-0338(99)80049-1;;12135677;;10.1016/s0301-472x(02)00812-3;;1689854;;10.1007/bf02739694;;10.1007/s004040050273;;10834322;;12037404;;10.1159/000058006;;10.1016/s0165-2427(01)00375-0;;11604158;;10.1515/cclm.2000.092;;11028769;;11835415;;10.1002/jca.1032;;12144534;;10.1034/j.1600-0609.2002.01682.x;;9027589;;10.1002/(sici)1097-4644(199702)64:2<295::aid-jcb12>3.0.co;2-i;;10.1002/(sici)1097-4644(199702)64:2<295::aid-jcb12>3.3.co;2-6;;12411045;;12456961;;10.1634/stemcells.20-6-530;;10.1097/00003086-200010001-00011;;11039755;;10983732;;10.2165/00003495-200060020-00002;;10998427;;10.3892/ijmm.6.4.363;;9852198;;10.3892/ijmm.1.1.55;;7593260;;10.1002/jcb.240580312;;7628536;;10.1006/excr.1995.1221;;9618145;;10.1002/(sici)1097-4652(199807)176:1<57::aid-jcp7>3.0.co;2-7;;10546632;;10.1097/00003086-199910001-00003;;10556859;;10.1002/(sici)1097-4636(1999)48:6<913::aid-jbm22>3.0.co;2-0;;10102814;;10.1126/science.284.5411.143;;10.1016/s1471-4914(01)02016-0;;11378515;;11284885;;10.1046/j.1525-1594.2001.025003187.x;;11518286;;10.1016/s0736-0266(00)00054-1;;10.1089/107632701300062859;;11304456;;10.1097/00006534-200201000-00030;;11786812;;10.1080/17453674.1998.11744808;;9333121;;10.1359/jbmr.1997.12.10.1606;;10.1002/jor.1100160309;;9671928;;9262062;;11711826;;10.1097/00001665-200111000-00015;;10.1038/79449;;10973216;;11506726;;10.1089/10763270152436427;;10556859;;10.1002/(sici)1097-4636(1999)48:6<913::aid-jbm22>3.0.co;2-0;;10.1016/s1471-4914(01)02016-0;;11378515;;10.1089/107632701300062859;;11304456;;10.1111/j.1749-6632.1990.tb24327.x;;2291566;;9728332;;10.1023/a:1005462804271;;10738576;;10.1002/(sici)1521-2254(199903/04)1:2<121::aid-jgm26>3.0.co;2-j;;10.1097/00003086-200010001-00011;;11039755;;7995370;;10.1007/bf00453875;;8526158;;10.1016/s0094-1298(20)32343-9;;11248861;;1896551;;10.1097/00006534-199110000-00038;;11134993;;10.1046/j.1524-4725.2000.00277.x;;10.1046/j.1524-4725.2000.t01-1-00277.x;;10.1007/s002669900055;;8849432;;10.1007/bf02390315;;9048302;;10.1089/end.1997.11.67;;11125386;;10.1097/00005392-200101000-00037;;10.1046/j.1365-2613.1996.00964.x;;8762864;;pmc2691621;;10.1016/s0940-2993(99)80076-1;;10048720;;10488710;;10.1016/s0168-8278(99)80043-9;;10.1016/0270-9139(95)90478-6;;7539398;;10.1002/hep.1840210632;;10.1016/s0940-2993(99)80076-1;;10048720;;pmc507709;;8958214;;10.1172/jci119070;;11287958;;10.1038/35070587;;11326230;;10.1067/mtc.2001.112937;;10.1161/01.cir.0000034046.87607.1c;;12370212;;10086387;;10.1038/6529;;10.1182/blood.v97.5.1227;;11222364;;11594767;;10.1006/bbrc.2001.5712;;11487017;;6382294;;10.1097/00003086-199810001-00026;;9917645;;11134993;;10.1046/j.1524-4725.2000.00277.x;;10.1046/j.1524-4725.2000.t01-1-00277.x;;11284885;;10.1046/j.1525-1594.2001.025003187.x;;11884830;;10.1097/00006534-200203000-00037;;10.1152/ajpendo.2001.281.5.e1037;;11595661;;pmc370387;;6306056;;10.1172/jci110937;;10.1046/j.1365-2613.1996.00964.x;;8762864;;pmc2691621;;11125386;;10.1097/00005392-200101000-00037;;12160849;;10.1016/s0301-472x(02)00867-6;;pmc507709;;8958214;;10.1172/jci119070;;10.1016/s0736-0266(00)00010-3;;11332607;;11877271;;10.1182/blood.v99.6.1995;;10.1111/j.1749-6632.2001.tb03592.x;;11458511;;11105688;;10.1016/s0079-6123(00)28026-6;;10.1182/blood.v92.2.362.414k38_362_367;;9657732;;10.1182/blood.v92.2.362;;10.1038/7434;;10202935;;7881356;;10.1002/stem.5530120602,"MASUDA, H.; C. KALKA; T. ASAHARA: ""Endothelial progenitor cells for regeneration"", HUM CELL, vol. 13, no. 4, 2000, pages 153 - 60;;KAUSHAL, S. ET AL.: ""Functional small-diameter neovessels created using endothelial progenitor cells expanded ex vivo"", NAT MED, vol. 7, no. 9, 2001, pages 1035 - 40;;KAWAMOTO, A. ET AL.: ""Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia"", CIRCULATION, vol. 103, no. 5, 2001, pages 634 - 7;;WILLIAMS, S. K.; S. MCKENNEY ET AL.: ""Collagenase lot selection and purification for adipose tissue digestion"", CELL TRANSPLANT, vol. 4, no. 3, 1995, pages 281 - 9;;TWENTYMAN, P. R.; J. M. YUHAS: ""Use of bacterial neutral protease for disaggregation of mouse tumours and multicellular tumor spheroids"", CANCER LETT, vol. 9, no. 3, 1980, pages 225 - 8;;RUSSELL, S. W.; W. F. DOE ET AL.: ""Inflammatory cells in solid murine neoplasms. I. Tumor disaggregation and identification of constituent inflammatory cells"", HIT J CANCER, vol. 18, no. 3, 1976, pages 322 - 30;;ENGELHOLM, S. A.; M. SPANG-THOMSEN: ""Disaggregation of human solid tumours by combined mechanical and enzymatic methods"", BR J CANCER, vol. 51, no. 1, 1985, pages 93 - 8;;HEMSTREET, G. P.; P. G. ENOCH ET AL.: ""Tissue disaggregation of human renal cell carcinoma with further isopyknic and isokinetic gradient purification"", CANCER RES, vol. 40, no. 4, 1980, pages 1043 - 9;;SCHWEITZER, C. M. ET AL.: ""Isolation and culture of human bone marrow endothelial cells"", EXP HEMATOL, vol. 23, no. 1, 1995, pages 41 - 8;;GRYN, J.; R. K. SHADDUCK ET AL.: ""Factors affecting purification of CD34(+) peripheral blood stem cells using the Baxter Isolex 300i"", J HEMATOTHER STEM CELL RES, vol. 11, no. 4, 2002, pages 719 - 30;;PRINCE, H. M.; J. BASHFORD ET AL.: ""Isolex 300i CD34-selected cells to support multiple cycles of high-dose therapy"", CYTOTHERAPY, vol. 4, no. 2, 2002, pages 137 - 45;;WATTS, M. J.; T. C. SOMERVAILLE ET AL.: ""Variable product purity and functional capacity after CD34 selection: a direct comparison of the CliniMACS (v2.1) and Isolex 300i (v2.5) clinical scale devices"", BR J HACMATOL, vol. 118, no. 1, 2002, pages 117 - 23;;MAINWARING, G.; A. F. ROWLEY: ""Separation of leucocytes in the dogfish (Scyliorhinus canicula) using density gradient centrifugation and differential adhesion to glass coverslips"", CELL TISSUE RES, vol. 241, no. 2, 1985, pages 283 - 90;;GREENBERG, A. W.; D. A. HAMMER: ""Cell separation mediated by differential rolling adhesion"", BIOTECHNOL BIOENG, vol. 73, no. 2, 2001, pages 111 - 24;;SOLI, M. ET AL.: ""A multicentre evaluation of a new filtration protocol for leucocyte depletion of high-haematocrit red blood cells collected by an automated blood collection system"", VOX SANG, vol. 81, no. 2, 2001, pages 108 - 12;;SMITH, J.W.: ""Apheresis techniques and cellular immunomodulation"", THER APHER, vol. 1, no. 3, 1997, pages 203 - 6;;BERDEL, W.E. ET AL.: ""Purification of human monocytes by adherence to polymeric fluorocarbon. Characterization of the monocyte-enriched cell fraction"", IMMUNOBIOLOGY, vol. 163, no. 5, 1982, pages 511 - 20;;BICKENBACH, J.R.; E. CHISM: ""Selection and extended growth of murine epidermal stem cells in culture"", EXP CELL RES, vol. 244, no. 1, 1998, pages 184 - 95;;GEISELHART, A. ET AL.: ""Positive selection of CD56+ lymphocytes by magnetic cell sorting"", NAT IMMUN, vol. 15, no. 5, 1996, pages 227 - 33;;FORMANEK, M. ET AL.: ""Magnetic cell separation for purification of human oral keratinocytes: an effective method for functional studies without prior cell subcultivation"", EUR ARCH OTORHINOLARYNGOL, vol. 255, no. 4, 1998, pages 211 - 5;;GRAEPLER, F.; U. LAUER; M. GREGOR: ""Magnetic cell sorting for parietal cell purification using a new monoclonal antibody without influence on cell function"", J BIOCHEM BIOPHYS METHODS, vol. 36, no. 2-3, 1998, pages 143 - 55;;KOBARI, L. ET AL.: ""CD133+ cell selection is an alternative to CD34+ cell selection for ex vivo expansion of hematopoietic stem cells"", J HEMATOTHER STEM CELL RES, vol. 10, no. 2, 2001, pages 273 - 81;;MOHR, M. ET AL.: ""Simultaneous immunomagnetic CD34+ cell selection and B-cell depletion in peripheral blood progenitor cell samples of patients suffering from B-cell non-Hodgkin's lymphoma"", CLIN CANCER RES, vol. 7, no. 1, 2001, pages 51 - 7;;PUGH, R.E. ET AL.: ""CD19 selection improves the sensitivity of B cell lymphoma detection"", J HEMATOTHER, vol. 7, no. 2, 1998, pages 159 - 68;;REYES, M. ET AL.: ""Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells"", BLOOD, vol. 98, no. 9, 2001, pages 2615 - 25;;JOYNER, C.J. ET AL.: ""Development of a monoclonal antibody to the aP2 protein to identify adipocyte precursors in tumours of adipose differentiation"", PATHOL RES PRACT, vol. 195, no. 7, 1999, pages 461 - 6;;QUIRICI, N. ET AL.: ""Isolation of bone marrow mesenchymal stem cells by anti-nerve growth factor receptor antibodies"", EXP HEMATOL, vol. 30, no. 7, 2002, pages 783 - 91;;CIVIN, C.I. ET AL.: ""Positive stem cell selection--basic science"", PROG CLIN BIOL RES, vol. 333, no. 387, 1990, pages 387 - 401;;QIAN, X.; L. JIN; R.V. LLOYD: ""Percoll Density Gradient-Enriched Populations of Rat Pituitary Cells: Interleukin 6 Secretion, Proliferative Activity, and Nitric Oxide Synthase Expression"", ENDOCR PATHOL, vol. 9, no. 1, 1998, pages 339 - 346;;SMITS, G.; W. HOLZGREVE; S. HAHN: ""An examination of different Percoll density gradients and magnetic activated cell sorting (MACS) for the enrichment of fetal erythroblasts from maternal blood"", ARCH GYNECOL OBSTET, vol. 263, no. 4, 2000, pages 160 - 3;;LEHNER, M.; W. HOLTER: ""Endotoxin-free purification of monocytes for dendritic cell generation via discontinuous density gradient centrifugation based on diluted Ficoll-Paque Plus"", INT ARCH ALLERGY IMMUNOL, vol. 128, no. 1, 2002, pages 73 - 6;;VAN MERRIS ET AL.: ""Separation of bovine bone marrow into maturation-related myeloid cell fractions"", VET IMMUNOL IMMUNOPATHOL, vol. 83, no. 1-2, 2001, pages 11 - 7;;LASCH, J.; G. KULLERTZ; J.R. OPALKA: ""Separation of erythrocytes into age-related fractions by density or size? Counterflow centrifugation"", CLIN CHEM LAB MED, vol. 38, no. 7, 2000, pages 629 - 32;;ITO, Y.; K. SHINOMIYA: ""A new continuous-flow cell separation method based on cell density: principle, apparatus, and preliminary application to separation of human buffy coat"", J CLIN APHERESIS, vol. 16, no. 4, 2001, pages 186 - 91;;DLUBEK, D. ET AL.: ""Enrichment of nonnal progenitors in counter-flow centrifugal elutriation (CCE) fractions of fresh chronic myeloid leukemia leukapheresis products"", EUR J HAEMATOL, vol. 68, no. 5, 2002, pages 281 - 8;;JAISWAL, N. ET AL.: ""Osteogenic differentiation of purified, culture-expanded human mesenchymal stem cells in vitro"", J CELL BIOCHEM, vol. 64, no. 2, 1997, pages 295 - 312;;HOU, L. ET AL.: ""Study of in vitro expansion and differentiation into neuron-like cells of human umbilical cord blood mesenchymal stem cells"", ZHONGHUA XUE YE XUE ZA ZHI, vol. 23, no. 8, 2002, pages 415 - 9;;SEKIYA, L ET AL.: ""Expansion of Human Adult Stem Cells from Bone Marrow Stroma: Conditions that Maximize the Yields of Early Progenitors and Evaluate Their Quality"", STEM CELLS, vol. 20, no. 6, 2002, pages 530 - 41;;J. D.; J. K. HENDRICKS ET AL.: ""Mesenchymal stem cells as vehicles for gene delivery"", CLIN ORTHOP, vol. 379, 2000, pages S71 - 90;;WALTHER, W.; U. STEIN: ""Viral vectors for gene transfer: a review of their use in the treatment of human diseases"", DRUGS, vol. 60, no. 2, 2000, pages 249 - 71;;ATHANASOPOULOS, T.; S. FABB ET AL.: ""Gene therapy vectors based on adeno-associated virus: characteristics and applications to acquired and inherited diseases (review"", INT J MOL MED, vol. 6, no. 4, 2000, pages 363 - 75;;MURAMATSU, T.; A. NAKAMURA ET AL.: ""In vivo electroporation: a powerful and convenient means of nonviral gene transfer to tissues of living animals (Review"", INT J MOL MED, vol. 1, no. 1, 1998, pages 55 - 62;;J. M., C. MORGAN ET AL.: ""Bone morphogenetic proteins inhibit adipocyte differentiation by bone marrow stromal cells"", J CELL BIOCHEM, vol. 58, no. 3, 1995, pages 393 - 402;;LEMION, D. P.; S. E. HAYNESWORTH ET AL.: ""A chemically defined medium supports in vitro proliferation and maintains the osteochondral potential of rat marrow-derived mesenchymal stem cells"", EXP CELL RES, vol. 219, no. 1, 1995, pages 211 - 22;;MAJUMDAR, M. K.; M. A. THIEDE ET AL.: ""Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (MSCs) and stromal cells"", J CELL PHYSIOL, vol. 176, no. 1, 1998, pages 57 - 66;;CAPLAN, A. I.; V. M. GOLDBERG: ""Principles of tissue engineered regeneration of skeletal tissues"", CLIN ORTHOP, no. 367, 1999, pages S12 - 6;;OHGUSHI, H.; A. 1. CAPLAN: ""Stem cell technology and bioceramics: from cell to gene engineering"", J BIOMED MATER RES, vol. 48, no. 6, 1999, pages 913 - 27;;PITTENGER, M. F.; A. M. MACKAY ET AL.: ""Multilineage potential of adult human mesenchymal stem cells"", SCIENCE, vol. 284, no. 5411, 1999, pages 143 - 7;;CAPLAN, A. 1.; S. P. BRUDER: ""Mesenchymal stem cells: building blocks for molecular medicine in the 21st century"", TRENDS MOL MED, vol. 7, no. 6, 2001, pages 259 - 64;;FUKUDA, K.: ""Development of regenerative cardiomyocytes from mesenchymal stem cells for cardiovascular tissue engineering"", AITIF ORGANS, vol. 25, no. 3, 2001, pages 187 - 93;;WORSTER, A. A.; B. D. BROWER-TOLAND ET AL.: ""Chondrocytic differentiation of mesenchymal stem cells sequentially exposed to transforming growth factor-betal in monolayer and insulin- like growth factor-I in a three-dimensional matrix"", J ORTHOP RES, vol. 19, no. 4, 2001, pages 738 - 49;;ZUK, P. A., M. ZHU ET AL.: ""Multilineage cells from human adipose tissue: implications for cell- based therapies"", TISSUE ENG, vol. 7, no. 2, 2001, pages 211 - 28;;MIZUNO, H.; P. A. ZUK ET AL.: ""Myogenic differentiation by human processed lipoaspirate cells"", PLAST RECONSTR SURG, vol. 109, no. 1, 2002, pages 199 - 209;;LIND, M.: ""Growth factor stimulation of bone healing. Effects on osteoblasts, osteomies, and implants fixation"", ACTA ORTHOP SCAND SUPPL, vol. 283, 1998, pages 2 - 37;;HANADA, K.; J.E. DENNIS; A.I. CAPLAN: ""Stimulatory effects of basic fibroblast growth factor and bone morphogenetic protein-2 on osteogenic differentiation of rat bone marrow-derived mesenchymal stem cells"", J BONE MINER RES, vol. 12, no. 10, 1997, pages 1606 - 14;;LIEBERMAN, J.R. ET AL.: ""Regional gene therapy with a BMP-2-producing murine stromal cell line induces heterotopic and orthotopic bone fonnation in rodents"", J ORTHOP RES, vol. 16, no. 3, 1998, pages 330 - 9;;JEAN, J.L.; S.J. WANG; M.K. AU: ""Treatment of a large segmental bone defect with allograft and autogenous bone marrow graft"", J FORMOS MED ASSOC, vol. 96, no. 7, 1997, pages 553 - 7;;SAADEH, P.B. ET AL.: ""Repair of a Critical Size Defect in the Rat Mandible Using Allogenic Type I Collagen"", J CRANIOFAC SURG, vol. 12, no. 6, 2001, pages 573 - 579;;PETITE, H. ET AL.: ""Tissue-engineered bone regeneration"", NAT BIOTECHNOL, vol. 18, no. 9, 2000, pages 959 - 63;;GAO, J. ET AL.: ""Tissue-Engineered Fabrication of an Osteochondral Composite Graft Using Rat Bone Marrow-Derived Mesenchymal Stem Cells"", TISSUE ENG, vol. 7, no. 4, 2001, pages 363 - 71;;OHGUSHI, H; A.I. CAPLAN: ""Stem cell technology and bioceramics: from cell to gene engineering"", J BIOMED MATER RES, vol. 48, no. 6, 1999, pages 913 - 27;;CAPLAN, A.I.; V.M. GOLDBERG: ""Principles of tissue engineered regeneration of skeletal tissues"", CLIN ORTHOP, no. 367, 1999, pages S12 - 6;;CAPLAN, A.I.; S.P. BRUDER: ""Mesenchymal stem cells: building blocks for molecular medicine in the 21st century"", TRENDS MOL MED, vol. 7, no. 6, 2001, pages 259 - 64;;PETITE, SUPRA; ZUK, P.A. ET AL.: ""Multilineage cells from human adipose tissue: implications for cell- based therapies"", TISSUE ENG, vol. 7, no. 2, 2001, pages 211 - 28;;LUSKEY, B.D. ET AL.: ""Gene transfer into murine hematopoietic stem cells and bone marrow stromal cells"", ANN N Y ACAD SCI, vol. 612, no. 398, 1990, pages 398 - 406;;GROMPE, M. ET AL.: ""Therapeutic trials in the murine model of hereditary tyrosinaemia type I: a progress report"", J INHERIT METAB DIS, vol. 21, no. 5, 1998, pages 518 - 31;;GAZIT, D. ET AL.: ""Engineered pluripotent mesenchymal cells integrate and differentiate in regenerating bone: a novel cell-mediated gene therapy"", J GENE MED, vol. 1, no. 2, 1999, pages 121 - 33;;MOSCA, J.D. ET AL.: ""Mesenchymal stem cells as vehicles for gene delivery"", CLIN ORTHOP, vol. 379, 2000, pages S71 - 90;;GREENBERG, A.W.; D.A. HAMMER: ""Cell separation mediated by differential rolling adhesion"", BIOTECHNOL BIOENG, vol. 73, no. 2, 2001, pages 111 - 24;;SCHWEITZER, C.M., CELL TISSUE RES, vol. 241, no. 2, 1985, pages 283 - 90;;""Isolation and culture of human bone marrow endothelial cells"", EXP HEMATOL, vol. 23, no. 1, 1995, pages 41 - 8;;COLEMAN, S. R.: ""Long-term survival of fat transplants: controlled demonstrations"", AESTHETIC PLAST SURG, vol. 19, no. 5, 1995, pages 421 - 5;;COLEMAN, S. R.: ""Structural fat grafts: the ideal filler?"", CLIN PLAST SURG, vol. 28, no. 1, 2001, pages 111 - 9;;COLEMAN, W. P.: ""Autologous fat transplantation"", PLAST RECONSTR SURG, vol. 88, no. 4, 1991, pages 736;;EREMIA, S.; N. NEWMAN: ""Long-term follow-up after autologous fat grafting: analysis of results from 116 patients followed at least 12 months after receiving the last of a minimum of two treatments"", DERMATOL SURG, vol. 26, no. 12, 2000, pages 1150 - 8;;GUERREROSANTOS, J.; A. GONZALEZ-MENDOZA ET AL.: ""Long-term survival of free fat grafts in muscle: an experimental study in rats"", AESTHETIC PLAST SURG, vol. 20, no. 5, 1996, pages 403 - 8;;PALMA, P. C.; C. L. RICCETTO ET AL.: ""Repeated lipoinjections for stress urinary incontinence"", J ENDOUROL, vol. 11, no. 1, 1997, pages 67 - 70;;LEE, P. E.; R. C. KUNG ET AL.: ""Pehurethral autologous fat injection as treatment for female stress urinary incontinence: a randomized double-blind controlled trial"", J UROL, vol. 165, no. 1, 2001, pages 153 - 8;;J. H.; Z. ILIC ET AL.: ""Cell kinetics of repair after allyl alcohol-induced liver necrosis in mice"", INT J EXP PATHOL, vol. 77, no. 2, 1996, pages 63 - 72;;WERLICH, T.; K. J. STILLER ET AL.: ""Experimental studies on the stem cell concept of liver regeneration."", EXP TOXICOL PATHOL, vol. 51, no. 1, 1999, pages 93 - 8;;YIN, L.; D. LYNCH ET AL.: ""Participation of different cell types in the restitutive response of the rat liver to periportal injury induced by allyl alcohol"", J HEPATOL, vol. 31, no. 3, 1999, pages 497 - 507;;YAVORKOVSKY, L.; E. LAI ET AL.: ""Participation of small intraportal stem cells in the restitutive response of the liver to periportal necrosis induced by allyl alcohol"", HEPATOLOGY, vol. 21, no. 6, 1995, pages 1702 - 12;;WERLICH, T.; K. J. STILLER ET AL.: ""Experimental studies on the stem cell concept of liver regeneration. II"", EXP TOXICOL PATHOL, vol. 51, no. 1, 1999, pages 93 - 8;;MURRY, C. E.; R. W. WISEMAN ET AL.: ""Skeletal myoblast transplantation for repair of myocardial necrosis"", J CLIN INVEST, vol. 98, no. 11, 1996, pages 2512 - 23;;ORLIC, D.; J. KAJSTURA ET AL.: ""Bone marrow cells regenerate infarcted myocardium"", NATURE, vol. 410, no. 6829, 2001, pages 701 - 5;;RAJNOCH, C.; J. C. CHACHQUES ET AL.: ""Cellular therapy reverses myocardial dysfunction."", J THORAC CARDIOVASC SURG, vol. 121, no. 5, 2001, pages 871 - 8;;STRAUER, B. E.; M. BREHM ET AL.: ""Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans"", CIRCULATION, vol. 106, no. 15, 2002, pages 1913 - 8;;HORWITZ, E. M.; D. J. PROCKOP ET AL.: ""Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta"", NAT MED, vol. 5, no. 3, 1999, pages 309 - 13;;HORWITZ, E. M.; D. J. PROCKOP ET AL.: ""Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta"", BLOOD, vol. 97, no. 5, 2001, pages 1227 - 31;;AVITAL, L; D. INDERBITZIN ET AL.: ""Isolation, characterization, and transplantation of bone marrow-derived hepatocyte stem cells"", BIOCHEM BIOPHYS RES COMMUN, vol. 288, no. 1, 2001, pages 156 - 64;;CARMELIET, P.; A. LUTTUN: ""The emerging role of the bone marrow-derived stem cells in (therapeutic) angiogenesis"", THROMB HAEMOST, vol. 86, no. 1, 2001, pages 289 - 97;;CASTRO-MALASPINA, H.; W. EBELL ET AL.: ""Human bone marrow fibroblast colony-forming units (CFU-F)."", PROG CLIN BIOL RES, vol. 154, 1984, pages 209 - 36;;""Clinical use of marrow osteoprogenitor cells to stimulate osteogenesis"", CLIN ORTHOP, vol. 355, 1998, pages 257 - 66;;EREMIA, S.; N. NEWMAN: ""Long-tenn follow-up after autologous fat grafting: analysis of results from 116 patients followed at least 12 months after receiving the last of a minimum of two treatments"", DERMATOL SURG, vol. 26, no. 12, 2000, pages 1150 - 8;;FUKUDA, K.: ""Development of regenerative cardiomyocytes from mesenchymal stem cells for cardiovascular tissue engineering"", ARTIF ORGANS, vol. 25, no. 3, 2001, pages 187 - 93;;HUANG, J. L; S. R. BEANES ET AL.: ""Rat extramedullary adipose tissue as a source of osteochondrogenic progenitor cells."", PLAST RECONSTR SURG, vol. 109, no. 3, 2002, pages 1033 - 41;;HUTLEY, L. J.; A. C. HERINGTON ET AL.: ""Human adipose tissue endothelial cells promote preadipocyte proliferation"", AM J PHYSIOL ENDOCRINOL METAB, vol. 281, no. 5, 2001, pages E1037 - 44;;KERN, P. A.; A. KNEDLER ET AL.: ""Isolation and culture of microvascular endothelium from human adipose tissue"", J CLIN INVEST, vol. 71, no. 6, 1983, pages 1822 - 9;;LEE, J. H.; Z. ILIC ET AL.: ""Cell kinetics of repair after allyl alcohol-induced liver necrosis in mice"", INT J EXP PATHOL, vol. 77, no. 2, 1996, pages 63 - 72;;LEE, P. E.; R. C. KUNG ET AL.: ""Periurethral autologous fat injection as treatment for female stress urinary incontinence: a randomized double-blind controlled trial"", J UROL, vol. 165, no. 1, 2001, pages 153 - 8;;MURAYAMA, T.; O. M. TEPPER ET AL.: ""Determination of bone marrow-derived endothelial progenitor cell significance in angiogenic growth factor-induced neovascularization in vivo"", EXP HEMATOL, vol. 30, no. 8, 2002, pages 967 - 72;;MUNY, C. E.; R. W. WISEMAN ET AL.: ""Skeletal myoblast transplantation for repair of myocardial necrosis"", J CLIN INVEST, vol. 98, no. 11, 1996, pages 2512 - 23;;MUSCHLER, G. F.; H. NITTO ET AL.: ""Age- and gender-related changes in the cellularity of human bone marrow and the prevalence of osteoblastic progenitors"", J ORTHOP RES, vol. 19, no. 1, 2001, pages 117 - 25;;NISHIMORI, M.; Y. YAMADA ET AL.: ""Health-related quality of life of unrelated bone marrow donors in Japan"", BLOOD, vol. 99, no. 6, 2002, pages 1995 - 2001;;ORLIC, D.; J. KAJSTURA ET AL.: ""Transplanted adult bone marrow cells repair myocardial infarcts in mice"", ANN N Y ACAD SCI, vol. 938, 2001, pages 221 - 9;;PROCKOP, D. J.; S. A. AZIZI ET AL.: ""Potential use of marrow stromal cells as therapeutic vectors for diseases of the central nervous system"", PROG BRAIN RES, vol. 128, 2000, pages 293 - 7;;RAJNOCH, C.; J. C. CHACHQUES ET AL.: ""Cellular therapy reverses myocardial dysfunction"", J THORAC CARDIOVASC SURG, vol. 121, no. 5, 2001, pages 871 - 8;;SHI, Q.; S. RAFII ET AL.: ""Evidence for circulating bone marrow-derived endothelial cells"", BLOOD, vol. 92, no. 2, 1998, pages 362 - 7;;TAKAHASHI, T.; C. KALKA ET AL.: ""Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization"", NAT MED, vol. 5, no. 4, 1999, pages 434 - 8;;THOMAS, E. D.: ""Stem Cell Transplantation: Past, Present and Future"", STEM CELLS, vol. 12, 1994, pages 539 - 544;;WERLICH, T.; K. J. STILLER ET AL.: ""Experimental studies on the stem cell concept of liver regeneration. II."", EXP TOXICOL PATHOL, vol. 51, no. 1, 1999, pages 93 - 8;;ZUK, P. A.; M. ZHU ET AL.: ""Multilineage cells from human adipose tissue: implications for cell- based therapies"", TISSUE ENG, vol. 7, no. 2, 2001, pages 211 - 28",EXPIRED
811,WO,A1,WO 2015/085362 A1,173-575-014-193-909,2015-06-18,2015,AU 2014/050406 W,2014-12-10,AU 2013/904823 A,2013-12-11,MEDICAMENT APPARATUS AND METHOD,"An apparatus for use in administering a particulate medicament to a biological subject's airway, the apparatus including an inlet that in use is in fluid communication with a supply of positive pressure gas, an outlet that in use is in fluid communication with the subject's airway to deliver the positive pressure gas thereto and a medicament supply that provides a dose of particulate medicament so that the particulate medicament is entrained in a gas flow from the inlet to the outlet, thereby delivering the particulate medicament to the subject's airway.",MOTU CORDIS DE,FRASER JOHN FRANCIS;;GREGORY SHAUN DAVID,,https://lens.org/173-575-014-193-909,Patent Application,yes,6,5,17,17,0,A61M11/02;;A61M11/06;;A61M15/0028;;A61M15/0065;;A61M16/0048;;A61M16/0078;;A61M16/06;;A61M16/208;;A61M2202/064;;A61M2206/14;;A61M2209/06;;A61M2230/06;;A61M2230/42;;A61M16/049;;A61M15/0021;;A61M15/0031;;A61M15/0043;;A61M15/0048;;A61M15/0051;;A61M16/0084;;A61M2205/50;;A61M16/14;;A61K31/4166;;A61K31/137;;A61K9/0075;;A61K31/485;;A61K31/5517;;A61K31/7004;;A61P9/04;;A61P3/00;;A61P37/00;;A61M16/0048;;A61M16/06;;A61M16/208;;A61M2206/14;;A61M15/0031;;A61M15/0048;;A61M16/0084;;A61M2209/06;;A61M16/0078;;A61M11/02;;A61M2230/06;;A61M15/0051;;A61M15/0043;;A61M2205/50;;A61M15/0065;;A61M2230/42;;A61M11/06;;A61M15/0028;;A61M15/0021;;A61M16/049;;A61M2202/064;;A61M16/14;;A61H31/00;;A61M16/0057;;A61M16/04;;A61M16/0816;;A61M2202/0208,A61M13/00;;A61M16/00;;A61M37/00,,2,0,,,"ASTHMA SOCIETY OF CANADA: ""How to use a Diskhaler"", 28 January 2015 (2015-01-28), XP055348835, Retrieved from the Internet <URL:http://www.asthma.ca/adults/treatment/diskhaler.php>;;See also references of EP 3079743A4",PENDING
812,NZ,A,NZ 519371 A,181-456-213-196-182,2004-11-26,2004,NZ 51937102 A,2002-06-04,NZ 51937102 A,2002-06-04,Immunomodulatory constructs and their uses,The application discloses an immunomodulator which comprises an antigen-presenting-cell (APC) targeting molecule coupled to an immunomodulatory antigen. The said APC targeting molecule mimics the superantigen SMEZ-2 but does not fully include a fully functional T-cell receptor binding site. Then use of the immunomodulator is also described in the preparation of a medicament for the prophylaxis or therapeutic treatment of a disorder which requires the induction or stimulation of the immune system.,AUCKLAND UNISERVICES LTD,FRASER JOHN DAVID;;NICHOLSON MELISSA JOY,,https://lens.org/181-456-213-196-182,Patent Application,no,0,0,14,14,0,A61K39/092;;A61K39/385;;A61K2039/6037;;C07K14/315;;A61P37/02;;C07K14/315;;A61K39/092;;A61K2039/6037;;A61K39/385,C12N15/09;;A61K39/00;;A61K39/09;;A61K39/385;;A61K39/39;;C07K14/315;;C07K19/00;;C12N15/31,,0,0,,,,DISCONTINUED
813,GB,B,GB 2372553 B,069-328-599-073-153,2003-01-15,2003,GB 0200812 A,2002-01-15,GB 0200812 A,2002-01-15,Paintball feed system,,NPF LTD,RICE JOHN RONALD;;MARKS NICHOLAS JOHN;;COLLEY FRASER,,https://lens.org/069-328-599-073-153,Granted Patent,no,0,0,5,5,0,F41B11/52;;F41B11/52,F41B11/52,F3C CFJ           CFJ;;F3C CSM           CSM,0,0,,,,EXPIRED
814,US,A1,US 2014/0265721 A1,013-084-225-889-959,2014-09-18,2014,US 201214351888 A,2012-11-05,US 201214351888 A;;US 201161560836 P;;IB 2012056152 W,2011-11-17,PRE-COLLAPSED CAPACITIVE MICRO-MACHINED TRANSDUCER CELL WITH ANNULAR-SHAPED COLLAPSED REGION,"The present invention relates to a pre-collapsed capacitive micro -machined transducer cell ( 10 ) comprising a substrate ( 12 ) comprising a first electrode ( 16 ), a membrane ( 14 ) comprising a second electrode ( 18 ), wherein the cell has an outer region ( 22 ) where the membrane ( 14 ) is mounted to the substrate ( 12 ) and an inner region ( 20 ) inside or surrounded by the outer region ( 22 ), wherein the membrane ( 14 ) is collapsed to the substrate ( 12 ) in a first collapsed annular-shaped region ( 24 ) located within the inner region ( 20 ).",KONINKL PHILIPS NV,ROBINSON ANDREW LEE;;FRASER JOHN DOUGLAS,KONINKLIJKE PHILIPS N.V (2012-06-17),https://lens.org/013-084-225-889-959,Patent Application,yes,3,47,16,16,0,B06B1/0292;;Y10T29/49005;;B06B1/02;;Y10T29/49005;;B06B1/0292;;B06B1/02;;H02N1/006,B06B1/02;;H02N1/00,310/300;;29/594,0,0,,,,ACTIVE
815,US,A1,US 2005/0048036 A1,025-741-972-601-843,2005-03-03,2005,US 88529404 A,2004-07-01,US 88529404 A;;US 31612702 A;;US 33885601 P,2001-12-07,"Methods of using regenerative cells in the treatment of inherited and acquired disorders of the bone, bone marrow, liver, and other tissues","Stem cells, e.g. HSC and MSC-like stem cells, present in adipose tissue are used to treat diseases and disorders that would benefit from a hematopoietic stem cell transplant. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic renal benefit.",HEDRICK MARC H.;;FRASER JOHN K.,HEDRICK MARC H;;FRASER JOHN K,CYTORI THERAPEUTICS INC (2005-07-11);;LOREM VASCULAR PTE. LTD (2019-04-24);;MACROPORE BIOSURGERY INC (2004-09-14),https://lens.org/025-741-972-601-843,Patent Application,yes,30,43,1,221,0,A61L27/3834;;A61L27/54;;A61L2300/414;;A61L2300/416;;A61L2430/40;;C12N5/0667;;A61K35/28;;A61K35/44;;A61K35/44;;A61L27/3834;;A61L2430/40;;A61L2300/416;;C12N5/0667;;A61L27/54;;A61L2300/414;;A61K35/28,A61K35/12;;A61K35/28;;A61K35/36;;A61K35/44;;C12N5/08,424/93.7,0,0,,,,DISCONTINUED
816,WO,A1,WO 2009/076548 A1,038-873-320-835-659,2009-06-18,2009,US 2008/0086470 W,2008-12-11,US 1344207 P,2007-12-13,METHODS OF INHIBITING TUMOR DEVELOPMENT USING ADIPOSE-DERIVED REGENERATIVE CELLS,"Provided herein are compositions that include adipose-derived regenerative cells, and methods of making and using the same, that are useful for the inhibition of tumor development.",CYTORI THERAPEUTICS INC;;HEDRICK MARK H;;FRASER JOHN K,HEDRICK MARK H;;FRASER JOHN K,,https://lens.org/038-873-320-835-659,Patent Application,yes,3,8,1,1,0,A61K38/09;;A61K35/28;;A61K35/35,A61K35/32;;A61K35/28;;A61K35/35,,0,0,,,,PENDING
817,WO,A1,WO 1995/029316 A1,025-039-033-442-127,1995-11-02,1995,AU 1947/095002 W,1995-04-26,AU PM530694 A,1994-04-26,SECURING APPARATUS,"Securing apparatus (10) is provided for securing a closure member such as a sliding window (12) which is selectively moveable between open and closed positions in an opening in guide tracks (14, 15) in any desired part open position. The securing apparatus (10) has a mounting body (16) on the window (12) which supports latching means (23) in engagement with the lower track (15). The latching means (23) is in the form of a lever which inclines downwardly and away from the window frame (12) such that when mounted on the window frame (11) remote from the opening it blocks movement of the window (12) in the opening direction by elevating and jamming the window (12) in its support tracks (14, 15).",JIMAC PTY LTD;;FRASER IAN;;MORAN JOHN;;MCDONALD KENNETH,FRASER IAN;;MORAN JOHN;;MCDONALD KENNETH,,https://lens.org/025-039-033-442-127,Patent Application,yes,11,1,4,6,0,E05C17/443;;E05C17/446;;E05C17/64,E05C17/44;;E05C17/64,,0,0,,,,PENDING
818,GB,A,GB 872321 A,019-128-468-149-066,1961-07-05,1961,GB 88659 A,1959-01-09,GB 88659 A,1959-01-09,Phosphate coatings,"Before being provided with a phosphate coating, steel is pickled in an aqueous sulphuric acid solution which is maintained free of simple ferrous ions. The ferrous ions may be removed from the pickling solution by (a) oxidation to the ferric state, e.g. by adding to the solution sodium nitrate, sodium bromate, potassium permanganate, ammonium persulphate, potassium dichromate, hydrogen peroxide, potassium iodate or ceric ammonium sulphate, (b) complexing, e.g. with ethylene-diaminetetraacetic acid or its sodium salt, or (c) absorption on an ion exchange resin. The pickling solution may also contain an inhibitor. Phosphating is preferably effected using a zinc, manganese or iron phosphate solution; specified solutions contain zinc, phosphate, nitrate and nickel, and manganese, phosphate and nitrate. Heavy coatings suitable for deep-drawing, pressing and extrusion are obtained.",WALTERISATION COMPANY LTD,DRYSDALE ROYSTON FRASER;;ELGAR DEREK JOHN,,https://lens.org/019-128-468-149-066,Granted Patent,no,0,3,1,1,0,C23G1/081;;C23C22/78,C23C22/78;;C23G1/08,C7U U4F1          4;;C7U U4M1          4;;C7U U7C           4,0,0,,,,EXPIRED
819,EP,B1,EP 1921133 B1,040-086-553-210-392,2015-05-20,2015,EP 07124088 A,2002-12-09,EP 02805565 A;;US 33885601 P,2001-12-07,System for processing lipoaspirate cells,,CYTORI THERAPEUTICS INC,FRASER JOHN K;;HEDRICK MARC H,"CYTORI THERAPEUTICS, INC. (2010-12-29)",https://lens.org/040-086-553-210-392,Granted Patent,yes,3,1,65,221,0,A61K35/28;;A61K35/28;;A61K48/00;;A61B10/0283;;A61B10/0283;;A61K9/0019;;A61K9/0019;;A61K35/32;;A61K35/35;;A61K35/35;;A61K35/36;;A61M1/76;;A61M2202/08;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/00;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;A61P43/00;;C12M47/04;;C12N5/0667;;C12N5/0667;;C12N5/069;;C12N5/069;;C12N2506/1384;;C12N2506/1384,A61M1/00;;C12M3/06;;A61K31/436;;A61K35/02;;A61K35/12;;A61K35/28;;A61K35/35;;A61K35/36;;A61K38/00;;A61K38/16;;A61K45/00;;A61L27/00;;A61P1/00;;A61P1/16;;A61P3/00;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P19/00;;A61P19/02;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;C12N5/07;;C12N5/0775,,1,0,,,"ZUK P A ET AL: ""Multilineage cells from human adipose tissue: Implications for cell-based therapies"" TISSUE ENGINEERING, LARCHMONT, NY, US, vol. 7, no. 2, April 2001 (2001-04), pages 211-228, XP002198710 ISSN: 1076-3279",EXPIRED
820,DE,A1,DE 1496076 A1,060-203-661-578-907,1970-10-22,1970,DE 1496076 A,1963-08-07,US 21560962 A,1962-08-08,Glas-Kristall-Mischkoerper und Verfahren zu seiner Herstellung,,CORNING GLASS WORKS,FRASER MACDOWELL JOHN;;ANDREW EPPLER RICHARD,,https://lens.org/060-203-661-578-907,Patent Application,no,0,0,5,6,0,C03C10/0045;;C03C10/0045,C03C10/00,,0,0,,,,PENDING
821,AU,A,AU 1983/011911 A,057-046-535-371-708,1983-09-08,1983,AU 1983/011911 A,1983-02-28,GB 8206355 A,1982-03-04,METHOD AND APPARATUS FOR CUTTING TOOL MANUFACTURE,,BUSM CO LTD,ARCHER JOHN RICHARD;;ROSS PETER FRASER,,https://lens.org/057-046-535-371-708,Patent Application,no,0,0,15,15,0,B21D7/12;;B21D11/10;;B21D37/205;;B23P15/40;;B21D37/205;;B21D7/12;;B21D11/10;;B23P15/40,B23P15/28;;B21D7/12;;B21D11/10;;B23P15/40;;B23Q15/00,,0,0,,,,DISCONTINUED
822,US,A,US 843803 A,060-506-091-133-743,1907-02-12,1907,US 1906/0304294 A,1906-03-05,US 1906/0304294 A,1906-03-05,MARINE-ENGINE GOVERNOR.,,JOHN J KELLEY;;FRASER SIMON A;;NICHOLS JOHN M,FRASER SIMON A;;NICHOLS JOHN M,,https://lens.org/060-506-091-133-743,Granted Patent,no,0,0,1,1,0,B63H23/32;;B63H23/32,,,0,0,,,,EXPIRED
823,SG,A,SG 11201604626V A,077-796-245-894-875,2016-07-28,2016,SG 11201604626V A,2014-12-10,AU 2013/904823 A;;AU 2014/050406 W,2013-12-11,MEDICAMENT APPARATUS AND METHOD,,MOTU CORDIS DE,FRASER JOHN FRANCIS;;GREGORY SHAUN DAVID,,https://lens.org/077-796-245-894-875,Unknown,no,0,0,17,17,0,A61M11/02;;A61M11/06;;A61M15/0028;;A61M15/0065;;A61M16/0048;;A61M16/0078;;A61M16/06;;A61M16/208;;A61M2202/064;;A61M2206/14;;A61M2209/06;;A61M2230/06;;A61M2230/42;;A61M16/049;;A61M15/0021;;A61M15/0031;;A61M15/0043;;A61M15/0048;;A61M15/0051;;A61M16/0084;;A61M2205/50;;A61M16/14;;A61K31/4166;;A61K31/137;;A61K9/0075;;A61K31/485;;A61K31/5517;;A61K31/7004;;A61P9/04;;A61P3/00;;A61P37/00;;A61M16/0048;;A61M16/06;;A61M16/208;;A61M2206/14;;A61M15/0031;;A61M15/0048;;A61M16/0084;;A61M2209/06;;A61M16/0078;;A61M11/02;;A61M2230/06;;A61M15/0051;;A61M15/0043;;A61M2205/50;;A61M15/0065;;A61M2230/42;;A61M11/06;;A61M15/0028;;A61M15/0021;;A61M16/049;;A61M2202/064;;A61M16/14;;A61H31/00;;A61M16/0057;;A61M16/04;;A61M16/0816;;A61M2202/0208,A61M13/00;;A61M16/00;;A61M37/00,,0,0,,,,PENDING
824,NO,L,NO 832688 L,084-696-985-531-151,1984-01-25,1984,NO 832688 A,1983-07-22,GB 8221457 A,1982-07-24,"2-SUBSTITUERTE 4-AMINO-6,7-DIMETOKSYKINOLINER.",,PFIZER,CAMPBELL SIMON FRASER;;HARDSTONE JOHN DAVID,,https://lens.org/084-696-985-531-151,Abstract,no,0,0,46,53,0,C07C255/00;;C07D215/42;;C07D215/48;;C07D295/195;;C07D401/04;;C07D401/12;;C07D405/12;;C07D413/12;;C07D417/12;;A61P9/12;;C07D215/20;;C07D295/195;;C07D405/12;;C07D401/04;;C07D413/12;;C07D417/12;;C07C255/00;;C07D215/42;;C07D401/12;;C07D215/48,A61K31/47;;C07D215/20;;A61K31/4709;;A61K31/495;;A61K31/50;;A61K31/505;;A61K31/53;;A61P9/12;;C07D215/42;;C07D215/48;;C07D295/195;;C07D401/04;;C07D401/12;;C07D401/14;;C07D405/12;;C07D405/14;;C07D413/12;;C07D413/14;;C07D417/12,,0,0,,,,EXPIRED
825,EP,A1,EP 3166987 A1,066-683-334-744-430,2017-05-17,2017,EP 15744637 A,2015-07-07,GB 201412053 A;;GB 201417601 A;;GB 2015051960 W,2014-07-07,POLYURETHANES FOR CONTACT LENSES,,OCUTEC LTD,RASHID ABDUL;;HONEYMAN GORDON;;FRASER JOHN,,https://lens.org/066-683-334-744-430,Patent Application,yes,0,0,11,13,0,C08G18/4833;;C08G18/4837;;C08G18/61;;C08G18/6517;;C08G18/6677;;C08G18/758;;C08G18/4808;;G02B1/043;;C08G2210/00;;B29D11/00038;;C08G18/4808;;C08G18/4837;;C08G18/61;;C08G18/6517;;C08G18/758;;G02B1/043;;C08J3/075;;G02C7/04;;B29D11/00038;;C08J2205/028;;C08J2205/022;;C08G18/758;;G02B1/043;;C08G2210/00;;C08G18/61;;C08G18/6677;;C08G18/4833;;C08G18/4808;;C08G18/4837;;C08G18/6517;;B29D11/00038;;C08G18/6674;;C08J3/075;;C08J2375/08;;C08K5/13,C08G18/75;;C08G18/48;;C08G18/61;;C08G18/65;;C08G18/66;;G02B1/04,,0,0,,,,DISCONTINUED
826,US,B2,US 7784699 B2,095-041-903-241-663,2010-08-31,2010,US 48542706 A,2006-07-13,GB 0514658 A,2005-07-16,Thermal identification of data storage devices,A data storage device includes a temperature sensor. The temperature sensor outputs a temperature signal corresponding to a detected temperature. An identification unit connected to the temperature sensor generates and outputs an identification signal based on the temperature signal. A plurality of such data storage devices can therefore be identified by their relative position to an interrogator which outputs heat.,HEWLETT PACKARD DEVELOPMENT CO,LOH WENG WAH;;DICKIN FRASER JOHN,HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2006-06-05),https://lens.org/095-041-903-241-663,Granted Patent,yes,5,0,5,5,0,G06K7/0008;;G06K19/0717;;G06K19/0723;;G01S13/751;;G06K7/0008;;G06K19/0723;;G06K7/0008;;G06K19/0717;;G06K19/0723,G06K19/06;;G06K7/00;;G06K7/08;;G06K19/00;;G06K19/07,235/492;;235/435;;235/439;;235/451;;235/487,1,0,,,"Abstract GB 2395592 Hewlett Packard Co May 26, 2004.",INACTIVE
827,CA,A,CA 27733 A,090-801-394-844-016,1887-10-03,1887,CA 27733D A,,CA 27733T A,,WAGGON BRAKE,,YOUMANS JACOB;;VROMAN SOLOMON;;FRASER JOHN,YOUMANS JACOB;;VROMAN SOLOMON;;FRASER JOHN,,https://lens.org/090-801-394-844-016,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
828,AU,B2,AU 548036 B2,095-441-324-425-559,1985-11-21,1985,AU 1983/017222 A,1983-07-22,GB 8221457 A,1982-07-24,"2-SUBSTITUTED-4-AMINO-6,7-DIMETHOXY QUINOLINES",,PFIZER,CAMPBELL SIMON FRASER;;HARDSTONE JOHN DAVID,,https://lens.org/095-441-324-425-559,Granted Patent,no,0,0,46,53,0,C07C255/00;;C07D215/42;;C07D215/48;;C07D295/195;;C07D401/04;;C07D401/12;;C07D405/12;;C07D413/12;;C07D417/12;;A61P9/12;;C07D215/20;;C07D295/195;;C07D405/12;;C07D401/04;;C07D413/12;;C07D417/12;;C07C255/00;;C07D215/42;;C07D401/12;;C07D215/48,C07D215/20;;A61K31/47;;A61K31/4709;;A61K31/495;;A61K31/50;;A61K31/505;;A61K31/53;;A61P9/12;;C07D215/42;;C07D215/48;;C07D295/195;;C07D401/04;;C07D401/12;;C07D401/14;;C07D405/12;;C07D405/14;;C07D413/12;;C07D413/14;;C07D417/12,,0,0,,,,EXPIRED
829,WO,A1,WO 2000/026124 A1,095-501-533-983-356,2000-05-11,2000,GB 9903575 W,1999-11-02,GB 9823900 A,1998-11-02,VIBRATORY SYSTEM,"A vibratory system and a controller therefor is disclosed, the controller including means by which the vibratory parameters of the system can be controlled. The controller can optionally have the facility to save the vibratory parameters so that the parameters are automatically restored in the event that the controller is switched off and switched on again. There is also disclosed an improved vibratory block (100) comprising at least one leaf spring (104a, 104b) made of composite material.",ARTHUR G RUSSELL LIMITED,WARDROP FRASER JOHN;;BUCHAS GERALD L,,https://lens.org/095-501-533-983-356,Patent Application,yes,3,2,6,6,0,B65G47/14;;B65G47/14;;B65G27/08;;B65G27/08;;B65G27/32;;B65G27/32,B65G27/08;;B65G27/32;;B65G47/14,,0,0,,,,PENDING
830,ES,T3,ES 2364957 T3,092-132-710-084-109,2011-09-19,2011,ES 04756623 T,2004-07-01,US 2004/0021415 W,2004-07-01,PROCEDIMIENTOS DE USO DE CELULAS REGENERATIVAS PARA PROMOVER LA CICATRIZACION DE HERIDAS.,"Cells present in adipose tissue are used to promote wound healing in a patient. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the regenerative cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic benefit.",CYTORI THERAPEUTICS INC,HEDRICK MARC;;FRASER JOHN;;DANIELS ERIC,,https://lens.org/092-132-710-084-109,Granted Patent,no,0,5,19,19,0,C12N5/0667;;C12N2506/1384;;A61K45/06;;A61K35/28;;A61P17/02;;A61P37/06;;A61P43/00;;C12N5/06;;C12N5/0602;;C12N5/00,C12N5/07;;C12N5/0775;;A61K35/28;;A61P17/02;;C12N5/00;;C12N5/071,,0,0,,,,ACTIVE
831,WO,A2,WO 2008/048124 A2,103-427-494-228-934,2008-04-24,2008,NZ 2007000315 W,2007-10-18,AU 2006/905858 A,2006-10-20,SSL7 MUTANTS AND USES THEREFOR,"The invention relates to SSL7 mutants which have no, or at least reduced, ability to bind to IgA. The mutants have significant application in the purification or isolation of C5 from samples and in the identification or detection, including quantitation, of C5 in samples. Use of the mutants has the benefit of minimising or preventing simultaneous isolation and/or detection of IgA in a sample, simplifying and improving methods relying on wild type SSL7.",AUCKLAND UNISERVICES LTD AND M;;FRASER JOHN DAVID;;WINES BRUCE DAVID,FRASER JOHN DAVID;;WINES BRUCE DAVID,,https://lens.org/103-427-494-228-934,Patent Application,yes,0,1,8,8,0,C07K1/14;;C07K14/31;;C07K16/12;;C07K14/31;;C07K14/31;;C07K2317/52;;C07K2317/52;;C07K2319/30;;C07K2319/30,,,0,0,,,,PENDING
832,IT,A0,IT 8022270 A0,097-569-601-237-018,1980-05-22,1980,IT 2227080 A,1980-05-22,US 4155779 A,1979-05-23,SISTEMA AD AUTOCOPIATURA PER LA RIPRODUZIONE DI IMMAGINI.,,MINNESOTA MINING & MFG,JOHN FRASER WILLIAM;;PAUL SWEENY NORMAN,,https://lens.org/097-569-601-237-018,Patent Application,no,0,0,10,10,0,B41M5/132;;Y10S428/914;;Y10S101/29;;B41M5/132;;Y10S101/29;;Y10S428/914,B41M5/132,,0,0,,,,EXPIRED
833,CN,A,CN 108025846 A,103-999-128-813-723,2018-05-11,2018,CN 201680054216 A,2016-07-21,GB 2015052154 W;;GB 201518819 A;;GB 201522544 A;;GB 201601501 A;;GB 2016052215 W,2015-07-24,Container and closure,"A plastic or metal wide mouth container (10) with a metal closure, the container having an opening defining an axis and an outwardly projecting first member around the external surface of the container, the first member comprising a plurality of circumferentially spaced apart first portions, each first portion having an element with elongate upper and lower surfaces, said upper and lower surfacesthereof being substantially horizontal in the circumferential direction. The metal closure has a top part and a skirt part, the skirt part comprising an inwardly projecting second member around an internal surface thereof, the second member comprising a plurality of circumferentially spaced apart second portions, each second portion having an element with elongate upper and lower surfaces, said upper and lower surfaces thereof being substantially horizontal in the circumferential direction. The horizontal elements of the second portions are of a length such that they can pass through spaces between the first portions and are locatable beneath the first portions so as to secure the metal closure to the container. The closure has a sealing member (23) for providing a seal with a sealing surface of the container, the sealing surface (13) being a substantially vertical surface about the interior or exterior of a neck portion of the container and the second portions on the closure having anupwardly inclined end at one end thereof and a downwardly inclined end at the other end thereof which extend beyond said elongate upper and lower surfaces thereof, respectively. Rotation of the metalclosure in a tightening direction drives the second portions down the downwardly inclined ends to move the closure downwards and to compress the seal member in a substantially horizontal direction into sealing engagement with the vertical sealing surface. Rotation of the closure in a loosening direction drives the second portions up the upwardly inclined ends to move the sealing member from the sealed position to a secured venting position. Further rotation in the loosening direction is required to remove the closure from the container.",THREADLESS CLOSURES LTD,FRASER ANTHONY HENRY JOSEPH;;HEIN JOHN,,https://lens.org/103-999-128-813-723,Patent Application,no,5,1,10,40,0,B65D41/065;;B65D41/065;;B65D43/0231;;B65D43/0231;;B65D2543/00972;;B65D2543/00972,B65D51/16;;B65D41/06;;B65D43/02,,0,0,,,,DISCONTINUED
834,EP,A1,EP 2268557 A1,116-023-334-769-433,2011-01-05,2011,EP 09721829 A,2009-03-19,GB 2009000744 W;;GB 0805113 A;;GB 0809263 A,2008-03-19,SEALED CONTAINER,"A container (1) for the storage of a carbonated drink, comprising a container body with an opening that defines an axis and a removable closure (3) for closing the opening, the closure including a foil (2) for bonding to the container to close the opening in a gas-tight manner, the foil also being connected to, or interacting with, the closure, such that initial rotation of the closure in a loosening direction relative to the container body distorts or deforms the foil in a manner such that further rotation of the. closure results in a peel force being applied to the bond between the foil and the container.",THREADLESS CLOSURES LTD,FRASER ANTHONY HENRY JOSEPH;;HEIN JOHN,,https://lens.org/116-023-334-769-433,Patent Application,yes,0,0,7,9,0,B65D51/228;;B65D2251/0018;;B65D2251/0093;;B65D41/08;;B65D51/228;;B65D2251/0093;;B65D2251/0018;;B65D41/08,B65D51/22,,0,0,,,,ACTIVE
835,HU,T2,HU E059911 T2,111-710-047-704-541,2023-01-28,2023,HU E14868882 A,2014-12-10,AU 2013/904823 A,2013-12-11,APPARATUS,,DE MOTU CORDIS PTY LTD,FRASER JOHN FRANCIS;;GREGORY SHAUN DAVID,,https://lens.org/111-710-047-704-541,Amended Patent,no,0,0,17,17,0,A61M11/02;;A61M11/06;;A61M15/0028;;A61M15/0065;;A61M16/0048;;A61M16/0078;;A61M16/06;;A61M16/208;;A61M2202/064;;A61M2206/14;;A61M2209/06;;A61M2230/06;;A61M2230/42;;A61M16/049;;A61M15/0021;;A61M15/0031;;A61M15/0043;;A61M15/0048;;A61M15/0051;;A61M16/0084;;A61M2205/50;;A61M16/14;;A61K31/4166;;A61K31/137;;A61K9/0075;;A61K31/485;;A61K31/5517;;A61K31/7004;;A61P9/04;;A61P3/00;;A61P37/00;;A61M16/0048;;A61M16/06;;A61M16/208;;A61M2206/14;;A61M15/0031;;A61M15/0048;;A61M16/0084;;A61M2209/06;;A61M16/0078;;A61M11/02;;A61M2230/06;;A61M15/0051;;A61M15/0043;;A61M2205/50;;A61M15/0065;;A61M2230/42;;A61M11/06;;A61M15/0028;;A61M15/0021;;A61M16/049;;A61M2202/064;;A61M16/14;;A61H31/00;;A61M16/0057;;A61M16/04;;A61M16/0816;;A61M2202/0208,A61M11/02;;A61K9/00;;A61M11/06;;A61M15/00;;A61M16/00;;A61M16/04;;A61M16/06;;A61M16/14;;A61M16/20;;A61P3/00;;A61P9/04;;A61P37/00,,0,0,,,,PENDING
836,WO,A2,WO 2008/013863 A2,137-786-442-302-58X,2008-01-31,2008,US 2007/0016750 W,2007-07-25,US 83356106 P,2006-07-26,GENERATION OF ADIPOSE TISSUE AND ADIPOCYTES,"The invention provides novel methods by which adipose tissue, preadipocytes, and adipocytes can be generated for research purposes, and methods for identifying cell populations that can proliferate and differentiate into adipocytes in vivo. The invention further provides a means for the in vivo derivation of ""designer"" or ""customized"" adipose tissue, preadipocytes, and adipocytes. Also provided are methods for identifying agents that affect adipocytes and adipose tissue, as well as the agents themselves. In particular, the present invention allows for creation of tissues and cells that can be used to screen for agents useful for treating human disorders associated with adipose tissue, including obesity, metabolic syndrome, and diabetes.",CYTORI THERAPEUTICS INC;;FRASER JOHN K;;DE EMIDIO MICHAEL,FRASER JOHN K;;DE EMIDIO MICHAEL,,https://lens.org/137-786-442-302-58X,Patent Application,yes,0,24,3,3,0,A61K35/12;;C12N5/0653;;C12N2501/599;;C12N2503/02;;A61P3/00;;C12N5/0653;;A61K35/12;;C12N2501/599;;C12N2503/02,A61K35/12;;A61K48/00;;C12N5/077,,0,0,,,,PENDING
837,US,A1,US 2005/0260174 A1,151-394-024-978-004,2005-11-24,2005,US 61464803 A,2003-07-07,US 61464803 A;;US 31612702 A;;US 33885601 P,2001-12-07,Systems and methods for treating patients with processed lipoaspirate cells,Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient.,FRASER JOHN K;;HEDRICK MARC H,FRASER JOHN K;;HEDRICK MARC H,CYTORI THERAPEUTICS INC (2005-07-11);;LOREM VASCULAR PTE. LTD (2019-04-24);;MACROPORE BIOSURGERY INC (2003-03-07),https://lens.org/151-394-024-978-004,Patent Application,yes,87,53,65,221,0,A61K35/28;;A61K35/28;;A61K48/00;;A61B10/0283;;A61B10/0283;;A61K9/0019;;A61K9/0019;;A61K35/32;;A61K35/35;;A61K35/35;;A61K35/36;;A61M1/76;;A61M2202/08;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/00;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;A61P43/00;;C12M47/04;;C12N5/0667;;C12N5/0667;;C12N5/069;;C12N5/069;;C12N2506/1384;;C12N2506/1384,A61M1/00;;A61K31/436;;A61K35/02;;A61K35/12;;A61K35/28;;A61K35/35;;A61K35/36;;A61K38/00;;A61K38/16;;A61K45/00;;A61L27/00;;A61P1/00;;A61P1/16;;A61P3/00;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P19/00;;A61P19/02;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;C12M3/06;;C12N5/0775,424/93.7,0,0,,,,EXPIRED
838,DE,B,DE 1200476 B,156-404-582-773-642,1965-09-09,1965,DE F0036520 A,1962-04-10,US 1200476X A,1961-04-10,Stabilisierung von trockenen Zubereitungen synthetischer Alkalisalze von OEstronsulfat,,FROSST & CO CHARLES E,MILLAR JOHN FRASER;;FINDLAY LLOYD EDWARD,,https://lens.org/156-404-582-773-642,Patent Application,no,1,1,1,1,0,C07J31/006,C07J31/00,,0,0,,,,DISCONTINUED
839,DE,C2,DE 3909539 C2,159-628-044-976-305,1999-09-30,1999,DE 3909539 A,1989-03-22,DE 3909539 A;;CA 594783 A;;FR 8905823 A;;HK 92794 A;;US 12107687 A,1987-11-16,Verwendung einer Glas-Keramik-Beschichtung als Schutzschicht gegen Sauerstoff bei Temperaturen oberhalb von 1000 DEG C,,CORNING GLASS WORKS,ANDRUS RONALD LOUIS;;MACDOWELL JOHN FRASER,,https://lens.org/159-628-044-976-305,Granted Patent,no,2,0,2,12,0,A61F13/023;;A61F2013/008;;A61F2013/00868;;C23D5/00;;C03C10/0036;;C23D13/00,A61F13/00;;A61F13/02;;C03C10/00;;C23D5/00;;C23D13/00,,2,0,,,"Emailliertechnik, Fachbuchverlag Leipzig 1956, S. 20-25;;DE-Buch: ""Emaillierung"", A. Dietzel, Berlin, Heidelberg, New York, Springer, 1981",EXPIRED
840,US,A1,US 2006/0240044 A1,162-206-318-932-413,2006-10-26,2006,US 51371305 A,2005-08-11,NZ 51888202 A;;NZ 51905202 A;;NZ 0300086 W,2002-05-09,Streptococcal superantigens spe-l and spe-m,"The invention provides superantigens SPE-L and SPE-M, and their functional equivalents. In addition, the invention relates to nucleic acid molecules encoding the superantigens and/or their functional equivalents, and variant nucleic acids. The invention also provides diagnostic and therapeutic applications based on such superantigens and nucleic acid molecules.",FRASER JOHN D;;PROFT THOMAS K,FRASER JOHN D;;PROFT THOMAS K,INEOS EUROPE LIMITED (2006-06-16);;AUCKLAND UNISERVICES LIMITED (2005-07-26),https://lens.org/162-206-318-932-413,Patent Application,yes,16,0,3,3,12,A61K39/00;;A61K2039/505;;C07K14/315;;C12Q1/14;;G01N33/56944;;G01N33/56944;;C07K14/315;;A61K2039/505;;A61K39/00;;C12Q1/14,A61K39/09;;A61K39/00;;C07H21/04;;C07K14/315;;C12N1/21;;C12N15/31;;C12N15/74;;C12Q1/14;;G01N33/569,424/244.1;;435/69.3;;435/252.3;;435/471;;530/350;;536/23.7,0,0,,,,DISCONTINUED
841,WO,A1,WO 2009/122144 A1,161-350-438-917-12X,2009-10-08,2009,GB 2009000804 W,2009-03-27,GB 0805723 A,2008-03-29,CLOSURE CAP FOR A CONTAINER,"A closure for a container body (1) having a circular opening (IA) with an axis (Al) though the centre thereof, the closure comprising a collar (3) which is mountable on the container body and a cap (2) for securing to the container body via the collar (3) to close the opening, the collar being movable between a contracted configuration and an expanded configuration so that parts thereof are radially moveable between inner and outer positions, the collar having one or more first thread features (3B) and the cap having one or more second thread features (2C) so that, upon rotation of the cap relative to the collar, engagement between the first and second thread features causes axial and/or radial movement between the cap and the collar, the cap being formed of metal, or other malleable material, with a top portion (2A) and a skirt portion (2B) depending therefrom,.parts of the skirt portion being deformed inwardly to form the second thread features. A cap having a shape capable of being formed in a pressing operation is described.",MEADWESTVACO CORPORTATION;;FRASER ANTHONY HENRY JOSEPH;;HEIN JOHN,FRASER ANTHONY HENRY JOSEPH;;HEIN JOHN,,https://lens.org/161-350-438-917-12X,Patent Application,yes,2,5,2,2,0,B65D41/08,B65D41/08,,0,0,,,,PENDING
842,EP,A1,EP 2576374 A1,165-320-237-290-314,2013-04-10,2013,EP 11727733 A,2011-06-03,GB 201011800 A;;GB 201009429 A;;GB 2011000846 W,2010-06-04,CLOSURE FOR A CONTAINER,,THREADLESS CLOSURES LTD,FRASER ANTHONY HENRY JOSEPH;;HEIN JOHN,,https://lens.org/165-320-237-290-314,Patent Application,yes,0,4,17,39,0,B65D41/04;;B65D41/0442;;B65D41/0442;;B65D41/00;;B65D41/08;;B65D41/08;;B65D41/08;;B65D41/086;;B65D41/086;;B65D41/62;;B65D53/02;;B65D53/02;;B65D53/02;;B65D2543/00564;;B65D2543/00564;;B65D2543/00972;;B65D2543/00972,B65D41/04;;B65D41/08;;B65D53/02,,1,0,,,See references of WO 2011151630A1,ACTIVE
843,US,A1,US 2013/0134123 A1,177-768-271-221-946,2013-05-30,2013,US 201113809443 A,2011-07-04,GB 201011800 A;;GB 2011001003 W,2010-07-14,Closure For A Container,"A closure for a container having a circular opening defining an axis and a lip around said opening, the closure comprising: an inner component having a collar portion for locating about the exterior of the container beneath the lip of the container and a sealing portion which extends from said collar portion over an upper surface of said lip; and an outer component for fitting over the inner component and interacting therewith for releasably securing the collar portion under the lip, wherein the outer component has a skirt part for locating about the collar portion of the inner component, and the collar portion comprising a plurality of spaced apart radially moveable parts around its circumference pivotally joined at their lower ends by a ring extending around the entire circumference of the collar portion. The sealing portion may be formed of flexible material or may be formed of a relatively rigid material with a flexible sealing member, eg an o-ring, carried thereby.",FRASER ANTHONY H J;;HEIN JOHN,FRASER ANTHONY H J;;HEIN JOHN,THREADLESS CLOSURES LIMITED (2013-02-01),https://lens.org/177-768-271-221-946,Patent Application,yes,39,19,20,39,0,B65D41/0442;;B65D41/08;;B65D41/086;;B65D53/02;;B65D2543/00564;;B65D2543/00972;;B65D43/0222;;B65D45/322;;B65D51/18;;B65D41/065;;B65D41/086;;B65D2251/026;;B65D41/04;;B65D41/08;;B65D53/02;;B65D2543/00564;;B65D41/086;;B65D2543/00972;;B65D53/02;;B65D41/08;;B65D41/0442;;B65D41/04,B65D41/04,215/328,0,0,,,,DISCONTINUED
844,US,A1,US 2008/0285086 A1,197-641-224-973-990,2008-11-20,2008,US 75051407 A,2007-05-18,US 75051407 A,2007-05-18,SYSTEM AND METHOD FOR AN IMPROVED ENGRAVING OF GRAVURE CYLINDERS,An engraver having a shoe sensor system for sensing a movement of the shoe and for adjusting an engraving signal in response thereto.,MAX DAETWYLER CORP,FRASER JOHN WILLIAM;;WINTER CHRISTOPHER DARRELL,OHIO GRAVURE TECHNOLOGIES INC (2009-05-18),https://lens.org/197-641-224-973-990,Patent Application,yes,7,0,2,2,0,B41C1/045;;B41C1/045,B41C1/02,358/3.29,0,0,,,,INACTIVE
845,BR,A2,BR 112018001517 A2,199-490-645-080-688,2018-09-11,2018,BR 112018001517 A,2016-07-21,GB 2016052215 W;;GB 2015052154 W;;GB 201518819 A;;GB 201522544 A;;GB 201601501 A,2015-07-24,recipiente e fecho,"trata-se de um recipiente de boca ampla de plástico ou de metal com um fecho de metal, em que o recipiente tem uma abertura que define um eixo geométrico e um primeiro membro que se projeta para fora ao redor da superfície externa do recipiente, em que o primeiro membro compreende uma pluralidade de primeiras porções circunferencialmente separadas, em que cada primeira porção tem um elemento com as superfícies superior e inferior alongadas, em que as ditas superfícies superior e inferior do mesmo são substancialmente horizontais na direção circunferencial. o fecho de metal tem uma parte de topo e uma parte de aba, em que a parte de aba compreende um segundo membro que se projeta para dentro ao redor de uma superfície interna do mesmo, em que o segundo membro compreende uma pluralidade de segundas porções circunferencialmente separadas, em que cada segunda porção tem um elemento com superfícies superior e inferior alongadas, em que as ditas superfícies superior e inferior do mesmo são substancialmente horizontais na direção circunferencial. os elementos horizontais das segundas porções são de um comprimento, de modo que possam passar através dos espaços entre as primeiras porções e são passíveis de localização abaixo das primeiras porções, de modo que prendam o fecho de metal ao recipiente. o fecho tem um membro de vedação pra fornecer uma a vedação uma superfície de vedação do recipiente, em que a superfície de vedação é uma superfície substancialmente vertical ao redro do interior ou do exterior de uma porção de gargalo do recipiente e em que as segundas porções no fecho têm uma extremidade inclinada para cima em uma extremidade das mesmas e uma extremidade inclinada para baixo na outra extremidade das mesmas, que se estendem além das ditas superfícies superior e inferior alongadas das mesmas, respectivamente. a rotação do fecho de metal em uma direção de aperto conduz as segundas porções de modo descendente pelas extremidades inclinadas para baixo para mover o fecho de modo descendente e para comprimir o membro de vedação em uma direção substancialmente horizontal para o engate vedante com a superfície vertical de vedação. a rotação do fecho em uma direção de afrouxamento conduz as segundas porções de modo ascendente até as extremidades inclinadas para cima para mover o membro de vedação a partir da posição vedada para uma posição de ventilação presa. é necessária a rotação adicional na direção de afrouxamento para remover o fecho do recipiente.",THREADLESS CLOSURES LTD,ANTHONY HENRY JOSEPH FRASER;;JOHN HEIN,,https://lens.org/199-490-645-080-688,Patent Application,no,0,0,10,40,0,B65D41/065;;B65D41/065;;B65D43/0231;;B65D43/0231;;B65D2543/00972;;B65D2543/00972,B65D41/06;;B65D43/02;;B65D51/16,,0,0,,,,DISCONTINUED
846,US,A1,US 2010/0233139 A1,192-482-408-023-60X,2010-09-16,2010,US 69410310 A,2010-01-26,US 69410310 A;;US 87150304 A;;US 31612702 A;;US 33885601 P;;US 47941803 P,2001-12-07,METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER,"Methods of treating patients for conditions such as breast augmentation, soft tissue defects, and urinary incontinence, are described. The methods include removing adipose tissue from a patient, processing a portion of the adipose tissue to obtain a substantially isolated population of cells comprising disaggregated adipose-derived stem cells, mixing the concentrated population of adipose-derived cells comprising disaggregated adipose-derived cells with a portion of unprocessed, intact, non-disaggregated adipose tissue to form a composition, and administering the composition to the patient from which the adipose tissue was removed.",HEDRICK MARC H;;FRASER JOHN K,HEDRICK MARC H;;FRASER JOHN K,LOREM VASCULAR PTE. LTD (2019-04-24),https://lens.org/192-482-408-023-60X,Patent Application,yes,96,9,6,221,0,A61L27/3604;;A61L27/3834;;A61L27/3886;;A61L27/54;;A61L2300/414;;A61L2300/416;;A61L2300/426;;A61L2430/34;;C12N5/0667;;C12N5/069;;C12N2506/1384;;A61K35/28;;A61K35/44;;A61P1/00;;A61P17/00;;A61P3/06;;A61P43/00;;A61P9/00;;A61K35/44;;A61L27/3604;;A61L27/3886;;A61L27/54;;A61L27/3834;;A61L2300/416;;C12N2506/1384;;A61L2300/414;;A61L2300/426;;C12N5/0667;;C12N5/069;;A61L2430/34;;A61K35/28,A61K35/28;;A61K35/12;;A61K35/36;;A61K35/44;;A61P43/00;;C12N5/08,424/93.7,0,0,,,,EXPIRED
847,DE,D1,DE 68911001 D1,160-594-845-244-625,1994-01-13,1994,DE 68911001 T,1989-03-07,ES 8800673 A;;ES 8803912 A,1988-03-07,Fahrzeughebebock.,,BATZ S COOP LTDA,DALY JOHN WILLIAM;;KENNEDY FRASER;;WHITLOCK PETER JOHN,,https://lens.org/160-594-845-244-625,Granted Patent,no,0,0,5,7,0,B66F3/12,B66F3/12,,0,0,,,,EXPIRED
848,EP,A1,EP 1962692 A1,169-956-594-723-535,2008-09-03,2008,EP 06832153 A,2006-12-07,IB 2006054671 W;;US 75064905 P,2005-12-14,TRANSDUCER CUFF FOR GUIDANCE AND APPLICATION OF HIGH INTENSITY FOCUSED ULTRASOUND FOR CONTROL OF BLEEDING DUE TO SEVERED LIMBS,"An ultrasonic diagnostic and therapy system is described for stopping the bleeding of severely damaged blood vessels or vessels severed in a limb amputation. A cuff ( 30 ) is attached to the stump of the severed limb which contains a diagnostic transducer array ( 52, 54, 56 ) and a HIFU transducer ( 42, 44 ). The diagnostic transducer surveys the tissue of the severed limb, searching for a Doppler flow signal. When a Doppler flow signal is detected, the range to and coordinates of the sample volume where the flow was detected are determined, as well as the flow velocity. This information is supplied to a HIFU therapy transducer controller, which controls the HIFU transducer to transmit focused ultrasound to the sample volume of the flow locus, the center of the lumen of a blood vessel. The focused ultrasound heats and coagulates blood in the severed vessel to stem the bleeding. Heat dissipation due to the blood flow is reduced by tracking and continuously heating the same bolus of blood as it flows, or by heating a significant length of the blood vessel instead of a fixed spot in the vessel .",KONINKL PHILIPS ELECTRONICS NV,FRASER JOHN;;ROUTH HELEN;;AYATI SHERVIN;;PETRUZZELLO JOHN,"KONINKLIJKE PHILIPS ELECTRONICS N.V., NL (2014-11-26);;KONINKLIJKE PHILIPS N.V., NL (2014-03-28)",https://lens.org/169-956-594-723-535,Patent Application,yes,0,0,9,9,0,A61B5/6843;;A61B8/06;;A61B8/4227;;A61B8/4281;;A61B8/4483;;A61B17/1355;;A61N7/02;;A61N2007/0065;;A61N2007/0095;;A61N2007/027;;A61B8/06;;A61B17/1355;;A61N2007/0065;;A61B8/4483;;A61B8/4281;;A61N2007/027;;A61N7/02;;A61B5/6843;;A61N2007/0095;;A61B8/4227,A61B8/06;;A61B8/00;;A61B17/132;;A61B17/135;;A61N7/02,,0,0,,,,ACTIVE
849,WO,A3,WO 2007/069157 A3,191-892-021-898-327,2009-04-16,2009,IB 2006054673 W,2006-12-07,US 75064805 P,2005-12-14,METHOD AND APPARATUS FOR GUIDANCE AND APPLICATION OF HIGH INTENSITY FOCUSED ULTRASOUND FOR CONTROL OF BLEEDING DUE TO SEVERED LIMBS,"An ultrasonic diagnostic and therapy system is described for stopping the bleeding of severely damaged blood vessels or vessels severed in a limb amputation. A cuff is attached to the stump of the severed limb which contains a diagnostic transducer array and a HIFU transducer. The diagnostic transducer surveys the tissue of the severed limb, searching for a Doppler flow signal. When a Doppler flow signal is detected, the flow velocity and range and coordinates of the sample volume are determined. This information is supplied to a HIFU therapy transducer controller, which controls the HIFU transducer to transmit focused ultrasound to the sample volume of the flow locus. The focused ultrasound heats and coagulates blood in the severed vessel to stem the bleeding. Heat dissipation is reduced by tracking and continuously heating the same bolus of blood as it flows, or by heating a significant length of the blood vessel.",KONINKL PHILIPS ELECTRONICS NV;;ROUTH HELEN;;FRASER JOHN;;PETRUZZELLO JOHN;;AYATI SHERVIN,ROUTH HELEN;;FRASER JOHN;;PETRUZZELLO JOHN;;AYATI SHERVIN,,https://lens.org/191-892-021-898-327,Search Report,yes,8,0,6,6,0,A61B8/06;;A61B8/4227;;A61B8/4281;;A61B8/4483;;A61N7/02;;A61N2007/0065;;A61N2007/0078;;A61N2007/0095;;A61N2007/027;;A61B8/4227;;A61B8/06;;A61N2007/027;;A61N2007/0078;;A61N2007/0065;;A61N2007/0095;;A61B8/4281;;A61B8/4483;;A61N7/02,A61B8/14;;A61B8/00,,0,0,,,,PENDING
850,US,A,US 4149792 A,013-313-273-063-47X,1979-04-17,1979,US 86585477 A,1977-12-30,US 86585477 A,1977-12-30,Misfocus prevention means for cameras having unidirectional automatic focusing,A variable focus lens capable of being moved within and outside of its normal focusing range by a manual and an automatic focus control system is provided with spring force biasing means to urge said lens into its normal focusing range to avoid the possibility of said lens being misfocused by said automatic focus control system.,POLAROID CORP,FRASER RICHARD J;;OSTROWSKI JOHN C,,https://lens.org/013-313-273-063-47X,Granted Patent,yes,8,13,16,16,0,G02B7/40;;G02B7/40,G03B19/02;;G02B7/09;;G02B7/28;;G02B7/40;;G03B13/36,354/195,0,0,,,,EXPIRED
851,EP,A1,EP 2150469 A1,020-971-602-747-484,2010-02-10,2010,EP 08737174 A,2008-05-06,GB 2008001567 W;;GB 0708626 A,2007-05-04,CLOSURE FOR A CONTAINER,,THREADLESS CLOSURES LTD,FRASER ANTHONY HENRY JOSEPH;;HEIN JOHN,,https://lens.org/020-971-602-747-484,Patent Application,yes,0,0,4,4,0,B65D41/08;;B65D41/08;;B65D2401/15;;B65D2401/15,B65D41/08,,1,0,,,See references of WO 2008135761A1,DISCONTINUED
852,AU,B2,AU 2011/260035 B2,022-968-907-582-92X,2016-03-03,2016,AU 2011/260035 A,2011-06-03,GB 201011800 A;;GB 201009429 A;;GB 2011000846 W,2010-06-04,Closure for a container,"A closure for a container ( 1 ) having a circular opening defining an axis (A), the closure being securable to the container so as to close said opening, the closure having an o-ring sealing member (5) mounted thereon so as to provide a seal with a sealing surface (IB) of the container, when the closure is secured to the container, the sealing surface extending around an upper surface or an internal surface of the container. The closure may comprise a bore feature (4) which, in use, extends through the opening into the interior of the container and the o-ring seal (5) may be provided on the bore feature. Various forms of closure are described, eg for closing a bottle neck and a wide-mouth closure. The closure may comprise an inner component (3) and an outer component (2), eg cap - on - collar closure, and the container preferably has no thread features on the exterior thereof so it is comfortable to drink from.",THREADLESS CLOSURES LTD,FRASER ANTHONY HENRY JOSEPH;;HEIN JOHN,,https://lens.org/022-968-907-582-92X,Granted Patent,no,13,0,17,39,0,B65D41/04;;B65D41/0442;;B65D41/0442;;B65D41/00;;B65D41/08;;B65D41/08;;B65D41/08;;B65D41/086;;B65D41/086;;B65D41/62;;B65D53/02;;B65D53/02;;B65D53/02;;B65D2543/00564;;B65D2543/00564;;B65D2543/00972;;B65D2543/00972,B65D41/04;;B65D41/08;;B65D53/02,,0,0,,,,INACTIVE
853,US,A1,US 2007/0036768 A1,033-884-837-716-929,2007-02-15,2007,US 58420206 A,2006-10-20,US 58420206 A;;US 31612702 A;;US 33885601 P,2001-12-07,Systems and methods for treating patients with processed lipoaspirate cells,Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient.,FRASER JOHN K;;HEDRICK MARC H,FRASER JOHN K;;HEDRICK MARC H,LOREM VASCULAR PTE. LTD (2019-04-24),https://lens.org/033-884-837-716-929,Patent Application,yes,44,101,65,221,0,A61K35/28;;A61K35/28;;A61K48/00;;A61B10/0283;;A61B10/0283;;A61K9/0019;;A61K9/0019;;A61K35/32;;A61K35/35;;A61K35/35;;A61K35/36;;A61M1/76;;A61M2202/08;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/00;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;A61P43/00;;C12M47/04;;C12N5/0667;;C12N5/0667;;C12N5/069;;C12N5/069;;C12N2506/1384;;C12N2506/1384,A61K35/12;;A61M1/00;;A61K31/436;;A61K35/02;;A61K35/28;;A61K35/35;;A61K35/36;;A61K38/00;;A61K38/16;;A61K45/00;;A61L27/00;;A61P1/00;;A61P1/16;;A61P3/00;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P19/00;;A61P19/02;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;C12M3/00;;C12M3/06;;C12N5/0775,424/93.7;;435/366;;435/289.1;;604/500,0,0,,,,EXPIRED
854,US,B2,US 7901672 B2,026-884-110-789-226,2011-03-08,2011,US 88635310 A,2010-09-20,US 88635310 A;;US 61464803 A;;US 31612702 A;;US 33885601 P,2001-12-07,"Methods of making enhanced, autologous fat grafts",Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient.,CYTORI THERAPEUTICS INC,FRASER JOHN K;;HEDRICK MARC H,LOREM VASCULAR PTE. LTD (2019-04-24),https://lens.org/026-884-110-789-226,Granted Patent,yes,7,84,65,221,0,A61K35/28;;A61K35/28;;A61K48/00;;A61B10/0283;;A61B10/0283;;A61K9/0019;;A61K9/0019;;A61K35/32;;A61K35/35;;A61K35/35;;A61K35/36;;A61M1/76;;A61M2202/08;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/00;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;A61P43/00;;C12M47/04;;C12N5/0667;;C12N5/0667;;C12N5/069;;C12N5/069;;C12N2506/1384;;C12N2506/1384,A61M1/00;;C12N5/00;;A01N63/00;;A61K31/436;;A61K35/02;;A61K35/12;;A61K35/28;;A61K35/35;;A61K35/36;;A61K38/00;;A61K38/16;;A61K45/00;;A61L27/00;;A61P1/00;;A61P1/16;;A61P3/00;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P19/00;;A61P19/02;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;C12M3/06;;C12N5/0775,424/93.7;;435/366;;435/325;;606/1;;606/131;;604/19;;604/22,1,1,048-726-894-033-877,12031117;;10.1089/107632702753725049,"Patrick et al. ""Long-term implantation of preadipocyte-seeded PLGA scaffolds."" Tissue Eng. 8(2):283-93 (2002).",EXPIRED
855,CA,A1,CA 2186766 A1,026-578-880-521-239,1995-10-12,1995,CA 2186766 A,1995-03-31,GB 9406486 A;;GB 9500734 W,1994-03-31,REMOVABLE VERTICAL FALL ARREST DEVICE,"A vertical fall arrest device is disclosed which combines in a single unit the means to arrest a fall, the capability to automatically traverse intermediate support means provided along a safety line, and ease of attachment to or detachment from the safety line at any point throughout its length. In the attached condition, in which a safety line (30) is captured in retaining recess (60), the device is always in a ready state to lock-on to the safety line in the event of a fall. The device is removed from the safety line by depressing release catch (44) against spring pressure and at the same time pulling wheel (42) in a direction away from body member (41). Movement of the wheel must also be effected against biasing pressure. This combined operation creates an opening for withdrawal of safety line (30). When the external forces are relaxed, internal springs (47a and 47b) ensure that both the wheel (42) and the release catch (44) return to their fully locked conditions.",LATCHWAYS LTD,ATKINSON GEOFFREY FRASER;;PATTERSON DAVID JOHN,,https://lens.org/026-578-880-521-239,Patent Application,no,0,0,12,12,0,A62B35/005;;A62B35/0087;;E06C7/18;;E06C7/186;;A62B35/0087;;A62B35/005;;E06C7/18;;E06C7/186,E06C9/14;;A62B1/14;;A62B35/00;;A62B35/04;;E06C7/18,,0,0,,,,EXPIRED
856,US,B2,US 8182511 B2,055-662-793-347-58X,2012-05-22,2012,US 68884810 A,2010-01-15,US 68884810 A;;US 35093609 A;;US 83264307 A;;US 83264607 A;;US 1962208 P;;US 9845608 P;;US 10486208 P;;US 12250608 P;;US 13803108 P;;US 88702207 P,2007-01-29,Craniospinal fusion method and apparatus,A spinal stabilization system that may be used to fix craniocervical junction. The system includes a cranial spinal attachment system that anchors one or more surgical instruments to a cranial surface using at least one cranial clamp and cranial fastener. The cranial spinal attachment system may be positioned along a perimeter of a cranial defect.,HENDERSON FRASER CUMMINS;;NEWMAN JOHN W;;POLARIS BIOTECHNOLOGY INC,HENDERSON FRASER CUMMINS;;NEWMAN JOHN W,POLARIS BIOTECHNOLOGY INC (2010-03-23);;LIFE SPINE INC (2014-09-24),https://lens.org/055-662-793-347-58X,Granted Patent,yes,105,4,4,27,0,A61B17/7011;;A61B17/7043;;A61B17/7044;;A61B17/7049;;A61B17/7052;;A61B17/7055;;A61B17/8061;;A61B17/7055;;A61B17/7052;;A61B17/7011;;A61B17/7049;;A61B17/7044;;A61B17/8061;;A61B17/7043,A61B17/70,606/246;;606/279;;623/17.19,94,90,161-967-379-592-424;;064-961-096-382-140;;025-129-192-071-684;;043-198-740-690-42X;;088-734-006-345-882;;007-966-469-765-837;;039-649-698-711-594;;101-748-145-810-496;;040-014-464-996-263;;022-863-083-303-762;;029-617-806-992-735;;013-523-154-430-463;;128-684-301-596-103;;094-449-008-946-344;;017-573-684-325-696;;046-767-629-817-484;;043-908-717-677-116;;063-950-537-045-263;;029-276-377-046-51X;;077-922-212-784-586;;076-382-054-205-508;;104-688-625-312-979;;001-011-237-647-268;;062-516-251-291-954;;075-209-944-982-485;;048-820-390-374-660;;011-413-665-818-996;;081-895-495-945-67X;;027-129-383-756-144;;030-467-413-752-508;;001-295-323-124-532;;035-750-137-625-101;;019-600-928-503-596;;072-254-793-619-737;;125-003-130-232-501;;085-615-660-336-47X;;038-184-885-142-418;;047-657-310-710-385;;073-700-598-417-439;;003-091-678-382-467;;006-779-111-684-557;;086-443-222-192-080;;050-550-902-973-574;;055-958-696-928-887;;135-058-861-995-343;;136-067-697-112-553;;023-147-592-549-452;;074-611-322-144-195;;040-263-466-037-282;;039-543-792-519-560;;100-395-282-383-024;;124-315-048-566-461;;096-562-248-680-263;;011-506-337-513-408;;058-544-875-340-471;;032-026-262-703-459;;066-629-021-636-984;;159-484-554-916-425;;013-665-423-408-023;;089-108-195-654-622;;022-878-261-499-22X;;015-362-829-154-988;;001-158-263-173-824;;058-107-204-029-425;;082-036-584-986-749;;010-852-616-837-902;;059-765-557-905-401;;053-925-680-701-000;;031-246-060-983-243;;022-633-504-719-923;;070-026-045-321-495;;090-792-868-576-34X;;126-299-114-397-113;;043-938-389-072-632;;043-272-767-469-816;;053-205-864-333-032;;038-227-892-072-048;;008-294-030-163-458;;067-011-505-873-929;;021-467-677-718-315;;035-206-517-188-733;;031-312-506-617-225;;000-186-482-604-016;;014-301-476-970-617;;006-037-018-652-689;;068-910-158-258-010;;096-315-283-501-795;;096-594-686-766-151;;106-953-475-365-262;;101-805-057-542-688,10.1097/00007632-199809150-00006;;10.1007/bf02172225;;8050980;;10.3171/jns.1982.57.1.0032;;7086498;;10.1016/j.humov.2004.08.019;;15541530;;1341941;;8683606;;10.1089/neu.1995.12.555;;10372899;;10.1016/s0387-7604(99)00009-1;;17110689;;pmc2802715;;10.1097/00007632-200207150-00003;;12131706;;10.1093/milmed/160.2.94;;7783927;;10.1017/s0954579402003085;;12349873;;10102725;;10.1111/1469-7610.00423;;10.1017/s0021963098003291;;9183141;;10.1097/00004583-199706000-00023;;14913631;;10.1136/jnnp.21.3.216;;pmc497322;;13576174;;10.1002/(sici)1097-4547(19971201)50:5<798::aid-jnr16>3.3.co;2-#;;10.1002/(sici)1097-4547(19971201)50:5<798::aid-jnr16>3.0.co;2-y;;9418967;;10.1148/66.2.259;;13297990;;7520459;;10.1007/bf02167898;;11086556;;10.1177/070674370004500806;;12543815;;10.1136/bmj.326.7382.173;;pmc1125046;;10.1097/00007632-199410000-00008;;7809750;;660249;;10.3171/jns.1978.48.6.0975;;9500320;;10.1016/s0140-6736(97)11096-0;;10.1007/978-1-4899-0792-9_7;;11245677;;10.1523/jneurosci.21-06-01923.2001;;pmc6762603;;16616445;;10.1016/j.braindev.2006.02.006;;10.1136/jnnp.39.4.381;;pmc492289;;932754;;11408325;;10.1093/brain/124.7.1299;;10.3171/spi.2004.1.3.0281;;15478366;;15478375;;10.4135/9781412961165.n51;;16247236;;10.2176/nmc.45.512;;10069589;;10.1097/00006123-199903000-00053;;10.1097/00006123-199903000-00050;;15835107;;10.3171/ped.2004.101.2.0189;;10.1136/jnnp.62.4.334;;9120444;;pmc1074087;;10.1136/jnnp.36.5.879;;pmc494486;;4753885;;10.1186/1471-2431-7-36;;18005455;;pmc2244616;;8207526;;10.3171/jns.1994.81.1.0043;;pmc460068;;10.1136/thx.40.5.364;;4023990;;16365484;;10.1177/230949900501300303;;10.1097/00007632-199103001-00005;;12590220;;10.1097/01.brs.0000048460.58471.db;;10.1097/00007632-200302150-00019;;10.1159/000056057;;12006755;;3993694;;3158201;;15371512;;10.1523/jneurosci.1362-04.2004;;pmc6729801;;10.1115/1.1324667;;11192383;;8669719;;10.1007/bf02770996;;5521533;;10.1016/0021-9290(70)90046-1;;9171173;;10.3171/jns.1997.86.6.0950;;9075019;;10.1177/088307389701200206;;348703;;10.2106/00004623-197860030-00001;;8420126;;8993707;;10.1111/1469-7610.00022;;11944873;;10.1097/00006123-199510000-00012;;10.1227/00006123-199510000-00012;;8559297;;10.1038/nm0197-73;;8986744;;11463182;;10.1017/s0012162201000901;;9696080;;10.1097/00006123-199808000-00056;;10.1227/00006123-198811000-00008;;3200390;;9647166;;10.3171/jns.1998.89.1.0008;;7052810;;10.1007/bf01531513;;10473304;;10.1017/s0033291799008508;;10.1001/jama.289.1.87;;12503982;;12610643;;10.1038/sj.mp.4001266;;3167146;;10.1016/0006-3223(88)90168-0;;8445893;;10.1115/1.2895464;;10.1016/s0002-9610(39)90309-0;;10.1046/j.1365-2990.2000.026002105.x;;10840273;;1621145;;10.1097/00007632-199205000-00003;;10.1227/00006123-200107000-00010;;11440461;;10.1097/00006123-200107000-00010;;10.1097/00007632-200111150-00014;;11707712;;10.1046/j.1469-7580.2001.19930339.x;;pmc1468336;;11554511;;8239756;;pmc1005138;;10.1136/ard.52.9.629;;10.1227/01.neu.0000157929.85251.7c;;15854260;;11074673;;10.1097/00007632-200011150-00007;;10.1227/00006123-198403000-00010;;6709158;;10.1097/01.brs.0000113874.82587.33;;15129062;;10.1177/1362361397012003;;11284555;;10.1089/08977150151071053;;14563145;;10.3171/spi.2003.99.3.0278;;10.1097/00007632-200207010-00009;;12131739;;10.1523/jneurosci.0515-03.2004;;pmc6729402;;15140932;;9840768;;10.1089/neu.1998.15.955;;10.1017/s0012162201000627;;10.1111/j.1469-8749.2001.tb00214.x;;11368487;;7623948;;10.2176/nmc.35.285;;9419028;;10.1159/000121176;;12454433;;10.1007/978-3-7091-8882-8_59;;10.1089/08977150360547071;;12675969;;3193195;;10.3171/jns.1988.69.6.0895;;10.1097/00006123-199905000-00042;;10232534,"Naderi, Sait, et al., ""Biomechanical Comparison of C1-C2 Posterior Fixations: Cable, Graft, and Screw Combinations"", Spine, 1998; 23(18): 1946-1955.;;Osterling, Julie, et al., ""Early Recognition of Children with Autism: A Study of First Birthday Home Videotapes"", J Autism Dev Disorders, 1994: 24(3): 247-257.;;Pang, Dachling, et al., ""Tethered cord syndrome in adults"", J Neurosurg, 1982. 57(1): 32-47.;;Piek, Jan P., et al., ""Sensory-motor deficits in children with developmental coordination disorder, attention deficit hyperactivity disorder and autistic disorder"", Hum Move Science, 2004. 23: 475-488.;;Povlishock, John T., ""Traumatically Induced Axonal Injury: Pathogenesis and Pathobiological Implications"", Brain Pathology, 1992. 2(1): 1-12.;;Povlishock, John T., et al., ""The Pathobiology of Traumatically Induced Axonal Injury in Animals and Humans: A Review of Current Thoughts"", J Neurotrama, 1995. 12(4): 555-564.;;Rapin, Isabelle, ""Appropriate investigations for clinical care versus research in children with autism"", Brain & Develop, 1999. 21: 152-156.;;Reich, D.S., et al., ""Quantitative Characterization of the Corticospinal Tract at 3T"", Am J Neuroradiol, 2006. 27: 2168-2178.;;Resnick, Daniel K., et al., ""Anatomic Suitability of the C1-C2 Complex for Pedicle Screw Fixation"", Spine, 2002. 27 (14): 1494-1498.;;Riggs, Jack E., et al., ""Spastic Quadriparesis, Dysarthria, and Dysphagia following Cervical Hyperextension: A Traumatic Pontomedullary Syndrome"", Military Medicine, 1995. 160(2): 94-95.;;Rodier, Patricia M., ""Converging evidence for brain stem injury on autism"", Develop and Psychopath, 2002. 14: 537-557.;;Rutter, Michael, et al., ""Genetics and Child Psychiatry: II Empirical Research Findings"", J Child Psychol Psychiatry, 1999. 40(1): 19-55.;;Scahill, Lawrence, et al., ""Children's Yale-Brown Obsessive Compulsive Scale: Reliability and Validity"", J Am Acad Child Adol Psychiatry, 1997. 36(6): 844-852.;;Scoville, W. B., et al., ""The Cervical Ruptured Disc; Report of 115 Operative Cases"", Trans Am Neurol Assoc, 1951. 56: 222-224.;;Schneider, Richard C., et al., ""The Syndrome of Acute Central Cervical Spinal Cord Injury"", J Neurol Neurosurg Psychiatry, 1958. 21: 216-227.;;Shuman, Sheri L., et al., ""Apoptosis of Microglia and Ogliodendrocytes After Spinal Cord Contusion in Rats"", J Neurosci Research, 1997. 50: 798-808.;;Smith, C. G., ""Changes in Length and Position of the Segments of the Spinal Cord with Changes in Posture in the Monkey"", Radiology, 1956. 66(2): 259-265.;;Stein, Mark A., et al., ""Psychometric Properties of the Children's Atypical Development Scale"", J Abnorm Child Psych, 1994. 22(2): 167-176.;;Szatmari, Peter, ""The Classification of Autism, Asperger's Syndrome, and Persuasive Developmental Disorder"", Can J Psychiatry, 2000. 45(8): 731-738.;;Szatmari, Peter, ""The causes of autism spectrum disorders"", BMJ, 2003. 326: 173-174.;;Tachibana, Shigekuni, et al., ""Spinal Cord Intramedullary Pressure. A Possible Factor in Syrinx Growth"", Spine, 1994. 19(19): 2174-2179.;;Tunturi, Archie R., ""Elasticity of the spinal cord, pia, and denticulate ligament in the dog"", J Neurosurg, 1978. 48: 975-979.;;Wakefield, A J, et al., ""Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children"", The Lancet, 1998. 351: 637-641.;;Wing, Lorna, ""Chapter 7-The Continuum of Autistic Characteristics"", Diagnosis and Assessment in Autism, 1993. 91-110.;;Wolf, John A., et al., ""Traumatic Axonal Injury Induces Calcium Influx Modulated by Tetrodotoxin-Sensitive Sodium Channels"", J Neurosci, 2001. 21(6): 1923-1930.;;Zeegers, Mijke, et al., ""Radiological findings in autistic and developmentally delayed children"", Brain & Develop, 2006. 28: 495-499.;;Corbett, J. J., et al., ""'Sneeze syncope,' basilar invagination and Arnold-Chiari type 1 malformation"", J Neurol, Neurosurg, and Psych, 1976; 39: 381-384.;;Geddes, J. F., et al., ""Neuropathology of inflicted head injury in children. II: Microscopic brain injury in infants"", Brain, 2001: 124: 1299-1306.;;Goel, Atul, ""Treatment of basilar invaginations by atlantoaxial joint distraction and direct lateral mass fixation"", J Neurosurg, 2004. 3: 281-286.;;Goel, Atul, et al., ""Craniovertebral Junction Realignment for the Treatment of Basilar Invagination With Syringomyelia: Preliminary Report of 12 Cases"", Neurol Med Chir, 2005. 45: 512-518.;;Grabb, Paul A., et al., ""Ventral Brain Stem Compression in Pediatric and Young Adult Patients with Chiari 1 Malformations"", Neurosurgery, 1999. 44(3): 520-528.;;Kim, Louis J., et al., ""Treatment of basilar invagination associated with Chiari 1 malformations in the pediatric population: cervical reduction and posterior occipitocervical fusion"", J Neurosurg, 2004. 101: 189-195.;;Levine, David N., ""Pathogenesis of cervical spondylotic myelopathy"", J Neurol, Neurosrug, and Psych, 1997. 62: 334-340.;;Phillips, Douglas G., ""Surgical treatment of myelopathy with cervical spondylosis"", J Neurol, Neurosrug, and Psych, 1973. 36: 879-884.;;Rossignol, Daniel A., et al., ""The effects on hyperbaric oxygen therapy on oxidative stress, inflammation, and symptoms in children with autism: an open-label pilot study"", BMC Pediatrics, 2007. 7: 36.;;Ryken, Timothy C., et al., ""Cervicomedullary compression in achondroplasia"", J Neurosurg, 1994. 81: 43-48.;;Stradling, J R, et al., ""Changes in ventilation and its components in normal subjects during sleep"", Thorax, 1985. 40: 364-370.;;Tassanwipas, A, et al., ""Magnetic resonance imaging study of the craniocervial junction"", J Ortho Surg, 2005. 13(3): 228-231.;;Grob, D., et al., ""Posterior Occipitocervical Fusion a Preliminary Report of a New Technique,"" Spine, vol. 16, No. 3 Supplement, Jan. 1, 1991, pp. S17-S24.;;Sandhu, Faheem A., MD, PhD, et al., ""Occipitocervical Fusion for Rheumatoid Arthritis Using the Inside-Outside Stabilzation Technique,"" SPINE, 2003, pp. 414-419, vol. 28, No. 4.;;Kumar, Raj et al., ""Management of Pediatric Congenital Atlantoaxial Dislocation: A Report of 23 Cases from Northern India,"" Pediatric Neurosurgery, 2002, pp. 197-208, vol. 36.;;Co-Pending U.S. Appl. No. 12/638,930, filed Dec. 15, 2009.;;Aman, Michael G., et al., ""The Aberrant Behavior Checklist: A Behavior Rating Scale for the Assessment of Treatment Effects"", Am J Ment Defic, 1985: 89(5): 485-491.;;Aman, Michael G., et al., ""Psychometric Characteristics of the Aberrant Behavior Checklist"", Am J Ment Defic, 1985: 89(5): 492-502.;;Arundine, Mark, et al., ""Vulnerability of Central Neurons to Secondary Insults after in Vitro Mechanical Stretch"", J Neurosci, 2004. 24(37): 8106-8123.;;Bain, Allison C., et al., ""Tissue-Level Thresholds for Axonal Damage in an Experimental Model of Central Nervous System White Matter Injury"", J Biomech Eng, 2000. 122: 615-622.;;Bilston, Lynne E., et al., ""The Mechanical Properties of the Human Cervical Spinal Cord In Vitro"", Ann Biomed Eng, 1996. 24: 67-74.;;Breig, A., ""Overstretching of and Circumscribed Pathological Tension in the Spinal Cord-A Basic Cause of Symptoms in Cord Disorders"", J Biomech, 1970. 3: 7-9.;;Sawin, Paul D., et al., ""Basilar invagination in osteogenesis imperfecta and related osteochondrodysplasias: medical and surgical management"", J Neurosurg, 1997. 86: 950-960.;;Brill, Charles B., et al., ""Chiari I Malformation: Association With Seizures and Developmental Disabilities"", J Child Neurog, 1997. 12(2): 101-106.;;Brooks, Arthur L., et al., ""Atlanto-axial arthrodesis by the wedge compression method"", J Bone Joint Surg Am, 1978. 60(3): 279-284.;;Bunge, Richard P., et al., ""Observations on the Pathology of Human Spinal Cord Injury. A Review and Classification of 22 New Cases with Details from a Case of Chronic Cord Compression with Extensive Focal Demyelination"", Adv Neurol, 1993. 59: 75-89.;;Bunge, Richard P., et al., ""Observations on the Pathology of Several Types of Human Spinal Cord Injury, with Emphasis on the Astrocyte Response to Penetrating Injuries"", Adv Neurol, 1997. 72: 305-315.;;Charman, Tony, et al., ""Practitioner Review: Diagnosis of autism spectrum disorder in 2- and 3-year-old children"", J Child Psychol Psychiatry, 2002. 43(3): 289-305.;;Coyne, Terry J., et al., ""C1-C2 Posterior Cervical Fusion: Long-term Evaluation of Results and Efficacy"", Neurosurgery, 1995. 37(4): 688-693.;;Crowe, Maria J., et al., ""Apoptosis and delayed degeneration after spinal cord injury in rats and monkeys"", Nat Med, 1997. 3(1): 73-76.;;Cushing, K E, et al., ""Tethering of the vertebral artery in the congenital arcuate foramen of the atlas vertebra: a possible cause of vertebral artery dissection in children"", Dev Med Child Neurol, 2001. 43(7): 491-496.;;Dickman, Curtis A., et al., ""Posterior C1-C2 Transarticular Screw Fixation for Atlantoaxial Arthrodesis"", Neurosurgery, 1998. 43(2): 275-280.;;Dyste, Gregg N., et al., ""Presentation and Management of Pediatric Chiari Malformations without Myelodysplasia"", Neurosurgery, 1988. 23(5): 589-597.;;Eleraky, Mohammed Aly, et al., ""Posterior atlantoaxial facet screw fixation in rheumatoid arthritis"", J Neurosurg, 1998. 89: 8-12.;;Fein, Deborah, et al., ""Clinical Correlates of Brainstem Dysfunction in Autistic Children"", J Autism and Dev Disorders, 1981. 11(3): 303-315.;;Fombonne, Eric, ""The epidemiology of autism: a review"", Psych Med, 1999. 29: 769-786.;;Fombonne, Eric, ""The Prevalence of Autism"", JAMA, 2003. 289(1): 87-89.;;Fombonne, Eric, et al., ""MMR and autistic enterocolitis: consistent epidemiological failure to find an association"", Mol Psychiatry, 2003. 8: 133-134.;;Gaffney, Gary R., et al., ""Morphological Evidence for Brainstem Involvement in Infantile Autism"", Biol Psychiatry, 1988. 24: 578-586.;;Galbraith, J. A., et al., ""Mechanical and Electrical Responses of the Squid Giant Axon to Simple Elongation"", J Biomech Eng, 1993. 115: 13-22.;;Gallie, W. E., ""Fractures and Dislocations of the Cervical Spine"", Am J Surg, 1939. 46: 495-499.;;Geddes, J. F., et al., ""Traumatic axonal injury: practical issues for diagnosis in medicolegal cases"", Neuorpath Appl Neurobio, 2000. 26: 105-116.;;Grob, Dieter, et al., ""Biomechanical Evaluation of Four Different Posterior Atlantoaxial Fixation Techniques"", Spine, 1992. 17(5): 480-490.;;Haid, Jr., Regis W., et al., ""C1-C2 Transarticular Screw Fixation for Atlantoaxial Instability: A 6-year Experience"", Neurosurgery, 2001. 49(1): 65-70.;;Harms, Jurgen, et al., ""Posterior C1-C2 Fusion With Polyaxial Screw and Rod Fixation"", Spine, 2001. 26(22): 2467-2471.;;Hasan, Mandi, et al., ""Posterolateral tunnels and ponticuli in human atlas vertebrae"", J Anat, 2001. 199(3): 339-343.;;Henderson, Fraser C., et al., ""Neuropathology of the brainstem and spinal cord in end stage rheumatoid arthritis: implications for treatment."", Ann Rheum Dis, 1993. 52(9): 629-637.;;Henderson, Fraser C., et al., ""Stretch-Associated Injury in Cervical Spondylotic Myelopathy: New Concept and Review"", Neurosurgery, 2005. 56(5): 1101-1113.;;Henriques, Thomas, et al., ""Biomechanical Comparison of Five Different Atlantoaxial Posterior Fixation Techniques"", Spine, 2000. 25(22): 2877-2883.;;Holness, Renn O., et al., ""Posterior Stabilization with an Interlaminar Clamp in Cervical Injuries: Technical Note and Review of the Long Term Experience with the Method"", Neurosurgery, 1984. 14(3): 318-322.;;Hong, Xia, et al., ""Posterior Screw Placement on the Lateral Mass of Atlas: An Anatomic Study"", Spine, 2004. 29(5): 500-503.;;Howlin, Patricia, et al., ""Diagnosis in Autism: A Survey of Over 1200 Patients in the UK"", autism, 1997. 1(2): 135-162.;;Ichihara, Kazuhiko, et al., ""Gray Matter of the Bovine Cervical Spinal Cord is Mechanically More Rigid and Fragile than the White Matter"", J Neurotrama, 2001. 18(3): 361-367.;;Ichihara, Kazuhiko, et al., ""Mechanism of the spinal cord injury and the cervical spondylotic myelopathy: new approach based on the mechanical features of the spinal cord white and gray matter"", J Neurosurg: Spine, 2003. 99: 278-285.;;Iwasaki, Motoki, et al., ""Cervical Kyphosis: Predictive Factors for Progression of Kyphosis and Myelopathy"", Spine, 2002. 27(13): 1419-1425.;;Iwata, Akira, et al., ""Traumatic Axonal Injury Induces Proteolytic Cleavage of the Voltage-Gated Sodium Channels Modulated by Tetrodotoxin and Protease Inhibitors"", J Neuroscience, 2004. 24(19): 4605-4613.;;Jafari, Saeed S., et al., ""Axonal Cytoskeletal Changes After Nondisruptive Axonal Inury. II. Intermediate Sized Axons"", J Neurotrama, 1998. 15(11): 955-966.;;Johansson, Maria, et al., ""Autistic spectrum disorders in Mobius sequence: a comprehensive study of 25 individuals"", Dev Med Child Neurology, 2001. 43: 338-345.;;Kitahara, Yukio, et al., ""Effect of Spinal Cord Stretching due to Head Flexion on Intramedullary Pressure"", Neurol Med Chir (Tokyo), 1995. 35: 285-288.;;Kocak, Ayhan, et al., ""A New Model for Tethered Cord Syndrome: A Biochemical, Electrophysiological, and Electron Microscopic Study"", Pediatr Neurosurg, 1997. 26(3): 120-126.;;Le Couteur, Ann, et al., ""National Autism Plan for Children (NAPC)"", National Initiative for Autism: Screening and Assessment (NIASA), 2003.;;Lusardi, Theresa A., et al., ""The separate roles of calcium and mechanical forces in mediating cell death in mechanically injured neurons"", Biorheology, 2003. 40: 401-409.;;Magerl, F., et al., ""Stable Posterior Fusion of the Atlas and Axis by Transarticular Screw Fixation"", Cervical Spine, 1987. 1: 322-327.;;Maxwell, William L., et al., ""Post-Acute Alterations in the Axonal Cytoskeleton after Traumatic Axonal Injury"", J Neurotrama, 2003. 20(2): 151-168.;;Menezes, Arnold H., et al., ""Transoral-transpharyngeal approach to the anterior craniocervical junction. Ten-year experience with 72 patients."", J Neurosurg, 1988. 69: 895-903.;;Milhorat, Thomas H., et al., ""Chiari I Malformation Redefined: Clinical and Radiographic Findings for 364 Symptomatic Patients"", Neurosurgery, 1999. 44(5): 1005-1017.;;International Search Report and Written Opinion for International Application No. PCT/US2011/021351 dated Sep. 21, 2011.;;Co-pending U.S. Appl. No. 13/163,650, filed Jun. 17, 2011.",ACTIVE
857,EP,A1,EP 2991912 A1,071-255-947-100-419,2016-03-09,2016,EP 14719849 A,2014-04-29,GB 201307767 A;;GB 201312536 A;;GB 201400221 A;;GB 201402642 A;;GB 201407157 A;;GB 2014051322 W,2013-04-30,A CLOSURE FOR A CONTAINER,,THREADLESS CLOSURES LTD,FRASER ANTHONY HENRY JOSEPH;;HEIN JOHN,,https://lens.org/071-255-947-100-419,Patent Application,yes,0,0,5,10,0,B65D41/086;;B65D41/165;;B65D41/0421;;B65D41/0428;;B65D41/165;;B65D43/0204;;B65D41/165;;B65D41/086;;A47G19/2205;;B65D45/322;;B65D85/72,B65D41/08;;B65D41/16,,0,0,,,,DISCONTINUED
858,DE,A1,DE 2519383 A1,073-271-378-092-115,1975-11-20,1975,DE 2519383 A,1975-04-30,CA 199202 A,1974-05-07,VERFAHREN ZUR HERSTELLUNG VON ALKALIMETALLAMIDEN,,CA ATOMIC ENERGY LTD,PRESCOTT JOHN FRASER;;SANFORD EMERSON CECIL,,https://lens.org/073-271-378-092-115,Patent Application,no,0,1,17,18,0,B01J31/4015;;B01J31/0252;;C01B21/082;;C01B21/0926;;Y02P20/584,C01B4/00;;B01J31/40;;B01J38/00;;C01B21/082;;C01B21/092;;C07F1/00,,0,0,,,,EXPIRED
859,KR,A,KR 20180034527 A,101-800-204-054-033,2018-04-04,2018,KR 20187005230 A,2016-07-21,GB 2015052154 W;;GB 201518819 A;;GB 201522544 A;;GB 201601501 A;;GB 2016052215 W,2015-07-24,용기 및 마개,"금속 마개를 구비하는 플라스틱 또는 금속의 주둥이가 큰 용기(10)에 있어서, 용기는 축을 정의하는 개구 및 용기의 외부 표면 주위에 외측으로 돌출된 제1 부재를 구비하고, 제1 부재는 복수 개의 원주방향으로 이격 배치된 제1 부분들을 포함하고, 각각의 제1 부분은 길쭉한 상부 및 하부 표면들을 구비하는 요소를 구비하고, 상기 상부 및 하부 표면들은 원주방향으로 실질적으로 수평한다. 금속 마개는 상부 부재 및 스커트 부재를 구비하고, 스커트 부재는 내부 표면 주위에서 내측으로 돌출된 제2 부재를 포함하고, 제2 부재는 복수 개의 원주방향으로 이격 배치된 제2 부분들을 포함하고, 각각의 제2 부분은 길쭉한 상부 및 하부 표면들을 구비하는 요소를 구비하고, 상기 상부 및 하부 표면들은 원주방향으로 실질적으로 수평한다. 제2 부분들의 수평 요소들은 제1 부분들 사이의 공간을 통과할 수 있는 길이로 되고 제1 부분들 아래에 위치 가능하여 용기에 금속 마개를 고정할 수 있다. 마개는 용기의 씰링 표면과 시일(seal)을 제공하기 위한 씰링 부재(23)를 구비하고, 씰링 표면(13)은 용기의 넥 부분의 내부 또는 외부에 대하여 실질적으로 수직인 표면이고, 마개 상의 제2 부분들은 일단에서 상방으로 경사진 단부 및 타단에서 하방으로 경사진 단부를 구비하고, 그것들은 각각 상기 길쭉한 상부 및 하부 표면들을 지나서 연장한다. 조임 방향으로 금속 마개의 회전은 제2 부분들을 하방으로 경사진 단부들을 아래로 이동하게 하여 마개가 하방으로 이동하고 실질적으로 수평 방향으로 씰링 부재를 압축시켜 수직인 씰링 표면과 씰링 결합되게 한다. 풀림 방향으로 마개의 회전은 제2 부분들을 상방으로 경사진 단부들 위로 이동하게 하여 실드 위치로부터 고정된 배치 위치로 씰링 부재를 이동시킨다. 풀림 방향으로 추가적인 회전은 용기로부터 마개를 제거하기 위해서 요구된다.",THREADLESS CLOSURES LTD,FRASER ANTHONY HENRY JOSEPH;;HEIN JOHN,,https://lens.org/101-800-204-054-033,Patent Application,no,0,0,10,40,0,B65D41/065;;B65D41/065;;B65D43/0231;;B65D43/0231;;B65D2543/00972;;B65D2543/00972,B65D41/06;;B65D43/02,,0,0,,,,PENDING
860,CA,A1,CA 2619916 A1,094-118-233-429-283,2007-03-01,2007,CA 2619916 A,2006-08-25,GB 0517382 A;;GB 2006003186 W,2005-08-26,METHOD,,PLASTICELL LTD,CHOO YEN;;HORNBY FRASER;;GIRDLESTONE JOHN,,https://lens.org/094-118-233-429-283,Patent Application,no,0,0,16,16,0,G01N33/5008;;G01N33/5023;;G01N33/5073;;Y10T436/2525;;Y10T436/25375;;Y10T436/13;;Y10T436/2525;;Y10T436/25375;;Y10T436/13;;G01N33/5008;;G01N33/5023;;G01N33/5073,C12N5/00;;G01N33/50,,0,0,,,,ACTIVE
861,US,A1,US 2004/0097867 A1,101-440-130-780-684,2004-05-20,2004,US 61443103 A,2003-07-07,US 61443103 A;;US 31612702 A;;US 33885601 P,2001-12-07,Systems and methods for treating patients with processed lipoaspirate cells,"
   Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient. 
",FRASER JOHN K.;;HEDRICK MARC H.,FRASER JOHN K;;HEDRICK MARC H,CYTORI THERAPEUTICS INC (2005-07-11);;LOREM VASCULAR PTE. LTD (2019-04-24);;MACROPORE BIOSURGERY INC (2003-03-07),https://lens.org/101-440-130-780-684,Patent Application,yes,32,102,65,221,0,A61K35/28;;A61K35/28;;A61K48/00;;A61B10/0283;;A61B10/0283;;A61K9/0019;;A61K9/0019;;A61K35/32;;A61K35/35;;A61K35/35;;A61K35/36;;A61M1/76;;A61M2202/08;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/00;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;A61P43/00;;C12M47/04;;C12N5/0667;;C12N5/0667;;C12N5/069;;C12N5/069;;C12N2506/1384;;C12N2506/1384,A61M1/00;;A61K31/436;;A61K35/02;;A61K35/12;;A61K35/28;;A61K35/35;;A61K35/36;;A61K38/00;;A61K38/16;;A61K45/00;;A61L27/00;;A61P1/00;;A61P1/16;;A61P3/00;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P19/00;;A61P19/02;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;C12M3/06;;C12N5/0775,604/27,0,0,,,,EXPIRED
862,GB,A,GB 2545672 A,103-067-899-808-455,2017-06-28,2017,GB 201522544 A,2015-12-21,GB 201522544 A,2015-12-21,Method of forming a closure,"A closure for releasably closing a circular opening (10A, fig 3) of a container 10, the closure comprising two initially separate components: an annular skirt portion 21 to be releasably secured to a neck of the container and a closing portion 22 irreversibly secured to the skirt portion to close an opening therein. The container is intended to be filled prior to the irreversible securing. The closing portion may be irreversibly secured to the skirt portion by way of a seamed joint (22A, fig 6). The skirt portion may be releasably secured to the neck of the container by way of mutually engaging threaded portions (11A/24A, fig 3). The container may be formed of a metal or plastics material, whilst the closure may be formed of metal. The contents of the container may be a carbonated beverage. The advantage of the invention is presented as the provision of a closure which may be sealed in the conventional seaming manner, whilst also being resealable by way of separate thread portions.",THREADLESS CLOSURES LTD,ANTHONY HENRY JOSEPH FRASER;;JOHN HEIN,,https://lens.org/103-067-899-808-455,Patent Application,no,3,2,14,40,0,B65D43/0231;;B65D2543/00092;;B65D2543/0024;;B65D2543/00277;;B65D2543/00972;;B67B3/20;;B67B3/22;;B67C7/00;;B65B3/18;;B65D41/00;;B65D43/02;;B65D51/18;;B65D2251/00;;B65D43/0231;;B67B3/20;;B67B3/22;;B67C7/00;;B65D2543/00092;;B65D2543/00972;;B65D2543/00277;;B65D2543/0024;;B65D2543/00092;;B65D2543/0024;;B65D2543/00277;;B65D2543/00972;;B67B3/20;;B67C7/00;;B65D43/0231;;B67B3/22;;B65D43/0283;;B67C3/02,B65D41/00;;B65B3/18;;B65D43/02;;B65D51/18,,0,0,,,,DISCONTINUED
863,ES,T3,ES 2927609 T3,116-604-050-992-778,2022-11-08,2022,ES 14868882 T,2014-12-10,AU 2013/904823 A;;AU 2014/050406 W,2013-12-11,Aparato,"Un aparato para usar en la administración de un medicamento en partículas a las vías respiratorias de un sujeto biológico, el aparato que incluye una entrada que en uso está en comunicación fluida con un suministro de gas a presión positiva, una salida que en uso está en comunicación fluida con las vías respiratorias del sujeto para suministrar el gas a presión positiva al mismo y un suministro de medicamento que proporciona una dosis de medicamento en partículas para que el medicamento en partículas sea arrastrado en un flujo de gas desde la entrada hasta la salida, suministrando así el medicamento en partículas a las vías respiratorias del sujeto. (Traducción automática con Google Translate, sin valor legal)",DE MOTU CORDIS PTY LTD,FRASER JOHN FRANCIS;;GREGORY SHAUN DAVID,,https://lens.org/116-604-050-992-778,Granted Patent,no,0,0,17,17,0,A61M11/02;;A61M11/06;;A61M15/0028;;A61M15/0065;;A61M16/0048;;A61M16/0078;;A61M16/06;;A61M16/208;;A61M2202/064;;A61M2206/14;;A61M2209/06;;A61M2230/06;;A61M2230/42;;A61M16/049;;A61M15/0021;;A61M15/0031;;A61M15/0043;;A61M15/0048;;A61M15/0051;;A61M16/0084;;A61M2205/50;;A61M16/14;;A61K31/4166;;A61K31/137;;A61K9/0075;;A61K31/485;;A61K31/5517;;A61K31/7004;;A61P9/04;;A61P3/00;;A61P37/00;;A61M16/0048;;A61M16/06;;A61M16/208;;A61M2206/14;;A61M15/0031;;A61M15/0048;;A61M16/0084;;A61M2209/06;;A61M16/0078;;A61M11/02;;A61M2230/06;;A61M15/0051;;A61M15/0043;;A61M2205/50;;A61M15/0065;;A61M2230/42;;A61M11/06;;A61M15/0028;;A61M15/0021;;A61M16/049;;A61M2202/064;;A61M16/14;;A61H31/00;;A61M16/0057;;A61M16/04;;A61M16/0816;;A61M2202/0208,A61M11/02;;A61K9/00;;A61K31/137;;A61K31/4166;;A61K31/485;;A61K31/5517;;A61K31/7004;;A61M11/06;;A61M15/00;;A61M16/00;;A61M16/04;;A61M16/06;;A61M16/14;;A61M16/20;;A61P3/00;;A61P9/04;;A61P37/00,,0,0,,,,ACTIVE
864,US,A1,US 2013/0121974 A1,117-892-032-121-392,2013-05-16,2013,US 201213725814 A,2012-12-21,US 201213725814 A;;US 201113042334 A;;US 88635310 A;;US 61464803 A;;US 31612702 A;;US 33885601 P,2001-12-07,"METHODS OF MAKING ENHANCED, AUTOLOGOUS FAT GRAFTS",Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient.,CYTORI THERAPEUTICS INC;;CYTORI THERAPEUTICS INC,FRASER JOHN K;;HEDRICK MARC H,LOREM VASCULAR PTE. LTD (2019-04-24),https://lens.org/117-892-032-121-392,Patent Application,yes,0,6,65,221,0,A61K35/28;;A61K35/28;;A61K48/00;;A61B10/0283;;A61B10/0283;;A61K9/0019;;A61K9/0019;;A61K35/32;;A61K35/35;;A61K35/35;;A61K35/36;;A61M1/76;;A61M2202/08;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/00;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;A61P43/00;;C12M47/04;;C12N5/0667;;C12N5/0667;;C12N5/069;;C12N5/069;;C12N2506/1384;;C12N2506/1384,A61K35/12;;A61M1/00;;A61K31/436;;A61K35/02;;A61K35/28;;A61K35/35;;A61K35/36;;A61K38/00;;A61K38/16;;A61K45/00;;A61L27/00;;A61P1/00;;A61P1/16;;A61P3/00;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P19/00;;A61P19/02;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;C12M3/06;;C12N5/0775,424/93.7,0,0,,,,EXPIRED
865,CN,A,CN 1878470 A,143-111-207-692-217,2006-12-13,2006,CN 200480033368 A,2004-07-01,US 50358903 P,2003-09-17,Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders,"Cells present in adipose tissue are used to treat patients, including patients with PVD and related diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic benefit.",MACROPORE BIOSURGERY INC,ERIC FRASER JOHN K HEDRICK MAR,,https://lens.org/143-111-207-692-217,Patent Application,no,0,5,19,221,0,A61K35/12;;A61P9/00;;A61P9/02;;A61P9/10;;A61P9/14;;A61P43/00;;C12N5/069;;C12N5/0667,A01N63/00;;A61K35/12;;C12N5/071;;C12N5/0775,,0,0,,,,DISCONTINUED
866,US,A1,US 2019/0277113 A1,147-887-228-484-728,2019-09-12,2019,US 201916422057 A,2019-05-24,US 201916422057 A;;GB 201401490 A;;GB 201415970 A;;GB 201419993 A;;US 201615100737 A;;GB 2015050185 W,2014-01-29,METHOD FOR LAUNCHING A CLEANING ELEMENT,A deformable cleaning element is encased within soluble packaging to maintain deformation. The deformed cleaning element is launched into the bore of a drill pipe/conduit or tubular. Contact with fluids within the bore dissolves the soluble packaging allowing the cleaning element to expand to its original shape.,CORETRAX TECH LIMITED,FRASER JOHN;;BODMAN CHERISH;;FONG JASON,CORETRAX GLOBAL LIMITED (2022-04-21);;CORETRAX TECHNOLOGY LIMITED (2016-05-20),https://lens.org/147-887-228-484-728,Patent Application,yes,0,0,10,13,0,B08B9/055;;B08B9/055;;B08B9/055;;B08B9/055;;B08B9/0555;;B65D65/46;;B65D81/264;;E21B37/10;;E21B37/10;;E21B37/00;;E21B37/02;;E21B37/08;;E21B37/08;;E21B37/08;;E21B37/10;;F16L55/40;;F16L55/42;;F16L55/42;;F16L55/44;;F16L55/46;;F16L55/46;;F16L2101/12,E21B37/10;;B08B9/055;;B65D65/46;;B65D81/26;;E21B37/08;;F16L55/46,,0,0,,,,DISCONTINUED
867,FI,A,FI 832658 A,196-485-615-029-368,1984-01-25,1984,FI 832658 A,1983-07-21,GB 8221457 A,1982-07-24,"2-SUBSTITUERADE 4-AMINO-6,7-DIMETOXIKINOLINER",,PFIZER,CAMPBELL SIMON FRASER;;HARDSTONE JOHN DAVID,,https://lens.org/196-485-615-029-368,Patent Application,no,0,0,46,53,0,C07C255/00;;C07D215/42;;C07D215/48;;C07D295/195;;C07D401/04;;C07D401/12;;C07D405/12;;C07D413/12;;C07D417/12;;A61P9/12;;C07D215/20;;C07D295/195;;C07D405/12;;C07D401/04;;C07D413/12;;C07D417/12;;C07C255/00;;C07D215/42;;C07D401/12;;C07D215/48,A61K31/47;;C07D215/20;;A61K31/4709;;A61K31/495;;A61K31/50;;A61K31/505;;A61K31/53;;A61P9/12;;C07D215/42;;C07D215/48;;C07D295/195;;C07D401/04;;C07D401/12;;C07D401/14;;C07D405/12;;C07D405/14;;C07D413/12;;C07D413/14;;C07D417/12,,0,0,,,,EXPIRED
868,GB,A,GB 2482000 A,017-913-597-312-748,2012-01-18,2012,GB 201011800 A,2010-07-14,GB 201011800 A,2010-07-14,Closure having Seal and Inner and Outer Components,"A closure for a container 2 having a circular lip 2A comprises an inner component 1 having a collar 3 locating under the lip, a seal 6 extending from the collar and an outer component 4 fitting over the inner component for securing the collar under the lip. The seal may be flexible and integrally formed with the rigid inner component by two shot moulding. Also claimed, radial, spaced, movable parts (fig 3A) on ring (3B, fig 3) for tightly, frictionally engaging the lip under action of cam 4B on an outer component having a skirt 4A, axial movement of the outer component pressing the radial parts into engagement with the lip and rotation through less than 180 degrees securing the outer component to the inner component. Securing may be by multi start bayonet or threaded engagement 3A, 5A. Also claimed, a closure having an inner portion with an expandable and contractable portion for high friction engagement with the lip, pressed into engagement by axial and/or rotational movement of an outer portion.",THREADLESS CLOSURES LTD,FRASER ANTHONY HENRY JOSEPH;;HEIN JOHN,,https://lens.org/017-913-597-312-748,Patent Application,no,7,0,20,39,0,B65D41/0442;;B65D41/08;;B65D41/086;;B65D53/02;;B65D2543/00564;;B65D2543/00972;;B65D43/0222;;B65D45/322;;B65D51/18;;B65D41/065;;B65D41/086;;B65D2251/026;;B65D41/04;;B65D41/08;;B65D53/02;;B65D2543/00564;;B65D41/086;;B65D2543/00972;;B65D53/02;;B65D41/08;;B65D41/0442;;B65D41/04,B65D43/02;;B65D45/32;;B65D51/18,,0,0,,,,DISCONTINUED
869,EP,A1,EP 2593377 A1,019-550-143-181-125,2013-05-22,2013,EP 11740969 A,2011-07-04,GB 201011800 A;;GB 2011001004 W,2010-07-14,CLOSURE FOR A CONTAINER,,THREADLESS CLOSURES LTD,FRASER ANTHONY HENRY JOSEPH;;HEIN JOHN,,https://lens.org/019-550-143-181-125,Patent Application,yes,0,0,20,39,0,B65D41/0442;;B65D41/08;;B65D41/086;;B65D53/02;;B65D2543/00564;;B65D2543/00972;;B65D43/0222;;B65D45/322;;B65D51/18;;B65D41/065;;B65D41/086;;B65D2251/026;;B65D41/04;;B65D41/08;;B65D53/02;;B65D2543/00564;;B65D41/086;;B65D2543/00972;;B65D53/02;;B65D41/08;;B65D41/0442;;B65D41/04,B65D41/04;;B65D41/08;;B65D53/02,,0,0,,,,DISCONTINUED
870,US,A1,US 2016/0143952 A1,020-174-654-185-821,2016-05-26,2016,US 201514954584 A,2015-11-30,US 201514954584 A;;US 201213725814 A;;US 201113042334 A;;US 88635310 A;;US 61464803 A;;US 31612702 A;;US 33885601 P,2001-12-07,ADIPOSE-DERIVED REGENERATIVE CELLS FOR TREATING LIVER INJURY,Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient.,CYTORI THERAPEUTICS INC,FRASER JOHN K;;HEDRICK MARC H,CYTORI THERAPEUTICS INC (2015-12-16);;LOREM VASCULAR PTE. LTD (2019-04-24),https://lens.org/020-174-654-185-821,Patent Application,yes,3,4,65,221,0,A61K35/28;;A61K35/28;;A61K48/00;;A61B10/0283;;A61B10/0283;;A61K9/0019;;A61K9/0019;;A61K35/32;;A61K35/35;;A61K35/35;;A61K35/36;;A61M1/76;;A61M2202/08;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/00;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;A61P43/00;;C12M47/04;;C12N5/0667;;C12N5/0667;;C12N5/069;;C12N5/069;;C12N2506/1384;;C12N2506/1384,A61K35/28;;A61M1/00;;A61K31/436;;A61K35/02;;A61K35/12;;A61K35/35;;A61K35/36;;A61K38/00;;A61K38/16;;A61K45/00;;A61L27/00;;A61P1/00;;A61P1/16;;A61P3/00;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P19/00;;A61P19/02;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;C12M3/06;;C12N5/0775,,0,0,,,,DISCONTINUED
871,AU,B2,AU 687181 B2,042-479-465-113-437,1998-02-19,1998,AU 1995/020802 A,1995-03-31,GB 9406486 A;;GB 9500734 W,1994-03-31,Removable vertical fall arrest device,,LATCHWAYS LTD,ATKINSON GEOFFREY FRASER;;PATTERSON DAVID JOHN,,https://lens.org/042-479-465-113-437,Granted Patent,no,0,0,12,12,0,A62B35/005;;A62B35/0087;;E06C7/18;;E06C7/186;;A62B35/0087;;A62B35/005;;E06C7/18;;E06C7/186,E06C9/14;;A62B1/14;;A62B35/00;;A62B35/04;;E06C7/18,,0,0,,,,EXPIRED
872,US,A,US 2982587 A,039-332-808-083-520,1961-05-02,1961,US 73010358 A,1958-04-22,US 73010358 A,1958-04-22,Bearing,,INGERSOLL RAND CO,FRASER GROVER D;;LE VALLEY JOHN,,https://lens.org/039-332-808-083-520,Granted Patent,no,7,5,1,1,0,F16C35/061;;F16C35/061;;F16C19/545;;F16C19/545,F16C19/54;;F16C19/56;;F16C35/06,,0,0,,,,EXPIRED
873,US,A1,US 2011/0100988 A1,047-486-588-678-048,2011-05-05,2011,US 92287009 A,2009-03-19,GB 0805113 A;;GB 0809263 A;;GB 2009000744 W,2008-03-19,SEALED CONTAINER,"A container ( 1 ) for the storage of a carbonated drink, comprising a container body with an opening that defines an axis and a removable closure ( 3 ) for closing the opening, the closure including a foil ( 2 ) for bonding to the container to close the opening in a gas-tight manner, the foil also being connected to, or interacting with, the closure, such that initial rotation of the closure in a loosening direction relative to the container body distorts or deforms the foil in a manner such that further rotation of the. closure results in a peel force being applied to the bond between the foil and the container.",FRASER ANTHONY HENRY JOSEPH;;HEIN JOHN,FRASER ANTHONY HENRY JOSEPH;;HEIN JOHN,THREADLESS CLOSURES LIMITED (2010-12-03),https://lens.org/047-486-588-678-048,Patent Application,yes,2,13,7,9,0,B65D51/228;;B65D2251/0018;;B65D2251/0093;;B65D41/08;;B65D51/228;;B65D2251/0093;;B65D2251/0018;;B65D41/08,B65D51/18;;B65D41/00,220/254.1;;220/359.1,0,0,,,,DISCONTINUED
874,WO,A1,WO 2007/139551 A1,045-524-114-592-746,2007-12-06,2007,US 2006/0021017 W,2006-05-30,US 2006/0021017 W,2006-05-30,SYSTEMS AND METHODS FOR MANIPULATION OF REGENERATIVE CELLS FROM ADIPOSE TISSUE,"The invention provides methods for manipulating regenerative cells from adipose tissue. Specifically, it provides methods for enrichment of desired cells and enhancement of their therapeutic effects.",CYTORI THERAPEUTICS INC;;HEDRICK MARC H;;FRASER JOHN K,HEDRICK MARC H;;FRASER JOHN K,,https://lens.org/045-524-114-592-746,Patent Application,yes,2,12,4,4,0,A61K35/35;;C12N2509/00;;C12N5/0653;;A61P43/00;;C12N2509/00;;A61K35/35;;C12N5/0653;;A61K9/0024;;A61K35/28;;C12N5/0667;;C12N2509/10,A61K35/35;;C12M3/00;;C12N5/077,,0,0,,,,PENDING
875,AU,A1,AU 2003/245182 A1,053-412-038-064-135,2003-11-11,2003,AU 2003/245182 A,2003-05-09,NZ 51888202 A;;NZ 51905202 A;;NZ 0300086 W,2002-05-09,STREPTOCOCCAL SUPERANTIGENS SPE-L AND SPE-M,,AUCKLAND UNISERVICES LTD,FRASER JOHN DAVID;;PROFT THOMAS KURT,,https://lens.org/053-412-038-064-135,Patent Application,no,0,0,3,3,0,A61K39/00;;A61K2039/505;;C07K14/315;;C12Q1/14;;G01N33/56944;;G01N33/56944;;C07K14/315;;A61K2039/505;;A61K39/00;;C12Q1/14,A61K39/00;;C07K14/315;;C12N15/31;;C12Q1/14;;G01N33/569,,0,0,,,,DISCONTINUED
876,EP,A1,EP 1427279 A1,046-770-831-361-30X,2004-06-16,2004,EP 02761654 A,2002-09-13,US 0229207 W;;US 32207001 P;;US 24209402 A,2001-09-14,PRESERVATION OF NON EMBRYONIC CELLS FROM NON HEMATOPOIETIC TISSUES,,MACROPORE BIOSURGERY INC,FRASER JOHN K;;HEDRICK MARC H,"CYTORI THERAPEUTICS, INC. (2006-11-29);;LOREM VASCULAR PTE. LTD. (2019-09-11)",https://lens.org/046-770-831-361-30X,Patent Application,yes,1,18,10,10,0,A01N1/02;;A01N1/0221;;A01N1/0284;;A01N1/02;;A01N1/0284;;A01N1/0221;;A01N1/02,A01N1/02;;C12N5/08,,0,0,,,,DISCONTINUED
877,DK,B,DK 159306 B,048-674-235-008-836,1990-10-01,1990,DK 498484 A,1984-10-18,GB 8327793 A,1983-10-18,"6-PHENOXYPYRID-2-YLMETHYL-ESTERE AF CYKLOPROPANCARBOXYLSYRER, INSEKTICIDE MIDLER MED INDHOLD HERAF SAMT FREMGANGSMAADE TIL INSEKTBEKAEMPELSE","Cyclopropane carboxylates of formula (I) are new. In (I) W= halogen; X=H, CN or -C=CH; Y=H, 1-4C alkyl, 1-4C alkoxy, 1-4C alkylthio, 1-4C alkylsulphonyl, trifluoromethyl, 3,4-methylene dioxy, Cl, F or Br; n=1 or 2; Z=H, Cl or F.",ICI PLC,BUSHELL MICHAEL JOHN;;FRASER ALASTAIR MCLAREN,,https://lens.org/048-674-235-008-836,Patent Application,no,0,0,27,27,0,A01N53/00;;C07D213/647,A01N29/00;;A01N31/00;;A01N53/04;;A01N43/40;;A01N53/00;;A01N53/08;;C07C13/04;;C07C21/00;;C07C25/00;;C07C43/20;;C07D213/00;;C07D213/64;;C07D213/647,,0,0,,,,EXPIRED
878,EP,B1,EP 1349568 B1,069-637-138-285-785,2009-09-16,2009,EP 01999384 A,2001-12-04,NZ 0100267 W;;US 25124300 P,2000-12-04,IMMUNOMODULATORY CONSTRUCTS AND THEIR USES,,AUCKLAND UNISERVICES LTD,FRASER JOHN DAVID;;NICHOLSON MELISSA JOY,AUCKLAND UNISERVICES LIMITED (2009-11-13),https://lens.org/069-637-138-285-785,Granted Patent,yes,3,0,12,12,0,A61K39/092;;A61K39/385;;A61K2039/5154;;A61K2039/57;;A61K2039/6068;;C07K14/31;;C07K14/315;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61K39/385;;A61K39/092;;A61K2039/5154;;A61K2039/57;;A61K2039/6068;;C07K14/31;;C07K14/315,A61K39/00;;C12N15/09;;A61K39/085;;A61K39/09;;A61K39/38;;A61K39/385;;A61K45/00;;A61K48/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;C07K14/31;;C07K14/315;;C12N15/31;;G01N33/53,,4,0,,,"LEDER LUKAS ET AL: ""A mutational analysis of the binding of staphylococcal enterotoxins B and C3 to the T cell receptor beta chain and major histocompatibility complex class II"" JOURNAL OF EXPERIMENTAL MEDICINE, vol. 187, no. 6, 16 March 1998 (1998-03-16), pages 823-833, XP002903430 ISSN: 0022-1007;;LI HONGMIN ET AL: ""Three-dimensional structure of the complex between a T cell receptor beta chain and the superantigen staphylococcal enterotoxin B"" IMMUNITY, vol. 9, no. 6, December 1998 (1998-12), pages 807-816, XP002314864 ISSN: 1074-7613;;FRASER JOHN ET AL: ""Superantigens: Powerful modifiers of the immune system"" MOLECULAR MEDICINE TODAY, vol. 6, no. 3, March 2000 (2000-03), pages 125-132, XP002314865 ISSN: 1357-4310;;PROFT T. AND FRASER J.: 'Superantigens: Just like peptides only different' JOURNAL OF EXPERIMENTAL MEDICINE vol. 187, no. 6, 1998, pages 819 - 821, XP002903301",EXPIRED
879,US,B2,US 9206309 B2,086-641-893-953-079,2015-12-08,2015,US 201313944961 A,2013-07-18,US 201313944961 A;;US 201113121086 A;;US 2009/0058220 W;;US 10042708 P,2008-09-26,"Systems, devices, and/or methods for manufacturing castings","Certain exemplary embodiments can provide a composition, system, machine, device, manufacture, circuit, and/or user interface adapted for, and/or a method and/or machine-readable medium comprising machine-implementable instructions for, activities that can comprise, after removing a cast device from a stack-lamination-derived mold, said cast device formed from a molding composition, applying a desired shape to said cast device to form a shaped cast device, said molding composition comprising: a ceramic composition comprising silica; an cycloaliphatic epoxy binder composition, said cycloaliphatic epoxy binder composition present in said molding composition in an amount up to 30% by weight of said molding composition; a silicone composition comprising a siloxane resin, said silicone composition present in said molding composition in an amount up to 30% by weight of said molding composition; and a solvent composition adapted to dissolve said cycloaliphatic epoxy binder composition and said silicone composition.",MIKRO SYSTEMS INC,APPLEBY MICHAEL;;FRASER IAIN;;PAULUS JOHN,MIKRO SYSTEMS INC (2013-08-08);;RTX CORPORATION (2018-06-18),https://lens.org/086-641-893-953-079,Granted Patent,yes,56,44,17,17,0,B23P15/246;;B29C33/301;;B29C33/38;;B29C33/3835;;A61B6/4258;;B22C9/04;;Y10T428/24479;;B22C9/10;;C08L63/00;;C08L83/04;;Y10T428/24479;;B23P15/246;;B29C33/301;;B29C33/38;;B29C33/3835;;A61B6/4258;;B22C9/04;;C08L63/00;;C08L83/04;;B22C9/10,C08L63/00;;A61B6/00;;B22C9/04;;B23P15/24;;B29C33/30;;B29C33/38;;C08L83/04,,0,0,,,,ACTIVE
880,DE,A1,DE 1512833 A1,076-436-928-911-990,1969-07-03,1969,DE 1512833 A,1967-06-28,US 56239466 A,1966-07-01,Automatische Einstellung der Belastung fuer Sprachinterpollationssystem mit Zeitzuteilung,,WESTERN ELECTRIC CO,FRASER JOHN MCBRIDE;;LONG NORWWOD GREYSON,,https://lens.org/076-436-928-911-990,Patent Application,no,0,1,11,12,0,H04J3/177;;H04J3/177,H04J3/17,,0,0,,,,EXPIRED
881,US,A,US 3116113 A,094-879-585-590-341,1963-12-31,1963,US 18849462 A,1962-04-18,US 18849462 A,1962-04-18,Process for purifying intermetallic binary antimonides containing zinc and cadmium impurities,,NAT RESCARCH DEV CORP,FRASER HULME KENNETH;;BRIAN MULLIN JOHN,,https://lens.org/094-879-585-590-341,Granted Patent,no,0,0,1,1,0,C30B29/40;;C30B29/40;;C22C1/007;;C22C1/007;;C30B13/00;;C30B13/00;;H01L21/00;;H01L21/00;;Y10S420/903;;Y10S420/903,C22C1/00;;C30B13/00;;H01L21/00,,0,0,,,,EXPIRED
882,NO,B,NO 171594 B,087-583-768-778-017,1992-12-28,1992,NO 832688 A,1983-07-22,GB 8221457 A,1982-07-24,"ANALOGIFREMGANGSMAATE FOR FREMSTILLING AV TERAPEUTISK AKTIVE 2-SUBSTITUERTE 4-AMINO-6,7-DIMETOKSYKINOLINER",,PFIZER,CAMPBELL SIMON FRASER;;HARDSTONE JOHN DAVID,,https://lens.org/087-583-768-778-017,Unknown,no,0,0,46,53,0,C07C255/00;;C07D215/42;;C07D215/48;;C07D295/195;;C07D401/04;;C07D401/12;;C07D405/12;;C07D413/12;;C07D417/12;;A61P9/12;;C07D215/20;;C07D295/195;;C07D405/12;;C07D401/04;;C07D413/12;;C07D417/12;;C07C255/00;;C07D215/42;;C07D401/12;;C07D215/48,A61K31/47;;A61K31/4709;;A61K31/495;;C07D215/20;;A61K31/50;;A61K31/505;;A61K31/53;;A61P9/12;;C07D215/42;;C07D215/48;;C07D295/195;;C07D401/04;;C07D401/12;;C07D401/14;;C07D405/12;;C07D405/14;;C07D413/12;;C07D413/14;;C07D417/12,,0,0,,,,EXPIRED
883,DE,C3,DE 2519383 C3,098-144-394-722-688,1980-01-31,1980,DE 2519383 A,1975-04-30,CA 199202 A,1974-05-07,DE 2519383 C3,,"ATOMIC ENERGY OF CANADA LTD., OTTAWA","PRESCOTT, JOHN FRASER;;SANFORD, EMERSON CECIL",,https://lens.org/098-144-394-722-688,Granted Patent,no,0,0,17,18,0,B01J31/4015;;B01J31/0252;;C01B21/082;;C01B21/0926;;Y02P20/584,C01B4/00;;B01J31/40;;B01J38/00;;C01B21/082;;C01B21/092;;C07F1/00,,0,0,,,,EXPIRED
884,AU,A,AU 1984/034055 A,092-783-346-158-595,1985-04-26,1985,AU 1984/034055 A,1984-10-09,GB 8327793 A,1983-10-18,"6-PHENOXYPYRID-2-YLMETHYL-TRIFLUOROPROP-1-EN-1-YL -2,2- DIMETHYLCYCLOPROPANE CARBOXYLATE DERIVATIVES","Cyclopropane carboxylates of formula (I) are new. In (I) W= halogen; X=H, CN or -C=CH; Y=H, 1-4C alkyl, 1-4C alkoxy, 1-4C alkylthio, 1-4C alkylsulphonyl, trifluoromethyl, 3,4-methylene dioxy, Cl, F or Br; n=1 or 2; Z=H, Cl or F.",ICI PLC,BUSHELL MICHAEL JOHN;;FRASER ALASTAIR MCLAREN,,https://lens.org/092-783-346-158-595,Patent Application,no,0,1,27,27,0,A01N53/00;;C07D213/647,A01N53/04;;A01N29/00;;A01N31/00;;A01N43/40;;A01N53/00;;A01N53/08;;C07C13/04;;C07C21/00;;C07C25/00;;C07C43/20;;C07D213/00;;C07D213/64;;C07D213/647,,0,0,,,,EXPIRED
885,EP,A3,EP 0006333 A3,116-913-273-545-771,1980-01-23,1980,EP 79301089 A,1979-06-08,AU 1979/053708 A;;GB 7826823 A;;ZA 796786 A,1978-06-13,CONTROL SYSTEM FOR HYDRAULICALLY OPERATED ELEMENTS OR SYSTEMS,"Apparatus and method for controlling the operation of two separately operable hydraulic arrangements such as elements, units circuits or systems, and in particular the winches (1P, 1S) for the warps (2P, 2S) of a trawl by monitoring the pressure conditions in the arrangements i.e. warps by transducers (45P, 45S) establishing reference pressures (57) for the primary operating conditions of the arrangements and comparing these reference pressures with the values obtained from monitoring in a comparator (54) and producing control signals which are use to vary the operation conditions of the arrangements to equalise them to the reference values. Provision is made for overall control by a microprocessor (55) to allow the system to deal with obstructions and to provide alarms and safety conditions when necessary.",JAMES ROBERTSON & SONS (FLEETWOOD) LIMITED;;J. MILLS ELECTRONICS LIMITED,"DEMPSTER, DAVID FRASER;;WILSON, JOHN JEFFREY",,https://lens.org/116-913-273-545-771,Search Report,yes,8,0,9,11,0,A01K73/06;;B66D1/50;;A01K73/06;;B66D1/50,A01K73/06;;B66D1/50,,0,0,,,,DISCONTINUED
886,GB,A,GB 189321593 A,115-779-768-116-898,1894-10-13,1894,GB 189321593D A,1893-11-13,GB 189321593T A,1893-11-13,Improvements in Golf Ball Cleaners.,,MOXON CHARLES;;BRAND JOHN ALEXANDER FRASER,MOXON CHARLES;;BRAND JOHN ALEXANDER FRASER,,https://lens.org/115-779-768-116-898,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
887,DK,T3,DK 1638507 T3,118-267-666-947-113,2017-06-19,2017,DK 04776784 T,2004-06-18,US 47941803 P;;US 2004/0019611 W,2003-06-18,FREMGANGSMÅDER TIL ANVENDELSE AF FEDTVÆVSAFLEDTE CELLER INDEN FOR FORSTØRRENDE AUTOLOG FEDTOVERFØRSEL,,CYTORI THERAPEUTICS INC,FRASER JOHN K;;HEDRICK MARC H,,https://lens.org/118-267-666-947-113,Granted Patent,no,0,5,14,221,0,A61K35/44;;A61K48/00;;A61K35/28;;A61P13/00;;A61P37/06;;A61P43/00;;C12N5/0602;;C12N5/0667,C12N5/0775;;A61K35/28;;A61K35/44,,0,0,,,,ACTIVE
888,GB,A,GB 2266299 A,145-493-277-217-912,1993-10-27,1993,GB 8906986 A,1989-03-28,CA 594783 A;;FR 8905823 A;;HK 92794 A;;US 12107687 A,1987-11-16,Coated metal article,"A coated article is composed of a metal alloy substrate, the metal alloy having a nickel, chromium, cobalt or iron base, and a coating that serves as an oxygen barrier to insulate the metal surface from oxygen attack at temperatures which may range upto 1200 DEG C. The coating comprises a glass-ceramic selected from barium silicate and strontium silicate systems characterized by additives that enable forming a continuous well flowed glass coating prior to setting of the coating by crystallization. These additives include the refractory oxides Al2O3, ZrO2 and Y2O3, the transition metal oxides MnO, CoO, NiO and FeO, and MgO.",CORNING GLASS WORKS,ANDRUS RONALD LOUIS;;MACDOWELL JOHN FRASER,,https://lens.org/145-493-277-217-912,Patent Application,no,2,2,9,12,0,A61F13/023;;A61F2013/008;;A61F2013/00868;;C03C10/0009;;C03C10/0036;;C23C24/10;;C23D5/00;;C23D13/00;;Y10T428/12618;;Y10T428/12618;;C03C10/0009;;C23C24/10;;A61F2013/00868;;C03C10/0036;;C23D5/00;;A61F2013/008;;A61F13/023;;C23D13/00;;Y02T50/60,A61F13/00;;A61F13/02;;C03C10/00;;C23C24/10;;C23D5/00;;C23D13/00,C1M MVK           MVK;;C1M M494          MVK;;U1S S1969;;U1S S2036;;U1S S3010,0,0,,,,EXPIRED
889,EP,A1,EP 2330991 A1,124-399-278-636-382,2011-06-15,2011,EP 08772358 A,2008-07-02,US 2008/0069036 W,2008-07-02,CRANIOSPINAL FUSION METHOD AND APPARATUS,,POLARIS BIOTECHNOLOGY INC,HENDERSON FRASER CUMMINS;;NEWMAN JOHN W,"LIFE SPINE, INC. (2015-01-07)",https://lens.org/124-399-278-636-382,Patent Application,yes,0,0,3,3,0,A61B17/7055;;A61B17/7011;;A61B17/7032;;A61B17/7052;;A61B17/7059,A61B17/70,,1,0,,,See references of WO 2010002409A1,ACTIVE
890,US,B2,US 10344566 B2,129-904-016-056-659,2019-07-09,2019,US 201515100737 A,2015-01-27,GB 201401490 A;;GB 201415970 A;;GB 201419993 A;;GB 2015050185 W,2014-01-29,Method for launching a cleaning element,A deformable cleaning element is encased within soluble packaging to maintain deformation. The deformed cleaning element is launched into the bore of a drill pipe/conduit or tubular. Contact with fluids within the bore dissolves the soluble packaging allowing the cleaning element to expand to its original shape.,CORETRAX TECH LIMITED,FRASER JOHN;;BODMAN CHERISH;;FONG JASON,CORETRAX GLOBAL LIMITED (2022-04-21);;CORETRAX TECHNOLOGY LIMITED (2016-05-20),https://lens.org/129-904-016-056-659,Granted Patent,yes,14,0,10,13,0,B08B9/055;;B08B9/055;;B08B9/055;;B08B9/055;;B08B9/0555;;B65D65/46;;B65D81/264;;E21B37/10;;E21B37/10;;E21B37/00;;E21B37/02;;E21B37/08;;E21B37/08;;E21B37/08;;E21B37/10;;F16L55/40;;F16L55/42;;F16L55/42;;F16L55/44;;F16L55/46;;F16L55/46;;F16L2101/12,B08B9/055;;B65D65/46;;B65D81/26;;E21B37/08;;E21B37/10;;F16L55/46,,3,0,,,"Combined Search and Examination Report from GB1501359.2 (counterpart) , dated Jan. 29, 2016.;;Examination Report from GB1501359.2 (counterpart), dated Apr. 25, 2016.;;PCT Search Report (PCT/GB2015/050185), dated Jun. 29, 2015.",ACTIVE
891,GB,A,GB 2427323 A,131-116-966-083-436,2006-12-20,2006,GB 0512014 A,2005-06-14,GB 0512014 A,2005-06-14,Enabling the release of stored content received from a memory tag,"A memory tag (for example an RFID tag) comprises a memory containing stored content and a transponder which enables wireless electromagnetic communication. A client interrogates the memory tag, receives content from the memory tag by wireless electromagnetic communication in response to the interrogation, and stores the content. The client then sends a release request to an authoriser. If appropriate, the authoriser then sends a release confirmation to the client in response to the release request, and the stored content can then be released in response to receipt of the release confirmation. The specific embodiment is of a memory tag storing encrypted content, and where a decryption key is provided to allow decryption of the content which has been downloaded from the memory tag. The stored content may include a cost indication, and the release request may be in the form of a Short Message Service (SMS) message.",HEWLETT PACKARD DEVELOPMENT CO,LAWRENCE RICHARD ANTHONY;;DICKIN FRASER JOHN,,https://lens.org/131-116-966-083-436,Patent Application,no,2,2,5,5,0,G06Q20/123;;G06Q20/327;;G01V15/00;;G06K19/0723;;G06Q20/123;;G06Q20/327,G06K19/07;;G01V15/00;;G06Q20/00,H4L LASS          LASS,0,0,,,,INACTIVE
892,US,A1,US 2017/0055571 A1,129-713-489-655-756,2017-03-02,2017,US 201514837860 A,2015-08-27,US 201514837860 A,2015-08-27,Dry Herb and Organic Material Water Pipe Body,"A portable, dishwasher safe, dry herb water pipe body capable of connection to a plethora of different fluid vessels. It has a flexible polymer bidirectional flow connector that facilitates the flow of smoke from and into the water pipe body. This flow connector also frictionally engages the neck of a bottle, jar or can, thereby sealing the fluid vessel to the body of the water pipe, completing its functionality. Ice can be placed in the water pipe to further cool the incoming smoke charge for the user. After use, if a disposable fluid vessel and fluid were used, the water pipe body can be removed and no further storage or cleaning action is required. With the optional plug, the device can be used in a dry smoke mode or fluid can be added into the plug for a shortened version of a water pipe.",REYES HARI MARK;;FRASER PHILLIP JOHN,REYES HARI MARK;;FRASER PHILLIP JOHN,,https://lens.org/129-713-489-655-756,Patent Application,yes,6,5,2,2,0,A24F1/32;;A24F1/32;;A24F1/30;;A24F1/30;;A24F5/00;;A24F5/00,A24F1/32;;A24F1/30;;A24F5/00,,0,0,,,,INACTIVE
893,US,A1,US 2007/0044973 A1,141-365-022-004-083,2007-03-01,2007,US 50848806 A,2006-08-23,US 50848806 A;;US 71041705 P;;US 75118505 P;;US 75118705 P,2005-08-23,Riser joint coupling,"An offshore riser system has riser joints, each having a pin and a box. The pin has an external grooved profile that is engaged by a locking element carried by the box of another riser joint. An actuating ring engages with the locking element to move it into the locked position. A retractable spider supports the string of riser while the new joint is being made up. A makeup tool on the riser deploying floor moves the ring relative to the locking element, causing the locking element to move to the locked position.",VETCO GRAY INC,FRASER THOMAS A;;NELSON JOHN E,HYDRIL USA DISTRIBUTION LLC (2021-09-01);;VETCO GRAY LLC (2017-05-16),https://lens.org/141-365-022-004-083,Patent Application,yes,47,60,28,33,0,E21B17/01;;E21B17/085;;E21B19/006;;E21B19/16;;Y10S285/922;;Y10T29/49947;;E21B17/01;;E21B17/085;;E21B19/16;;E21B17/01;;E21B17/085;;E21B19/006;;E21B19/16;;Y10T29/49947;;E21B17/01;;E21B17/085;;E21B19/16;;E21B19/006;;Y10S285/922,E21B17/01,166/367,0,0,,,,ACTIVE
894,CN,A,CN 101897724 A,152-688-174-683-113,2010-12-01,2010,CN 201010105630 A,2002-12-09,US 33885601 P;;CN 02827968 A,2001-12-07,Method for producing a soft tissue filler and method for producing an adipose tissue transplant,"The invention provides a method for producing a soft tissue filler, comprising mixing a processed adipose suction article and an integral, not-depolymerized adipose tissue segment. The invention also provides a method for producing an adipose tissue transplant, mixing a cell group containing adipose derived stem cell and a second part of the integral adipose tissue to obtain the adipose tissue transplant. The soft tissue filler is used for correcting the appearance defect. The adipose tissue derived cell in the adipose tissue trnasplant provides the environment for supporting the living and the function of extending the transplant.",MACROPORE BIOSURGERY INC,HEDRICK MARC H;;FRASER JOHN K,,https://lens.org/152-688-174-683-113,Patent Application,no,3,3,65,221,0,A61K35/28;;A61K35/28;;A61K48/00;;A61B10/0283;;A61B10/0283;;A61K9/0019;;A61K9/0019;;A61K35/32;;A61K35/35;;A61K35/35;;A61K35/36;;A61M1/76;;A61M2202/08;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/00;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;A61P43/00;;C12M47/04;;C12N5/0667;;C12N5/0667;;C12N5/069;;C12N5/069;;C12N2506/1384;;C12N2506/1384,A61K35/12;;A61M1/00;;A61K31/436;;A61K35/02;;A61K35/28;;A61K35/35;;A61K35/36;;A61K38/00;;A61K38/16;;A61K45/00;;A61L27/00;;A61P1/00;;A61P1/16;;A61P3/00;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P19/00;;A61P19/02;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;A61P43/00;;C12M3/06;;C12N5/0775;;C12N5/0789,,1,0,,,"王大为等: ""脂肪移植与整形外科——基础研究综述"", 《中国修复重建外科杂》",EXPIRED
895,CO,A2,CO 2017001525 A2,155-908-567-367-825,2017-05-10,2017,CO 2017001525 A,2017-02-15,GB 2015052154 W;;GB 201413249 A;;GB 201503512 A,2014-07-25,Recipiente y cierre y manufactura de los mismos,"Se revela un recipiente (10) y un cierre (20), por ejemplo para alojar una bebida carbonatada, también como métodos de manufactura del recipiente y cierre. El cierre es asegurado al recipiente por medio de una proyección (11, 24) que se extiende alrededor de la circunferencia de cada parte, las proyecciones comprenden una serie de elementos horizontales espaciados circunferencialmente (11, 24) dispuestos de tal manera que los elementos en el cierre pueden pasar a través de los espacios entre los elementos en recipiente y colocarse debajo de ellos para asegurar el cierre al recipiente. Los elementos de la proyección sobre el recipiente están separados entre sí en dirección circunferencial y no se superponen o traslapan entre sí en dirección vertical y los elementos de la proyección sobre el cierre están separados entre sí en dirección circunferencial y no se superponen entre sí en dirección vertical. Las primeras porciones tienen un extremo inclinado hacia arriba (24D) en un extremo de las mismas y/o un extre o inclinado hacia abajo (24E) en el otro extremo. Tras la rotación del cierre en una dirección, los extremos inclinados hacia abajo actúan para accionar las segundas porciones (y de aquí el cierre) hacia abajo y tras la rotación en la otra dirección, los extremos inclinados hacia arriba actúan para impulsar las segundas porciones hacia arriba.",THREADLESS CLOSURES LTD,HEIN JOHN;;FRASER ANTHONY HENRY JOSEPH,,https://lens.org/155-908-567-367-825,Patent Application,no,0,0,11,40,0,B65D51/1688;;B65D51/1688;;B65D51/1688;;B65D41/065;;B65D41/065;;B65D41/065,B65D51/16;;B65D41/06,,0,0,,,,PENDING
896,DK,D0,DK 337383 D0,158-058-194-396-48X,1983-07-22,1983,DK 337383 A,1983-07-22,GB 8221457 A,1982-07-24,"FREMGANGSMADE TIL FREMSTILLING AF 4-AMINO-6,7-DIMETHOXYQUINOLIN-FORBINDELSER ELLER FARMACEUTISK ACCEPTABLE SYREADDITIONSSALTE DERAF",,PFIZER,CAMPBELL SIMON FRASER;;HARDSTONE JOHN DAVID,,https://lens.org/158-058-194-396-48X,Patent Application,no,0,0,46,53,0,C07C255/00;;C07D215/42;;C07D215/48;;C07D295/195;;C07D401/04;;C07D401/12;;C07D405/12;;C07D413/12;;C07D417/12;;A61P9/12;;C07D215/20;;C07D295/195;;C07D405/12;;C07D401/04;;C07D413/12;;C07D417/12;;C07C255/00;;C07D215/42;;C07D401/12;;C07D215/48,A61K31/47;;C07D215/20;;A61K31/4709;;A61K31/495;;A61K31/50;;A61K31/505;;A61K31/53;;A61P9/12;;C07D215/42;;C07D215/48;;C07D295/195;;C07D401/04;;C07D401/12;;C07D401/14;;C07D405/12;;C07D405/14;;C07D413/12;;C07D413/14;;C07D417/12,,0,0,,,,EXPIRED
897,US,A1,US 2005/0025755 A1,166-227-920-310-199,2005-02-03,2005,US 87150304 A,2004-06-18,US 87150304 A;;US 31612702 A;;US 33885601 P;;US 47941803 P,2001-12-07,Methods of using adipose tissue-derived cells in augmenting autologous fat transfer,"Methods of treating patients for conditions such as breast augmentation, soft tissue defects, and urinary incontinence, are described. The methods include removing adipose tissue from a patient, processing a portion of the adipose tissue to obtain a substantially isolated population of regenerative cells, mixing the regenerative cells with another portion of adipose tissue to form a composition, and administering the composition to the patient from which the adipose tissue was removed.",HEDRICK MARC H.;;FRASER JOHN K.,HEDRICK MARC H;;FRASER JOHN K,CYTORI THERAPEUTICS INC (2005-07-11);;LOREM VASCULAR PTE. LTD (2019-04-24);;MACROPORE BIOSURGERY INC (2004-09-15),https://lens.org/166-227-920-310-199,Patent Application,yes,36,150,6,221,0,A61L27/3604;;A61L27/3834;;A61L27/3886;;A61L27/54;;A61L2300/414;;A61L2300/416;;A61L2300/426;;A61L2430/34;;C12N5/0667;;C12N5/069;;C12N2506/1384;;A61K35/28;;A61K35/44;;A61P1/00;;A61P17/00;;A61P3/06;;A61P43/00;;A61P9/00;;A61K35/44;;A61L27/3604;;A61L27/3886;;A61L27/54;;A61L27/3834;;A61L2300/416;;C12N2506/1384;;A61L2300/414;;A61L2300/426;;C12N5/0667;;C12N5/069;;A61L2430/34;;A61K35/28,A61K35/12;;A61K35/28;;A61K35/36;;A61K35/44;;C12N5/08,424/93.21;;424/93.7;;435/366,0,0,,,,EXPIRED
898,AT,T1,AT E548289 T1,161-015-483-674-122,2012-03-15,2012,AT 09721829 T,2009-03-19,GB 0805113 A;;GB 0809263 A;;GB 2009000744 W,2008-03-19,ABGEDICHTETER BEHÄLTER,"A container (1) for the storage of a carbonated drink, comprising a container body with an opening that defines an axis and a removable closure (3) for closing the opening, the closure including a foil (2) for bonding to the container to close the opening in a gas-tight manner, the foil also being connected to, or interacting with, the closure, such that initial rotation of the closure in a loosening direction relative to the container body distorts or deforms the foil in a manner such that further rotation of the. closure results in a peel force being applied to the bond between the foil and the container.",THREADLESS CLOSURES LTD,FRASER ANTHONY HENRY JOSEPH;;HEIN JOHN,,https://lens.org/161-015-483-674-122,Granted Patent,no,0,0,7,9,0,B65D51/228;;B65D2251/0018;;B65D2251/0093;;B65D41/08;;B65D51/228;;B65D2251/0093;;B65D2251/0018;;B65D41/08,,,0,0,,,,ACTIVE
899,CA,A1,CA 2529954 A1,177-668-033-680-188,2005-02-10,2005,CA 2529954 A,2004-06-18,US 47941803 P;;US 2004/0019611 W,2003-06-18,METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER,"Methods of treating patients for conditions such as breast augmentation, sof t tissue defects, and urinary incontinence, are described. The methods include removing adipose tissue from a patient, processing a portion of the adipose tissue to obtain a substantially isolated population of regenerative cells, mixing the regenerative cells with another portion of adipose tissue to form a composition, and administering the composition to the patient from which the adipose tissue was removed.",MACROPORE BIOSURGERY INC,HEDRICK MARC H;;FRASER JOHN K,,https://lens.org/177-668-033-680-188,Patent Application,no,0,0,14,221,0,A61K35/44;;A61K48/00;;A61K35/28;;A61P13/00;;A61P37/06;;A61P43/00;;C12N5/0602;;C12N5/0667,A61K35/12;;A61K35/28;;A61K35/44;;C12M3/00;;C12N5/0775;;C12N5/22,,0,0,,,,DISCONTINUED
900,EP,A2,EP 2559534 A2,169-114-704-577-663,2013-02-20,2013,EP 12191595 A,2009-09-24,US 10042708 P;;EP 09737489 A;;US 2009/0058220 W,2008-09-26,"Systems, devices, and/or methods for manufacturing castings","Certain exemplary embodiments can provide a composition, system, machine, device, manufacture, circuit, and/or user interface adapted for, and/or a method and/or machine-readable medium comprising machine-implementable instructions for, activities that can comprise, after removing a cast device from a stack-lamination-derived mold, said cast device formed from a molding composition, applying a desired shape to said cast device to form a shaped cast device, said molding composition comprising: a ceramic composition comprising silica; an cycloaliphatic epoxy binder composition, said cycloaliphatic epoxy binder composition present in said molding composition in an amount up to 30% by weight of said molding composition; a silicone composition comprising a siloxane resin, said silicone composition present in said molding composition in an amount up to 30% by weight of said molding composition; and a solvent composition adapted to dissolve said cycloaliphatic epoxy binder composition and said silicone composition.
",MIKRO SYSTEMS INC,APPLEBY MICHAEL;;FRASER IAIN;;PAULUS JOHN,RAYTHEON TECHNOLOGIES CORPORATION (2021-03-24);;UNITED TECHNOLOGIES CORPORATION (2019-04-24);;RTX CORPORATION (2023-11-01),https://lens.org/169-114-704-577-663,Patent Application,yes,160,13,17,17,0,B23P15/246;;B29C33/301;;B29C33/38;;B29C33/3835;;A61B6/4258;;B22C9/04;;Y10T428/24479;;B22C9/10;;C08L63/00;;C08L83/04;;Y10T428/24479;;B23P15/246;;B29C33/301;;B29C33/38;;B29C33/3835;;A61B6/4258;;B22C9/04;;C08L63/00;;C08L83/04;;B22C9/10,B29C33/30;;A61B6/00;;B22C9/00;;B23P15/24;;B29C33/38;;C08K3/22,,0,0,,,,ACTIVE
901,PH,A,PH 19424 A,188-022-478-241-539,1986-04-15,1986,PH 29286 A,1983-07-25,GB 8221457 A,1982-07-24,"2-SUBSTITUTED 4 AMINO 6,7 DIMETHOXYQUINOLINES",,PFIZER,CAMPBELL SIMON FRASER;;HARDSTONE JOHN DAVID,,https://lens.org/188-022-478-241-539,Granted Patent,no,0,0,46,53,0,C07C255/00;;C07D215/42;;C07D215/48;;C07D295/195;;C07D401/04;;C07D401/12;;C07D405/12;;C07D413/12;;C07D417/12;;A61P9/12;;C07D215/20;;C07D295/195;;C07D405/12;;C07D401/04;;C07D413/12;;C07D417/12;;C07C255/00;;C07D215/42;;C07D401/12;;C07D215/48,A61K31/47;;A61K31/4709;;C07D215/20;;A61K31/495;;A61K31/50;;A61K31/505;;A61K31/53;;A61P9/12;;C07D215/42;;C07D215/48;;C07D295/195;;C07D401/04;;C07D401/12;;C07D401/14;;C07D405/12;;C07D405/14;;C07D413/12;;C07D413/14;;C07D417/12,,0,0,,,,EXPIRED
902,US,A1,US 2017/0353129 A1,186-879-319-731-485,2017-12-07,2017,US 201715683097 A,2017-08-22,US 201715683097 A;;US 201414351888 A;;IB 2012056152 W;;US 201161560836 P,2011-11-17,PRE-COLLAPSED CAPACITIVE MICRO-MACHINED TRANSDUCER CELL WITH ANNULAR-SHAPED COLLAPSED REGION,"The present invention relates to a pre-collapsed capacitive micro-machined transducer cell ( 10 ) comprising a substrate ( 12 ) comprising a first electrode ( 16 ), a membrane ( 14 ) comprising a second electrode ( 18 ), wherein the cell has an outer region ( 22 ) where the membrane ( 14 ) is mounted to the substrate ( 12 ) and an inner region ( 20 ) inside or surrounded by the outer region ( 22 ), wherein the membrane ( 14 ) is collapsed to the substrate ( 12 ) in a first collapsed annular-shaped region ( 24 ) located within the inner region ( 20 ).",KONINKLIJKE PHILIPS NV,ROBINSON ANDREW LEE;;FRASER JOHN DOUGLAS,,https://lens.org/186-879-319-731-485,Patent Application,yes,0,0,16,16,0,B06B1/0292;;Y10T29/49005;;B06B1/02;;Y10T29/49005;;B06B1/0292;;B06B1/02;;H02N1/006,H02N1/00;;B06B1/02,,0,0,,,,ACTIVE
903,US,A1,US 2011/0003388 A1,197-252-753-669-530,2011-01-06,2011,US 88635310 A,2010-09-20,US 88635310 A;;US 61464803 A;;US 31612702 A;;US 33885601 P,2001-12-07,"METHODS OF MAKING ENHANCED, AUTOLOGOUS FAT GRAFTS",Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient.,CYTORI THERAPEUTICS INC,FRASER JOHN K;;HEDRICK MARC H,LOREM VASCULAR PTE. LTD (2019-04-24),https://lens.org/197-252-753-669-530,Patent Application,yes,7,7,65,221,0,A61K35/28;;A61K35/28;;A61K48/00;;A61B10/0283;;A61B10/0283;;A61K9/0019;;A61K9/0019;;A61K35/32;;A61K35/35;;A61K35/35;;A61K35/36;;A61M1/76;;A61M2202/08;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/00;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;A61P43/00;;C12M47/04;;C12N5/0667;;C12N5/0667;;C12N5/069;;C12N5/069;;C12N2506/1384;;C12N2506/1384,A61M1/00;;C12N5/071;;A61K31/436;;A61K35/02;;A61K35/12;;A61K35/28;;A61K35/35;;A61K35/36;;A61K38/00;;A61K38/16;;A61K45/00;;A61L27/00;;A61P1/00;;A61P1/16;;A61P3/00;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P19/00;;A61P19/02;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;C12M3/06;;C12N5/0775,435/379;;435/325;;435/378,0,0,,,,EXPIRED
904,DE,B2,DE 2519383 B2,192-314-387-102-022,1979-05-03,1979,DE 2519383 A,1975-04-30,CA 199202 A,1974-05-07,DE 2519383 B2,,"ATOMIC ENERGY OF CANADA LTD., OTTAWA","PRESCOTT, JOHN FRASER;;SANFORD, EMERSON CECIL",,https://lens.org/192-314-387-102-022,Patent Application,no,0,0,17,18,0,B01J31/4015;;B01J31/0252;;C01B21/082;;C01B21/0926;;Y02P20/584,C01B4/00;;B01J31/40;;B01J38/00;;C01B21/082;;C01B21/092;;C07F1/00,,0,0,,,,EXPIRED
905,AU,A1,AU 2011/260035 A1,013-626-791-874-886,2013-01-17,2013,AU 2011/260035 A,2011-06-03,GB 201011800 A;;GB 201009429 A;;GB 2011000846 W,2010-06-04,Closure for a container,"A closure for a container ( 1 ) having a circular opening defining an axis (A), the closure being securable to the container so as to close said opening, the closure having an o-ring sealing member (5) mounted thereon so as to provide a seal with a sealing surface (IB) of the container, when the closure is secured to the container, the sealing surface extending around an upper surface or an internal surface of the container. The closure may comprise a bore feature (4) which, in use, extends through the opening into the interior of the container and the o-ring seal (5) may be provided on the bore feature. Various forms of closure are described, eg for closing a bottle neck and a wide-mouth closure. The closure may comprise an inner component (3) and an outer component (2), eg cap - on - collar closure, and the container preferably has no thread features on the exterior thereof so it is comfortable to drink from.",THREADLESS CLOSURES LTD,FRASER ANTHONY HENRY JOSEPH;;HEIN JOHN,,https://lens.org/013-626-791-874-886,Patent Application,no,0,0,17,39,0,B65D41/04;;B65D41/0442;;B65D41/0442;;B65D41/00;;B65D41/08;;B65D41/08;;B65D41/08;;B65D41/086;;B65D41/086;;B65D41/62;;B65D53/02;;B65D53/02;;B65D53/02;;B65D2543/00564;;B65D2543/00564;;B65D2543/00972;;B65D2543/00972,B65D41/04;;B65D41/08;;B65D53/02,,0,0,,,,INACTIVE
906,AU,B2,AU 562055 B2,015-439-506-103-660,1987-05-28,1987,AU 1983/014213 A,1983-05-04,GB 8228778 A,1982-10-08,CHOCKS LOCKED TO WHEEL TO PREVENT VEHICLE THEFT,,LIONWELD LTD,MILNER ALLEN JOHN;;FRASER JAMES EDWARD,,https://lens.org/015-439-506-103-660,Granted Patent,no,0,0,2,4,0,,B60R25/00,,0,0,,,,EXPIRED
907,GB,A,GB 2189406 A,016-674-219-466-705,1987-10-28,1987,GB 8708921 A,1987-04-14,GB 8609958 A,1986-04-23,Mineral sizer/breaker,"A mineral sizer/breaker has a generally rectangular casing, open top and bottom, in which the spaced longitudinal sidewalls (12, 13) are aligned, having common top and bottom surfaces lying in respective parallel horizontal planes. One end wall (14) of the casing has its bottom surface raised above the plane containing the bottom surfaces of the longitudinal side walls and is inclined at an angle to the vertical, lying parallel to the other end wall, the end walls supporting a rotatable breaker drum shaft (22) which is normal to said end walls. When the sizer is mounted on a conveyor, improved clearance between the conveyor and said end wall (14) at the delivery end assists conveying away of sized material. Also, the relative low height of the top surface of the other end wall facilitates impact of mineral material. <IMAGE>",ANSEC DESIGN & ENG LTD,HUNT NOEL;;SECRETAN MICHAEL JOHN FRASER,,https://lens.org/016-674-219-466-705,Patent Application,no,0,3,4,4,0,B02C18/28;;B02C4/10;;B02C13/282,B02C4/10;;B02C13/282;;B02C18/28,B2A A7A2          A7;;B2A A7P1          A7;;B2A A7R1X         A7;;B2A A7R12         A7;;B2A A7R4          A7;;B2A A7R5          A7;;B2A A7R8          A7;;U1S S1265,0,0,,,,EXPIRED
908,FR,A,FR 1391668 A,023-248-259-631-287,1965-03-12,1965,FR 891901 A,1962-03-22,FR 891901 A,1962-03-22,Procédé de stabilisation du sulfate d'oestrone synthétique de sodium ou de potassium,,FROSST & CO CHARLES E,MILLAR JOHN FRASER;;FINDLAY LLYOD EDWARD,,https://lens.org/023-248-259-631-287,Granted Patent,no,0,0,1,1,0,C07J31/00;;C07J75/00,C07J31/00;;C07J75/00,,0,0,,,,EXPIRED
909,FI,C,FI 78296 C,010-557-942-295-107,1989-07-10,1989,FI 832658 A,1983-07-21,GB 8221457 A,1982-07-24,"FOERFARANDE FOER FRAMSTAELLNING AV TERAPEUTISKT AKTIVA 2-SUBSTITUERADE 4-AMINO-6,7-DIMETOXIKINOLINDERIVAT.",,PFIZER,CAMPBELL SIMON FRASER;;HARDSTONE JOHN DAVID,,https://lens.org/010-557-942-295-107,Granted Patent,no,0,0,46,53,0,C07C255/00;;C07D215/42;;C07D215/48;;C07D295/195;;C07D401/04;;C07D401/12;;C07D405/12;;C07D413/12;;C07D417/12;;A61P9/12;;C07D215/20;;C07D295/195;;C07D405/12;;C07D401/04;;C07D413/12;;C07D417/12;;C07C255/00;;C07D215/42;;C07D401/12;;C07D215/48,A61K31/47;;A61K31/4709;;A61K31/495;;A61K31/50;;A61K31/505;;C07D215/20;;A61K31/53;;A61P9/12;;C07D215/42;;C07D215/48;;C07D295/195;;C07D401/04;;C07D401/12;;C07D401/14;;C07D405/12;;C07D405/14;;C07D413/12;;C07D413/14;;C07D417/12,,0,0,,,,EXPIRED
910,US,B2,US 8119121 B2,019-430-790-558-498,2012-02-21,2012,US 61464803 A,2003-07-07,US 61464803 A;;US 31612702 A;;US 33885601 P,2001-12-07,Autologous adipose tissue implant with concentrated stem cells,Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient.,FRASER JOHN K;;HEDRICK MARC H;;CYTORI THERAPEUTICS INC,FRASER JOHN K;;HEDRICK MARC H,CYTORI THERAPEUTICS INC (2005-07-11);;LOREM VASCULAR PTE. LTD (2019-04-24);;MACROPORE BIOSURGERY INC (2003-03-07),https://lens.org/019-430-790-558-498,Granted Patent,yes,100,40,65,221,0,A61K35/28;;A61K35/28;;A61K48/00;;A61B10/0283;;A61B10/0283;;A61K9/0019;;A61K9/0019;;A61K35/32;;A61K35/35;;A61K35/35;;A61K35/36;;A61M1/76;;A61M2202/08;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/00;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;A61P43/00;;C12M47/04;;C12N5/0667;;C12N5/0667;;C12N5/069;;C12N5/069;;C12N2506/1384;;C12N2506/1384,A61M1/00;;C12N5/00;;A61K31/436;;A61K35/02;;A61K35/12;;A61K35/28;;A61K35/35;;A61K35/36;;A61K38/00;;A61K38/16;;A61K45/00;;A61L27/00;;A61P1/00;;A61P1/16;;A61P3/00;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P19/00;;A61P19/02;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;C12M3/06;;C12N5/0775,424/93.7;;435/366;;604/19;;604/22;;606/1;;606/131,99,97,047-253-510-312-524;;036-252-293-129-219;;016-725-607-839-435;;086-462-532-224-686;;094-547-639-217-227;;012-100-750-932-039;;062-596-462-103-530;;155-317-023-938-779;;054-506-496-484-990;;024-543-293-226-152;;071-429-593-853-516;;015-065-365-556-91X;;073-024-866-252-802;;013-619-248-169-661;;008-689-173-407-727;;005-046-972-638-291;;104-867-388-312-53X;;054-783-391-382-440;;011-805-902-464-128;;060-346-109-363-548;;038-374-873-783-178;;042-752-396-214-211;;047-615-077-646-421;;123-676-259-156-005;;053-378-748-216-731;;119-279-899-568-792;;000-409-808-541-605;;013-585-462-742-366;;002-574-351-412-169;;022-168-856-452-360;;052-138-454-301-405;;073-243-305-396-996;;055-939-072-605-234;;100-021-019-543-442;;006-388-312-315-426;;010-094-842-952-554;;083-745-638-097-33X;;108-011-138-630-620;;089-952-471-760-805;;074-361-613-484-000;;066-881-033-465-881;;068-663-145-216-705;;092-718-714-276-800;;126-822-003-009-011;;026-980-293-507-059;;026-519-654-455-165;;007-593-741-676-368;;088-484-373-248-225;;000-625-008-142-215;;033-642-914-335-547;;014-595-660-154-907;;017-165-339-699-387;;125-995-223-966-197;;060-272-195-296-337;;042-873-767-839-626;;003-133-282-606-391;;033-525-386-964-397;;060-747-209-758-763;;012-478-225-854-882;;026-194-281-031-26X;;027-822-501-366-119;;032-321-978-707-262;;122-318-219-266-473;;099-752-629-708-684;;149-114-581-210-021;;079-996-894-321-080;;003-830-438-296-822;;079-304-670-311-107;;007-590-158-070-744;;027-075-600-131-626;;040-763-736-139-475;;017-051-509-991-917;;023-863-661-792-008;;017-240-552-754-928;;037-896-221-394-486;;001-680-566-813-683;;159-966-370-938-701;;049-914-070-892-93X;;006-283-622-386-181;;001-540-649-917-213;;035-599-261-405-529;;009-217-401-539-352;;002-046-778-412-775;;024-155-477-095-201;;086-723-562-959-600;;009-409-750-213-445;;103-583-683-515-232;;020-337-057-544-762;;053-546-763-509-946;;119-279-899-568-792;;063-854-944-766-893;;140-579-283-445-044;;083-507-264-928-958;;041-128-004-154-032;;125-070-604-309-436;;012-374-600-750-30X;;105-396-044-542-989,11594767;;10.1006/bbrc.2001.5712;;11487017;;6382294;;10.1007/bf00453875;;8526158;;10.1016/s0094-1298(20)32343-9;;11248861;;1896551;;10.1097/00006534-199110000-00038;;10.1097/00003086-199810001-00026;;9917645;;11134993;;10.1046/j.1524-4725.2000.00277.x;;10.1046/j.1524-4725.2000.t01-1-00277.x;;11284885;;10.1046/j.1525-1594.2001.025003187.x;;10.1007/s002669900055;;8849432;;10.1007/bf02390315;;10086387;;10.1038/6529;;10.1182/blood.v97.5.1227;;11222364;;11884830;;10.1097/00006534-200203000-00037;;10.1152/ajpendo.2001.281.5.e1037;;11595661;;pmc370387;;6306056;;10.1172/jci110937;;10.1046/j.1365-2613.1996.00964.x;;8762864;;pmc2691621;;11125386;;10.1097/00005392-200101000-00037;;10.1097/00006534-200201000-00030;;11786812;;12160849;;10.1016/s0301-472x(02)00867-6;;pmc507709;;8958214;;10.1172/jci119070;;10.1016/s0736-0266(00)00010-3;;11332607;;11877271;;10.1182/blood.v99.6.1995;;10.1111/j.1749-6632.2001.tb03592.x;;11458511;;11287958;;10.1038/35070587;;9048302;;10.1089/end.1997.11.67;;10102814;;10.1126/science.284.5411.143;;11105688;;10.1016/s0079-6123(00)28026-6;;11326230;;10.1067/mtc.2001.112937;;10.1182/blood.v92.2.362.414k38_362_367;;9657732;;10.1182/blood.v92.2.362;;10.1161/01.cir.0000034046.87607.1c;;12370212;;10.1038/7434;;10202935;;7881356;;10.1002/stem.5530120602;;10.1016/s0940-2993(99)80076-1;;10048720;;10.1016/0270-9139(95)90478-6;;7539398;;10.1002/hep.1840210632;;10488710;;10.1016/s0168-8278(99)80043-9;;10.1089/107632701300062859;;11304456;;8967480;;10.1152/ajpendo.1996.270.5.e895;;9202388;;10.1242/jcs.110.11.1279;;8928727;;10.1152/ajpcell.1996.270.4.c1011;;10.1016/0026-0495(94)90275-5;;8028517;;8121307;;10.1016/0026-0495(94)90250-x;;10.2527/1996.7492117x;;8880414;;10.1152/ajpcell.1993.265.6.c1729;;8279534;;7545105;;10.1210/endo.136.10.7545105;;10.1210/en.136.10.4582;;8680482;;10.1080/10408369991239169;;10094092;;7962109;;10.1002/jcp.1041610209;;8544774;;10.1016/s0026-0495(96)90197-3;;1757497;;10.1242/jcs.99.1.131;;3489608;;10.1210/endo-119-4-1776;;10.1126/science.283.5401.534;;9915700;;9027588;;10.1002/(sici)1097-4644(199702)64:2<278::aid-jcb11>3.0.co;2-f;;2144412;;10.1007/bf00174624;;10.1210/endo.134.1.8275945;;8275945;;10.1210/en.134.1.277;;10.1210/endo-114-2-477;;6690287;;10.1002/(sici)1097-4652(199910)181:1<67::aid-jcp7>3.0.co;2-c;;10457354;;10.1002/(sici)1097-4652(199910)181:1<67::aid-jcp7>3.3.co;2-3;;10.1677/joe.0.1630159;;10556763;;7589892;;10.1046/j.1432-0436.1995.5910025.x;;10.1046/j.1432-0436.1999.6420067.x;;10234804;;7568133;;pmc40985;;10.1073/pnas.92.20.9363;;9182762;;10.1016/s0092-8674(00)80257-3;;10.1126/science.279.5356.1528;;9488650;;10.1523/jneurosci.08-04-01144.1988;;3357014;;pmc6569254;;10.1002/ijc.2910510513;;1319408;;10.1083/jcb.106.6.2139;;pmc2115137;;3384856;;10.1210/endo-106-4-1198;;7188899;;7031026;;10.1007/bf01002713;;9027589;;10.1002/(sici)1097-4644(199702)64:2<295::aid-jcb12>3.0.co;2-i;;10.1002/(sici)1097-4644(199702)64:2<295::aid-jcb12>3.3.co;2-6;;10.1006/excr.1997.3858;;9457080;;2249771;;10.1101/gad.4.10.1701;;10.1002/1097-4644(20010101)80:1<115::aid-jcb100>3.0.co;2-r;;11029758;;3754261;;pmc2114156;;10.1083/jcb.102.4.1151;;10.1111/j.1432-0436.1984.tb00280.x;;6084626;;1710251;;pmc1467750;;10.1046/j.1469-7580.1998.19220161.x;;9643417;;10.1002/jcp.1041460306;;2022691;;1689217;;10.1016/0092-8674(90)90662-x;;10688780;;10.1126/science.287.5457.1425;;11326082;;10.1126/science.1058866;;7813631;;10.1006/excr.1995.1005;;8126078;;10.1002/jcp.1041580322;;1511696;;10.1006/excr.1999.4708;;10585291;;10.1101/gad.10.10.1173;;8675005;;8791524;;10.1016/s0959-437x(96)80066-9;;9182765;;10.1016/s0092-8674(00)80260-3;;pmc2288926;;2007619;;10.1083/jcb.113.1.147;;1694181;;10.1002/jcp.1041430304;;2015398;;10.1182/blood.v77.8.1723.1723;;10.1182/blood.v77.8.1723.bloodjournal7781723;;10102814;;10.1126/science.284.5411.143;;9082988;;10.1126/science.276.5309.71;;10.1006/excr.1995.1329;;7556447;;9369534;;10.1007/s004410050964;;10915564;;10.1006/exnr.2000.7389;;10.1006/dbio.1999.9565;;10656756;;10.1006/excr.1998.4045;;9633508;;8609176;;10.1083/jcb.133.2.457;;pmc2120800,"U.S. Appl. No. 09/936,665, filed Sep. 10, 2001, Katz et al., Adipose-Derived Stem Cells and Lattices.;;U.S. Appl. No. 09/952,522, filed Sep. 10, 2001, Katz et al., Adipose-Derived Stem Cells and Lattices.;;Avital, I., D. Inderbitzin, et al. (2001). ""Isolation, characterization, and transplantation of bone marrow-derived hepatocyte stem cells."" Biochem Biophys Res Commun 288(1):156-64.;;Carmeliet, P. and A. Luttan (2001). ""The emerging role of the bone marrow-derived stem cells in (therapeutic) angiogenesis."". Thromb Haemost 86(1): 289-97.;;Castro-Malaspina, H., W. Ebell, et al. (1984). ""Human bone marrow fibroblast colony-forming units (CFU-F)."" Prog Clin Biol Res 154: 209-36.;;Coleman, S. R. (1995). ""Long-term survival of fat transplants: controlled demonstrations."" Aesthetic Plast Surg 19(5): 421-5.;;Coleman, S. R. (2001). ""Structural fat grafts: the ideal filler?"" Clin Plast Surg 28(1): 111-9.;;Coleman, W. P., 3rd (1991). ""Autologous fat transplantation."" Plast Reconstr Surg 88(4): 736.;;Connolly, J. F. (1998). ""Clinical use of marrow osteoprogenitor cells to stimulate osteogenesis."" Clin Orthop(355 Suppl): S257-66.;;Eremia, S. and N. Newman (2000). ""Long-term follow-up after autologous fat grafting: analysis of results from 116 patients followed at least 12 months after receiving the last of a minimum of two treatments."" Dermatol Surg 26(12): 1150-8.;;Fukuda, K. (2001). ""Development of regenerative cardiomyocytes from mesenchymal stem cells for cardiovascular tissue engineering."" Artif Organs 25(3): 187-93.;;Guerreresantos, J., A. Gonzalez-Mendoza, et al. (1996). ""Long-term survival of free fat grafts in muscle: an experimental study in rats."" Aesthetic Plast Surg 20(5): 403-8.;;Herwitz, E. M., D.J. Prockop, et al. (1999). ""Transplantability and therapeutic effects of bone marrow-derived meseachymal cells in children with osteogenesis imperfecta."" Nat Med 5(3): 309-13.;;Horwitz, E. M., D.J. Prochop, et al. (2001). ""Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta."" Blood 97(5): 1227-31.;;Huang, J.I., S.R. Beanes, et al. (2002). ""Rat extramedullary adipose tissue as a source of osteochondrogenic progenitor cells."" Plast Reconstr Surg 109(3): 1033-41; discussion 1042-3.;;Hutley L. J., A. C. Herington, et al. (2001). ""Human adipose tissue endothelial cells promote preadipocyte proliferation."" Am J Physiol Endocrinol Metab 281(5): E1037-44.;;Kern, P.A., A. Knedler, et al. (1983). ""Isolation and culture of microvascular endothelium from human adipose tissue."" J Clin Invest 71(6): 1822-9.;;Lee, J. H., Z. Ille, et al. (1996). ""Cell kinetics of repair after allyl alcohol-induced liver necrosis in mice."" Int J Exp Pathol 77(2): 63-72.;;Lee, P. E., R. C. Kung, et al. (2001). ""Periurethral autologous fat injection as treatment for female stress urinary incontinence: a randomized double-blind controlled trial."" J Urol 165(1): 153-8.;;Mizuno, H., P.A. Zuk, et al. (2002). ""Myogenic differentiation by human processed lipoaspirate cells."" Plast Reconstr Surg 109(1): 199-209; discussion 210-1.;;Murayama, T., O. M. Tepper, et al. (2002). ""Determination of bone marrow-derived endothelial progenitor cell significance in angiogenic growth factor-induced neovascularization in vivo."" Exp Hematol 30(8): 967-72.;;Murry C. E., R. W. Wiseman, et al. (1996). ""Skeletal myoblast transplantation for repair of myocardial necrosis."" J Clin Invest 98(11):2512-23.;;Muschier, G. F., H. Nitto, et al. (2001). ""Age- and gender-related changes in the cellularity of human bone marrow and the prevalence of osteoblastic progenitors."" J Orthop Res 19(1): 117-25.;;Nishimori, M., Y. Yamada, et al. (2002). ""Health-related quality of life of unrelated bone marrow donors in Japan."" Blood 99(6): 1995-2001.;;Orlic, D., J. Kajstura, et al. (2001). ""Transplanted adult bone marrow cells repair myocardial infarcts in mice."" Ann N Y Acad Sci 938: 221-9: discussion 229-30.;;Orlic, D., J. Kajstura, et al. (2001). ""Bone marrow cells regenerate infarcted myocardium."" Nature 410(6829): 701-5.;;Palma, P. C., C. L. Riccetto, et al. (1997). ""Repeated lipoinjections for stress urinary incontinence."" J Endourol 11(1): 67-70.;;Pittenger, M. F., A. M. Mackay, et al. (1999). ""Multilineage potential of adult human mesenchymal stem cells."" Science 284(5411): 143-7.;;Prockop, D. J., S. A. Azizi, et al. (2000). ""Potential use of marrow stromal cells as therapeutic vectors for diseases of the central nervous system."" Prog Brain Res 128: 293-7.;;Rajnoch, C., J. C. Chachques, et al. (2001) ""Cellular therapy reverses myocardial dysfunction."" J Thorac Cardiovasc Surg 121(5): 871-8. t&artType=abs&id=a112937&target=.;;Shi, Q., S. Rafil, et al. (1998). ""Evidence for circulating bone marrow-derived endothelial cells."" Blood 92(2): 362-7.;;Strauer, B. E., M. Brehm, et al. (2002). ""Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans."" Circulation 106(15): 1913-8.;;Takahashi T., C. Kalka, et al. (1999). ""Ischemia- and cytokine-inducted mobilization of bone marrow-derived endothelial progenitor cells for neovascularization."" Nat Med 5(4): 434-8.;;Thomas, E. D. (1994). ""Stem Cell Transplantation: Past, Present and Future."" Stem Cells 12: 539-544.;;Werlich, T., K.J. Stiller, et al. (1999). ""Experimental studies on the stem cell concept of liver regeneration. II."" Exp Toxicol Pathol 51(1): 93-8.;;Yavorkovsky, L., E. Lai, et al. (1995). ""Participation of small intraportal stem cells in tbe restitutive response of the liver to periportal necrosis Induced by allyl alcohol."" Hepatology 21(6): 1702-12.;;Yin, L., D. Lynch, et al. (1999). ""Participation of different cell types in the restitutive response of the rat liver to periportal injury induced by allyl alcohol."" J Hepatol 31(3): 497-507.;;Zak, P. A., M. Zhu, et al. (2001). ""Multilineage cells from human adipose tissue: implications for cell-based therapies."" Tissue Eng 7(2): 211-28.;;Considine, et al., ""Paracrine stimulation of preadipocyte-enriched cell cultures by mature adipocytes,"" American Journal of Physiology 1996 270(5) E895-E899 (Exhibit 6).;;Dani, et al., ""Differentiation of embryonic stem cells into adipocytes in vitro,""J.Cell Sci. 1997 110. 1279-1285 (Exhibit 7).;;Entenmann, et al., ""Relationship between replication and differentiation cultured human adipocyte precursor cells,"" American Phys.Soc. 1996 270,C1011-C1016 (Exhibit 8).;;Eslami Varzaneh, et al. ""Extracellular Matrix Components Secreted by Microvascular Endothelial Cells Stimulate Preadipocyte Differentiation in Vitro,"" Metabolism 1994 43(7), 906-912 (Exhibit 9).;;Hauner, et al., ""Endothelin-I Inhibits the Adipose Differentiation of Cultured Human Adipocyte Precursor Cells""; Metabolism 1994 43(2) pp. 227-232 (Exhibit 10).;;Hausman, et al., ""The Influence of Extracellular Matrix Substrata on Preadipocyte Development in Serum-Free Cultures of Stromal-Vascular Cells,"" J. Anim.Sci. 1996 74(9):2117-2128 (Exhibit 11).;;Hui-Ling et al., ""Increased expression of G in mouse embryo stem cells promotes terminal differentiation to adipocytes"" American Physiological Society 1993 265(6), C1729-C1735 (Exhibit 12).;;Marko, et al., ""Isolation of a Preadipocyte Cell Line from Rat Bone Marrow and Differentiation to Adipocytes,"" Endocrinology 1995 136(10), 4582-4588 (Exhibit 13).;;Shillabeer, et al., ""A novel method for studying preadipocyte differentiation in vitro."" Intl. J. Obesity 1996 20(Supp. 3), S77-S83 (Exhibit 14).;;Sorisky et al., ""From preadipocyte to Adipocyte: Differentiation-Directed Signals of Insulin from the Cell Surface to the Nucleus,"" Critical Review in Clinical Laboratory Sciences 1999 36(1),1-34 (Exhibit 15).;;Vassaux et al., ""Proliferation and differentiation of Rat Adipose Precursor Cells in Chemically Defined Medium: Differential Action of Anti-Adipogenic Agents,"" Journal of Cellular Physiology 1994 161(2), 249-256 (Exhibit 16).;;Wabitsch, et al., ""Biological Effects of Human Growth Hormone in Rat Adipocyte Precursor Cells and Newly Differentiated Adipocytes in primary Culture,"" Metabolism 1996 vol. 45, No. 1 pp. 34-42 (Exhibit 17).;;Bennett, JH, et al. 1991 J. Cell Sci. ""Adipocytic cells cultured from marrow have osteogenic potential,"" 99(Ptl):131-139 (Exhibit 26).;;Beresford, et al., 1986 Endo. ""1,25- Dihydroxyvitamin D3 and Human Bone-Derived Cells in Vitro: Effects on Alkaline Phosphatase, Type I Collagen and Proliferation""; 119:1776-1785 (Exhibit 27).;;Bjornson, et al., 1999 Science ""Turning Brain into Blood: A Hematopoetic Fate Adopted by Adult Neural Stem Cells in Vivo,"" 283:534-537 (Exhibit 28).;;Bruder, et al., 1997 J. Cell Biochem ""Growth Kinetics, Self-Renewal, and the Osteogenic Potential of Purified Human Mesenchymal Stem Cells During Extensive Subcultivation and Following Cryopreservation,"" 64:278-294 (Exhibit 29).;;Butler-Browne, et al., 1990 Anat. Embryol. (Berl) ""Myosin heavy and light chain expression during human skeletal muscle development and precocious muscle maturation induced by thyroid hormone,"" 181:513-522 (Exhibit 30).;;Cheng S-L., et al.,1994 Endo ""Differentiation of Human Bone Marrow Osteogenic Stromal Cells in Vitro: Induction of the Osteoblast Phenotype by Dexamethasone,"" 134: 277-286 (Exhibit 31).;;Chyun, et al., 1984 Endo. ""Cortisol Decreases Bone Formation by Inhibiting Periosteal Cell Proliferation,"" 114:477-480 (Exhibit 32).;;Conger, PA and JJ Minguell 1999 J. Cell. Physiol""Phenotypical and Functional Properties of Human Bone Marrow Mesenchymal Progenitor Cells,"" 181:67-73 (Exhibit 33).;;Cooper, et al 1999 J. Endocrinol. ""Glucocorticoid activity, inactivity and the osteoblast,"" 163:159-164 (Exhibit 34).;;Deaker, A.E., et al.,1995 Differentiation ""Formation of cartilage-like spheroids by micromass cultures of murine C3H101/2 cells upon treatment with transforming growth factor-beta1,"" 59: 25-34 (Exhibit 35).;;Deaker, et al., 1999 Differentiation ""Chondrogenic differentiation of murine C3HI0T1/2 multipotential mesenchymal cells: I. Stimulation by bone morphogenetic protein-2 in high-density micromass cultures,"" 64:67-76(Ezhibit 36).;;Dimri, et, al., 1995 Proc. Natl. Acad. Sci. USA ""A biomarker that identifies a senescent human cells in culture and in aging skin in vivo,"" 92: 9363-9367 (Exhibit 37).;;Ducy, et, al., 1997 Cell ""Osf2/Cbfa1: A Transcriptional Activator of Osteoblast Differentiation,"" 89:747-754 (Exhibit 38).;;Ferrari G., et al., 1998 Science ""Muscle Regeneration by Bone Marrow-Derived Myogenic Progenitors,"" 279:1528-1530 (Exhibit 39).;;Frederikson and McKay 1988 J. Neurosci. ""Proliferation and Differentiation of Rat Neuroepithelial Precursor Cells in vivo,"" 8:1144-1151 (Exhibit 40).;;Fridman, et al, 1992 Int. J. Cancer ""Malignant Transformation ofNIH-3T3 Cells After Subcutaneous co-Injection With a Reconstituted Basement Membrane (Matrigel),"" 51(5), 740-44 (Exhibit 41).;;Grigoradis A., et al., 1988 J. Cell Biol. ""Differentiation of Muscle, Fat, Cartilage, and Bone from Progenitor Cells Present in a Bone-derived Clonal Cell Population: Effect of Dexamethasone,"" 106: 2139-2151(Exhibit 42).;;Guerriero, V and JR Florini 1980 Endocrinology ""Dexamethasone Effects on Myoblast Proliferation and differentiation,"" 106:1198-1202(Exhibit 43).;;Hall, BK 1981 ""Intracellular and extracellular control of differentiation of cartilage and bone,"" Histochem. J. 13:599-614(Exhibit 44).;;Jaiswal, et al., 1997 ""Osteogenic Differentiation of Purified, Culture-Expanded Human Mesenchymal Stem Cells In Vitro,"" J. Cell Biochem. 64:295-312(Exhibit 45).;;Johnstone B., et al., 1998 ""In Vitro Chondrogenesis of Bone Marrow-Derived Mesenchymal Progenitor Cells,"" Exp. Cell Res. 238: 265-272(Exhibit 46).;;Kania, et al., 1990 ""The Drosophila segmentation gene runt encodes a novel nuclear regulatory protein that is also expressed in the developing nervous system,"" Genes Dev. 4:1701-1713(Exhibit 47).;;Kehlen, A. et al., 2000 J. Cell Biochem. ""Increased Lymphocytic Aminopeptidase N/CD13 Promoter Activity After Cell-Cells Contact."" 80:115-123(Exhibit 48).;;Kosher, RA, et al., 1986 J. Cell Biol. ""Collagen Gene Expression During Limb Cartilage Differentiation."" 102:1151-1156(Exhibit 49).;;Kuri-Harcuch, W. et al., 1984, Differentiation ""Extracellular matrix production by mouse 3T3-F442A cells during adipose differentiation in culture,"" 28(Exhibit 50).;;Lanier, L.L. et al., 1991 J. Immunol. ""Molecular and Functional Analysis of Human Natural Killer Cell-Associated Neural Cells Adhesion Molecule (N-Cam/CD56),""146:4421-4426(Exhibit 51).;;Lawson-Smith, M.J. and McGeachie, J.K. 1998 J. Anat. ""The identification of myogenic cells in skeletal muscle, with emphasis on the use of tritiated thymidine autoradiography and desmin antibodies,"" 192:161-171 (Exhibit 52).;;Leboy, et al.,1991 J. Cell Physiol. ""Dexamethasone Induction of Osteoblast mRNAs in Rat Marrow Stromal Cell Cultures,"" 146:370-378 (Exhibit 53).;;Lendahl, et al., 1990 Cell ""CNS Stem Cells Express a New Class of Intermediate Filament Protein,"" 60:585-595 (Exhibit 54).;;Lenoir, N. 2000 Science ""Europe Confronts the Embryonic Stem Cell Research Challenge,"" 287:1425-1427 (Exhibit 55).;;Lumelsky, N., et al. 2001 Science ""Differentiation of Embryonic Stem Cells to Insulin-Secreting Structures Similar to Pancreatic Islets,"" 292:1389-1394. (Exhibit 56).;;Lynch, et al., 1995, Exp. Cell Res. ""The Influence of Type I Collagen on the Development and Maintenance of the Osteoblast Phenotype in Primary and Passaged Rat Calvarial Osteoblasts: Modification of Expression of Genes Supporting Cell Growth, Adhesion, and Extracelluar Matrix Mineralization,"" 216:35-45 (Exhibit 57).;;Malaval, et al, 1994 J. Cell. Physiol. ""Cellular Expression of Bone-Related Proteins During In Vitro Ostegenesis in Rat Bone Marrow Stromal Cell Culture,"" 158:555-572 (Exhibit 58).;;Manduca, et al., 1992 Eur J. Cell Biol. ""Chondrogenic differentiation in chick embryo osteoblast cultures,"" 57:193-201 (Exhibit 59).;;Martin, et al., 1999 Exp. Cell Res. ""Mammalian Chondrocytes Expanded in the Presence of Fibroblast Growth Factor 2 Maintain the Ability to Differentiate and Regenerate Three-Dimensional Cartilaginous Tissue,"" 253:681-688 (Exhibit 60).;;Megeney, et al., 1996 Genes Dev. ""MyoD is required for myogenic stem cell function in adult skeletal muscle,"" 10:1173-1183 (Exhibit 61).;;Molkentin and Olson 1996 Curr. Opin. Genet. Dev. ""Defining the regulatory networks for muscle development."" 6:445-453 (Exhibit 62).;;Mundlos, et al., 1997 Cell ""Mutations Involving the Transcription Factor CBFA12 Cause Cleidocranial Dysplasia,"" 89:773-779 (Exhibit 63).;;Nehls, A. and D Drenckhahn 1991 J. Cell Biol. ""Heterogeneity of Microvascular Pericytes for Smooth Muscle Type Alpha-Actin,"" 113:147-154 (Exhibit 64).;;Owen, TA, et al., 1990 J. Cell Physiol. ""Progressive Development of the Rat Osteoblast Phenotype in Vitro: Reciprocal Relationships in Expression of Genes Associated with Osteoblast Proliferation and Differentiation During Formation of the Bone Extracellular Matrix,"" 143:420-430 (Exhibit 65).;;Paul S.R., et al., 1991 Blood ""Stromal Cell-Associated Hematopoiesia Immortalization and Characterization of Primate Bone Marrow-Derived Stromal Cell Line."" 77: 1723-33 (Exhibit 66).;;Pittenger M.F., et al., 1999 Science ""Multilineage Potential of Adult Human Mesenchymal Stem Cells,"" 284:143-147 (Exhibit 67).;;Prockop D.J. 1997 Science ""Marrow Stromal Cells as Stem Cells for Nonhematopoietic Tissues,"" 276: 71-74 (Exhibit 68).;;Rando, et al., 1995 Exp. Cell Res. ""The Fate of Myoblasts Following Transportation into Mature Muscle,"" 220:383-389 (Exhibit 69).;;Saalbach, A., et al., 1997 Cell and Tiss. Res. ""The Fibroblast-specific MAb AS02: a novel tool for detection and elimination of human fibroblasts,"" 290:593-599 (Exhibit 70).;;Sanchez-Ramos, et al., 2000 ""Adult Bone Marrow Stromal Cells Differentiate into Neural Cells in Vitro"" Exp. Neurol. 164:247-256 (Exhibit 71).;;Seale and Rudnicki 2000 Dev. Biol. ""A New Look at the Origin, Function, and ""Stem-Cell"" Status of Muscle Satellite Cells,"" 218:115-124 (Exhibit 72).;;Shukunami, C., et al., 1998 Exp. Cell Res. ""Sequential Progression of the Differentiation Program by Bone Morphogenetic Protein-2 in Chondrogenic Cell Line ATDC5,"" 241:1-11 (Exhibit 73).;;Shukunami C., et. al., 1996 Journ. of Cell Bio. ""Chrondrogenic Differentiation of Clonal Mouse Embryonic Cell Line ATDC5 In Vitro: Differentiation-dependent Gene Expression of Parathyroid Hormone (PTH)/PTH-related Peptide Receptor,"" 133:2:457-468 (Exhibit 74).",INACTIVE
911,US,A,US 1068493 A,037-499-090-623-496,1913-07-29,1913,US 1911/0621807 A,1911-04-18,US 1911/0621807 A,1911-04-18,FOLLOWER.,,GEORGE B MELENEY,FRASER JOHN A;;MARTIN CHESTER H,,https://lens.org/037-499-090-623-496,Granted Patent,no,0,1,1,1,0,B42F17/02;;B42F17/02,,,0,0,,,,EXPIRED
912,BR,A2,BR PI0908977 A2,037-264-406-857-568,2015-08-04,2015,BR PI0908977 A,2009-03-19,GB 0805113 A;;GB 0809263 A;;GB 2009000744 W,2008-03-19,Recipiente selado,"A container (1) for the storage of a carbonated drink, comprising a container body with an opening that defines an axis and a removable closure (3) for closing the opening, the closure including a foil (2) for bonding to the container to close the opening in a gas-tight manner, the foil also being connected to, or interacting with, the closure, such that initial rotation of the closure in a loosening direction relative to the container body distorts or deforms the foil in a manner such that further rotation of the. closure results in a peel force being applied to the bond between the foil and the container.",THREADLESS CLOSURES LTD,FRASER ANTHONY HENRY JOSEPH;;HEIN JOHN,,https://lens.org/037-264-406-857-568,Patent Application,no,0,0,7,9,0,B65D51/228;;B65D2251/0018;;B65D2251/0093;;B65D41/08;;B65D51/228;;B65D2251/0093;;B65D2251/0018;;B65D41/08,B65D51/22,,0,0,,,,DISCONTINUED
913,GB,A,GB 809860 A,051-282-973-834-860,1959-03-04,1959,GB 1033056 A,1956-04-04,GB 1033056 A,1956-04-04,Improvements relating to chairs convertible into beds and also collapsible for stowage and transport purposes,"809,860. Bed-settees. FRASER Ltd., H. S. April 4, 1957 [April 4, 1956], No. 10330/36, Class 52(2) In a bed-settee the foot section 20 is slidably housed in the seat frame 1 and the back frame 15 is mounted on links 7 which support it for use as a chair, the ends 16 of the frame Fig. 9 below the link pivots 18 bearing against stops 10 on the seat frame. The back frame can also fold forwardly over the seat 'frame for stowage as in Fig. 3.",H S FRASER LTD,FRASER JOHN ARTHUR;;BROWN SIDNEY FREDERICK,,https://lens.org/051-282-973-834-860,Granted Patent,no,0,0,1,1,0,A47C17/2073,A47C17/207,A4J J11B6CY       -5;;A4J J11B6C3       -5;;A4J J11B6D        -5;;A4J J11B6E        -5;;A4J J11B6FY       -5;;A4J J11B6F1       -5;;A4J J11B6F2       -5;;A4J J11B8B1       -5;;A4J J11B8B2B      -5;;A4J J11B9B3       -5;;A4J J11B9C1       -5,0,0,,,,EXPIRED
914,FI,A,FI 36809 A,049-899-008-974-456,1967-04-10,1967,FI 36809D A,1960-08-15,FI 36809T A,1960-08-15,"Förfarande för framställning av en med överdrag försedd, medicinsk doseringsenhet",,FROSST & CO CHARLES E,FRASER MILLAR JOHN;;HARDER SAMUEL W,,https://lens.org/049-899-008-974-456,Granted Patent,no,0,0,1,1,0,,A61K9/00,,0,0,,,,EXPIRED
915,CA,A,CA 678970 A,065-608-543-170-086,1964-01-28,1964,CA 678970D A,,CA 678970T A,,TELEPHONE CABLE CONSTRUCTION AND METHOD OF MAKING THE SAME,,WHITNEY BLAKE CO,FRASER WILLIAM T;;COOK JOHN B,,https://lens.org/065-608-543-170-086,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
916,US,B2,US 9955722 B2,059-015-486-261-502,2018-05-01,2018,US 201514837860 A,2015-08-27,US 201514837860 A,2015-08-27,Dry herb and organic material water pipe body,"A portable, dishwasher safe, dry herb water pipe body capable of connection to a plethora of different fluid vessels. It has a flexible polymer bidirectional flow connector that facilitates the flow of smoke from and into the water pipe body. This flow connector also frictionally engages the neck of a bottle, jar or can, thereby sealing the fluid vessel to the body of the water pipe, completing its functionality. Ice can be placed in the water pipe to further cool the incoming smoke charge for the user. After use, if a disposable fluid vessel and fluid were used, the water pipe body can be removed and no further storage or cleaning action is required. With the optional plug, the device can be used in a dry smoke mode or fluid can be added into the plug for a shortened version of a water pipe.",REYES HARI MARK;;FRASER PHILLIP JOHN,REYES HARI MARK;;FRASER PHILLIP JOHN,,https://lens.org/059-015-486-261-502,Granted Patent,yes,6,5,2,2,0,A24F1/32;;A24F1/32;;A24F1/30;;A24F1/30;;A24F5/00;;A24F5/00,A24B3/14;;A24F1/30;;A24F1/32;;A24F5/00,,0,0,,,,INACTIVE
917,AU,A1,AU 2006/283366 A1,062-109-435-540-398,2007-03-01,2007,AU 2006/283366 A,2006-08-25,GB 0517382 A;;GB 2006003186 W,2005-08-26,Method,,PLASTICELL LTD,HORNBY FRASER;;GIRDLESTONE JOHN;;CHOO YEN,,https://lens.org/062-109-435-540-398,Patent Application,no,0,0,16,16,0,G01N33/5008;;G01N33/5023;;G01N33/5073;;Y10T436/2525;;Y10T436/25375;;Y10T436/13;;Y10T436/2525;;Y10T436/25375;;Y10T436/13;;G01N33/5008;;G01N33/5023;;G01N33/5073,C12N5/00;;G01N33/50,,0,0,,,,ACTIVE
918,CH,A,CH 133833 A,072-982-299-104-573,1929-06-30,1929,CH 133833D A,1928-03-01,GB 133833X A,1927-03-15,Appareil pour la mesure de liquide.,,FRASER JOHN;;BRITISH PETROLEUM CO,JOHN FRASER;;COMPANY LIMITED BRITISH PETROL,,https://lens.org/072-982-299-104-573,Granted Patent,no,0,0,1,1,0,,,60,0,0,,,,EXPIRED
919,WO,A1,WO 2008/135761 A1,051-528-200-222-536,2008-11-13,2008,GB 2008001567 W,2008-05-06,GB 0708626 A,2007-05-04,CLOSURE FOR A CONTAINER,"A closure comprising a cap (31) and a collar (32) by means of which the cap (31) can be secured to the container (33), the collar (32) comprising a ring (32A) and being moveable between a contracted configuration and an expanded configuration such that parts of the collar (32) are radially moveable between inner and outer positions. The cap (31) and collar (32) having mutually engageable parts (32c, 42c) providing for rotatable engagement between the cap (31) and collar (32) between a first position in which the collar (32) is in the expanded configuration (so the closure can be fitted to and removed from the container (33)) and a second position in which the collar (32) is in the contracted configuration so said radially moveable parts are held in engagement with the container (33) (whereby the closure is secured to the container). Furthermore, the closure has a tamper-evident feature (34, 35).",MEADWESTVACO CORP;;FRASER ANTHONY HENRY JOSEPH;;HEIN JOHN,FRASER ANTHONY HENRY JOSEPH;;HEIN JOHN,,https://lens.org/051-528-200-222-536,Patent Application,yes,7,4,4,4,0,B65D41/08;;B65D41/08;;B65D2401/15;;B65D2401/15,B65D41/08,,0,0,,,,PENDING
920,EP,A1,EP 3079743 A1,071-178-454-198-415,2016-10-19,2016,EP 14868882 A,2014-12-10,AU 2013/904823 A;;AU 2014/050406 W,2013-12-11,MEDICAMENT APPARATUS AND METHOD,,MOTU CORDIS DE,FRASER JOHN FRANCIS;;GREGORY SHAUN DAVID,,https://lens.org/071-178-454-198-415,Patent Application,yes,0,0,17,17,0,A61M11/02;;A61M11/06;;A61M15/0028;;A61M15/0065;;A61M16/0048;;A61M16/0078;;A61M16/06;;A61M16/208;;A61M2202/064;;A61M2206/14;;A61M2209/06;;A61M2230/06;;A61M2230/42;;A61M16/049;;A61M15/0021;;A61M15/0031;;A61M15/0043;;A61M15/0048;;A61M15/0051;;A61M16/0084;;A61M2205/50;;A61M16/14;;A61K31/4166;;A61K31/137;;A61K9/0075;;A61K31/485;;A61K31/5517;;A61K31/7004;;A61P9/04;;A61P3/00;;A61P37/00;;A61M16/0048;;A61M16/06;;A61M16/208;;A61M2206/14;;A61M15/0031;;A61M15/0048;;A61M16/0084;;A61M2209/06;;A61M16/0078;;A61M11/02;;A61M2230/06;;A61M15/0051;;A61M15/0043;;A61M2205/50;;A61M15/0065;;A61M2230/42;;A61M11/06;;A61M15/0028;;A61M15/0021;;A61M16/049;;A61M2202/064;;A61M16/14;;A61H31/00;;A61M16/0057;;A61M16/04;;A61M16/0816;;A61M2202/0208,A61M13/00;;A61M16/00;;A61M37/00,,0,0,,,,ACTIVE
921,CA,A,CA 1246480 A,074-418-730-595-695,1988-12-13,1988,CA 494940 A,1985-11-08,CA 494940 A,1985-11-08,METHOD OF REMOVING SOLID WAX STRUCTURES DEPOSITED IN OIL AND GAS FACILITIES,": A method is described for removing solid adherent wax structures deposited in oil and gas production and processing facilities. It comprises contacting a gas with the wax deposit at superatmospheric pressure, so that the gas dissolves into the solid wax thereby causing the wax structure to liquify or else a subsequent pressure reduction causes the wax structure for foam and break up for easy removal.",PETRO CANADA INC,NENNIGER JOHN E;;CUTTEN FRASER B,,https://lens.org/074-418-730-595-695,Granted Patent,no,0,0,1,1,0,B08B3/003;;B08B3/08;;B08B7/00;;C09K8/524;;E21B37/06,B08B3/00;;B08B3/08;;B08B7/00;;C09K8/524;;E21B37/06,196-68,0,0,,,,EXPIRED
922,US,A1,US 2010/0152575 A1,087-950-160-330-523,2010-06-17,2010,US 63893009 A,2009-12-15,US 63893009 A;;US 35093609 A;;US 1962208 P;;US 9845608 P;;US 12250608 P;;US 10486208 P;;US 13803108 P,2008-01-08,"Mathematical Relationship of Strain, Neurological Dysfunction and Abnormal Behavior Resulting from Neurological Dysfunction of the Brainstem",A therapeutic method for treating a neurological disease by evaluating and correcting an abnormal neuraxial angle that cause abnormal biomechanically induced neuraxial stress and strain.,POLARIS BIOTECHNOLOGY INC,HENDERSON FRASER CUMMINS;;NEWMAN JOHN W,POLARIS BIOTECHNOLOGY INC (2010-02-04),https://lens.org/087-950-160-330-523,Patent Application,yes,99,11,2,27,0,A61B17/7055;;A61B17/7055;;A61B17/7011;;A61B17/7011;;A61B17/7043;;A61B17/7043;;A61B17/7044;;A61B17/7044;;A61B17/7049;;A61B17/7049;;A61B17/7052;;A61B17/7052;;A61B17/8061;;A61B17/8061,A61B5/05;;A61B17/70,600/425;;606/279,0,0,,,,ACTIVE
923,EP,A4,EP 3079743 A4,085-363-415-078-827,2018-02-28,2018,EP 14868882 A,2014-12-10,AU 2013/904823 A;;AU 2014/050406 W,2013-12-11,MEDICAMENT APPARATUS AND METHOD,,DE MOTU CORDIS PTY LTD,FRASER JOHN FRANCIS;;GREGORY SHAUN DAVID,,https://lens.org/085-363-415-078-827,Search Report,no,10,0,17,17,0,A61M11/02;;A61M11/06;;A61M15/0028;;A61M15/0065;;A61M16/0048;;A61M16/0078;;A61M16/06;;A61M16/208;;A61M2202/064;;A61M2206/14;;A61M2209/06;;A61M2230/06;;A61M2230/42;;A61M16/049;;A61M15/0021;;A61M15/0031;;A61M15/0043;;A61M15/0048;;A61M15/0051;;A61M16/0084;;A61M2205/50;;A61M16/14;;A61K31/4166;;A61K31/137;;A61K9/0075;;A61K31/485;;A61K31/5517;;A61K31/7004;;A61P9/04;;A61P3/00;;A61P37/00;;A61M16/0048;;A61M16/06;;A61M16/208;;A61M2206/14;;A61M15/0031;;A61M15/0048;;A61M16/0084;;A61M2209/06;;A61M16/0078;;A61M11/02;;A61M2230/06;;A61M15/0051;;A61M15/0043;;A61M2205/50;;A61M15/0065;;A61M2230/42;;A61M11/06;;A61M15/0028;;A61M15/0021;;A61M16/049;;A61M2202/064;;A61M16/14;;A61H31/00;;A61M16/0057;;A61M16/04;;A61M16/0816;;A61M2202/0208,A61M11/02;;A61K9/00;;A61K9/16;;A61K31/137;;A61K31/7004;;A61M11/06;;A61M15/00;;A61M16/00;;A61M16/04;;A61M16/06;;A61M16/14;;A61M16/20,,1,0,,,See also references of WO 2015085362A1,ACTIVE
924,EP,A2,EP 2559533 A2,103-103-458-638-011,2013-02-20,2013,EP 12191590 A,2009-09-24,US 10042708 P;;EP 09737489 A;;US 2009/0058220 W,2008-09-26,Casting,"Certain exemplary embodiments can provide a composition, system, machine, device, manufacture, circuit, and/or user interface adapted for, and/or a method and/or machine-readable medium comprising machine-implementable instructions for, activities that can comprise, after removing a cast device from a stack-lamination-derived mold, said cast device formed from a molding composition, applying a desired shape to said cast device to form a shaped cast device, said molding composition comprising: a ceramic composition comprising silica; an cycloaliphatic epoxy binder composition, said cycloaliphatic epoxy binder composition present in said molding composition in an amount up to 30% by weight of said molding composition; a silicone composition comprising a siloxane resin, said silicone composition present in said molding composition in an amount up to 30% by weight of said molding composition; and a solvent composition adapted to dissolve said cycloaliphatic epoxy binder composition and said silicone composition.
",MIKRO SYSTEMS INC,APPLEBY MICHAEL;;FRASER IAIN;;PAULUS JOHN,UNITED TECHNOLOGIES CORPORATION (2019-04-24),https://lens.org/103-103-458-638-011,Patent Application,yes,159,15,17,17,0,B23P15/246;;B29C33/301;;B29C33/38;;B29C33/3835;;A61B6/4258;;B22C9/04;;Y10T428/24479;;B22C9/10;;C08L63/00;;C08L83/04;;Y10T428/24479;;B23P15/246;;B29C33/301;;B29C33/38;;B29C33/3835;;A61B6/4258;;B22C9/04;;C08L63/00;;C08L83/04;;B22C9/10,B29C33/30;;A61B6/00;;B22C9/00;;B23P15/24;;B29C33/38;;C08K3/22,,0,0,,,,ACTIVE
925,CA,A,CA 1247741 A,100-135-305-779-216,1988-12-28,1988,CA 508862 A,1986-05-12,US 73603385 A,1985-05-20,OPTICALLY PULSED ELECTRON ACCELERATOR,"An optically pulsed electron accelerator can be used as an injector for a free electron laser and comprises a pulsed light source, such as a laser, for providing discrete incident light pulses. A photoemissive electron source emits electron bursts having the same duration as the incident light pulses when impinged upon by same. The photoemissive electron source is located on an inside wall of a radio frequency-powered accelerator cell which accelerates the electron burst emitted by the photoemissive electron source.",US GOV ENERGY,FRASER JOHN S;;SHEFFIELD RICHARD L,,https://lens.org/100-135-305-779-216,Granted Patent,no,0,0,10,10,0,H01S3/0903;;H05H7/18;;H05H9/00;;H01S3/0903;;H05H9/00;;H05H7/18,H01S3/09;;H05H7/18;;H05H9/00,353-14,0,0,,,,EXPIRED
926,EP,A1,EP 0857302 A1,104-438-195-859-429,1998-08-12,1998,EP 96935076 A,1996-10-24,GB 9602602 W;;GB 9522060 A,1995-10-27,CHARACTERISATION OF FLOWING DISPERSIONS,,DISPERSE TECH LTD,WILLIAMS RICHARD ANDREW;;DICKIN FRASER JOHN,DISPERSE LIMITED (2002-06-19),https://lens.org/104-438-195-859-429,Patent Application,yes,0,0,8,8,0,G01N15/1031;;G01N27/20;;G01N2015/1024;;G01N27/20;;G01N15/1031;;G01N2015/1024,G01N15/06;;G01N15/10;;G01N27/20,,0,0,,,,EXPIRED
927,EP,A3,EP 0841644 A3,113-667-133-312-415,1999-02-03,1999,EP 97308839 A,1997-11-04,GB 9623190 A,1996-11-06,Cash handling,"A cash dispensing apparatus characterised by comprising:
 a storage unit (11) having a plurality of discrete locations (13) within which parcels (21) of cash of one or more predetermined values can be stored, input means for a user to input a demand for a parcel, and, a mechanism (15) for, on demand, extracting an appropriate parcel (21) from its predetermined location and delivering that parcel to a collection location (22) for receipt by the demander.",AIR TUBE CONVEYORS,HENDERSON FRASER CRISFIELD;;LIVY JOHN VICTOR,,https://lens.org/113-667-133-312-415,Search Report,yes,7,0,4,4,0,G07D11/135;;G07D11/34;;G07D11/40,G07D11/00,,0,0,,,,DISCONTINUED
928,US,A1,US 2016/0305220 A1,126-441-654-603-277,2016-10-20,2016,US 201515100737 A,2015-01-27,GB 201401490 A;;GB 201415970 A;;GB 201419993 A;;GB 2015050185 W,2014-01-29,IMPROVED METHOD FOR LAUNCHING A CLEANING ELEMENT,A deformable cleaning element is encased within soluble packaging to maintain deformation. The deformed cleaning element is launched into the bore of a drill pipe/conduit or tubular. Contact with fluids within the bore dissolves the soluble packaging allowing the cleaning element to expand to its original shape.,CORETRAX TECH LTD,FRASER JOHN;;BODMAN CHERISH;;FONG JASON,CORETRAX GLOBAL LIMITED (2022-04-21);;CORETRAX TECHNOLOGY LIMITED (2016-05-20),https://lens.org/126-441-654-603-277,Patent Application,yes,1,7,10,13,0,B08B9/055;;B08B9/055;;B08B9/055;;B08B9/055;;B08B9/0555;;B65D65/46;;B65D81/264;;E21B37/10;;E21B37/10;;E21B37/00;;E21B37/02;;E21B37/08;;E21B37/08;;E21B37/08;;E21B37/10;;F16L55/40;;F16L55/42;;F16L55/42;;F16L55/44;;F16L55/46;;F16L55/46;;F16L2101/12,E21B37/10;;B08B9/055;;B65D65/46;;B65D81/26;;F16L55/46,,0,0,,,,ACTIVE
929,AU,A1,AU 2007/313555 A1,131-050-171-311-58X,2008-04-24,2008,AU 2007/313555 A,2007-10-18,AU 2006/905858 A;;NZ 2007000315 W;;AU 2007/313555 A,2006-10-20,SSL7 mutants and uses therefor,,AUCKLAND UNISERVICES LTD;;MACFARLANE BURNET INSTITUTE FOR MEDICAL RES AND PUBLIC HEALTH LIMITED,WINES BRUCE DAVID;;FRASER JOHN DAVID,,https://lens.org/131-050-171-311-58X,Patent Application,no,0,0,8,8,0,C07K1/14;;C07K14/31;;C07K16/12;;C07K14/31;;C07K14/31;;C07K2317/52;;C07K2317/52;;C07K2319/30;;C07K2319/30,C07K1/14;;C07K16/12;;C12N15/11;;C12N15/31,,0,0,,,,DISCONTINUED
930,DK,T3,DK 3079743 T3,121-183-472-353-966,2022-10-17,2022,DK 14868882 T,2014-12-10,AU 2013/904823 A;;AU 2014/050406 W,2013-12-11,ANORDNING,,DE MOTU CORDIS,FRASER JOHN FRANCIS;;GREGORY SHAUN DAVID,,https://lens.org/121-183-472-353-966,Granted Patent,no,0,0,17,17,0,A61M11/02;;A61M11/06;;A61M15/0028;;A61M15/0065;;A61M16/0048;;A61M16/0078;;A61M16/06;;A61M16/208;;A61M2202/064;;A61M2206/14;;A61M2209/06;;A61M2230/06;;A61M2230/42;;A61M16/049;;A61M15/0021;;A61M15/0031;;A61M15/0043;;A61M15/0048;;A61M15/0051;;A61M16/0084;;A61M2205/50;;A61M16/14;;A61K31/4166;;A61K31/137;;A61K9/0075;;A61K31/485;;A61K31/5517;;A61K31/7004;;A61P9/04;;A61P3/00;;A61P37/00;;A61M16/0048;;A61M16/06;;A61M16/208;;A61M2206/14;;A61M15/0031;;A61M15/0048;;A61M16/0084;;A61M2209/06;;A61M16/0078;;A61M11/02;;A61M2230/06;;A61M15/0051;;A61M15/0043;;A61M2205/50;;A61M15/0065;;A61M2230/42;;A61M11/06;;A61M15/0028;;A61M15/0021;;A61M16/049;;A61M2202/064;;A61M16/14;;A61H31/00;;A61M16/0057;;A61M16/04;;A61M16/0816;;A61M2202/0208,A61M11/02;;A61K9/00;;A61K31/137;;A61K31/4166;;A61K31/485;;A61K31/5517;;A61K31/7004;;A61M11/06;;A61M15/00;;A61M16/00;;A61M16/04;;A61M16/06;;A61M16/14;;A61M16/20;;A61P3/00;;A61P9/04;;A61P37/00,,0,0,,,,ACTIVE
931,US,A,US 3102160 A,142-785-758-783-777,1963-08-27,1963,US 16159561 A,1961-12-22,US 16159561 A,1961-12-22,Telephone cable construction,,WHITNEY BLAKE CO,COOK JOHN B;;FRASER WILLIAM T,,https://lens.org/142-785-758-783-777,Granted Patent,no,1,51,1,1,0,H01B11/00;;H01B11/00;;H01B7/361;;H01B7/361,H01B7/36;;H01B11/00,,0,0,,,,EXPIRED
932,US,B1,US 6229147 B1,149-903-083-263-376,2001-05-08,2001,US 5126098 A,1998-09-03,GB 9520384 A;;GB 9602238 W,1995-10-06,Detector and method for autoradiography,"There is disclosed an autoradiography system which includes an autoradiography sample, a substantially radioisotope free microchannel plate (MCP), and an MCP signal collection means, wherein the MCP directly measures beta particles from radioisotopes within the sample.",UNIV LEICESTER,FRASER GEORGE WILLIAM;;LEES JOHN ERNEST,,https://lens.org/149-903-083-263-376,Granted Patent,yes,1,0,10,10,0,G01T1/28;;G01T1/2942;;G01T1/28;;G01T1/2942,G01T1/28;;G01T1/29,250/393;;250/370.09,0,0,,,,EXPIRED
933,GB,A,GB 2119299 A,147-697-519-678-584,1983-11-16,1983,GB 8206355 A,1982-03-04,GB 8206355 A,1982-03-04,MAKING CUTTING TOOLS,"Method and apparatus for constructing a pressknife for cutting out sheet material such as a leather, wherein machine instructions are generated containing data relating to a desired configuration of the press knife for cutting out a particular profile, the machine instructions are supplied to a bending device (36, 38, 40) and to a strip material feed device (62), the feed device supplies the strip material to the bending device so the bends are introduced into the strip material in accordance with the machine instructions, the formed strip material then being cut off from the stock and assembled and fixed to form the desired knife configuration, preferably being fixed around a support plate which is produced by a forming device (30) fed with machine instructions derived from the same source (12) as those controlling the bending and feeding devices.",PA MANAGEMENT CONSULT,ARCHER JOHN RICHARD;;ROSS PETER FRASER,,https://lens.org/147-697-519-678-584,Patent Application,no,6,0,15,15,0,B21D7/12;;B21D11/10;;B21D37/205;;B23P15/40;;B21D37/205;;B21D7/12;;B21D11/10;;B23P15/40,B21D7/12;;B23P15/28;;B21D11/10;;B23P15/40;;B23Q15/00,B3A A92           A92;;B3E EAE           EAE;;B3E E1EX          EAE;;B3E E1Y           EAE;;B3E E10F          EAE;;B3E E14J          EAE;;U1S S1643,0,0,,,,DISCONTINUED
934,BR,A2,BR 112018012822 A2,181-431-844-056-329,2018-12-04,2018,BR 112018012822 A,2016-12-15,GB 2016053945 W;;GB 201522544 A,2015-12-21,método de formação de um fecho de metal e fecho para recipiente,"um método de formação de um fecho liberável para um recipiente (10) tendo uma abertura circular (10a, 21b, 21), o método compreendendo liberar de forma amovível (23) uma porção da saia anular (21) do fecho a uma porção de gargalo do recipiente (10), por exemplo, por meio de uma rosca, subsequentemente localizando uma porção do fecho separada (22) do fecho sobre uma abertura (10a, 21b, 21) na porção de saia (21), e fixando de forma irreversível (23) a porção de fecho (22c, 22) à porção de saia (21), por exemplo, costurando, para formar um fecho que doseia a abertura (10a, 21b, 21) do recipiente (10) mas é liberável a partir disso desparafusando a porção de saia (21) da porção de gargalo do recipiente (10). um fecho compreendendo dois componentes, inicialmente separados, também é descrito: uma porção da saia anular (21) e uma porção de fecho (22c, 22) que podem ser fixadas de forma irreversível à porção de saia (21) depois da porção da saia anular (21) ter sido fixada de forma amovível à porção de gargalo de um recipiente (10). um produto intermediário compreendendo um recipiente (10) tendo uma porção da saia anular (21) de um fecho liberável fixado de forma amovível a uma porção de gargalo da mesma também é descrito bem como um método de encher um recipiente (10) compreendendo as etapas de fornecer um recipiente (10) tendo uma porção da saia anular (21) de um fecho liberável fixado de forma amovível a ele, enchendo o recipiente (10) através de uma abertura (10a, 21b, 21) na porção de saia (21) e subsequentemente localizando uma porção do fecho separada (22) do fecho sobre a abertura (10a, 21b, 21) na porção de saia (21), e fixando de forma irreversível (23) a porção de fecho (22c, 22) à porção de saia (21) de modo a formar um fecho que fecha a abertura (10a, 21b, 21) do recipiente (10) mas é liberável a partir disso. a abertura (10a, 21b, 21) da porção da saia anular (21) pode simular que a porção de abertura (10a, 21b, 21) (22c, 22) pode ser de forma similar à extremidade da lata aplicada a um corpo da lata convencional de modo que a porção de fecho (22c, 22) pode ser fixada de forma irreversível a uma porção de saia (21) (que foi fixada de forma amovível à porção de gargalo de um recipiente (10)) em uma linha de enchimento e fechamento de lata convencional.",THREADLESS CLOSURES LTD,ANTHONY HENRY JOSEPH FRASER;;JOHN HEIN,,https://lens.org/181-431-844-056-329,Patent Application,no,0,0,14,40,0,B65D43/0231;;B65D2543/00092;;B65D2543/0024;;B65D2543/00277;;B65D2543/00972;;B67B3/20;;B67B3/22;;B67C7/00;;B65B3/18;;B65D41/00;;B65D43/02;;B65D51/18;;B65D2251/00;;B65D43/0231;;B67B3/20;;B67B3/22;;B67C7/00;;B65D2543/00092;;B65D2543/00972;;B65D2543/00277;;B65D2543/0024;;B65D2543/00092;;B65D2543/0024;;B65D2543/00277;;B65D2543/00972;;B67B3/20;;B67C7/00;;B65D43/0231;;B67B3/22;;B65D43/0283;;B67C3/02,B65D41/06;;B65D43/02;;B65D51/16;;B67B3/20;;B67B3/22;;B67C3/02,,0,0,,,,DISCONTINUED
935,CA,A,CA 210219 A,185-195-202-050-770,1921-04-05,1921,CA 210219D A,,CA 210219T A,,DOOR FASTENER,,FRASER JOHN GEO;;EVANS GARFIELD I,FRASER JOHN GEO;;EVANS GARFIELD I,,https://lens.org/185-195-202-050-770,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
936,GB,A,GB 2339892 A,188-127-579-671-440,2000-02-09,2000,GB 9815707 A,1998-07-21,GB 9815707 A,1998-07-21,An underwater halogen lamp assembly,,CERTIKIN INTERNATIONAL LTD,FRASER JAMIE DAVID;;WHITESIDE JOHN MARK,,https://lens.org/188-127-579-671-440,Patent Application,no,5,0,3,3,0,F21V31/00;;F21S8/00;;F21W2131/401,F21S8/00;;F21V31/00,F4R RPR           RPR;;F4R R288          RPR;;F4R R335          RPR;;F4R R41Y          RPR;;F4R R410          RPR;;F4R R421          RPR;;F4R R514          RPR;;F4R R614          RPR;;F4R R653          RPR,0,0,,,,EXPIRED
937,EP,A2,EP 0006333 A2,197-706-795-986-722,1980-01-09,1980,EP 79301089 A,1979-06-08,AU 1979/053708 A;;GB 7826823 A;;ZA 796786 A,1978-06-13,Control system for hydraulically operated elements or systems.,"Apparatus and method for controlling the operation of two separately operable hydraulic arrangements such as elements, units circuits or systems, and in particular the winches (1P, 1S) for the warps (2P, 2S) of a trawl by monitoring the pressure conditions in the arrangements i.e. warps by transducers (45P, 45S) establishing reference pressures (57) for the primary operating conditions of the arrangements and comparing these reference pressures with the values obtained from monitoring in a comparator (54) and producing control signals which are use to vary the operation conditions of the arrangements to equalise them to the reference values. Provision is made for overall control by a microprocessor (55) to allow the system to deal with obstructions and to provide alarms and safety conditions when necessary.",ROBERTSON JAMES & SONS;;MILLS ELECTRONICS LTD,DEMPSTER DAVID FRASER;;WILSON JOHN JEFFREY,,https://lens.org/197-706-795-986-722,Patent Application,yes,0,1,9,11,0,A01K73/06;;B66D1/50;;A01K73/06;;B66D1/50,A01K73/06;;B66D1/50,,0,0,,,,DISCONTINUED
938,MX,A,MX 2018001065 A,000-060-050-365-230,2018-05-17,2018,MX 2018001065 A,2016-07-21,GB 2015052154 W;;GB 201518819 A;;GB 201522544 A;;GB 201601501 A;;GB 2016052215 W,2015-07-24,CONTAINER AND CLOSURE.,"A plastic or metal wide mouth container (10) with a metal closure, the container having an opening defining an axis and an outwardly projecting first member around the external surface of the container, the first member comprising a plurality of circumferentially spaced apart first portions, each first portion having an element with elongate upper and lower surfaces, said upper and lower surfaces thereof being substantially horizontal in the circumferential direction. The metal closure has a top part and a skirt part, the skirt part comprising an inwardly projecting second member around an internal surface thereof, the second member comprising a plurality of circumferentially spaced apart second portions, each second portion having an element with elongate upper and lower surfaces, said upper and lower surfaces thereof being substantially horizontal in the circumferential direction. The horizontal elements of the second portions are of a length such that they can pass through spaces between the first portions and are locatable beneath the first portions so as to secure the metal closure to the container. The closure has a sealing member (23) for providing a seal with a sealing surface of the container, the sealing surface (13) being a substantially vertical surface about the interior or exterior of a neck portion of the container and the second portions on the closure having an upwardly inclined end at one end thereof and a downwardly inclined end at the other end thereof which extend beyond said elongate upper and lower surfaces thereof, respectively. Rotation of the metal closure in a tightening direction drives the second portions down the downwardly inclined ends to move the closure downwards and to compress the seal member in a substantially horizontal direction into sealing engagement with the vertical sealing surface. Rotation of the closure in a loosening direction drives the second portions up the upwardly inclined ends to move the sealing member from the sealed position to a secured venting position. Further rotation in the loosening direction is required to remove the closure from the container.",THREADLESS CLOSURES LTD,JOHN HEIN;;ANTHONY HENRY JOSEPH FRASER,,https://lens.org/000-060-050-365-230,Patent Application,no,0,0,10,40,0,B65D41/065;;B65D41/065;;B65D43/0231;;B65D43/0231;;B65D2543/00972;;B65D2543/00972,B65D51/16;;B65D41/06;;B65D43/02,,0,0,,,,PENDING
939,EP,A3,EP 2559534 A3,015-961-314-104-935,2016-09-07,2016,EP 12191595 A,2009-09-24,US 10042708 P;;EP 09737489 A;;US 2009/0058220 W,2008-09-26,"Systems, devices, and/or methods for manufacturing castings","Certain exemplary embodiments can provide a composition, system, machine, device, manufacture, circuit, and/or user interface adapted for, and/or a method and/or machine-readable medium comprising machine-implementable instructions for, activities that can comprise, after removing a cast device from a stack-lamination-derived mold, said cast device formed from a molding composition, applying a desired shape to said cast device to form a shaped cast device, said molding composition comprising: a ceramic composition comprising silica; an cycloaliphatic epoxy binder composition, said cycloaliphatic epoxy binder composition present in said molding composition in an amount up to 30% by weight of said molding composition; a silicone composition comprising a siloxane resin, said silicone composition present in said molding composition in an amount up to 30% by weight of said molding composition; and a solvent composition adapted to dissolve said cycloaliphatic epoxy binder composition and said silicone composition.
",MIKRO SYSTEMS INC,APPLEBY MICHAEL;;FRASER IAIN;;PAULUS JOHN,RAYTHEON TECHNOLOGIES CORPORATION (2021-03-24);;UNITED TECHNOLOGIES CORPORATION (2019-04-24);;RTX CORPORATION (2023-11-01),https://lens.org/015-961-314-104-935,Search Report,yes,8,0,17,17,0,B23P15/246;;B29C33/301;;B29C33/38;;B29C33/3835;;A61B6/4258;;B22C9/04;;Y10T428/24479;;B22C9/10;;C08L63/00;;C08L83/04;;Y10T428/24479;;B23P15/246;;B29C33/301;;B29C33/38;;B29C33/3835;;A61B6/4258;;B22C9/04;;C08L63/00;;C08L83/04;;B22C9/10,B29C33/30;;A61B6/00;;B22C9/00;;B23P15/24;;B29C33/38;;C08K3/22,,0,0,,,,ACTIVE
940,EP,B1,EP 1638507 B1,012-679-000-406-203,2017-03-22,2017,EP 04776784 A,2004-06-18,US 2004/0019611 W;;US 47941803 P,2003-06-18,METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER,,CYTORI THERAPEUTICS INC,HEDRICK MARC H;;FRASER JOHN K,"CYTORI THERAPEUTICS, INC. (2006-11-22)",https://lens.org/012-679-000-406-203,Granted Patent,yes,1,0,14,221,0,C12N5/0667;;A61K35/28;;A61K35/44;;A61P13/00;;A61P37/06;;A61P43/00;;A61K48/00;;C12N5/0602,C12N5/0775;;A61K35/28;;A61K35/44,,6,5,010-094-842-952-554;;125-457-618-257-610;;075-313-715-654-605;;104-867-388-312-53X;;018-186-924-290-282,10.1089/107632701300062859;;11304456;;12475952;;10.1091/mbc.e02-02-0105;;pmc138633;;12573059;;10.1089/10430340360464714;;11125386;;10.1097/00005392-200101000-00037;;10.1111/j.1442-2042.2012.02999.x;;22435469,"ZUK P A ET AL: ""Multilineage cells from human adipose tissue: implications for cell-based therapies."", TISSUE ENGINEERING APR 2001, vol. 7, no. 2, April 2001 (2001-04-01), pages 211 - 228, ISSN: 1076-3279;;ZUK PATRICIA A ET AL: ""Human adipose tissue is a source of multipotent stem cells."", MOLECULAR BIOLOGY OF THE CELL DEC 2002, vol. 13, no. 12, December 2002 (2002-12-01), pages 4279 - 4295, ISSN: 1059-1524;;MORIZONO KOUKI ET AL: ""Multilineage cells from adipose tissue as gene delivery vehicles."", HUMAN GENE THERAPY 1 JAN 2003, vol. 14, no. 1, 1 January 2003 (2003-01-01), pages 59 - 66, ISSN: 1043-0342;;DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; November 2001 (2001-11-01), SELL S: ""The role of progenitor cells in repair of liver injury and in liver transplantation."", Database accession no. NLM11896989;;LEE ET AL: ""PERIURETHRAL AUTOLOGOUS FAT INJECTION AS TREATMENT FOR FEMALE STRESS URINARY INCONTINENCE: A RANDOMIZED DOUBLE-BLIND CONTROLLED TRIAL"", JOURNAL OF UROLOGY, LIPPINCOTT WILLIAMS & WILKINS, BALTIMORE, MD, US, vol. 165, no. 1, 1 January 2001 (2001-01-01), pages 153 - 158, XP005554356, ISSN: 0022-5347, DOI: 10.1097/00005392-200101000-00037;;YAMAMOTO T ET AL: ""Periurethral injection of autologous adipose-derived regenerative cells for the treatment of male stress urinary incontinence: Report of three initial cases"", INTERNATIONAL JOURNAL OF UROLOGY, CHURCHILL LIVINGSTONE, TOKYO, JP, vol. 19, no. 7, 1 July 2012 (2012-07-01), pages 652 - 659, XP009168249, ISSN: 0919-8172, [retrieved on 20120321]",ACTIVE
941,EP,A3,EP 2559535 A3,023-882-549-828-852,2016-09-07,2016,EP 12191597 A,2009-09-24,EP 09737489 A;;US 10042708 P,2008-09-26,"Systems, devices, and/or methods for manufacturing castings","Certain exemplary embodiments can provide a composition, system, machine, device, manufacture, circuit, and/or user interface adapted for, and/or a method and/or machine-readable medium comprising machine-implementable instructions for, activities that can comprise, after removing a cast device from a stack-lamination-derived mold, said cast device formed from a molding composition, applying a desired shape to said cast device to form a shaped cast device, said molding composition comprising: a ceramic composition comprising silica; an cycloaliphatic epoxy binder composition, said cycloaliphatic epoxy binder composition present in said molding composition in an amount up to 30% by weight of said molding composition; a silicone composition comprising a siloxane resin, said silicone composition present in said molding composition in an amount up to 30% by weight of said molding composition; and a solvent composition adapted to dissolve said cycloaliphatic epoxy binder composition and said silicone composition.
",MIKRO SYSTEMS INC,APPLEBY MICHAEL;;FRASER IAIN;;PAULUS JOHN,RAYTHEON TECHNOLOGIES CORPORATION (2021-03-24);;UNITED TECHNOLOGIES CORPORATION (2019-04-24);;RTX CORPORATION (2023-11-01),https://lens.org/023-882-549-828-852,Search Report,yes,9,0,17,17,0,B23P15/246;;B29C33/301;;B29C33/38;;B29C33/3835;;A61B6/4258;;B22C9/04;;Y10T428/24479;;B22C9/10;;C08L63/00;;C08L83/04;;Y10T428/24479;;B23P15/246;;B29C33/301;;B29C33/38;;B29C33/3835;;A61B6/4258;;B22C9/04;;C08L63/00;;C08L83/04;;B22C9/10,B29C33/30;;A61B6/00;;B22C9/00;;B23P15/24;;B29C33/38;;C08K3/22,,0,0,,,,PENDING
942,NO,L,NO 20053107 L,025-771-803-912-808,2005-08-26,2005,NO 20053107 A,2005-06-24,US 30589602 A;;IB 0306396 W,2002-11-27,Fleksibelt rorformet element med tettende tape lag.,Et fleksibelt rør hvor et lag av viklet bånd strekker seg nærliggende en overflate av et rørelement for å begrense eller hindre molekylmigrering gjennom rørelementet.,WELLSTREAM INT LTD,FRASER DANA JOHN;;FIRTH CHARLES BASIL,"TRINITY BAY EQUIPEMENT HOLDINGS, US (2017-10-02)",https://lens.org/025-771-803-912-808,Abstract,no,0,0,26,26,0,F16L11/04;;F16L11/081;;F16L11/081;;F16L11/081;;F16L11/04;;F16L11/04;;F16L11/08;;F16L11/12;;F16L11/12;;F16L11/12,F16L11/04;;F16L11/12,,0,0,,,,EXPIRED
943,GB,A,GB 2422669 A,055-299-077-865-403,2006-08-02,2006,GB 0501878 A,2005-01-31,GB 0501878 A,2005-01-31,Article and a mobile networkable device for reading navigational data from an article,"A mobile networkable device eg. mobile phone or PDA (50), includes a reader (60) adapted to read a memory tag (20) on an article (2), such as a printed document. In use, the reader (60) reads the memory tag (20) on the article (2) to obtain co-ordinate data for a location B of a place mentioned in the article. The device (50) communicates the co-ordinate data of destination location B to the server system (76) in addition to the location of the device (50). The device (50) then receives route data from the server (76). The route (and/or map) data received is dependent on the location of the device (50), and location of the destination B.",HEWLETT PACKARD DEVELOPMENT CO,DICKIN FRASER JOHN;;LOH WENG WAH,,https://lens.org/055-299-077-865-403,Patent Application,no,7,5,3,3,0,G01C21/3623;;G01C21/3623;;G09B29/10;;G09B29/10,G01C21/00;;G01C21/20;;G01C21/36;;G09B29/10,G1F F1H           F1H,0,0,,,,DISCONTINUED
944,GB,A8,GB 2558172 A8,051-983-335-003-749,2018-12-26,2018,GB 201606224 A,2016-04-12,GB 201606224 A,2016-04-12,A method for cleaning drill pipe,A method of cleaning the internal diameters of drill pipe comprises of a cleaning tool 1 comprising a cleaning element such as radially extending bristles 4; the overall mass of the tool overcomes the buoyancy and friction force of the fluid in the pipe and allows the cleaning tool to fall through the pipe under its own weight; the method further comprises a landing sub 7 (Figure 4) with an internal profile which catches and prevents the tool from travelling further down the pipe. The tool may comprise a handle 2 and a nose 5. The tool can be uncoupled so that different sections can be replaced. The cleaning tool may comprise a tracking device so that it can be located in the pipe.,CORETRAX TECH LIMITED,JOHN FRASER;;CHERISH BODMAN;;JASON FONG,,https://lens.org/051-983-335-003-749,Patent Application,no,0,0,3,3,0,E21B37/02;;E21B17/006;;B08B9/049;;B08B9/04;;E21B37/02;;F16L55/26,E21B37/02;;B08B9/04;;E21B31/00;;F16L55/26,,0,0,,,,ACTIVE
945,EP,A1,EP 3172145 A1,076-558-118-229-039,2017-05-31,2017,EP 15747182 A,2015-07-24,GB 201413249 A;;GB 201503512 A;;GB 2015052154 W,2014-07-25,CONTAINER AND CLOSURE AND MANUFACTURE THEREOF,,THREADLESS CLOSURES LTD,HEIN JOHN;;FRASER ANTHONY HENRY JOSEPH,,https://lens.org/076-558-118-229-039,Patent Application,yes,0,0,11,40,0,B65D51/1688;;B65D51/1688;;B65D51/1688;;B65D41/065;;B65D41/065;;B65D41/065,B65D51/16;;B65D41/06,,1,0,,,See references of WO 2016012810A1,DISCONTINUED
946,GB,A,GB 2421092 A,070-995-234-975-140,2006-06-14,2006,GB 0426773 A,2004-12-07,GB 0426773 A,2004-12-07,Segmenting packet data for ease of writing to memory.,"This invention provides a processor 900 for writing data contained in payload data (1006) of a data packet (1000) to memory, especially for use as the central processing unit of a memory tag (1200). The processor 900 does not include a write buffer. The processor 900 comprises a first register 910 adapted to latch first data corresponding to a segment of the payload data; and a second register 224 adapted to receive second data from the payload data (1006) to enable the validity of the data latched into the first register 910 to be established before data is written to memory. A memory device, a method for writing data contained in payload data (1006), a data packet (1000), a method of writing data into a non-volatile memory and a memory tag are also provided.",HEWLETT PACKARD DEVELOPMENT CO,DICKIN FRASER JOHN;;LOH WENG WAH,,https://lens.org/070-995-234-975-140,Patent Application,no,2,0,5,5,0,G06F11/1004;;G06F11/1004,G06F11/00,G4A AMX           MX;;NOT CLASSIFIED    NONE,0,0,,,,INACTIVE
947,CO,A2,CO 2018007531 A2,082-013-918-148-525,2018-07-31,2018,CO 2018007531 A,2018-07-18,GB 2016053945 W;;GB 201522544 A,2015-12-21,Método para formar un cierre de metal y cierre para recipiente,"Método para formar un cierre de metal y cierre para recipiente Un método para formar un cierre liberable para un recipiente (10) que tiene una abertura (10A, 21B, 21) circular, el método comprende asegurar de forma liberable (23) una porción (21) de faldón anular del cierre a una porción (10) de cuello del recipiente, por ejemplo, por medio de una rosca, ubicar posteriormente una porción (22) de cierre separada del cierre sobre una abertura (10A, 21B, 21) en la porción (21) de faldón, y asegurar de forma irreversible (23) la porción (22C, 22) de cierre a la porción (21) de faldón, por ejemplo, mediante soldadura, para formar un cierre que cierra la abertura (10A, 21B, 21) del recipiente (10) pero que se puede liberar del mismo al desenroscar la porción (21) de faldón de la porción (10) de cuello del recipiente. También se describe un cierre que comprende dos, componentes inicialmente separados: una porción (21) de faldón anular y una porción (22C, 22) de cierre que se puede asegurar de forma irreversible a la porción (21) de faldón después de que la porción (21) de faldón anular se ha asegurado de forma liberable a la porción de cuello de un recipiente (10). También se describe un producto intermedio que comprende un recipiente (10) que tiene una porción (21) de faldón anular de un cierre liberable que se asegura de forma liberable a una porción de cuello de la misma así como también un método para llenar un recipiente (10) que comprende las etapas de proporcionar un recipiente (10) que tiene una porción (21) de faldón anular de un cierre liberable que se asegura de forma liberable e este, llenar el recipiente (10) a través de una abertura (10A, 21B, 21) en la porción (21) de faldón y ubicar posteriormente una porción (22) de cierre separada del cierre sobre la abertura (10A, 21B, 21) en la porción (21) de faldón, y asegurar de forma irreversible (23) la porción (22C, 22) de cierre a la porción (21) de faldón con el fin de formar un cierre que cierra la abertura (10A, 21B, 21) del recipiente (10) pero que se puede liberar del mismo. La abertura (10A, 21B, 21) de la porción (21) de faldón anular puede simular la abertura (10A, 21B, 21) de un cuerpo de lata convencional y la porción (22C, 22) de cierre puede de forma similar al extremo de la lata ser aplicada a un cuerpo de lata convencional con el fin de que la porción (22C, 22) de cierre se pueda asegurar de forma irreversible a una porción (21) de faldón (que se ha asegurado de forma liberable a la porción de cuello de un recipiente (10)) en una línea de llenado y cierre de lata convencional.",THREADLESS CLOSURES LTD,FRASER ANTHONY HENRY JOSEPH;;HEIN JOHN,,https://lens.org/082-013-918-148-525,Patent Application,no,0,0,14,40,0,B65D43/0231;;B65D2543/00092;;B65D2543/0024;;B65D2543/00277;;B65D2543/00972;;B67B3/20;;B67B3/22;;B67C7/00;;B65B3/18;;B65D41/00;;B65D43/02;;B65D51/18;;B65D2251/00;;B65D43/0231;;B67B3/20;;B67B3/22;;B67C7/00;;B65D2543/00092;;B65D2543/00972;;B65D2543/00277;;B65D2543/0024;;B65D2543/00092;;B65D2543/0024;;B65D2543/00277;;B65D2543/00972;;B67B3/20;;B67C7/00;;B65D43/0231;;B67B3/22;;B65D43/0283;;B67C3/02,B65D51/16;;B65D41/06;;B65D43/02;;B67B3/20;;B67B3/22;;B67C3/02,,0,0,,,,PENDING
948,GB,A,GB 853975 A,091-265-105-013-073,1960-11-16,1960,GB 4039857 A,1957-12-31,GB 4039857 A,1957-12-31,Improvements in or relating to the preparation of purified single elements or compounds,"<PICT:0853975/III/1> Indium antimonide is purified by maintaining a molten mass of material in an evaporation chamber for a period to drive off volatile impurities which are collected on a cool part of the chamber, introducing an inert gas into the chamber to inhibit further evaporation and zone refining the mass in the presence of the inert gas. The Figure shows an apparatus for preparing purified indium antimonide by the above method. Indium and antimony are placed in a crucible 1 in proportions such that there is an excess of antimony over the stoichiometric ratio. The crucible is positioned within a quartz tube 2, connected by a valve 6 to a vacuum pump, and is heated by strip heaters 10. Volatile impurities (e.g. zinc and cadmium) and some antimony are driven off and condensed on the top surface 12 of the tube 2 which is cooled by air from a multiple jet pipe 13. After five hours heating the vacuum pump is disconnected, hydrogen is admitted to the tube 2 via the valve 5 and the trolley 7 carrying the heaters 10 is moved to and fro to zone refine the indium antimonide.",NAT RES DEV,HULME KENNETH FRASER;;MULLIN JOHN BRIAN,,https://lens.org/091-265-105-013-073,Granted Patent,no,0,1,5,5,0,C30B29/40;;C22B5/16;;C30B13/00,C22B5/16;;C30B13/00,B1S SCDN          SCDN;;B1S S129          SCDN;;C1A AP15          AP15,0,0,,,,EXPIRED
949,US,A,US 2748427 A,090-926-366-431-184,1956-06-05,1956,US 37956453 A,1953-09-11,GB 2748427X A,1952-10-20,Process and device for converting a continuous tow of artificial filaments into a sliver comprising staple lengths,,ICI LTD,FRASER STEWART IAN;;BRYAN SEED JOHN,,https://lens.org/090-926-366-431-184,Granted Patent,no,2,1,1,1,0,D01G1/10;;D01G1/10,D01G1/10,,0,0,,,,EXPIRED
950,WO,A1,WO 2009/115811 A1,099-961-297-111-144,2009-09-24,2009,GB 2009000744 W,2009-03-19,GB 0805113 A;;GB 0809263 A,2008-03-19,SEALED CONTAINER,"A container (1) for the storage of a carbonated drink, comprising a container body with an opening that defines an axis and a removable closure (3) for closing the opening, the closure including a foil (2) for bonding to the container to close the opening in a gas-tight manner, the foil also being connected to, or interacting with, the closure, such that initial rotation of the closure in a loosening direction relative to the container body distorts or deforms the foil in a manner such that further rotation of the. closure results in a peel force being applied to the bond between the foil and the container.",MEADWESTVACO CORP;;FRASER ANTHONY HENRY JOSEPH;;HEIN JOHN,FRASER ANTHONY HENRY JOSEPH;;HEIN JOHN,,https://lens.org/099-961-297-111-144,Patent Application,yes,4,2,7,9,0,B65D51/228;;B65D2251/0018;;B65D2251/0093;;B65D41/08;;B65D51/228;;B65D2251/0093;;B65D2251/0018;;B65D41/08,B65D51/22,,0,0,,,,PENDING
951,AU,B2,AU 2014/361743 B2,106-172-609-141-52X,2019-09-26,2019,AU 2014/361743 A,2014-12-10,AU 2013/904823 A;;AU 2014/050406 W;;AU 2014/361743 A,2013-12-11,Medicament apparatus and method,"An apparatus for use in administering a particulate medicament to a biological subject's airway, the apparatus including an inlet that in use is in fluid communication with a supply of positive pressure gas, an outlet that in use is in fluid communication with the subject's airway to deliver the positive pressure gas thereto and a medicament supply that provides a dose of particulate medicament so that the particulate medicament is entrained in a gas flow from the inlet to the outlet, thereby delivering the particulate medicament to the subject's airway.",DE MOTU CORDIS PTY LTD,FRASER JOHN FRANCIS;;GREGORY SHAUN DAVID,DE MOTU CORDIS PTY. LTD. (2017-02-23),https://lens.org/106-172-609-141-52X,Granted Patent,no,3,0,17,17,0,A61M11/02;;A61M11/06;;A61M15/0028;;A61M15/0065;;A61M16/0048;;A61M16/0078;;A61M16/06;;A61M16/208;;A61M2202/064;;A61M2206/14;;A61M2209/06;;A61M2230/06;;A61M2230/42;;A61M16/049;;A61M15/0021;;A61M15/0031;;A61M15/0043;;A61M15/0048;;A61M15/0051;;A61M16/0084;;A61M2205/50;;A61M16/14;;A61K31/4166;;A61K31/137;;A61K9/0075;;A61K31/485;;A61K31/5517;;A61K31/7004;;A61P9/04;;A61P3/00;;A61P37/00;;A61M16/0048;;A61M16/06;;A61M16/208;;A61M2206/14;;A61M15/0031;;A61M15/0048;;A61M16/0084;;A61M2209/06;;A61M16/0078;;A61M11/02;;A61M2230/06;;A61M15/0051;;A61M15/0043;;A61M2205/50;;A61M15/0065;;A61M2230/42;;A61M11/06;;A61M15/0028;;A61M15/0021;;A61M16/049;;A61M2202/064;;A61M16/14;;A61H31/00;;A61M16/0057;;A61M16/04;;A61M16/0816;;A61M2202/0208,A61M13/00;;A61M16/00;;A61M37/00,,0,0,,,,ACTIVE
952,CA,A,CA 844797 A,143-057-826-438-205,1970-06-16,1970,CA 844797D A,,CA 844797T A,,AUTOMATIC LOAD ADJUSTMENT FOR TIME ASSIGNMENT SPEECH INTERPOLATION SYSTEMS,,WESTERN ELECTRIC CO,FRASER JOHN M;;LONG NORWOOD G,,https://lens.org/143-057-826-438-205,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
953,US,A1,US 2005/0074436 A1,127-482-147-023-494,2005-04-07,2005,US 61464303 A,2003-07-07,US 61464303 A;;US 31612702 A;;US 33885601 P,2001-12-07,Systems and methods for treating patients with processed lipoaspirate cells,Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient.,FRASER JOHN K.;;HEDRICK MARC H.,FRASER JOHN K;;HEDRICK MARC H,CYTORI THERAPEUTICS INC (2005-07-11);;LOREM VASCULAR PTE. LTD (2019-04-24);;MACROPORE BIOSURGERY INC (2003-03-07),https://lens.org/127-482-147-023-494,Patent Application,yes,39,10,65,221,0,A61K35/28;;A61K35/28;;A61K48/00;;A61B10/0283;;A61B10/0283;;A61K9/0019;;A61K9/0019;;A61K35/32;;A61K35/35;;A61K35/35;;A61K35/36;;A61M1/76;;A61M2202/08;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/00;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;A61P43/00;;C12M47/04;;C12N5/0667;;C12N5/0667;;C12N5/069;;C12N5/069;;C12N2506/1384;;C12N2506/1384,A61M1/00;;A61K31/436;;A61K35/02;;A61K35/12;;A61K35/28;;A61K35/35;;A61K35/36;;A61K38/00;;A61K38/16;;A61K45/00;;A61L27/00;;A61P1/00;;A61P1/16;;A61P3/00;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P19/00;;A61P19/02;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;C12M3/06;;C12N5/0775,424/93.7;;X6045,0,0,,,,EXPIRED
954,EP,B1,EP 2268557 B1,121-397-853-450-691,2012-03-07,2012,EP 09721829 A,2009-03-19,GB 2009000744 W;;GB 0805113 A;;GB 0809263 A,2008-03-19,SEALED CONTAINER,"A container (1) for the storage of a carbonated drink, comprising a container body with an opening that defines an axis and a removable closure (3) for closing the opening, the closure including a foil (2) for bonding to the container to close the opening in a gas-tight manner, the foil also being connected to, or interacting with, the closure, such that initial rotation of the closure in a loosening direction relative to the container body distorts or deforms the foil in a manner such that further rotation of the. closure results in a peel force being applied to the bond between the foil and the container.",THREADLESS CLOSURES LTD,FRASER ANTHONY HENRY JOSEPH;;HEIN JOHN,,https://lens.org/121-397-853-450-691,Granted Patent,yes,4,0,7,9,0,B65D51/228;;B65D2251/0018;;B65D2251/0093;;B65D41/08;;B65D51/228;;B65D2251/0093;;B65D2251/0018;;B65D41/08,B65D51/22,,0,0,,,,ACTIVE
955,US,B2,US 9198937 B2,136-926-496-329-863,2015-12-01,2015,US 201213725814 A,2012-12-21,US 201213725814 A;;US 201113042334 A;;US 88635310 A;;US 61464803 A;;US 31612702 A;;US 33885601 P,2001-12-07,Adipose-derived regenerative cells for treating liver injury,Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient.,CYTORI THERAPEUTICS INC,FRASER JOHN K;;HEDRICK MARC H,LOREM VASCULAR PTE. LTD (2019-04-24),https://lens.org/136-926-496-329-863,Granted Patent,yes,99,6,65,221,0,A61K35/28;;A61K35/28;;A61K48/00;;A61B10/0283;;A61B10/0283;;A61K9/0019;;A61K9/0019;;A61K35/32;;A61K35/35;;A61K35/35;;A61K35/36;;A61M1/76;;A61M2202/08;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/00;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;A61P43/00;;C12M47/04;;C12N5/0667;;C12N5/0667;;C12N5/069;;C12N5/069;;C12N2506/1384;;C12N2506/1384,A61M1/00;;C12N5/00;;A61B10/02;;A61K9/00;;A61K31/436;;A61K35/02;;A61K35/12;;A61K35/28;;A61K35/35;;A61K35/36;;A61K38/00;;A61K38/16;;A61K45/00;;A61L27/00;;A61P1/00;;A61P1/16;;A61P3/00;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P19/00;;A61P19/02;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;C12M1/00;;C12M3/06;;C12N5/071;;C12N5/0775,,99,96,070-839-046-502-27X;;010-540-013-256-049;;134-654-757-212-403;;032-404-259-701-837;;001-174-850-465-856;;059-588-500-547-821;;042-989-386-993-552;;014-008-860-336-482;;029-946-078-457-714;;075-284-732-479-861;;101-877-952-875-22X;;116-024-403-014-056;;071-709-364-692-057;;011-072-762-416-590;;027-803-020-078-075;;173-002-914-257-594;;007-172-022-414-518;;078-144-091-568-913;;047-253-510-312-524;;023-961-417-626-568;;116-871-349-386-357;;007-886-031-008-735;;097-867-342-595-907;;015-569-025-003-488;;090-815-773-677-26X;;004-182-422-100-243;;043-014-435-315-202;;007-742-922-258-989;;019-679-035-676-507;;106-649-915-724-737;;078-698-146-972-599;;000-625-008-142-215;;114-069-508-870-517;;033-642-914-335-547;;160-132-718-714-712;;069-962-637-789-469;;000-247-718-432-449;;113-062-358-749-472;;014-595-660-154-907;;019-368-227-595-121;;092-482-123-514-901;;042-772-099-513-918;;076-945-814-976-839;;149-453-463-380-579;;005-376-980-059-70X;;035-961-317-498-39X;;006-652-397-889-647;;017-165-339-699-387;;018-369-175-290-657;;043-947-449-038-108;;055-646-074-155-100;;027-339-475-967-163;;125-995-223-966-197;;070-522-011-983-995;;031-206-044-096-031;;015-599-406-080-089;;108-799-353-449-53X;;069-205-374-732-453;;036-607-251-048-680;;003-264-302-978-919;;036-252-293-129-219;;019-888-471-790-198;;000-503-988-011-572;;009-545-708-254-047;;031-856-752-899-649;;123-956-839-153-069;;016-725-607-839-435;;053-963-206-893-495;;068-189-597-689-823;;003-050-327-178-826;;015-055-316-845-193;;033-814-301-870-318;;030-847-714-444-597;;060-272-195-296-337;;011-995-010-843-384;;028-547-919-869-891;;004-509-498-015-514;;020-498-500-483-165;;044-955-100-185-726;;042-873-767-839-626;;106-603-013-159-878;;063-946-362-236-807;;101-420-359-134-80X;;069-042-212-344-227;;086-462-532-224-686;;094-547-639-217-227;;012-100-750-932-039;;000-601-113-139-927;;003-133-282-606-391;;062-596-462-103-530;;083-745-638-097-33X;;033-525-386-964-397;;052-765-611-707-875;;025-384-766-848-404;;031-353-044-011-130;;108-011-138-630-620,10.1002/jcp.10174;;12384991;;7540405;;10.1016/8756-3282(94)00044-1;;198274;;10.1016/0012-1606(77)90110-5;;6352350;;10.1051/rnd:19850201;;3887522;;10.1002/mus.880120705;;2674704;;15869434;;10.1089/ten.2005.11.556;;10611546;;10.1089/ten.1999.5.545;;pmc1219645;;10.1042/bj3330787;;9677341;;9519353;;10.1159/000019544;;10.1038/nm747;;12161747;;10.1097/01.prs.0000055043.62589.05;;12711954;;10.1111/j.1524-4725.1990.tb01561.x;;2229639;;7646489;;10.1006/bbrc.1995.2141;;11181551;;10.1210/endo.142.3.8006;;10.1210/en.142.3.1325;;10.2337/diabetes.50.8.1691;;11473026;;10.1161/01.cir.0000043246.74879.cd;;12473544;;10998427;;10.3892/ijmm.6.4.363;;11594767;;10.1006/bbrc.2001.5712;;10.1002/jcp.10260;;12811816;;10.1016/s1043-2760(02)00010-3;;12475611;;10.1007/s002239900683;;10441651;;11697641;;10.3109/10428190109097705;;10.1080/15513819809168768;;9566278;;10.1182/blood.v97.10.2957;;11342417;;10548503;;10.1006/bbrc.1999.1620;;10.1177/019459989010200402;;2136268;;6866054;;10.1056/nejm198308043090509;;10.1002/jbmr.5650111114;;8915778;;pmc6517823;;10.1111/j.1582-4934.2000.tb00125.x;;12067460;;2292654;;1757497;;10.1242/jcs.99.1.131;;10.1016/s0171-2985(82)80064-8;;6984421;;3489608;;10.1210/endo-119-4-1776;;6043938;;10.1016/0006-291x(85)91209-4;;2415129;;10.1016/j.stem.2008.03.002;;pmc2613570;;18397751;;11094627;;10.1126/science.283.5401.534;;9915700;;10.1016/s0022-2275(20)41303-3;;206638;;10931522;;10.1002/1097-4547(20000815)61:4<364::aid-jnr2>3.0.co;2-c;;10.1002/1097-4547(20000815)61:4<364::aid-jnr2>3.3.co;2-3;;10.1097/00005392-200301000-00098;;12478183;;10.1016/s0022-5347(05)64118-3;;5337892;;10.1016/s0007-1226(67)80033-x;;10.1001/archopht.1988.01060130181012;;3341968;;12115867;;10.1002/path.1158;;10.1007/bf02557680;;3922598;;8040190;;10.1002/jcp.1041600214;;9027588;;10.1002/(sici)1097-4644(199702)64:2<278::aid-jcb11>3.0.co;2-f;;9621889;;10.1002/jor.1100160202;;10961917;;10.1042/0300-5127:0280350;;10.1042/bst0280350;;0010961917;;11248860;;10.1016/s0094-1298(20)32342-7;;10.1161/01.cir.0000074209.17561.99;;12835229;;2144412;;10.1007/bf00174624;;10.1097/00003086-199609000-00031;;8804298;;6370890;;10.1016/s0074-7696(08)62444-4;;10.1016/s1471-4914(01)02016-0;;11378515;;1870029;;10.1002/jor.1100090504;;10.1016/s0094-1298(20)31020-8;;7924141;;10.1016/s1359-6446(03)02866-6;;14643161;;10.1038/74651;;10742145;;11487017;;10.1007/bf00444241;;8122570;;10541768;;10.1007/s002239900721;;pmc3097937;;21607134;;10.4252/wjsc.v3.i4.25;;12193778;;10.1126/science.297.5585.1299;;10.1126/science.1080631;;10.1126/science.1079318;;12595675;;6382294;;9541256;;10.1111/j.1600-0722.1998.tb02206.x;;10.1016/s0021-9258(18)41732-2;;1326540;;12609969;;10.1161/01.res.0000063425.51108.8d;;12949903;;10.1002/jnr.10691;;6300083;;10.1016/s0021-9258(18)32630-9;;10.1016/s0167-4889(97)00083-9;;9409810;;10.1210/endo.134.1.8275945;;8275945;;10.1210/en.134.1.277;;10213083;;15621248;;10.1016/j.biomaterials.2004.09.013;;16690020;;10.1016/j.bbrc.2006.04.089;;10.1016/j.biomaterials.2005.02.022;;15949551;;10.1016/j.bbrc.2006.04.128;;16696950;;10.1210/endo-114-2-477;;6690287;;1689854;;11532401;;10.1016/s0959-437x(00)00235-5;;17016179;;10.1097/01.prs.0000221037.34883.0a;;10.1111/j.1524-4725.1993.tb00996.x;;8245302;;10.1007/bf00453875;;8526158;;10.1016/s0094-1298(20)32343-9;;11248861;;1896551;;10.1097/00006534-199110000-00038;;11711959;;10.1097/00006534-200111000-00051;;10.1002/(sici)1097-4652(199910)181:1<67::aid-jcp7>3.0.co;2-c;;10457354;;10.1002/(sici)1097-4652(199910)181:1<67::aid-jcp7>3.3.co;2-3;;10.1097/00003086-199810001-00026;;9917645;;8967480;;10.1152/ajpendo.1996.270.5.e895;;10.1677/joe.0.1630159;;10556763;;9703958;;10.1006/bbrc.1998.8997;;15095817;;10.1023/b:abme.0000017545.84833.7c;;10.1097/01.prs.0000095942.71618.9d;;14707645;;9202388;;10.1242/jcs.110.11.1279,"Abbate, A., Biondi-Zoccai, G.G. and Baldi, A. (2002) ""Pathophysiologic role of myocardial apoptosis in post-infarction left ventricular remodeling"" J Cell Physiol 193, 145-53.;;Aharinejad, S., Mars, S.C., Jr., Bock P., Mason-Savas, A., MacKay, C.A. Larson, E.K., Jackson, M.E., Luftensteiner, M. and Weisbauer, E. (1995) ""CSF-1 treatment promotes angiogenesis in the metaphysics of osteopetrotic (toothless, tl) rats"" Bone 16, 315-324.;;Ahrens, Patricia Buckley et al., ""Stage-Related Capacity for Limb Chondrogenesis in Cell Culture,"" Developmental Biology, 1977, 60:69-82.;;Ailhaud, et al., 1983, ""Hormonal requirements for growth and differentiation of OB17 preadipocyte cells in vitro,"" Diabete & Metabolisme, vol. 9:125-133.;;Ailhaud, et al., 1985, ""Lipoprotiene lipase et differenciation adipocytaire,"" Reprod. Nutr. Develop., vol. 25:153-158.;;Alameddine, Hala S. et al., ""Regeneration of Skeletal Muscle Fibers from Autologous Satellite Cells Multiplied In Vitro. An Experimental Model for Testing Cultured Cell Myogenicity,"" Muscle & Nerve, 1989, 12:544-55.;;Alhadlaq et al. ""Engineered adipose tissue from human mesenchymal stem cells maintains predefined shape and dimension: implications in soft tissue augmentation and reconstruction."" Tissue Eng 11, 556-566 (2005).;;Angele, P. et al., ""Engineering of Osteochondral Tissue with Bone Marrow Mesenchymal Progenitor Cells in a Derivatized Hyaluronan-Gelatin Composite Sponge,"" Tissue Engineering, 1999, 5:545-53.;;Ankrom et al., 1998, Age-related changes in human oestrogen receptor function and levels in osteoblasts, Biochem J. 333:787-794.;;Aragona, F., L. D'Urso et al (1998) ""Immunologic aspects of bovine injectable collagen in humans. A review"" Eur Urol 33(2): 129-33.;;Arvidsson, A., Collin, T., Kirk, D., Kokaia, Z., and Lindvall, O. (2002) ""Neuronal replacement from endogenous precursors in the adult brain after stroke"" Nat Med 8, 963-70.;;Ashjian et al., 2003, In vitro differentiation of human processed lipoaspirate cells into early neural progenitors Plast Reconstr Surg 111 1922-1931.;;Asken, S. (1990) ""Microliposuction and autologous fat transplantation for aesthetic enhancement of the aging face"" J Dermatol Surg Oncol 16(10): 965-72.;;Aso et al., Aug. 15, 1995, A Preadipocyte Clonal Line from bovine Intramuscular Adipose Tissue: Nonexpression of GLUT-4 protein during Adipocyte Differentiation, Biochem. Biophys. Res. Commun. 213:369-375.;;Asou, Y., Rittling, S.R., Yoshitake, H., Tsuji, K., Shinomiya, K., Nifuji, A., Denhardt, D.T., and Noda, M. (2001) ""Osteopontin facilitates angiogenesis, accumulation of osteoclasts, and resorption in ectopic bone"" Endocrinology 142, 1325-1332.;;Assady, S., Maor, G., Amit, M., ltskovitz-Eldor, J., Skorecki, K.L., and Tzukerman, M. (2001) ""Insulin production by human embryonic stem cells"" Diabetes 50, 1691-7.;;Assmus et al., 2002, Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI) Circulation 106, pp. 3009-3017.;;Athanasopoulos, T., Fabb, S., and Dickson, G. (2000) ""Gene therapy vectors based on adeno-associated virus: characteristics and applications to acquired and inherited diseases (review)"" Int J Mol Med 6, 363-75.;;ATTC Preservation Methods: Freezing and Free-Drying, ATCC, 2nd Edition, 1991.;;Avital, I., D. Inderbitzin, et al. (2001) ""Isolation, characterization and transplantation of bone marrow-derived hepatocyte stem cells"" Biochem Biophys Res Commun 288(1): 156-64.;;Badiavas, et al. ""Participation of bone marrow derived cells in cutaneous would healing."" Journal of Cellular Physiology. 196(2): 245-250 (2003).;;Bagnato et al., Jan. 2002, Emerging role of endothelin-1 in tumor angiogenesis, Trends in Endocrinology and Metabolism, 14(1):44-50.;;Bailey, A. J. et al., ""Age-Related Changes in the Biochemical Properties of Human Cancellous Bone Collagen: Relationship to Bone Strength,"" Calcified Tissue International, 1999, 65:203-10.;;Banfi, A., Bianchi, G., Galotto, M., Cancedda, R., and Quarto, R. (2001) ""Bone marrow stromal damage after chemo/radiotherapy: occurrence, consequences and possibilities of treatment"" Leuk Lymphoma 42, 863-70.;;Barghorn, A. et al., ""a-Smooth Muscle Actin Distribution in the Pulmonary Vasculature Comparing Hypoplastic and Normal Fetal Lungs,"" Pediatric Pathology & Laboratory Medicine, 1998, 18:5-22.;;Barker et al., 2001, Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of huan leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis, Blood, 97:2957-61.;;Barry, F.P., Boynton, R.E., Haynesworth, S., Murphy, J.M., and Zaia, J. (1999) ""The monoclonal antibody SH-2, raised against human mesenchymal stem cells, recognizes an epitope on endoglin (CD105)"" Biochem Biophys Res Commun 265, 134-9.;;Bartynski, J.M., S. Marion et al. (1990) ""Histopathologic evaluation of adipose autografts in a rabit ear model"" Otolaryngol Hea Neck Surg 102(4): 314-21.;;Bastard, J. P. et al., ""A Mini-Liposuction Technique Adapted to the Study of Human Adipocyte Glucose Transport System,"" Diabetologia, 36(Suppl. 1):A135, 1993.;;Baylink, David J., ""Glucocorticoid-Induced Osteoporosis,"" The New England Journal of Medicine, 1983, 309:306-8.;;Becerra, José et al., ""Demineralized Bone Matrix Mediates Differentiation of Bone Marrow Stromal Cells In Vitro: Effect of Age of Cell Donor,"" Journal of Bone and Mineral Research, 1996, 11:1703-14.;;Beecken, W.D., Kramer, W., and Jonas, D. (2000) ""New molecular mediators in tumor angiogenesis"" J Cell Mol Med 4, 262-269.;;Beiser, Ian H. and Irvin O. Kanat, ""Subchondral Bone Drilling: A Treatment for Cartilage Defects,"" Journal of Foot Surgery, 1990, 29:595-601.;;Bennett, JH, et al., 1991 J. Cell Sci. ""Adipocytic cells cultured from marrow have osteogenic potential,"" 99(Pt1):131-139.;;Berdel et al., 1982, Purification of human monocytes by adherence to polymeric fluorocarbon. Characterization of the monocyte-enriched cell fraction, Immunobiology, 163:511-520.;;Beresford, et al., 1986 Endo. ""1,25-Dihydroxyvitamin D3 and Human Bone-Derived Cells in Vitro: Effects on Alkaline Phosphatase, Type I Collagen and Proliferation,"" 119:1776-1785.;;Bergeon, M.T. (1967) ""Collagen: a review"" J Okla State Med Assoc 60(6): 330-2.;;Bernlohr, David A. et al., ""Tissue Specific Expression of p422 protein , A putative Lipid Carrier, In Mouse Adipocytes,"" Biochem. Biophys. Res. Comun. 1985 132:850-855.;;Bianco et al., Apr. 2008, Mesenchymal stem cells: revisiting history, concepts, and assays, Cell Stem Cell, 2:313-319.;;Bickenbach, J.R. and Dunnwald, M. (2000) ""Epidermal stem cells: characteristics and use in tissue engineering and gene therapy"" Adv Dermatol 16, 159-83.;;Bjornson, et al., 1999 Science ""Turning Brain into Blood: A Hematopoetic Fate Adopted by Adult Neural Stem Cells in Vivo,"" 283:534-537.;;Björntrop, et al. ""Isolation and characterization of cells from rat adipose tissue developing into adipocytes."" J. Lipid Res. 19:316-324 (1978).;;Black et al., 2000, Adult Rat and Human Bone Marrow Stromal cells Differentiate Into Neurons, J. Neurosci. Res. Science 61:364-370.;;Block, C.A., C.S. Cooper (2003) ""Long-term Efficacy of periurethral collagen injection for the treatment of urinary incontinence secondary to myelomeningocele"" J Urol 169(1): 327-329.;;Boering, G. and A.J. Huffstadt (1967) ""The use of derma-fat grafts in the face"" Br J Plast Surg 20(2): 172-8.;;Boerner, C.F. (1988) ""Allergic response to a porcine collagen corneal shield. Case report"" Arch Opthalmol 106(2): 171.;;Bond et al., 1999, ""Human Subcutaneouspreadipocytes Differentiate Into osteoblasts,"" FASEB Journal 13:600A.;;Bonner-Weir, S. and Sharma, A. (2002) ""Pancreatic stem cells"" J Pathol 197, 519-526.;;Boskey, et al., 1985, ""The Effect of Osteocalcin on In Vitro Lipid-Induced Hydroxyapatite Formation and Seeded Hydroxyapatite Growth,"" Calc. Tiss. Int. 37:75.;;Breen, Ellen C. et al., ""TGFb Alters Growth and Differentiation Related Gene Expression in Proliferating Osteoblasts In Vitro, Preventing Development of the Mature Bone Phenotype,"" Journal of Cellular Physiology, 1994, 160:323-35.;;Bruder, et al., 1997 J. Cell Biochem. ""Growth Kinetics, Self-Renewal, and the Osteogenic Potential of Purified Human Mesenchymal Stem Cells During Extensive Subcultivation and Following Cryopreservation,"" 64:278-294.;;Bruder, Scott P. et al., ""Bone Regeneration by Implantation of Purified, Culture-Expanded Human Mesenchymal Stem Cells,"" Journal of Orthopaedic Research, 1998, 16:155-62.;;Bulleid, J.J., D.C. John et al (2000) ""Recombinant expression systems for the production of collagen"" Biochem Soc Trans 28(4): 350-3.;;Burres, S. (2001) ""Soft-tissue augmentation with fascian"" Clin Plast Surg 28(1): 101-10.;;Buschmann, I.R. Busch, H.J., Mies, G., and Hossmann, K.A. (2003) ""Therapeutic induction of arteriogenesis in hypoperfused rat brain via granulocyte-macrophage colony-stimulating factor"" Circulation 108, 610-615.;;Butler-Browne, et al., 1990 Anat. Embryol. (Berl) ""Myosin heavy and light chain expression during human skeletal muscle development and precocious muscle maturation induced by thyroid hormone,"" 181:513-522.;;Butnariu-Ephrat, Miriam et al., ""Resurfacing of Goat Articular Cartilage by Chondrocytes Derived From Bone Marrow,"" Clinical Orthopaedics and Related Research, 1996, 330:234-43.;;Campion, Dennis R., ""The Muscle Satellite Cell: A Review,"" Internationals Review of Cytology, 1984, 87:225-51.;;Caplan, A.I. and Bruder, S.P. (2001) ""Mesenchymal stem cells: building blocks for molecular medicine in the 21st century"" Trends Mol Med 7, 259-64.;;Caplan, Arnold I., ""Mesenchymal Stem Cells,"" Journal of Orthopaedic Research, 1991, 9:641-50.;;Caplan, Arnold I., ""The Mesengenic Process,"" Clinics in Plastic Surgery, 21:429-35, 1994.;;Carano, R.A. and Filvaroff, E.H. (2003) ""Angiogenesis and bone repair"" Drug Discov. Today 8, 980-989.;;Carmeliet, P. (2000) ""Mechamisms of angiogenesis and arteriogenesis"" Nat Med 6, 389-395.;;Carmeliet, P. and A. Luttun (2001) ""The emerging role of the bone marrow-derived stem cells in (therapeutic angiogenesis"" Thromb Haemost 86(1): 289-97.;;Carpandena, C.A. ""Collagen alterations in adipose autograft's."" Aesthetic Plastic Surgery vol. 18, 11-15 (1994).;;Carranza-Bencano, A. et al., ""Comparative Study of the Reconstruction of Articular Cartilage Defects with Free Costal Perichondrial Grafts and Free Tibial Periosteal Grafts: An Experimental Study on Rabbits,"" Calcified Tissue International, 1999, 65:402-7.;;Casteilla et al., Apr. 26, 2011, Adipose-derived stromal cells: their identity and uses in clinical trials, an update, World J. Stem Cells, 3(4):25-33.;;Castro, et al. ""Failure of Bone Marrow Cells to Transdifferentiate into Neural Cells in Vivo."" Science. 297:1299 (2002).;;Castro, et al. ""Response to Comment on 'Failure of Bone Marrow Cells to Transdifferentiate into Neural Cells in Vivo.'"" Science. 299:1184c (2003).;;Castro-Malaspina, H., W. Ebell, et al. (1984) ""Human bone marrow fibroblast colony-forming units (CFU-F""Prog Clin Ciol Res 154: 209-36.;;Cheifetz et al., 1988, Analysis of intracellular osteopontin as a marker of osteoblastic cell differentiation and mesenchymal cell migration,European Journal of Oral Sciences, 106(Supp. 1):401-7.;;Cheifetz, S. et al., ""Endoglin is a Component of the Transforming Growth Factor-beta Receptor System in Human Endothelial Cells,"" J. Biol. Chem., 1992 267:19027-19030.;;Chen, J. et al. Intravenous Administration of Human Bone Marrow Stromal Cells Induces Angiogenesis in the Ischemic Boundary Zone After Stroke in Rats, Circulation Research, Apr. 2003, vol. 92, pp. 692-699.;;Chen, J. et al. Intravenous Bone Marrow Stromal Cell Therapy Reduces Apoptosis and Promotes Endogenous Cell Proliferation After Stroke in Femal Rat, J. Neuroscience Research, Sep. 2003, vol. 73 pp. 778-786.;;Chen, Theresa L. et al., ""1alpha,25-Dihydroxyvitamin D3 Receptors in Cultured Rat osteoblast-like Cells,"" J. Biol. Chem. 1983 258:4350-4355.;;Chen, Xiaoli et al., ""Differentiation-dependent expression of obese (ob) gene by preadipocytes and adipocytes in primary cultures of porcine stromal-vascular cells,"" Biochimica et Biophysica Acta, 1997, 1359:136-42.;;Cheng S-L., et al., 1994 Endo ""Differentiation of Human Bone Marrow Osteogenic Stromal Cells in Vitro: Induction of the Osteoblast Phenotype by Dexamethasone,"" 134: 277-286.;;Chimal-Monroy et al., 1999, Expression of N-cadherin, N-CAM, fibronectin tenascin is stimulated by TGF-b1, b2, b3 and b5 during the formation of precartilage condensations, The International Journal of Developmental Biology, 43:59-67.;;Cho,S.W. et al. ""Engineering of volume-stable adipose tissues."" Biomaterials 26, 3577-3585 (2005).;;Cho,S.W. et al. ""Enhancement of adipose tissue formation by implantation of adipogenic-differentiated preadipocytes."" Biochem Biophys Res Commun 345, 588-594 (2006).;;Choi et al. ""Adipose tissue engineering using mesenchymal stem cells attached to injectable PLGA spheres."" Biomaterials 26, 5855-5863 (2005).;;Choi,Y.S. et al. ""Adipogenic differentiation of adipose tissue derived adult stem cells in nude mouse."" Biochem Biophys Res Commun 345, 631-637 (2006).;;Chyun, et al., 1984 Endo. ""Cortisol Decreases Bone Formation by Inhibiting Periosteal Cell Proliferation,"" 114:477-480.;;Civin, C.I., Strauss, L.C., Fackler, M.J., Trischmann, T.M., Wiley, J.M., and Loken, M.R. (1990) ""Positive stem cell selection-basic science"" Prog Clin Biol Res 333, 387-401.;;Clarke, D. and Frisen, J. (2001) ""Differentiation potential of adult stem cells"" Curr Opin Genet Dev 11, 575-80.;;Clavijo-Alvarez,J.A. et al. ""A novel perfluoroelastomer seeded with adipose-derived stem cells for soft-tissue repair."" Plast Reconstr Surg 118, 1132-1142 (2006).;;Coleman III, et al. ""Autologous Collagen? Lipocytic Dermal Augmentation. A Histopathologic Study"". J. Dermatol Surg Oncol. vol. 19, 1032-1040 (1993).;;Coleman, S.R. (1995) ""Long-term survival of fat transplants: controlled demonstrations"" Aesthetic Plast Surg 19(5): 421-5.;;Coleman, S.R. (2001). ""Structural fat grafts: the ideal filler?"" Clin Plast Surg 28(1): 111-9.;;Coleman, W.P., 3rd (1991) ""Autologous fat transplantation"" Plast Reconstr Surg 88(4): 736.;;Commons, G.W., Halperin, B., and Chang, C.C. (2001) ""Large-volume liposuction: a review of 631 consecutive cases over 12 years"" Plast Reconstr Surg 108, 1753-63.;;Conget, PA and JJ Minguell 1999 J. Cell. Physiol ""Phenotypical and Functional Properties of Human Bone Marrow Mesenchymal Progenitor Cells,"" 181:67-73.;;Connolly, J.F. (1998) ""Clinical use of marrow osteoprogenitor cells to stimulate osteogenesis"" Clin Orthop(355 Suppl): S257-66.;;Considine, et al., ""Paracrine stimulation of preadipocyte-enriched cell cultures by mature adipocytes,"" American Journal of Physiology 1996 270(5) E895-E899.;;Cooper, et al., 1999 J. Endocrinol. ""Glucocorticoid activity, inactivity and the osteoblast,"" 163: 159-164.;;Crandall, David L. et al., ""Identification of Estrogen Receptor b RNA in Human Breast and Abdominal Subcutaneous Adipose Tissue,"" Biochemical and Biophysical Research Communications, 248:523-6, 1998.;;Crevensten et al. ""Intervertebral Disc Cell Therapy for Regeneration: Mesenchymal Stem Cell Implantation in Rat Intervertebral Discs."" Annals of Biomedical Engineering. 32(3):430-434 (2004).;;Cronin,K.J. et al. ""New murine model of spontaneous autologous tissue engineering, combining an arteriovenous pedicle with matrix materials."" Plast Reconstr Surg 113, 260-269 (2004).;;Dani, et al., ""Differentiation of embryonic stem cells into adipocytes in vitro,""J.Cell Sci. 1997 110, 1279-1285.",EXPIRED
956,KR,A,KR 20170075708 A,175-830-835-475-397,2017-07-03,2017,KR 20177003388 A,2015-07-07,GB 201412053 A;;GB 201417601 A;;GB 2015051960 W,2014-07-07,POLYURETHANES FOR CONTACT LENSES,"본 발명은, 특히 컨택트 렌즈의 제조에 유용한 폴리(에틸렌) 글리콜계 폴리우레탄 중합체 조성물을 제공한다. 일반적으로 상기 중합체를 생성하는데 사용된 상기 반응 혼합물은 분지된 사슬연장제를 포함한다. 또한, 상기 중합체로부터 생성된 컨택트 렌즈의 제조방법이 제공된다.",OCUTEC LTD,RASHID ABDUL;;HONEYMAN GORDON;;FRASER JOHN,,https://lens.org/175-830-835-475-397,Patent Application,no,3,1,11,13,0,C08G18/4833;;C08G18/4837;;C08G18/61;;C08G18/6517;;C08G18/6677;;C08G18/758;;C08G18/4808;;G02B1/043;;C08G2210/00;;B29D11/00038;;C08G18/4808;;C08G18/4837;;C08G18/61;;C08G18/6517;;C08G18/758;;G02B1/043;;C08J3/075;;G02C7/04;;B29D11/00038;;C08J2205/028;;C08J2205/022;;C08G18/758;;G02B1/043;;C08G2210/00;;C08G18/61;;C08G18/6677;;C08G18/4833;;C08G18/4808;;C08G18/4837;;C08G18/6517;;B29D11/00038;;C08G18/6674;;C08J3/075;;C08J2375/08;;C08K5/13,C08G18/48;;B29D11/00;;C08G18/61;;C08G18/65;;C08G18/75;;C08J3/075;;G02B1/04;;G02C7/04,,0,0,,,,ACTIVE
957,ES,T3,ES 2439940 T3,170-816-843-731-714,2014-01-27,2014,ES 06779217 T,2006-08-25,GB 0517382 A;;GB 2006003186 W,2005-08-26,"Complejo que comprende un microvehículo que tiene una carga positiva conjugada con una marca cargada negativamente, cuya marca es una microesfera, cuya microesfera no está revestida con proteínas, y usos del mismo","Un complejo que comprende un microvehículo que tiene una carga positiva conjugada a una marca con carganegativa, marca que es una microesfera, microesfera que no está revestida con proteínas, en el que dichomicrovehículo comprende proteína, celulosa, polietileno, polistirol, vidrio, colágeno, colágeno-glucosa-5 aminoglucanoy/o gelatina.",PLASTICELL LTD,CHOO YEN;;HORNBY FRASER;;GIRDLESTONE JOHN,,https://lens.org/170-816-843-731-714,Granted Patent,no,0,0,16,16,0,G01N33/5008;;G01N33/5023;;G01N33/5073;;Y10T436/2525;;Y10T436/25375;;Y10T436/13;;Y10T436/2525;;Y10T436/25375;;Y10T436/13;;G01N33/5008;;G01N33/5023;;G01N33/5073,C12N5/00;;G01N33/50,,0,0,,,,ACTIVE
958,CN,A,CN 1585602 A,168-432-838-271-528,2005-02-23,2005,CN 02822628 A,2002-09-13,US 32207001 P;;US 24209402 A,2001-09-14,Preservation of non embryonic cells from non hematopoietic tissues,,MACROPORE BIOSURGERY INC,FRASER JOHN K;;HEDRICK MARC H,,https://lens.org/168-432-838-271-528,Patent Application,no,0,3,10,10,0,A01N1/02;;A01N1/0221;;A01N1/0284;;A01N1/02;;A01N1/0284;;A01N1/0221;;A01N1/02,A01N1/02;;C12N5/08,,0,0,,,,DISCONTINUED
959,US,B2,US 7390484 B2,169-669-330-076-942,2008-06-24,2008,US 61464403 A,2003-07-07,US 61464403 A;;US 31612702 A;;US 33885601 P,2001-12-07,Self-contained adipose derived stem cell processing unit,Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient.,CYTORI THERAPEUTICS INC,FRASER JOHN K;;HEDRICK MARC H,CYTORI THERAPEUTICS INC (2005-07-11);;LOREM VASCULAR PTE. LTD (2019-04-24);;MACROPORE BIOSURGERY INC (2003-03-07),https://lens.org/169-669-330-076-942,Granted Patent,yes,89,159,65,221,0,A61K35/28;;A61K35/28;;A61K48/00;;A61B10/0283;;A61B10/0283;;A61K9/0019;;A61K9/0019;;A61K35/32;;A61K35/35;;A61K35/35;;A61K35/36;;A61M1/76;;A61M2202/08;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/00;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;A61P43/00;;C12M47/04;;C12N5/0667;;C12N5/0667;;C12N5/069;;C12N5/069;;C12N2506/1384;;C12N2506/1384,A01N63/00;;A61M1/00;;A61K31/436;;A61K35/02;;A61K35/12;;A61K35/28;;A61K35/35;;A61K35/36;;A61K38/00;;A61K38/16;;A61K45/00;;A61L27/00;;A61P1/00;;A61P1/16;;A61P3/00;;A61P3/10;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P19/00;;A61P19/02;;A61P21/00;;A61P25/00;;A61P27/02;;A61P37/06;;C12M3/06;;C12N5/0775,424/93.7;;435/325;;435/366;;606/1;;606/131;;604/19;;604/22,99,97,047-253-510-312-524;;036-252-293-129-219;;016-725-607-839-435;;086-462-532-224-686;;094-547-639-217-227;;012-100-750-932-039;;062-596-462-103-530;;155-317-023-938-779;;054-506-496-484-990;;024-543-293-226-152;;071-429-593-853-516;;015-065-365-556-91X;;073-024-866-252-802;;013-619-248-169-661;;008-689-173-407-727;;005-046-972-638-291;;104-867-388-312-53X;;054-783-391-382-440;;011-805-902-464-128;;060-346-109-363-548;;038-374-873-783-178;;042-752-396-214-211;;047-615-077-646-421;;123-676-259-156-005;;053-378-748-216-731;;119-279-899-568-792;;000-409-808-541-605;;013-585-462-742-366;;002-574-351-412-169;;022-168-856-452-360;;052-138-454-301-405;;073-243-305-396-996;;055-939-072-605-234;;100-021-019-543-442;;006-388-312-315-426;;010-094-842-952-554;;083-745-638-097-33X;;108-011-138-630-620;;089-952-471-760-805;;074-361-613-484-000;;066-881-033-465-881;;068-663-145-216-705;;092-718-714-276-800;;126-822-003-009-011;;026-980-293-507-059;;026-519-654-455-165;;007-593-741-676-368;;088-484-373-248-225;;000-625-008-142-215;;033-642-914-335-547;;014-595-660-154-907;;017-165-339-699-387;;125-995-223-966-197;;060-272-195-296-337;;042-873-767-839-626;;003-133-282-606-391;;033-525-386-964-397;;060-747-209-758-763;;012-478-225-854-882;;026-194-281-031-26X;;027-822-501-366-119;;032-321-978-707-262;;122-318-219-266-473;;099-752-629-708-684;;149-114-581-210-021;;079-996-894-321-080;;003-830-438-296-822;;079-304-670-311-107;;007-590-158-070-744;;027-075-600-131-626;;040-763-736-139-475;;017-051-509-991-917;;023-863-661-792-008;;017-240-552-754-928;;037-896-221-394-486;;001-680-566-813-683;;159-966-370-938-701;;049-914-070-892-93X;;006-283-622-386-181;;001-540-649-917-213;;035-599-261-405-529;;009-217-401-539-352;;002-046-778-412-775;;024-155-477-095-201;;086-723-562-959-600;;009-409-750-213-445;;103-583-683-515-232;;020-337-057-544-762;;053-546-763-509-946;;119-279-899-568-792;;063-854-944-766-893;;140-579-283-445-044;;083-507-264-928-958;;041-128-004-154-032;;125-070-604-309-436;;012-374-600-750-30X;;105-396-044-542-989,11594767;;10.1006/bbrc.2001.5712;;11487017;;6382294;;10.1007/bf00453875;;8526158;;10.1016/s0094-1298(20)32343-9;;11248861;;1896551;;10.1097/00006534-199110000-00038;;10.1097/00003086-199810001-00026;;9917645;;11134993;;10.1046/j.1524-4725.2000.00277.x;;10.1046/j.1524-4725.2000.t01-1-00277.x;;11284885;;10.1046/j.1525-1594.2001.025003187.x;;10.1007/s002669900055;;8849432;;10.1007/bf02390315;;10086387;;10.1038/6529;;10.1182/blood.v97.5.1227;;11222364;;11884830;;10.1097/00006534-200203000-00037;;10.1152/ajpendo.2001.281.5.e1037;;11595661;;pmc370387;;6306056;;10.1172/jci110937;;10.1046/j.1365-2613.1996.00964.x;;8762864;;pmc2691621;;11125386;;10.1097/00005392-200101000-00037;;10.1097/00006534-200201000-00030;;11786812;;12160849;;10.1016/s0301-472x(02)00867-6;;pmc507709;;8958214;;10.1172/jci119070;;10.1016/s0736-0266(00)00010-3;;11332607;;11877271;;10.1182/blood.v99.6.1995;;10.1111/j.1749-6632.2001.tb03592.x;;11458511;;11287958;;10.1038/35070587;;9048302;;10.1089/end.1997.11.67;;10102814;;10.1126/science.284.5411.143;;11105688;;10.1016/s0079-6123(00)28026-6;;11326230;;10.1067/mtc.2001.112937;;10.1182/blood.v92.2.362.414k38_362_367;;9657732;;10.1182/blood.v92.2.362;;10.1161/01.cir.0000034046.87607.1c;;12370212;;10.1038/7434;;10202935;;7881356;;10.1002/stem.5530120602;;10.1016/s0940-2993(99)80076-1;;10048720;;10.1016/0270-9139(95)90478-6;;7539398;;10.1002/hep.1840210632;;10488710;;10.1016/s0168-8278(99)80043-9;;10.1089/107632701300062859;;11304456;;8967480;;10.1152/ajpendo.1996.270.5.e895;;9202388;;10.1242/jcs.110.11.1279;;8928727;;10.1152/ajpcell.1996.270.4.c1011;;10.1016/0026-0495(94)90275-5;;8028517;;8121307;;10.1016/0026-0495(94)90250-x;;10.2527/1996.7492117x;;8880414;;10.1152/ajpcell.1993.265.6.c1729;;8279534;;7545105;;10.1210/endo.136.10.7545105;;10.1210/en.136.10.4582;;8680482;;10.1080/10408369991239169;;10094092;;7962109;;10.1002/jcp.1041610209;;8544774;;10.1016/s0026-0495(96)90197-3;;1757497;;10.1242/jcs.99.1.131;;3489608;;10.1210/endo-119-4-1776;;10.1126/science.283.5401.534;;9915700;;9027588;;10.1002/(sici)1097-4644(199702)64:2<278::aid-jcb11>3.0.co;2-f;;2144412;;10.1007/bf00174624;;10.1210/endo.134.1.8275945;;8275945;;10.1210/en.134.1.277;;10.1210/endo-114-2-477;;6690287;;10.1002/(sici)1097-4652(199910)181:1<67::aid-jcp7>3.0.co;2-c;;10457354;;10.1002/(sici)1097-4652(199910)181:1<67::aid-jcp7>3.3.co;2-3;;10.1677/joe.0.1630159;;10556763;;7589892;;10.1046/j.1432-0436.1995.5910025.x;;10.1046/j.1432-0436.1999.6420067.x;;10234804;;7568133;;pmc40985;;10.1073/pnas.92.20.9363;;9182762;;10.1016/s0092-8674(00)80257-3;;10.1126/science.279.5356.1528;;9488650;;10.1523/jneurosci.08-04-01144.1988;;3357014;;pmc6569254;;10.1002/ijc.2910510513;;1319408;;10.1083/jcb.106.6.2139;;pmc2115137;;3384856;;10.1210/endo-106-4-1198;;7188899;;7031026;;10.1007/bf01002713;;9027589;;10.1002/(sici)1097-4644(199702)64:2<295::aid-jcb12>3.0.co;2-i;;10.1002/(sici)1097-4644(199702)64:2<295::aid-jcb12>3.3.co;2-6;;10.1006/excr.1997.3858;;9457080;;2249771;;10.1101/gad.4.10.1701;;10.1002/1097-4644(20010101)80:1<115::aid-jcb100>3.0.co;2-r;;11029758;;3754261;;pmc2114156;;10.1083/jcb.102.4.1151;;10.1111/j.1432-0436.1984.tb00280.x;;6084626;;1710251;;pmc1467750;;10.1046/j.1469-7580.1998.19220161.x;;9643417;;10.1002/jcp.1041460306;;2022691;;1689217;;10.1016/0092-8674(90)90662-x;;10688780;;10.1126/science.287.5457.1425;;11326082;;10.1126/science.1058866;;7813631;;10.1006/excr.1995.1005;;8126078;;10.1002/jcp.1041580322;;1511696;;10.1006/excr.1999.4708;;10585291;;10.1101/gad.10.10.1173;;8675005;;8791524;;10.1016/s0959-437x(96)80066-9;;9182765;;10.1016/s0092-8674(00)80260-3;;pmc2288926;;2007619;;10.1083/jcb.113.1.147;;1694181;;10.1002/jcp.1041430304;;2015398;;10.1182/blood.v77.8.1723.1723;;10.1182/blood.v77.8.1723.bloodjournal7781723;;10102814;;10.1126/science.284.5411.143;;9082988;;10.1126/science.276.5309.71;;10.1006/excr.1995.1329;;7556447;;9369534;;10.1007/s004410050964;;10915564;;10.1006/exnr.2000.7389;;10.1006/dbio.1999.9565;;10656756;;10.1006/excr.1998.4045;;9633508;;8609176;;10.1083/jcb.133.2.457;;pmc2120800,"U.S. Appl. No. 09/936.665, filed Sep. 10, 2001, Katz et al., Adipose-Derived Stem Cells and Lattices.;;U.S. Appl. No. 09/952,522, filed Sep. 10, 2001, Katz et al., Adipose-Derived Stem Cells and Lattices.;;Avital, L., D. Inderbitzin, et al. (2001). ""Isolation, characterization, and transplantation of bone marrow-derived hepatoryte stem cells."" Biochem Biophys Res Commun 288(1): 156-64.;;Carmeliet, P. and A. Luttun (2001). ""The emerging role of the bone marrow-derived stem cells in (therapeutic) angiogenesis,"" Thromb Haemost 86(1): 289-97.;;Castro-Malaspina, H., W. Ebell, et al. (1984). ""Human bone marrow fibroblast colony-forming units (CFU-F)."" Prog Clin Biol Res 154:209-36.;;Coleman, S. R. (1995). ""Long-term survival of fat transplants: controlled demonstrations."" Aesthetic Plast Surg 19(5): 421-5.;;Coleman, S. R. (2001). ""Structural fat grafts: the ideal filler?"" Clin Plast Surg 28(1): 111-9.;;Coleman, W. P., 3rd (1991). ""Autologous fat transplantation."" Plast Reconstr Surg 88(4): 736.;;Connolly, J.F. (1998). ""Clinical use of marrow osteoprogenitor cells to stimulate osteogenesis."" Clin Orthop(355 Suppl):S257-66.;;Eremia, S. and N. Newman (2000). ""Long-term follow-up after autologous fat grafting: analysis of results from 116 patients followed at least 12 months after receiving the last of a minimum of two treatments."" Dermatol Surg 26(12): 1150-8.;;Fukuda, K. (2001). ""Development of regenerative cardiomyocytes from mesenchymal stem cells for cardiovascular tissue engineering."" Artif Organs 25(3): 187-93.;;Guerrerosantos, J., A. Gonzalez-Mendoza, et al. (1996). ""Long-term survival of free fat grafts in muscle: an experimental study in rats."" Aesthetic Plast Surg 20(5): 403-8.;;Horwitz, E. M., D. J. Prockop, et al. (1999). ""Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta."" Nat Med 5(3): 309-13.;;Horwitz, E. M., D. J. Prockop, et al. (2001). ""Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta."" Blood 97(5): 1227-31.;;Huang, J. I., S. R. Beanes, et al. (2002). ""Rat extramedullary adipose tissue as a source of osteochondrogenic progenitor cells."" Plast Reconstr Surg 109(3): 1033-41; discussion 1042-3.;;Hutley, L. J., A. C. Herington, et al. (2001). ""Human adipose tissue endothelial cells preadipocyte proliferation."" Am J Physiol Endocrinol Metab 281(5): E1037-44.;;Kern, P. A., A. Knedler, et al. (1983). ""Isolation and culture of microvascular endothelium from human adipose tissue."" J Clin Invest 71(6): 1822-9.;;Lee, J. H., Z. Ilic, et al. (1996). ""Cell kinetics of repair after allyl alcohol-induced liver necrosis in mice."" Int J Exp Pathol 77(2): 63-72.;;Lee, P. E., R. C. Kung, et al. (2001). ""Periurethral autologous fat injection as treatment for female stress urinary incontinences a randomized double-blind controlled trial."" J Urol 165(1): 153-8.;;Mizuno, H., P. A. Zuk, et al. (2002). ""Myogenic differentiation by human processed lipoaspirate cells."" Plast Reconstr Surg 109(1): 199-209; discussion 210-1.;;Murayama, T., O. M. Tepper, et al. (2002). ""Determination of bone marrow-derived endothelial progenitor cell significance in angiogenic growth factor-induced neovascularization in vivo."" Exp Hematol 30(8): 967-72.;;Murry, C. E., R. W. Wiseman, et al. (1996). ""Skeletal myoblast transplantation for repair of myocardial necrosis."" J Clin Invest 98(11): 2512-23.;;Muschler, G. F., H. Nitto, et al. (2001). ""Age-and gender-related changes in the cellularity of human bone marrow and the prevalence of osteoblastic progenitors."" J Orthop Res 19(1): 117-25.;;Nishimori, M., Y. Yamada, et al. (2002). ""Health-related quality of life of unrelated bone marrow donors in Japan."" Blood 99(6): 1995-2001.;;Orlic, D., J. Kajstura, et al. (2001). ""Transplanted adult bone marrow cells repair myocardial infarcts in mice."" Ann N Y Acad Sci 938: 221-9; discussion 229-30.;;Orlic, D., J. Kajstura, et al. (2001). ""Bone marrow cells regenerate infarcted myocardium."" Nature 410(6829): 701-5.;;Palma, P. C., C. L. Riccetto, et al. (1997). ""Repeated lipoinjections for stress urinary incontinence."" J Endourol 11(1): 67-70.;;Pittenger, M. F., A. M. Mackay, et al. (1999). ""Multilineage potential of adult human mesenchymal stem cells."" Science 284(5411): 143-7.;;Prockop, D. J., S. A. Azizi, et al. (2000). ""Potential use of marrow stromal cells as therapeutic vectors for diseases of the central nervous system."" Prog Brain Res 128: 293-7.;;Rajnoch, C., J. C. Chachques, et al. (2001). ""Cellular therapy reverses myocardial dysfunction."" J Thorac Cardiovasc Surg 121(5): 871-8. t&artType=abs&id=a112937&target=.;;Shi, Q., S. Rafii, et al. (1998). ""Evidence for circulating bone marrow-derived endothelial cells."" Blood 92(2): 362-7.;;Strauer, B. E., M. Brehm, et al. (2002). ""Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans."" Circulation 106(15): 1913-8.;;Takahashi, T., C. Kalka, et al. (1999). ""Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization."" Nat Med 5(4): 434-8.;;Thomas, E. D. (1994). ""Stem Cell Transplantation: Past, Present and Future."" Stem Cells 12: 539-544.;;Werlich, T., K. J. Stiller, et al. (1999). ""Experimental studies on the stem cell concept of liver regeneration. II."" Exp Toxicol Pathol 51(1): 93-8.;;Yavorkovsky, L., E. Lai, et al. (1995). ""Participation of small intraportal stem cells in the restitutive response of the liver to periportal necrosis induced by allyl alcohol."" Hepatology 21(6): 1702-12.;;Yin, L., D. Lynch, et al. (1999). ""Participation of different cell types in the restitutive response of the rat liver to periportal injury induced by allyl alcohol."" J Hepatol 31(3): 497-507.;;Zuk, P. A., M. Zhu, et al. (2001). ""Multilineage cells from human adipose tissue: implications for cell- based therapies."" Tissue Eng 7(2): 211-28.;;Considine, et al., ""Paracrine stimulation of preadipocyte-enriched cell cultures by mature adipocytes,"" American Journal of Physiology 1996 270(5) E895-E899 (EXHIBIT 6).;;Dani, et al., ""Differentiation of embryonic stem cells into adipocytes in vitro,"" J. Cell Sci. 1997 110, 1279-1285 (EXHIBIT 7).;;Entenmann, et al., ""Relationship between replication and differentiation cultured human adipocyte precursor cells,"" American Phys.Soc. 1996 270,C1011-C1016 (EXHIBIT 8).;;Eslami Varzaneh, et al., ""Extracellular Matrix Components Secreted by Microvascular Endothelial Cells Stimulate Preadipocyte Differentiation In Vitro,"" Metabolism 1994 43 (7), 906-912 (EXHIBIT 9).;;Hauner, et al., ""Endothelin-1 Inhibits the Adipose Differentiation of Cultured Human Adipocyte Precursor Cells,"" Metabolism 1994 43(2) pp. 227-232 (EXHIBIT 10).;;Hausman, et al., ""The Influence of Extracellular Matrix Substrata on Preadipocyte Development in Serum-Free Cultures of Stromal-Vascular Cells,"" J. Anim.Sci. 1996 74(9), 2117-2128 (EXHIBIT 11).;;Hui-Ling et al., ""Increased expression of G in mouse embryo stem cells promotes terminal differentiation to adipocytes,"" American Physiological Society 1993 265(6), C1729-C1735 (EXHIBIT 12).;;Marko, et al., ""Isolation of a Preadipocyte Cell Line from Rat Bone Marrow and Differentiation to Adipocytes,"" Endocrinology 1995 136(10), 4582-4588 (EXHIBIT 13).;;Shillabeer, et al., ""A novel method for studying preadipocyte differentiation in vitro, "" Intl. J. Obesity 1996 20(Supp. 3), S77-S83 (EXHIBIT 14).;;Sorisky et al., ""From preadipocyte to Adipocyte: Differentiation-Directed Signals of Insulin from the Cell Surface to the Nucleus,"" Critical Review in Clinical Laboratory Sciences 1999 36(1), 1-34 (EXHIBIT 15).;;Vassaux, et al., ""Proliferation and differentiation of Rat Adipose Precursor Cells in Chemically Defined Medium: Differential Action of Anti-Adipogenic Agents,"" Journal of Cellular Physiology 1994 161(2), 249-256 (EXHIBIT 16).;;Wabitsch, et al., ""Biological Effects of Human Growth Hormone in Rat Adipocyte Precursor Cells and Newly Differentiated Adipocytes in primary Culture,"" Metabolism 1996 vol. 45,No. 1 pp. 34-42 (EXHIBIT 17).;;Bennett, JH, et al., 1991 J. Cell Sci. ""Adipocytic cells cultured from marrow have osteogenic potential,"" 99(Pt1):131-139 (Exhibit 26).;;Beresford, et al., 1986 Endo. ""1,25-Dihydroxyvitamin D<SUB>3 </SUB>and Human Bone-Derived Cells in Vitro: Effects on Alkaline Phosphatase, Type I Collagen and Proliferation,"" 119:1776-1785 (Exhibit 27).;;Bjornson, et al., 1999 Science ""Turning Brain into Blood: A Hematopoetic Fate Adopted by Adult Neural Stem Cells in Vivo,"" 283:534-537 (Exhibit 28).;;Bruder, et al., 1997 J. Cell Biochem. ""Growth Kinetics, Self-Renewal, and the Osteogenic Potential of Purified Human Mesenchymal Stem Cells During Extensive Subcultivation and Following Cryopreservation,"" 64:278-294 (Exhibit 29).;;Butler-Browne, et al., 1990 Anat. Embryol. (Berl) ""Myosin heavy and light chain expression during human skeletal muscle development and precocious muscle maturation induced by thyroid hormone,"" 181:513-522 (Exhibit 30).;;Cheng S-L., et al., 1994 Endo ""Differentiation of Human Bone Marrow Osteogenic Stromal Cells in Vitro: Induction of the Osteoblast Phenotype by Dexamethasone,"" 134: 277-286 (Exhibit 31).;;Chyun, et al., 1984 Endo. ""Cortisol Decreases Bone Formation by Inhibiting Periosteal Cell Proliferation,"" 114:477-480 (Exhibit 32).;;Conget, PA and JJ Minguell 1999 J. Cell. Physiol ""Phenotypical and Functional Properties of Human Bone Marrow Mesenchymal Progenitor Cells,"" 181:67-73 (Exhibit 33).;;Cooper, et al., 1999 J. Endocrinol. ""Glucocorticoid activity, inactivity and the osteoblast,"" 163:159-164 (Exhibit 34).;;Denker, A.E., et al., 1995 Differentiation ""Formation of cartilage-like spheroids by micromass cultures of murine C3H101/2 cells upon treatment with transforming growth factor-beta1,"" 59: 25-34 (Exhibit 35).;;Denker, et al., 1999 Differentiation ""Chondrogenic differentiation of murine C3H10T1/2 multipotential mesenchymal cells: I. Stimulation by bone morphogenetic protein-2 in high-density micromass cultures,"" 64:67-76 (Exhibit 36).;;Dimri, et, al., 1995 Proc. Natl. Acad. Sci. USA ""A biomarker that identifies a senescent human cells in culture and in aging skin in vivo, "" 92: 9363-9367 (Exhibit 37).;;Ducy, et, al., 1997 Cell ""Osf2/Cbfa 1: A Transcriptional Activator of Osteoblast Differentiation,"" 89:747-754 (Exhibit 38).;;Ferrari G., et al., 1998 Science ""Muscle Regeneration by Bone Marrow-Derived Myogenic Progenitors,"" 279: 1528-1530 (Exhibit 39).;;Frederikson and McKay 1988 J. Neurosci. ""Proliferation and Differentiation of Rat Neuroepithelial Precursor Cells in vivo,"" 8:1144-1151 (Exhibit 40).;;Fridman, et al., 1992 Int. J. Cancer ""Malignant Transformation of NIH-3T3 Cells After Subcutaneous co-Injection With A Reconstituted Basement Membrane (Matrigel),"" 51(5), 740-44 (Exhibit 41).;;Grigoradis A., et al., 1988 J. Cell Biol. ""Differentiation of Muscle, Fat, Cartilage, and Bone from Progenitor Cells Present in a Bone-derived Clonal Cell Population: Effect of Dexamethasone,"" 106: 2139-2151(Exhibit 42).;;Guerriero, V and JR Florini 1980 Endocrinology ""Dexamethasone Effects on Myoblast Proliferation and differentiation,"" 106:1198-1202(Exhibit 43).;;Hall, BK 1981 ""Intracellular and extracellular control of differentiation of cartilage and bone,"" Histochem. J. 13:599-614(Exhibit 44).;;Jaiswal, et al., 1997 ""Osteogenic Differentiation of Purified, Culture-Expanded Human Mesenchymal Stem Cells In Vitro,"" J. Cell Biochem. 64:295-312(Exhibit 45).;;Johnstone B., et al., 1998 ""In Vitro Chondrogenesis of Bone Marrow-Derived Mesenchymal Progenitor Cells,"" Exp. Cell Res. 238: 265-272(Exhibit 46).;;Kania, et al., 1990 ""The Drosophila segmentation gene runt encodes a novel nuclear regulatory protein that is also expressed in the developing nervous system,"" Genes Dev. 4:1701-1713(Exhibit 47).;;Kehlen, A. et al., 2000 J. Cell Biochem. ""Increased Lymphocytic Aminopeptidase N/CD13 Promoter Activity After Cell-Cells Contact,"" 80:115-123(Exhibit 48).;;Kosher, RA, et al., 1986 J. Cell Biol. ""Collagen Gene Expression During Limb Cartilage Differentiation,"" 102:1151-1156(Exhibit 49).;;Kuri-Harcuch, W. et al., 1984, Differentiation ""Extracellular matrix production by mouse 3T3-F442A cells during adipose differentiation in culture,"" 28(Exhibit 50).;;Lanier, L.L. et al, 1991 J. Immunol. ""Molecular and Functional Analysis of Human Natural Killer Cell-Associated Neural Cells Adhesion Molecule (N-Cam/CD56),"" 146:4421-4426(Exhibit 51).;;Lawson-Smith, M.J. and McGeachie, J.K. 1998 J. Anat. ""The identification of myogenic cells in skeletal muscle, with emphasis on the use of tritiated thymidine autoradiography and desmin antibodies,"" 192:161-171 (Exhibit 52).;;Leboy, et al., 1991 J. Cell Physiol. ""Dexamethasone Induction of Osteoblast mRNAs in Rat Marrow Stromal Cell Cultures,"" 146:370-378 (Exhibit 53).;;Lendahl, et al., 1990 Cell ""CNS Stem Cells Express a New Class of Intermediate Filament Protein,"" 60:585-595 (Exhibit 54).;;Lenoir, N. 2000 Science ""Europe Confronts The Embryonic Stem Cell Research Challenge,"" 287:1425-1427 (Exhibit 55).;;Lumelsky, N. et al. 2001 Science ""Differentiation of Embryonic Stem Cells to Insulin-Secreting Structures Similar to Pancreatic Islets,"" 292:1389-1394. (Exhibit 56).;;Lynch, et al., 1995, Exp. Cell Res. ""The Influence of Type I Collagen on the Development and Maintenance of the Osteoblast Phenotype in Primary and Passaged Rat Calvarial Osteoblasts: Modification of Expression of Genes Supporting Cell Growth, Adhesion, and Extracelluar Matrix Mineralization,"" 216:35-45 (Exhibit 57).;;Malaval, et al., 1994 J. Cell. Physiol. ""Cellular Expression of Bone-Related Proteins During In Vitro Ostegenesis in Rat Bone Marrow Stromal Cell Culture,"" 158:555-572 (Exhibit 58).;;Manduca, et al., 1992 Eur. J. Cell Biol. ""Chondrogenic differentiation in chick embryo osteoblast cultures,"" 57:193-201 (Exhibit 59).;;Martin, et al., 1999 Exp. Cell Res. ""Mammalian Chondrocytes Expanded in the Presence of Fibroblast Growth Factor 2 Maintain the Ability to Differentiate and Regenerate Three-Dimensional Cartilaginous Tissue,"" 253:681-688 (Exhibit 60).;;Megeney, et al., 1996 Genes Dev. ""MyoD is required for myogenic stem cell function in adult skeletal muscle,"" 10:1173-1183 (Exhibit 61).;;Molkentin and Olson 1996 Curr. Opin. Genet. Dev. ""Defining the regulatory networks for muscle development,"" 6:445-453 (Exhibit 62).;;Mundlos, et al., 1997 Cell ""Mutations Involving the Transcription Factor CBFA12 Cause Cleidocranial Dysplasia,"" 89:773-779 (Exhibit 63).;;Nehls, A. and D Drenckhahn 1991 J. Cell Biol.""Heterogeneity of Microvascular Pericytes for Smooth Muscle Type Alpha-Actin,"" 113:147-154 (Exhibit 64).;;Owen, TA, et al., 1990 J. Cell Physiol. ""Progressive Development of the Rat Osteoblast Phenotype in Vitro: Reciprocal Relationships in Expression of Genes Associated with Osteoblast Proliferation and Differentiation During Formation of the Bone Extracellular Matrix,"" 143:420-430 (Exhibit 65).;;Paul S.R., et al., 1991 Blood ""Stromal Cell-Associated Hematopoiesis: Immortalization and Characterization of Primate Bone Marrow-Derived Stromal Cell Line,"" 77: 1723-33 (Exhibit 66).;;Pittenger M.F., et al., 1999 Science ""Multilineage Potential of Adult Human Mesenchymal Stem Cells,"" 284: 143-147 (Exhibit 67).;;Prockop D.J. 1997 Science ""Marrow Stromal Cells as Stem Cells for Nonhematopoietic Tissues,"" 276: 71-74 (Exhibit 68).;;Rando, et al., 1995 Exp. Cell Res. ""The Fate of Myoblasts Following Transportation into Mature Muscle,"" 220:383-389 (Exhibit 69).;;Saalbach, A., et al., 1997 Cell and Tiss. Res. ""The Fibroblast-specific MAb AS02: a novel tool for detection and elimination of human fibroblasts,"" 290:593-599 (Exhibit 70).;;Sanchez-Ramos, et al., 2000 ""Adult Bone Marrow Stromal Cells Differentiate into Neural Cells in Vitro,"" Exp. Neurol. 164:247-256 (Exhibit 71).;;Seale and Rudnicki 2000 Dev. Biol. ""A New Look at the Origin, Function, and ""Stem-Cell"" Status of Muscle Satellite Cells,"" 218:115-124 (Exhibit 72).;;Shukunami, C., et al., 1998 Exp. Cell Res. ""Sequential Progression of the Differentiation Program by Bone Morphogenetic Protein-2 in Chondrogenic Cell Line ATDC5,"" 241:1-11 (Exhibit 73).;;Shukunami C., et al., 1996 Journ. Of Cell Bio. ""Chrondrogenic Differentiation of Clonal Mouse Embryonic Cell Line ATDC5 In Vitro: Differentiation-dependent Gene Expression of Parathyroid Hormone (PTH)/PTH-related Peptide Receptor,"" 133:2:457-468 (Exhibit 74).",ACTIVE
960,DE,T2,DE 68909726 T2,171-722-627-893-531,1994-03-03,1994,DE 68909726 T,1989-07-25,US 23988888 A,1988-09-02,Schwingungsdämpfer für einen Kraftgetriebemechanismus.,,FORD WERKE AG,MACDONALD FRASER JOHN;;KIRKWOOD MALCOLM EDWIN,,https://lens.org/171-722-627-893-531,Granted Patent,no,0,0,6,6,0,F16F15/129;;F16F2230/0064;;F16H45/02;;F16H47/08;;F16H2045/0268;;F16H2045/0278;;F16H45/02;;F16H2045/0268;;F16H2045/0278;;F16F15/129;;F16F2230/0064;;F16H47/08,F16F15/129;;F16H45/02;;F16H47/08,,0,0,,,,EXPIRED
961,WO,A1,WO 2001/002693 A1,187-210-889-753-151,2001-01-11,2001,US 0018129 W,2000-06-30,US 34758699 A,1999-07-01,GAS LIFT UMBILICAL CABLE AND TERMINATION ASSEMBLIES THEREFOR,A gas lift umbilical (10) including a flexible pipe (14) having a collapse resistant wall (12) and a first sealing layer (15) formed on an interior surface of the collapse resistant wall (12). The interior surface defines a longitudinal passage. A flexible gas lift hose (16) is mounted within the longitudinal passage extending from a first end of the flexible pipe (14) to a second end thereof. A first fitting (104) is attached to the collapse resistant wall (12) of the flexible pipe (14) at a first end thereof. A second fitting (106) is attached to the collapse resistant wall (12) of the flexible pipe (14) at a second end thereof. A first adapter joins a first end of the gas lift hose (16) to the first fitting and a second adapter joins a second end of the gas lift hose (16) to the second fitting.,KELLOGG BROWN & ROOT INC;;FRASER DANA JOHN;;DAVIS ALVA W,FRASER DANA JOHN;;DAVIS ALVA W,,https://lens.org/187-210-889-753-151,Patent Application,yes,3,3,9,9,0,E21B17/203;;E21B17/203,E21B17/20,,1,0,,,See also references of EP 1200703A4,PENDING
962,BR,A2,BR 112014011644 A2,176-993-351-917-42X,2017-05-02,2017,BR 112014011644 A,2012-11-05,IB 2012056152 W;;US 201161560836 P,2011-11-17,célula transdutora micromecanizada capacitiva pré-colapsada e método de fabricação de uma célula transdutora micromecanizada capacitiva pré-colapsada,"resumo célula transdutora micromecanizada capacitiva pré- colapsada e método de fabricação de uma célula transdutora micromecanizada capacitiva pré-colapsada a presente invenção se refere a uma célula transdutora micromecanizada capacitiva pré-colapsada (10) que compreende um substrato (12) que compreende um primeiro eletrodo (16), uma membrana (14) que compreende um segundo eletrodo (18), em que a célula tem uma região externa (22) na qual a membrana (14) é montada ao substrato (12), e uma região interna (20) no interior ou cercada pela região externa (22), em que a membrana (14) está colapsada no substrato (12) em uma primeira região de forma anular colapsada (24) localizada na região interna (20). 1/1",KONINKLIJKE PHILIPS NV,ANDREW LEE ROBINSON;;JOHN DOUGLAS FRASER,,https://lens.org/176-993-351-917-42X,Patent Application,no,0,0,16,16,0,B06B1/0292;;Y10T29/49005;;B06B1/02;;Y10T29/49005;;B06B1/0292;;B06B1/02;;H02N1/006,B06B1/02,,0,0,,,,DISCONTINUED
963,ES,T3,ES 2633604 T3,183-798-841-663-549,2017-09-22,2017,ES 04756641 T,2004-07-01,US 50358903 P;;US 2004/0021480 W,2003-09-17,Métodos para usar células regenerativas derivadas de adiposo en el tratamiento de una enfermedad vascular periférica,"Una composición que comprende una población concentrada de células derivadas del tejido adiposo para su uso en el tratamiento de la enfermedad vascular periférica (PVD) fuera del corazón y del sistema nervioso central en un sujeto que lo necesite, en la que dicha población concentrada de células derivadas de adiposo se administrará a un paciente que lo necesite sin cultivar las células derivadas del tejido adiposo antes de administrarlas al sujeto, en la que las células derivadas de adiposo se obtienen mediante el procesamiento de tejido adiposo para separar las células derivadas de adiposo de adipocitos maduros y tejido conectivo, y lavando, separando y concentrando dichas células derivadas de adiposo, en la que dicha población concentrada de células derivadas del tejido adiposo comprende una concentración celular mínima de aproximadamente 1 x 105 a aproximadamente 1 x 107 células/ml, y en la que al menos el 0,1 % del componente celular de la población concentrada de células derivadas de adiposo son células madre.",CYTORI THERAPEUTICS INC,FRASER JOHN;;HEDRICK MARC;;DANIELS ERIC,,https://lens.org/183-798-841-663-549,Granted Patent,no,0,5,19,221,0,A61K35/12;;A61P9/00;;A61P9/02;;A61P9/10;;A61P9/14;;A61P43/00;;C12N5/069;;C12N5/0667,C12N5/071;;A01N63/00;;A61K35/12;;C12N5/0775,,0,0,,,,ACTIVE
964,US,A1,US 2016/0113967 A1,190-509-706-426-671,2016-04-28,2016,US 201514860416 A,2015-09-21,US 201514860416 A;;US 201313926854 A;;US 30278709 A;;US 2006/0021017 W,2006-05-30,SYSTEMS AND METHODS FOR MANIPULATION OF REGENERATIVE CELLS FROM ADIPOSE TISSUE,"The invention provides methods for manipulating regenerative cells from adipose tissue. Specifically, it provides methods for enrichment of desired cells and enhancement of their therapeutic effects.",CYTORI THERAPEUTICS INC,HEDRICK MARC H;;FRASER JOHN K,CYTORI THERAPEUTICS INC (2015-10-30);;LOREM VASCULAR PTE. LTD (2019-04-24),https://lens.org/190-509-706-426-671,Patent Application,yes,1,10,4,4,0,A61K35/35;;C12N2509/00;;C12N5/0653;;A61P43/00;;C12N2509/00;;A61K35/35;;C12N5/0653;;A61K9/0024;;A61K35/28;;C12N5/0667;;C12N2509/10,A61K35/28;;A61K9/00;;A61K35/35;;C12N5/077;;C12N5/0775,,0,0,,,,DISCONTINUED
965,CA,C,CA 2619916 C,190-877-284-008-101,2016-06-14,2016,CA 2619916 A,2006-08-25,GB 0517382 A;;GB 2006003186 W,2005-08-26,METHODS AND COMPLEXES FOR DETERMINING CELL CULTURE HISTORY,The present invention relates in one aspect to a method for determining the cell culture history of a cell unit labelled with more than one type of tag comprising the steps of: (a) measuring one or more parameters of each tag that is used to label the cell unit; (b) identifying each tag in the cell unit; and (c) correlating the identity of each tag to the identity of the cell unit and/or the specific cell culture conditions to which the cell unit has been exposed.,PLASTICELL LTD,CHOO YEN;;HORNBY FRASER;;GIRDLESTONE JOHN,,https://lens.org/190-877-284-008-101,Granted Patent,no,0,0,16,16,0,G01N33/5008;;G01N33/5023;;G01N33/5073;;Y10T436/2525;;Y10T436/25375;;Y10T436/13;;Y10T436/2525;;Y10T436/25375;;Y10T436/13;;G01N33/5008;;G01N33/5023;;G01N33/5073,C12N5/00;;G01N33/50,,0,0,,,,ACTIVE
966,PH,A1,PH 12018500404 A1,191-902-925-995-580,2018-08-29,2018,PH 12018500404 A,2018-02-23,GB 201601501 A;;GB 201518819 A;;GB 201522544 A;;GB 2015052154 W;;GB 2016052215 W,2015-07-24,CONTAINER AND CLOSURE,"A plastic or metal wide mouth container (10) with a metal closure, the container having an opening defining an axis and an outwardly projecting first member around the external surface of the container, the first member comprising a plurality of circumferentially spaced apart first portions, each first portion having an element with elongate upper and lower surfaces, said upper and lower surfaces thereof being substantially horizontal in the circumferential direction. The metal closure has a top part and a skirt part, the skirt part comprising an inwardly projecting second member around an internal surface thereof, the second member comprising a plurality of circumferentially spaced apart second portions, each second portion having an element with elongate upper and lower surfaces, said upper and lower surfaces thereof being substantially horizontal in the circumferential direction. The horizontal elements of the second portions are of a length such that they can pass through spaces between the first portions and are locatable beneath the first portions so as to secure the metal closure to the container. The closure has a sealing member (23) for providing a seal with a sealing surface of the container, the sealing surface (13) being a substantially vertical surface about the interior or exterior of a neck portion of the container and the second portions on the closure having an upwardly inclined end at one end thereof and a downwardly inclined end at the other end thereof which extend beyond said elongate upper and lower surfaces thereof, respectively. Rotation of the metal closure in a tightening direction drives the second portions down the downwardly inclined ends to move the closure downwards and to compress the seal member in a substantially horizontal direction into sealing engagement with the vertical sealing surface. Rotation of the closure in a loosening direction drives the second portions up the upwardly inclined ends to move the sealing member from the sealed position to a secured venting position. Further rotation in the loosening direction is required to remove the closure from the container.",THREADLESS CLOSURES LTD,FRASER ANTHONY HENRY JOSEPH;;HEIN JOHN,,https://lens.org/191-902-925-995-580,Patent Application,no,0,0,10,40,0,B65D41/065;;B65D41/065;;B65D43/0231;;B65D43/0231;;B65D2543/00972;;B65D2543/00972,B65D41/06;;B65D43/02;;B65D51/16,,0,0,,,,PENDING
967,CA,A1,CA 2436856 A1,198-805-533-805-338,2002-06-13,2002,CA 2436856 A,2001-12-04,NZ 0100267 W;;US 25124300 P,2000-12-04,IMMUNOMODULATORY CONSTRUCTS AND THEIR USES,"An immunomodulator which comprises an antigen-presenting-cell (APC) targetin g molecule coupled to an immunomodulatory antigen, wherein said APC-targeting molecule mimics a superantigen but does not include a fully functional T-cel l receptor binding site.",AUCKLAND UNISERVICES LTD,NICHOLSON MELISSA JOY;;FRASER JOHN DAVID,,https://lens.org/198-805-533-805-338,Patent Application,no,0,0,12,12,22,A61K39/092;;A61K39/385;;A61K2039/5154;;A61K2039/57;;A61K2039/6068;;C07K14/31;;C07K14/315;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61K39/385;;A61K39/092;;A61K2039/5154;;A61K2039/57;;A61K2039/6068;;C07K14/31;;C07K14/315,C12N15/09;;A61K39/00;;A61K39/085;;A61K39/09;;A61K39/385;;A61K45/00;;A61K48/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;C07K14/31;;C07K14/315;;C12N15/31,,0,0,,,,DISCONTINUED
968,CN,A,CN 102046489 A,184-762-311-751-527,2011-05-04,2011,CN 200980109814 A,2009-03-19,GB 2009000744 W;;GB 0805113 A;;GB 0809263 A,2008-03-19,Sealed container,"A container (1) for the storage of a carbonated drink, comprising a container body with an opening that defines an axis and a removable closure (3) for closing the opening, the closure including a foil (2) for bonding to the container to close the opening in a gas-tight manner, the foil also being connected to, or interacting with, the closure, such that initial rotation of the closure in a loosening direction relative to the container body distorts or deforms the foil in a manner such that further rotation of the. closure results in a peel force being applied to the bond between the foil and the container.",THREADLESS CLOSURES LTD,JOSEPH FRASER ANTHONY HENRY;;JOHN HEIN,,https://lens.org/184-762-311-751-527,Patent Application,no,0,2,7,9,0,B65D51/228;;B65D2251/0018;;B65D2251/0093;;B65D41/08;;B65D51/228;;B65D2251/0093;;B65D2251/0018;;B65D41/08,B65D51/22,,0,0,,,,DISCONTINUED
969,GB,A,GB 2568224 A,011-999-624-261-782,2019-05-15,2019,GB 201715160 A,2017-09-20,GB 201715160 A,2017-09-20,"A method of monitoring fluid flow and fluid position behind conductor, casing or tubing during wellbore clean up and/or abandonment operations","Disclosed is a method of monitoring flowing or static fluid and simulating a fluid 10 in an oil or gas well. Tracking devices or location tags 11 such as nano chips, pip, PIT or RFID tags are suspended or mixed within a fluid which is then displaced down a well. A detector or a series of detectors mounted on a work string or similar is able to read the signals of the tracking devices. Computer software will decode the signals to show their real-time location in the wellbore. The method may use the fluid for wellbore clean-up or abandonment operations. An additive such as a gel, cellulose fiber, viscosified fluid or cement may be added to the fluid to increase the carrying capacity of the fluid.",CORETRAX TECH LIMITED,JASON FONG;;JOHN FRASER;;CHERISH BODMAN,,https://lens.org/011-999-624-261-782,Patent Application,no,4,2,2,2,0,E21B33/1204;;E21B33/14;;E21B47/005;;E21B47/11;;E21B47/00;;E21B47/01;;E21B47/005;;E21B47/11;;E21B47/11,E21B47/00;;E21B47/005,,0,0,,,,DISCONTINUED
970,EP,A4,EP 1349568 A4,038-714-109-974-647,2005-03-30,2005,EP 01999384 A,2001-12-04,NZ 0100267 W;;US 25124300 P,2000-12-04,IMMUNOMODULATORY CONSTRUCTS AND THEIR USES,,AUCKLAND UNISERVICES LTD,FRASER JOHN DAVID;;NICHOLSON MELISSA JOY,AUCKLAND UNISERVICES LIMITED (2009-11-13),https://lens.org/038-714-109-974-647,Search Report,no,0,0,12,12,0,A61K39/092;;A61K39/385;;A61K2039/5154;;A61K2039/57;;A61K2039/6068;;C07K14/31;;C07K14/315;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61K39/385;;A61K39/092;;A61K2039/5154;;A61K2039/57;;A61K2039/6068;;C07K14/31;;C07K14/315,C12N15/09;;A61K39/00;;A61K39/085;;A61K39/09;;A61K39/385;;A61K45/00;;A61K48/00;;A61P31/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;C07K14/31;;C07K14/315;;C12N15/31,,4,3,072-117-375-070-090;;014-056-638-943-210;;029-465-313-002-422,pmc2212189;;9500785;;10.1084/jem.187.6.823;;10.1016/s1074-7613(00)80646-9;;9881971;;10689316;;10.1016/s1357-4310(99)01657-3,"LEDER LUKAS ET AL: ""A mutational analysis of the binding of staphylococcal enterotoxins B and C3 to the T cell receptor beta chain and major histocompatibility complex class II"", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 187, no. 6, 16 March 1998 (1998-03-16), pages 823 - 833, XP002903430, ISSN: 0022-1007;;LI HONGMIN ET AL: ""Three-dimensional structure of the complex between a T cell receptor beta chain and the superantigen staphylococcal enterotoxin B"", IMMUNITY, vol. 9, no. 6, December 1998 (1998-12-01), pages 807 - 816, XP002314864, ISSN: 1074-7613;;FRASER JOHN ET AL: ""Superantigens: Powerful modifiers of the immune system"", MOLECULAR MEDICINE TODAY, vol. 6, no. 3, March 2000 (2000-03-01), pages 125 - 132, XP002314865, ISSN: 1357-4310;;See also references of WO 0245739A1",EXPIRED
971,AU,A,AU 1983/014213 A,032-819-601-731-56X,1984-04-12,1984,AU 1983/014213 A,1983-05-04,GB 8228778 A,1982-10-08,CHOCKS LOCKED TO WHEEL TO PREVENT VEHICLE THEFT,,LIONWELD KENNEDY LTD,MILNER ALLEN JOHN;;FRASER JAMES EDWARD,,https://lens.org/032-819-601-731-56X,Patent Application,no,0,0,2,4,0,,B60R25/00,,0,0,,,,EXPIRED
972,DK,B1,DK 166821 B1,048-014-950-199-404,1993-07-19,1993,DK 337383 A,1983-07-22,GB 8221457 A,1982-07-24,"ANALOGIFREMGANGSMAADE TIL FREMSTILLING AF 4-AMINO-6,7-DIMETHOXYQUINOLINDERIVATER ELLER FARMACEUTISK ACCEPTABLE SYREADDITIONSSALTE DERAF",,PFIZER,CAMPBELL SIMON FRASER;;HARDSTONE JOHN DAVID,,https://lens.org/048-014-950-199-404,Granted Patent,no,0,0,46,53,0,C07C255/00;;C07D215/42;;C07D215/48;;C07D295/195;;C07D401/04;;C07D401/12;;C07D405/12;;C07D413/12;;C07D417/12;;A61P9/12;;C07D215/20;;C07D295/195;;C07D405/12;;C07D401/04;;C07D413/12;;C07D417/12;;C07C255/00;;C07D215/42;;C07D401/12;;C07D215/48,A61K31/47;;A61K31/4709;;A61K31/495;;A61K31/50;;A61K31/505;;A61K31/53;;A61P9/12;;C07D215/42;;C07D215/48;;C07D295/195;;C07D401/04;;C07D401/12;;C07D401/14;;C07D405/12;;C07D405/14;;C07D413/12;;C07D413/14;;C07D417/12;;C07D215/20,,0,0,,,,EXPIRED
973,AT,T1,AT E501247 T1,051-223-767-732-361,2011-03-15,2011,AT 04756623 T,2004-07-01,US 2004/0021415 W,2004-07-01,VERFAHREN ZUR VERWENDUNG REGENERATIVER ZELLEN ZUR FÖRDERUNG DER WUNDHEILUNG,"Cells present in adipose tissue are used to promote wound healing in a patient. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the regenerative cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic benefit.",CYTORI THERAPEUTICS INC,HEDRICK MARC;;FRASER JOHN;;DANIELS ERIC,,https://lens.org/051-223-767-732-361,Granted Patent,no,0,0,19,19,0,C12N5/0667;;C12N2506/1384;;A61K45/06;;A61K35/28;;A61P17/02;;A61P37/06;;A61P43/00;;C12N5/06;;C12N5/0602;;C12N5/00,C12N5/07;;A61K35/28;;A61P17/02;;C12N5/00;;C12N5/071;;C12N5/0775,,0,0,,,,INACTIVE
974,AR,A1,AR 107497 A1,063-835-035-217-930,2018-05-02,2018,AR P170100249 A,2017-02-01,AR P170100249 A,2017-02-01,ENVASE Y CIERRE,"Un envase de boca ancha de plástico o metal con un cierre de metal, el envase tiene una abertura que define un eje y un primer miembro que se proyecta hacia afuera alrededor de una superficie externa del envase, el primer miembro comprende una pluralidad de primeras partes circunferencialmente separadas, cada primera parte tiene elementos con superficies superiores e inferiores alargadas, dichas superficies superiores e inferiores son sustancialmente horizontales en dirección circunferencial. El cierre de metal tiene una parte superior y una parte de faldón, la parte de faldón comprende un segundo miembro que se proyecta hacia dentro alrededor de su superficie interna, dicho segundo miembro comprende una pluralidad de segundas partes circunferencialmente separadas, cada segunda parte tiene elementos con superficies superiores e inferiores alargadas, dichas superficies superiores e inferiores son sustancialmente horizontales en dirección circunferencial. Los elementos horizontales de las segundas partes tienen una longitud tal que pueden pasar a través de los espacios entre las primeras partes y se ubican debajo de las primeras partes a fin de asegurar el cierre de metal al envase. El cierre tiene un miembro de sellado para proporcionar un cierre hermético con una superficie de sellado del envase, y la superficie de sellado es una superficie sustancialmente vertical alrededor del interior o exterior de una parte de cuello del envase y las segundas partes en el cierre tienen un extremo que se inclina hacia arriba en uno de sus extremos y un extremo que se inclina hacia abajo en el otro de sus extremos que se extienden mas allá de dichas superficies superiores e inferiores alargadas, respectivamente. La rotación del cierre de metal en una dirección de ajuste dirige las segundas partes hacia abajo por los extremos inclinados hacia abajo para mover el cierre hacia abajo y comprimir el miembro de sellado en una dirección sustancialmente horizontal hacia un acoplamiento por sellado con la superficie de sellado vertical. La rotación del cierre en una dirección de aflojamiento dirige las segundas partes hacia arriba por los extremos inclinados hacia arriba para mover el miembro de sellado desde la posición de sellado a una posición de ventilación asegurada. Se requiere una posterior rotación en la dirección de aflojamiento para remover el cierre del envase.",THREADLESS CLOSURES LTD,HEIN JOHN;;FRASER ANTHONY HENRY JOSEPH,,https://lens.org/063-835-035-217-930,Patent Application,no,0,0,1,1,0,,B65D51/16;;B65D41/06;;B65D43/02,,0,0,,,,PENDING
975,EP,B1,EP 2576374 B1,067-301-772-652-392,2016-09-28,2016,EP 11727733 A,2011-06-03,GB 201011800 A;;GB 201009429 A;;GB 2011000846 W,2010-06-04,CLOSURE FOR A CONTAINER,,THREADLESS CLOSURES LTD,FRASER ANTHONY HENRY JOSEPH;;HEIN JOHN,,https://lens.org/067-301-772-652-392,Granted Patent,yes,13,12,17,39,0,B65D41/04;;B65D41/0442;;B65D41/0442;;B65D41/00;;B65D41/08;;B65D41/08;;B65D41/08;;B65D41/086;;B65D41/086;;B65D41/62;;B65D53/02;;B65D53/02;;B65D53/02;;B65D2543/00564;;B65D2543/00564;;B65D2543/00972;;B65D2543/00972,B65D41/04;;B65D41/08;;B65D53/02,,0,0,,,,ACTIVE
976,EP,A2,EP 0841644 A2,078-039-922-874-90X,1998-05-13,1998,EP 97308839 A,1997-11-04,GB 9623190 A,1996-11-06,Cash handling,"A cash dispensing apparatus characterised by comprising:
 a storage unit (11) having a plurality of discrete locations (13) within which parcels (21) of cash of one or more predetermined values can be stored, input means for a user to input a demand for a parcel, and, a mechanism (15) for, on demand, extracting an appropriate parcel (21) from its predetermined location and delivering that parcel to a collection location (22) for receipt by the demander.",AIR TUBE CONVEYORS,HENDERSON FRASER CRISFIELD;;LIVY JOHN VICTOR,,https://lens.org/078-039-922-874-90X,Patent Application,yes,0,9,4,4,0,G07D11/135;;G07D11/34;;G07D11/40,G07D11/00,,0,0,,,,DISCONTINUED
977,EP,B1,EP 3079743 B1,069-771-951-740-426,2022-08-03,2022,EP 14868882 A,2014-12-10,AU 2013/904823 A;;AU 2014/050406 W,2013-12-11,APPARATUS,,DE MOTU CORDIS PTY LTD,FRASER JOHN FRANCIS;;GREGORY SHAUN DAVID,,https://lens.org/069-771-951-740-426,Granted Patent,yes,16,0,17,17,0,A61M11/02;;A61M11/06;;A61M15/0028;;A61M15/0065;;A61M16/0048;;A61M16/0078;;A61M16/06;;A61M16/208;;A61M2202/064;;A61M2206/14;;A61M2209/06;;A61M2230/06;;A61M2230/42;;A61M16/049;;A61M15/0021;;A61M15/0031;;A61M15/0043;;A61M15/0048;;A61M15/0051;;A61M16/0084;;A61M2205/50;;A61M16/14;;A61K31/4166;;A61K31/137;;A61K9/0075;;A61K31/485;;A61K31/5517;;A61K31/7004;;A61P9/04;;A61P3/00;;A61P37/00;;A61M16/0048;;A61M16/06;;A61M16/208;;A61M2206/14;;A61M15/0031;;A61M15/0048;;A61M16/0084;;A61M2209/06;;A61M16/0078;;A61M11/02;;A61M2230/06;;A61M15/0051;;A61M15/0043;;A61M2205/50;;A61M15/0065;;A61M2230/42;;A61M11/06;;A61M15/0028;;A61M15/0021;;A61M16/049;;A61M2202/064;;A61M16/14;;A61H31/00;;A61M16/0057;;A61M16/04;;A61M16/0816;;A61M2202/0208,A61M11/02;;A61K9/00;;A61K31/137;;A61K31/4166;;A61K31/485;;A61K31/5517;;A61K31/7004;;A61M11/06;;A61M15/00;;A61M16/00;;A61M16/04;;A61M16/06;;A61M16/14;;A61M16/20;;A61P3/00;;A61P9/04;;A61P37/00,,1,0,,,"ASTHMA SOCIETY OF CANADA: 'How to use a Diskhaler' 28 January 2015, XP055348835 Retrieved from the Internet: <URL:http://www.asthma.ca/adults/treatment/ diskhaler.php>",ACTIVE
978,CH,A,CH 454372 A,094-287-938-798-860,1968-04-15,1968,CH 622766 A,1966-04-29,US 17134371 A;;US 45238865 A,1965-04-30,Procédé de fabrication d'un objet en verre céramique,,CORNING GLASS WORKS,DAVID ALLEN DUKE;;JOHN FRASER MACDOWELL,,https://lens.org/094-287-938-798-860,Granted Patent,no,0,0,7,8,0,C03C10/0018;;C03C10/0054;;C03C10/0018;;C03C10/0054,C03C10/00,"32B,3/30",0,0,,,,EXPIRED
979,US,B2,US 9762148 B2,088-121-343-259-553,2017-09-12,2017,US 201214351888 A,2012-11-05,US 201214351888 A;;US 201161560836 P;;IB 2012056152 W,2011-11-17,Pre-collapsed capacitive micro-machined transducer cell with annular-shaped collapsed region,"The present invention relates to a pre-collapsed capacitive micro-machined transducer cell ( 10 ) comprising a substrate ( 12 ) comprising a first electrode ( 16 ), a membrane ( 14 ) comprising a second electrode ( 18 ), wherein the cell has an outer region ( 22 ) where the membrane ( 14 ) is mounted to the substrate ( 12 ) and an inner region ( 20 ) inside or surrounded by the outer region ( 22 ), wherein the membrane ( 14 ) is collapsed to the substrate ( 12 ) in a first collapsed annular-shaped region ( 24 ) located within the inner region ( 20 ).",KONINKLIJKE PHILIPS NV,ROBINSON ANDREW LEE;;FRASER JOHN DOUGLAS,KONINKLIJKE PHILIPS N.V (2012-06-17),https://lens.org/088-121-343-259-553,Granted Patent,yes,12,1,16,16,0,B06B1/0292;;Y10T29/49005;;B06B1/02;;Y10T29/49005;;B06B1/0292;;B06B1/02;;H02N1/006,B06B1/02;;H02N1/00,,0,0,,,,ACTIVE
980,CN,A,CN 108473239 A,089-788-720-172-405,2018-08-31,2018,CN 201680079073 A,2016-12-15,GB 201522544 A;;GB 2016053945 W,2015-12-21,Method of forming a metal closure and closure for container,"A method of forming a releasable closure for a container (10) having a circular opening (10A, 21B, 21), the method comprising releasably securing (23) an annular skirt portion (21) of the closure to aneck portion of the container (10), eg by means of a thread, subsequently locating a separate closing portion (22) of the closure over an opening (10A, 21B, 21) in the skirt portion (21), and irreversibly securing (23) the closing portion (22C, 22) to the skirt portion (21), eg by seaming, to form a closure that closes the opening (10A, 21B, 21) of the container (10) but is releasable therefrom by unscrewing the skirt portion (21) from the neck portion of the container (10). A closure comprising two, initially separate, components is also described: an annular skirt portion (21) and a closingportion (22C, 22) which can be irreversibly secured to the skirt portion (21) after the annular skirt portion (21) has been releasably secured to the neck portion of a container (10). An intermediateproduct comprising a container (10) having an annular skirt portion (21) of a releasable closure releasably secured to a neck portion thereof is also described as well as a method of filling a container (10) comprising the steps of providing a container (10) having an annular skirt portion (21) of a releasable closure releasably secured thereto, filling the container (10) through an opening (10A,21B, 21) in the skirt portion (21) and subsequently locating a separate closing portion (22) of the closure over the opening (10A, 21B, 21) in the skirt portion (21), and irreversibly securing (23) the closing portion (22C, 22) to the skirt portion (21) so as to form a closure that closes the opening (10A, 21B, 21) of the container (10) but is releasable therefrom. The opening (10A, 21B, 21) of the annular skirt portion (21) may simulate the opening (10A, 21B, 21) of a conventional can body and the closing portion (22C, 22) may be of similar form to the can end applied to a conventional can body so the closing portion (22C, 22) can be irreversibly secured to a skirt portion (21) (that has been releasably secured to the neck portion of a container (10)) in a conventional can filling and closing line.",THREADLESS CLOSURES LTD,FRASER ANTHONY HENRY JOSEPH;;HEIN JOHN,,https://lens.org/089-788-720-172-405,Patent Application,no,8,2,14,40,0,B65D43/0231;;B65D2543/00092;;B65D2543/0024;;B65D2543/00277;;B65D2543/00972;;B67B3/20;;B67B3/22;;B67C7/00;;B65B3/18;;B65D41/00;;B65D43/02;;B65D51/18;;B65D2251/00;;B65D43/0231;;B67B3/20;;B67B3/22;;B67C7/00;;B65D2543/00092;;B65D2543/00972;;B65D2543/00277;;B65D2543/0024;;B65D2543/00092;;B65D2543/0024;;B65D2543/00277;;B65D2543/00972;;B67B3/20;;B67C7/00;;B65D43/0231;;B67B3/22;;B65D43/0283;;B67C3/02,B65D51/16;;B65D41/06;;B65D43/02;;B67B3/20;;B67B3/22;;B67C3/02,,0,0,,,,INACTIVE
981,AU,A,AU 1995/020802 A,100-222-840-441-976,1995-10-23,1995,AU 1995/020802 A,1995-03-31,GB 9406486 A;;GB 9500734 W,1994-03-31,Removable vertical fall arrest device,,LATCHWAYS LTD,ATKINSON GEOFFREY FRASER;;PATTERSON DAVID JOHN,,https://lens.org/100-222-840-441-976,Patent Application,no,0,0,12,12,0,A62B35/005;;A62B35/0087;;E06C7/18;;E06C7/186;;A62B35/0087;;A62B35/005;;E06C7/18;;E06C7/186,E06C9/14;;A62B1/14;;A62B35/00;;A62B35/04;;E06C7/18,,0,0,,,,EXPIRED
982,US,A1,US 2011/0313323 A1,110-266-016-190-352,2011-12-22,2011,US 201113163650 A,2011-06-17,US 201113163650 A;;US 63893009 A;;US 35093609 A;;US 68884810 A;;US 83264307 A;;US 83264607 A;;US 1962208 P;;US 9845608 P;;US 10486208 P;;US 12250608 P;;US 13803108 P;;US 88702207 P,2007-01-29,Method for treating a neurological disorder,"A therapeutic method for treating a neurological disease by accessing a neuraxial deformity and abnormal neuraxial stress. The method involves calculating a neuraxial stress, determining whether the neurological disorder is attributed at least in part to the neuraxial stress; and treating the neurological disorder by normalizing the neuraxial stress.",HENDERSON FRASER CUMMINS;;NEWMAN JOHN W;;POLARIS BIOTECHNOLOGY INC,HENDERSON FRASER CUMMINS;;NEWMAN JOHN W,LIFE SPINE INC (2014-09-24),https://lens.org/110-266-016-190-352,Patent Application,yes,3,30,2,27,0,A61B17/7055;;A61B17/7055;;A61B17/7011;;A61B17/7011;;A61B17/7043;;A61B17/7043;;A61B17/7044;;A61B17/7044;;A61B17/7049;;A61B17/7049;;A61B17/7052;;A61B17/7052;;A61B17/8061;;A61B17/8061,A61B5/107;;A61B17/88,600/594;;600/587;;606/279,5,5,027-129-383-756-144;;035-750-137-625-101;;081-485-342-365-760;;044-956-771-501-245;;042-466-100-597-632,10.3171/spi.2004.1.3.0281;;15478366;;15478375;;10.4135/9781412961165.n51;;15835107;;10.3171/ped.2004.101.2.0189;;10.3171/spi-07/10/444;;17933321;;10.3171/spi.2007.7.4.444;;10.1016/s0090-3019(81)80043-2;;7280961;;10.1097/00006123-199512000-00005,"Atul Goel, Treatment of basilar invagination by atlantoaxial joint distraction and direct lateral mass fixation, J. Neurosurg: Spine/Volume 1/October 2004 (pgs 281-286);;Louis J. Kim, Harold L.Rekate, Jeffrey D. Klopfenstein, and Volker K. H. Sonntag, Treatment of basilar invagination associated with Chiari I malformations in the pediatric population: cervical reduction and posterior occipitocervical fusion, J. Neurosurg: Pediatrics/Volume 101/November 2004 (pgs.189-195);;Ricardo V. Botelho, Eliseu B. Neto, Gustavo C. Patriota, Jefferson W. Daniel, Paulo A.S. Dumont, and Jose M. Rotta, Basilar invagination: craniocervical instability treated with cervical traction and occipitocervical fixation, J. Neurosurg: Spine/Volume 7/October 2007 (pgs 444-449);;Tin-Kan Hung, Guan-Liang Chang, Juei-Ling Chang, and Maurice S. Albin, Stress-Strain Relationship and Neurological Sequelae of Uniaxial Elongation of the Spinal Cord of Cats, Surgical Neurology Vol.15, No.6, June 1981, by Little, Brown and Company (pgs 471-476);;Ajay K. Bindal, Stewart B. Dunsker, and John M. Tew, Jr., Chiari I Malformation: Classification and Management; Department of Neurosurgery, University of Cincinnati College of Medicine, and the Mayfield Neurological Institute; Neurosurgery, Col.37, No.6, Decemeber 1995 (pgs.1069-1074)",ACTIVE
983,EP,A4,EP 1200703 A4,096-752-954-247-130,2003-11-05,2003,EP 00945056 A,2000-06-30,US 0018129 W;;US 34758699 A,1999-07-01,GAS LIFT UMBILICAL CABLE AND TERMINATION ASSEMBLIES THEREFOR,,KELLOGG BROWN & ROOT INC,FRASER DANA JOHN;;DAVIS ALVA W,,https://lens.org/096-752-954-247-130,Search Report,no,3,0,9,9,0,E21B17/203;;E21B17/203,E21B17/20,,2,0,,,"""Recommended practice for flexible pipe"", 1 July 1998, AMERICAN PETROLEUM INSTITUTE, API RECOMMENDED PRACTICE 17B, XP001147493;;See also references of WO 0102693A1",DISCONTINUED
984,WO,A1,WO 2023/017234 A1,112-416-016-108-981,2023-02-16,2023,GB 2022051444 W,2022-06-09,GB 202111484 A,2021-08-10,A CLOSURE FOR A CONTAINER AND A CONTAINER AND CLOSURE,"A closure 10 for a container 20, the container having a side surface 21 and a rim 22 that defines an opening 23 and an opening axis A that is perpendicular to the opening, the closure comprising: a top portion 11 configured to cover the opening of the container; and a skirt portion 12, connected to the top portion and configured to surround an upper region of the side surface of a container when the closure is connected to the container; wherein the skirt portion comprises one or more thread portions 13 configured to cooperate with one or more thread portions 26 provided on the side surface of a container to define movement of the closure relative to the container in a direction parallel to the opening axis as the closure rotates about the opening axis relative to the container; the closure further comprises a liner 90 that extends across the surface of the top portion of the closure and at least partway across the skirt portion away from the top portion; and the liner is configured to seal the opening of a container when the closure is connected to the container.",THREADLESS CLOSURES LTD,FRASER ANTHONY HENRY JOSEPH;;HEIN JOHN,,https://lens.org/112-416-016-108-981,Patent Application,yes,13,0,3,3,0,B65D53/04;;B65D41/0435;;B65D41/0442;;B65D41/02;;B65D51/1661,B65D41/04;;B65D41/02;;B65D41/06;;B65D51/16;;B65D53/04,,0,0,,,,PENDING
985,GB,A,GB 1124942 A,114-948-110-744-714,1968-08-21,1968,GB 2234664 A,1964-05-29,GB 2234664 A,1964-05-29,Semiconductor p-n junctions,,MINI OF TECHNOLOGY,HULME KENNETH FRASER;;MORGAN JOHN ROWLAND,,https://lens.org/114-948-110-744-714,Granted Patent,no,0,0,1,1,0,C30B19/02;;C30B19/106;;C30B29/06;;C30B31/02;;H01L21/00;;H01L29/00,C30B19/02;;C30B19/10;;C30B31/02;;H01L21/00;;H01L29/00,H1K KLAB          LAB;;H1K K1A1          LA;;H1K K2S1B         LA;;H1K K2S11G        LA;;H1K K2S2D         LA;;H1K K2S2P         LA;;H1K K2S20         LA;;H1K K3E4Y         LA;;H1K K3E5B         LA;;H1K K3E5D         LA;;H1K K4F11G        LA;;H1K K4F2D         LA;;H1K K4F2P         LA;;H1K K4F20         LA;;H1K K7T           LA;;H1K K8V9          LA;;H1K K9N2          LA;;H1K K9R           LA,0,0,,,,EXPIRED
986,DE,A1,DE 3616879 A1,118-354-437-124-346,1986-11-20,1986,DE 3616879 A,1986-05-20,US 73603385 A,1985-05-20,OPTISCH GEPULSTER ELEKTRONENBESCHLEUNIGER,,US ENERGY,FRASER JOHN STILES;;SHEFFIELD RICHARD LEE,,https://lens.org/118-354-437-124-346,Patent Application,no,3,4,10,10,0,H01S3/0903;;H05H7/18;;H05H9/00;;H01S3/0903;;H05H9/00;;H05H7/18,H01S3/09;;H05H7/18;;H05H9/00,,3,0,,,"Hg. M.L. STITCH u. M. BASS ""Laser Hand- book"" Bd.4 Verl. North-Holland Amsterdam (1985) S.1 u. S.106-112;;Nucl. Instrum. a. Meth. in Phys. Res. Bd.A 237 (1985) S.180-186;;Nucl. Instrum. a. Meth. in Phys. Res. Bd.A 237 (1985) S.309-317",DISCONTINUED
987,US,A,US 1624347 A,116-545-405-781-471,1927-04-12,1927,US 11099026 A,1926-05-22,GB 1624347X A,1925-05-26,Sighting indicator for firearms,,LAMONT,FRASER LAMONT JOHN WILLIAM;;HERBERT DICKINSON,,https://lens.org/116-545-405-781-471,Granted Patent,no,0,3,3,3,0,F41A33/02;;F41A33/02;;F41C27/00;;F41C27/00;;F41G1/35;;F41G1/35;;Y10S362/802;;Y10S362/802,F41A33/02;;F41C27/00;;F41G1/35,,0,0,,,,EXPIRED
988,US,A,US 4301252 A,124-797-040-750-381,1981-11-17,1981,US 13727480 A,1980-04-04,US 13727480 A,1980-04-04,Controlled environment incubator for light microscopy,"A miniature, biological incubator for continuous light microscopic observation of cells in cell cultures under environmentally controlled conditions for use in conjunction with petri dishes or similar types of culture dishes, in which different covers are provided to accommodate different types of microscopes and magnification, the incubator being small enough to fit on a microscope stage and to have a sufficiently small internal volume to facilitate maintenance of a controlled atmosphere having stable temperature, humidity and mixture of gases therein and to permit rapid restoration of controlled environment lost during replacement of dishes or during changing of covers to suit particular microscopic observation. The chamber contains a means for humidifying the gases contained therein by evaporation from water-saturated absorbent pads of large surface area, plus a means for humidifying particular gaseous mixtures used to purge the chamber, utilizing at least one hollow fiber tube in intimate contact with water-saturated absorbent pads through which the purging gases are passed, the hollow fiber tube presenting to the purging gases a large wetted surface area resulting in efficient humidification of the purging gases.",BAKER FRASER L;;BAUMANN JOHN H,BAKER FRASER L;;BAUMANN JOHN H,,https://lens.org/124-797-040-750-381,Granted Patent,yes,11,67,1,1,0,C12M23/48;;C12M23/48;;C12M23/10;;C12M23/10;;C12M23/54;;C12M23/54;;C12M41/14;;C12M41/14;;C12M41/36;;C12M41/36;;Y10S435/809;;Y10S435/809,C12M1/02;;C12M1/34;;C12M1/38,435/290,0,0,,,,EXPIRED
989,CA,A1,CA 3227723 A1,132-273-674-440-580,2023-02-16,2023,CA 3227723 A,2022-06-09,GB 202111484 A;;GB 2022051444 W,2021-08-10,A CLOSURE FOR A CONTAINER AND A CONTAINER AND CLOSURE,"A closure 10 for a container 20, the container having a side surface 21 and a rim 22 that defines an opening 23 and an opening axis A that is perpendicular to the opening, the closure comprising: a top portion 11 configured to cover the opening of the container; and a skirt portion 12, connected to the top portion and configured to surround an upper region of the side surface of a container when the closure is connected to the container; wherein the skirt portion comprises one or more thread portions 13 configured to cooperate with one or more thread portions 26 provided on the side surface of a container to define movement of the closure relative to the container in a direction parallel to the opening axis as the closure rotates about the opening axis relative to the container; the closure further comprises a liner 90 that extends across the surface of the top portion of the closure and at least partway across the skirt portion away from the top portion; and the liner is configured to seal the opening of a container when the closure is connected to the container.",THREADLESS CLOSURES LTD,FRASER ANTHONY HENRY JOSEPH;;HEIN JOHN,,https://lens.org/132-273-674-440-580,Patent Application,no,0,0,3,3,0,B65D53/04;;B65D41/0435;;B65D41/0442;;B65D41/02;;B65D51/1661,B65D41/06;;B65D53/04,,0,0,,,,PENDING
990,GB,B,GB 2175738 B,130-940-896-066-102,1989-07-26,1989,GB 8611114 A,1986-05-07,US 73603385 A,1985-05-20,OPTICALLY PULSED ELECTRON ACCELERATOR,,US ENERGY,FRASER JOHN STILES;;SHEFFIELD RICHARD LEE,,https://lens.org/130-940-896-066-102,Granted Patent,no,3,0,10,10,0,H01S3/0903;;H05H7/18;;H05H9/00;;H01S3/0903;;H05H9/00;;H05H7/18,H01S3/09;;H05H7/18;;H05H9/00,H1C CBX           CBX;;H1C C470          CBX;;H1D DL            L;;H1D D17C          L;;H1D D18AY         L;;H1D D18A1AY       L;;H1D D18A1A2       L;;H1D D18A1Y        L;;H1D D18A2A        L;;H1D D18A2E        L;;H1D D18A2Y        L;;H1D D20HY         L;;H1D D20H1         L;;H1D D20H2         L;;H1D D20M          L;;H1D D50           L;;U1S S1032;;U1S S1911,0,0,,,,EXPIRED
991,CA,A1,CA 2932159 A1,133-526-536-279-548,2015-06-18,2015,CA 2932159 A,2014-12-10,AU 2013/904823 A;;AU 2014/050406 W,2013-12-11,MEDICAMENT APPARATUS AND METHOD,"An apparatus for use in administering a particulate medicament to a biological subject's airway, the apparatus including an inlet that in use is in fluid communication with a supply of positive pressure gas, an outlet that in use is in fluid communication with the subject's airway to deliver the positive pressure gas thereto and a medicament supply that provides a dose of particulate medicament so that the particulate medicament is entrained in a gas flow from the inlet to the outlet, thereby delivering the particulate medicament to the subject's airway.",DE MOTU CORDIS,FRASER JOHN FRANCIS;;GREGORY SHAUN DAVID,,https://lens.org/133-526-536-279-548,Patent Application,no,0,0,17,17,0,A61M11/02;;A61M11/06;;A61M15/0028;;A61M15/0065;;A61M16/0048;;A61M16/0078;;A61M16/06;;A61M16/208;;A61M2202/064;;A61M2206/14;;A61M2209/06;;A61M2230/06;;A61M2230/42;;A61M16/049;;A61M15/0021;;A61M15/0031;;A61M15/0043;;A61M15/0048;;A61M15/0051;;A61M16/0084;;A61M2205/50;;A61M16/14;;A61K31/4166;;A61K31/137;;A61K9/0075;;A61K31/485;;A61K31/5517;;A61K31/7004;;A61P9/04;;A61P3/00;;A61P37/00;;A61M16/0048;;A61M16/06;;A61M16/208;;A61M2206/14;;A61M15/0031;;A61M15/0048;;A61M16/0084;;A61M2209/06;;A61M16/0078;;A61M11/02;;A61M2230/06;;A61M15/0051;;A61M15/0043;;A61M2205/50;;A61M15/0065;;A61M2230/42;;A61M11/06;;A61M15/0028;;A61M15/0021;;A61M16/049;;A61M2202/064;;A61M16/14;;A61H31/00;;A61M16/0057;;A61M16/04;;A61M16/0816;;A61M2202/0208,A61M13/00;;A61M16/00;;A61M37/00,,0,0,,,,ACTIVE
992,EP,A3,EP 0088576 A3,142-276-392-921-470,1984-03-28,1984,EP 83301076 A,1983-03-01,GB 8206355 A,1982-03-04,METHODS AND APPARATUS FOR CONSTRUCTING CUTTING TOOLS,"Method and apparatus for constructing a press knife for cutting out sheet material such as a leather, wherein machine instructions are generated containing data relating to a desired configuration of the press knife for cutting out a particular profile, the machine instructions are supplied to a bending device (36,38, 40) and to a strip material feed device (62), the feed device supplies the strip material to the bending device so the bends are introduced into the strip material in accordance with the machine instructions, the formed strip material then being cut off from the stock and assembled and fixed to form the desired knife configuration, preferably being fixed around a support plate which is produced by a forming device (30) fed with machine instructions derived from the same source (12) as those controlling the bending and feeding devices.",P.A. CONSULTING SERVICES LIMITED,"ARCHER, JOHN RICHARD;;ROSS, PETER FRASER",BUSM CO. LIMITED (1985-05-08);;THE BRITISH UNITED SHOE MACHINERY COMPANY LIMITED (1985-03-20);;P.A. CONSULTING SERVICES LIMITED (1983-11-16);;USM CORPORATION (1985-05-08);;CESSIONE;BUSM CO. LIMITED (1988-03-15);;CAMBIO RAGIONE SOCIALE;BRITISH UNITED SHOE MACHINE (1988-05-31),https://lens.org/142-276-392-921-470,Search Report,yes,6,0,15,15,0,B21D7/12;;B21D11/10;;B21D37/205;;B23P15/40;;B21D37/205;;B21D7/12;;B21D11/10;;B23P15/40,B21D7/12;;B21D11/10;;B23P15/28;;B23P15/40;;B23Q15/00,,0,0,,,,EXPIRED
993,FR,A1,FR 2413679 A1,147-889-740-982-178,1979-07-27,1979,FR 7900018 A,1979-01-02,US 86585477 A,1977-12-30,APPAREIL DE PRISE DE VUES MUNI DE MOYENS POUR EVITER UNE MAUVAISE MISE AU POINT ET POSSEDANT UN SYSTEME DE MISE AU POINT AUTOMATIQUE UNIDIRECTIONNEL,"<P>APPAREIL DE PRISE DE VUES POSSEDANT UN PLAN DE FILM, ET UN OBJECTIF A FOCALE VARIABLE.</P><P>L'OBJECTIF A FOCALE VARIABLE EST SUSCEPTIBLE DE SE DEPLACER DANS ET A L'EXTERIEUR DE SA GAMME NORMALE DE MISE AU POINT PAR UN SYSTEME DE COMMANDE DE MISE AU POINT MANUELLE ET ATUTOMATIQUE, MUNI DE MOYENS DE RAPPEL A RESSORT POUR RAPPELER L'OBJECTIF EN SA GAMME NORMALE DE MISE AU POINT, POUR EVITER LE RISQUE D'UNE MAUVAISE MISE AU POINT DE L'OBJECTIF PAR LE SYSTEME DE COMMANDE AUTOMATIQUE DE MISE AU POINT.</P><P>APPLICATION A LA PHOTOGRAPHIE.</P>",POLAROID CORP,FRASER RICHARD J;;OSTROWSKI JOHN C,,https://lens.org/147-889-740-982-178,Patent Application,no,2,0,16,16,0,G02B7/40;;G02B7/40,G03B19/02;;G02B7/09;;G02B7/28;;G02B7/40;;G03B13/36,,0,0,,,,EXPIRED
994,MX,A,MX 2013000512 A,144-132-388-527-323,2013-04-03,2013,MX 2013000512 A,2011-07-04,GB 201011800 A;;GB 2011001003 W,2010-07-14,CLOSURE FOR A CONTAINER.,"A closure for a container (2) having a circular opening defining an axis (A) and a lip (2A) around said opening, the closure comprising: an inner component (1) having a collar portion for locating about the exterior of the container beneath the lip of the container and a sealing portion (6) which extends from said collar portion over an upper surface of said lip; and an outer component (4) for fitting over the inner component and interacting therewith for re] easably securing the collar portion under the lip, wherein the outer component has a skirt part (4A) for locating about the collar portion of the inner component, and the collar portion comprising a plurality of spaced apart radially moveable parts (3) around its circumference pivotally joined at their lower ends by a ring (3B) extending around the entire circumference of the collar portion. The sealing portion may be formed of flexible material or may be formed of a relatively rigid material with a flexible sealing member, eg an o-ring (18), carried thereby.",THREADLESS CLOSURES LTD,FRASER ANTHONY HENRY JOSEPH;;HEIN JOHN,,https://lens.org/144-132-388-527-323,Patent Application,no,0,0,20,39,0,B65D41/0442;;B65D41/08;;B65D41/086;;B65D53/02;;B65D2543/00564;;B65D2543/00972;;B65D43/0222;;B65D45/322;;B65D51/18;;B65D41/065;;B65D41/086;;B65D2251/026;;B65D41/04;;B65D41/08;;B65D53/02;;B65D2543/00564;;B65D41/086;;B65D2543/00972;;B65D53/02;;B65D41/08;;B65D41/0442;;B65D41/04,B65D41/04;;B65D41/08;;B65D53/02,,0,0,,,,DISCONTINUED
995,EP,A2,EP 1638507 A2,180-272-728-992-177,2006-03-29,2006,EP 04776784 A,2004-06-18,US 2004/0019611 W;;US 47941803 P,2003-06-18,METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER,,MACROPORE BIOSURGERY INC,HEDRICK MARC H;;FRASER JOHN K,"CYTORI THERAPEUTICS, INC. (2006-11-22)",https://lens.org/180-272-728-992-177,Patent Application,yes,0,0,14,221,0,A61K35/44;;A61K48/00;;A61K35/28;;A61P13/00;;A61P37/06;;A61P43/00;;C12N5/0602;;C12N5/0667,C12N5/0775;;A61K35/28;;A61K35/44,,0,0,,,,ACTIVE
996,NO,L,NO 20016415 L,162-360-044-721-568,2002-02-28,2002,NO 20016415 A,2001-12-28,US 34758699 A;;US 0018129 W,1999-07-01,Gasslöft-kontrollkabel og avslutningsmontasjer for samme,"En gassløftkontrollkabel (10) omfattende et fleksibelt rør (14) som har en sammenbruddsbestandig vegg (12) og et første tetningslag (15) som er dannet på en indre overflate av den sammenbruddsbestandige vegg (12). Den indre overflate avgrenser en langsgående passasje. En fleksibel gassløftslange (16) er montert inne i den langsgående passasje som strekker seg fra en første ende av det fleksible rør (14) til en andre ende av dette. En første rørdel (104) er festet ril den sammenbruddsbestandige vegg (12) av det fleksible rør (14) ved en første ende av dette. En andre rørdel (106) er festet til den sammenbruddsbestandige vegg (12) av det fleksible rør (14) ved en andre ende av dette. En første adapter forbinder en første ende av gassløftslangen (16) med den første rørdel, og en andre adapter forbinder en andre ende av gassløftslangen (16) med den andre rørdel.",KELLOGG BROWN & ROOT INC,FRASER DANA JOHN;;DAVIS ALVA W,,https://lens.org/162-360-044-721-568,Abstract,no,0,0,9,9,0,E21B17/203;;E21B17/203,E21B17/20,,0,0,,,,DISCONTINUED
997,NO,B1,NO 342110 B1,155-782-972-996-43X,2018-03-26,2018,NO 20161522 A,2016-09-23,US 30589602 A;;IB 0306396 W,2002-11-27,Fleksibelt rørformet element med tettende tapelag,Et fleksibelt rør hvor et lag av viklet bånd strekker seg nærliggende en overflate av et rørelement for å begrense eller hindre molekylmigrering gjennom rørelementet.,TRINITY BAY EQUIPEMENT HOLDINGS LLC,FRASER DANA JOHN;;FIRTH CHARLES BASIL,"TRINITY BAY EQUIPEMENT HOLDINGS, US (2017-10-02)",https://lens.org/155-782-972-996-43X,Granted Patent,no,2,0,26,26,0,F16L11/04;;F16L11/081;;F16L11/081;;F16L11/081;;F16L11/04;;F16L11/04;;F16L11/08;;F16L11/12;;F16L11/12;;F16L11/12,F16L11/04;;F16L11/08;;F16L11/12,,0,0,,,,EXPIRED
998,EP,A2,EP 2559535 A2,172-639-075-788-950,2013-02-20,2013,EP 12191597 A,2009-09-24,EP 09737489 A;;US 10042708 P,2008-09-26,"Systems, devices, and/or methods for manufacturing castings","Certain exemplary embodiments can provide a composition, system, machine, device, manufacture, circuit, and/or user interface adapted for, and/or a method and/or machine-readable medium comprising machine-implementable instructions for, activities that can comprise, after removing a cast device from a stack-lamination-derived mold, said cast device formed from a molding composition, applying a desired shape to said cast device to form a shaped cast device, said molding composition comprising: a ceramic composition comprising silica; an cycloaliphatic epoxy binder composition, said cycloaliphatic epoxy binder composition present in said molding composition in an amount up to 30% by weight of said molding composition; a silicone composition comprising a siloxane resin, said silicone composition present in said molding composition in an amount up to 30% by weight of said molding composition; and a solvent composition adapted to dissolve said cycloaliphatic epoxy binder composition and said silicone composition.
",MIKRO SYSTEMS INC,APPLEBY MICHAEL;;FRASER IAIN;;PAULUS JOHN,RAYTHEON TECHNOLOGIES CORPORATION (2021-03-24);;UNITED TECHNOLOGIES CORPORATION (2019-04-24);;RTX CORPORATION (2023-11-01),https://lens.org/172-639-075-788-950,Patent Application,yes,159,14,17,17,0,B23P15/246;;B29C33/301;;B29C33/38;;B29C33/3835;;A61B6/4258;;B22C9/04;;Y10T428/24479;;B22C9/10;;C08L63/00;;C08L83/04;;Y10T428/24479;;B23P15/246;;B29C33/301;;B29C33/38;;B29C33/3835;;A61B6/4258;;B22C9/04;;C08L63/00;;C08L83/04;;B22C9/10,B29C33/30;;A61B6/00;;B22C9/00;;B23P15/24;;B29C33/38;;C08K3/22,,0,0,,,,PENDING
999,WO,A2,WO 2005/011569 A2,177-766-616-937-458,2005-02-10,2005,US 2004/0019611 W,2004-06-18,US 47941803 P,2003-06-18,METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER,"Methods of treating patients for conditions such as breast augmentation, soft tissue defects, and urinary incontinence, are described. The methods include removing adipose tissue from a patient, processing a portion of the adipose tissue to obtain a substantially isolated population of regenerative cells, mixing the regenerative cells with another portion of adipose tissue to form a composition, and administering the composition to the patient from which the adipose tissue was removed.",MACROPORE BIOSURGERY INC;;HEDRICK MARC H;;FRASER JOHN K,HEDRICK MARC H;;FRASER JOHN K,,https://lens.org/177-766-616-937-458,Patent Application,yes,13,36,14,221,0,A61K35/44;;A61K48/00;;A61K35/28;;A61P13/00;;A61P37/06;;A61P43/00;;C12N5/0602;;C12N5/0667,A61K35/28;;A61K35/44;;C12N5/0775,,1,0,,,See also references of EP 1638507A4,PENDING
1000,NO,D0,NO 20022127 D0,190-850-115-413-288,2002-05-03,2002,NO 20022127 A,2002-05-03,US 16390899 P;;US 70530900 A;;US 0030513 W,1999-11-05,Fleksible rör med ventileringspassasjer,,WELLSTREAM INC,FRASER DANA JOHN;;KALMAN MARK D,"GE OIL & GAS UK LIMITED, GB (2015-01-19)",https://lens.org/190-850-115-413-288,Patent Application,no,0,0,15,38,0,B29D23/001;;B29L2023/005;;F16L11/082;;B29D23/001;;F16L11/082;;B29L2023/005,B29D23/00;;F16L11/08,,0,0,,,,DISCONTINUED
